<DOC>
<DOCNO>WT01-B04-1</DOCNO>
<DOCOLDNO>IA046-000815-B033-15</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/product/2_2.htm 205.178.27.23 19970119002809 text/html 14592
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:31:28 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Fri, 18 Oct 1996 00:51:40 GMT
Content-Length: 14393
</DOCHDR>
<HTML><HEAD>   <TITLE>Pipeline</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#232B68" ALINK="#FFFFFF"VLINK="#232B68"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP></P><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=550>   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=bottom usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="2"><AREA SHAPE=rect COORDS="140,51,232,67" HREF="2_0.htm"></MAP>         </P>                  <P><IMG SRC="images/2_2.gif" WIDTH=240 HEIGHT=95 BORDER=0         ALIGN=left usemap="#2">      </TD></TR>   <br><br><TR>      <TD>         <BLOCKQUOTE><br><br><P><FONT SIZE=4>This information is provided for         investor evaluation of the product areas, markets and stages         of development of SuperGen's products under investigation.         Any discussion of products on this website is not intended         as consumer information. The products discussed here which         have not yet been cleared for marketing in the U.S. are         still in clinical or preclinical stages. They are not         commercial products. For more information about SuperGen         products currently being marketed in the U.S., please refer         to the package insert or Physician's Desk Reference.</FONT>         </P>                  <P><FONT SIZE=4>Click on any specific drug         for further discussion of the product or product under         investigation, as well as the other drugs in that product area.</FONT></BLOCKQUOTE>      </TD></TR></TABLE></P><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=590 HEIGHT=11>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT SIZE=5 COLOR="#007F68">Generic</FONT></B>            </TD><TD COLSPAN=6>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#2B2368"><A HREF="2_3_1.htm#pent">Pentostatin</A></FONT></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_1.htm#pent"><IMG SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif" WIDTH=400 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8 HEIGHT=15         BORDER=0 ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#2B2368"><A HREF="2_3_1.htm#meth">Methrotrexate</A></FONT></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_1.htm#meth"><IMG SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif" WIDTH=400 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8 HEIGHT=15         BORDER=0 ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#2B2368"><A HREF="2_3_1.htm#mege">Megestrol         Acetate</A></FONT></B>      </TD><TD COLSPAN=6>         <P><A HREF="2_3_1.htm#mege"><IMG SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif" WIDTH=400 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8 HEIGHT=15         BORDER=0 ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#2B2368"><A HREF="2_3_1.htm#leuc">Leucovorin         Calcium</A></FONT></B>      </TD><TD COLSPAN=6>         <P><A HREF="2_3_1.htm#leuc"><IMG SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif" WIDTH=400 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8 HEIGHT=15         BORDER=0 ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_1.htm#mito">Mitomycin-C</A></FONT></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_1.htm#mito"><IMG SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif" WIDTH=295 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8 HEIGHT=15         BORDER=0 ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_1.htm#etop">Etoposide</A></FONT></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_1.htm#etop"><IMG SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif" WIDTH=190 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8 HEIGHT=15         BORDER=0 ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_1.htm#cisp">Cisplatin</A></FONT></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_1.htm#cisp"><IMG SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif" WIDTH=190 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8 HEIGHT=15         BORDER=0 ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_1.htm#vinc">Vincristine</A></FONT></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_1.htm#vinc"><IMG SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif" WIDTH=85 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8 HEIGHT=15         BORDER=0 ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_1.htm#vinb">Vinblastine</A></FONT></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_1.htm#vinb"><IMG SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif" WIDTH=85 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8 HEIGHT=15         BORDER=0 ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_1.htm#bleo">Bleomycin</A></FONT></B>            </TD><TD COLSPAN=6>         <P><IMG SRC="images/white.gif" WIDTH=5 HEIGHT=15         X-SAS-UseImageWidth X-SAS-UseImageHeight ALIGN=bottom>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT SIZE=5 COLOR="#007F68">SuperGeneric</FONT></B>            </TD><TD COLSPAN=6>         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_2.htm#1">Mitomycin         Extra</FONT><SUP><FONT COLOR="#232B68">tm</A></FONT></SUP></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_2.htm#1"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=85 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_2.htm#2">Paclitaxel         Extra</FONT><SUP><FONT COLOR="#232B68">tm</A></FONT></SUP></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_2.htm#2"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=45 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_2.htm#3">Doxorubicin         Extra</FONT><SUP><FONT COLOR="#232B68">tm</A></FONT></SUP></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_2.htm#1"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=45 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_2.htm#4">Daunorubicin         Extra</FONT><SUP><FONT COLOR="#232B68">tm</A></FONT></SUP></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_2.htm#4"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=45 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_2.htm#5">Cisplatin         Extra</FONT><SUP><FONT COLOR="#232B68">tm</A></FONT></SUP></B>            </TD><TD COLSPAN=6>         <P><A HREF="2_3_2.htm#5"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=45 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT SIZE=5 COLOR="#007F68">Blood Cell         Disorders</FONT></B>      </TD><TD COLSPAN=6>         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_3.htm#1">RF         1012</A></FONT></B>      </TD><TD COLSPAN=6>         <P><A HREF="2_3_3.htm#1"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=140 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_3.htm#2">RF         1017</A></FONT></B>      </TD><TD COLSPAN=6>         <P><A HREF="2_3_3.htm#2"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=140 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_3.htm#3">RF         1010</A></FONT></B>      </TD><TD COLSPAN=6>         <P><A HREF="2_3_3.htm#3"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=140 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT SIZE=5 COLOR="#007F68">Obesity</FONT></B>            </TD><TD COLSPAN=6>         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_4.htm#1">RF         1051</A></FONT></B>      </TD><TD COLSPAN=6>         <P><A HREF="2_3_4.htm#1"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=140 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P ALIGN=CENTER><B><FONT COLOR="#232B68"><A HREF="2_3_4.htm#1">RF         1051 </FONT></B><FONT COLOR="#232B68">(Prader-Willi         syndrome)</A></FONT>      </TD><TD COLSPAN=6>         <P><A HREF="2_3_4.htm#1"><IMG SRC="images/barL.gif" WIDTH=7         HEIGHT=15 BORDER=0 ALIGN=bottom><IMG SRC="images/barC.gif"         WIDTH=85 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif" WIDTH=8 HEIGHT=15 BORDER=0         ALIGN=bottom></A>      </TD></TR></TABLE></P><P>&nbsp;</P><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-2</DOCNO>
<DOCOLDNO>IA046-000815-B033-63</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_4.htm 205.178.27.23 19970119002832 text/html 12797
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:31:53 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Fri, 20 Dec 1996 02:19:41 GMT
Content-Length: 12598
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Press Release Archive</title>
<meta name="FORMATTER" content="Microsoft FrontPage 2.0">
</head>

<body bgcolor="#FFFFFF" link="#872659" vlink="#872659"
alink="#FFFFFF">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        src="../images/newnav.gif" align="left" border="0"
        hspace="0" width="528" height="136" ismap startspan --><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/6_4.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="38769" --><a
        href="../_vti_bin/shtml.exe/invest/6_4.htm/map"></a> </td>
    </tr>
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (116,37) (308, 60)  6_0.htm"
        src="images/6_4.gif" align="left" border="0" hspace="0"
        width="306" height="80" ismap startspan --><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="116, 37, 308, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/6_4.htm/map1"><img
        align="left" src="images/6_4.gif" width="306" ismap
        usemap="#FrontPageMap1" hspace="0" height="80" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="61011" --><a
        href="../_vti_bin/shtml.exe/invest/6_4.htm/map1"></a> </td>
    </tr>
</table>

<p><font color="#FFFFFF">------------------------------------------------------------
-------------------------------------------------------------</font>
</p>

<table border="0" width="590" height="288">
    <tr>
        <td width="150"><a href="9612121.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Dec 12, 1996</font></a></td>
        <td colspan="4"><font size="4">SuperGen Obtains Right To
        License Novel Anticancer Compounds</font></td>
    </tr>
    <tr>
        <td width="150">&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td width="150"><a href="9612041.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Dec 4, 1996</font></a></td>
        <td colspan="4"><font size="4">SuperGen Appoints
        Frederick Grab, Ph.D. As Vice President, Pharmaceutical
        Operations</font></td>
    </tr>
    <tr>
        <td width="150">&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td width="150"><a href="9611251.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Nov 25, 1996</font></a></td>
        <td colspan="4"><font size="4">SuperGen And Galenica
        Pharmaceuticals Announce Anticancer Collaboration</font> </td>
    </tr>
    <tr>
        <td width="150">&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td width="150"><a href="9611141.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Nov 14, 1996</font></a></td>
        <td colspan="4"><font size="4">SuperGen, Inc. Reports
        Third Quarter Results</font></td>
    </tr>
    <tr>
        <td width="150">&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td width="150"><a href="9611121.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Nov 12, 1996</font></a></td>
        <td colspan="4"><font size="4">SuperGen, Inc. Appoints
        Rajesh Shrotriya, M.D. As Senior Vice President</font></td>
    </tr>
    <tr>
        <td width="150">&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td width="150"><a href="9610021.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Oct 2, 1996</font></a></td>
        <td colspan="4"><font size="4">SuperGen Receives Patent
        Allowance For Extra<sup>TM</sup> Technology</font></td>
    </tr>
    <tr>
        <td width="150">&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td width="150"><a href="9610011.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Oct 1, 1996</font></a></td>
        <td colspan="4"><font size="4">SuperGen Acquires
        Anticancer Drug From Warner-Lambert</font></td>
    </tr>
    <tr>
        <td width="150">&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td width="150"><a href="6_4_7.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Aug 27, 1996</font></a> </td>
        <td valign="bottom" colspan="4"><font size="4">Inflazyme
        Signs Letter Of Intent To License Anti-Cancer Drugs To
        SuperGen</font> </td>
    </tr>
    <tr>
        <td width="150">&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td width="150"><a href="9608141.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">August 14, 1996</font></a> </td>
        <td valign="top" colspan="4"><font size="4">SuperGen,
        Inc. Reports Second Quarter Results</font></td>
    </tr>
    <tr>
        <td width="150">&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
    </tr>
    <tr>
        <td width="150"><a href="6_4_6.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">July 25, 1996</font></a> </td>
        <td valign="bottom" colspan="4"><font size="4">SuperGen,
        Inc. Acquires Rights To Market Three Anticancer Products</font>
        </td>
    </tr>
    <tr>
        <td width="150">&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
    </tr>
    <tr>
        <td width="150"><a href="6_4_5.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">May 28, 1996</font></a> </td>
        <td valign="bottom" colspan="4"><font size="4">SuperGen,
        Inc. Appoints Hank Settle As Chief Financial Officer</font>
        </td>
    </tr>
    <tr>
        <td width="150">&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
    </tr>
    <tr>
        <td width="150"><a href="6_4_4.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">May 20, 1996</font></a> </td>
        <td valign="bottom" colspan="4"><font size="4">SuperGen,
        Inc. Receives Orphan Drug Status For Prader-Willi
        Treatment</font> </td>
    </tr>
    <tr>
        <td width="150">&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
    </tr>
    <tr>
        <td width="150"><a href="6_4_3.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">May 13, 1996</font></a> </td>
        <td colspan="4"><font size="4">SuperGen, Inc. Reports
        First Quarter Results</font> </td>
    </tr>
    <tr>
        <td width="150">&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
    </tr>
    <tr>
        <td width="150"><a href="6_4_2.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Apr 18, 1996</font></a> </td>
        <td colspan="4"><font size="4">SuperGen, Inc. Begins
        Human Trials of New Anticancer Drug</font> </td>
    </tr>
    <tr>
        <td width="150">&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
        <td>&nbsp; </td>
    </tr>
    <tr>
        <td width="150"><a href="6_4_1.htm"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"><font size="4">Apr 16, 1996</font></a> </td>
        <td valign="bottom" colspan="4"><font size="4">SuperGen,
        Inc. Gains IND For New Phase II Study of Obesity Pill.</font>
        </td>
    </tr>
</table>

<p><font color="#FFFFFF">&nbsp;</font> </p>

<p><font color="#FFFFFF"><!--webbot bot="ImageMap"
rectangle=" (67,10) (111, 19)  ../people/5_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
src="../images/lowNAV.gif" border="0" width="530" height="31"
ismap startspan --><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 10, 111, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"></MAP><a
href="../_vti_bin/shtml.dll/invest/6_4.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a><!--webbot
bot="ImageMap" endspan i-checksum="63111" --></font><a
href="../_vti_bin/shtml.exe/invest/6_4.htm/map2"></a> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-3</DOCNO>
<DOCOLDNO>IA046-000815-B033-91</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_5.htm 205.178.27.23 19970119002844 text/html 2955
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:32:04 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Fri, 18 Oct 1996 22:38:49 GMT
Content-Length: 2757
</DOCHDR>
<HTML><HEAD>   <TITLE>Links to SuperGen Stock Quotes</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=550>   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map2"><AREA SHAPE="rect" COORDS="116,37,308,60" HREF="6_0.htm"></MAP><IMG ISMAP         SRC="images/6_5.gif" WIDTH=381 HEIGHT=79 BORDER=0 ALIGN=left         usemap="#map2">      </TD></TR></TABLE><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=550>   <TR>      <TD>       &nbsp;            </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P><A HREF="http://quote.pathfinder.com/money/quote/qc?symbols=supg"         TARGET="new"><IMG SRC="../images/invesbut.gif" WIDTH=21         HEIGHT=20 BORDER=0         ALIGN=bottom><B><FONT SIZE=5 COLOR="#872659">Quote.Pathfinder.Com</A></FONT></B>            </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD></TR></TABLE><P>&nbsp;<P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF=".../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-4</DOCNO>
<DOCOLDNO>IA046-000815-B033-131</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_6.htm 205.178.27.23 19970119002907 text/html 7354
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:32:26 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 05 Dec 1996 00:34:36 GMT
Content-Length: 7156
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>SEC 10-Q &amp; 10-K Filings</title>
<meta name="FORMATTER" content="Microsoft FrontPage 2.0">
</head>

<body bgcolor="#FFFFFF" link="#872659" vlink="#872659"
alink="#FFFFFF">

<table border="0" cellpadding="0" cellspacing="0" width="550">
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        src="../images/newnav.gif" align="left" border="0"
        hspace="0" width="528" height="136" startspan --><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/6_6.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="26243" --> </td>
    </tr>
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (116,37) (308, 60)  6_0.htm"
        src="images/6_6.gif" align="left" border="0" hspace="0"
        width="305" height="79" ismap startspan --><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="116, 37, 308, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/6_6.htm/map1"><img
        align="left" src="images/6_6.gif" width="305" ismap
        usemap="#FrontPageMap1" hspace="0" height="79" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="61316" --> </td>
    </tr>
</table>

<p>&nbsp;</p>

<table border="0" width="550">
    <tr>
        <td><a
        href="http://www.sec.gov/Archives/edgar/data/919722/0000912057-96-017626.txt"
        target="new_window"><img src="../images/invesbut.gif"
        border="0" width="21" height="20"></a><a
        href="http://www.sec.gov/Archives/edgar/data/919722/0000912057-96-026490.txt"
        target="new_window" height="300" width="300"><font
        size="4"><b>10-Q third quarter 1996</b></font></a> </td>
    </tr>
    <tr>
        <td><a
        href="http://www.sec.gov/Archives/edgar/data/919722/0000912057-96-017626.txt"
        target="new_window"><img src="../images/invesbut.gif"
        border="0" width="21" height="20"></a><a
        href="http://www.sec.gov/Archives/edgar/data/919722/0000912057-96-017626.txt"
        target="new_window" height="300" width="300"><font
        size="4"><b>10-Q second quarter 1996</b></font></a> </td>
    </tr>
    <tr>
        <td><a href="javaScript:window.openMe2()"
        target="new_window"><img src="../images/invesbut.gif"
        border="0" width="21" height="20"></a><a
        href="http://www.sec.gov/Archives/edgar/data/919722/0000912057-96-009351.txt"
        target="new_window" height="300" width="300"><font
        size="4"><b>10-Q first quarter 1996</b></font></a> </td>
    </tr>
    <tr>
        <td><a
        href="http://www.sec.gov/Archives/edgar/data/919722/0000912057-96-013507.txt"
        target="new_window"><font color="#872659"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"></font><font color="#872659" size="4"><b>SuperGen
        Inc. S-8</b></font></a> </td>
    </tr>
    <tr>
        <td target="new"><a
        href="http://www.sec.gov/Archives/edgar/data/919722/0000912057-96-013507.txt"
        target="new_window"><font color="#872659"><img
        src="../images/invesbut.gif" border="0" width="21"
        height="20"></font></a><a
        href="http://www.sec.gov/cgi-bin/srch-edgar?supergen"
        target="new_window"><font color="#872659" size="4"><b>Search
        the SEC EDGAR database for other SuperGen Listings</b></font></a>
        </td>
    </tr>
</table>

<p>&nbsp; </p>

<p>&nbsp; </p>

<p>&nbsp; </p>

<p><!--webbot bot="ImageMap"
rectangle=" (67,10) (111, 19)  ../people/5_0.htm"
rectangle=" (128,11) (186, 19)  .../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
src="../images/lowNAV.gif" border="0" width="530" height="31"
startspan --><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 10, 111, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF=".../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"></MAP><a href="../_vti_bin/shtml.dll/invest/6_6.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a><!--webbot
bot="ImageMap" endspan i-checksum="10945" --> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-5</DOCNO>
<DOCOLDNO>IA046-000815-B033-168</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/perform/3_2.htm 205.178.27.23 19970119002935 text/html 11704
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:32:57 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Fri, 06 Dec 1996 03:07:16 GMT
Content-Length: 11505
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Milestones</title>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
<meta name="FORMATTER" content="Microsoft FrontPage 2.0">
</head>

<body bgcolor="#FFFFFF" link="#023338" vlink="#023338"
alink="#FFFFFF">

<table cellpadding="0" cellspacing="0" width="550">
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  ../invest/6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) ../invest/6_0.htm"
        rectangle=" (196,30) (282, 41)  3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) 3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        src="../images/newnav.gif" align="bottom" border="0"
        width="528" height="136" startspan --><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="../invest/6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="../invest/6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"></MAP><a
        href="../_vti_bin/shtml.dll/perform/3_2.htm/map"><img
        align="bottom" src="../images/newnav.gif" width="528"
        ismap usemap="#FrontPageMap" height="136" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="49072" --> </td>
    </tr>
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (153,44) (280, 60)  3_0.htm"
        src="images/3_2.gif" align="left" border="0" hspace="0"
        width="287" height="91" startspan --><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="153, 44, 280, 60" HREF="3_0.htm"></MAP><a
        href="../_vti_bin/shtml.dll/perform/3_2.htm/map1"><img
        align="left" src="images/3_2.gif" width="287" ismap
        usemap="#FrontPageMap1" hspace="0" height="91" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="1837" --> </td>
    </tr>
</table>

<p>&nbsp;</p>

<p align="center"><font color="#023833"><font size="5"><b>SuperGen:
Near-term Milestones</b></font></font></p>

<p align="center">&nbsp;</p>

<p><font color="#023833"><font size="5"><b><u>Achieved since IPO:
</u></b></font></font></p>

<table width="540">
    <tr>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
    </tr>
    <tr>
        <td width="180"><img src="images/bullseye.GIF"
        align="bottom" width="87" height="100"> </td>
        <td width="180"><img src="images/bullseye.GIF"
        align="bottom" width="87" height="100"> </td>
        <td width="180"><img src="images/bullseye.GIF"
        align="bottom" width="87" height="100"> </td>
    </tr>
    <tr>
        <td width="180"><font size="4"><b>File IND for Mitomycin
        Extra</b></font><sup><font size="4"><b>TM</b></font></sup><font
        size="4"><b> </b></font></td>
        <td width="180"><p align="center"><font size="4"><b>Expand
        anemia/growth factor trials</b></font> </p>
        </td>
        <td width="180"><p align="center"><font size="4"><b>Expand
        obesity pill human clinical trials</b></font> </p>
        </td>
    </tr>
    <tr>
        <td width="180"><a href="../invest/6_4_2.htm"><font
        size="2"><i>SuperGen, Inc. Begins Human Trials of New
        Anticancer Drug</i></font></a><font size="2"><i></i></font></td>
        <td width="180">&nbsp; </td>
        <td width="180"><a href="../invest/6_4_1.htm"><font
        size="2"><i>SuperGen, Inc. Gains IND for New Phase II
        Study of Obesity Pill</i></font></a><font size="2"><i></i></font></td>
    </tr>
</table>

<p></p>

<table width="540">
    <tr>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
    </tr>
    <tr>
        <td width="180"><img src="images/bullseye.GIF"
        align="bottom" width="87" height="100"> </td>
        <td width="180"><img src="images/bullseye.GIF"
        align="bottom" width="87" height="100">&nbsp; </td>
        <td width="180"><img src="images/bullseye.GIF"
        align="bottom" width="87" height="100"> </td>
    </tr>
    <tr>
        <td width="180"><font size="4"><b>Begin marketing of
        Megestrol, Methotrexate, and Leucovorin. </b></font></td>
        <td width="180"><font size="4"><b>Begin marketing of
        Pentostatin</b></font></td>
        <td width="180"><font size="4"><b>Extra</b></font><sup><font
        size="4"><b>TM</b></font></sup><font size="4"><b> patent
        allowed. </b></font></td>
    </tr>
    <tr>
        <td width="180"><a href="../invest/6_4_6.htm"><font
        size="2"><i>SuperGen, Inc. Acquires Rights To Market
        Three Anticancer Products</i></font></a></td>
        <td width="180"><p align="left"><a
        href="../invest/6_4_6.htm"><font size="2"><i>SuperGen
        Acquires Anticancer Drug from Warner-Lambert</i></font></a></p>
        </td>
        <td width="180"><a href="../invest/9610021.htm"><font
        size="2"><i>SuperGen Receives Patent Allowance for Extra</i></font><sup><font
        size="2"><i>TM</i></font></sup><font size="2"><i>
        Technology</i></font></a></td>
    </tr>
</table>

<p></p>

<table width="540">
    <tr>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
    </tr>
    <tr>
        <td width="180"></td>
        <td width="180"><img src="images/bullseye.GIF"
        align="bottom" width="87" height="100">&nbsp; </td>
        <td width="180">&nbsp;</td>
    </tr>
    <tr>
        <td width="180">&nbsp;</td>
        <td width="180"><font size="4"><strong>Build team for
        transition from development to emerging status</strong></font></td>
        <td width="180">&nbsp;</td>
    </tr>
    <tr>
        <td width="180">&nbsp;</td>
        <td width="180"><a href="../invest/9612041.htm"><font
        size="2"><em>SuperGen Appoints Frederick Grab, Ph.D. As
        Vice President, Pharmaceutical Operations</em></font></a><font
        size="2"><em></em></font><p><a
        href="../invest/9611121.htm"><font size="2"><em>SuperGen,
        Inc. Appoints Rajesh Shrotriya, M.D. As Senior Vice
        President</em></font></a></p>
        </td>
        <td width="180">&nbsp;</td>
    </tr>
</table>

<p><br>
<font color="#023833"><font size="5"><b><u>Targeted: </u></b></font></font></p>

<table width="540">
    <tr>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
    </tr>
    <tr>
        <td width="180"><img src="images/arrow.GIF"
        align="bottom" width="24" height="75"> </td>
        <td width="180"><img src="images/arrow.GIF"
        align="bottom" width="24" height="75"> </td>
        <td width="180"><img src="images/arrow.GIF"
        align="bottom" width="24" height="75"> </td>
    </tr>
    <tr>
        <td width="180"><font size="4"><b>Complete Phase II
        obesity trials and expand to include diabetes, lupus,
        etc. </b></font></td>
        <td width="180"><p align="center"><font size="4"><b>Expand
        anti-cancer portfolio to at least six cleared drugs.</b></font>
        </p>
        </td>
        <td width="180"><p align="center"><font size="4"><b>Submit
        three (supergeneric) marketing applications.</b></font> </p>
        </td>
    </tr>
    <tr>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
    </tr>
</table>

<p></p>

<table width="540">
    <tr>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
    </tr>
    <tr>
        <td width="180"><img src="images/arrow.GIF"
        align="bottom" width="24" height="75"> </td>
        <td width="180">&nbsp; </td>
        <td width="180"><img src="images/arrow.GIF"
        align="bottom" width="24" height="75"> </td>
    </tr>
    <tr>
        <td width="180"><font size="4"><b>Continue Phase II
        studies in blood-cell disorders. </b></font></td>
        <td width="180">&nbsp; </td>
        <td width="180"><p align="center"><font size="4"><b>Continue
        pursuing in-licensing and partnership opportunities.</b></font>
        </p>
        </td>
    </tr>
    <tr>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
        <td width="180">&nbsp; </td>
    </tr>
</table>

<p>&nbsp;</p>

<p><!--webbot bot="ImageMap"
rectangle=" (67,10) (111, 19)  ../people/5_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  ../invest/6_0.htm"
rectangle=" (420,11) (504, 19)  3_0.htm"
src="../images/lowNAV.gif" align="bottom" border="0" width="530"
height="31" startspan --><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 10, 111, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="../invest/6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="3_0.htm"></MAP><a
href="../_vti_bin/shtml.dll/perform/3_2.htm/map2"><img
align="bottom" src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a><!--webbot
bot="ImageMap" endspan i-checksum="48999" --></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-6</DOCNO>
<DOCOLDNO>IA046-000815-B033-241</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/product/2_3.htm 205.178.27.23 19970119003019 text/html 3684
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:33:36 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 17 Oct 1996 22:08:47 GMT
Content-Length: 3486
</DOCHDR>
<HTML><HEAD>   <TITLE>Drugs</TITLE>   <META NAME=GENERATOR CONTENT="Claris Home Page 1.0">   <X-SAS-WINDOW TOP=55 BOTTOM=589 LEFT=111 RIGHT=641></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#232B68" ALINK="#FFFFFF"VLINK="#2B2368"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=542 HEIGHT="1%">   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=bottom usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="2"><AREA SHAPE=rect COORDS="140,51,232,67" HREF="2_0.htm"></MAP>         </P>                  <P><IMG         SRC="images/2_3.gif"         WIDTH=240 HEIGHT=95 BORDER=0 ALIGN=left usemap="#2">      </TD></TR></TABLE></P><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=550>   <TR>      <TD>         <BLOCKQUOTE><P><A HREF="2_3_1.htm"><IMG         SRC="../images/produbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=bottom><B><FONT SIZE=4 COLOR="#232B68">Generic         Anti-Cancer Pharmaceuticals</A></FONT></B></BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <BLOCKQUOTE><P><A HREF="2_3_2.htm"><IMG         SRC="../images/produbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=bottom><B><FONT SIZE=4 COLOR="#232B68">SuperGenerics</A></FONT></B>         </BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <BLOCKQUOTE><P><A HREF="2_3_3.htm"><IMG         SRC="../images/produbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=bottom><B><FONT SIZE=4 COLOR="#232B68">Proprietary         Blood Cell Disorder Products</A></FONT></B></BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <BLOCKQUOTE><P><A HREF="2_3_4.htm"><IMG         SRC="../images/produbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=bottom><B><FONT SIZE=4 COLOR="#232B68">Obesity         Products</A></FONT></B></BLOCKQUOTE>      </TD></TR></TABLE></P><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-7</DOCNO>
<DOCOLDNO>IA046-000815-B033-308</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/product/2_3_1.htm 205.178.27.23 19970119003102 text/html 17135
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:34:14 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Wed, 16 Oct 1996 22:20:45 GMT
Content-Length: 16936
</DOCHDR>
<!--This file created 10/16/96 3:20 PM by Claris Home Page version 1.0--><HTML><HEAD>   <TITLE>Generic Anticancer Pharmaceuticals</TITLE>   <META NAME=GENERATOR CONTENT="Claris Home Page 1.0">   <X-SAS-WINDOW TOP=48 BOTTOM=624 LEFT=59 RIGHT=730></HEAD><BODY BGCOLOR="#FFFFFF"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP></P><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=550>   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD VALIGN=top>         <P><MAP NAME="2"><AREA SHAPE=rect COORDS="140,51,232,67" HREF="2_0.htm"><AREA SHAPE=rect COORDS="30,85,88,96" HREF="2_3.htm"></MAP>         </P>                  <P><IMG SRC="images/2_3_1.gif" WIDTH=472 HEIGHT=117 BORDER=0         ALIGN=left usemap="#2">      </TD></TR></TABLE></P><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=623>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>The Company currently has four         generic drugs cleared for the U.S. market, and also is         waiting to receive clearance for its generic version of         mitomycin. Five other generic drugs currently are in         development. The Company believes that early         commercialization of its generic drugs will assist it in         developing its reputation and presence in the market while         it continues to develop its supergeneric and proprietary         products.</FONT></P>                  <P><FONT SIZE=4>Generic drugs currently being marketed by         SuperGen are as follows<A NAME="pent"></A>:</FONT></P>                  <P>&nbsp;</BLOCKQUOTE>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">P</FONT></B><FONT SIZE=5 COLOR="#232B68">entostatin</FONT>            </TD><TD COLSPAN=5>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=400 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>Pentostatin is indicated for the         treatment of hairy cell leukemia, for which it has been         granted Orphan Drug status in the U.S. Orphan Drug status         also has been granted for its use in chronic lymphocytic         leukemia. The total U.S. market for these two diseases is         estimated at </FONT><B><FONT SIZE=4>$65 million for         1996.</FONT></B><FONT SIZE=4> While the patent for the drug         has expired, SuperGen's exclusive rights are protected by         Orphan Drug status until October,         1998<A NAME="meth"></A>.</FONT></BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">M</FONT></B><FONT SIZE=5 COLOR="#232B68">ethotrexate</FONT>            </TD><TD COLSPAN=5>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=400 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>Methotrexate, manufactured for         SuperGen under a license from Barr Laboratories, is used in         the treatment of leukemias, lymphomas, breast cancer, head         and neck cancer. Estimated U.S. sales of Methotrexate were         approximately </FONT><B><FONT SIZE=4>$70 million in 1995 and         $78.5 million in 1994<A NAME="mege"></A>.</FONT></B>         </BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD VALIGN=bottom COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">M</FONT></B><FONT SIZE=5 COLOR="#232B68">egestrol</FONT>            </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD VALIGN=top COLSPAN=2>         <P><FONT SIZE=5 COLOR="#232B68">Acetate</FONT>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=400 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>Megestrol acetate, manufactured         for SuperGen under a license from Barr Laboratories, is         indicated for the palliative treatment of advanced carcinoma         of the breast and endometrium, with an estimated U.S. market         of </FONT><B><FONT SIZE=4>$39 million in 1995 and $35         million in 1994<A NAME="leuc"></A>.</FONT></B></BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD VALIGN=bottom COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">L</FONT></B><FONT SIZE=5 COLOR="#232B68">eucovorin</FONT>            </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD VALIGN=top COLSPAN=2>         <P><FONT SIZE=5 COLOR="#232B68">Calcium</FONT>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=400 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>Leucovorin calcium, manufactured         for SuperGen under a license from Barr Laboratories in two         different tablet dosage forms, is used as a rescue treatment         for high dose methotrexate therapy. The estimated U.S.         market for this drug was approximately         </FONT><B><FONT SIZE=4>$9 million in 1995 and also in         1994.</FONT></B></P>                  <P><FONT SIZE=4>&nbsp;</FONT></P>                  <P><FONT SIZE=4>The Company's generic drugs currently under         development are as follows<A NAME="mito"></A>:</FONT>         </BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">M</FONT></B><FONT SIZE=5 COLOR="#232B68">itomycin</FONT>            </TD><TD COLSPAN=5>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=295 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>Mitomycin, with estimated sales         in the U.S. of approximately </FONT><B><FONT SIZE=4>$36.4         million in 1995 and $41.5 million in         1994</FONT></B><FONT SIZE=4>, is indicated for gastric and         pancreatic carcinoma. The patent for mitomycin expired in         1987, and as of December 31, 1995 only one generic version         of mitomycin had been approved for commercial sale in         addition to the original version produced by Bristol-Myers         Squibb<A NAME="cisp"></A>.</FONT></BLOCKQUOTE>      </TD></TR>   <TR>      <TD COLSPAN=7>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">C</FONT></B><FONT SIZE=5 COLOR="#232B68">isplatin</FONT>            </TD><TD COLSPAN=5>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=190 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>Cisplatin is indicated for the         treatment of metastatic testicular tumors, metastatic         ovarian tumors, and advanced bladder cancer. Sales of         Cisplatin in the U.S. were estimated to be approximately         </FONT><B><FONT SIZE=4>$41.4 million in 1995 and $42.4         million in 1994</FONT></B><FONT SIZE=4>. A patent for         cisplatin is expiring in December, 1996. Therefore, no         generic versions of Cisplatin have been approved for         commercial sale to date.<A NAME="etop"></A>. </FONT>         </BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">E</FONT></B><FONT SIZE=5 COLOR="#232B68">toposide</FONT>            </TD><TD COLSPAN=5>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=190 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>In combination with other         chemotherapeutic agents, etoposide is indicated for the         management of refractory testicular tumors and small cell         lung cancer. Sales of Etoposide in the U.S. were estimated         to be </FONT><B><FONT SIZE=4>$104.9 million in 1995 and         $140.9 million in 1994.</FONT></B><FONT SIZE=4> The patent         for Etoposide expired in November 1993. There are currently         three generic versions of Etoposide that have been approved         for commercial sale, in addition to the original version         produced by Bristol Myers-Squibb<A NAME="vinc"></A>. </FONT>         </BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">V</FONT></B><FONT SIZE=5 COLOR="#232B68">incristine</FONT>            </TD><TD COLSPAN=5>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=85 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>Vincristine is used to treat         Hodgkin's disease, lymphomas, acute leukemia,         rhabdomyosarcoma, neuroblastoma, and Wilm's tumor. Sales of         Vincristine in the U.S. were estimated to be approximately         </FONT><B><FONT SIZE=4>$5.8 million in 1995 and $7.9 million         in 1994.</FONT></B><FONT SIZE=4> The patent for Vincristine         expired in 1982 and there are other generic versions of         Vincristine that have been approved for commercial sale, in         addition to the original version produced by Eli Lilly and         Company<A NAME="vinb"></A>. </FONT></BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><FONT SIZE=5 COLOR="#232B68">Vinblastine</FONT>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=85 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>Vinblastine is indicated for the         palliative treatment of generalized Hodgkin's disease         (Stages III and IV) and Kaposi's sarcoma. Estimated U.S.         sales currently are approximately </FONT><B><FONT SIZE=4>$2         million</FONT></B><FONT SIZE=4><A NAME="bleo"></A>.</FONT>         </BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=5>         <P><IMG SRC="images/marker2.gif" WIDTH=420 HEIGHT=36         ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><FONT SIZE=5 COLOR="#232B68">Bleomycin</FONT>      </TD><TD COLSPAN=5>         <P>      </TD></TR>   <TR>      <TD COLSPAN=7>         <BLOCKQUOTE><P><FONT SIZE=4>Bleomycin is indicated for         palliative treatment in the management of squamous cell         carcinoma of the head and neck, Hodgkin's disease, reticulum         cell sarcoma, lymphosarcoma, and testicular carcinoma. Sales         of bleomycin in the U.S. were estimated to be         approximately</FONT><B><FONT SIZE=4> $43.5 million in 1995         and $43.5 million in 1994.</FONT></B><FONT SIZE=4> The         patent for bleomycin expired in 1989 and one generic version         has been approved for commercial sale to date.</FONT>         </BLOCKQUOTE>      </TD></TR></TABLE></P><P>&nbsp;</P><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-8</DOCNO>
<DOCOLDNO>IA046-000815-B034-20</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/product/2_3_2.htm 205.178.27.23 19970119003136 text/html 13646
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:34:50 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 17 Oct 1996 22:24:40 GMT
Content-Length: 13447
</DOCHDR>
<HTML><HEAD>   <TITLE>Supergenerics</TITLE></HEAD><BODY BGCOLOR="#FFFFFF"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP></P><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=557 HEIGHT=35>   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=bottom usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="2"><AREA SHAPE=rect COORDS="140,51,232,67" HREF="2_0.htm"><AREA SHAPE=rect COORDS="30,85,88,96" HREF="2_3.htm"></MAP>         </P>                  <P><IMG SRC="images/2_3_2.gif" WIDTH=241 HEIGHT=117 BORDER=0         ALIGN=bottom usemap="#2">      </TD></TR></TABLE></P><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=590>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><FONT SIZE=4>The Company is developing         "supergenerics" that it believes may significantly improve         the safety profile and handling characteristics of certain         generic anticancer drugs currently on the market (the         "supergeneric technology"). Some anticancer generic drugs         are available only in a powder form and have to be mixed and         dissolved in the correct liquid prior to administration. The         Company's supergeneric technology enables certain anticancer         drugs to be made in ready-to-inject, stable solutions. The         ready-to-inject stable solution not only increases the ease         of administration and saves time by eliminating the mixing         procedure, but also increases the safety for the person         administering the dose by minimizing the risk of exposure to         these toxic drugs. Moreover, the Company believes that         certain of its ready-to-inject, stable solutions may have a         significantly longer shelf-life at room-temperature than the         mixed generic solutions. </FONT></P>                  <P><FONT SIZE=4>In addition, the Company believes that its         supergeneric technology may increase the safety of certain         existing anticancer drugs by minimizing the problem of         ulceration associated with extravasation. Extravasation is         accidental leakage of the drug into a patient's muscle or         skin from a blood vessel. Many existing anticancer         pharmaceuticals, including those under development by the         Company, can cause serious ulceration if extravasated. The         resulting damage can be extensive and can require plastic         surgery to repair. As a result, the Company believes that         its supergeneric products may have a significant competitive         advantage over their generic counterparts currently on the         market. </FONT></P>                  <P><FONT SIZE=4>The Company has filed an application for         worldwide patent protection for certain of its anticancer         supergeneric products. The U.S. patent for these         applications has been allowed. </FONT></P>                  <P><FONT SIZE=4>The Company's supergeneric drugs currently         under development are as follows:<A NAME="1"></A> </FONT>         </P>                  <P>&nbsp;</BLOCKQUOTE>      </TD></TR>   <TR>      <TD VALIGN=bottom COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">M</FONT></B><FONT SIZE=5 COLOR="#232B68">itoExtra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP><FONT SIZE=5 COLOR="#232B68">         </FONT>      </TD><TD COLSPAN=6>         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23         ALIGN=bottom>      </TD></TR>   <TR>      <TD VALIGN=top COLSPAN=2>         <P>      </TD><TD COLSPAN=6>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=85 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><FONT SIZE=4>Mitomycin is currently available         commercially in powder form only. The Company has completed         its formulation and preclinical testing for its Mitomycin         Extra<sup>tm</sup> for injection and has filed an IND with the FDA and         begun Phase I/II trials<A NAME="2"></A></FONT></P>                  <P>&nbsp;</BLOCKQUOTE>      </TD></TR>   <TR>      <TD COLSPAN=8>         <P>      </TD></TR>   <TR>      <TD VALIGN=bottom COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">P</FONT></B><FONT SIZE=5 COLOR="#232B68">acoExtra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP><FONT SIZE=5 COLOR="#232B68">         </FONT>      </TD><TD COLSPAN=6>         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23         ALIGN=bottom>      </TD></TR>   <TR>      <TD VALIGN=top COLSPAN=2>         <P>      </TD><TD COLSPAN=6>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=45 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><FONT SIZE=4>Paclitaxel is indicated as         second-line therapy to treat ovarian cancer. It is the         fastest growing anticancer agent, with sales in the U.S. of         approximately </FONT><B><FONT SIZE=4>$386.5 million in 1995         and $262.2 million in 1994.</FONT></B><FONT SIZE=4> The         current paclitaxel formulation has numerous problems because         the high level of Cremophor&reg;EL solvent used for the         injection concentrate causes hypersensitivity reactions,         leaching of plasticizer from PVC infusion bags, haziness of         diluted solutions and the need for in-line filters. The         Company believes that its potential product may eliminate or         minimize these problems.<A NAME="3"></A></FONT></P>                  <P>&nbsp;</BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD VALIGN=bottom COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">D</FONT></B><FONT SIZE=5 COLOR="#232B68">oxoExtra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP>            </TD><TD COLSPAN=6>         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23         ALIGN=bottom>      </TD></TR>   <TR>      <TD VALIGN=top COLSPAN=2>         <P>      </TD><TD COLSPAN=6>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=45 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><FONT SIZE=4>Doxorubicin is indicated to         treat major cancers including acute lymphoblastic and         myeloblastic leukemia, malignant lymphoma, breast and         ovarian carcinoma, soft tissue and bone sarcomas,         neuroblastoma osteosarcoma, Wilms' tumor and others.         Doxorubicin is currently sold as a powder by four companies,         and in solution form by two of these companies. Sales of         Doxorubicin in the U.S. were estimated to be approximately         </FONT><B><FONT SIZE=4>$55.3 million in 1995 and $60.9         million in 1994</FONT></B><FONT SIZE=4>, of which sales of         the solution form represented 75.8% and 76.7%,         respectively.<A NAME="4"></A> </FONT></P>                  <P>&nbsp;</BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD VALIGN=bottom COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">D</FONT></B><FONT SIZE=5 COLOR="#232B68">aunoExtra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP>            </TD><TD COLSPAN=6>         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23         ALIGN=bottom>      </TD></TR>   <TR>      <TD VALIGN=top COLSPAN=2>         <P>      </TD><TD COLSPAN=6>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=45 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><FONT SIZE=4>Daunorubicin is indicated to         treat acute nonlymphocytic and acute lymphocytic leukemia.         Sales of daunorubicin in the U.S. were estimated to be         approximately </FONT><B><FONT SIZE=4>$10.9 million in 1995         and $10.3 million in 1994.</FONT></B><FONT SIZE=4>         Daunorubicin is currently sold in powder form only. The         Company believes that daunorubicin represents a niche market         with limited competition from large pharmaceutical companies         due to its relatively small market size. However, the         Company believes the use of daunorubicin may increase         substantially in the future, as recent experimental studies         suggest that daunorubicin may be used in an increasing         number of combination drug protocols treating a number of         cancers.<A NAME="5"></A></FONT></P>                  <P>&nbsp;</BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD VALIGN=bottom COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#232B68">C</FONT></B><FONT SIZE=5 COLOR="#232B68">isplatin</FONT>            </TD><TD COLSPAN=6>         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23         ALIGN=bottom>      </TD></TR>   <TR>      <TD VALIGN=top COLSPAN=2>         <P><FONT SIZE=5 COLOR="#232B68">Extra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP>            </TD><TD VALIGN=top COLSPAN=6>         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=45 HEIGHT=15         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8         HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=8>         <P>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><FONT SIZE=4>Cisplatin is indicated for the         treatment of metastatic testicular tumors, metastatic         ovarian tumors and advanced bladder cancer. Sales of         cisplatin in the U.S. were estimated to be approximately         </FONT><B><FONT SIZE=4>$41.4 million in 1995 and $42.4         million in 1994</FONT></B><FONT SIZE=4>.</FONT></P>                  <P><FONT SIZE=4>&nbsp;</FONT></P>                  <P><FONT SIZE=4>&nbsp;</FONT></P>                  <P><FONT SIZE=4>The Company currently intends to develop         other supergeneric products, such as VP-16 Extra, to         complement its anticancer product portfolio. The Company         continues to research other applications to use its         supergeneric technology to enhance existing anticancer         drugs. </FONT></BLOCKQUOTE>      </TD></TR></TABLE></P><P>&nbsp;</P><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-9</DOCNO>
<DOCOLDNO>IA046-000815-B034-66</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/product/2_3_3.htm 205.178.27.23 19970119003158 text/html 10281
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:35:16 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Tue, 15 Oct 1996 19:56:34 GMT
Content-Length: 10082
</DOCHDR>
<HTML><HEAD>   <TITLE>Proprietary Blood Disorder Products</TITLE></HEAD><BODY BGCOLOR="#FFFFFF"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP></P><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=550>   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="2"><AREA SHAPE=rect COORDS="140,51,232,67" HREF="2_0.htm"><AREA SHAPE=rect COORDS="30,85,88,96" HREF="2_3.htm"></MAP>         </P>                  <P><IMG         SRC="images/2_3_3.gif"         WIDTH=481 HEIGHT=117 BORDER=0 ALIGN=bottom usemap="#2">      </TD></TR></TABLE></P><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=590>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><FONT SIZE=4>The Company is developing a         series of proprietary blood cell disorder products to treat         various forms of anemia. Anemia is the destruction of white         and/or red blood cells, which weakens the immune system,         leaving patients susceptible to infection that could result         in serious illness or death. Anemia frequently results as a         side effect of existing anticancer therapies, including         chemotherapy and radiation, and from renal failure. The         Company believes that its products under development may         have improved therapeutic benefits relative to existing         drugs available commercially, and may be used in conjunction         with existing drugs or, in certain cases, may replace         existing drugs.</FONT></P>                  <P><FONT SIZE=4>The Company's products under development in         this area consist of the following<A NAME="1"></A>: </FONT>         </P>                  <P>&nbsp;</BLOCKQUOTE>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=6>         <P><IMG         SRC="images/markers.gif"         WIDTH=425 HEIGHT=23 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><SUP><FONT SIZE=5 COLOR="#232B68">RF 1012</FONT></SUP>      </TD><TD COLSPAN=6>         <P><IMG         SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif"         WIDTH=140 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif"         WIDTH=8 HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><B><FONT SIZE=4 COLOR="#232B68">Chemoprotective         and Radioprotective Agent.</FONT></B><FONT SIZE=4>         Chemotherapy and radiation, used in the treatment of cancer,         deplete the patient's white blood cell supply, thereby         weakening the patient's immune system. This side effect,         which can be life-threatening itself, requires the extension         of the period between chemotherapy and radiation treatments,         which may reduce their effectiveness in combating the         cancer. As a result, therapeutic agents that effectively and         speedily treat the side effect of anemia may significantly         enhance the effectiveness of anticancer treatments. Sales in         the U.S. of such drugs, estimated to be approximately $617.0         million in 1994, as reported by Medical Advertising News, is         dominated by Amgen's product GCSF/Neupogen. Patients using         this product typically require 14 to 21 days to recover in         the hospital, and until they have recovered they are         generally not able to have another treatment of chemotherapy         or radiation. </FONT></P>                  <P><FONT SIZE=4>The Company's preclinical tests indicate         that its proprietary chemoprotective and radioprotective         agent may reduce the patient recovery period, and may also         reduce the side effects associated with existing drugs. As a         result, the Company believes that its product may have         significant market potential and that its use may enhance or         replace existing drugs. The Company has received an IND and         has commenced Phase I/II clinical trials on this potential         product<A NAME="2"></A>. </FONT></BLOCKQUOTE>      </TD></TR>   <TR>      <TD COLSPAN=8>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=6>         <P><IMG         SRC="images/markers.gif"         WIDTH=425 HEIGHT=23 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><SUP><FONT SIZE=5 COLOR="#232B68">RF 1017</FONT></SUP>      </TD><TD COLSPAN=6>         <P><IMG         SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif"         WIDTH=140 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif"         WIDTH=8 HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><B><FONT SIZE=4 COLOR="#232B68">Aplastic         Anemia Agent.</FONT></B><FONT SIZE=4> Aplastic anemia is a         disease that depletes white and red blood cells, platelets         and neutrophils. The disease affects an estimated patient         population of 2,000 people per year. No current therapeutic         agent in the market effectively treats all symptoms of         aplastic anemia. </FONT></P>                  <P><FONT SIZE=4>The Company believes that its proprietary         aplastic anemia agent has the potential to be to be the         first therapeutic agent to treat all symptoms of aplastic         anemia. The Company believes that the potential market size         opportunity for such a product is $20 million. The Company         received an Orphan Drug Grant for its potential aplastic         anemia product from the FDA in June 1995 and an Orphan Drug         Designation for this product in November 1995. The Company         has received an IND and commenced Phase I/II clinical         trials<A NAME="3"></A>.</FONT></BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=6>         <P><IMG         SRC="images/markers.gif"         WIDTH=425 HEIGHT=23 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><SUP><FONT SIZE=5 COLOR="#232B68">RF 1010</FONT></SUP>      </TD><TD COLSPAN=6>         <P><IMG         SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barC.gif"         WIDTH=140 HEIGHT=15 BORDER=0 ALIGN=bottom><IMG         SRC="images/barR.gif"         WIDTH=8 HEIGHT=15 BORDER=0 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><B><FONT SIZE=4 COLOR="#232B68">Renal Agent.         </FONT></B><FONT SIZE=4> Anemia associated with kidney         disease is the depletion of red blood cells. The market for         U.S. sales of therapeutic agents treating anemia associated         with renal failure, estimated to be approximately         </FONT><B><FONT SIZE=4>$721.0 million in         1994</FONT></B><FONT SIZE=4>, as reported by Medical         Advertising News, is dominated by Amgen's EPO/Epogen.         Current therapeutic agents do not result in complete patient         recovery of the red blood cell supply and further have the         negative side effect of depleting white blood cells,         rendering the patient more susceptible to infection. </FONT>         </P>                  <P><FONT SIZE=4>The Company's preclinical tests indicate         that its proprietary renal agent may enable complete patient         recovery of the red blood cell supply without the negative         side effect of depleting white blood cells. As a result, the         Company believes that its renal agent may offer significant         benefits over existing therapies. The Company has received         an IND and commenced Phase I/II clinical trials. </FONT>         </BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD><TD>         <P>      </TD></TR></TABLE></P><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-10</DOCNO>
<DOCOLDNO>IA046-000815-B034-100</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/product/2_3_4.htm 205.178.27.23 19970119003218 text/html 6602
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:35:33 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Tue, 15 Oct 1996 19:54:24 GMT
Content-Length: 6404
</DOCHDR>
<HTML><HEAD>   <TITLE>Obesity Products</TITLE></HEAD><BODY BGCOLOR="#FFFFFF"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=550>   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="2"><AREA SHAPE=rect COORDS="140,51,232,67" HREF="2_0.htm"><AREA SHAPE=rect COORDS="30,85,88,96" HREF="2_3.htm"></MAP>         </P>                  <P><IMG         SRC="images/2_3_4.gif"         WIDTH=254 HEIGHT=117 BORDER=0 ALIGN=left usemap="#2">      </TD></TR></TABLE></P><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=590>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><FONT SIZE=4>Obesity is a disorder with         significant mortality and morbidity due to heart, joint or         respiratory problems. The U.S. Department of Health and         Human Services has estimated that 28% or 36 million of U.S.         adults (20-74 years of age) are defined as obese and that         effective prevention of obesity could save $50 billion         annually in health care costs. Obesity drugs currently on         the market are dependent on targeting the brain for their         mode of action which is to suppress the appetite or         accelerate the metabolism by amphetamine-like activity.         While many of these drugs have demonstrated an ability to         assist short-term weight loss, the long-term effects of         their use have been less satisfactory as users tend to         regain the weight initially lost ("bounce back         effect")<A NAME="1"></A>. </FONT></P>                  <P>&nbsp;</BLOCKQUOTE>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P>      </TD><TD COLSPAN=6>         <P><IMG         SRC="images/markers.gif"         WIDTH=425 HEIGHT=23 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=2>         <P><B><SUP><FONT SIZE=4 COLOR="#232B68">RF         1051</FONT></SUP></B>      </TD><TD COLSPAN=6>         <P><IMG         SRC="images/barL.gif"         WIDTH=7 HEIGHT=15 ALIGN=bottom><IMG         SRC="images/barC.gif"         WIDTH=140 HEIGHT=15 ALIGN=bottom><IMG         SRC="images/barR.gif"         WIDTH=8 HEIGHT=15 ALIGN=bottom>      </TD></TR>   <TR>      <TD COLSPAN=8>         <BLOCKQUOTE><P><FONT SIZE=4>The Company is developing a         proprietary oral product for the treatment of obesity. Based         on preliminary results from animal studies, the Company         believes that the product's activity is not based on         appetite suppression or on stimulating increased metabolic         activity but on modification of the energy balance equation.         This means that for the same amount of food intake, the body         may store less fat in the presence of the product.         Additionally, the product may also increase the amount of         fat used to produce a given amount of energy. In animal         studies conducted at Jackson Laboratories, genetically obese         and diabetic mice were given the Company's proprietary         product and were compared against a control group which was         not given the product. Both groups ate the same amount of         food. Test results showed that the mice that were given the         product appeared normal (no longer obese) while the control         group remained obese. </FONT></P>                  <P><FONT SIZE=4>Under a Physician's IND, in a randomized,         double-blind crossover study with 17 obese human subjects         over a 20-week period, subjects lost significantly more         weight when given the Company's obesity drug than during         placebo administration, and preliminary results indicated         that the subjects maintained such weight loss over an         extended period (10 weeks). </FONT></P>                  <P><FONT SIZE=4>The Company in 1994 completed under its own         company-sponsored IND a Phase I tolerance and safety study         that showed no adverse effects resulting from the obesity         drug. The Company is augmenting significant existing animal         and human data by sponsoring several additional animal         studies and Phase I/II clinical human studies, as well as         Phase II human studies with a less stringent dosing schedule         for general obesity. SuperGen also is investigating RF 1051         for related genetic diseases in which the major cause of         morbidity and mortality is massive obesity. The drug         currently is in Phase I/II human studies for Prader-Willi         Syndrome, for which The Company has received Orphan Drug         status.</FONT></BLOCKQUOTE>      </TD></TR></TABLE></P><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-11</DOCNO>
<DOCOLDNO>IA046-000815-B034-157</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_1.htm 205.178.27.23 19970119003244 text/html 7998
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:35:58 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Wed, 23 Oct 1996 22:51:47 GMT
Content-Length: 7800
</DOCHDR>
<HTML><HEAD>   <TITLE>Order Supergen Investor Materials</TITLE>   <X-SAS-WINDOW TOP=42 BOTTOM=632 LEFT=4 RIGHT=638></HEAD><BODY BGCOLOR="#FFFFFF"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">   <TR>      <TD>         <P><IMG SRC="http://www.supergen.com/images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=top usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map2"><AREA SHAPE="rect" COORDS="116,37,308,60" HREF="6_0.htm"></MAP><IMG ISMAP         SRC="http://www.supergen.com/invest/images/6_1.gif" WIDTH=419 HEIGHT=79 BORDER=0 ALIGN=left         usemap="#map2">      </TD></TR></TABLE></P><P>&nbsp;</P><FORM METHOD="POST" ACTION="http://www.supergen.com/scripts/polyform.dll/orders"><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=547 HEIGHT=11>   <TR>      <TD>         <P ALIGN=RIGHT><FONT SIZE=4>First Name:</FONT>      </TD><TD COLSPAN=2>         <P><INPUT TYPE="text" NAME="oofirstname" VALUE="" SIZE=26>      </TD><TD>         <P ALIGN=RIGHT><FONT SIZE=4>Last Name:</FONT>      </TD><TD COLSPAN=2>         <P><INPUT TYPE="text" NAME="01lastname" VALUE="" SIZE=25>      </TD></TR>   <TR>      <TD>         <P ALIGN=RIGHT><FONT SIZE=4>Company:</FONT>      </TD><TD COLSPAN=2>         <P><INPUT TYPE="text" NAME="02company" VALUE="" SIZE=26>      </TD><TD>         <P ALIGN=RIGHT><FONT SIZE=4>Describe yourself:</FONT>      </TD><TD COLSPAN=2>         <P><SELECT NAME="03description">            <OPTION SELECTED>Selections            <OPTION>Broker            <OPTION>Analyst            <OPTION>Individual Investor            <OPTION>Institutional Investor            <OPTION>Media            <OPTION>Other         </SELECT>      </TD></TR>   <TR>      <TD>         <P ALIGN=RIGHT><FONT SIZE=4>Area Code:</FONT>      </TD><TD>         <P><INPUT TYPE="text" NAME="04phareacode" VALUE="" SIZE=10>      </TD><TD>         <P ALIGN=RIGHT><FONT SIZE=4>Phone:</FONT>      </TD><TD>         <P><INPUT TYPE="text" NAME="05phone" VALUE="" SIZE=10>      </TD><TD>         <P ALIGN=RIGHT><FONT SIZE=4>Ext:</FONT>      </TD><TD>         <P><INPUT TYPE="text" NAME="06phext" VALUE="" SIZE=10>      </TD></TR>   <TR>      <TD>         <P ALIGN=RIGHT><FONT SIZE=4>Area Code:</FONT>      </TD><TD>         <P><INPUT TYPE="text" NAME="07faxareacode" VALUE="" SIZE=10>      </TD><TD>         <P ALIGN=RIGHT><FONT SIZE=4>Fax:</FONT>      </TD><TD>         <P><INPUT TYPE="text" NAME="08fax" VALUE="" SIZE=10>      </TD><TD>         <P ALIGN=RIGHT><FONT SIZE=4>Ext:</FONT>      </TD><TD>         <P><INPUT TYPE="text" NAME="09faxext" VALUE="" SIZE=10>      </TD></TR>   <TR>      <TD>         <P ALIGN=RIGHT><FONT SIZE=4>Email:</FONT>      </TD><TD COLSPAN=2>         <P><INPUT TYPE="text" NAME="10email" VALUE="" SIZE=26>      </TD><TD>         <P ALIGN=RIGHT><FONT SIZE=4>Assistant:</FONT>      </TD><TD COLSPAN=2>         <P><INPUT TYPE="text" NAME="11assistant" VALUE="" SIZE=26>      </TD></TR>   <TR>      <TD>         <P ALIGN=RIGHT><FONT SIZE=4>Address:</FONT>      </TD><TD COLSPAN=5>         <P><INPUT TYPE="text" NAME="12address" VALUE="" SIZE=71>      </TD></TR>   <TR>      <TD>         <P ALIGN=RIGHT><FONT SIZE=4>City:</FONT>      </TD><TD COLSPAN=2>         <P><INPUT TYPE="text" NAME="13city" VALUE="" SIZE=26>      </TD><TD>         <P ALIGN=RIGHT><FONT SIZE=4>State:</FONT>      </TD><TD COLSPAN=2>         <P><INPUT TYPE="text" NAME="14state" VALUE="" SIZE=25>      </TD></TR>   <TR>      <TD>         <P ALIGN=RIGHT><FONT SIZE=4>Country:</FONT>      </TD><TD COLSPAN=2>         <P><INPUT TYPE="text" NAME="15country" VALUE="" SIZE=26>      </TD><TD>         <P ALIGN=RIGHT><FONT SIZE=4>Zip Code:</FONT>      </TD><TD COLSPAN=2>         <P><INPUT TYPE="text" NAME="16zipcode" VALUE="" SIZE=25>      </TD></TR></TABLE></P><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=467 HEIGHT=178>   <TR>      <TD>         <P>&nbsp;      </TD><TD COLSPAN=2>         <P><B><FONT SIZE=5 COLOR="#731754">Please send         me:</FONT></B>      </TD><TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD><TD COLSPAN=2>         <P><INPUT TYPE="checkbox" NAME="17invest_press"         VALUE="investors_presskit"><FONT SIZE=4>The Investors/Press Kit</FONT>      </TD><TD COLSPAN=2>         <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD><TD COLSPAN=2>         <P><INPUT TYPE="checkbox" NAME="18prospectus"         VALUE="prospectus"><FONT SIZE=4>Just the prospectus</FONT>      </TD><TD COLSPAN=2>         <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD><TD COLSPAN=2>         <P><INPUT TYPE="checkbox" NAME="19audiotape"         VALUE="audiotape"><FONT SIZE=4>The audio tape</FONT>      </TD><TD COLSPAN=2>         <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD><TD COLSPAN=2>         <P><INPUT TYPE="checkbox" NAME="20videotape"         VALUE="videotape"><FONT SIZE=4>The video tape</FONT>      </TD><TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD><TD>         <P>&nbsp;      </TD><TD>         <P ALIGN=RIGHT><INPUT TYPE="submit" NAME="21submit"         VALUE="submit">      </TD><TD>         <P><INPUT TYPE="reset" VALUE="Reset">      </TD><TD>         <P>&nbsp;      </TD></TR></TABLE></P><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><FONT COLOR="#FFFFFF"><IMGSRC="http://www.supergen.com/images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></FONT></P></FORM></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-12</DOCNO>
<DOCOLDNO>IA046-000815-B034-195</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_3.htm 205.178.27.23 19970119003317 text/html 4846
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:36:31 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 05 Sep 1996 05:43:40 GMT
Content-Length: 4648
</DOCHDR>
<HTML><HEAD>   <TITLE>News Items</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map2"><AREA SHAPE="rect" COORDS="116,37,308,60" HREF="6_0.htm"></MAP><IMG ISMAP         SRC="images/6_3.gif" WIDTH=306 HEIGHT=80 BORDER=0 ALIGN=left         usemap="#map2">      </TD></TR></TABLE><P><FONT COLOR="#FFFFFF">-------------------------------------------------------------------------------------------------------------------------</FONT><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=557 HEIGHT=288>   <TR>      <TD>         <P><A HREF="6_3_1.htm%7F%7F" TARGET="NEW"><IMG         SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=middle><FONT SIZE=4>Drug Makers Target Fat, Pique         Investor Appetites</A></FONT><FONT SIZE=4>         </FONT><I><FONT SIZE=4>Investor's Business         Daily</FONT></I><FONT SIZE=4> July 30, 1996</FONT>      </TD></TR>   <TR>      <TD>         <P><A HREF="6_3_2.htm" TARGET="NEW"><IMG         SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=middle><FONT SIZE=4>Going For The Gold By Burning Up         The Fat</A></FONT><I><FONT SIZE=4> Investor's Business         Daily</FONT></I><FONT SIZE=4> July 18, 1996</FONT>      </TD></TR>   <TR>      <TD>         <P><A HREF="http://www.sfgate.com/programs/srch_archive/srch_archive_wrap?unregistered=true&=/WAISlink/chronicle/archive/1996/07/15/BU5288.DTL&=/doc_root/wais/chronicle/1996&=retrieve&=9349518057+0+0+0&=+3+CEOs+With"         TARGET="NEW"><IMG SRC="../images/invesbut.gif" WIDTH=21         HEIGHT=20 BORDER=0 ALIGN=middle><FONT SIZE=4>3 CEOs With the         Right Stuff </A></FONT><I><FONT SIZE=4> San Francisco         Chronicle </FONT></I><FONT SIZE=4> July 15, 1996</FONT>      </TD></TR>   <TR>      <TD>         <P><A HREF="6_3_3.htm" TARGET="NEW"><IMG         SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=middle><FONT SIZE=4>Rubinfield, at 62, hopes SuperGen         crowns career</A></FONT><FONT SIZE=4>         </FONT><I><FONT SIZE=4>The Oakland Tribune         </FONT></I><FONT SIZE=4>October 15, 1995</FONT>      </TD></TR>   <TR>      <TD>         <P><A HREF="http://www.sjmercury.com/reprints/081195.htm"         TARGET="NEW"><IMG SRC="../images/invesbut.gif" WIDTH=21         HEIGHT=20 BORDER=0 ALIGN=middle><FONT SIZE=4>Fat pill         trumpeted</A></FONT><FONT SIZE=4> </FONT><I><FONT SIZE=4>San         Jose Mercury News</FONT></I><FONT SIZE=4> August 11,         1995</FONT>      </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P>&nbsp;      </TD></TR></TABLE><P><FONT COLOR="#FFFFFF">&nbsp;</FONT><P><FONT COLOR="#FFFFFF"><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP></FONT><FONT COLOR="#FFFFFF"><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></FONT></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-13</DOCNO>
<DOCOLDNO>IA046-000815-B035-228</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/9612121.htm 205.178.27.23 19970119003818 text/html 25326
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:41:20 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Fri, 13 Dec 1996 20:20:18 GMT
Content-Length: 25127
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>December 12, 1996</title>
<meta name="FORMATTER" content="Microsoft FrontPage 2.0">
</head>

<body stylesrc="6_4_7.htm" bgcolor="#FFFFFF" link="#872659"
vlink="#872659" alink="#FFFFFF">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,51) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,110) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,26) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,51) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,110) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,26) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  Rhttp://206.24.121.44/product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) Rhttp://206.24.121.44/product/2_0.htm"
        rectangle=" (393,114) (525, 124)  Rhttp://206.24.121.44/patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) Rhttp://206.24.121.44/patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  Rhttp://206.24.121.44/invest/6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) Rhttp://206.24.121.44/invest/6_0.htm"
        rectangle=" (196,30) (282, 41)  Rhttp://206.24.121.44/perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) Rhttp://206.24.121.44/perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  Rhttp://206.24.121.44/index.htm"
        rectangle=" (9,46) (81, 61)  Rhttp://206.24.121.44/contact.htm"
        rectangle=" (10,62) (80, 77)  Rhttp://206.24.121.44/search.htm"
        rectangle=" (10,78) (79, 93)  Rhttp://206.24.121.44/map.htm"
        src="../images/newnav.gif" align="left" border="0"
        hspace="0" width="528" height="136" startspan --><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="Rhttp://206.24.121.44/index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="Rhttp://206.24.121.44/contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="Rhttp://206.24.121.44/search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="Rhttp://206.24.121.44/map.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/9612121.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="5115" --></td>
    </tr>
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (30,67) (252, 80)  6_4.htm"
        rectangle=" (118,40) (306, 60)  6_0.htm"
        rectangle=" (30,67) (252, 80)  6_4.htm"
        rectangle=" (118,40) (306, 60)  6_0.htm"
        src="images/6_4_top.gif" border="0" width="307"
        height="81" startspan --><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/9612121.htm/map1"><img
        src="images/6_4_top.gif" width="307" ismap
        usemap="#FrontPageMap1" height="81" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="25141" --><br>
        <font color="#800040" size="2"><sup><strong><img
        src="images/6_4_bottom.gif" width="60" height="22"></strong></sup></font><font
        color="#800040" size="4"><sup><strong>DECEMBER 12, 1996</strong></sup></font></td>
    </tr>
</table>

<table border="0" width="530">
    <tr>
        <td><blockquote>
            <p align="center"><font size="4"><b>SuperGen Obtains
            Right To License Novel Anticancer Compounds</b></font></p>
            <p>EMERYVILLE, CA (December 12, 1996) &#150;
            SuperGen, Inc. (Nasdaq: SUPG &amp; SUPGW), an
            emerging pharmaceutical company, announced it has
            signed an agreement giving it the right to license
            from Garnett McKeen Laboratory, Inc. (GML) the
            worldwide therapeutic rights to develop and
            commercialize a novel class of metalo-organic
            compounds. SuperGen initially will explore the
            compounds&#146; potential for the treatment of a
            broad range of cancers. </p>
            <p>SuperGen will be responsible for clinical
            development and commercialization efforts for the
            drug candidates that SuperGen chooses to pursue. GML
            will receive royalty payments on eventual product
            sales by SuperGen, as well as SuperGen stock based on
            the achievement of certain human clinical and
            regulatory milestones.</p>
            <p>&quot;We continue to secure proprietary platforms
            for the anticancer drugs of tomorrow even as we
            pursue our more near-term tiers of products
            today&quot; said Dr. Joseph Rubinfeld, Chief
            Executive Officer of SuperGen. &quot;Our focus
            remains on clinical development rather than basic
            research, but it is easier to start the game at the
            fifty-yard line when you already own the ball. We
            believe these compounds already are viable candidates
            for human clinical studies.&quot;</p>
            <p>Based in Emeryville, CA, SuperGen is an emerging
            pharmaceutical company dedicated to the development
            and commercialization of products intended to treat
            life-threatening diseases, particularly cancer and
            blood cell disorders, as well as other serious
            conditions such as obesity. SuperGen is developing
            its anticancer portfolio of ten generic products and
            five enhanced or &quot;supergeneric&quot; products.
            SuperGen now is marketing four drugs for the
            treatment of cancer patients. Blood cell disorder
            products under development currently target anemias
            associated with chemotherapy and radiotherapy, renal
            failure and aplastic anemia. The company's obesity
            pill currently is in Phase II human clinical trials.</p>
            <p><font size="2"><i>This press release contains
            forward looking statements that involve certain risks
            and uncertainties associated with a development stage
            pharmaceutical company. Actual results could differ
            materially from those projected in the forward
            looking statements as a result of the risk factors
            discussed in SuperGen's reports on file with the U.S.
            Securities Exchange Commission (including but not
            limited to the report on Form 10-Q for the quarter
            ended September 30, 1996).</i></font></p>
        </blockquote>
        <p>&nbsp; </p>
        </td>
    </tr>
    <tr>
        <td><a href="6_4.htm"><font color="#731754" size="5"><b><img
        src="../images/invesbut.gif" align="middle" border="0"
        width="21" height="20"></b></font></a><a href="6_4.htm"><font
        color="#731754" size="4"><b>Return to Press Release
        Archive</b></font></a></td>
    </tr>
</table>

<p><!--webbot bot="ImageMap"
rectangle=" (67,8) (115, 19)  ../people/5_0.htm"
rectangle=" (128,9) (191, 19)  ../product/2_0.htm"
rectangle=" (199,9) (342, 19)  ../patent/4_0.htm"
rectangle=" (347,9) (407, 19)  6_0.htm"
rectangle=" (415,10) (506, 20)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (67,8) (115, 19)  ../people/5_0.htm"
rectangle=" (128,9) (191, 19)  ../product/2_0.htm"
rectangle=" (199,9) (342, 19)  ../patent/4_0.htm"
rectangle=" (347,9) (407, 19)  6_0.htm"
rectangle=" (415,10) (506, 20)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  Rhttp://206.24.121.44/product/2_0.htm"
rectangle=" (204,11) (336, 19)  Rhttp://206.24.121.44/patent/4_0.htm"
rectangle=" (353,11) (403, 19)  Rhttp://206.24.121.44/invest/6_0.htm"
rectangle=" (420,11) (504, 19)  Rhttp://206.24.121.44/perform/3_0.htm"
src="../images/lowNAV.gif" border="0" width="530" height="31"
startspan --><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="Rhttp://206.24.121.44/perform/3_0.htm"></MAP><a
href="../_vti_bin/shtml.dll/invest/9612121.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a><!--webbot
bot="ImageMap" endspan i-checksum="15889" --> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-14</DOCNO>
<DOCOLDNO>IA046-000815-B035-275</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/9612041.htm 205.178.27.23 19970119003858 text/html 25675
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:42:07 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Wed, 04 Dec 1996 18:29:35 GMT
Content-Length: 25476
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>December 4, 1996</title>
<meta name="FORMATTER" content="Microsoft FrontPage 2.0">
</head>

<body stylesrc="6_4_7.htm" bgcolor="#FFFFFF" link="#872659"
vlink="#872659" alink="#FFFFFF">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,51) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,110) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,26) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,51) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,110) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,26) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  Rhttp://206.24.121.44/product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) Rhttp://206.24.121.44/product/2_0.htm"
        rectangle=" (393,114) (525, 124)  Rhttp://206.24.121.44/patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) Rhttp://206.24.121.44/patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  Rhttp://206.24.121.44/invest/6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) Rhttp://206.24.121.44/invest/6_0.htm"
        rectangle=" (196,30) (282, 41)  Rhttp://206.24.121.44/perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) Rhttp://206.24.121.44/perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  Rhttp://206.24.121.44/index.htm"
        rectangle=" (9,46) (81, 61)  Rhttp://206.24.121.44/contact.htm"
        rectangle=" (10,62) (80, 77)  Rhttp://206.24.121.44/search.htm"
        rectangle=" (10,78) (79, 93)  Rhttp://206.24.121.44/map.htm"
        src="../images/newnav.gif" align="left" border="0"
        hspace="0" width="528" height="136" startspan --><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="Rhttp://206.24.121.44/index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="Rhttp://206.24.121.44/contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="Rhttp://206.24.121.44/search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="Rhttp://206.24.121.44/map.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/9612041.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="62803" --></td>
    </tr>
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (30,67) (252, 80)  6_4.htm"
        rectangle=" (118,40) (306, 60)  6_0.htm"
        rectangle=" (30,67) (252, 80)  6_4.htm"
        rectangle=" (118,40) (306, 60)  6_0.htm"
        src="images/6_4_top.gif" border="0" width="307"
        height="81" startspan --><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/9612041.htm/map1"><img
        src="images/6_4_top.gif" width="307" ismap
        usemap="#FrontPageMap1" height="81" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="25144" --><br>
        <font color="#800040" size="2"><sup><strong><img
        src="images/6_4_bottom.gif" width="60" height="22"></strong></sup></font><font
        color="#800040" size="4"><sup><strong>DECEMBER 4, 1996</strong></sup></font></td>
    </tr>
</table>

<table border="0" width="530">
    <tr>
        <td><p align="center"><font size="4"><b>SuperGen Appoints
        Frederick Grab, Ph.D. As Vice President, Pharmaceutical
        Operations</b></font></p>
        <blockquote>
            <p>EMERYVILLE, CA (December 4, 1996) &#150; SuperGen,
            Inc., an emerging pharmaceutical company, announced
            it has appointed Frederick L. Grab, Ph.D. as Vice
            President of Pharmaceutical Operations. Dr. Grab was
            recently hired by the company as Vice President of
            Manufacturing. His responsibilities now will be
            expanded to include all activities from formulation
            development through manufacturing for SuperGen
            developed products.</p>
            <p>Prior to joining SuperGen, Dr. Grab, 55, was at
            Pharmacia Inc./Adria Laboratories from 1982 to 1996,
            most recently as Director of Regulatory Affairs. From
            1971 to 1982, he served in several senior
            pharmaceutical development positions at Bristol Myers
            Company International Division. Prior to that he
            worked in pharmaceutical development at Wyeth
            Laboratories. He received his Ph.D. in Pharmaceutical
            Chemistry from the University of California, San
            Francisco Medical Center and his B.S. in Pharmacy
            from Columbia University.</p>
            <p>&quot;Now that SuperGen has turned the corner to
            become an increasingly commercial presence in the
            pharmaceutical market, Fred is an ideal and essential
            addition to our management team,&quot; said Joseph
            Rubinfeld, Ph.D., SuperGen&#146;s Chief Executive
            Officer. &quot;We have extremely high standards for
            experience and proven performance, and I know from
            having worked with Fred at Bristol Myers that he
            exceeds those standards. Moreover, our rapid pace of
            growth has been built on teams of people who have
            worked successfully together for years at other
            companies.&quot;</p>
            <p>Based in Emeryville, CA, SuperGen is an emerging
            pharmaceutical company dedicated to the development
            and commercialization of products intended to treat
            life-threatening diseases, particularly cancer and
            blood cell disorders, as well as other serious
            conditions such as obesity. SuperGen is developing
            its anticancer portfolio of ten generic products and
            five enhanced or &quot;supergeneric&quot; products.
            SuperGen now is marketing four drugs for the
            treatment of cancer patients. Blood cell disorder
            products under development currently target anemias
            associated with chemotherapy and radiotherapy, renal
            failure and aplastic anemia. The company's obesity
            pill currently is in Phase II human clinical trials.</p>
            <p><font size="2"><i>This press release contains
            forward looking statements that involve certain risks
            and uncertainties associated with a development stage
            pharmaceutical company. Actual results could differ
            materially from those projected in the forward
            looking statements as a result of the risk factors
            discussed in SuperGen's reports on file with the U.S.
            Securities Exchange Commission (including but not
            limited to the report on Form 10-Q for the quarter
            ended September 30, 1996).</i></font></p>
        </blockquote>
        <p>&nbsp; </p>
        </td>
    </tr>
    <tr>
        <td><a href="6_4.htm"><font color="#731754" size="5"><b><img
        src="../images/invesbut.gif" align="middle" border="0"
        width="21" height="20"></b></font></a><a href="6_4.htm"><font
        color="#731754" size="4"><b>Return to Press Release
        Archive</b></font></a></td>
    </tr>
</table>

<p><!--webbot bot="ImageMap"
rectangle=" (67,8) (115, 19)  ../people/5_0.htm"
rectangle=" (128,9) (191, 19)  ../product/2_0.htm"
rectangle=" (199,9) (342, 19)  ../patent/4_0.htm"
rectangle=" (347,9) (407, 19)  6_0.htm"
rectangle=" (415,10) (506, 20)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (67,8) (115, 19)  ../people/5_0.htm"
rectangle=" (128,9) (191, 19)  ../product/2_0.htm"
rectangle=" (199,9) (342, 19)  ../patent/4_0.htm"
rectangle=" (347,9) (407, 19)  6_0.htm"
rectangle=" (415,10) (506, 20)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  Rhttp://206.24.121.44/product/2_0.htm"
rectangle=" (204,11) (336, 19)  Rhttp://206.24.121.44/patent/4_0.htm"
rectangle=" (353,11) (403, 19)  Rhttp://206.24.121.44/invest/6_0.htm"
rectangle=" (420,11) (504, 19)  Rhttp://206.24.121.44/perform/3_0.htm"
src="../images/lowNAV.gif" border="0" width="530" height="31"
startspan --><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="Rhttp://206.24.121.44/perform/3_0.htm"></MAP><a
href="../_vti_bin/shtml.dll/invest/9612041.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a><!--webbot
bot="ImageMap" endspan i-checksum="15901" --> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-15</DOCNO>
<DOCOLDNO>IA046-000815-B035-344</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/9611251.htm 205.178.27.23 19970119003922 text/html 27857
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:42:34 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Wed, 04 Dec 1996 01:19:33 GMT
Content-Length: 27658
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>November 25, 1996</title>
<meta name="FORMATTER" content="Microsoft FrontPage 2.0">
</head>

<body stylesrc="6_4_7.htm" bgcolor="#FFFFFF" link="#872659"
vlink="#872659" alink="#FFFFFF">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,51) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,110) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,26) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,51) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,110) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,26) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../index.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  Rhttp://206.24.121.44/product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) Rhttp://206.24.121.44/product/2_0.htm"
        rectangle=" (393,114) (525, 124)  Rhttp://206.24.121.44/patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) Rhttp://206.24.121.44/patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  Rhttp://206.24.121.44/invest/6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) Rhttp://206.24.121.44/invest/6_0.htm"
        rectangle=" (196,30) (282, 41)  Rhttp://206.24.121.44/perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) Rhttp://206.24.121.44/perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  Rhttp://206.24.121.44/index.htm"
        rectangle=" (9,46) (81, 61)  Rhttp://206.24.121.44/contact.htm"
        rectangle=" (10,62) (80, 77)  Rhttp://206.24.121.44/search.htm"
        rectangle=" (10,78) (79, 93)  Rhttp://206.24.121.44/map.htm"
        src="../images/newnav.gif" align="left" border="0"
        hspace="0" width="528" height="136" startspan --><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="Rhttp://206.24.121.44/index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="Rhttp://206.24.121.44/contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="Rhttp://206.24.121.44/search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="Rhttp://206.24.121.44/map.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/9611251.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="62859" --></td>
    </tr>
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (30,67) (252, 80)  6_4.htm"
        rectangle=" (118,40) (306, 60)  6_0.htm"
        rectangle=" (30,67) (252, 80)  6_4.htm"
        rectangle=" (118,40) (306, 60)  6_0.htm"
        src="images/6_4_top.gif" border="0" width="307"
        height="81" startspan --><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/9611251.htm/map1"><img
        src="images/6_4_top.gif" width="307" ismap
        usemap="#FrontPageMap1" height="81" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="25020" --><br>
        <font color="#800040" size="2"><sup><strong><img
        src="images/6_4_bottom.gif" width="60" height="22"></strong></sup></font><font
        color="#800040" size="4"><sup><strong>NOVEMBER 25, 1996</strong></sup></font></td>
    </tr>
</table>

<table border="0" width="530">
    <tr>
        <td><p align="center"><font size="4"><b>SuperGen And
        Galenica Pharmaceuticals Announce Anticancer
        Collaboration</b></font> </p>
        <blockquote>
            <p>EMERYVILLE, CA and FREDERICK, MD (November 25,
            1996) &#150; SuperGen, Inc. (Nasdaq: SUPG &amp;
            SUPGW) and Galenica Pharmaceuticals, Inc., both
            emerging pharmaceutical companies, announced they
            have agreed to a strategic collaboration aimed at the
            discovery and development of new anticancer drugs
            based on natural products. SuperGen will make an
            equity investment giving it a minority interest in
            Galenica, as well as payments based on milestones
            achieved by Galenica during the collaboration.
            SuperGen obtains exclusive worldwide rights to
            anticancer drugs discovered under Galenica&#146;s
            program with the Peruvian University of Cayetano
            Heredia (UPCH) to screen plants in Peru&#146;s rain
            forest, mountain and coastal regions for therapeutic
            biological activity. SuperGen also gains rights of
            first refusal to drug candidates for prostate and
            colon cancer being developed in other Galenica
            programs.</p>
            <p>SuperGen will be responsible for clinical
            development and commercialization efforts following
            mechanism of action and safety studies by Galenica
            for promising anticancer drug candidates. Galenica
            also will receive a royalty payment on all eventual
            product sales by SuperGen.</p>
            <p>According to published reports, approximately 25
            percent of all prescription drugs in the U.S. contain
            a plant-derived compound, yet less than two percent
            of the world&#146;s higher plant species have been
            studied exhaustively for therapeutic value. Galenica
            and UPCH use indigenous &quot;folk medicine&quot;
            knowledge and bioassays together with chemical
            analysis in their search for plant-derived bioactive
            compounds. Numerous plants used in indigenous
            medicine have been collected, identified and are
            being studied in the program.</p>
            <p>&quot;SuperGen is the ideal complement as a
            partner for our anticancer efforts,&quot; said Dr.
            Dante Marciani, Chief Executive Officer of Galenica.
            &quot;Our focus is on the vast potential of
            plant-based drug discovery and adjuvant development.
            Their focus is at the clinical level, and they have
            become a commercial presence in the U.S. oncology
            market.&quot;</p>
            <p>&quot;We are absolutely committed to expanding our
            portfolio of anticancer drugs, especially in the area
            of prostate cancer, and building on our philosophy of
            making strategic investments in myriad potential
            sources of future products&quot; said Dr. Joseph
            Rubinfeld, Chief Executive Officer of SuperGen.
            &quot;We are excited about the possibilities we see
            in Galenica&#146;s novel adjuvant technologies,
            natural product approach and expertise. Our goal is
            that this collaboration will add SuperGen drugs to
            the impressive list of blockbusters already derived
            from plant-based compounds.&quot;</p>
            <p>Based in Emeryville, CA, SuperGen is an emerging
            pharmaceutical company dedicated to the development
            and commercialization of products intended to treat
            life-threatening diseases, particularly cancer and
            blood cell disorders, as well as other serious
            conditions such as obesity. SuperGen is developing
            its anticancer portfolio of ten generic products and
            five enhanced or &quot;supergeneric&quot; products.
            Blood cell disorder products under development
            currently target anemias associated with chemotherapy
            and radiotherapy, renal failure and aplastic anemia.
            The company's obesity pill currently is in Phase II
            human clinical trials.</p>
            <p>Galenica Pharmaceuticals, Inc. is an emerging
            biopharmaceuticals company based in Frederick, MD.
            The company is developing preventive and therapeutic
            pharmaceuticals based on natural products.
            Galenica&#146;s initial product focus is on its
            proprietary adjuvants for use in vaccines, for both
            the animal and human health markets. Galenica&#146;s
            Adjuvant Program is developing novel synthetic and
            semi-synthetic immunotherapeutics for cancer, viral
            infections and other indications in conjunction with
            its academic collaborators. In a program with the
            Peruvian University of Cayetano Heredia in Lima,
            Peru, Galenica is screening natural products for
            anticancer, wound healing and antibacterial activity.
            The privately held company was founded by Dr. Dante
            Marciani, who previously was the first Chief
            Scientist at Cambridge Biotech Corporation, where he
            developed the following products: QS-21 (Stimulon),
            considered to be the &quot;gold standard&quot;
            adjuvant, now in Phase III clinical trials; the
            world&#146;s only commercial serological recombinant
            HIV test; and the only commercial recombinant subunit
            vaccine against a retrovirus.</p>
        </blockquote>
        <p>&nbsp; </p>
        </td>
    </tr>
    <tr>
        <td><a href="6_4.htm"><font color="#731754" size="5"><b><img
        src="../images/invesbut.gif" align="middle" border="0"
        width="21" height="20"></b></font></a><a href="6_4.htm"><font
        color="#731754" size="4"><b>Return to Press Release
        Archive</b></font></a></td>
    </tr>
</table>

<p><!--webbot bot="ImageMap"
rectangle=" (67,8) (115, 19)  ../people/5_0.htm"
rectangle=" (128,9) (191, 19)  ../product/2_0.htm"
rectangle=" (199,9) (342, 19)  ../patent/4_0.htm"
rectangle=" (347,9) (407, 19)  6_0.htm"
rectangle=" (415,10) (506, 20)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (67,8) (115, 19)  ../people/5_0.htm"
rectangle=" (128,9) (191, 19)  ../product/2_0.htm"
rectangle=" (199,9) (342, 19)  ../patent/4_0.htm"
rectangle=" (347,9) (407, 19)  6_0.htm"
rectangle=" (415,10) (506, 20)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  Rhttp://206.24.121.44/product/2_0.htm"
rectangle=" (204,11) (336, 19)  Rhttp://206.24.121.44/patent/4_0.htm"
rectangle=" (353,11) (403, 19)  Rhttp://206.24.121.44/invest/6_0.htm"
rectangle=" (420,11) (504, 19)  Rhttp://206.24.121.44/perform/3_0.htm"
src="../images/lowNAV.gif" border="0" width="530" height="31"
startspan --><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="Rhttp://206.24.121.44/perform/3_0.htm"></MAP><a
href="../_vti_bin/shtml.dll/invest/9611251.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a><!--webbot
bot="ImageMap" endspan i-checksum="15915" --> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-16</DOCNO>
<DOCOLDNO>IA046-000815-B035-379</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/9611141.htm 205.178.27.23 19970119003948 text/html 16282
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:43:04 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Fri, 22 Nov 1996 00:36:28 GMT
Content-Length: 16083
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3O/DTD HTML//EN">

<html>
<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>November 14, 1996</title>
<meta name="FORMATTER" content="Microsoft FrontPage 1.1">
</head>
<body bgcolor="#FFFFFF" link="#872659" vlink="#872659"
alink="#FFFFFF">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="Rhttp://206.24.121.44/index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="Rhttp://206.24.121.44/contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="Rhttp://206.24.121.44/search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="Rhttp://206.24.121.44/map.htm"></MAP><a
        href="../_vti_bin/shtml.exe/invest/9611141.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a></td>
    </tr>
    <tr>
        <td><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.exe/invest/9611141.htm/map1"><img
        src="images/6_4_top.gif" width="307" ismap
        usemap="#FrontPageMap1" height="81" border="0"></a><br>
        <font color="#800040" size="2"><sup><strong><img
        src="images/6_4_bottom.gif" width="60" height="22"></strong></sup></font><font
        color="#800040" size="4"><sup><strong>NOVEMBER 14, 1996</strong></sup></font></td>
    </tr>
</table>
<table border="0" width="530">
    <tr>
        <td>
        <p align="center"><font size="4"><b>SuperGen, Inc.
        Reports Third Quarter Results</b></font> </p>
        <blockquote>
            <p>EMERYVILLE, CA (November 14, 1996) -- SuperGen,
            Inc. (Nasdaq: SUPG &amp; SUPGW), an emerging
            pharmaceutical company, today reported financial
            results for the quarter ended September 30, 1996.
            Total operating expenses for the quarter increased to
            $3,379,340 in 1996 from $1,018,356 in 1995. Operating
            expenses for the quarter ended September 30, 1996
            reflect non-recurring charges of approximately
            $900,000, including $442,000 for in-process research
            and development costs related to product
            acquisitions. Revenues were $11,195, compared to no
            revenues in the same quarter last year. The net loss
            for the quarter was $3,120,699 ($0.19 per share),
            compared to $988,745 ($0.08 per share) in last year's
            period. As of September 30, 1996, SuperGen had
            $16,657,028 in cash and cash equivalents.</p>
            <p>For the nine months ended September 30, 1996, the
            company had operating expenses of $6,265,984 and a
            net loss of $5,674,311 ($0.36 per share). This
            compares to operating expenses of $3,207,819 and a
            net loss of $3,034,682 ($0.24 per share) in the first
            nine months of 1995.</p>
            <p>During the quarter, SuperGen acquired the rights
            to market three generic anticancer drugs from Barr
            Laboratories and also signed a letter of intent to
            acquire development stage anticancer drugs from
            Inflazyme Pharmaceuticals. Just before the close of
            the quarter, the company also acquired exclusive
            North American rights to pentostatin (trade name
            &quot;Nipent&quot;) from Warner-Lambert Company.</p>
            <p>&quot;The close of this quarter marked a turning
            point for us that is central to our overall strategy
            -- early product revenues -- which we already are
            beginning to see during the fourth quarter,&quot;
            said Joseph Rubinfeld, Ph.D., SuperGen's Chief
            Executive Officer. &quot;With the further acquisition
            of pentostatin and the continuing growth of our sales
            team, SuperGen now has sales from four commercial
            products that establishes our presence in the
            anticancer market. We also continue to keep pace on
            the rapid development of the proprietary products for
            cancer, anemias and obesity which represent our
            long-term potential.&quot;</p>
            <p>Based in Emeryville, CA, SuperGen is an emerging
            pharmaceutical company dedicated to the development
            and commercialization of products intended to treat
            life-threatening diseases, particularly cancer and
            blood cell disorders, as well as other serious
            conditions such as obesity. SuperGen is developing
            its anticancer portfolio of ten generic products and
            five enhanced or &quot;supergeneric&quot; products.
            Blood cell disorder products under development
            currently target anemias associated with chemotherapy
            and radiotherapy, renal failure and aplastic anemia.
            The company<font face="WP TypographicSymbols">'</font>s
            obesity pill currently is in Phase II human clinical
            trials.</p>
        </blockquote>
        <p>&#160; </p>
        </td>
    </tr>
    <tr>
        <td><a href="6_4.htm"><font color="#731754" size="5"><b><img
        src="../images/invesbut.gif" align="middle" border="0"
        width="21" height="20"></b></font></a><a href="6_4.htm"><font
        color="#731754" size="4"><b>Return to Press Release
        Archive</b></font></a></td>
    </tr>
</table>
<p><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="Rhttp://206.24.121.44/perform/3_0.htm"></MAP><a href="../_vti_bin/shtml.exe/invest/9611141.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-17</DOCNO>
<DOCOLDNO>IA046-000815-B036-36</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/9611121.htm 205.178.27.23 19970119004020 text/html 21542
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:43:32 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Sat, 16 Nov 1996 00:26:34 GMT
Content-Length: 21343
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3O/DTD HTML//EN">

<html>
<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>November 12, 1996</title>
<meta name="FORMATTER" content="Microsoft FrontPage 1.1">
</head>
<body bgcolor="#FFFFFF" link="#872659" vlink="#872659"
alink="#FFFFFF">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="Rhttp://206.24.121.44/index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="Rhttp://206.24.121.44/contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="Rhttp://206.24.121.44/search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="Rhttp://206.24.121.44/map.htm"></MAP><a
        href="../_vti_bin/shtml.exe/invest/9611121.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a></td>
    </tr>
    <tr>
        <td><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.exe/invest/9611121.htm/map1"><img
        src="images/6_4_top.gif" width="307" ismap
        usemap="#FrontPageMap1" height="81" border="0"></a><br>
        <font color="#800040" size="2"><sup><strong><img
        src="images/6_4_bottom.gif" width="60" height="22"></strong></sup></font><font
        color="#800040" size="4"><sup><strong>NOVEMBER 12, 1996</strong></sup></font></td>
    </tr>
</table>
<table border="0" width="530">
    <tr>
        <td>
        <p align="center"><font size="4"><b>SuperGen, Inc.
        Appoints Rajesh Shrotriya, M.D. As Senior Vice President</b></font></p>
        <blockquote>
            <p>EMERYVILLE, CA (November 12, 1996) &#150;
            SuperGen, Inc., an emerging pharmaceutical company,
            today announced that Rajesh Shrotriya, M.D., has
            joined the company as Senior Vice President. Dr.
            Shrotriya will provide direction for SuperGen&#146;s
            scientific planning and operations.</p>
            <p>Prior to joining SuperGen, Dr. Shrotriya, 52, was
            Vice President and Chief Medical Officer of MGI
            Pharma, Inc., where he was responsible for setting
            and implementing overall strategy for the clinical
            development of compounds in the fields of oncology,
            rheumatology and others; evaluating licensing
            opportunities; and providing technical support to
            marketing and sales. Previously, he spent 18 years at
            Bristol-Myers Squibb Company, most recently as
            Executive Director, Worldwide CNS Clinical Research.
            He also has served as a Medical Advisor to Hoechst
            Pharmaceuticals, and as an attending physician and
            member of the faculty at St. Joseph Hospital in
            Stamford, CT.</p>
            <p>&quot;Raj Shrotriya is an exciting addition to our
            team as SuperGen moves to the next level,&quot; said
            Joseph Rubinfeld, Ph.D., SuperGen's Chairman and
            Chief Executive Officer. &quot;Raj and I have enjoyed
            extraordinary success together before at
            Bristol-Myers International Division, and we are
            looking forward to even greater success at
            SuperGen.&quot;</p>
            <p>Dr. Shrotriya has filed numerous Investigational
            New Drug applications (INDs), New Drug Applications
            (NDAs) and Supplemental New Drug Applications (SNDAs)
            with the U.S. Food and Drug Administration and
            internationally, as well as directed the development
            of several novel pharmaceutical compounds through all
            phases of human clinical trials. He is an author of
            more than 35 scientific or medical publications, and
            has been awarded U.S. and international patents. In
            addition to his M.D., he received a certificate for
            Advanced Biomedical Research Management from Harvard
            University.</p>
            <p>Based in Emeryville, CA, SuperGen is a
            pharmaceutical company dedicated to the development
            and commercialization of products intended to treat
            life-threatening diseases, particularly cancer and
            blood cell disorders, as well as other serious
            conditions such as obesity. SuperGen is developing
            its anticancer portfolio of ten generic products and
            five enhanced or &quot;supergeneric&quot; products.
            Blood cell disorder products under development
            currently target anemias associated with chemotherapy
            and radiotherapy, renal failure and aplastic anemia.
            The company&#146;s obesity pill currently is in Phase
            II human clinical trials.</p>
            <p><font size="2"><i>This press release contains
            forward looking statements that involve certain risks
            and uncertainties associated with a development stage
            pharmaceutical company. Actual results could differ
            materially from those projected in the forward
            looking statements as a result of the risk factors
            discussed in SuperGen</i></font><font size="2"
            face="WP TypographicSymbols"><i>'</i></font><font
            size="2"><i>s reports on file with the U.S.
            Securities Exchange Commission (including but not
            limited to the report on Form 10-Q for the quarter
            ended June 30, 1996).</i></font> </p>
        </blockquote>
        <p>&#160; </p>
        </td>
    </tr>
    <tr>
        <td><a href="6_4.htm"><font color="#731754" size="5"><b><img
        src="../images/invesbut.gif" align="middle" border="0"
        width="21" height="20"></b></font></a><a href="6_4.htm"><font
        color="#731754" size="4"><b>Return to Press Release
        Archive</b></font></a></td>
    </tr>
</table>
<p><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="Rhttp://206.24.121.44/perform/3_0.htm"></MAP><a href="../_vti_bin/shtml.exe/invest/9611121.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-18</DOCNO>
<DOCOLDNO>IA046-000815-B036-95</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/9610021.htm 205.178.27.23 19970119004053 text/html 13261
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:43:57 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Sat, 16 Nov 1996 00:25:43 GMT
Content-Length: 13062
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3O/DTD HTML//EN">

<html>
<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>October 2, 1996</title>
<meta name="FORMATTER" content="Microsoft FrontPage 1.1">
</head>
<body bgcolor="#FFFFFF" link="#872659" vlink="#872659"
alink="#FFFFFF">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td>
        <p align="left"><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="Rhttp://206.24.121.44/index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="Rhttp://206.24.121.44/contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="Rhttp://206.24.121.44/search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="Rhttp://206.24.121.44/map.htm"></MAP><a
        href="../_vti_bin/shtml.exe/invest/9610021.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a></p>
        </td>
    </tr>
    <tr>
        <td>
        <p align="left"><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.exe/invest/9610021.htm/map1"><img
        src="images/6_4_top.gif" width="307" ismap
        usemap="#FrontPageMap1" height="81" border="0"></a><br>
        <font color="#800040" size="2"><sup><strong><img
        src="images/6_4_bottom.gif" width="60" height="22"></strong></sup></font><font
        color="#800040" size="4"><sup><strong>OCTOBER 2, 1996</strong></sup></font></p>
        </td>
    </tr>
</table>
<table border="0" width="530">
    <tr>
        <td>
        <p align="center"><font size="4"><b>SUPERGEN RECEIVES
        PATENT ALLOWANCE FOR EXTRA</b><sup><b>TM</b></sup><b>
        TECHNOLOGY</b></font></p>
        <p align="center"><font size="4"><b>-- Technology Used In
        Formulation Of &quot;Supergeneric&quot; Anticancer Drugs
        --</b></font></p>
        <blockquote>
            <p>EMERYVILLE, CA (October 2, 1996) -- SuperGen, Inc.
            (Nasdaq: SUPG &amp; SUPGW), a development stage
            pharmaceutical company, today announced it has
            received a U.S. patent allowance for its proprietary
            Extra<sup>TM</sup> technology for use in the
            reformulation of anticancer drugs. SuperGen currently
            is applying this technology to five existing
            anticancer drugs: mitomycin, doxorubicin,
            daunorubicin, paclitaxel and cisplatin. The company's
            first drug in this area, MitoExtra<sup>TM</sup>,
            currently is in Phase II human clinical trials.</p>
            <p>SuperGen believes its Extra<sup>TM</sup>
            technology may significantly enhance the safety
            profile and handling characteristics of certain
            existing anticancer drugs by providing stable,
            ready-to-inject solutions that diminish the handling
            risks for health care providers that are associated
            with mixing current powder formulations prior to
            injection, and by diminishing the ulceration risks to
            patients by &quot;shielding&quot; the drug at the
            injection site.</p>
            <p>&quot;Supergenerics are the second tier of our
            three-tiered product strategy and this patent
            allowance solidifies our dominant ownership of the
            product area,&quot; said Joseph Rubinfeld, Ph.D.,
            SuperGen's Chairman and Chief Executive Officer.
            &quot;With our strong proprietary position we intend
            to expand the use of this technology beyond our
            initial five product targets.&quot;</p>
            <p>Based in Emeryville, CA, SuperGen is a development
            stage pharmaceutical company dedicated to the
            development and commercialization of products
            intended to treat life-threatening diseases,
            particularly cancer and blood cell disorders, as well
            as other serious conditions such as obesity. SuperGen
            is developing its anticancer portfolio of ten generic
            products and five enhanced or
            &quot;supergeneric&quot; products. Blood cell
            disorder products under development currently target
            anemias associated with chemotherapy and
            radiotherapy, renal failure and aplastic anemia. The
            company's obesity pill currently is in Phase II human
            clinical trials.</p>
            <p><font size="2"><i>This press release contains
            forward looking statements that involve certain risks
            and uncertainties associated with a development stage
            pharmaceutical company. Actual results could differ
            materially from those projected in the forward
            looking statements as a result of the risk factors
            discussed in SuperGen</i></font><font size="2"
            face="WP TypographicSymbols"><i>'</i></font><font
            size="2"><i>s reports on file with the U.S.
            Securities Exchange Commission (including but not
            limited to the report on Form 10-Q for the quarter
            ended June 30, 1996).</i></font></p>
        </blockquote>
        <p>&#160; </p>
        </td>
    </tr>
    <tr>
        <td><a href="6_4.htm"><font color="#731754" size="5"><b><img
        src="../images/invesbut.gif" align="middle" border="0"
        width="21" height="20"></b></font><font color="#731754"
        size="4"><b>Return to Press Release Archive</b></font></a></td>
    </tr>
</table>
<p><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="Rhttp://206.24.121.44/perform/3_0.htm"></MAP><a href="../_vti_bin/shtml.exe/invest/9610021.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-19</DOCNO>
<DOCOLDNO>IA046-000815-B036-127</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/9610011.htm 205.178.27.23 19970119004109 text/html 24041
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:44:25 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Wed, 20 Nov 1996 02:49:40 GMT
Content-Length: 23842
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3O/DTD HTML//EN">

<html>
<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>October 1, 1996</title>
<meta name="FORMATTER" content="Microsoft FrontPage 1.1">
</head>
<body bgcolor="#FFFFFF" link="#872659" vlink="#872659"
alink="#FFFFFF">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td>
        <p align="left"><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="Rhttp://206.24.121.44/index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="Rhttp://206.24.121.44/contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="Rhttp://206.24.121.44/search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="Rhttp://206.24.121.44/map.htm"></MAP><a
        href="../_vti_bin/shtml.exe/invest/9610011.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a></p>
        </td>
    </tr>
    <tr>
        <td>
        <p align="left"><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.exe/invest/9610011.htm/map1"><img
        src="images/6_4_top.gif" width="307" ismap
        usemap="#FrontPageMap1" height="81" border="0"></a><br>
        <font color="#800040" size="2"><sup><strong><img
        src="images/6_4_bottom.gif" width="60" height="22"></strong></sup></font><font
        color="#800040" size="4"><sup><strong>OCTOBER 1, 1996</strong></sup></font></p>
        </td>
    </tr>
</table>
<table border="0" width="530">
    <tr>
        <td>
        <p align="center"><font size="4"><strong>SUPERGEN
        ACQUIRES ANTICANCER DRUG FROM WARNER-LAMBERT</strong></font></p>
        <p align="center"><font size="4"><b>-- Pentostatin, Trade
        Name &quot;NIPENT&quot;, Will Be Sold By SuperGen In U.S.
        And Canada --</b></font></p>
        <blockquote>
            <p>EMERYVILLE, CA (October 1, 1996) &#150; SuperGen,
            Inc. (Nasdaq: SUPG &amp; SUPGW), a development stage
            pharmaceutical company, today announced it has
            acquired exclusive rights to the anticancer drug
            pentostatin in the United States, Canada and Mexico
            from Warner-Lambert Company.</p>
            <p>SuperGen acquired pentostatin, sold under the
            trade name NIPENT, for an undisclosed cash payment
            and shares of SuperGen common stock. While precise
            terms were not disclosed, SuperGen said the equity
            payment is significantly below one percent of the
            company&#146;s outstanding shares.</p>
            <p>Pentostatin currently has regulatory clearance in
            the U.S. and elsewhere for the treatment of hairy
            cell leukemia, for which the drug has been granted
            Orphan Drug status by the U.S. Food and Drug
            Administration. Orphan Drug status also has been
            granted for its use in chronic lymphocytic leukemia.
            The total U.S. market for drugs used in the treatment
            of these two diseases is estimated at $65 million of
            1996. Pentostatin also currently is in Phase II human
            clinical studies for rheumatoid arthritis, the most
            prevalent autoimmune disease.</p>
            <p>&quot;This is an extremely positive development
            for SuperGen on a number of levels,&quot; said Joseph
            Rubinfeld, Ph.D., SuperGen&#146;s Chairman and
            Executive Officer. &quot;Pentostatin becomes the
            fourth drug we can immediately market through our
            oncology sales force. Senior members of our clinical
            development team previously had been intimately
            involved with the development of the drug, and see
            enormous promise in its full potential. Finally, this
            acquisition fits SuperGen&#146;s model of taking time
            out of the equation in bringing products to
            market.&quot;</p>
            <p>Based in Emeryville, CA., SuperGen is a
            development stage pharmaceutical company dedicated to
            the development and commercialization of products
            intended to treat life-threatening diseases,
            particularly cancer and blood cell disorders, as well
            as other serious conditions such as obesity. SuperGen
            is developing its anticancer portfolio of nine
            generic products and five enhanced or
            &quot;supergeneric&quot; products. Blood cell
            disorder products under development currently target
            anemias associated with chemotherapy and
            radiotherapy, renal failure and aplastic anemia. The
            company&#146;s obesity pill currently is in Phase II
            human clinical trial.</p>
            <p>&#160;</p>
        </blockquote>
        </td>
    </tr>
    <tr>
        <td><a href="6_4.htm"><font color="#731754" size="5"><b><img
        src="../images/invesbut.gif" align="middle" border="0"
        width="21" height="20"></b></font></a><a href="6_4.htm"><font
        color="#731754" size="4"><b>Return to Press Release
        Archive</b></font></a></td>
    </tr>
</table>
<p><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="Rhttp://206.24.121.44/perform/3_0.htm"></MAP><a href="../_vti_bin/shtml.exe/invest/9610011.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-20</DOCNO>
<DOCOLDNO>IA046-000815-B036-170</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_4_7.htm 205.178.27.23 19970119004154 text/html 10144
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:45:07 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 17 Oct 1996 21:26:49 GMT
Content-Length: 9946
</DOCHDR>
<HTML><HEAD>   <TITLE>August 27, 1996</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map3"><AREA SHAPE="rect" COORDS="117,37,310,62" HREF="6_0.htm"><AREA SHAPE="rect" COORDS="26,66,253,83" HREF="6_4.htm"></MAP><IMG ISMAP         SRC="images/6_4_7.gif" WIDTH=307 HEIGHT=101 BORDER=0         ALIGN=left usemap="#map3">      </TD></TR></TABLE><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=550>   <TR>      <TD>         <P><TABLE BORDER=0 CELLPADDING=1 WIDTH=530>            <TR>               <TD>                  <BLOCKQUOTE><P ALIGN=CENTER><B><FONT SIZE=4>Inflazyme                  Signs Letter Of Intent To License Anti-Cancer Drugs                  To SuperGen</FONT></B>                                    <P><FONT SIZE=4>VANCOUVER, BC and EMERYVILLE, CA                  (August 27, 1996) -- Inflazyme Pharmaceuticals Ltd.                  (Vancouver Stock Exchange: IZP) and SuperGen, Inc.                  (Nasdaq: SUPG &amp; SUPGW) jointly announced today                  that the two companies have signed a letter of                  intent that grants SuperGen exclusive worldwide                  rights to anti-cancer and all other applications,                  except inflammation, of certain Inflazyme                  technologies and drugs.</FONT>                                    <P><FONT SIZE=4>Inflazyme stated that preclinical                  studies of its drugs have shown effectiveness                  against lung, colon and skin cancers, as well as                  lymphomas and leukemias.  Additionally, certain of                  the drugs target multi-drug resistant (MDR) cancers                  that no longer respond to available therapies.                   Based on results to date, the companies said U.S.                  human clinical trials could begin as early as                  1997.</FONT>                                    <P><FONT SIZE=4>While the terms of the agreement                  have been defined, they were not specifically                  disclosed.  The companies said the license granted                  to SuperGen is based on a combination of equity                  investment in Inflazyme's common stock, milestone                  payments and royalties to Inflazyme on net product                  sales.  The final licensing agreement between the                  companies remains subject to mutual review, which                  is expected be completed within 60 days.</FONT>                                    <P><FONT SIZE=4>"We are convinced that SuperGen is                  an excellent partner for Inflazyme's oncology                  opportunities since that is one of SuperGen's                  primary areas of focus," said Hassan Salari, Ph.D.,                  President and CEO of Inflazyme.  "Our primary focus                  remains inflammation, and we retain those rights.                   We are confident that due diligence for the final                  agreement can proceed quickly."</FONT>                                    <P><FONT SIZE=4>"Inflazyme's compounds can be a                  strong addition to our growing pipeline of                  anti-cancer drugs, expanding our existing tier of                  proprietary, value-added products," said Joseph                  Rubinfeld, Ph.D., President and CEO of SuperGen.                   "The value Inflazyme has already built into these                  drugs is consistent with our strategy of entering                  the game at the 50-yard line and allows us to                  leverage our core strengths in clinical                  development."</FONT>                                    <P><FONT SIZE=4>Based in Emeryville, CA, SuperGen                  is a development stage pharmaceutical company                  dedicated to the development and commercialization                  of products intended to treat life-threatening                  diseases, particularly cancer and blood cell                  disorders, as well as other serious conditions such                  as obesity.  SuperGen is developing its anticancer                  portfolio of nine generic products and five                  enhanced or "supergeneric" products.  Blood cell                  disorder products under development currently                  target anemias associated with chemotherapy and                  radiotherapy, renal failure and aplastic anemia.                   The company's obesity pill currently is in Phase II                  human clinical trials.</FONT>                                    <P><FONT SIZE=4>Inflazyme Pharmaceuticals is a                  biopharmaceutical company specializing in the                  design, discovery and commercialization of novel                  generations of drugs which combat such major                  diseases as asthma, allergies, arthritis and                  numerous other illnesses categorized as                  inflammatory diseases.  The company's proprietary                  small-molecule pharmaceuticals are the products of                  its own Transcription Factor-based drug development                  programs involving the utilization,                  synergistically, of a variety of combinatorial                  chemistry, molecular modeling, and structural                  synthesizing and screening techniques.  Inflazyme's                  existing world-patented 50-compound family of                  drugs, capable of functioning as both therapeutics                  and preventatives, have exhibited efficacies,                  potencies and durations-of-action which are                  significantly greater than steroids, yet cause none                  of the pervasive side effects which steroids                  typically produce.  Because of their universal                  applicability and ready adaptability to delivery                  via inhaler or in pill, powder or syrup form, the                  company's proprietary compounds are projected to                  replace steroids as first-line therapies for the                  management of a wide variety of inflammatory                  diseases.  Inflazyme's current lead drugs are                  Apanol for asthma, Tiesole for allergies, and                  Bispan for arthritis.  In its search for                  anti-inflammatory drugs, the company has also                  discovered a novel generation of small molecules                  that may provide treatment for various cancer                  types, which are the subject of the license                  agreement with SuperGen.</FONT>                                    <P><FONT SIZE=4>	</FONT>                                    <P><FONT SIZE=4>This press release contains forward                  looking statements that involve certain risks and                  uncertainties associated with a development stage                  pharmaceutical company.  Actual results could                  differ materially from those projected in the                  forward looking statements as a result of the risk                  factors discussed in SuperGen's reports on file                  with the U.S. Securities Exchange Commission                  (including but not limited to the report on Form                  10-Q for the quarter ended June 30, 1996).</FONT>                  </BLOCKQUOTE>                                    <P>&nbsp;               </TD></TR>            <TR>               <TD>                  <P><B><FONT SIZE=5 COLOR="#731754"><A HREF="6_4.htm"><IMG                  SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20                  BORDER=0                  ALIGN=middle></FONT><FONT SIZE=4 COLOR="#731754">Return                  to Press Release Archive</A></FONT></B>               </TD></TR>         </TABLE>      </TD></TR></TABLE><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-21</DOCNO>
<DOCOLDNO>IA046-000815-B036-207</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/9608141.htm 205.178.27.23 19970119004212 text/html 25601
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:45:29 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Fri, 20 Dec 1996 02:20:28 GMT
Content-Length: 25402
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>August 14, 1996</title>
<meta name="FORMATTER" content="Microsoft FrontPage 2.0">
</head>

<body stylesrc="6_4_7.htm" bgcolor="#FFFFFF" link="#872659"
vlink="#872659" alink="#FFFFFF">

<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,51) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,110) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,26) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (396,1) (440, 12)  ../people/5_0.htm"
        polygon=" (344,11) (374,2) (391,16) (394,30) (371,37) (368,61) (349,59) (341,33) (344,11) ../people/5_0.htm"
        rectangle=" (435,51) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,110) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,26) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  ../product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) ../product/2_0.htm"
        rectangle=" (393,114) (525, 124)  ../patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) ../patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) 6_0.htm"
        rectangle=" (196,30) (282, 41)  ../perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) ../perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  ../Default.htm"
        rectangle=" (9,46) (81, 61)  ../contact.htm"
        rectangle=" (10,62) (80, 77)  ../search.htm"
        rectangle=" (10,78) (79, 93)  ../map.htm"
        rectangle=" (435,54) (495, 65)  Rhttp://206.24.121.44/product/2_0.htm"
        polygon=" (406,27) (424,46) (428,72) (407,94) (386,90) (385,84) (369,66) (369,61) (371,38) (406,27) Rhttp://206.24.121.44/product/2_0.htm"
        rectangle=" (393,114) (525, 124)  Rhttp://206.24.121.44/patent/4_0.htm"
        polygon=" (330,75) (366,64) (384,86) (390,110) (366,134) (334,126) (325,103) (330,75) Rhttp://206.24.121.44/patent/4_0.htm"
        rectangle=" (205,75) (271, 96)  Rhttp://206.24.121.44/invest/6_0.htm"
        polygon=" (313,56) (329,74) (324,102) (327,110) (313,123) (286,117) (273,91) (279,65) (313,56) Rhttp://206.24.121.44/invest/6_0.htm"
        rectangle=" (196,30) (282, 41)  Rhttp://206.24.121.44/perform/3_0.htm"
        polygon=" (291,28) (323,16) (338,34) (345,58) (330,72) (313,54) (290,61) (286,49) (291,28) Rhttp://206.24.121.44/perform/3_0.htm"
        rectangle=" (8,2) (105, 25)  Rhttp://206.24.121.44/index.htm"
        rectangle=" (9,46) (81, 61)  Rhttp://206.24.121.44/contact.htm"
        rectangle=" (10,62) (80, 77)  Rhttp://206.24.121.44/search.htm"
        rectangle=" (10,78) (79, 93)  Rhttp://206.24.121.44/map.htm"
        src="../images/newnav.gif" align="left" border="0"
        hspace="0" width="528" height="136" startspan --><MAP NAME="FrontPageMap"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="396, 1, 440, 12" HREF="../people/5_0.htm"><AREA SHAPE="POLYGON" COORDS="344, 11, 374, 2, 391, 16, 394, 30, 371, 37, 368, 61, 349, 59, 341, 33, 344, 11" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="435, 51, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 110, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 26, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="../product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="../patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="../perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="../Default.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="../contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="../search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="../map.htm"><AREA SHAPE="RECT" COORDS="435, 54, 495, 65" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="POLYGON" COORDS="406, 27, 424, 46, 428, 72, 407, 94, 386, 90, 385, 84, 369, 66, 369, 61, 371, 38, 406, 27" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="393, 114, 525, 124" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="POLYGON" COORDS="330, 75, 366, 64, 384, 86, 390, 110, 366, 134, 334, 126, 325, 103, 330, 75" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="205, 75, 271, 96" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="POLYGON" COORDS="313, 56, 329, 74, 324, 102, 327, 110, 313, 123, 286, 117, 273, 91, 279, 65, 313, 56" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="196, 30, 282, 41" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="POLYGON" COORDS="291, 28, 323, 16, 338, 34, 345, 58, 330, 72, 313, 54, 290, 61, 286, 49, 291, 28" HREF="Rhttp://206.24.121.44/perform/3_0.htm"><AREA SHAPE="RECT" COORDS="8, 2, 105, 25" HREF="Rhttp://206.24.121.44/index.htm"><AREA SHAPE="RECT" COORDS="9, 46, 81, 61" HREF="Rhttp://206.24.121.44/contact.htm"><AREA SHAPE="RECT" COORDS="10, 62, 80, 77" HREF="Rhttp://206.24.121.44/search.htm"><AREA SHAPE="RECT" COORDS="10, 78, 79, 93" HREF="Rhttp://206.24.121.44/map.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/9608141.htm/map"><img
        align="left" src="../images/newnav.gif" width="528" ismap
        usemap="#FrontPageMap" hspace="0" height="136" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="5823" --></td>
    </tr>
    <tr>
        <td><!--webbot bot="ImageMap"
        rectangle=" (30,67) (252, 80)  6_4.htm"
        rectangle=" (118,40) (306, 60)  6_0.htm"
        rectangle=" (30,67) (252, 80)  6_4.htm"
        rectangle=" (118,40) (306, 60)  6_0.htm"
        src="images/6_4_top.gif" border="0" width="307"
        height="81" startspan --><MAP NAME="FrontPageMap1"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="30, 67, 252, 80" HREF="6_4.htm"><AREA SHAPE="RECT" COORDS="118, 40, 306, 60" HREF="6_0.htm"></MAP><a
        href="../_vti_bin/shtml.dll/invest/9608141.htm/map1"><img
        src="images/6_4_top.gif" width="307" ismap
        usemap="#FrontPageMap1" height="81" border="0"></a><!--webbot
        bot="ImageMap" endspan i-checksum="25849" --><br>
        <font color="#800040" size="2"><sup><strong><img
        src="images/6_4_bottom.gif" width="60" height="22"></strong></sup></font><font
        color="#800040" size="4"><sup><strong>AUGUST 14, 1996</strong></sup></font></td>
    </tr>
</table>

<table border="0" width="530">
    <tr>
        <td><blockquote>
            <p align="center"><font size="4"><b>SuperGen, Inc.
            Reports Second Quarter Results</b></font></p>
            <p>EMERYVILLE, CA (August 14, 1996) -- SuperGen, Inc.
            (Nasdaq: SUPG &amp; SUPGW), a development stage
            pharmaceutical company, today reported financial
            results for the quarter ended June 30, 1996. Total
            operating expenses for the quarter increased to
            $1,670,180 in 1996 from $945,371 in 1995. Revenues
            were $16,473, compared to $9,779 in the same quarter
            last year. The net loss for the quarter was
            $1,394,652 ($0.08 per share), compared to $907,902
            ($0.07 per share) in last year&#146;s period. As of
            June 30, 1996, SuperGen had approximately $20,760,000
            in cash and cash equivalents. The cash balance
            includes approximately $2,900,000 net to the company
            from the exercise of the underwriters' overallotment
            option in April, 1996 subsequent to SuperGen's
            initial public offering.</p>
            <p>For the six months ended June 30, 1996, the
            company had operating expenses of $2,886,644 and a
            net loss of $2,553,612 ($0.17 per share). This
            compares to operating expenses of $2,189,463 and a
            net loss of $2,045,937 ($0.17 per share) in the first
            six months of 1995.</p>
            <p>During the quarter, SuperGen began Phase II human
            clinical trials for its antiobesity pill, RF1051, and
            also received Orphan Drug Status for the drug in the
            treatment of Prader-Willi Syndrome. Phase I trials
            were begun for the company's first
            &quot;supergeneric&quot; anticancer drug. Just after
            the close of the quarter, the company announced it
            has acquired the rights to market three additional
            generic anticancer drugs already cleared by the FDA,
            and will begin marketing these drugs during the third
            quarter.</p>
            <p>&quot;We now have 19 drugs in our pipeline, all of
            which are well beyond the stage of basic
            research,&quot; said Joseph Rubinfeld, Ph.D.,
            SuperGen&#146;s Chief Executive Officer.
            &quot;Despite having accelerated the timetable for
            our first product revenues from generics and for
            eventual overall profitability, we nevertheless
            continue to manage our operating loss in the interim.
            We believe our cash burn and per share results remain
            exemplary for a company at our stage.&quot;</p>
            <p>Based in Emeryville, CA, SuperGen is a development
            stage pharmaceutical company dedicated to the
            development and commercialization of products
            intended to treat life-threatening diseases,
            particularly cancer and blood cell disorders, as well
            as other serious conditions such as obesity. SuperGen
            is developing its anticancer portfolio of nine
            generic products and five enhanced or
            &quot;supergeneric&quot; products. Blood cell
            disorder products under development currently target
            anemias associated with chemotherapy and
            radiotherapy, renal failure and aplastic anemia. The
            company&#146;s obesity pill currently is in Phase II
            human clinical trials.</p>
        </blockquote>
        </td>
    </tr>
    <tr>
        <td><a href="6_4.htm"><font color="#731754" size="5"><b><img
        src="../images/invesbut.gif" align="middle" border="0"
        width="21" height="20"></b></font></a><a href="6_4.htm"><font
        color="#731754" size="4"><b>Return to Press Release
        Archive</b></font></a></td>
    </tr>
</table>

<p><!--webbot bot="ImageMap"
rectangle=" (67,8) (115, 19)  ../people/5_0.htm"
rectangle=" (128,9) (191, 19)  ../product/2_0.htm"
rectangle=" (199,9) (342, 19)  ../patent/4_0.htm"
rectangle=" (347,9) (407, 19)  6_0.htm"
rectangle=" (415,10) (506, 20)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (67,8) (115, 19)  ../people/5_0.htm"
rectangle=" (128,9) (191, 19)  ../product/2_0.htm"
rectangle=" (199,9) (342, 19)  ../patent/4_0.htm"
rectangle=" (347,9) (407, 19)  6_0.htm"
rectangle=" (415,10) (506, 20)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  ../product/2_0.htm"
rectangle=" (204,11) (336, 19)  ../patent/4_0.htm"
rectangle=" (353,11) (403, 19)  6_0.htm"
rectangle=" (420,11) (504, 19)  ../perform/3_0.htm"
rectangle=" (128,11) (186, 19)  Rhttp://206.24.121.44/product/2_0.htm"
rectangle=" (204,11) (336, 19)  Rhttp://206.24.121.44/patent/4_0.htm"
rectangle=" (353,11) (403, 19)  Rhttp://206.24.121.44/invest/6_0.htm"
rectangle=" (420,11) (504, 19)  Rhttp://206.24.121.44/perform/3_0.htm"
src="../images/lowNAV.gif" border="0" width="530" height="31"
startspan --><MAP NAME="FrontPageMap2"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="67, 8, 115, 19" HREF="../people/5_0.htm"><AREA SHAPE="RECT" COORDS="128, 9, 191, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="199, 9, 342, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="347, 9, 407, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="415, 10, 506, 20" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="../product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="../patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="../perform/3_0.htm"><AREA SHAPE="RECT" COORDS="128, 11, 186, 19" HREF="Rhttp://206.24.121.44/product/2_0.htm"><AREA SHAPE="RECT" COORDS="204, 11, 336, 19" HREF="Rhttp://206.24.121.44/patent/4_0.htm"><AREA SHAPE="RECT" COORDS="353, 11, 403, 19" HREF="Rhttp://206.24.121.44/invest/6_0.htm"><AREA SHAPE="RECT" COORDS="420, 11, 504, 19" HREF="Rhttp://206.24.121.44/perform/3_0.htm"></MAP><a
href="../_vti_bin/shtml.dll/invest/9608141.htm/map2"><img
src="../images/lowNAV.gif" width="530" ismap
usemap="#FrontPageMap2" height="31" border="0"></a><!--webbot
bot="ImageMap" endspan i-checksum="15916" --> </p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-22</DOCNO>
<DOCOLDNO>IA046-000815-B036-249</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_4_6.htm 205.178.27.23 19970119004228 text/html 7314
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:45:48 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Tue, 27 Aug 1996 19:57:28 GMT
Content-Length: 7116
</DOCHDR>
<HTML><HEAD>   <TITLE>July 25, 1996</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map3"><AREA SHAPE="rect" COORDS="117,37,310,62" HREF="6_0.htm"><AREA SHAPE="rect" COORDS="26,66,253,83" HREF="6_4.htm"></MAP><IMG ISMAP         SRC="images/6_4_6.gif" WIDTH=307 HEIGHT=101 BORDER=0         ALIGN=left usemap="#map3">      </TD></TR></TABLE><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=550>   <TR>      <TD>         <P><TABLE BORDER=0 CELLPADDING=1 WIDTH=530>            <TR>               <TD>                  <P><B><FONT SIZE=4>SuperGen, Inc. Acquires Rights                  To Market Three Anticancer Products</FONT></B>                                    <BLOCKQUOTE><P><FONT SIZE=4>EMERYVILLE, CA (July                  25, 1996) -- SuperGen, Inc., a development stage                  pharmaceutical company, announced it has acquired                  the non-exclusive rights to market three generic                  anticancer products from Barr Laboratories, Inc. of                  Pomona, NY. The products, which will be                  manufactured by Barr Laboratories and distributed                  by SuperGen, are oral formulations of Methotrexate,                  Megestrol acetate and calcium Leucovorin (in two                  different tablet dosage forms). The combined total                  market for these products in the United States                  currently is estimated at approximately $110                  million.</FONT>                                    <P><FONT SIZE=4>SuperGen expects to begin marketing                  these products under its own labelling, with Barr                  manufacturing imprints, as early as September or                  October of this year, representing SuperGen's first                  revenues from product sales. SuperGen also has                  filed with the FDA for marketing clearance of its                  own generic version of the anticancer drug                  Mitomycin-C.</FONT>                                    <P><FONT SIZE=4>"The Barr products allow us to                  implement our near-term strategy right now," said                  Joseph Rubinfeld, Ph.D., SuperGen's Chief Executive                  Officer. "We'll have even earlier market presence,                  an expanded early product line and earlier product                  revenues. This essentially represents an                  acceleration of what was already an aggressive                  timetable for our first tier of drugs."</FONT>                                    <P><FONT SIZE=4>Based in Emeryville, CA, SuperGen                  is a development stage pharmaceutical company                  dedicated to the development and commercialization                  of products intended to treat life-threatening                  diseases, particularly cancer and blood cell                  disorders, as well as other serious conditions such                  as obesity. SuperGen is developing its anticancer                  portfolio of six generic products and five enhanced                  or "supergeneric" products. The company currently                  anticipates marketing clearance of its first                  generic drug, mitomycin C, in late 1996. In April,                  1996 the company announced the initiation of Phase                  I human trials with MitoExtra, its first                  supergeneric reformulation of an anticancer drug.                  SuperGen's blood cell disorder products under                  development, all in Phase I/II human trials, target                  anemias associated with chemotherapy and                  radiotherapy, renal failure and aplastic anemia.                  The company's obesity pill currently is in Phase II                  human clinical trials for general obesity and has                  been granted Orphan Drug Status for chronic genetic                  obesity.</FONT>                                    <P><FONT SIZE=4>This press release contains forward                  looking statements that involve certain risks and                  uncertainties associated with a development stage                  pharmaceutical company. Actual results could differ                  materially from those projected in the forward                  looking statements as a result of the risk factors                  discussed in the company's reports on file with the                  U.S. Securities Exchange Commission (including but                  not limited to the report on Form 10-Q for the                  quarter ended March 31, 1996).</FONT></BLOCKQUOTE>                                    <P>&nbsp;               </TD></TR>            <TR>               <TD>                  <P><B><FONT SIZE=5 COLOR="#731754"><A HREF="6_4.htm"><IMG                  SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20                  BORDER=0                  ALIGN=middle></FONT><FONT SIZE=4 COLOR="#731754">Return                  to Press Release Archive</A></FONT></B>               </TD></TR>         </TABLE>      </TD></TR></TABLE><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-23</DOCNO>
<DOCOLDNO>IA046-000815-B036-280</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_4_5.htm 205.178.27.23 19970119004242 text/html 6254
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:46:03 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Tue, 27 Aug 1996 19:57:16 GMT
Content-Length: 6056
</DOCHDR>
<HTML><HEAD>   <TITLE>May 28, 1996</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map3"><AREA SHAPE="rect" COORDS="117,37,310,62" HREF="6_0.htm"><AREA SHAPE="rect" COORDS="26,66,253,83" HREF="6_4.htm"></MAP><IMG ISMAP         SRC="images/6_4_5.gif" WIDTH=307 HEIGHT=101 BORDER=0         ALIGN=left usemap="#map3">      </TD></TR></TABLE><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=530>   <TR>      <TD>         <P ALIGN=CENTER><B><FONT SIZE=4>SuperGen, Inc. Appoints Hank         Settle As Chief Financial Officer</FONT></B>                  <P ALIGN=CENTER><FONT SIZE=4>&nbsp;</FONT>                  <BLOCKQUOTE><P><FONT SIZE=4>EMERYVILLE, CA (May 28, 1996) --         SuperGen, Inc. (Nasdaq: SUPG &amp; SUPGW), a development         stage pharmaceutical company, announced the appointment of         Hank Settle as Chief Financial Officer. Mr. Settle, 48,         previously was a partner at Ernst &amp; Young LLP, where he         advised emerging growth companies in life sciences and other         high technology industries. Prior to joining SuperGen, he         was an independent financial consultant.</FONT>                  <P><FONT SIZE=4>"As SuperGen matures from development stage         status, we will continue to create an infrastructure and         management team of the highest caliber and accomplishment,"         said Joseph Rubinfeld, Ph.D., SuperGen's Chairman and Chief         Executive Officer.</FONT>                  <P><FONT SIZE=4>From 1992 to 1995, Mr. Settle was a partner         in Ernst &amp; Young's High Technology practice in Palo         Alto. Prior to that, he was a partner in the firm's Tokyo         office for five years, and also was a member of its         International Mergers and Acquisition Network. He began his         career in 1974 in Ernst &amp; Young's San Diego office,         where he headed the group specializing in emerging         businesses.</FONT>                  <P><FONT SIZE=4>Mr. Settle received his MBA in Finance from         the University of California, Los Angeles.</FONT>                  <P><FONT SIZE=4>Based in Emeryville, CA, SuperGen is a         development stage pharmaceutical company dedicated to the         development and commercialization of products intended to         treat life-threatening diseases, particularly cancer and         blood cell disorders, as well as other serious conditions         such as obesity. SuperGen is developing its anticancer         portfolio of six generic products and five enhanced or         "supergeneric" products. The company currently anticipates         marketing clearance of its first generic drug, mitomycin C,         in late 1996. In April, 1996 the company announced the         initiation of Phase I human trials with MitoExtra, its first         supergeneric reformulation of an anticancer drug. SuperGen's         blood cell disorder products under development, all in Phase         I/II human trials, target anemias associated with         chemotherapy and radiotherapy, renal failure and aplastic         anemia. The company's obesity pill currently is in Phase II         human clinical trials.</FONT>                  <P><FONT SIZE=4>This press release contains forward looking         statements that involve certain risks and uncertainties         associated with a development stage pharmaceutical company.         Actual results could differ materially from those projected         in the forward looking statements as a result of the risk         factors discussed in the company's reports on file with the         U.S. Securities and Exchange Commission (including but not         limited to the report on Form 10-Q for the quarter ended         March 31, 1996).</FONT></BLOCKQUOTE>                  <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P><B><FONT SIZE=5 COLOR="#731754"><A HREF="6_4.htm"><IMG         SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=middle></FONT><FONT SIZE=4 COLOR="#731754">Return to         Press Release Archive</A></FONT></B>      </TD></TR></TABLE><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-24</DOCNO>
<DOCOLDNO>IA046-000815-B036-334</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_4_4.htm 205.178.27.23 19970119004317 text/html 5889
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:46:20 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Tue, 27 Aug 1996 23:01:46 GMT
Content-Length: 5691
</DOCHDR>
<HTML><HEAD>   <TITLE>May 20, 1996</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=top usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map3"><AREA SHAPE="rect" COORDS="117,37,310,62" HREF="6_0.htm"><AREA SHAPE="rect" COORDS="26,66,253,83" HREF="6_4.htm"></MAP><IMG ISMAP         SRC="images/6_4_4.gif" WIDTH=307 HEIGHT=101 BORDER=0         ALIGN=left usemap="#map3">      </TD></TR></TABLE><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=530>   <TR>      <TD>         <P ALIGN=CENTER><B><FONT SIZE=4>SuperGen, Inc. Receives         Orphan Drug Status For Prader-Willi Treatment</FONT></B>                  <BLOCKQUOTE><P><FONT SIZE=4>EMERYVILLE, CA (May 20, 1996) --         SuperGen, Inc. (Nasdaq: SUPG &amp; SUPGW), a development         stage pharmaceutical company, announced it has received         orphan drug status from the U.S. Food and Drug         Administration for its antiobesity pill, RF 1051, in the         treatment of Prader-Willi Syndrome (PWS). The drug currently         is in Phase I/II human trials for PWS, a rare chronic         genetic disease characterized by extreme obesity, short         stature and mental retardation affecting an estimated 15,000         persons in the U.S. RF1051 also currently is in Phase II         human trials for general obesity.</FONT>                  <P><FONT SIZE=4>Previously, the company also received orphan         drug status, as well as an orphan drug grant for development         expenses, from the FDA for its drug RF1017 for the treatment         of aplastic anemia. Orphan drug status grants the company         seven years of market exclusivity, independent of patent         protection, upon clearance of the drug for the U.S.         market.</FONT>                  <P><FONT SIZE=4>Based in Emeryville, CA, SuperGen is a         development stage pharmaceutical company dedicated to the         development and commercialization of products intended to         treat life-threatening diseases, particularly cancer and         blood cell disorders, as well as other serious conditions         such as obesity. SuperGen is developing its anticancer         portfolio of six generic products and five enhanced or         "supergeneric" products. The company currently anticipates         marketing clearance of its first generic drug, mitomycin C,         in late 1996. In April, 1996 the company announced the         initiation of Phase I human trials with MitoExtra, its first         supergeneric reformulation of an anticancer drug.</FONT>                  <P><FONT SIZE=4>SuperGen's blood cell disorder products         under development, all in Phase I/II human trials, target         anemias associated with chemotherapy and radiotherapy, renal         failure and aplastic anemia. The company's obesity pill         currently is in Phase II human clinical trials.</FONT>                  <P><FONT SIZE=4>This press release contains forward looking         statements that involve certain risks and uncertainties         associated with a development stage pharmaceutical company.         Actual results could differ materially from those projected         in the forward looking statements as a result of the risk         factors discussed in the company's reports on file with the         U.S. Securities Exchange Commission (including but not         limited to the report on Form 10-Q for the quarter ended         March 31, 1996).</FONT></BLOCKQUOTE>                  <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P><B><FONT SIZE=5 COLOR="#731754"><A HREF="6_4.htm"><IMG         SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=middle></FONT><FONT SIZE=4 COLOR="#731754">Return to         Press Release Archive</A></FONT></B>      </TD></TR></TABLE><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-25</DOCNO>
<DOCOLDNO>IA046-000815-B037-2</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_4_3.htm 205.178.27.23 19970119004344 text/html 5618
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:47:04 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Tue, 27 Aug 1996 23:02:12 GMT
Content-Length: 5420
</DOCHDR>
<HTML><HEAD>   <TITLE>May 13, 1996</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map3"><AREA SHAPE="rect" COORDS="117,37,310,62" HREF="6_0.htm"><AREA SHAPE="rect" COORDS="26,66,253,83" HREF="6_4.htm"></MAP><IMG ISMAP         SRC="images/6_4_3.gif" WIDTH=307 HEIGHT=101 BORDER=0         ALIGN=left usemap="#map3">      </TD></TR></TABLE><P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=530>   <TR>      <TD>         <P ALIGN=CENTER><B><FONT SIZE=4>SuperGen, Inc. Reports First         Quarter Results</FONT></B>                  <P ALIGN=CENTER><FONT SIZE=4>&nbsp;</FONT>                  <BLOCKQUOTE><P><FONT SIZE=4>EMERYVILLE, CA (May 13, 1996) --         SuperGen, Inc. (Nasdaq: SUPG &amp; SUPGW), a development         stage pharmaceutical company, today reported financial         results from the quarter ended March 31, 1996. Total         operating expenses for the quarter decreased to $1,216,464         in 1996 from $1,244,092 for the same period in 1995.         Revenues were $10,047, compared to $73,499 in the same         quarter last year. The net loss for the quarter was         $1,158,960 ($0.09 per share), compared to $1,138,035 ($0.09         per share) in last year's period. As of March 31, 1996,         SuperGen had approximately $19,588,000 in cash and cash         equivalents.</FONT>                  <P><FONT SIZE=4>During the quarter, SuperGen completed an         initial public offering of 3,500,000 units (each consisting         of one share of common stock and one warrant), which netted         the company approximately $18,600,000. In April, 1996, the         underwriter's exercise of its overallotment option resulted         in additional net proceeds of approximately $2,900,000         (which is not reflected in the currently reported cash         balance).</FONT>                  <P><FONT SIZE=4>"The successful IPO was a significant         financing milestone that allows us to proceed confidently in         meeting our clinical and product development milestones,"         said Joseph Rubinfeld, Ph.D., SuperGen's Chief Executive         Officer. "We already have met two of those milestones in the         beginning of the second quarter, with Phase II clearance for         our obesity pill and Phase I clearance for our supergeneric         MitoExtra."</FONT>                  <P><FONT SIZE=4>Based in Emeryville, CA, SuperGen is a         development stage pharmaceutical company dedicated to the         development and commercialization of products intended to         treat life-threatening diseases, particularly cancer and         blood cell disorders, as well as other serious conditions         such as obesity. SuperGen is developing its anticancer         portfolio of six generic products and five enhanced or         "supergeneric" products. Blood cell disorder products under         development currently target anemias associated with         chemotherapy and radiotherapy, renal failure and aplastic         anemia. The company's obesity pill currently is in Phase II         human clinical trials.</FONT>                  <P>&nbsp;</BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P><B><FONT SIZE=5 COLOR="#731754"><A HREF="6_4.htm"><IMG         SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=middle></FONT><FONT SIZE=4 COLOR="#731754">Return to         Press Release Archive</A></FONT></B>      </TD></TR></TABLE><P>&nbsp;<P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-26</DOCNO>
<DOCOLDNO>IA046-000815-B037-32</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_4_2.htm 205.178.27.23 19970119004414 text/html 5593
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:47:28 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 17 Oct 1996 21:27:23 GMT
Content-Length: 5395
</DOCHDR>
<HTML><HEAD>   <TITLE>April 18, 1996</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=top usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map3"><AREA SHAPE="rect" COORDS="117,37,310,62" HREF="6_0.htm"><AREA SHAPE="rect" COORDS="26,66,253,83" HREF="6_4.htm"></MAP><IMG ISMAP         SRC="images/6_4_2.gif" WIDTH=307 HEIGHT=104 BORDER=0         ALIGN=left usemap="#map3">      </TD></TR></TABLE><P>&nbsp;<P><TABLE BORDER=0 CELLPADDING=1 WIDTH=530>   <TR>      <TD>         <BLOCKQUOTE><P ALIGN=CENTER><B><FONT SIZE=4>SUPERGEN, INC.         BEGINS HUMAN TRIALS OF NEW ANTICANCER DRUG</FONT></B>                  <P><FONT SIZE=4>EMERYVILLE, CA (April 18, 1996) -- SuperGen,         Inc. (Nasdaq: SUPG) announced the initiation of human safety         and bioequivalency trials of MitoExtraTM, under a         company-sponsored Investigational New Drug application         cleared by the U.S. Food and Drug Administration. The trials         will be conducted at the M.D. Anderson Cancer Research         Center in Houston, Texas.</FONT>                  <P><FONT SIZE=4>MitoExtraTM is a proprietary reformulation         of the approved anticancer drug Mitomycin C, which is used         primarily to treat gastric and pancreatic cancers.         SuperGen's reformulation is based on technology designed to         improve the handling characteristics and safety profile of         Mitomycin and other anticancer drugs by enhancing the drugs'         stability in solution form and "shielding" it at the         injection site. Mitomycin and many other cytotoxic agents         can cause ulceration and local tissue damage. The current         studies will focus on a comparison of MitoExtra's biological         availability, activity and distribution with that of the         currently available formulation.</FONT>                  <P><FONT SIZE=4>"This is an important milestone in an         expanding portfolio of 'supergeneric' products being         developed at SuperGen," said Joseph Rubinfeld, Ph.D., the         company's Chief Executive Officer. "We will continue to add         to the data needed to demonstrate the value we see in our         ExtraTM technology for oncologists and patients."</FONT>                  <P><FONT SIZE=4>SuperGen previously has filed an application         with the FDA to market a generic version of Mitomycin C in         finished form.</FONT>                  <P><FONT SIZE=4>Based in Emeryville, CA, SuperGen is a         development stage pharmaceutical company dedicated to the         development and commercialization of products intended to         treat life-threatening diseases, particularly cancer and         blood cell disorders, as well as other serious conditions         such as obesity. SuperGen is developing its anticancer         portfolio of five generic products and four enhanced or         "supergeneric" products. Blood cell disorder products under         development currently target anemias associated with         chemotherapy and radiotherapy, renal failure and aplastic         anemia. The company's obesity pill currently is in Phase II         human clinical trials. </FONT></BLOCKQUOTE>      </TD></TR>   <TR>      <TD>         <P><B><FONT SIZE=5 COLOR="#731754"><A HREF="6_4.htm"><IMG         SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=middle></FONT><FONT SIZE=4 COLOR="#731754">Return to         Press Release Archive</A></FONT></B>      </TD></TR></TABLE><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-27</DOCNO>
<DOCOLDNO>IA046-000815-B037-84</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_4_1.htm 205.178.27.23 19970119004448 text/html 7296
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:47:53 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 17 Oct 1996 21:27:08 GMT
Content-Length: 7098
</DOCHDR>
<HTML><HEAD>   <TITLE>April 16, 1996</TITLE></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP><TABLEBORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH="100%">   <TR>      <TD>         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136         BORDER=0 ALIGN=left usemap="#newnav">      </TD></TR>   <TR>      <TD>         <P><MAP NAME="map3"><AREA SHAPE="rect" COORDS="117,37,310,62" HREF="6_0.htm"><AREA SHAPE="rect" COORDS="26,66,253,83" HREF="6_4.htm"></MAP><IMG ISMAP         SRC="images/6_4_1.gif" WIDTH=307 HEIGHT=104 BORDER=0         ALIGN=left usemap="#map3">      </TD></TR></TABLE><P><TABLE BORDER=0 CELLPADDING=1 WIDTH="100%">   <TR>      <TD>         <P ALIGN=CENTER><B><FONT SIZE=4>&nbsp;</FONT></B>                  <P ALIGN=CENTER><B><FONT SIZE=4>SUPERGEN, INC. GAINS IND FOR         NEW PHASE II STUDY OF OBESITY PILL</FONT></B>                  <P ALIGN=CENTER><B><FONT SIZE=4>-- New Human Studies Will         Focus On Intermittent Dosing --</FONT></B>                  <BLOCKQUOTE><P><FONT SIZE=4>EMERYVILLE, CA (April 16, 1996)         -- SuperGen, Inc. (Nasdaq: SUPG), a development stage         pharmaceutical company, announced today that its         Investigational New Drug (IND) application with the U.S.         Food and Drug Administration for a new Phase II human         clinical study of its proprietary antiobesity drug has been         cleared. The drug, "RF 1051", is administered in pill form.         RF 1051 currently is in ongoing Phase I/II human clinical         studies, under a separate IND, based on a daily dosage         schedule. The new IND was filed for concurrent trials with         an intermittent schedule of dosing every two days.</FONT>                  <P><FONT SIZE=4>The new study will involve approximately 80         patients at two sites, Evanston Hospital in Illinois and the         Orlando Clinical Center in Florida.</FONT>                  <P><FONT SIZE=4>RF 1051 is an orally administered         formulation of a human steroidal hormone which also has been         successfully tested in the ob/ob (obese) mouse and the db/db         (diabetic) mouse models. SuperGen believes that RF 1051         plays a role in the intake and output of energy, rather than         relying on appetite suppression or the stimulation of         increased metabolic activity.</FONT>                  <P><FONT SIZE=4>Under a Physician's IND, in a randomized,         double-blind crossover study with 17 obese human subjects         over a 20-week period, patients lost significantly more         weight during RF 1051 administration than during placebo         administration. Their weight loss was maintained for an         additional 10-week follow-up period.</FONT>                  <P><FONT SIZE=4>"While we believe an oral rather than         injectable drug will be critical to the success of long-term         antiobesity treatment, we also believe the least stringent         dosing schedule will have the most advantage," said Joseph         Rubinfeld, Ph.D., Chairman and Chief Scientific Officer of         SuperGen.</FONT>                  <P><FONT SIZE=4>"Results from previous human studies suggest         that RF 1051 has a serum half-life that may support         administration on less than a daily basis, and our ultimate         goal is a twice-weekly dosage regimen," Dr. Rubinfeld         continued. "No clinical side effects from RF 1051 have yet         been observed. This trial was designed to obtain preliminary         efficacy results from intermittent dosage, concurrent with         ongoing daily dosage trials, and to help us plan later-stage         clinical trials with the optimal dosing schedule."</FONT>                  <P><FONT SIZE=4>Dr. Rubinfeld cautioned that, while recently         lauded injectable approaches to obesity have garnered         enormous public attention even prior to any human data,         SuperGen's obesity pill still is in early human studies. He         said that results to date are scientifically and clinically         encouraging to the company, but that long-term patient         benefit cannot be established without further trials. He         added that initial results in humans, ob/ob mice and db/db         mice have established RF 1051 as a top priority for         SuperGen.</FONT>                  <P><FONT SIZE=4>Based in Emeryville, CA, SuperGen is a         development stage pharmaceutical company dedicated to the         development and commercialization of products intended to         treat life-threatening diseases, particularly cancer and         blood cell disorders, as well as other serious conditions         such as obesity. SuperGen is developing its anticancer         portfolio of five generic products and four enhanced or         "supergeneric" products. Blood cell disorder products under         development currently target anemias associated with         chemotherapy and radiotherapy, renal failure and aplastic         anemia.</FONT></BLOCKQUOTE>                  <P>&nbsp;      </TD></TR>   <TR>      <TD>         <P><B><FONT SIZE=5 COLOR="#731754"><A HREF="6_4.htm"><IMG         SRC="../images/invesbut.gif" WIDTH=21 HEIGHT=20 BORDER=0         ALIGN=middle></FONT><FONT SIZE=4 COLOR="#731754">Return to         Press Release Archive</A></FONT></B>      </TD></TR></TABLE><P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMGSRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottomusemap="#lowNAV"></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-28</DOCNO>
<DOCOLDNO>IA046-000815-B038-138</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_3_2.htm 205.178.27.23 19970119004911 text/html 696
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:52:32 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 05 Sep 1996 03:39:42 GMT
Content-Length: 499
</DOCHDR>
<!--This file created 9/4/96 7:39 PM by Claris Home Page version 1.0b1--><HTML><HEAD>   <TITLE>News Items</TITLE>   <X-SAS-WINDOW TOP=70 BOTTOM=624 LEFT=46 RIGHT=634></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=557 HEIGHT=288>   <TR>      <TD>         <P><FONT SIZE=4>insert article "Going for the Gold by         Burning up the Fat" - Investor's Business Daily</FONT>      </TD></TR></TABLE></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-29</DOCNO>
<DOCOLDNO>IA046-000815-B038-180</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/invest/6_3_3.htm 205.178.27.23 19970119004932 text/html 697
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:52:52 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 05 Sep 1996 03:34:40 GMT
Content-Length: 500
</DOCHDR>
<!--This file created 9/4/96 7:34 PM by Claris Home Page version 1.0b1--><HTML><HEAD>   <TITLE>News Items</TITLE>   <X-SAS-WINDOW TOP=46 BOTTOM=624 LEFT=42 RIGHT=630></HEAD><BODY BGCOLOR="#FFFFFF" LINK="#872659" ALINK="#FFFFFF"VLINK="#872659"><P><TABLE BORDER=0 CELLPADDING=1 WIDTH=557 HEIGHT=288>   <TR>      <TD>         <P><FONT SIZE=4>insert article "Rubenfield, at 62, hopes         SuperGen crowns career" - The Oakland Tribune</FONT>      </TD></TR></TABLE></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-30</DOCNO>
<DOCOLDNO>IA046-000815-B031-111</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/ 205.178.27.23 19970119002222 text/html 4481
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:25:38 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 07 Nov 1996 19:45:43 GMT
Content-Length: 4283
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>index</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<P><TABLE BORDER=0 CELLPADDING=1 WIDTH=550>
   <TR>
      <TD>
         <P><IMG SRC="images/SGlogo.GIF" WIDTH=326 HEIGHT=77
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD>
         <P><IMG SRC="images/MAINnav.GIF" WIDTH=530 HEIGHT=271
         BORDER=0 ALIGN=bottom usemap="#MAINnav">
      </TD></TR>
</TABLE>

<P><MAP NAME="MAINnav"><AREA SHAPE=poly COORDS="244,33,299,18,329,44,335,69,292,82,286,126,251,121,235,73,244,33" HREF="people/5_0.htm"><AREA SHAPE=rect COORDS="331,16,392,30" HREF="people/5_0.htm"><AREA SHAPE=poly COORDS="353,62,292,80,286,125,289,133,316,165,319,175,357,182,397,143,388,95,353,62" HREF="product/2_0.htm"><AREA SHAPE=rect COORDS="404,110,493,126" HREF="product/2_0.htm"><AREA SHAPE=poly COORDS="218,151,284,131,315,167,328,213,286,258,226,245,209,199,218,151" HREF="patent/4_0.htm"><AREA SHAPE=rect COORDS="328,224,523,239" HREF="patent/4_0.htm"><AREA SHAPE=poly COORDS="128,134,188,114,216,149,216,156,207,197,213,214,189,236,136,225,115,181,128,134" HREF="invest/6_0.htm"><AREA SHAPE=rect COORDS="13,154,109,185" HREF="invest/6_0.htm"><AREA SHAPE=poly COORDS="148,64,205,46,231,76,245,121,216,147,189,112,146,126,137,104,148,64" HREF="perform/3_0.htm"><AREA SHAPE=rect COORDS="9,69,133,84" HREF="perform/3_0.htm"></MAP>


<P><TABLE BORDER=0 CELLPADDING=1 WIDTH="100%">
   <tr valign=top>
   <td>This site is designed to be viewed with <a href="http://home.netscape.com/comprod/mirror/client_download.html">Netscape Navigator 2.0</a> or higher, or <a href="http://www.microsoft.com/ie/download/">Microsoft Internet Explorer 2.0</a> or higher, or a comparable web-browser. If you are unable to navigate through this site, you may download a version of one of these browsers by clicking on the name of the browser above. Please return to this site once you have the browser properly installed on your computer.
</td>
      <TD>
         <BLOCKQUOTE><P><B><FONT SIZE=4>Letter From Joseph Rubinfeld,
         Ph.D.,<br> CEO of SuperGen </FONT></B>
         
         <P><FONT SIZE=4>Welcome to SuperGen. We hope this web site
         will help you learn more about our company and stay in touch
         with the continuous progress we intend to make for patients,
         health care providers, our investors and our
         employees.</FONT>
         
         <P><FONT SIZE=4>SuperGen was founded to provide an
         increasing number of products that treat life-threatening
         diseases such as cancer, blood cell disorders and obesity.
         In just five years, we are well on our way to achieving
         leadership in this mission. Our company is absolutely
         focused on products and performance, and on the people and
         patents necessary to realize our vision for creating
         enduring long-term value. We invite you to explore and share
         that vision. </FONT>
         
         <P><FONT SIZE=4>Joseph Rubinfeld, Ph.D. </FONT>
         
         <P><FONT SIZE=4>Chairman and</FONT> <FONT SIZE=4>Chief
         Executive Officer</FONT>
         
         <P><B><FONT SIZE=5 COLOR="#232B68">&nbsp;</FONT></B>
         
         <P><B><FONT SIZE=5 COLOR="#232B68">S</FONT></B><FONT SIZE=4>uperGen,
         Inc. is a pharmaceutical company dedicated to the
         development and commercialization of products intended to
         treat life-threatening diseases, particularly cancer and
         blood cell (hematological) disorders, and other serious
         conditions such as obesity. SuperGen is developing its
         anticancer portfolio of nine generic products and five
         enhanced or "supergeneric" products. The Company is also
         developing a group of proprietary blood cell disorder
         products for the treatment of anemia associated with
         chemotherapy, radiotherapy, renal failure and aplastic
         anemia. SuperGen's proprietary obesity pill, which has shown
         promise in early preclinical and animal studies for chronic
         genetic obesity, general obesity and Type II diabetes, is
         currently in Phase II clinical trials.</FONT></BLOCKQUOTE>
      </TD></TR>
</TABLE>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-31</DOCNO>
<DOCOLDNO>IA008-000078-B002-367</DOCOLDNO>
<DOCHDR>
http://www.althab.com:80/index.html 206.42.104.204 19970222072128 text/html 1800
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 07:16:20 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1629
Last-modified: Thu, 16 Jan 1997 19:39:07 GMT
</DOCHDR>
<! Created with an Unregistered version of Enhanced HTML Pro http://www.enhance.co.uk/enhance/html/ >
<HEAD>
<TITLE>Altreuter and Habermehl</TITLE>
<META Name="description" Content="The Law Offices of Altreuter and Habermehl"> <META Name="keywords" Content="Law Legal Altreuter Habermehl Parker Keopsell, International Liability Update Product"> </HEAD>


<body bgcolor="FFFFFF">
<center>
<img src="althablogo.gif">
<h1>Altreuter and Habermehl</h1>
<h4>Attorneys at Law</h4>

<p>Altreuter and Habermehl is a general practice and commercial litigation law firm with a practice emphasizing products libability, international and trade law, intellectual property and computer law, insurance law and construction litigation.
<p>The firm practices throughout the state of New York, the New York metropolitan area, each of the four Federal Districts in New York, as well as in all four New York State Appellate Divisions, the New York Court of Appeals, the Second Circuit Court of Appeals and the Court of International Trade.

<hr>
<hr>

<a href="bios.html"><img border=0 src="bios.gif"></a>
<a href="pubs.html"><img border=0 src="pubs.gif"></a>
<a href="update.html"><img border=0 src="update.gif"></a>
<a href="ifocus.html"><img border=0 src="ifocus.gif"></a>
<p>
<table cellpadding=10>
<tr><td align=center><font size=2>Market Arcade Complex<br>617 Main Street<br>Buffalo, New York 14203<br>(716)853-1150<br>Fax: 853-1156</font></td>
<td align=center><font size=2>53 Wall Street<br>Fifth Floor<br>New York, New York 10005<br>(212)858-7736<br>Fax: 858-7750</font></td></tr></table>

</center>
</body>

</DOC>
<DOC>
<DOCNO>WT01-B04-32</DOCNO>
<DOCOLDNO>IA008-000078-B002-294</DOCOLDNO>
<DOCHDR>
http://www.althab.com:80/bios.html 206.42.104.204 19970222072044 text/html 3578
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 07:15:38 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3407
Last-modified: Tue, 31 Dec 1996 15:51:34 GMT
</DOCHDR>
<! Created with an Unregistered version of Enhanced HTML Pro http://www.enhance.co.uk/enhance/html/ >
<title>Altreuter and Habermehl Attorney Biographies</title>

<body bgcolor="FFFFFF">
<center>
<img src="althablogo.gif">
</center>
<h1>Attorney Biographies</h1>

<img height=175 align=left hspace=7 vpsace=10 src="bill.jpg">
<p><b>William C. Altreuter</b> focuses his practice on the litigation of complex liability matters  and catastrophic injury cases, the prosecution and defense of commercial disputes, and alternative dispute resolution. He is a member of the Defense Research Institute, the <a href="http://www.nystla.org/">New York Trial Lawyer's Association</a>, The International Association of Young Lawyers, the <a href="http://www.globalone.net/nysba/"> New York State Bar Association </a> and Erie County Bar Association. In addition, he is a member of the Federal Mediation Panel for the Western District of New York, and is an occasional legal affairs commentator for <a href="http://wings.buffalo.edu/services/wbfo/">WBFO</a>, the Buffalo area National Public Radio outlet, as well as a frequent lecturer before local, national, and international bar and professional associations.

<br clear=left>
<img height=175  align=right hspace=7 vpsace=10 src="kate.jpg">
<p align=right><b>Catherine Habermehl</b> concentrates her practice on international law and complex personal injury and insurance coverage issues. She lectures on a broad array of legal topics, including product liability issues before professional organizations, both locally and internationally. Catherine is active in the National Association of Insurance Women, the International Trade Council, and the Buffalo Lille Association. She is also Vice President Delegate for the Eastern United States in L'Association International de Jeune Avocats.

<br clear=left>

<img height=175 align=left hspace=10 vspace=10 src="michelle.jpg">
<p><br><b>Michelle Parker's</b> practice emphasizes <br>
litigation, in both state and Federal Court, and in <br>
alternative dispute resolution forums, particularly<br>
in the defense of transportation, construction, and <br>
insurance coverage disputes. Michelle is a member <br>
of the Ontario Insurance Adjusters Association.

<br clear=right>
<img height=175 align=right hspace=10 vspace=10 src="david.jpg">
<p align=right><br><br><b>David Koepsell</b> is  an intellectual property attorney who focuses primarily on computer law issues. 
 He is active in the <a href="http://www.eff.org">Electronic Frontier Foundation</a>
 and is presently at work writing his doctoral <br>dissertation, 
 <i>The Ontology of Cyberspace</i> at the <br><a href="http://www.buffalo.edu">State University of New York at Buffalo</a>

<br clear=left>
<br clear=all>
<hr>
<hr>
<center>
<a href="index.html"><img border=0 src="homebut.gif"></a>
<a href="pubs.html"><img border=0 src="pubs.gif"></a>
<a href="update.html"><img border=0 src="update.gif"></a>
<a href="ifocus.html"><img border=0 src="ifocus.gif"></a>

<p>
<table cellpadding=10>
<tr><td align=center><font size=2>Market Arcade Complex<br> 617 Main Street<br>Buffalo, New York 14203<br>(716)853-1150<br>Fax: 853-1156</font></td>
<td align=center><font size=2>53 Wall Street<br>Fifth Floor<br>New York, New York 10005<br>(212)858-7736<br>Fax: 858-7750</font></td></tr></table>

</center>
</body>

</DOC>
<DOC>
<DOCNO>WT01-B04-33</DOCNO>
<DOCOLDNO>IA008-000078-B002-308</DOCOLDNO>
<DOCHDR>
http://www.althab.com:80/pubs.html 206.42.104.204 19970222072052 text/html 2463
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 07:15:46 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2292
Last-modified: Thu, 16 Jan 1997 19:36:45 GMT
</DOCHDR>
<! Created with an Unregistered version of Enhanced HTML Pro http://www.enhance.co.uk/enhance/html/ >
<title>Altreuter and Habermehl</title>

<body bgcolor="FFFFFF">

<img src="althablogo.gif">
<h1>Publications</h1>


<p>You can order free copies of the following publications by Altreuter &amp; Habermhel attorneys via e-mail by filling out the order form at the bottom of the page.

<ul>
<li><i>Contractual Indemnification and New York Labor Law &#167; 240, </i> William C. Altreuter, Michelle Parker, New York State Bar Journal, 1995

<li><i>Limiting the Scope of the Duty to Warn, Not an Impossibility, </i> Catherine Habermehl, DRI Monograph, 1994

<li><i>Products Liability Defenses: A State-by-State Compendium (New York Chapter), </i> William C. Altreuter, DRI, 1992

</ul>
<hr>
<h4>Order Form</h4>

<form action="http://www.localnet.com/cgi-bin/formmail.pl" method=POST>
<input type = "hidden" name="recipient" value="althab@localnet.com">
<input type="hidden" name="subject" value="Response from order form">

Name:
<input size="53" type = "text" name="realame" >
<br>
Your e-mail address:
<input size="42" type = "text" name="username" >
<br>
Address:
<input size="51" type = "text" name="Address" >
<br>
City:
<input size="25" type = "text" name="City" >
State:
<input size="5" type = "text" name="State" >
Zip:
<input size="12" type = "text" name="Zip" >
<br>
Phone:
<input size="52" type = "text" name="Phone" >
<p>
<hr>
Which publication(s) are you interested in:
<input size="72" type = "text" name="Publication">

<p>

Thank you very much!
<input type="submit" value="submit">
<input type="reset" value="clear" >

<hr>
<hr>
<center>
<a href="index.html"><img border=0 src="homebut.gif"></a>
<a href="bios.html"><img border=0 src="bios.gif"></a>
<a href="update.html"><img border=0 src="update.gif"></a>
<a href="ifocus.html"><img border=0 src="ifocus.gif"></a>

<p>
<table cellpadding=10>
<tr><td align=center><font size=2>Market Arcade Complex<br>617 Main Street<br>Buffalo, New York 14203<br>(716)853-1150<br>Fax: 853-1156</font></td>
<td align=center><font size=2>53 Wall Street<br>Fifth Floor<br>New York, New York 10005<br>(212)858-7736<br>Fax: 858-7750</font></td></tr></table>
</center>

</body>

</DOC>
<DOC>
<DOCNO>WT01-B04-34</DOCNO>
<DOCOLDNO>IA008-000078-B002-325</DOCOLDNO>
<DOCHDR>
http://www.althab.com:80/update.html 206.42.104.204 19970222072103 text/html 18137
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 07:15:55 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 17965
Last-modified: Thu, 16 Jan 1997 19:37:57 GMT
</DOCHDR>
<! Created with an Unregistered version of Enhanced HTML Pro http://www.enhance.co.uk/enhance/html/ >
<title>Altreuter and Habermehl</title>

<body bgcolor="FFFFFF">

<img src="althablogo.gif">
<h1>Liability Update</h1>


<p>Altreuter &amp; Habermehl posts case law notes and brief articles of interest pertaining to the firm's practice areas on this page. Bookmark this site so that you can stay current with developments in the law.
<hr>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.5 --></head><body>LIABILITY ON THE INTERNET : INTRODUCTION (for footnotes, send us an e-mail request) c. David R. Koepsell, 1996)<p>
	The Internet promises to open up a wide new market for information
vendors.  It is estimated that online services and the Internet will comprise a
nearly 14 billion dollar industry within a year or two.  The growth of  public
consumption of online services and the Internet has been geometric.
Entreprenuers and established content providers, software companies and bold
new start-ups are clamboring for domain names and Internet connections.  The
once-wide-open frontier is being settled and these pioneers are looking to
build their fortunes on the information industry that is replacing our
industrial past.  <p>
	But this frontier has been lawless for some time.  Some groups have revelled
in the Internet's lawlessness in the understandable belief that governmental
interference should be avoided at all costs.  "That government is best which
governs least, or not at all."  However, frontiers are not as hospitable to
industry as they are to civil liberties.  The result in cyberspace is vast
areas of uncharted legal wilderness of which those who seek their fortunes on
the net are probably ill informed.  <p>
	The law of intellectual property is, as it stands, ill-equiped to protect
content and information providers seeking to peddle their wares on the net.
There is a dangerous ambiguity in the statutory and common law of copyright as
it applies to the net.  This ambiguity threatens the integrity of providers'
property claims to information distributed on networks.   <p>
<p>
BACKGROUND<p>
	Advances in technology have had a phenomenal impact upon copyright law since
its inception. In order to safeguard the exclusive rights to reproduction,
distribution and first-sale of works granted to authors under copyright law,
sweeping changes in statutory implementation and interpretation of copyright
have ocurred as reproduction and distribution of works has become easier.  For
example, the photocopying machine and recordable audio cassettes posed
potential challenges to the security of intellectual property rights, but these
advances were only a minor threat to written works and a somewhat more serious
but still negligible threat to audio works given the inherent limitations of
the technologies.  The relatively low fidelity of photocopies and analog audio
and video tapes present little threat to a copyright owner that her works will
be unlawfully reproduced beyond one generation (typically a user's own archival
or delayed viewing purposes for audio and video).  However, with the advent of
digital reproduction, new measures such as the Audio Home Recording Act of
1992<a href="int_fn.html#fn0">[1]</a> were deemed necessary.<p>
	A new threat to copyright owners' control over their works looms in the same
advance which promises a great new market for such works.  The Internet ("net")
and the proposed National Information Infrastructure ("NII") pose both such a
threat and promise.  The Internet exists now.  It is the name given the
interconnected computer networks which grew around the U.S. Army's Arpanet
developed in the late sixties and seventies.<a href="int_fn.html#fn1">[2]</a><p>
	Over the Internet countless pieces of e-mail and software travel between
computers in nearly every conceivable corner of the earth.  The NII which is
now "under construction" is the name given the foreseen nexus of current
technologies such as cable television and telephones and the Internet.<a
href="int_fn.html#fn1">[3]</a>  The NII is being constructed now by private
entities and will be run by cable, telephone and perhaps entirely new
industries.  The NII or "information superhighway" will carry all sorts of
content ranging from entertainment to raw data.  A broadband network combined
with television set-top boxes or tied into personal computers will allow users
to view movies, download books, browse countless information databanks, conduct
financial transactions, videoconference and enjoy numerous other as yet
unforeseen services.<a href="int_fn.html#fn1">[4]</a>  Clearly, such a future
holds many possible conflicts in the area of copyright law.  Some of the
sources of these conflicts are already becoming apparent through disputes
regarding the Internet.  What follows is a discussion of some of those disputes
which center around the issues of reproduction, distribution, the first sale
doctrine and transmission of copyrighted materials over the net.<p>
<p>
<u>TRADITIONALLY COPYRIGHTED MATERIALS AND THE NET</u><p>
	The net poses a number of challenges to traditional legal notions and terms
concerning copyrighted materials.  Such materials include written works such as
books and magazines, audio recordings, motion pictures, and photographs.  A
producer of any of these works may, under copyright law, reserve for herself
certain exclusive rights.<a href="int_fn.html#fn2">[5]</a>subject to sections
107 through 118, the owner of copyright under this title has the exclusive
rights to do and authorize any of the following:<p>
<p>
(1) to reproduce the copyrighted work ...<p>
(2) to prepare derivative works ...<p>
(3) to distribute copies or phonorecords of the copyrighted work ...  <p>
<p>
	The rights of a holder of a copyright may be infringed by, <u>inter</u>
<u>alia</u>, unauthorized reproduction or distribution of the copyrighted
works.  For books, photos and motion pictures, infringement is not a
complicated matter to assess.  Photocopies of  books are easy to spot and of
lower quality than originals and it is too expensive and risky for a small
printing company to pirate an entire book profitably.  Analog audio tapes also
degrade in quality from generation to generation and illegal copies are less
desirable to consumers than originals.  Moreover the unauthorized reproduction
of books, motion pictures and audio tapes is an act which is easy to locate in
time and space.  That is, a book is reproduced when it is photocopied or
typeset.  An audio tape is reproduced when it is dubbed.  Each of these is
distributed when an unauthorized reproduction is sold.  The moment of sale
implicates the distribution and the moment of copying, the reproduction.  These
concepts of reproduction and distribution are not so easily applied to
transactions over the Internet.<p>
	Take, for instance, "browsing" on the World Wide Web ("Web").  When one uses
the Mosaic or Netscape software to browse on the Web one may view text and
graphics on one's own computer the originals of which reside on another
computer which may be physically located far away but connected to the net.
The originals are <a href="int_fn.html#fn2">[6]</a>reconstructed in the local
computer's memory as it was on the server site.  This information may further
be transferred through phone lines to a user's computer through a modem.  The
information, in such a configuration exists simultaneously and identically at
the server (original site), host (the computer the user has called with his
modem), and the terminal (the user's own computer).  An author could
conceivably have a Web "site" containing an electronically typeset version of
her novel which could be browsed page-by-page on the Web.  Such a site might
look to the browser who is connecting to the site just like a page of actually
typeset text yet be entirely virtual.<a href="int_fn.html#fn2">[7]</a>  When
would such a novel be reproduced or distributed?  This question is even more
complicated if our hypothetical cyber-author decides to make the entire text
downloadable.  The browsing of the Web site involves reproducing the binary
code of the original document on the browser's computer.  It may actually
involve more than one reproduction if the user is tied into a host computer as
well as a terminal.  If such browsing is deemed to be reproduction then the law
must clarify this so that such reproductions may be liscenced as need be.  <p>
<p>
<u>DISTRIBUTION RIGHTS: THE FIRST SALE DOCTRINE</u><p>
	What is more problematic is the question of distribution.  Ordinarily,
distribution in copyright law involves the changing of hands of physical copies
of a work.  The owner of a copyright has an exclusive right in the first
distribution of a work pursuant to the so-called "first sale doctrine".<a
href="int_fn.html#fn2">[8]</a>  Once an authorized copy of a work is
distributed, however, the copyright holder has no control over subsequent
re-distribution of a work.  This doctrine protects the right of purchasers of
copyrighted works to freely alienate such legally obtained copies.  If our
hypothetical Web-novel browser is actually reading a licensed reproduction of a
distributed work may he then freely alienate that reproduction pursuant to the
first-sale doctrine?  This is an issue which remains as-yet unresolved in the
courts, but it is one which will soon need addressing as the NII takes shape.<p>
	In fact a Federal District court in the Eleventh Circuit recently ruled that
an owner of an electronic bulletin board system ("BBS") was liable for unlawful
display and distribution of copyrighted materials when he made digitized
copyrighted photographs which he unlawfully reproduced available for
downloading from his computer over the phone lines.<a
href="int_fn.html#fn2">[9]</a>  This decision made no mention of unauthorized
reproduction.  Rather, the only mention made of copying in <u>Frena</u> is
defendant's digitization of the photographs which was easily inferred through
circumstantial evidence.<a href="int_fn.html#fn3">[10]</a>  The <u>Frena</u>
court proceeded to inquire into defendant's violation of plaintiff's exclusive
public distribution and display rights.  The court glossed over the
distribution issue finding only that "[t]here is no dispute that Defendant
Frena supplied a product containing unauthorized copies of a copyrighted
work."<a href="int_fn.html#fn3">[11]</a>  This was enough to convince the court
that plaintiff's distribution rights had been infringed.  The Frena court, in
reaching this conclusion, may have opened a can of worms given the current
state of copyright law.<p>
	Returning to our hypothetical Web-novel scenario, the <u>Frena</u> decision
would make our browser the recipient of a lawful distribution of the electronic
novel.  As such a lawful recipient, she would be able to re-distribute the
lawfully obtained copy pursuant to the first-sale doctrine.<a
href="int_fn.html#fn3">[12]</a>  This result should make prospective producers
of copyrighted materials reluctant to take advantage of the net as a new and
potentially profitable marketplace because, under the <u>Frena</u> decision,
any information provided on the net may be deemed a distribution which, if
authorized by the copyright holder, would comprise a "first-sale" of the
copyrighted work.  Following such a distribution, it must be remembered, the
purchaser may freely alienate the lawfully obtained copy.  The problem with
this scenario is, given the ease with which information may be transferred on
the net, a content-provider's control over its product should extend as far as
possible.  <p>
	An information transaction on the net rarely involves the destruction of the
original copy.  When content is transferred from one site to another, as
described in the hypothetical used above, the orginal copy is generally
maintained by the producer.  Transferring information like this is more like
reproduction than distribution.  By treating these transactions as
reproductions, a copyright holder's rights over these transactions may be more
carefully safeguarded.<p>
	The plaintiffs in <u>Frena</u> probably pursued their distribution claim in
lieu of a reproduction claim because defendant's only act of reproduction was
the copying of the photographs into digitized form onto the hard drives of his
system.  The subsequent reproductions over the phone lines into other people's
computers occurred not by the acts of the defendant, but by those of the
numerous people who chose to download the pictures.  By making the distribution
claim, plaintiffs could allege that every transfer over the phone lines to the
public was an infringing act by one specific defendant rather than alleging
violations by perhaps hundred of infringers.  But the distribution analysis
puts the burden on information providers instead of where it belongs, the
consuming public.  It is like making a library liable for the unauthorized
reproductions of a borrower.  This situation will stifle the content providing
market on the Internet. <p>
	By treating such transactions as reproductions, the use of the NII and
Internet may be encouraged without the first-sale alienation problems
associated with treating such transactions as distributions.  If Web browsers
are treated as recipients of lawful distributions then, without the further
treatment of such transactions as reproductions, the recipients could
presumably establish their own Web sites which may include their lawfully
distributed copies of copyrighted information.  Others could then browse the
first-sale recipient's Web site and receive further lawful copies pursuant to
the first-sale doctrine without compensating the producer of the work.  Such a
scenario  would involve the proliferation of countless lawful copies without
benefitting the original producer.  This would clearly be a disincentive for
producers of copyrighted materials to take advantage of the Internet or the NII
as a medium for their works.  			Information transactions such as those
outlined in the hypothetical and described in <u>Frena</u> should be treated as
reproductions.  The only practical problem with treating these transactions as
reproductions is the fact that the recipients will most reasonably be
interpreted as the reproducers.  In <u>Frena</u>, this would mean plaintiffs
should have sued the recipients as well as the supplier of the infringing
information.  For most net transactions tracking down the recipients of
unlawfully reproduced information will be a herculean task compared with suing
the distributors.  But, as the law stands, the distribution of lawfully
obtained copies is legal pursuant to the first-sale doctrine while reproduction
of such copies is not.<a href="int_fn.html#fn4">[13]</a><p>
	To guard against this loop-hole which could result in the lawful proliferation
of copies without compensation to the producers as noted above, the Working
Group on Intellectual Property Rights, a sub-group of the Information
Infrastructure Task Force established by President Clinton, has proposed that
Section 109 of the Copyright Act, which embodies the first-sale doctrine, be
amended as follows:<p>
(a)(1) Notwithstanding the provisions of section 106(3), the owner of a
particular copy or phonorecord lawfully made under this title, or any person
authorized by such owner, is entitled, without the authority of the copyright
owner, to sell or otherwise dispose of the possession of that copy or
phonorecord.<p>
<p>
(2) This subsection does not apply to the sale or other disposal of the
possession of that copy or phonorecord by transmission.<a
href="int_fn.html#fn5">[14]</a><p>
<p>
This amendment is proposed pursuant to the Task Force's recognition that
transactions on the net frequently involve both the reproduction and
distribution of the reproduction simultaneously.<a
href="int_fn.html#fn6">[15]</a>  It would adequately resolve the difficulties
which might arise under the current copyright law as applied to the Internet
and, eventually, the NII.<p>
CONCLUSION<p>
	It is clear that, if content providers are to be encouraged to use the
Internet and the forthcoming NII to develop the emerging information economy,
the law as it stands is inadequate to protect their interests.  Software
authors and creators of other digital content must be wary of the loop-hole
described above.  They should lobby for the adoption of the Task Force's
proposed amendment.  But this amendment is a compromise of sorts.  It does not
recognize the simple fact that apparent distributions over the net are actually
reproductions.  Recognition of this fact alone would solve the dillema posed by
the law as it stands and pave the way for content providers to safely stake
their claims on this narrowing frontier.<p>
</body></html>

<hr>
<center>
<a href="index.html"><img border=0 src="homebut.gif"></a>
<a href="bios.html"><img border=0 src="bios.gif"></a>
<a href="pubs.html"><img border=0 src="pubs.gif"></a>
<a href="ifocus.html"><img border=0 src="ifocus.gif"></a>

<p>
<table cellpadding=10>
<tr><td align=center><font size=2>Market Arcade Complex<br>617 Main Street<br>Buffalo, New York 14203<br>(716)853-1150<br>Fax: 853-1156</font></td>
<td align=center><font size=2>53 Wall Street<br>Fifth Floor<br>New York, New York 10005<br>(212)858-7736<br>Fax: 858-7750</font></td></tr></table>
</center>

</body>

</DOC>
<DOC>
<DOCNO>WT01-B04-35</DOCNO>
<DOCOLDNO>IA008-000078-B002-339</DOCOLDNO>
<DOCHDR>
http://www.althab.com:80/ifocus.html 206.42.104.204 19970222072114 text/html 7136
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 07:16:07 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 6965
Last-modified: Thu, 16 Jan 1997 20:03:49 GMT
</DOCHDR>
<! Created with an Unregistered version of Enhanced HTML Pro http://www.enhance.co.uk/enhance/html/ >
<title>Altreuter and Habermehl</title>

<body bgcolor="FFFFFF">

<img src="althablogo.gif">
<h1>International Focus</h1>


<h4>Check here for frequent updates on international law and commerce</h4>




<hr>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.5 --></head><body><p>
<p>
<BR> <B> <b>TRADE AND LEGAL IMPLICATIONS OF PRIVACY ON THE NET</b><p>
William C. Altreuter<p>
<BR> </B></B></B></P></FONT> <FONT  COLOR="#"> <TAB> Although little noticed by the trade community, an important trade policy debate has been raging between the Clinton Administration and the computer industry.  Because Government regulators are able to cite "law and order" and "national security" in support of a policy which treats software which incorporates meaningful privacy protection as the equivalent of a Claymore Mine, US software developers -- and the US computer industry as a whole -- are being 
denied an opportunity to compete in what may be the most meaningful segment of the coming Internet economy.
<BR> 
<BR> <TAB> Before meaningful commerce can occur in cyberspace, there must first be a method of insuring that transactions over the Internet are secure.  Encryption offers the only feasible method for protecting the privacy of such transactions.  US law, 
however, bars the exportation of "strong" encryption software, and in fact treats the exportation of such software in the same manner as munitions.  The reasoning behind this policy is, in essence, that strong encrypted communications would not be accessible to legitimate governmental surveillance, and might therefore be used to plan terrorist activities, or commit criminal acts such as money laundering.
<BR> 
<BR> <TAB> As a compromise, several proposals have been floated, most recently a plan to allow software makers to export encryption programs with up to 56-bit code keys in exchange for an industry commitment to develop a system which would provide law enforcement officials with the encryption key in appropriate circumstances.  A previous proposed policy, "key escrow", would have placed the encryption key under the control of either a governmental agency, or some designated private agent, which would turn the key over to law enforcement authorities on demand.
<BR> 
<BR> <TAB> The flaws with either policy should be immediately obvious and go beyond the fact that the Administration's proposal for exportation of 56-bit encryption is technologically outmoded (Netscape Communications, for example, distributed a 128-bit system to US users of the Internet in July but cannot market it overseas).  As is so often the case, this wrong-headed policy is best understood by considering what US reaction would be to such a policy were it to be implemented by another nation.  Obviously, the US would never stand for an international standard for encryption which placed the key to the code in anyone else's hands, and plainly the US's trading partners feel the same way.  As a purely practical matter, there is little difference between the current proposal and its predecessor.  The dilemma here is that this is simply not an area where US law will succeed in jamming US policy down the throats of the rest of the world.
<BR> 
<BR> <TAB> Because the Internet knows no international borders, powerful encryption programs are already widely available.  By artificially hobbling the ability of US software developers to compete in this area, US policy is effectively cutting off its own manufactures' ability to be competitive in a growth segment of the global economy.  Ironically, this is occurring because the most trade-friendly Administration the US has seen in years has adopted, on this issue, a police-state mentality that would earn outspoken condemnation from the same Administration were it to be enacted by any other government.
<BR> 
<BR> <TAB> Encryption policy is unlikely to be the sort of issue which will ever excite heated debate in the halls of Congress, since the specter of bomb-carrying terrorists using the Internet to undermine national security is easier to explain than is the importance of confidentiality in business communications.
<BR> 
<BR> <TAB> As a purely practical matter, however, the effect of this policy is to badly undermine the use of the Internet as a tool for international trade.  For example, current encryption standards seriously compromise the ability of lawyers and clients 
to communicate privately via E-mail, even though the lawyer-client principle is a bedrock concept in American jurisprudence.
<BR> 
<BR> <TAB> More importantly, the Administration's policy on encryption hamstrings the ability of US software developers to compete internationally by imposing an artificial constraint on a technological problem.  Assuredly, the vacuum that is created by 
this short-sighted thinking will be filled.  It is almost as certain that this vacuum will be filled to the detriment of a segment of the economy where the US has long held dominance.
<BR> 
<BR> <TAB> The Clinton Administration has demonstrated that it is both technologically savvy, and in favor of open trade.  This is clearly not an issue where Congress is likely to be helpful, since it is plainly complex, and susceptible to the sort of negative spin which legislators abhor.  We are not likely to attend any pancake breakfasts where our congressional representatives will boast of making the Internet secure, but it is a safe bet that a vote against strong encryption will be presented as a 
vote which gives terrorists and criminals a new tool to defeat law enforcement efforts.  Just because this is a patently absurd  argument doesn't make it any less likely to be used as a fear-mongering electoral gambit.  Altreuter & Habermehl  invites all interested readers of International Focus to E-mail a copy of this essay, along with your own thoughts to Vice President Gore at <I>agore@whitehouse.gov</I> in the hope that a demonstration of our concerns will compel a re-thinking of a policy which is antithetical to the principles of free trade, economic development, and privacy which are essential to the development of electronic commerce.</FONT>
</body></html>

<hr>
<center>
<a href="index.html"><img border=0 src="homebut.gif"></a>
<a href="bios.html"><img border=0 src="bios.gif"></a>
<a href="update.html"><img border=0 src="update.gif"></a>
<a href="pubs.html"><img border=0 src="pubs.gif"></a>

<p>
<table cellpadding=10>
<tr><td align=center><font size=2>Market Arcade Complex<br>617 Main Street<br>Buffalo, New York 14203<br>(716)853-1150<br>Fax: 853-1156</font></td>
<td align=center><font size=2>53 Wall Street<br>Fifth Floor<br>New York, New York 10005<br>(212)858-7736<br>Fax: 858-7750</font></td></tr></table>
</center>

</body>



</DOC>
<DOC>
<DOCNO>WT01-B04-36</DOCNO>
<DOCOLDNO>IA008-000078-B002-278</DOCOLDNO>
<DOCHDR>
http://www.althab.com:80/ 206.42.104.204 19970222072036 text/html 1800
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 07:15:31 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1629
Last-modified: Thu, 16 Jan 1997 19:39:07 GMT
</DOCHDR>
<! Created with an Unregistered version of Enhanced HTML Pro http://www.enhance.co.uk/enhance/html/ >
<HEAD>
<TITLE>Altreuter and Habermehl</TITLE>
<META Name="description" Content="The Law Offices of Altreuter and Habermehl"> <META Name="keywords" Content="Law Legal Altreuter Habermehl Parker Keopsell, International Liability Update Product"> </HEAD>


<body bgcolor="FFFFFF">
<center>
<img src="althablogo.gif">
<h1>Altreuter and Habermehl</h1>
<h4>Attorneys at Law</h4>

<p>Altreuter and Habermehl is a general practice and commercial litigation law firm with a practice emphasizing products libability, international and trade law, intellectual property and computer law, insurance law and construction litigation.
<p>The firm practices throughout the state of New York, the New York metropolitan area, each of the four Federal Districts in New York, as well as in all four New York State Appellate Divisions, the New York Court of Appeals, the Second Circuit Court of Appeals and the Court of International Trade.

<hr>
<hr>

<a href="bios.html"><img border=0 src="bios.gif"></a>
<a href="pubs.html"><img border=0 src="pubs.gif"></a>
<a href="update.html"><img border=0 src="update.gif"></a>
<a href="ifocus.html"><img border=0 src="ifocus.gif"></a>
<p>
<table cellpadding=10>
<tr><td align=center><font size=2>Market Arcade Complex<br>617 Main Street<br>Buffalo, New York 14203<br>(716)853-1150<br>Fax: 853-1156</font></td>
<td align=center><font size=2>53 Wall Street<br>Fifth Floor<br>New York, New York 10005<br>(212)858-7736<br>Fax: 858-7750</font></td></tr></table>

</center>
</body>

</DOC>
<DOC>
<DOCNO>WT01-B04-37</DOCNO>
<DOCOLDNO>IA080-000557-B034-238</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/ 137.79.14.197 19970103071212 text/html 718
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f27b.317@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:17:15 GMT
Last-Modified: Thursday, 20-Jul-95 23:16:18 GMT
Content-type: text/html
Content-length: 473
</DOCHDR>
<TITLE>Homepage Menu</title>
<CENTER>
<H2>Robotics & Mars Exploration Technology Program</h2>
<H1>HOMEPAGE MENU</h1><p>
<img src="Chuck.GIF">Charles R. Weisbin, Manager<p>
<img src="Lori.GIF">Lori Mooradian, Secretary<p>
</CENTER>
<p>
<p>
<img src="bullet.gif">Click here to access the <a href="TRProgram.html">Rover and Telerobotics Technology Homepage</a><p>

<img src="bullet.gif">Click here to access the <a href="mars.html">Mars Exploration Technology Homepage</a><p>
</DOC>
<DOC>
<DOCNO>WT01-B04-38</DOCNO>
<DOCOLDNO>IA080-000557-B034-256</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/TRProgram.html 137.79.14.197 19970103071222 text/html 8549
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f286.318@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:17:26 GMT
Last-Modified: Monday, 29-Jan-96 18:05:06 GMT
Content-type: text/html
Content-length: 8305
</DOCHDR>
<TITLE>JPL ROVER AND TELEROBOTICS PROGRAM</title>
<img src="logo.gif"><p>
<H1>ROVER AND TELEROBOTICS PROGRAM:</h1>
<H2><I>ACCOMPLISHMENTS AND TECHNOLOGY TRANSFER - January 1996</i></h2><img src="TRGRP2.GIF"><img src="ROVGRP2.GIF">
<H2>Point of Contact:	C. R. Weisbin, Program Manager</h2>
<H4>					Charles.R.Weisbin@jpl.nasa.gov</h4>

<H3>INTRODUCTION</h3>
The JPL Rover and Telerobotics Technology Program, sponsored by the National Aeronautics and Space Administration (NASA), responds to opportunities presented by NASA space missions and systems, and seeds commercial applications of the emerging robotics technology.  The primary goals of the JPL program, listed below, are derived from the overall NASA Telerobotics Program goals.<p>
<blockquote>
<B><I>Develop, integrate, and demonstrate the science and technology of remote telerobotics leading to increases in operational capability, safety, cost effectiveness, and probability of success of NASA missions<p>
Develop and demonstrate the required technology so that a significant number of operations in Earth orbit and on planetary surfaces may be conducted telerobotically.</b></i><p>
</blockquote>
The scope of the JPL Rover and Telerobotics Technology program ranges from basic research, through synthesis of complete systems, and to evaluation in realistic ground and flight experiments.  Emerging technologies have important dual uses in support of NASA thrusts in space and in such commercial areas as medical robotics.  <p>
The Rover and Telerobotics Technology Program comprises four major segments of activity:  robotic systems for planetary exploration, robotic systems for on-orbit servicing tasks, robotic systems for terrestrial and commercial applications, and technology for non-NASA sponsors, Significant technical achievements have been reached in each of these areas, including complete telerobotic system prototypes that have been built and tested in realistic scenarios relevant to prospective users.  In addition, the program has conducted complementary basic research and created innovative technology and terrestrial applications, as well as enabled a variety of commercial spin-offs.<p>
The Rover and Telerobotics Technology Program is an element of NASA's ongoing research program under the Office of Space Access and Technology.  Universities and industrial partners are major participants in the JPL program.  An operating division of the California Institute of Technology, JPL performs research, development, and related activities for NASA and plays a key role as NASA's lead center for the robotic exploration of space.<p>
This summary provides selected highlights of the technical achievements of the JPL program.  <p>
<img src="bullet.gif"><a href="Planetrobs.html"><B>Planetary Robotics:</b></a>This segment of the Rover and Telerobotics Technology Program develops robots to satisfy the planned requirements for exploring planetary surfaces:  Exploring potential landing sites and areas of scientific interest, placing science instruments, and gathering samples for analysis and possible return to Earth.  the robots for such operations will require high levels of local autonomy, including the ability to perform local navigation, identify areas of potential scientific  interest, regulate onboard resources, and schedule activities --all with limited ground command intervention.  These robots must be low-cost and miniaturized to satisfy stringent mass and volume constraints.  Specific applications include the Mars Pathfinder Project and the Mars surveyor Program.  Technology developed for planetary rovers will also enable technological options for other efforts such as inner-planet and small-body exploration.<p>
<a href="ExRobs.html"><B>Exploration Robotics:  Archive</b></a><p>
<img src="bullet.gif"><a href="Platformrobs.html"><B>Platform Robotics:</b></a>
This segment of the Rover and Telerobotics Technology Program develops technology for application to on-orbit satellite and large-platform servicing by both free-flying and platform-attached servicing robots.  The target applications emphasize ground control and include such tasks as remote surface inspection of Earth-orbiting platforms using telerobotic systems, and dual-arm autonomous manipulator control for free-flying servicing (such as the Ranger Flight Experiment).<p>
<a href="Servicing.html"><B>On-orbit servicing:  Archive</b></a><p>
<img src="bullet.gif"><a href="Techcom.html"><B>Technology Commercialization:</b></a>This segment of the Rover and Telerobotics Technology Program provides a means to test and demonstrate space-targeted technologies in realistic terrestrial settings and additionally includes tasks intended to rapidly move program-developed technology to commercial applications.  These tasks are jointly conducted by JPL and industrial partners to create and demonstrate full-system prototypes that offer solutions to terrestrial problems; such solutions can positively impact significant areas of the national economy.  Illustrative initiatives include a micromanipulator for retinal surgery and advanced manipulator control methods for high-precision robots.<p>
<a href="TerrComm.html"><B>Terrestrial and Commercial Applications:  Archive</b></a><p>
<img src="bullet.gif"><a href="Non-NASA.html"><B>Non-NASA Tasks:</b></a>
This segment of the Rover and Telerobotics Technology Program --typically about 20 percent of the total program-- develops technologies in areas of national importance, in support of non-NASA sponsors.  Examples are machine vision for autonomous ground vehicles, and biologically inspired vehicles.  These technologies have important concurrent applications to NASA missions.<p>
<a href="Comptech.html"><B>Component technology:  Archive</b></a><p>
<a href="Spinoffs.html"><B>Spin-offs and Commercialization:  Archive</b></a><p>

<H3>CONCLUSIONS</h3>
While the JPL Rover and Telerobotics Program has built a record of substantial achievement, important technical and programmatic challenges remain.  The ultimate goal is to build autonomous robots that can significantly assist humans in space and that can, with little direct human intervention, explore remote planetary surfaces.<p>

<H4>Near-Term Technical and Programmatic Goals</h4>
<UL>
<LI>Enable next-generation affordable rover missions to Mars (for example, as part of Mars Surveyor Program)<p>
<LI>Reduce landed mass over Mars Pathfinder rover of at least a factor of two (demonstrate feasibility of a less-than-5-kilogram rover).<p>
<LI>Achieve higher science return in rover missions by enabling many short-to-medium range traverses, active and passive power management, and effective science site exploration and sampling.  Such tasks would include confirming and mapping science targets, retrieving fresh rock and other samples, and accurate deployment and pointing of instruments.<p>
<LI>Enable ground controls of dexterous telerobotics operating in Earth-orbiting missions and flight experiments, such as teh space shuttle and the space station.
</ul>
<H4>Long-Term Challenges</h4>
<UL>
<LI>Develop a robot explorer with the ability to autonomously confirm goal success, combine skills to achieve complex tasks, and learn and discover new and important information.
<LI>Fly a human-like robot that can autonomously retrieve, service, and repair satellites in Earth orbit, incorporating the capabilities of three-dimensional autonomous navigation, vision- and touch-guided rendezvous and docking, and satellite grappling.<p>
</ul>
An important future goal is to broaden the range of applications of telerobotics in space.  Emphasis on manipulators for servicing tasks and mobile robots for surface operations has resulted in significant opportunities for flight experiments and missions.  Telerobotics technology can however enable a much broader range of missions, such as Venus flyer robotis, and robotic devices for asteroid sample retrieval.  Synthesizing new classes of robot configurations for such missions, and evaluating the corresponding benefits also pose an important future challenge.  In addition, terrestrial and commercial applications will continue to be important program thrusts.<p>

More information available  from  <a href= http://robotics.jpl.nasa.gov>Automation and Control</a> Section Homepage

</DOC>
<DOC>
<DOCNO>WT01-B04-39</DOCNO>
<DOCOLDNO>IA080-000557-B034-278</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/mars.html 137.79.14.197 19970103071239 text/html 2074
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f294.319@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:17:40 GMT
Last-Modified: Monday, 05-Aug-96 17:47:56 GMT
Content-type: text/html
Content-length: 1830
</DOCHDR>
<TITLE>MARS EXPLORATION TECHNOLOGY PROGRAM PLAN</TITLE>
<CENTER>
<H1>MARS EXPLORATION TECHNOLOGY PROGRAM</h1></c><p>
<H2>C. R. Weisbin, D. Rapp, G. Rodriguez</h2></c><p>
<H3>August 1996</h3></c><p>
</center>
<img src="met.GIF">
<H5>P-46312</h5><p>
<A HREF="emphsum.html"><h3>PROGRAM EMPHASIS AND SUMMARY</h3></a><p>
<A HREF="emphsum.html#Bkgrnd">Background</a><p>
<A HREF="emphsum.html#Progemph">Program Emphasis</a><p>
<A HREF="emphsum.html#Progcont">Program Content</a><p>
 <A HREF="emphsum.html#Strat">Strategy</a><p>
<A HREF="multistones.html"><h3>MULTIYEAR TASK OVERVIEWS AND MILESTONES</h3></a>
 <A HREF="multistones.html#Progmgmt">Program Management</a><p>
 <A HREF="multistones.html#Preclndg">Precision Landing</a><p>
 <A HREF="ISPP.html">In Situ Propellant Production (ISPP)</a><p>
 <A HREF="Sampacq.html">Sample Acquisition</a><p>
 <A HREF="Isinstr.html">In Situ Instruments</a><p>
 <A HREF="Lowthide.html">Low Temperature, High Density Electronics</a><p>
 <A HREF="Thermcon.html">Thermal Control</a><p>
 <A HREF="Hiplotb.html">High Performance, Low Temperature Batteries</a><p>
 <A HREF="Smldst.html">Small Deep Space Transponder</a><p>
<p>
<H3>ACKNOWLEDGEMENTS:</h3><p>
The contributions to this plan from the leaders for the individual tasks (and their colleagues) within the MET program were essential, and are gratefully acknowledged: S. Kim, R. Manvi, N. Moore,  D. Farless, S. Rao, and P. Schenker.  Valuable contributions from the Mars Exploration Program Office at JPL were also pivotal in determining the program contents and balance; acknowledgments here are due to: S. Bailey, L. Lowry, P. Sutton, J. B. Mc Namee, and D. Shirley.<p>


More information is available on the <A HREF="http://mpfwww.jpl.nasa.gov>Mars Pathfinder</a> homepage.

<A HREF="References.html"><H3>For reference information</h3></a><p>

</DOC>
<DOC>
<DOCNO>WT01-B04-40</DOCNO>
<DOCOLDNO>IA080-000557-B034-296</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Planetrobs.html 137.79.14.197 19970103071251 text/html 26411
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f2a1.320@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:17:53 GMT
Last-Modified: Thursday, 15-Feb-96 18:01:25 GMT
Content-type: text/html
Content-length: 26164
</DOCHDR>
<TITLE> PLANETARY ROBOTICS 1/96</title>
<img src="logo.gif"><H3>Rover and Telerobotics Technology Program</h3><p>
<H1>PLANETARY ROBOTICS</h1><p>
<A NAME="segment">In this segment:</a>
<UL>
<LI><A HREF="#MoSciLab">Mobile Science Laboratory</a>
<LI><A HREF="#MiniTech">Rover Miniaturization and Survival Technology</a>
<LI><A HREF="#Nanorovers">Nanorovers</a>
<LI><A HREF="#MarsYard">JPL MarsYard</a>
<LI><A HREF="#MarsLandexMan">Mars Lander Dexterous Manipulator</a>
<LI><A HREF="#Aerobots">Aerobots</a>
<LI><A HREF="#SmallBodies">Exploration of Small Bodies</a>
<LI><A HREF="#EPMActuators">Electrostrictive Polymer Muscle Actuators</a><p>
</ul>
Other Segments on this homepage:
<UL>
<LI><A HREF="Platformrobs.html">Platform Robotics</a>
<LI><A HREF="Techcom.html">Technology Commercialization</a>
<LI><A HREF="Non-NASA.html">Non-NASA Tasks</a>
</ul><p>
<A HREF="Menu.html">Back to Main Menu</a><p>
<B>========================================</b><p>
<A NAME="MoSciLab"><H3>Mobile Science Laboratory</h3></a><p>
JPL is developing small robotic rovers for planetary surface exploration.  The Microrover flight Experiment on the Mars Pathfinder mission (scheduled to arrive at Mars in 1997) is a focused rover flight demonstration program.  In parallel, research and technology development are being conducted to expand the current capabilities of these microrovers, while further reducing their mass and power consumption.  The rover technology efforts have two major thrusts:  Science rover development and miniaturized rovers.<p>
<CENTER>
<img src="Rocky7.GIF"><p>
<H5>JPL-26482 Ac</h5><p>
<H4>Rocky 7, a next-generation microrover with low-power stereovision.</h4><p>
</center>
The Mobile Science Laboratory task develops technologies that enable 20-kilogram-class microrovers to autonomously traverse many kilometers on the surface of Mars, perform scientist-directed experiments, and return relevant data back to Earth.  Present microrover technology has several limitations precluding more ambitious science-rich missions.  Current microrovers have very limited traverse capability (tens of meters), are not capable of sample acquisition and manipulation --that is, soil and rock acquisition, subsurface access, and burial of instruments-- have limited science packages on board, are designed for short-term (10-day) missions, and require careful and repetitive ground monitoring and control (limited autonomy).<p>

A complementary activity involves autonomous acquisition of multiple science targets and sites.  Given specified goal locations for daily operations, new capabilities are being developed to maximize the number of science activities that the rover system can perform between cycles of communication with Earth.  Primary among three new capabilities is autonomous goal identification, together with autonomous performance of the designated science sample acquisition task.  Onboard machine intelligence provides capabilities for autonomous search and recognition of potentially interesting targets, as well as capabilities for sensor platform planning and utilization.  Acquisition of scientific samples requires miniature sampling devices and autonomous control of them.  New robotic mechanisms are being developed to enable the performance of science tasks such as<p>
<UL>
<LI>Sensor pointing, emplacement, or burial.
<LI>Soil and rock sample acquisition and transport.
<LI>Fresh rock Exposure.
<LI>Camera positioning for scientific imaging, navigation, and vehicle self-inspection.<p>
</ul>
Recent experimental tests conducted in the JPL MarsYard reflect the status of the technology under development by the Mobile Science Laboratory task.  One such test involved an experimental microrover named Rocky 7, which has low-power stereovision, a manipulator arm, and the ability to autonomously recognize designated targets.  Rocky 7 performed a survey of a 20- x 20-meter area, in variable terrain ranging from 0.6 to 2 large obstacles per square meter.  Executing 10 science sorties, the microrover performed site imaging and soil sampling with only five command uplinks.  In each sortie, the microrover identified at least one scientific target or acquired at least one sample at designated sites, then returned to  the vicinity of the lander.  As part of the test, recovery from selected major failure modes was demonstrated.<p>

One additional goal of the Mobile Science Laboratory task is to enable and enhance rover-based scientific exploration of planetary surfaces by integrating science instruments on small rover platforms for field testing of terrestrial prototypes.  The task involves collaboration with planetary scientists to identify science instruments important to future missions, and science data reduction methods.  Two main areas are being explored:<p>
<UL>
<LI>Science instrument usage --the identification and integration of science instruments on small rover platforms for experimentation and demonstration of capabilities.
<LI>Science data analysis --computer-based characterization of data via heuristics and data analysis methods, allowing confirmation of science objectives as well as prioritization of data returned to Earth.<p>
</ul>
Closely related to these two areas is research in intelligent vision and touch-guided grasping being done in collaboration with researchers (K. Salisbury is the principal investigator) at the Massachusetts Institute of Technology.  The goal is to develop the technology required for the autonomous onboard selection of interesting rock samples, and for autonomous execution of the subsequent rock-grasp and -retrieve operation.  The capability will allow a human controller to command and operate the remote system using only relatively easy-to-use high-level commands, while relying on the remote system itself to perform the desired operation reliably.<p>
<CENTER>
<img src="r7-spec.gif"><p>
<H4>Rover-mounted spectrometer for analysis of rock and soil samples</h4><p>
<img src="computer.gif"><p>
<H4>Computer-generated model of a planetary surface and rover</h4><p>
</center>
The Mobile Science Laboratory task is also developing a ground-based operator interface and associated enabling technologies for control of planetary science missions.  The interface will enable multiple mission scientists at various locations to view downlink science and terrain data and interactively and simultaneously input desired mission tasks for the next command cycle.  These commands will be merged into a daily mission command sequence by the mission sequence planner module based on task priorities and terrain traversability.<p>

<H5><B>Point of Contact:</b>  Samad.A.Hayati@jpl.nasa.gov</h5><p>
<p>
<A HREF="#segment">Return to Segment Menu</a><p>
<B>========================================</b><p>
<A NAME="MiniTech"><H3>Rover Miniaturization and Survival Technology</h3></a><p>

The basic goal of this work is to shift the 5-kilogram microrover paradigm to one of higher-yield, longer-duration science --for both equatorial and polar Martian extremes.  Fundamental issues include<p>
<UL>
<LI>Reducing mass and volume of rover structural and actuator design.
<LI>Achieving high-density power delivery over wide thermal ranges.
<LI>Maintaining a stable thermal environment, which will facilitate use of more conventional, mass-and-volume-efficient commercial electronics.
<LI>Creating new classes of ultra-light, environmentally resistant miniaturized robotic sampling devices, including active tooling.
<LI>Controlling force-contact tasks of an ultra-light rover-manipulator platform on uneven terrain.
<LI>Integrating broad-capability science instruments into these rover architectural innovations.<p>
</ul>
In fiscal year 1996, the goal is to develop and demonstrate in ground operational configuration a new collapsible mobility architecture enabling approximate doubling of the wheel diameter of the Mars Pathfinder rover (named Sojourner), while allowing rover stowage in a smaller flight volume.  The overall design will be consistent with a target flight rover mass of 5 kilograms.  The Rover Miniaturization and Survival Technology task will evaluate the ability of the new rover to traverse up to 10 meters in simulated Mars Viking Lander-1 and -2 scenarios while using onboard navigational guidance and hazard-detection capabilities.  The task will benchmark against relevant Sojourner and Rocky 7 characteristics.<p>
<CENTER>
<img src="5kgrover.gif"><p>
<H4>Under 5-kilogram rover prototype, using Mars Pathfinder heritage.</h4><p>
</center>
The technology products resulting from the Rover Miniaturization and Survival Technology task will be valuable both to breakthrough microrover design for local operations, and the larger-scale science rovers dedicated to long-distance traverse and orbiter-based communications.  If most of these objectives can be addressed, a 5-kilogram rover would become a viable vehicle for extended-duration Mars Surveyor Program science under line-of-sight (10-100 meters), and could also provide a major technology option for a sample-return mission around 2005, particularly in the context of a likely precision landing capability by that time.<p>

In fiscal year 1995, an intensive effort was established to examine the feasibility of providing a viable near-term, low-mass, low-cost 5-kilogram rover that could be available for the Mars '98 mission of the Mars Surveyor Program.  This paradigm allows for sophisticated instrumentation on the lander, with the small rover obtaining samples and returning them to the lander.  Led by W. F. Zimmerman and B. H. Wilcox, the effort addressed the following key issues:<p>
<UL>
<LI>Mass reduction over Sojourner of at least a factor of two.
<LI>Cost reduction over Sojourner of a factor of five.
<LI>Providing minimal soil/rock retrieval and return-to-lander capability.
<LI>Providing minimal mobility capability to deploy science instruments away from the lander, on the order of 5-30 meters maximum.
<LI>Examining viable rover deployment and sample-delivery concepts.
<LI>Demonstrating target selection, sample retrieval, and return to lander using a prototype system that is within the mass and functionality envelopes.
<LI>Providing instrument/vehicle packaging concepts.<p>
</ul>
As a follow-up to this initial FY'95 effort, a longer range thrust toward miniaturization and survival technology was --- for future missions.<p>

<H5><B>Point of Contact:</b>	Pauls.S.Schenker@jpl.nasa.gov</h5><p>
<p>
<A HREF="#segment">Return to Segment Menu</a><p>
<B>========================================</b><p>
<A NAME="Nanorovers"><H3>Nanorovers</h3></a><p>
<img src="nrov.GIF"><p>
<H4>Nanorover prototype with 25-gram mobility chassis.</h4><p>
Nanorovers are small planetary surface explorers with a mass of 10-100 grams.  The principal objective of such explorers is to move about on the surface of another planet such as Mars in search of scientific and engineering resources like water ice or other volatiles, or to take photomicrographs of surface features.  The large number of such systems that can be accommodated help to enhance the overall robustness of the mission to individual failures.<p>

One concept for a nanorover is a small tracked vehicle, like a tank.  It is powered by solar cells on the top surface and has an ultra-miniaturized sensing and control package combining vision, planning, and control in a package of 1 gram or less.  It moves about in a "reactive" mode on the surface, much the same way as an insect does.  That is, if there is an obstacle on the left, it moves right, and vice versa.  If it begins to move out of the sunlight and is losing power, it changes course.  If it senses more of what it is seeking (e.g., water vapor) on one side than the other, it turns toward its goal.  Solid-state adsorption-based chemical sensing will be the principal means of scientific exploration with these devices, in addition to imaging.<p>

<H5><B>Point of Contact:</b>  Brian.H.Wilcox@jpl.nasa.gov</h5><p>
<p>
<A HREF="#segment">Return to Segment Menu</a><p>
<B>========================================</b><p>
<A NAME="MarsYard"><H3>JPL MarsYard</h3></a><p>
<img src="marsyard.gif"><p>
The MarsYard is a simulated Mars landscape developed by the JPL Rover and Telerobotics Technology Program for testing and evaluation of rovers and robotics technology for future Mars surface exploration.<p>
<CENTER>
<img src="r7inyard.GIF"><p>
<H4>Rover undergoing testing in MarsYard's simulated Mars landscape.</h4><p>
</center>
An Important part of rover and robotics development is testing of prototype systems in relevant environments.  Outdoor evaluation is particularly important as it provides natural lighting conditions and large test areas.  In the past, rover testing was done in the Arroyo Seco east of JPL but this was less than ideal as the terrain was not representative of Mars' and excessive time was spent in setting up and breaking down the equipment each day.  Development of a large outdoor test area within the bounds of JPL seemed most desirable.<p>

The MarsYard, located at the corner of Explorer and Surveyor roads near the center of the JPL Oak Grove facility, has an area of approximately 450 square meters (about 24 by 18 meters).  Decomposed granite fines (sand) material was selected as ground cover because its spectral qualities are similar to those expected on Mars.  (This is the same material used by scientists at the University of Arizona Mars Garden.)  To provide approximately 20 centimeters of cover over the entire area, 200 tons of decomposed granite were used.  A hill or sand dune was developed in the middle of the area to add variety.  To populate the area, 20 tons of volcanic rocks of different types (different colors, textures, and densities) were used.<p>

On a concrete retaining wall along the west, north, and east sides of the MarsYard is a mural depicting the Red Planet.  The mural, based on Viking Lander-1 and -2 imagery, shows a rocky plain extending to the horizon.<p>

One of the most important features of the MarsYard is the distribution of rocks based on actual Viking Lander data.  The Moore's model, a probabilistic rock density for a given rock size based on Viking Lander-1 and -2 imagery, was used to generate the rock distribution map required to lay out the volcanic rocks in the MarsYard --recreating areas like those associated with both landing sites, as well as a Mars nominal environment with theoretical average Mars rock density.  Having good models of rock distribution is critical for testing rovers of all sizes to ensure that they are able to effectively maneuver and carry out scientific exploration.<p>

<H5><B>Point of Contact:</b>  Richard.V.Welch@jpl.nasa.gov
<B>Point of Contact:</b>  Richard.A.Volpe@jpl.nasa.gov</h5><p>
<p>
<A HREF="#segment">Return to Segment Menu</a><p>
<B>========================================</b><p>
<A NAME="MarsLandexMan"><H3>Mars Lander Dexterous Manipulator</h3></a><p>

This task develops robotic capabilities for lander-based planetary exploration and emphasizes technology innovations that will reduce robotic payload mass, volume, power, and cost.  NASA's planned Mars Surveyor Program missions of 1998-2005 are possible applications, in which lander-based robots may acquire soil and rock specimens, deploy and retrieve surface instrumentation, and microscopically view and spectroscopically scan surface features of interest --often working over large lander near-field areas of 2-3-meter radius and carrying end-effector payloads over 1 kilogram.  To gain a sense of this application scale, note that the Mars '98 mission lander science package is limited to 20 kilograms, 70 liters, 25 watts (daytime average), and $20 million, and the science payload allocates 25 percent or less of these resources to a robot giving good 2-3-meter near-field coverage (a large arm) or beyond (viz., a small rover).<p>
<CENTER>
<img src="sampacq.GIF"><p>
<H4>New high-strength lightweight, composite-material robot arm.</h4><p>
</center>
Correspondingly, the Mars Lander Dexterous Manipulator task focuses on coordinated innovation in structural, electromechanical, and materials designs and their integration into minimum mass/volume/power flight engineering concept robots of potentially large reach.  One important development, in cooperation with the Massachusetts Institute of Technology, targets new flight-qualifiable miniature solid-state motors (piezoelectrically driven); another technology thrust develops new robot-arm architectures based in high-strength, lightweight composites.  The fiscal year 1995 effort has demonstrated the first such 3-degrees-of-freedom laboratory arm design.  This novel telescopically deployed arm has been utilized in a realistic laboratory simulation of Mars lander-based sample access and analysis, enabling such functions as sample microviewing, point spectrometry, and physical sample acquisition via an instrumented end-effector.  A derived flight concept for use in the Mars '98 mission has been proposed and approved.  Flight design goals include a 3.5-kilogram mass (arm and actuation), 1.5-kilogram arm payload, 2-meter reach, and gas-deployable segmented linkage allowing arm launch stowage in a volume of 10 liters or less.<p>

<H5><B>Point of Contact:</b>  Paul.S.Schenker@jpl.nasa.gov</h5><p>
<p>
<A HREF="#segment">Return to Segment Menu</a><p>
<B>========================================</b><p>
<A NAME="Aerobots"><H3>Aerobots</h3></a><p>

Planetary aerobots are an innovative, new type of lightweight and low-cost telerobot, on that can fly and navigate in planetary atmospheric environments.  The challenges of flying a planetary aerobot are providing mobility and autonomous navigation in a constantly changing three-dimensional environment --one in which the robotic vehicle is almost never stationary.  JPL has recently developed and demonstrated a balloon buoyancy control concept applicable to several planets.  This altitude  control concept employs phase change fluids such that a planet's atmosphere is used as a giant heat engine to provide the mobility energy to ascend and descend at will.  There are potential flight experiment opportunities as early as 1999 for Venus, 2001 for Mars, and 2000-2004 for Saturn's moon Titan.<p>

Planetary Aerobots will enable the acquisition of surface and atmospheric science at multiple sites designated by scientists and mission designers providing possibly global coverage over a planet surface.  there are, however, challenging technical problems in vehicle mobility, onboard perception, and autonomous control and navigation.  Technology in these areas will be demonstrated in a series of gradually more ambitious terrestrial flights.  There are also concurrent terrestrial applications to global climate and pollution studies as well as to autonomous ocean exploration.<p>
<CENTER>
<img src="Titan.GIF"><p>
<H5>P-46531Ac</h5><p>
<H4>Artist's rendering of an aerobot a flying robot, for exploring Titan</h4><p>
</center>
A proposed vehicle concept for Venus, Titan, and the outer planets is a closed-system reversible-fluid balloon that uses the atmospheric temperature difference as a function of altitude as a heat engine to provide the motive power to effect altitude change.  A reversible fluid is either a gas or a liquid, depending on pressure and temperature.  It is this phase change that can be used to control the buoyancy of a balloon system.  When the reversible fluid is in the gas phase, the balloon has a lower average density than the surrounding atmosphere, thus providing a net increase in lift.  Conversely, when the fluid is in the liquid phase, the balloon has a higher average density than the surrounding atmosphere, thus providing a negative lift.<p>

The choice of reversible fluid determines the equilibrium altitude about which the balloon system oscillates indefinitely.  However, if the liquid is sealed in a pressure vessel before the balloon drops below this equilibrium altitude, the balloon will descend to the surface or a deep atmosphere of a planet.  To control altitude range and equilibrium level, a primary balloon filled with helium or hydrogen can be combined with a secondary buoyancy-control balloon filled with a reversible fluid that allows the vehicle to go to a high equilibrium altitude.<p>
<CENTER>
<img src="Jupiter.GIF"><p>
<H5>P-46531 Ac</h5><p>
<H4>Aerobot designed with balloon buoyancy control for vertical mobility</h4><p>
</center>
By controlling vertical mobility, aerobots can select altitudes where wind speeds and directions provide them with a wide range of horizontal mobility.  This is especially true at Mars and Venus where rich altitude-variable wind gradients enable near-global planetary access.<p>

The objectives of the fiscal year 1996 program are to<p>
<UL>
<LI>Develop telerobotic control of aerobots, including vertical and horizontal mobility with landing ability and autonomous navigation using onboard flight dynamics models and sensory perception.
<LI>Construct a Planetary Aerobot Testbed vehicle for conducting a series of Earth-based demonstrations beginning with teleoperation and leading to long-range autonomous mobility.
<LI>Transfer telerobotics technology to emerging flight opportunities.
</ul>
Testing of the Planetary Aerobot Testbed vehicle will exploit the fact that Earth's troposphere at an altitude between 0 and 6 kilometers has similar temperature-versus-pressure gradients as the Venus atmosphere at an altitude of 50-60 kilometers.  Several passive, free-flight terrestrial experiments have been conducted using prototype vehicles developed by some of the researchers in a program funded by the JPL Director's Discretionary Fund.<p>

<H5><B>Point of Contact:</b>  Kerry.T.Nock@jpl.nasa.gov</h5><p>
<p>
<A HREF="#segment">Return to Segment Menu</a><p>
<B>========================================</b><p>
<A NAME="SmallBodies"><H3>Exploration of Small Bodies</h3></a><p>

Landing and operation in the low-gravity environments of small bodies are extremely challenging and require technology development in a variety of areas to ensure mission success.  The Exploration of Small Bodies task is therefore focusing on developing the technologies enabling in situ scientific studies of these interplanetary objects.  This multiyear task explores three key technology areas:<p>
<UL>
<LI>Surface and subsurface sampling.  The gathering of surface and subsurface samples for scientific exploration is an important part of such missions.  Low-mass/low-power mechanisms for sample acquisition are explored as well as concurrent development of sensors and control methods enabling autonomous operation in materials of unknown composition.
<LI>Sample manipulation.  Once a sample is acquired, it must be delivered to onboard science instruments for in situ analysis.  Systems for sample handling and sample preparation in a microgravity environment will therefore be developed.
<LI>Landing and anchoring.  The low-gravity environment of small bodies allows for free-fall and unpowered landing but requires ways of absorbing impact energy as well as attaching the lander to the surface and reacting to sampling forces.  Passive energy absorption systems such as crushable materials, as well as anchoring systems such as rocket-deployed spikes, are explored.<p>
</ul><p>
<CENTER>
<img src="comet-sampler.gif"><p>
<H4>Device for obtaining samples from the surface and subsurface of a comet.</h4><p>
</center>
In fiscal year 1995, work began by developing and testing sampling systems specific to comets to meet the technology needs of the NASA-Centre National d'Etudes Spatiales Champollion comet lander (part of the European Space Agency's International Rosetta Mission).  The comet-sampling system is required to gather several cubic centimeters of material from up to a meter beneath a comet's surface and deliver that sample to multiple onboard instruments within an extremely challenging mass/power budget.  A prototype system has been developed that incorporates multiple sensors --not only allowing autonomous operation but also gathering data on material properties as sampling is done.  A cryogenic test chamber enabling testing of a prototype sampling system in cryogenic comet facsimile materials of various densities has also been assembled.<p>

<H5><B>Point of Contact:</b>  Donald.R.Sevilla@jpl.nasa.gov</h5><p>
<p>
<A HREF="#segment">Return to Segment Menu</a><p>
<B>========================================</b><p>
<A NAME="EPMActuators"><H3>Electrostrictive Polymer Muscle Actuators</h3></a><p>

This research program is dedicated to the development of actuation technology based on electrostrictive polymers (ESP).  Efficient ESP materials and actuation mechanisms are being developed in the form of "muscles."  The goals of the program are as follows.<p>
<UL>
<LI>Demonstrate the unique and superior actuation capabilities of ESP compared to those of electrostrictive ceramics.
<LI>Establish muscle-drive mechanisms for potential application to powered space suits and for future technology transfer to meet medical requirements.<p>
</ul>
ESP materials will be developed and fabricated using a polymer combination of a backbone and a pendant group.  The pendant group, which is a polymer having a high polarity, is needed to produce the desired strong electrostriction effect.  The backbone polymer provides a large free-volume to allow easy alignment of the pendant groups in response to an activating electric field.<p>

The application of ESP involves technical challenges being addressed by this program.  Muscle drivers are currently being configured, and their performance will be demonstrated in a series of rigorous tests.  i-PMMA, reported to have a relatively high electrostriction effect, is being studied as a baseline.  To demonstrate the performance of ESP, the program will design and fabricate an arm that will be driven by ESP muscle actuators.  This arm will be designed to represent technology relevant to a flight experiment.<p>

<H5><B>Point of Contact:</b>  Yoseph.Bar-Cohen@jpl.nasa.gov</h5><p>
<A HREF="#segment">Return to Segment Menu</a><p>


</DOC>
<DOC>
<DOCNO>WT01-B04-41</DOCNO>
<DOCOLDNO>IA080-000557-B034-316</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/ExRobs.html 137.79.14.197 19970103071303 text/html 11263
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f2ac.321@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:18:04 GMT
Last-Modified: Monday, 29-Jan-96 18:06:22 GMT
Content-type: text/html
Content-length: 11018
</DOCHDR>
<TITLE>JPL EXPLORATION ROBOTICS</title>
<img src="logo.gif"><img src="Rover.GIF"><p>
<H1>EXPLORATION ROBOTICS:  ARCHIVE - DEC. 1994</h1>
<H3>PLANETARY ROVER TECHNOLOGY</h3>

<B><I>The microrovers that are currently the focus of the rover technology program draw from a large technology base in larger rovers and control strategies designed and tested in the 1980's.</i></b><p>

<B>Mars Rovers for Sample Return:  1980's View</b><p>

<B>Robby:  </b>
Robby is a six-wheeled, three-body, articulated vehicle that offers enhanced mobility compared to a conventional four-wheeled, single body vehicle.  The three-cab design allows the front and rear cabs to steer and roll with respect to the vehicle center-line, and the vehicle hinges about the center axle as well to allow the six wheels to comply to complex terrain geometry.  Figure 1 illustrates Robby navigating in outdoor terrain. 
This vehicle provided a substantial technology base in navigation and remote control to support development of the microrovers which are currently the focus of this program.  Some of these control strategies are outlined below.<p>
<img src="Robby.gif">
<H5>P-35715 Bc</h5><p>
<H4>Fig. 1 Robby, A Planetary Rover Testbed Navigating in Outdoor Terrain</h4><p>
<H5>Point of Contact:  B. H. Wilcox, wilcox@robotics.jpl.nasa.gov</h5><p>

<B>Rover Control Strategies:  </b>
Rover control and navigation is one the key technologies where JPL has made significant contributions.  Operation of rovers with some form of remote or semi-autonomous control is desirable to reduce the cost and increase the capability and safety of many types of missions.  However, the long time delays and relatively low bandwidths associated with radio communications between planets preclude a total telepresence approach to controlling the vehicle.  Different control implementations with varying degrees of human supervision can be contrasted; three of these developed at JPL are illustrated by Computer Aided Remote Driving (CARD), Semiautonomous Navigation (SAN), and Behavior Control. Each of these represents points on a continuous spectrum of human-machine interaction.  With CARD, stereo pictures from the rover are sent to Earth, where they are viewed by a human operator using a stereoscopic display.  The operator designates a path using a 3-D cursor, giving a safe path for the vehicle to follow as far ahead as the operator can see accurately in three dimensions.  A ground based computer computes the turn angles and path segment distances that correspond to the designated path.  The information is then up-linked to the rover for execution, and the process repeats.  With Semiautonomous Navigation, local routes are planned autonomously using range information obtained on the vehicle, guided by global routes planned on Earth using a topographic map which is obtained from images produced by a satellite orbiting the planet of interest.  Expectations are monitored, and a perception-planning-monitoring-execution cycle is instantiated.  In Behavior Control, an approximate range and heading to a goal location is up-linked to the vehicle which attempts to reach its destination by autonomously instantiating sensor- based reactive behaviors of varying complexity.  These might include obstacle avoidance, search for specific features, sample acquisition, etc.  Behaviors can be combined and layered to give more robust and richer overall system performance.  Important considerations in choice between alternative control techniques concern robustness, predictability, and validation for mission use on one hand, and computational, sensor, and other resource requirements on the other.<p>
<B>B. Microrovers</b><p>
In response to NASA's goals of implementing more affordable, faster, better missions, the JPL Rover and Telerobotics Technology Program has a thrust in miniature rovers to do science and exploration missions which can serve as precursors to larger robotic and possibly manned missions.  This includes a complete system (i.e. microrover, lander, and control station) developed from the outset using science requirements and potential flight constraints as drivers (plausible mass, power, communication, and computation).<p>
<B>Rocky-4:  </b>
The Rocky-4 chassis is a springless suspension system called the rocker-bogie, which consists of two pairs of rocker arms or bogies.  Each pair consists of a main rocker arm and a secondary arm whose pivot point is at the front end of the main arm.  The two rocker-arm assemblies are connected through a differential gear at the center of gravity.  The main body of the robot is mounted on the differential.  The pitch of the main body is thus the average pitch of the two rocker-arm assemblies, providing a stable mount for instruments and sensors.  Rocky-4 is 61 cm long , 38 cm  wide and 36 cm  high.  The rover has six 13 cm diameter  wheels made of strips of steel foil and cleats to provide traction.  It weighs about 7 kilograms  but eventually may have to be scaled down to 5 kg for inclusion in future missions (e.g. Mars Surveyor).  There is a motor in the hub of each wheel so the vehicle can be steered by its front or rear wheels.  The suspension system is unique in that it does not use springs and provides a great degree of stability for traversing rocky, uneven targets including rocks as high as 18 cm.  Proximity and tilt sensors are used to prevent rollover.<p>
<B>Mars Science Microrover Demonstration.  </b>
A ground based demonstration of relevant capability was performed at JPL in June 1992 using Rocky-4.  The experiment demonstrated the (a) ability to deploy a small(<150 gm) seismometer within 5-10 meters from the lander, (b) ability to acquire a soil sample and return it to the lander, (c) ability to integrate and operate a small (<500 gm) spectrometer to determine mineralogical composition, (d) ability to conduct visible imaging (camera < 150 gm) of local terrain, (e) ability to navigate in a field with rock distribution similar to that seen in the Viking 1 mission, and (f) ability to remove 10-30 microns from a weathered rock to perform spectrometry.<p>
This experiment suggested further study, several of which are currently being conducted.  These include safe operation of the rover without line-of-sight to the lander.  This involves the addition of proximity and ranging sensors on the microrover, fusion of ranging at the lander with imagery captured directly on the rover, addition of low-cost machine vision on the rover for terminal corrections, etc.  A number of technology and design measurements quantify the paths taken by the rover under various scenarios, determine designation accuracies, test macro-commanding options, measure the traversability of terrain, etc.  In addition, manipulation capability is being tested for instrument emplacement capability, surface grinding, and sample acquisition.  Improved algorithms for data compression can make a significant contribution.  Finally, tradeoffs of tether management vs. autonomy and flight electronic/software constraints needs to be further evaluated.<p>
<img src="Rocky4.gif">
<H5>JPL-19278 Ac</h5><p>
<H4>Fig. 2 Rocky 4 During Mars Science Microrover Demonstration</h4>
<H5>Point of Contact:  J. A. Cutts, james.a.cutts@jpl.nasa.gov</h5><p>

<B>MFEX:  Microrover Flight Experiment</b><p>
The success of the rover technology development and demonstration program led to a plan to incorporate a microrover with roughly the same size and control approach into the Mars Pathfinder mission.  This mission calls for a small landed package to arrive at Mars in July, 1997 with a lander and a microrover.  The MFEX is a focused rover flight demonstration program (distinct from the Rover and Telerobotics Technology Program) responsible for developing, building and operating the Mars Pathfinder microrover.  MFEX is part of the Office of Mars Exploration which is managed by Donna Shirley.  The current development model for the Mars Pathfinder microrover builds upon the technology provided by the Rover and Telerobotics Technology Program, but equips it with flight-like processors and sensors and deals with such other disciplines as telecommunications, power, and data compression.  The MFEX program offers the prospect that small rovers and small missions will accomplish the science objectives which were once believed to be possible only with larger rovers and multi-billion dollar missions.<p>
<img src="MFEX.GIF"><p>
<H4>Fig. 3 MFEX is part of the Pathfinder Mission to Mars</h4>
<H5>Point of Contact:  D. L. Shirley, donna.l.shirley@cc:mail.jpl.nasa.gov</h5><p>

<B>Microrovers Beyond Pathfinder</b><p>
An active research and development program aimed at significant capabilities beyond the Pathfinder microrover is in place at JPL.  This technology base will greatly expand the current MESUR/Pathfinder micro-rover performance in the areas of goal identification, increased vehicle mobility, intelligent terrain navigation with in-situ
resource management, and manipulation of science instrumentation.  The goal is to combine both research and system demonstrations to advance the state of rover technologies while maintaining flight program relevance.  Specific goals over the next four years are:  (1) Performance characterization of multiple short traverses over Viking I type terrain within sight of lander; (2) Fresh rock sampling mechanism integrated on rover, single science target confirmation, traverse variable terrain (VL I and VL II), deployable or pointable solar array; (3) 9-10 kg vehicle, thermal insulation, multiple science target confirmation, multiple sampling and instrument pointing/deployment modes, traverse with return to lander; (4) Miniaturized vehicle (goal is 5 kg); non line of sight traverse, component capabilities tested in vacuum chamber.<p>
A series of rover vehicles are being used to conduct these tests.  Rocky 3.2 is a research vehicle shown in Fig. 4 that is being used to test and demonstrate the advanced rover technologies.  The Rocky 3.2 vehicle has been equipped with CCD imagers and laser stripe projectors which allow a wide range of plausible terrain hazards to be detected prior to a possible catastrophic engagement with the vehicle.  This rover is currently used for research in the rover technology program, which is developing hardware and algorithms for advanced science sampling, dense-hazard navigation, and further miniaturization of these rover systems.<p>
<img src="rocky3.gif">
<H5>P-43160 Ac</h5>
<H4>Fig. 4 Rocky 3.2 Microrover Technology Beyond Pathfinder</h4><p>

The rover technology program is being implemented with extensive university and industrial involvement in such areas as:  Sensor suites for long distance navigation on planetary surfaces; legged vs. wheeled vehicle mobility; virtual environment operator interfaces; robotic grasping devices; and behavior based obstacle avoidance and fault-tolerance.<p>
<H5>Point of Contact:  W. Zimmerman, zimmerman@telerobotics.jpl.nasa.gov</h5><p>


</DOC>
<DOC>
<DOCNO>WT01-B04-42</DOCNO>
<DOCOLDNO>IA080-000557-B034-335</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Platformrobs.html 137.79.14.197 19970103071314 text/html 9076
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f2b8.322@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:18:16 GMT
Last-Modified: Thursday, 15-Feb-96 18:09:39 GMT
Content-type: text/html
Content-length: 8830
</DOCHDR>
<TITLE>PLATFORM ROBOTICS</title>
<img src="logo.gif"><H3>Rover and Telerobotics Technology Program</h3><p>
<H1>PLATFORM ROBOTICS</h1><p>
<A NAME="segment2">In this segment:</a>
<UL>
<LI><A HREF="#SurfaceInsp">Remote Surface Inspection</a>
<LI><A HREF="#DexArm4Ranger">Dexterous Arm Control for the Ranger Flight Experiment</a>
<LI><A HREF="RangerInsp">Ranger Automated Inspection</a>
<LI><A HREF="CalibSynView">Calibrated Synthetic Viewing</a>
</ul><p>
Other Segments on this homepage:
<UL>
<LI><A HREF="Planetrobs.html">Planetary Robotics</a>
<LI><A HREF="Techcom.html">Technology Commercialization</a>
<LI><A HREF="Non-NASA.html">Non-NASA Tasks</a>
</ul><p>
<A HREF="Menu.html">Back to Main</a><p>
<B>========================================</b><p>
<A NAME="SurfaceInsp"><H3>Remote Surface Inspection</h3></a><p>

Complex space missions require routine and unscheduled inspection for safe operation.  A research and development program is being conducted to develop supervised inspection techniques for tedious tasks as an aid to the operator.  The telerobotic system would perform inspection relative to a given reference (e.g., the status of the facility at the time of the last inspection) and alert the operator to potential anomalies for verification and action.  One example is the inspection of truss struts for micrometeoroid damage and visible cracks on thermal radiator surfaces.  In the research being conducted, simulation of realistic dynamic lighting conditions is included.  In addition, configuration control of manipulators with redundant degrees of freedom, pioneered by JPL, has been implemented to assure dexterous manipulation near complete structures.<p>
<CENTER>
<img src="SURFINSP.GIF"><p>
<H4>Teleoperated robotic arm carrying a pair of miniwrist cameras</h4><p>
<img src="cupola.GIF"><p>
<H4>Surface Inspection robot control station</h4><p>
</center>
The baseline inspection task is to teleoperate a robotic arm carrying a pair of miniwrist cameras.  The operator uses a pair of 3-degrees-of-freedom joysticks and can control the lighting to better view the scene.  Additional cameras with pan/tilt and zoom/focus control are controlled by the operator to observe the arm's motion and to inspect objects that are far away from the arm.  A local-remote architecture is employed so that space and time distances can be effectively treated.  Multisensor-based inspection of gas leak, temperature, and damage is conducted.   Subsequently, inspection tasks requiring contact, such as eddy current-based crack detection, are performed.<p>

Technologies developed for the application include:<p>
<UL>
<LI>Simulation of realistic dynamic lighting conditions
<LI>Teleoperation and automated inspection
<LI>Configuration-control redundant-arm kinematics and automated manipulator base placement
<LI>Force control
<LI>Multisensor inspection - vision, gas, temperature, and eddy current
<LI>Serpentine manipulator development
<LI>Multisensor integrated gripper development
<LI>Virtual-window viewing
</ul><p>
Technology is currently being transferred to prospective Space Station applications at the NASA Johnson Space Center.<p>

<H5><B>Point of Contact:</b>  Won.S.Kim@jpl.nasa.gov</h5><p>
<A HREF="#segment2">Return to Segment Menu</a><p>
<B>========================================</b><p>
<A NAME="DexArm4Ranger"><H3>Dexterous Arm Control for the Ranger Flight Experiment</h3></a><p>

The NASA Ranger Flight Experiment, led by the University of Maryland, is aimed at the development and demonstration of robotic technologies for executing manipulation tasks in space.  The Ranger robot incorporates two dexterous 7-degrees-of-freedom manipulator arms mounted on a free-flying base.  These arms will be used, both individually and cooperatively, to perform a variety of manipulation experiments and servicing operations.  Based on a recent trade study on dexterous arm control, the configuration-control approach developed at JPL has been adopted for implementation on the Ranger dexterous arms.<p>
<CENTER>
<img src="Ranger3.GIF"><p>
<H4>Ground-controlled Ranger robot for servicing operations in space</h4><p>
</center>
The goal of the JPL task is to augment the operational capabilities of the dexterous arms in the Ranger Flight Experiment within the configuration-control framework.  There are two specific objectives of the task.  The first is to develop the capability of on-line collision detection and avoidance for the Ranger dexterous arms.  This capability does not currently exist in the Ranger baseline control system, and erroneous operator commands can use collision between the dexterous arms and the camera and grapple arms, the base, or the task board.  This added capability will enable collision-free motions of the arms throughout the work space.  It will also cause a reduction in the Ranger operation time, since several possible motions with potential collision are not executed.  In addition, this capability will increase the safety of the Ranger during the operation of the arms, a feature vital to the success of the Ranger mission.<p>

The second objective of the task is to provide the ground operator with a software tool for optimal placement of the Ranger base.  This algorithm will ensure that both dexterous arms can reach the task site and that the useful work space volume is maximized.  The algorithm will take into account the fact that the Ranger base is attached to the spacecraft by the grapple arm.  Therefore, the configuration of the grapple arm will also be taken into consideration.  At present, the placement of the Ranger base is done by the ground operator in an iterative trial-and-error fashion.<p>

The collision avoidance and base placement capabilities will considerably enhance the robustness and reliability of the Ranger control system and will significantly expand the range of tasks that can be accomplished in the Ranger Flight Experiment.  A series of technology experiments will be conducted at JPL to demonstrate the efficacy of the collision avoidance and base placement algorithms.<p>

<H5><B>Point of Contact:</b>  Homayoun.Seraji@jpl.nasa.gov</h5><p>
<A HREF="#segment2">Return to Segment Menu</a><p>
<p>
<B>========================================</b><p>
<A NAME="RangerInsp"><H3>Ranger Automated Inspection</h3></a><p>

The objective of this task is to apply this JPL remote surface inspection technology to the Ranger Flight Experiment for the purpose of assessing/validating the telerobotic automated inspection technology in real space conditions.  A Ranger inspection taskboard will be fabricated and used in both ground-based preflight and actual flight tests.  Onboard and ground-site requirements for this task --including task scenario, user interface, command sequences, arm motion control, lighting control, and image capture/down-link-- will be defined.  A standalone automated inspection software package based on the JPL inspection technology will be developed and evaluated by analyzing Ranger inspection flight data.<p>
<CENTER>
<img src="Flawdet.GIF"><p>
<H4>Automated flaw detection equipment.</h4><p>
</center>
In the illustration above, the reference image shown on the left corresponds to an unflawed object.  The image on the right shows the same object after a flaw is detected autonomously.  The image on teh bottom shows the detected flaw.<p>

<H5><B>Point of Contact:</b>  Won.S.Kim@jpl.nasa.gov</h5><p>
<A HREF="#segment2">Return to Segment Menu</a><p>
<p>
<B>========================================</b><p>
<A NAME="CalibSynView"><H3>Calibrated Synthetic Viewing</h3></a><p>

Payload alignment/mating techniques are critically needed in space station operations.  Performance of payload alignment and mating often requires the use of multiple cameras.  However, the objects being manipulated are not always seen completely by the available cameras.  Inadequate viewing camera coverage is a major concern.  The objectives of the Calibrated Synthetic Viewing task are to<p>
<UL>
<LI>Develop and evaluate a computer-vision-assisted calibrated synthetic viewing software environment to resolve the problem of visual occlusion and limited camera viewing during the performance of telerobotic operations.
<LI>Demonstrate reliable model/payload alignment and berthing operations under limited camera-viewing conditions for space station telerobotic onboard and ground control.
<LI>Install the calibrated synthetic viewing system at the NASA Johnson Space Center's Automated robotic Maintenance for Space Station (ARMSS) testbed for technology assessment and demonstration to the space station program.
</ul><p>
<CENTER>
<img src="Viewing.GIF"><p>
<H4>Calibrated synthetic viewing equipment.</h4><p>
</center>
<H5><B>Point of Contact:</b>  Won.S.Kim@jpl.nasa.gov</h5><p>
<A HREF="#segment">Return to Segment Menu</a><p>

</DOC>
<DOC>
<DOCNO>WT01-B04-43</DOCNO>
<DOCOLDNO>IA080-000557-B034-352</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Servicing.html 137.79.14.197 19970103071324 text/html 12159
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f2c4.323@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:18:28 GMT
Last-Modified: Monday, 29-Jan-96 18:06:50 GMT
Content-type: text/html
Content-length: 11914
</DOCHDR>
<TITLE>ON-ORBIT SERVICING</title>
<img src="logo.gif"><img src="SURFINSP.gif">
<H1>ON-ORBIT SERVICING ROBOTS:  ARCHIVE - DEC. 1994</h1><p>

Significant accomplishments have resulted from JPL activities in remote control of semi-autonomous robots.  The thrust of these activities has been to learn how to operate a remote system from a local control site.  A series of laboratory telerobotic systems have been built at JPL, and experiments have been conducted, since the early 1980's.  The spectrum of human machine interaction varies from direct operator control (i.e. teleoperation) with computer assistance to more autonomous operation with fail-safe back to a human operator to cope with conditions beyond our current technological capability in autonomous operations.  The term telerobotics refers to system capability which integrates both of these approaches.  Advanced teleoperation is particularly well suited for non-repetitive, less well modeled tasks, such as repair operations.  For more autonomous systems, the objective is to embed enough intelligence in the remote robot so that it can respond correctly to high-level commands from the operator.  The operator then assumes a supervisory role in commanding the remote robotic system.<p>
<B>A. Surface Inspection Robot</b><a href="rsi-movie">(Movie)</a>
<p>
Complex missions require routine and unscheduled inspection for safe operation.  The purpose of research in this task is to  facilitate structural inspection of the planned Space Station while mitigating the need for EVA, and giving the operator supervisory control over detailed and somewhat mundane, but important tasks.  The telerobotic system enables inspection relative to a given reference (e.g. the status of the facility at the time of the last inspection) and alerts the operator to potential anomalies for verification and action.  One example might be the inspection of truss struts for micrometeoroid damage and visible cracks on the thermal radiator surface.  Simulation of realistic dynamic lighting is included.  In addition, configuration control of manipulators with redundant degrees of freedom has been developed and implemented to assure dexterous manipulation near complex structures.  To assure safe operation, collision detection and avoidance algorithms are used to monitor the arm motion while the operator commands the arm during the inspection.<p>
<img src="cupola.gif">
<H5>JPL-17787 Ac</h5><p>
<H4>Fig. 5 Surface Inspection Robot Control Station<p>
<img src="RSI.gif">
<H5>JPL-23600 Bc</h5><p>
Fig. 6 Surface Inspection Remote Manipulator System</h4><p>

A multi-sensor end-effector includes a gas sensor for detection of gas leaks and a pyrometer to measure surface temperatures, in addition to CCD cameras.  This end-effector also houses two proximity sensors to provide collision avoidance and a force/torque sensor for safe contact with the environment.  Algorithms for flaw detection based on real-time image differencing with appropriate registration to account for variable lighting and manipulator/camera position have been developed and validated.  Several of the developed technologies within this task have successfully been transferred to the Johnson Space Center (JSC) for realistic tests in a high fidelity robotics laboratory with evaluation by astronauts.<p>

<H5>Point of Contact:  S. Hayati, (818) 354-8273, hayati@telerobotics.jpl.nasa.gov</h5><p>

<B>B. Ground Operator Environment</b><p>
There are two primary objectives of this project:  To develop technologies that enable well-integrated NASA ground-to-orbit telerobotics operations, and to develop a prototype common architecture workstation which implements these capabilities for other NASA technology projects and planned NASA flight applications.<p>
This task develops and supports three telerobot control modes which are applicable to time delay operation:  Preview teleoperation, teleprogramming, and supervised autonomy.  Preview teleoperation provides a graphical robot simulation which moves in real time according to the operators motion input to a hand controller.  This same teleoperation motion is sent to the real robotic system for execution.  In teleprogramming, the operators manual interaction with a 3-D virtual environment (physically identical to preview teleoperation) is symbolically interpreted by computer software  (e.g. for a grasping operation) to a low-bandwidth, low-level sequence of autonomous commands that are synchronously transmitted to the remote site, which has a simple sensor-referenced behavioral control capability.  The best features of dexterous teleoperation are preserved, while providing greatly increased operational robustness against extended (2-10 secs.) and possibly intermittent time delay.  The operators graphical workstation environment can be automatically updated based upon modeled sensor data feedback from the remote site, and robot sensor data is used instantaneously at the remote site to behaviorally compensate operator motion errors and positioning uncertainties.  Finally, supervised autonomy provides capability to generate high-level autonomous command sequences via either a graphically programmed operator interaction with the modeled environment, or using conventional menus.<p>
The ground control capability is targeted to support as a first user, the Dexterous Orbiter Servicing System (DOSS), a dexterous manipulator for the Orbiter payload bay. It is a sidewall mounted robot that operates from a fixed base or from the end of the Remote Manipulator System (RMS).  This arm will provide the crew and mission controllers with an alternative to EVA for performing payload bay operations.  These activities include EVA worksite setup, payload operations, and many contingency operations (e.g., repairs).  The DOSS is designed for repetitive flights and can be used as a baseline operational capability similar to the RMS.  It can also function as a testbed for future telerobotic experiments.  The DOSS will utilize many technologies developed within NASAs Telerobotics  Program, including robot control from Langley Research Center, remote surface inspection from JPL, and  ground operator control from JPL.<p>
<H5>Point of Contact:  S. Hayati, hayati@telerobotics.jpl.nasa.gov</h5><p>

<B>C. Distributed Space Telerobotics</b><p>
This effort is being developed as a cooperative research and development activity between NASA-JPL and MITI-Electrotechnical Laboratory (ETL) of Tsukuba, Japan.  The main technical thrust of the project is safe ground control of orbital robots under operational uncertainties caused by impaired remote viewing, communication time delay, and tasking contingencies.  Each of these technological areas manifest themselves in respective application interests; the main Japanese application interest is in space assembly, while the U.S. focus is in space servicing.<p>
There are two key research areas currently under development.  Intelligent Viewing Control (IVC) involves computerized planning and sequencing of multi-camera views which are fused with calibrated 3-D virtual workspace presentations.  This capability includes software facilities for interactive modeling, i.e., the capture of new workspace features, their rendering/presentation, and calibration, intended to improve  workspace perception and facilitate camera management.  Intelligent Motion Control (IMC) or teleprogramming has already been mentioned in the previous section.  The teleprogrammed mode is intended to extend time-delay teleoperation to useful LEO applications, and provides a mission resource for contingency tasking in partially structured environments (having geometric uncertainties).<p>
Initial interface specifications have already been developed resulting in successful remote operation of robots in the collaborating country.<p>
<H5>Point of Contact:  P. Schenker, schenker@telerobotics.jpl.nasa.gov</h5><p>

<B>D. supervised Telerobotics in the 1980's</b><p>
In the 1980's, this program developed a substantial technology base and experience that constitutes the foundation for today's program.  Important lessons learned during this period are: 
<UL>
<LI>Near-term  system  demonstrations  are  needed to  build  user  confidence
<LI>Robust  performance is a prerequisite to acceptance 
<LI>Rapid prototyping yields faster investment return and stimulates use of     cutting edge technology 
</ul>
Prime examples of telerobotic systems built during the 1980's include: the JPL Telerobotics Testbed; the Supervised Telerobotics Laboratory; and the Advanced Teleoperation Laboratory for Satellite Repair. <p>

<B>1. Telerobotics Testbed:  </b>The JPL telerobotics testbed was one of the most complete research telerobotic systems ever built.  Its main goal was to augment teleoperation with semi-autonomous capabilities at the robot site.  Typical demonstrations conducted with this system included that of satellite grappling with two arms and ORU replacement, as shown respectively in Fig. 7.  Technical areas of emphasis included:  Coordinated dual arm manipulation, force-reflecting operator control, and use of AI tools for task sequence planning and execution.  Major accomplishments included:  Synthesis of one of the most complete laboratory telerobots ever built; integration of AI and robot control techniques in control architecture; fast robot motion planners for collision avoidance; execution of dexterous tasks targeted to space; performance evaluation and demonstration in realistic servicing scenarios.<p>
<img src="grap.gif">
<H5>JPL-452</h5><p>
<H4>Fig. 7 Satellite Grappling Demonstration</h4><p>
<H5>Point of Contact:  S. Hayati, hayati@telerobotics.jpl.nasa.gov</h5><p>

<B>2. Supervised Telerobotics Laboratory:  </b>This laboratory was a focus for the JPL research in supervisory control of servicing telerobots, targeting Space Station as its intended application.  Its main accomplishments were:  Development of a complete system for dual arm supervisory control operations, a generalized-compliant-motion primitive for dual arm robot programming, and a modular control architecture for ground remote operations.  It demonstrated several complex tasks in ORU replacement during telerobotic satellite servicing.  It also produced experimental data for use in design of Space Station robotics operations.<p>
<img src="ORU.GIF">
<H5>JPL-15585 Ac</h5><p>
<H4>Fig. 8 ORU Replacement in Supervised Telerobotics Laboratory</h4>
<H5>Point of Contact:  P. Backes, backes@telerobotics.jpl.nasa.gov</h5><p>

<B>3. Solar Max Repair by Advanced Teleoperation:  </b>The advanced teleoperation laboratory was used extensively to evaluate and demonstrate a number of important capabilities:  Use of force reflection in teleoperation, predictive displays for task preview; and compensation for time-delay in conduct of remote operations.  The NASA 1984 Solar Maximum Satellite EVA Repair operation was used as the basis for an experimental paradigm.  Tasks that were performed in 1984 by two astronauts were duplicated in the laboratory.  These tasks included replacement of the modular attitude control subsystem and the main electronics box on the Solar Max Satellite.  The research revealed information about suitable tasks for teleoperated repairs, training in virtual environments, and teleoperation of redundant manipulators.<p>
<img src="control.gif"><img src="SatRep.gif">
<H5>from P-42661 Ac</h5><p>
<H4>Fig. 9 Solar Max Repair Ground Demonstration Using Teleoperation</h4><p>
The system is illustrated in Fig. 9.  Effort is directed toward giving the operator a feeling of being at the remote site, by using a variety of sensors and displays.  Sensor feedback includes force reflection, audio, and video images.  In addition, graphics displays of non-visual sensory information are provided.<p>
<H5>Point of Contact:  A. Bejczy, bejczy@telerobotics.jpl.nasa.gov</h5><p>


</DOC>
<DOC>
<DOCNO>WT01-B04-44</DOCNO>
<DOCOLDNO>IA080-000557-B034-369</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Techcom.html 137.79.14.197 19970103071333 text/html 12535
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f2cd.324@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:18:37 GMT
Last-Modified: Monday, 18-Mar-96 22:22:30 GMT
Content-type: text/html
Content-length: 12290
</DOCHDR>
<TITLE>TECHNOLOGY COMMERCIALIZATION</title><p>
<img src="logo.gif"><H3>Rover and Telerobotics Technology Program</h3><p>
<H1>TECHNOLOGY COMMERICALIZATION</h1><p>
<A NAME="segment3">In this segment:</a>
<UL>
<LI><A HREF="#Medicalrobs">Microtelerobotics and Medical Applications</a>
<LI><A HREF="#DexArmAlgorithms">Dexterous Arm Control Algorithms</a>
<LI><A HREF="#VRCalibTech">Virtual-Reality Calibration Technology</a>
<LI><A HREF="#RovTelepresence">Rover Telepresence and Control Technology</a>
</ul>><p>
Other Segments on this homepage:
<UL>
<LI><A HREF="Planetrobs">Planetary Robotics</a>
<LI><A HREF="Platformrobs.html">Platform Robotics</a>
<LI><A HREF="Non-NASA.html">Non-NASA Tasks</a>
</ul><p>
<A HREF="Menu.html">Back to Main Menu</a><p>

<B>========================================</b><p>
<A NAME="Medicalrobs"><H3>Microtelerobotics and Medical Applications</h3></a><p>

Medical applications of robotics are attracting major interest in both the commercial and research and development sectors.  Advances in small manipulators, miniaturized in situ sensors, dexterous teleoperative controls, virtual-reality/telepresence displays, and real-time three-dimensional imaging --and their integration into robotic and computer-assisted surgical systems-- promise to extend surgeons' capabilities, improve operative outcomes, minimize patient recovery times, and lower the compounded costs of overall health-care delivery.<p>
<CENTER>
<img src="RAMS.GIF"><p>
<H5>P-46531 Bc</h5><p>
<H4>Novel telerobotic system for dexterity-enhanced microsurgery.</h4><p>
</center>
Working through a Technology Cooperation Agreement with the Memphis-based MicroDexterity Systems (MDS), Inc., JPL is developing a novel telerobotic system for dexterity-enhanced microsurgical procedures of the brain, eye, ear, face, hand, and spine.  The JPL task effort, entitled Robot-Assisted Microsurgery (RAMS), is funded by NASA and performs robotic technology design, development, and engineering benchtop evaluation.  MDS carries out complementary work in medical requirements, system concept definition, and medical testing under independent funding.  A NASA-convened medical advisory board periodically reviews the overall JPL-MDS effort.  MDS, with end-market distributor participation, plans to have its first clinical trials in two-three years and seeks widespread market availability of dexterity-enhancement microsurgery system/tooling within this decade.<p>

The RAMS concept is a master/slave, motion-and-force-scaling telemanipulator with user-programmable controls.  JPL has completed design, fabrication, and preliminary testing of a new 6-degrees-of-freedom slave robot, as well as a new master hand controller with force reflection in the three Cartesian axes.  The primary system mode is teleoperative positioning.  The surgeon will also be able to interactively designate and "share" automated presentation and control of robot trajectories --e.g., implement virtual force boundaries/constraints on motions (in position, velocity, or acceleration) or program supervisory motion controls referenced to three-dimensional medical imagery.  The RAMS system, as currently configured, will enable highly gifted surgeons to teleoperatively refine the physical scale of their unaided manual procedures by two to five times.  The RAMS controls also provide a "tremor compensation" function to smooth input positioning in the face of myoclonic jerk and tremor that limit most individuals' fine-motion skills.<p>

The 6-degrees-of-freedom slave has a body consisting of a torso, shoulder, and elbow, with a non-intersecting three-axis wrist (the kinematic design of which is based on Ross-Hime Designs, Inc., "Omni-Wrist" and related patents licensed to MDS).  The slave is approximately 40 centimeters full extent, including the base with drive-train --the motors of which are fully enclosed and easily detached and reattached to facilitate sterilization of the remaining assembly.  Slave actuation is based on a new JPL revolute joint and cable-drive mechanism design providing near-zero backlash, constant cable-length excursions, and minimized joint coupling.  The robot electromechanical design and associated controls are conceived to ultimately allow relative positioning of surgical tools to within 10 micrometers of a target throughout a continuous hemispherical work space of more than 400 cubic centimeters.  In the first engineering laboratory experiments, repeatable, smoothly resolved motions as fine as 25 micrometers were achieved.<p>

<H5><B>Point of Contact:</b>  Hari.Das@jpl.nasa.gov</h5><p>
<A HREF="#segment3">Return to Segment Menu</a><p>
<p>
<B>========================================</b><p>
<A NAME="DexArmAlgorithms"><H3>Dexterous Arm Control Algorithms</a></h3><p>

Robotics Research Corporation (RRC) manufactures a family of dexterous 7-degrees-of-freedom arms that are used extensively at JPL and at NASA's Johnson Space Center, as well as by a number of government agencies, private companies, and universities.  These robotic arms are anthropomorphic and have the potential to perform complex tasks that demand human-like dexterity and versatility unavailable in standard 6-degrees-of-freedom industrial robots.  The 7-degrees-of-freedom arm is sold with a rudimentary controller that provides only basic capabilities that do not exploit the arm's intrinsic dexterity.<p>
<CENTER>
<img src="RRC.GIF"><p>
<H4>Personal computer-based control of RRC seven-jointed robot arm.</h4><p>
</center>
Since 1987, JPL has been developing for NASA advanced control techniques for seven-jointed arms such as the RRC arms.  A new approach to configuration control of redundant manipulators with seven or more joints has been developed at JPL.  The research leading to this development has evolved from analysis and simulation to full-scale implementation and experimentation.  The configuration -control approach provides a general framework in which the user can utilize arm redundancy to accomplish a variety of additional tasks beyond the basic task of end-effector placement.  This research has been reported in many publications and patents and has been implemented at a number of universities and research and development centers.<p>

RRC has been very interested in transferring the JPL-developed configuration-control techniques and algorithms to its next-generation commercial products, since these techniques will enhance the functionality and capability of RRC products considerably.  A Joint Technology Cooperation Agreement was signed by JPL and RRC in 1993 for commercialization of the JPL configuration-controls methods.  At the present time, JPL is achieving this transfer into a real-time system, based on a personal computer, that will be the new platform for RRC;s next-generation products.  The JPL configuration-control software was successfully integrated into the first RRC new commercial product, which was delivered to the Army Research and Development Laboratory in New Jersey in May 1995.<p>

<H5><B>Point of Contact:</b>  Homayoun.Seraji@jpl.nasa.gov</h5><p>
<A HREF="#segment3">Return to Segment Menu</a><p>
<p>
<B>========================================</b><p>
<A NAME="VRCalibTech"<H3>Virtual-Reality Calibration Technology</a></h3><p>

There is a growing interest in the virtual-reality calibration technique of matching graphically simulated virtual environments in three-dimensional geometry and perspective with actual video-camera views.  JPL recently developed such a technique that enables high-fidelity preview/predictive displays with reliable, accurate calibrated graphics overlay on live video for telerobotic applications, and demonstrated its effectiveness in the May 1993 JPL-NASA Goddard Space Flight Center remote servicing task.<p>

Within NASA's recent thrust for industrial collaboration, in September 1993, JPL established a Technology Cooperation Agreement with Deneb Robotics, Inc.  Through this agreement, JPL has been transferring the virtual-reality calibration technology and its evolving additions to Deneb, and Deneb has been inserting this technology into its commercial product.  This joint technology collaborative work enables Deneb to commercialize an upgraded industry product that will greatly benefit both space and terrestrial telerobotic applications.<p>
<CENTER>
<img src="vidimage.gif"><p>
<H4>System that calibrates robot-arm simulation with actual video image.</h4><p>
</center>
Deneb recently completed the beta version of the operator-interactive virtual-reality calibration option for the new release of TELEGRIP 2.4 and already shipped three copies to customers.  This option allows a multiple windows display of graphics, video, and calibrated graphics overlay on video, as shown in the figure above.  Seen in the figure are three views of a robot arm:  A calibrated video overlay in the lower-left window, a simulation in the large main window, and a video image in the right window.  The buttons on the right side of the main window provide the interface for the operator-interactive virtual-reality calibration consisting of camera calibration and object localization.<p>

<H5><B>Point of Contact:</b>  Won.S.Kim@jpl.nasa.gov</h5><p>
<A HREF="#segment3">Return to Segment Menu</a><p>
<p>
<B>========================================</b><p>
<A NAME="RovTelepresence"><H3>Rover Telepresence and Control Technology</h3></a><p>

Development of planetary rover telepresence and control technology is a central JPL thrust in planetary robotics.  In parallel with the ongoing technology development focusing on planetary missions, a Technology Cooperation Agreement has been established between JPL and International Space Enterprises, Inc., to explore the latter's concurrent, dual-use application of this technology in the commercial sector.  The near-term goal of this agreement is the development of technology required to support commercial applications of rover and control products for schools and science centers.  The longer-term goal is the development of technologies to support low-cost lunar and Mars missions that may be partially supported commercially.<p>

A closely related objective of the Technology Cooperation Agreement is that of educational and public outreach, intended to stimulate and inspire student and public interest in space exploration in general, and more specifically, in planetary rover technologies and missions.  To this end, a series of demonstrations are being conducted:  Planetary rover prototypes are operating in simulated Mars terrain at JPL with the rovers being commanded remotely from a school or museum site participating in the Technology Cooperation Agreement Program.<p>

In June 1995, such a demonstration was conducted from the Thomas Jefferson High School for Science and Technology in Alexandria, Virginia.  This demonstration involved an integrated system consisting of a planetary rover prototype and a command and control workstation at the school.  Students at the school, drawing from JPL's technology base in planetary rovers, assisted in the setup of the workstation and in conducting the remote control operations.  International Space Enterprises plans to use this initial demonstration system as a baseline for development, in fiscal year 1996 and beyond, of a commercial product consisting of the rover and the corresponding command and control workstation.<p>

In addition to the development of commercialization opportunities, the Technology Cooperation Agreement is also contributing to NASA missions.  The demonstrations and tests conducted as a part of the agreement increase the robustness and reliability of the planetary rover technology to be used in space.  A particular technical challenge is to guarantee robustness and reliability while testing with unspecialized operators (e.g., students).  Another challenge is that of repeated operations from various control sites.  In the longer term, it is anticipated that the Technology Cooperation Agreement-supported demonstrations will increase public interest in the JPL rover technology base, and in planetary missions in NASA's short-term and long-term horizons<p>

<H5><B>Point of Contact:</b>  Guillermo.Rodriguez@jpl.nasa.gov</h5><p>
<A HREF="#segment2">Return to Segment Menu</a><p>

</DOC>
<DOC>
<DOCNO>WT01-B04-45</DOCNO>
<DOCOLDNO>IA080-000557-B034-383</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/TerrComm.html 137.79.14.197 19970103071341 text/html 3988
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f2d6.325@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:18:46 GMT
Last-Modified: Monday, 29-Jan-96 18:07:15 GMT
Content-type: text/html
Content-length: 3744
</DOCHDR>
<TITLE>TERRESTRIAL AND COMMERCIAL APPLICATIONS</title>
<img src="logo.gif">
<H1>TERRESTRIAL AND COMMERCIAL APPLICATIONS:  ARCHIVE - DEC. 1994</h1>
<B>A. Ground Emergency Response Vehicle</b><p>
Following four years of research, this effort has prototyped a teleoperated mobile robot enabling the JPL HAZMAT (hazardous material) response team to remotely explore sites where hazardous materials have been accidentally spilled or released rather than risk entry team personnel.  JPL robotic researchers, engineers, Fire Department and Safety personnel have worked in close cooperation to develop the system.  The primary mission of the robot, called HAZBOT, is first entry and reconnaissance of an incident site; the most dangerous part of a response since the type of materials involved and the magnitude of the spill may not be fully known.  During such missions, HAZBOT must first gain entry into the incident site which may involve climbing stairs, unlocking and opening doors, and maneuvering in tight spaces.  Once the spill is located, an on- board chemical gas sensor is used for material identification.  The robot can also be used to aid in remediation or containment of the incident by, for instance, closing a leaking valve, deploying absorbent material, or placing a broken container in secondary containment.  HAZBOT has been specially designed to enclose all electrical components and provide internal pressurization, enabling operation in atmospheres that contain combustible vapors.  Other system features include a track drive base with front and rear articulating sections for obstacle/stair climbing, a six DOF manipulator with five foot reach and 40 pound payload capacity, custom tools for unlocking and opening doors, and 2 color CCD cameras.  To date, the robot has been used by the JPL HAZMAT team in three simulated response missions to test and demonstrate system capability.  HAZBOT is currently being used in the field for reconnaissance missions.  Future work includes the integration of on-board sensors as well as improvement to the operator control station.<p>
<img src="hazbot.gif">
<H5>P-42148 Ac</h5><p>
<H4>Fig. 10 HAZBOT III Entering Hazardous Material Storage Facility at JPL</h4>
<H5>Point of Contact:  R. Welch, welch@telerobotics.jpl.nasa.gov</h5><p>

<B>B. Satellite Test Assistant Robot (STAR):  A Robotic Inspection System for Thermal/Vacuum Environments.  </b><p>
STAR is a remote inspection robot which has been developed to assist engineers in the ground testing of spacecraft in simulated space environments.  STAR is designed to operate inside JPL's 10-ft and 25-ft thermal/vacuum test chambers where temperatures range from -190 C to +100 C and extremely high vacuums can be achieved.  STAR consists of a 25 ft vertical axis and an Azimuthal axis which provides mobility around the inside diameter of the chamber.  A 2-axis scanning platform is instrumented with two high resolution video cameras, controlled lighting and an Infrared Imaging Camera.<p>
At an Operator Control Station  engineers  remotely control the position and orientation of STAR's lighting and camera instrumentation allowing close-up real-time visual inspection and infrared thermal mapping of a spacecraft under test in the simulated space environment inside the chamber.  STAR will help engineers by improving test reliability and reducing overall test costs.<p>
STAR is installed and operational in the test chamber.  Its first application to a JPL flight project will be for the Mars Pathfinder Spacecraft which begins test in FY 95.<p>
<img src="STAR.GIF">
<H5>JPL-22049 Cc</h5><p>
<H4>Fig. 11 Spacecraft Being Tested in 25-Foot Chamber Using STAR</h4>
<H5>Point of Contact:  Douglas McAffee, (818) 354-1740</h5><p>


</DOC>
<DOC>
<DOCNO>WT01-B04-46</DOCNO>
<DOCOLDNO>IA080-000557-B034-404</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Non-NASA.html 137.79.14.197 19970103071401 text/html 9763
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f2e8.326@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:19:04 GMT
Last-Modified: Thursday, 15-Feb-96 18:11:07 GMT
Content-type: text/html
Content-length: 9517
</DOCHDR>
<TITLE>NON-NASA TASKS</title>
<img src="logo.gif"><H3>Rover and Telerobotics Technology Program</h3><p>
<H1>NON-NASA TASKS</h1><p>
<A NAME="segment4">In this segment:</a>
<UL>
<LI><A HREF="#AircraftInspect">Miniaturization Technologies for Aircraft Inspection</a><p>
<LI><A HREF="#ObstacleDet">Obstacle Detection for Autonomous Ground Vehicles</a><LI><A HREF="#BioRobotics">Biologically Inspired Robotics</a>
</ul><p>
Other Segments on this homepage:
<UL>
<LI><A HREF="Planetrobs.html">Planetary Robotics</a>
<LI><A HREF="Platformrobs.html">Platform Robotics</a>
<LI><A HREF="Techcom.html">Technology Commercialization</a>
</ul><p>
<A HREF="Menu.html">Back to Main Menu</a><p>

<B>========================================</b><p>
<A NAME="AircraftInsp"><H3>Miniaturization Technologies for Aircraft Inspection</h3></a><p>

This task for the U.S. Air Force studies how to apply miniaturization technologies to aircraft inspection to make existing inspection processes more efficient and to enable new inspection modalities.  Regular inspection of aircraft is critical for safety and to determine what and when repairs are needed.  Aircraft inspection can be both time consuming and difficult because of the size of aircraft, such as external inspection of the C-5A, and because of difficult access, such as internal engine and fuel tank inspection.  Recent advances in miniaturization technologies have produced technologies enabling development of new inspection systems to enhance aircraft inspection.<p>

The four objectives of the Miniaturization Technologies for Aircraft Inspection task are to<p>
<UL>
<LI>Determine aircraft inspection application areas that could most greatly benefit from the application of miniaturization technologies.
<LI>Evaluate the current state of the art in aircraft inspection technologies with primary focus on small and miniature technologies.
<LI>Identify for development promising candidate miniaturization technologies that would benefit aircraft inspection applications.
<LI>Develop a plan for development of target technologies and their application to aircraft inspection.
</ul>
<H5><B>Point of Contact:</b>  Paul.G.Backes@jpl.nasa.gov</h5><p>
<A HREF="#segment4">Return to Segment Menu</a>
<p>
<B>========================================</b><p>
<A NAME="ObstacleDet"><H3>Obstacle Detection for Autonomous Ground Vehicles</h3></a><p>

Autonomous ground vehicles are being developed for a variety of applications in the military, in hazardous waste remediation, and in planetary exploration.  Such applications often involve limitations on communications that require such a vehicle to navigate autonomously for extended distances and extended periods of time.  Under these circumstances, the vehicle must be equipped with sensors for detecting obstacles in its path.  JPL is developing obstacle detection sensors for the "Demo II" Unmanned Ground Vehicle (UGV) Program, which is sponsored by the Advanced Research Projects Agency and the Office of the Secretary of Defense.<p>
<CENTER>
<img src="vehicle.gif"><p>
<H4>Testbed vehicle with stereovision system for real-time obstacle detection.</h4><p>
</center>
The goal of the Demo II Program is to develop technology enabling ground vehicles to perform autonomous scouting missions.  In its full generality, this application will require operating during the day or night, in clear or obscured weather conditions, and over terrain that will include a variety of natural and human-made obstacles.  Obstacle detection sensors must be able to perceive terrain geometry and the material type of any ground cover (terrain type), an do so at night and through haze.<p>

The JPL task has been addressing the problem of perceiving daytime and nighttime terrain geometry and is beginning to address the problem of perceiving terrain type by day.  For sensing geometry, stereovision is being used; its properties of being nonemissive, nonscanning, and nonmechanical make it attractive for military vehicles that require a low-signature sensor performing well while jostling over rough terrain.  In collaboration with other laboratories, the JPL task has recently begun experimenting with stereovision and thermal imagery to address night operations.  For sensing terrain type, preliminary investigations have been conducted that use visible, near-infrared, and polarization imagery to discriminate soil, vegetation, and water.<p>
<CENTER>
<img src="map.gif"><p>
<H4>Elevation map of a road, generated by stereovision system.</h4><p>
</center>
Over the past five years, the JPL task has developed a real-time stereovision system that currently produces range imagery from a 256- x 45-pixel window of attention in about 0.6 second per frame, using a Datacube MV-200 image-processing board and a 68040 central-processing-unit board as the sole computing engines.  This vision system is installed on a roboticized modern military jeep that serves as a testbed UGV.  Enhancements currently in progress on this system include the addition of algorithms for real-time obstacle detection, focus of attention, and software-based lens aperture control.  The vision system has been used to drive the jeep autonomously at speeds up to 10 kilometers per hour.  This work has been the first to show that stereovision can provide range data of sufficient quality, at sufficient speeds, and with sufficiently small computing resources to be practical for autonomous vehicle navigation.  Future work will attempt to increase the quality of the range data, miniaturize the computing system, and integrate terrain classification with range imaging.<p>

<H5><B>Point of Contact:</b>  Larry.H.Matthies@jpl.nasa.gov</h5><p>
<A HREF="#segment4">Return to Segment Menu</a><p>
<p>
<B>========================================</b><p>
<A NAME="BioRobotics"><H3>Biologically Inspired Robotics</h3></a><p>

This task explores the use of legged robots in environments typical for various military missions.  It is supported by a basic research grant from the Office of Naval Research and is a part of that office's Perceptual Sciences Program.  Focusing on issues related to the control of legged robots that perform extended autonomous operations, the task investigates the feasibility of such concepts for Navy operations in shallow waters, such as surveillance and mine discharging.  the resulting technologies also address some f the issues related to planetary exploration on surfaces that might be more rocky than the Viking Lander-1 and -2 sites and provide the design tools and test data necessary for the investigation of legged rovers for future NASA missions.<p>

The problem of controlling legged robots has been perceived as a complex one, possibly requiring extensive computation.  This is, perhaps, one of the reasons for the choice of wheeled rovers over legged rovers in many military, civilian, and space applications, where the constraints on mass, power, and/or computational requirements often have a compelling impact on vehicle design.  On the other hand, there exists a rich spectrum of simple biological systems that perform stable locomotion with relative ease in the presence of large amounts of uncertainties.  It is therefore natural to seek biological principles that might simplify control and improve mechanical design, so that legged concepts may become competitive enough for serious consideration in a variety of applications.<p>

Perhaps the most fascinating aspect of biological locomotion is the notion of a gait, and the study of underlying mechanisms used for choosing, modifying, and maintained gaits.  A gait is quantified by the phase relationship maintained between the motions of individual legs and appears to be related to the overall stability of the animal performing locomotion.  The premise of the research conducted in this task, therefore, is that a systematic study of gait modeling and gait control could result in computationally efficient locomotion controllers.<p>

To date, a simple gait model has been developed for the emulation of two-, four-, and six-legged gaits, and a locomotion control architecture has been determined for choosing, adapting, and maintaining gaits.  JPL has built a six-legged robot, about 0.4 meter long, 0.25 meter wide, and about 0.1 meter in height.  The control programs that drive the legs have been developed and tested.  Programs are being developed to enable coordinated movement of the legs for stable locomotion on rough terrain.  Currently, experiments are being performed indoors to be followed by a series of outdoor tests in the near future.<p>
<CENTER>
<img src="BIOBOT.GIF><p>
<H4>Biologically inspired microbot.</h4><p>
</center>
the payoff for the Navy from such an investigation lies in the realization of vehicles that could operate autonomously in the near-surf zone in beaches as well as on a wide variety of terrains, and perform surveillance and mine-discharging operations.  The payoff for NASA would be the realization of rover concepts for autonomous operation on extremely rocky surfaces, such as descending into volcanic craters.  In addition, microinstruments and microsampling devices could be packaged within the lets of such a robot, so that geological surveying and sampling could potentially occur even while the rover is navigating from one site to another.  The legs could also be utilized as deployment mechanisms.<p>

<H5><B>Point of Contact:</b>  Subramani.T.Venkataraman@jpl.nasa.gov</h5><p>
<A HREF="#segment4">Return to Segment Menu</a><p>
</DOC>
<DOC>
<DOCNO>WT01-B04-47</DOCNO>
<DOCOLDNO>IA080-000557-B034-422</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Comptech.html 137.79.14.197 19970103071411 text/html 8584
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f2f3.327@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:19:15 GMT
Last-Modified: Monday, 29-Jan-96 18:07:50 GMT
Content-type: text/html
Content-length: 8340
</DOCHDR>
<TITLE>COMPONENT TECHNOLOGIES</title>
<img src="logo.gif">
<H1>COMPONENT TECHNOLOGIES:  ARCHIVE - DEC. 1994</h1><p>
The program is developing a number of component technologies, which complement the demonstration-driven tasks.  Illustrative examples of these component technologies are provided below.<p>
<B>Telepresence/Exoskeleton</b><p>
This project augments telemanipulation capabilities through the development and evaluation of a unique force-reflecting master-slave exoskeleton anthropomorphic arm-hand system, with the emphasis on the use of EVA-rated tools and on minimum training requirements.  There is also strong interest for the backdriveable glove as a physical therapy aid to rehabilitate stroke patients paralytic hands.<p>
<img src="exo.gif">
<H5>JPL-23094</h5><p>
<H4>Fig. 14 Exoskeleton Controlled by Human Operator</h4><p>

The focus of this task involves the augmentation to telemanipulation capabilities through the development of human-equivalent dexterity of remotely operated hands, with emphasis on minimal training and use of human rated tools.  The technical objective is to prototype a force-reflecting master-slave arm-hand system in exoskeleton form with a 7-DOF arm and 16-DOF four fingered hand.  This includes integration with a visual telepresence system.  The programmatic objective is to determine how far an exoskeleton alternative can perform EVA-glove rated manipulative activities without changing EVA tools or adding new ones to the existing repertoire.<p>
<H5>Point of Contact:  A. K. Bejczy, bejczy@telerobotics.jpl.nasa.gov</h5><p>

<B>Wide Field-of-View Stereo</b><p>
WFOV, the Wide Field-of-View stereo system, is a JPL-based technology developed for the DOD's Unmanned Ground Vehicles Project, UGV.  It is a real-time system which produces dense range maps from a stereo pair of cameras mounted on a HMMWV ("Hum-Vee"), the military's modern-day Jeep equivalent.  The range data is being used by higher-level vehicle-control systems for autonomously navigating around local obstacles encountered during battlefield maneuvers.<p> 
Below is a sample image.  In the lower-right corner is the left image from a stereo pair taken in the Arroyo next to JPL.  The upper-right shows range data as distance from the cameras.  The upper left contains the subpixel disparity image, produced by the stereo system, from which the range data was computed.  The lower-left shows confidence data.  In all cases the colors span the rainbow, with red being low values and violet being high values.<p>
Robotic vehicles have important applications in planetary exploration, hazardous waste handling, battlefield operations, and factory material transportation.  To enable these applications, robotic vehicles must be equipped to automatically detect obstacles in their path.  Obstacle detection can be achieved by using range sensors to observe the geometry of the environment, then by analyzing the geometry to find passable routes for the vehicle.  However, range sensors have not been available that meet the cost and performance requirements of most applications.  JPL has taken a major step forward in this area by demonstrating a practical range sensing system to be based on stereo vision.<p>
Stereo vision uses two cameras to observe the environment, finds the same object in each image, and measures range to the object by triangulation; that is, by intersecting the lines of sight from each camera to the object.  Finding the same object in each image is called matching and is the fundamental computational task underlying stereo vision.  Matching objects at each pixel in the image produces a range estimate at each pixel; together, these range estimates form a range image of the scene.  Geometric analysis of the range image identifies passable routes.  For robotic vehicle applications, the primary alternatives to stereo vision-based range estimation use acoustics, radar, or scanning lasers.  Compared to these alternatives, stereo vision has the significant advantage that it achieves high resolution and simultaneous acquisition of the entire range image without energy emission or moving parts.  The key issue in making stereo vision practical was to find a combination of algorithms and processors that led to reliable, real-time range estimation with a computer system small and cheap enough to use on robotic vehicles.<p>
The stereo vision algorithm (1) re-samples the input images to correct for geometric nonlinearities, (2) reduces the resolution of the re-sampled images by computing image pyramids, (3) applies cross-correlation to the low resolution images to find matching objects at each pixel, and (4) performs triangulation with the result of the matching process to generate range estimates.  Steps (1) through (3) involve low-level, integer operations on the image pixels and are implemented on one special-purpose image processing board.  Step (4) involves floating functions and coordinate transformations and is implemented on a general purpose CPU.  The entire computing system occupies five slots in a dual-height VME card cage, including the image processor, the CPU, and two analog-to-digital conversion boards for video acquisition.  The system currently produces 64x60-pixel range images in one-third of a second, which is a speedup of three orders of magnitude over what was possible prior to this work.<p>
In a major demonstration performed in 1990, for the NASA planetary rover program, JPL used a version of this vision system to show that a robotic vehicle could perform autonomous obstacle avoidance while traversing 100 meters of off-road terrain.  This demonstration established the viability and practicality of stereo vision-based range imaging for robotic vehicle applications.  The impact of this work is reflected by the adoption of similar approaches for subsequent, NASA-funded robotic expeditions to volcanoes in Antarctica and Alaska, by the potential use of these algorithms in upcoming robotic missions to Mars, and by the transfer of this technology to military robotics programs funded by the Department of Defense.<p>
<H5>Point of Contact:  L. Matthies, matthies@telerobotics.jpl.nasa.gov</h5><p>

<B>Serpentine Robot</b><p>
<img src="serp.gif">
<H5>P-44487</h5><p>
<H4>Fig. 16 a Small, light-weight, and highly dexterous serpentine robot or visual inspection</h4><p>

A telerobotics inspection system has been developed to perform remote inspection experiments in realistic space-like environments.  The main application focus of this task is the Space Station.  The Space Station is a large space platform with complex mechanical, electrical, thermal, fluid and gas interfaces, and a changing suite of internal and external scientific experimental apparatus.  On-orbit maintenance of such a complex, changing facility requires periodic as well as "on demand" inspection capabilities.<p>
The inspection system consists of two seven-degrees-of-freedom (7-DOF) Robotics Research Corporation manipulator arms which are mounted on two one-degree-of-freedom mobile platforms.  The arms carry cameras and lights for inspection.  These arms, however, are too large to enter the small truss structure openings.  A smaller and more dexterous arm was needed to perform inspection tasks in highly restricted regions.<p>
JPL has developed a serpentine robot to test the feasibility of robotic inspection of such restricted areas.  The robot is 3.8 centimeters in diameter, approximately 90 centimeters  long, weighs 2.7 kilograms, and has 11 degrees of freedom.  All joints are direct-drive motor controlled, and all motors are mounted internally.  Inspection capability is provided by a fiber-optics borescope embedded inside the arm.  This borescope transfers images to a camera at the base of the arm and illuminates the inspection site.<p>
The goal is to use this robot as an inspection tool to be picked up by one of the large manipulators.  The combined macro/micro arm will have 21 degrees of freedom.  Algorithms have been developed to guide this arm through small openings in such a way that the rest of the arm automatically follows the tip's path, thus avoiding collisions with the environment.  This technology can be used in industry and medical applications.<p>
<H5>Point of Contact:  Samad Hayati, hayati@telerobotics.jpl.nasa.gov</h5><p>



</DOC>
<DOC>
<DOCNO>WT01-B04-48</DOCNO>
<DOCOLDNO>IA080-000557-B035-10</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Spinoffs.html 137.79.14.197 19970103071421 text/html 7110
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f2fc.328@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:19:24 GMT
Last-Modified: Monday, 29-Jan-96 18:08:28 GMT
Content-type: text/html
Content-length: 6866
</DOCHDR>
<TITLE>COMMERCIALIZATION SPIN-OFFS</title>
<img src="logo.gif">
<H1>COMMERCIALIZATION SPIN-OFFS:  ARCHIVE - DEC. 1994</h1><p>
<B>A. Robot Assisted Microsurgery:  A New Telerobot Enhances and Extends Surgeons' Skills.</b><p>
Building from its established NASA technology base in teleoperations and telerobotics, JPL is developing a new robotic microdexterity platform with important applications to medicine.  Through a cooperative NASA-Industry effort, the Robot Assisted Microsurgery (RAMS) task develops a dexterity-enhanced master-slave telemanipulator enabling breakthrough procedures in micro/minimally invasive surgery.  A cooperative commercial development agreement with Micro Dexterity Systems, Inc. is in place to bring the JPL technology to the point of application.  The applicable medical practice includes eye, ear, nose, throat, face, hand, and cranial surgeries.  As part of planned task activities, the resulting NASA robot technologies will be benchmarked in actual operating room procedures for vitreous retinal surgery.<p>
The primary objective of this task is to provide an integrated robotic platform for master-slave dual-arm manipulation operational in a one cubic inch work volume at features in the 100 micron range (our goal is to extend these capabilities to features in the 20 micron range).  The research is a natural evolution of our extensive experience in force-reflecting teleoperation with dissimilar master/slave.  Capabilities will include force-reflection and textural tactile feedback, and in situ multiple-imaging modalities for improved surgical visualization and tissue discrimination. Potential NASA applications may include EVA/IVA telescience, bioprocessing, materials process and micro mechanical assembly, small-instrument servicing, and terrestrial environmental testing in vacuum.<p>
A joint Technology Cooperation Agreement with Micro-Dexterity Systems, Inc., is in place to further develop and commercialize the JPL RAMS technology, with vitreous retinal surgery as the initial application.  Longer range application targets include ear, nose, throat, face, hand, and cranial surgeries.<p>
<H5>Point of Contact:  P. S. Schenker, schenker@telerobotics.jpl.nasa.gov</h5><p>

<B>B. Commercialization of Virtual Environment Calibration Technology</b><p>
<img src="deneb.gif">
<H5>Photo Courtesy of Deneb Robotics</h5><p>
<H4>Fig. 12 Overlay of calibrated 3-D graphic models (wire frames with semi-transparent surfaces) on live video for telerobotic satellite servicing</h4><p>
JPL recently developed a virtual reality calibration technique that enables reliable and accurate matching of a graphically simulated virtual environment in 3-D geometry and perspective with actual video camera views.  This technique enables high-fidelity preview/predictive displays with calibrated graphic overlay on live video for telerobotic servicing applications.  Its effectiveness was successfully demonstrated in a recent JPL/NASA-GSFC ORU (Orbital Replacement Unit) change-out remote servicing task.  With NASA's recent thrust toward increased collaboration with industry, JPL and Deneb Robotics, Inc., have established a technology cooperation agreement.  JPL transfers the virtual reality calibration software technology to Deneb, and Deneb inserts this software technology into its commercial product, thus enabling  Deneb to commercialize an upgraded  product.<p>
Key new features of the JPL calibration technique include; 1) An operator-interactive method is adopted to obtain reliable correspondence data.  2) A robot arm itself is used as a calibration fixture for camera calibration, eliminating a cumbersome procedure of using external calibration fixtures.  3) The object localization procedure is added after the camera calibration as a new approach to obtain graphic overlay of both the robot arm and the object(s) on live video and enable effective use of the computer-generated trajectory mode in addition to the teleoperation mode.  4) A projection-based linear least-squares algorithm is extended to handle multiple camera views for object localization.  5) Nonlinear least-squares algorithms combined with linear ones are employed for both camera calibration and object localization.  The enhanced product, including the JPL-developed technology, will be in market in early 1995.<p>
<H5>Point of Contact:  kim@telerobotics.jpl.nasa.gov</h5><p>

<B>C. Commercialization of Redundant Arm Control Algorithms:  Robot Control Schemes are Transferred to Commercial Products</b><p>
Robotics Research Corporation (RRC) manufactures a family of dexterous 7-DOF arms that are used extensively at JPL, JSC, LaRC, GSFC, as well as by a number of government agencies, private companies, and universities.  These robotic arms are anthropomorphic and have the potential to perform complex tasks that demand human-like dexterity and versatility unavailable in the standard 6-DOF industrial robots.  The 7-DOF arms are sold with a rudimentary controller that provides only basic capabilities that do not exploit the intrinsic dexterity present in the 7-DOF arms.<p>
Since 1987, JPL has been developing for NASA advanced control techniques for seven jointed arms, such as the Robotics Research Arms.  A new approach to "Configuration Control" of redundant manipulators with seven or more joints has been developed at JPL.  The research leading to this development has evolved from analysis and simulation to full-scale implementation and experimentation.  The configuration control approach provides a general framework in which the user can utilize the arm redundancy in order to accomplish a variety of additional tasks beyond the basic task of end-effector placement.  Typical additional tasks that have been implemented and demonstrated are:  Elbow placement, joint limit avoidance, singularity robustness, base placement, and collision avoidance.  This research has been reported in many publications and patents, and has been implemented at a number of universities and R & D centers.<p>
The Robotics Research Corporation has been very interested in transferring the JPL developed configuration control techniques and algorithms to their next generation commercial products, since they have realized that it will enhance the functionality and capability of their products considerably.  A Joint Technology Cooperation Agreement was signed in 1993 between JPL and RRC for commercialization of the JPL configuration control methods.  At the present time, JPL is achieving this transfer into a PC-based real-time system which will be the new platform for their next generation products.  The enhanced product will be in the market in 1995.<p>
<img src="arm.gif">
<H5>P-36299 Ac</h5><p>
<H4>Fig. 13 Robotics Research Arm Under Configuration Control</h4>
<H5>Point of Contact:  H. Seraji, seraji@telerobotics.jpl.nasa.gov</h5><p>


</DOC>
<DOC>
<DOCNO>WT01-B04-49</DOCNO>
<DOCOLDNO>IA080-000557-B035-28</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/emphsum.html 137.79.14.197 19970103071432 text/html 7413
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f307.329@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:19:35 GMT
Last-Modified: Tuesday, 28-Nov-95 23:28:15 GMT
Content-type: text/html
Content-length: 7168
</DOCHDR>
<TITLE>Emphasis and Summary</title>
<CENTER>
<H2>Mars Exploration Technology Program</h2><p>
<H1>PROGRAM EMPHASIS AND SUMMARY</h1><p>
</center>
On this page:<p>
<UL>
<LI><A HREF="#Bkgrnd">Background</a>
<LI><A HREF="#Progemph">Program Emphasis</a>
<LI><A HREF="#Progcont">Program Content</a>
<LI><A HREF="#Strat">Strategy</a>
</ul>
<p>
<H3><A NAME="Bkgrnd">Background</a></h3><p>
Exploration of Mars is a major thrust of NASA.  Some of the important goals of this exploration are (1) the search for life and understanding of the evolution of the planet, (2) the discovery of accessible water, (3) understanding how the climate has changed, and (4) developing an inventory of useful resources precursor to further human exploration.<p>

While many useful scientific investigations can be done in situ on the surface of Mars, there seems to be agreement that the main scientific objectives of exploration can only be achieved with the return of samples to Earth for analysis. For example, Ref. 1 says:  It has been the stated position of the Mars science community for some time that a Mars sample return mission is the highest priority science objective for Mars.  Ref. 2 says in reference to in situ analysis:  However, it must be recognized that these are lower priority goals, and that they cannot be allowed to compromise the primary objective of returning scientifically interesting samples from the surface of Mars. Ref. 1 also says:  The first priority goal of intensively understanding the details of the diversity of local materials at the surface of Mars can best (and perhaps only) be addressed by a mission that carefully samples Martian materials and returns them intact to Earth for intensive, detailed analysis.<p>
<img src="metintro.gif"><p>

However, a sample return mission from Mars is a very significant undertaking. Vigorous attempts are now being made to develop new programmatic approaches to lower the cost of such a mission, with an eye toward a potential return in 2005.  NASA plans a series of nearer-term exploration missions involving landers which will provide important in situ data on Martian materials, but not as much as a sample return. These planned nearer-term affordable missions will be vital in solidifying capabilities for a series of evolving Mars missions with ever increasing capabilities.<p> 

In formulating a program emphasis for the Mars Exploration Technology Program, we were guided by several important factors:<p>
<OL>
<LI>A MSR mission appears to be of highest importance in the scientific exploration of Mars.
<LI>Past MSR mission plans do not appear to be affordable, and although new concepts are now being explored to reduce cost, the need for new technology to reduce cost appears necessary for there to be a MSR mission.
<LI>It is unlikely that there ever will be a MSR mission unless near and mid-term Mars surface exploration gets off to a strong and successful start to provide a foundation for an eventual MSR mission, and therefore the development of technology to strengthen these missions has very high priority.
</ol>
<A HREF="Mars.html">Return to menu</a><p>

<A NAME="Progemph"><H3>Program Emphasis</h3></a><p>
In view of the arguments presented in the previous section, it was decided that the thrust of this Technology Program will be divided between:<p>
<OL>
<LI>developing technology which will contribute to enabling a MSR mission, and 
<LI>developing critical technologies for near-term and mid-term Mars lander projects.  
</ol>
The choice of specific research topics for inclusion in this Technology Program is not a simple task. The NASA programmatic format for a future MSR mission will undoubtedly undergo a great deal of evolution over the next several years. At present, a system study led by Richard A. Wallace of JPL (Ref. 3) is exploring a number of possible alternate scenarios for a low cost MSR mission, and depending on the results of this study, the prioritization of various technologies for a MSR might be significantly altered. Although there is considerable previous literature on plans and needs for MSR missions, it is likely that funding limitations will dictate use of very different approaches than had been contemplated in the era 1970-1994.<p>

It is also difficult to prioritize technology for near-term and mid-term lander missions because the nature of these missions depends significantly on responses obtained from future requests for proposals. Also, there is not much time to develop technology for the first of these missions. However, the JPL Mars Exploration Office provided important analysis and advice in this regard. A number of generic needs were identified. These include a miniaturized telecommunications system, autonomous sample acquisition, in situ instruments, and various aspects of lander survivability and versatility, such as low temperature flight electronics, low temperature batteries and improved thermal control. <p>
<A HREF="Mars.html">Return to menu</a><p>
<A NAME="Progcont"><H3>Program Content</h3></a>
The Mars Exploration Program is planning a series of missions involving landers launched in 1998, 2001, and 2003, and a sample return mission (if feasible) in 2005. The technology addressed in this Mars Exploration Technology Program is divided in its intent to provide technology products in time for these various missions. The longest term task is In Situ Propellant Production (ISPP) which is aimed at the sample return mission in 2005, although a prototype demonstration system could conceivably fly as a technology demonstration on an earlier mission. All the other tasks in the Mars Exploration Technology Program are aimed at either the 1998 lander or the 2001 lander, although in some tasks, such as autonomous sampling and instrument deployment, it is intended to seek an evolutionary development plan.  In terms of missions and timing, the various tasks are aimed at readiness on the time scales shown in Table 1.<p>
<img src="Table1.GIF"><p>
<A HREF="Mars.html">Return to menu</a><p>
<A NAME="Strat"><H3>Strategy</h3></a><p>
The strategy of the Mars Exploration Technology (MET) Program is to place high priority on development of the core technologies for a sample return mission, while at the same time developing the most vital expected needs for near-term and mid-term lander missions.  The program plan will follow a path toward demonstrating significant new technological capabilities at NASA Readiness Level ~5 to 6 in several years. At each yearly step along the way, it is planned to consistently integrate these technologies into laboratory prototypes to assure that they function together as systems.  At intervals, these prototypes will be demonstrated in a more developed form to foster transfer to projects.  Wherever possible, the near-term demonstrations will be configured in such a way as to serve needs for near-term lander missions. Thus, we will steer a course, always following a beacon representing the shortest path toward the longer term goals, but branching activities off from this path to provide shorter term needs wherever they are compatible. <p>

<A HREF="Mars.html">Return to menu</a>

</DOC>
<DOC>
<DOCNO>WT01-B04-50</DOCNO>
<DOCOLDNO>IA080-000557-B035-50</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/multistones.html 137.79.14.197 19970103071443 text/html 17917
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f311.330@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:19:45 GMT
Last-Modified: Monday, 27-Nov-95 23:12:51 GMT
Content-type: text/html
Content-length: 17672
</DOCHDR>
<TITLE>Multiyear Task Overviews and Milestones</title>
<H2>Mars Exploration Technology Program</h2><p>
<H1>MULTIYEAR TASK OVERVIEWS AND MILESTONES</h1><p>
<UL>
<LI><A HREF="#Progmgmt">Program Management</a>
<LI><A HREF="#Preclndg">Precision Landing</a>
<LI><A HREF="ISPP.html">In Situ Propellant Production (ISPP)</a>
<LI><A HREF="Sampacq.html">Sample Acquisition</a>
<LI><A HREF="Isinstr.html">In Situ Instruments</a>
<LI><A HREF="Lowthide.html">Low Temperature, High Density Electronics</a>
<LI><A HREF="Thermcon.html">Thermal Control</a>
<LI><A HREF="Hiplotb.html">High Performance, Low Temperature Batteries</a>
<LI><A HREF="Smldst.html">Small Deep Space Transponder</a>
</ul>
<p>
<A NAME="Progmgmt"><H3>Program Management</h3><a/><p>
This task  includes technical and financial management, interfacing with other related technology tasks and Mars development and planning programs, and most important of all,  assuring that all of the tasks in the MET program address Mars Exploration mission needs in a timely way. This, in turn, requires familiarity with Mars mission plans, and in some cases, detailed analyses of the impact of technologies on the Mars missions.<p>

As program planning for a Mars Sample Return mission progresses outside this RTOP, it is anticipated to eventually establish technology readiness benchmarks to measure relative levels of technology readiness for the determined cost, mass, and reliability drivers in a Mars Sample Return mission. This will be combined with an approach to select and prioritize technologies for the duration of the program, as well as an investment return analysis to provide continuous feedback that we are not only =doing things right= but also =doing the right thing=.<p>
<A HREF="Mars.html">Return to menu</a><p>

<A NAME="Preclndg"><H3>Precision Landing</h3></a><p>
<H5>Point of Contact:  David L. Farless</h5><p>
<img src="MARS.GIF"><p>
<H4>Viking Lander 2, Camera 1 Picture (21F243)</h4><p>
<CENTER>
<H2>So, you want to land on Mars?</h2>
</center><p>
Mars landing site selection is based primarily on science objectives and landing safety but is complicated by the current inability to navigate to an actual landing location close to the desired location.  Precision landing is an important and perhaps enabling capability for several future Mars missions because many interesting areas of scientific investigation on Mars are either small in extent or lie within regions of hazardous terrain (see for example the picture below).  Also, precision landing may be crucial to Mars sample return scenarios in which a sample is left from a previous mission to be acquired by a return vehicle via a rover or a lander manipulator. This task will advance the state-of-the-art in specific precision landing technologies, building upon the work of others, and utilizing resources of other organizations wherever appropriate.  For example, contacts have already been established with Johnson Space Center, Lockheed-Martin Company, Phillips Laboratory, and Draper Labs. These relationships will be continued and formalized as appropriate.<p>
<H4>LANDING ACCURACY IMPROVEMENT ILLUSTRATION</h4><p>
<img src="Gusev.GIF"><p>
<H4>Definition of Terms</h4><p>
For purposes of this task, precision landing is defined as safely setting a craft down on the surface of Mars, next to a predetermined site, with some small error in position.  This error is variable, dependent on specific mission requirements, but will be defined here to be less than 1 km.  The reference to a predetermined site in this definition presumes an accurate landing, as well as a precise landing.  That is, it is not sufficient to land precisely (using a high precision terminal descent system to avoid rocks and land softly with no horizontal drift) at an arbitrary location on Mars.  The landing must be near a pre-defined target location.<p>

<H4>The Mars Landing Mission</h4><p>
The Mars landing mission begins with launch and escape from the Earth onto a Sun-centered trajectory (heliocentric).  The spacecraft travels about half way around the Sun while moving outward from the Sun.  When it reaches the distance of Mars, it is moving slower than Mars so the planet overtakes it from behind.  On arrival at Mars, the spacecraft may impact (i.e., land) directly or it may establish an orbit about Mars first, and then descend to land.  This task is primarily concerned with the direct Mars landing mission because it is less complex and shorter in duration.  However, the use of an orbital phase will be optional, and the development work done for each of the other mission phases will be largely applicable in the case of descent from orbit.<p>

The table below defines a set of mission phases for the Mars lander mission:
<img src="Phase.GIF"><P>
Based on todays technology, as represented by the Mars Pathfinder and Mars Surveyor 98 lander mission designs, landing location errors can be more than 150 km.  Most of this error derives from two sources:  Navigation errors on the approach to Mars, and corruption of the trajectory during the entry phase by aerodynamic uncertainties.  It is also in these two mission phases, the Planetary Approach Phase and the Atmospheric Entry Phase, where the control power exists to correct errors of this magnitude.  In the subsequent mission phases, the Parachute Phase and the Terminal Descent Phase, landing location correction is very expensive in terms of landed mass, and so will be limited to a few km at best.<p>

Navigation on the  Approach Phase of the interplanetary trajectory (the last 15 days before arrival), using current-technology Earth-based radio tracking, provides position errors at the entry point of 10-30 km (entry flight path angle error of 0.5-1.5 deg).  These values are the navigation knowledge at 10-15 days before entry, where the final correction maneuver is traditionally performed.  After this time, knowledge accuracy continues to improve slowly until the last few hours before entry, when it rapidly improves to about 3 km (0.15 deg entry angle error).  Maneuvers late in the  Approach Navigation Phase could convert these knowledge errors to control errors at entry.  Another option for improving these errors is the use of optical navigation on the approach to Mars (imaging the Mars moons, Phobos and Deimos) and/or the use of new radiometric data types (e.g.; Differenced Doppler, multi-s/c tracking).  These techniques could potentially reduce the entry error to the 3-km level earlier on the approach trajectory, perhaps as early as 2-4 days before entry.<p>

Even if the approach navigation were perfect, errors and unknowns in the atmosphere of Mars and in the aerodynamic behavior of the entry vehicle would corrupt the trajectory during the entry phase so that the landing point error would be on the order of 100 km.  The actual error is highly dependent on the nominal entry angle (shallower entry angles lead to higher landed dispersions) and on the real (but unknown) variability in the atmosphere.<p>

The only way to correct these large errors is to provide active control of the trajectory during the Entry Phase of the mission.  This can be done most effectively by the use of aerodynamic lift, modulated either by changing the pitch angle of the vehicle to change the magnitude of the lift vector or by rolling the vehicle to point the lift vector up, down, left, or right.  Current Mars entry vehicle shapes (i.e., Pathfinder and Mars 1998) could generate a lift-to-drag ratio (L/D) of only about 0.3.  This may provide enough control authority to correct for atmospheric variations and small entry errors (i.e., the 3 km errors discussed above).  To correct for the current approach navigation errors (i.e., 10-30 km), a higher L/D may be required, probably 0.8 or greater.  This could be provided by a new technology entry shape (e.g., a symmetrical bi-conic).  In either case, residual dispersions at the end of the entry phase are expected to be less than 10 km.<p>

At the conclusion of the Approach and Entry phases of the Mars landing mission, the lander is left at a position a few km above the surface, and a few km away from the intended landing location (distance and direction perhaps unknown), probably hanging on a parachute.  To get from there to a safe landing near the target point, the lander will need to perform a propulsive Terminal Descent Phase, navigating to the desired landing site location.  The (unknown) distance and direction to the target site at the initiation of the Terminal Descent Phase are primarily functions of the navigation and control errors of the previous mission phases, but will also include additional components from parachute drift in the local wind and from map-tie errors. (Map-tie errors are errors or uncertainties in connecting the local coordinate frame of the map identifying the landing site with the coordinate frame of the rotating globe defined in the approach and entry trajectory model.)<p>

Navigation to this target site requires a system to sense and measure the distance and direction to the target.  The only reasonable systems for this measurement are on-board systems which sense and measure the local environment directly.  For example, optical systems (cameras) could image the terrain below the lander at visible or infrared frequencies and process the image to compare it with stored map data and match the imaged terrain to a known map location.  With a known location on a map which also contains the desired landing site location, the direction and distance to the site are known.  The descent system will almost certainly include a radar altimeter as a requirement for soft landing.  The available altitude measurement can be of significant help in solving the target recognition problem by providing a scale for the optical image.  An imaging system like this could also provide hazard avoidance information late in the descent with some different image processing algorithm to look for smooth terrain.<p>

<H4>Landing Accuracy Improvement Strategy</h4>
As part of the FY95 work accomplished to date, a strategy has been developed for improving the accuracy and precision of landings on Mars.  This strategy is outlined below:<p>
<UL>
<LI>The Approach and Entry Phase and the Parachute and Terminal Descent Phase can be considered as separate and distinct portions of the landing mission, with an interface at parachute deployment.  That is, landed accuracy down to a few kilometers depends only on what happens in the Approach and Entry Phases, while landed accuracy below the level of a few km depends only on what happens in the Parachute and Terminal Descent Phases.
<LI>For the Approach/Entry Phase, the goal is to reduce the position error at parachute deployment below the current value of ~  150 km.  Reduction to  50 km would be of use, but reduction to less than  10 km is needed before precision landings can be accomplished.
<LI>For the Terminal Descent Phase, the goal is to navigate over several km, correcting for;  1) errors at parachute deployment left over from the approach/entry phase, 2) wind-induced errors while on the parachute, and 3) map-tie errors.  It is assumed that a propulsion system and radar altimeter are required, regardless of precision landing requirements, just to provide a soft landing with no horizontal motion.  Both accuracy and precision in this phase require the ability to sense target-relative location and/or to sense hazards.
</ul>
The following chart illustrates this gradation in landed accuracy and how the application of specific technology advances can enable precision landing at Mars.
<img src="Strategy.GIF"><p>
<H4>FY 95 Milestones</h4><p>
<UL>
<LI>Quantify errors in landing site location and develop a strategy to reduce these errors. Determine approaches to error reduction through the use of technologies in on-board guidance, navigation and control, vehicle configuration, propulsive maneuverability, and remote sensing. Include approach navigation in this investigation. Evolve vehicle configuration from Mars 98 baseline. The study will compute: 1) the entry angle accuracy achievable from ground tracking versus on-board optical navigation; 2) aerodynamic error reduction using lifting body control; and 3) map-tie error reduction based local terrain navigation. The study will identify technologies that can be progressed to detailed computer simulations and selected hardware experiments and demonstrations in FY 96.
<LI>Define potential opportunities for demonstration of technology in the 98 Lander mission (or possible Code X experiment). Focus on demonstrations of software only, with minimal effect on mission operations.
</ul>
<H4>FY 95 Level 1 Milestone Accomplishments</h4><p>
<UL>
<LI>Contributions to the error in landing site location from all mission phases have been quantified and assessed for the potential to contribute to improvement in the landing error.
<LI>The current landing error is in the range from 100 km to 300 km, depending on mission specifics and environmental assumptions. 
<LI>The error resulting from the Approach Navigation Phase using standard Earth-based radio navigation is about 30 km in position (about 0.15 deg in flight path angle).  This error could realistically be reduced by an order of magnitude by using optical navigation techniques in conjunction with radio navigation.  However, subsequent corruption of the trajectory during the Atmospheric Entry Phase still leaves a landing error of from 50 km to 100 km.
<LI>Active aerodynamic maneuvering during the Atmospheric Entry Phase may reduce this error to less than 10 km, but this is still to be demonstrated.  A next-generation entry vehicle configuration with a lift-to-drag ratio of 1.1 was demonstrated to have the control authority to correct for expected atmospheric variability and the current radio-only approach navigation entry errors.  Use of a low-lift Mars 98 entry vehicle configuration severely limits the control authority available for aerodynamic maneuvering and will require the use of optical approach navigation and less conservative assumptions about atmospheric variability to achieve an accuracy of less than 10 km.
<LI>During the Parachute Phase an additional error of up to 2 km may be accumulated due to wind drift.  There is no capability to control the trajectory in this Phase
<LI>Reduction of these last few km of error will require the ability to navigate during the powered Terminal Descent Phase relative to the local terrain.  Guidance and control errors in this phase are small, on the order of meters, so the final landing error will depend on the quality of the navigation information.  This terminal navigation process will likely involve imaging of the surface for comparison with a terrain map stored on the lander.
<LI>A landing accuracy improvement strategy has been developed and used to identify two areas of the Mars Landing Mission where development of new capabilities is necessary before a precision landing mission can be attempted.  Autonomous aerodynamic maneuvering in the Entry Phase is found to be the only way to compensate for the large errors introduced in this phase, and autonomous acquisition and analysis of terrain-relative position data is needed to allow navigation during the powered Terminal Descent Phase.  The two specific technologies identified for future work are:  1) control system design for active trajectory control in the Entry Phase and 2) terrain matching for terminal navigation using real-time visible light images.
</ul>
<H4>FY 95 Level 2 Milestone Accomplishment</h4><p>
<UL>
<LI>The Mars 98 lander mission and systems were examined for opportunities to demonstrate some aspects of precision landing technology.  The only potential uncovered is in the Approach Navigation Phase where it may be possible to do independent ground processing of new radio data types to try to improve the approach trajectory knowledge error.  The recent selection, as one of the lander science instruments, of a camera for terrain imaging during the Parachute and Terminal Descent Phases may open new opportunities.
</ul>
<H4>FY 96 Milestones</h4><p>
<UL>
<LI>Develop and demonstrate via computer simulation a six degree-of-freedom flight control system concept for autonomous aero-maneuvering for flight path control during the Entry Phase.  This concept will use a low lift-to-drag ratio entry vehicle configuration, a nonlinear inversion control scheme, and state-of-the-art characteristics for on-board systems (i.e., sensors, attitude control, computers, etc.).  The computer simulations will evaluate the control authority and terminal errors of this concept for a wide range of variations in the environment and in the initial state control and knowledge (i.e., Approach Navigation Phase errors).
<LI>Develop and test techniques for terrain-matching of visible-light images of Mars-like terrain.  Images of California desert terrain (Amboy Crater in the Mojave desert and Mars Hill, in Death Valley) are available from previous Mars landing studies and these data will be used to develop specific terrain-matching techniques to demonstrate the viability of the concept.  Low-altitude images will be correlated to locations in high-altitude images with similar lighting conditions.  The correlations will be performed autonomously in computer simulations.  Algorithms which are successful in cases of similar lighting angles and look angles will then be tested for robustness with images at differing lighting and look angles.  The computer power and time constants required for successful terrain-matching will be documented.
</ul>

</DOC>
<DOC>
<DOCNO>WT01-B04-51</DOCNO>
<DOCOLDNO>IA080-000557-B035-64</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/ISPP.html 137.79.14.197 19970103071502 text/html 23030
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f31c.331@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:19:56 GMT
Last-Modified: Friday, 02-Aug-96 20:23:48 GMT
Content-type: text/html
Content-length: 22785
</DOCHDR>
<TITLE>ISPP</title>
<img src="ISPP.GIF">
<H3>In Situ Propellant Production (ISPP)</h3><p>
<H5>Point of Contact:  Donald Rapp</h5><p>
</center>
Use of the Martian atmosphere to produce oxygen propellant for a return trip to Earth can dramatically lower the mission payload and hence the cost and launch requirements of a Mars Sample Return mission. A figure of merit for this technology is the mass that must be launched in order to return a sample of any given weight and diversity of Mars materials to Earth. The degree to which In Situ Propellant Production (ISPP) reduces this mass is the main value of ISPP. There is also a less tangible value in that this use of ISPP provides a precursor to the more general need for In Situ Resource Utilization for human exploration. The total value must be pitted against the additional complexity and risk associated with use of ISPP, as well as the cost of developing and implementing ISPP. Various elements of prototype hardware to demonstrate these processes have been developed by several organizations, notably Lockheed Martin and the University of Arizona. The object now is to take these beginnings, and demonstrate that viable systems can be produced from them. Ultimately, these chemical conversion systems must be integrated and combined with storage/cryogenic systems, energy systems, and propulsion systems. <p>

The potential for ISPP to reduce the mass of a direct entry/direct return (DE/DR) MSR mission is significant, although the benefits will be mission-dependent, and proper account must be taken of the mass of the ISPP system including its power system. Whether the actual mass reduction will be enough to reduce the required launch vehicle size remains to be seen. Ultimately, other mass reduction steps may need to be taken in conjunction with ISPP in order to secure a significant reduction in launch vehicle size (and cost). ISPP will have to be made essentially self-regulating and autonomous, including the capability of dealing with off-design conditions. Nevertheless, ISPP is clearly the single step with by far, the greatest leverage for mass reduction of a DE/DR MSR mission, and on this ground should be pursued further. On the other hand, other approaches than a DE/DR mission, if developed and verified in space, may reduce the need for ISPP. However, schemes which depend on autonomous rendezvous, docking and sample transfer in heliocentric space with time delays is a very difficult technology that will require considerable further development and expensive verification in space. If they also depend on pinpoint landing, that adds another major element of risk to such an approach. Regardless of how vital ISPP will be for a 2005 MSR mission, ISPP is one of the technical cornerstones for human exploration of Mars and the Moon. Human exploration sources might provide additional funds to speed up development of ISPP.<p> 

A typical Mars ISPP process includes many steps ranging from carrying propellant tanks to Mars surface, to compressing the Martian atmosphere, chemically converting CO2 to O2 and possibly a hydrocarbon propellant, compressing, cooling and liquefying product gases and storing in empty propellant tanks and lifting off using thrusters specifically designed for the propellants produced. <p>

There are two overall processes for ISPP which are the most mature.<p>

One process uses the Sabatier/Electrolysis (S/E) process, in which hydrogen (brought from Earth) is reacted with compressed CO2 in a heated chemical reactor:<p>

[1]	CO2 + 4 H2    ----->   CH4  +  2 H2O<p>

The methane so formed is collected and saved for use as a propellant. The water is collected, deionized, and electrolyzed in an electrolysis cell:<p>

[2]	2H2O + electricity ------> 2H2  +  O2<p>

The oxygen is saved for use as a propellant. Under support from this RTOP, the S/E process has been studied in some detail ("In Situ Propellant Production Demonstration," Final report, Report No. MCR-95-561, JPL Contract 960247, LMA, April 3, 1996) at a lab bench level. The great advantage of this process is that it is fairly well understood and seems to work well as a system. There do not seem to be any fundamental technological challenges ahead in further perfection of the conversion plant system, although a number of engineering improvements are necessary. There are two potential problems with the S/E process. One is that the process is fairly complex and requires a number of vessels and considerable plumbing, which could drive the mass up and increase system risk. The other, which appears to be more serious, is the requirement of bringing hydrogen from Earth. This is a potential mass/cost driver for a mission, and at this juncture, it is not clear how to transport and store hydrogen on Mars within acceptable mass and power limits. If the S/E process is to be developed to a flight system, it will be important to investigate hydrogen storage.<p>

The second process, typically known as the "zirconia approach," partially dissociates Martian CO2 and utilizes a solid state electrolyte (typically yttria-stabilized zirconia at ~ 900oC) to transport oxygen ions across a membrane in order to remove O2 from the partially dissociated mixture. This requires a suitable catalyst/electrode at the surface of the electrolyte to convert gaseous oxygen to oxygen ions.<p>

The great attraction of the zirconia process is the conceptual simplicity of the oxygen separation process and the potential for a compact cell. However, in practice, the tradition has been to rely on tubular ceramic cells for test purposes. These are not compact, and appear to be structurally flimsy and liable to failure under launch or landing loads. A new concept for combining planar fuel cell geometry with the use of rugged single crystal sheets of zirconia interspersed with platinum electrodes holds promise for simple, inexpensive, rugged zirconia assemblies. However, these must be proven by experiment.<p>

Other ISPP approaches have been proposed. These are under review. They include use of the Reverse Water Gas Shift reaction to enhance oxygen production, possible use of a gas discharge front-end for Zirconia, and possible use of diborane and carbon dioxide as propellants.<p>
<H3>The JPL Program Plan for ISPP Technology Development</h3><p>

In developing ISPP, our goal is to demonstrate a viable technology in the form of a compact, flight-like unit which can be tested in a relevant environment, consistent with sample return programmatic objectives.<p>

<H3>1st Year's Work Plan (April 1995 - April 1996):</h3><p>

After reviewing the funding available and the state of the technology, it was decided that the following constraints would apply to the first year's work:<p>
<OL>
<LI>initial work was concentrated on determining the performance characteristics and general viability of the S/E and Zirconia processes in laboratory bench scale prototypes.  
<LI>It was decided that when sufficient data become available to indicate with reasonable probability that at least one of these processes is indeed viable, the more attractive of these will be selected for demonstration as a compact, flight-like unit which can be tested in a relevant environment. 
<LI>Technology development on the interface technologies which tie directly to ISPP: (i) thermal and power management, (ii) compatibility with designs and configurations of descent and ascent vehicles, and (iii) gas pressurization, liquefaction and cryogenic storage, and (iv) compatibility with propulsion systems (gas-feed, and thruster performance) will follow after demonstration of compact, processing unit in later years.
<LI>We will stay alert to new ideas in ISPP as they arise, but only as a distant secondary priority behind developing S/E or Zirconia to the demonstration stage (unless a new idea arrives which is so overwhelmingly attractive as to cause us to change this Plan). 
</ol>
In the first year, the two competing processes (S/E and Zirconia) were developed over a 12 month period, having starting in April 1995, with a comprehensive review and decision point on April 3, 1996 as to how to proceed with further development (select one process, go with both in parallel, or start anew).<p>

This program began in January 1995, when requests were made to important players in the ISPP community to make proposals for research. Ten proposals were received. Two contracts were issued. One contract was issued to Lockheed-Martin to upgrade their S/E brassboard and carry out medium duration testing to assure that we understand its performance prior to building a compact end-to-end system. The other contract was issued to the University of Arizona to build a prototype multiple electrode zirconia cell system using flat plate (fuel cell) geometry with new approaches for seals and materials, and with an single crystal zirconia, which does not suffer from crumbling problems associated with ceramics. An all-metal system completely eliminated ceramics from the system. This system is intended to demonstrate that zirconia systems can be built rugged, resistant to thermal shock, and with adequate performance, as a precursor to a compact end-to-end system.<p>
<H3>Review of 1st Year's Accomplishments (April 1995 - April 1996):</h3><p>

The following conclusions are based on a full day review of the two competing processes held at JPL April 3, 1996.<p>

Several unsettled major issues loom over any potential ISPP process, including the need for:<p>
<OL>
<LI>a sorption pump for carbon dioxide acquisition which can function in the Mars environment on a diurnal cycle, acquiring carbon dioxide at night with atmospheric filtering, while remaining insulated during the day, integrable with reactor waste heat; all with acceptable power requirements
<LI>liquefaction and cryo-storage of oxygen, and 
<LI>an adequate power system based on demonstrated long term performance of large solar arrays in the Mars environment.<p> 
The Lockheed Martin development of the Sabatier/Water Electrolysis (S/E) process represents an outstanding achievement in terms of quality and quantity of progress made on a minimal budget. They have gone a long way toward demonstrating that an ISPP conversion system utilizing an S/E reactor and electrolyzer system is a viable process under controlled laboratory conditions. They have also made impressive progress in raising the conversion efficiency, hydrogen recovery, and automation and control of the process, as well as acquisition of carbon dioxide by a sorption pump. We also acknowledge the vital help received from Hamilton-Standard by Lockheed Martin, particularly in electrolysis unit, catalyst materials and in the hydrogen recovery pump. Hamilton-Standard has been a major contributor to this program. However, several critical issues specific to the S/E process remain:<p> 

<LI>transport and long-term storage of hydrogen, 
<LI>definition and analysis of the operating modes on Mars including a materials inventory profile including tankage use, rate of production of water, storage of water, etc., 
<LI>procedures for start-up and shut-down, purging of lines and filters, and sensors and control system to handle off-design conditions
<LI>liquefaction and cryo-storage of methane
<LI>purity of gases produced.<p>

The University of Arizona development of a unique zirconia process reactor design is based on two very good ideas: single crystal zirconia and an all-metal rugged structure. This design approach is worth developing further. However, this concept will not work unless several fundamental problems are solved:<p>
<LI>a reliable method for applying Pt electrodes of desired thickness and porosity to single crystal zirconia
<LI>a reliable method for providing uniform current density across an entire zirconia wafer (spoked electrodes, metal inserts, ...)
<LI>a credible analysis to demonstrate reasonable gas flow and temperature uniformity in the various plena between cells
<LI>a credible mechanical design for series connection of the cells which provides a context and configuration for the design of small experiments to verify issues 9, 10 and 11 above
<LI>a comprehensive coupled electro/thermal/mass model must be developed which provides an understanding of the gas flows, heat flows and electrical current distribution in a cell, which provides a framework for defining acceptable gas inlets and outlets and current carrying elements attached to the wafers to achieve acceptable cell efficiency and reliability. Concomitant with this is a credible analysis of requirements for initial heating in the morning and time delays before processing can begin.<p>

Future work must deal directly with these problems as well as quantification of leak rates and sealing requirements, and further vibration and shock testing.<p> 

The S/E chemical conversion system is clearly more mature than the zirconia chemical conversion system. However, we are still dubious about the S/E process as a system  because <p>

<LI>it requires three cryogenic subsystems: methane, oxygen and hydrogen as opposed to zirconia which only requires oxygen 
<LI>there is no satisfactory definition and analysis of the operating modes on Mars including a materials and mass inventory profile of tankage use, rate of production of water, storage of water, etc., 
<LI>procedures for start-up and shut-down, purging of lines and filters, and controlling the system under off-design conditions, and separation of products need to be clarified
<LI>of its general complexity and reliance on many valves and plumbing elements, as well as sensors and controls
</ol>
Financial constraints and programmatic imperatives toward a 2005 MSR launch dictate that the JPL ISPP Program should limit itself to only one process: S/E or zirconia; and at this stage the choice has been reluctantly made for zirconia. The S/E process has been demonstrated to be viable in a laboratory breadboard, but there remain deep-rooted concerns about the S/E process' need for hydrogen, the need to liquefy two propellants, the general complexity of the process, and uncertainties about the materials inventory profile of tankage use, rate of production of water, storage of water, etc. Although there have been significant problems in the initial development of the zirconia system, the ultimate potential product has great appeal because of its innate potential simplicity, compactness, ease of control, freedom from hydrogen, and lesser need for cryogenics. We have therefore opted for putting all of the program's 2nd year resources into a concerted effort to verify that a zirconia cell system is viable.<p> 

Most of the testing of ISPP systems can be done on Earth in Mars simulation chambers. However, it is almost certain that some aspects of ISPP technology will need to be verified via a flight demonstration (probably on the 2001 Lander) through the sequence of transport to Mars, entry, landing and operation on the surface. The leading candidates for flight experiments or demonstrations are:<p>
<UL>
<LI>either an experiment to characterize the dust environment for purposes of designing filters for intake into the sorption pump, or a direct demonstration of an atmospheric filter operating as the front end of a sorption pump for carbon dioxide acquisition 
<LI>a typical solar array element operating for extended periods in the Mars environment
<LI>heat rejection measurements to characterize the ability of surfaces to exchange heat with the dusty Mars environment
<LI>entry and landing accelerometer measurements 
</ul>
These demonstrations can be done on a small scale, with minimal mass and power impacts on the Landers. It is hoped to find funds external to the RTOP to develop a flight package to demonstrate these capabilities on Mars.<p>

<H3>2nd Year's Work Plan:</h3><p>
<UL>
<LI>A new design concept was received from Arizona for a modified approach to zirconia
<LI>This was reviewed favorably by JPL engineers
<LI>The design provides good gas flow, even voltage distribution and series connection of cells 
<LI>A new proposal was received from Arizona to build and test an improved version of the zirconia MOXCE device. It has been accepted.
<LI>A plan to develop an improved sorption pump for CO2 acquisition was developed and is now being implemented through the contract process.
</ul>
<H3>ISPP Roadmap:</h3><p>

In order for ISPP to be ready for use on a Mars Sample Return (MSR) mission, a number of technical and systems issues must be addressed to a level of completeness and satisfaction that a hard-nosed project manager would be willing to rely on this technology for the successful completion of the mission. A critical decision would presumably be made around June 2002, 36 months before launch. <p>

Four phases of development and demonstration are described in Table I which must be achieved prior to acceptance for a 2005 MSR mission. Each phase should be essentially completed before investing in the next level. These four levels are spread across the time period June, 1996 to June 2002, providing six years for development and demonstration.<p>

With these assumptions, Table I shows the elements that can be funded from the combination of the JPL ISPP Task within the Mars Exploration RTOP plus HEDS funding of Row #5. The unshaded blocks represent tasks that require additional funding.<p> 
<CENTER>
<img src="ISPPBarGrph.GIF"><p>
<B>Figure 1. RTOP and HEDS/Mars Project Funding for ISPP.</b><p>
</center>

<I>Table I. Phased Development Showing Shaded Regions for those Elements Which Would be Funded by the JPL ISPP Task within the Mars Exploration RTOP plus HEDS funding of Row #5</i><p>
<CENTER>
<img src="ISPPTbl1.GIF"><p>
</center>
<U><H3>Appendix I. How much leverage is there in an ISPP MSR mission?</h3></u><p>
A crude estimation has been made of the mass of an ISPP version of the above Baseline MSR mission, assuming that oxygen only is produced by the Zirconia Electrolysis process and propane is brought from Earth.  The mass saving compared to the baseline mission is 550 kg for the injected mass, or approximately 37%.<p>
<I>Table A1-1. Masses (kg) of the sub-spacecraft estimated for an ISPP MSR mission as estimated by D. Rapp</i><p>
<CENTER>
<img src="ISPPTblA11.GIF">
</center>
** Need not be brought from Earth - made from Martian atmosphere<p>

Note that even a hypothetically perfect ISPP conversion system with zero mass cannot reduce the mass of the mission by more than roughly a factor of two because ascent propellants amount to less than half the total mass of the Baseline MSR mission.  Therefore, the oft-discussed "leverage" of various ISPP processes<p>
<CENTER>
<img src="ISPPEquation.GIF"><p>
</center><p>
is only of remote importance.  Even if this ratio is infinity, the maximum possible leverage for the mission mass is less than a factor of two.<p>

On the other hand, roughly 600 kg of the ~1490 kg total mass of the Baseline MSR mission (see Table 2) is allocated to space storable propellants.  The ISPP system reduces this in two ways (the higher Isp requires less propellant, and only ~20% of the propellants (propane) need be brought from Earth).  The net result is that the total mass of the ISPP system and its concomitant power system and chemicals brought from Earth is only about 175kg, resulting in a saving of 432 kg.  Furthermore, a ripple effect will reduce many other masses (structure, propulsion for Mars entry, parachutes, etc.) because one does not have to land all this propellant on Mars.  This has been taken into account in the mass assessments, and saves about another 50 kg of dry mass and 70 kg of entry propellants, so that the total mass savings from ISPP is roughly 550 kg.  Note that the guess of 40 kg for the ISPP power system is a wild guess, and may not be accurate at all.  This estimate is based on the assumption that an ultra-lightweight inflatable array can be developed.<p>

<U><H3>Appendix II. Mars Scenario for ISPP</u></h3><p>

The first step in any ISPP process is usually compression of the indigenous carbon dioxide from its natural pressure of roughly 7 millibars to roughly 1 bar.  After that, chemical conversion may take place.  It appears likely that radioactive thermal generators (RTGs) will not be permitted on future Mars landers and therefore the probable scenario for operation of the S/E process will absorb carbon dioxide from the atmosphere at night in cold sorbents, while the reactor is shut down.  When the sun comes up, the initial available power is first used to pre-heat the sorption pump and generate high pressure (~1 bar) CO2.  Then the reactor is pre-heated.  Finally, power is used to operate the ISPP system and the cryo-coolers.  At night, absorption of carbon dioxide is repeated, etc.  This pump is a non-trivial part of an ISPP system, and is likely to require a canister perhaps 0.7 m high by 0.2 m in dia, weighing perhaps 10 kg.  A significant portion of the heat required to produce high pressure gas could likely come from waste heat from the reactor.<p>

The Mars Lander would put the ISPP unit into operation and it would fellow this diurnal cycle for about 600 days, producing roughly 0.6 kg of oxygen every day.  After this period, the positions of Mars and Earth would be right for ascent and return to Earth.  By contrast, in the Baseline mission, the stay on Mars might be a relatively short period.  Thus, the mission operations cost of an ISPP mission is bound to be considerably higher than the Baseline mission.  However, it is possible that much exploration, science observation and sample gathering could be achieved in this 600 day period, resulting in a much bigger science payoff than would be possible with a short mission.<p>

In the simplest form of the Zirconia process, fuel (probably in the form of propane) is brought from Earth.  The process produces only oxygen.  Compressed Martian CO2 is introduced into a chamber heated to ~900oC where it is partly dissociated.  A zirconia membrane coated with porous platinum on a wall of this chamber has a voltage applied to it, allowing oxygen to be conducted as ions across the membrane into an antechamber containing pure oxygen.  The oxygen is cryo-cooled and stored.<p>

The design of the Mars Ascent Vehicle has significant impact on the value of any particular ISPP system, and vice versa.  The staging of the Mars Ascent Vehicle, the sizing and positioning of the tankage, and the utilization of tankage for storage of chemicals and propulsion are all closely coupled to the ISPP system.  An ISPP system cannot and should not be developed in isolation, but rather as a part of an overall program to develop a propulsion system for the MAV.<p>
<A HREF="Mars.html">Return to menu</a><p>

</DOC>
<DOC>
<DOCNO>WT01-B04-52</DOCNO>
<DOCOLDNO>IA080-000557-B035-86</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Sampacq.html 137.79.14.197 19970103071514 text/html 18013
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f330.332@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:20:16 GMT
Last-Modified: Tuesday, 28-Nov-95 00:43:51 GMT
Content-type: text/html
Content-length: 17767
</DOCHDR>
<TITLE>Sample Acquisition</title>
<H3>Sample Acquisition</h3><p>
<H5>Point of Contact:  Paul S. Schenker</h5><p>
<img src="MLRS.GIF"><p>
Sample acquisition is a significant part of any surface exploration project, whether it be in situ or sample return (ref. 25, 26). Ref. 1 discusses sampling requirements for a MSR. These requirements are summarized in Table 2.<p>
<p>
<img src="Table2.GIF"><p>
<p>
Even for a low cost sample return, careful sample selection will be necessary, and rocks are highly desirable, although constraints may be such that only loose soil and pebbles may be collected. In Ref. 1, size and power limitations were thought to preclude sawing or coring, and it was hoped that the need for unweathered rock would be answered by collecting pebbles and utilizing material from their interiors. However, the ability to chip or core during the sample collection process itself might still prove feasible, and could be of great scientific value. Furthermore, a mission concerned with water detection would probably concentrate on acquisition of sub-soil samples by drilling.<p>

It is possible that in order to reduce costs, future MSR planners may accept smaller samples, but the values given in Table 1 seem to represent a consensus of opinion of the minimum desired sample size. Note that Ref. 13 assumes a 5 kg sample on the grounds that the MESUR-based sample return study (conducted by Lockheed-Martin and JPL in 1993) determined that for any given sample, 100 grams of material is sufficient to correctly characterize the sample type. However, they recommend 5 kg as a reasonable starting point for the total sample set in order to carry out needed analyses on a range of samples.<p> 

In Ref. 1, it was conjectured that a scoop mounted on a one degree-of-freedom (DOF) arm at the front of a mini-rover should be sufficient to obtain samples of both pebbles and regolith. Samples would be stored in a carousel assembly in the Lander, consisting of three carousels stacked vertically. Prior to taking a sample, a can is placed on the rover by a mechanism on the lander. Sampling takes place on the rover, the forward motion of which scoops material into the can. Cans are retrieved and sealed by the Lander.<p>

It is difficult to know how appropriate this scenario from Ref. 1 will be for use in a future MSR mission. Questions remain as to how much intervention and selection will be made by operators from Earth, and whether we will be able to afford a rover. All samples might be taken directly by a Lander, using various Lander-based robotic mechanisms and controls to selectively sample both the near surface area and sub-surface strata of the landing site. Thus, the Lander-based phase of the scenario, e.g. sample acquisition and transfer to the Lander, sample preparation, in situ analysis and packaging (for a potential sample return) all need further elucidation, and are a central focus of this program.  Because these capabilities are important whether or not a rover operates in conjunction with the Lander, we give them priority in our program planning, both as to earlier development and relative technology  emphasis.<p>

Sampling requirements for the 1998 and 2001 Lander missions are also somewhat unclear. Thirty-six of the 64 potential Mars surface instruments would require horizontal deployment on the surface, with roughly 2/3 of these requiring deployment distances of  1 m, and about 1/3 requiring deployment distances of 1 to 10 m. Two instruments need deployment distances greater than 10 m (Ref. 15). Some instruments require vertical deployment with a mast or balloon. Thirty-nine instruments require bringing a sample back to the instrument. Of these, 17 required soil, 11 rock, 7 unweathered rock, 2 duricrust and 2 required ice. Surface manipulators to acquire these samples were suggested as scoops, soil cores, trenchers, chippers, augers and drills. It seems highly desirable to develop a limited sampling capability which might be applicable to the 1998 mission (as a prelude to more capable sampling systems on future missions), which emphasizes mass and power reduction, and allows for maximal flexibility for sample selection.<p>

Based on this mission perspective, the starting assumptions for Sample Acquisition/Evaluation Testbed (SA/ET) technology work of the program are:<p>
<OL>
<LI>Initial sampling capability development within this program will be Lander based; rover based sampling is being developed in a complementary Rover Technology Program also supportive of the Mars Exploration Program. 
<LI>The Lander will have a capability to examine its surroundings, either by remote near-field observation, or by applying a probe on a sampling arm to nearby soil and rocks.).
<LI>Operators on Earth may make limited selections of areas for taking samples, by visually designating areas/objects of science interest about the Lander.
<LI>Mechanisms deployed by the Lander will take samples, by limited degree-of-freedom manipulation of a robot arm in the near field, or possibly by coring below the lander site. Use of a robotic arm will initially emphasize grasping and scooping, and evolve to probing and actively controlled sample extraction (e.g., core-drill, chip, scrape).
<LI>The sampling system for an in situ project will be similar to that for a sample return project, the difference being that in the former case, samples are analyzed with instruments on the Lander, while in the latter case, samples are processed and loaded into cans in a carousel and transferred to a sample return capsule.
<LI>It is desirable to have an evolutionary program which can contribute increasingly more capable sampling technology to a succession of landers, leading eventually to a sample return mission.
</ol>
Specifically, this program will develop capabilities in the following sampling technology areas:<p>
<UL>
<LI>visual user interfaces and work site calibration for the operators sample selection
<LI>efficient control of robotic motions during sampling (free-space, guarded, and contact) including power and energy conservation/management
<LI>sensor processing/perception for robot guidance, sample acquisition and analysis
<LI>robot control behavior for robust autonomy in response to real-time sensor data
<LI>control architecture integrating sensor and knowledge-driven sampling activities
</ul>
These advances will be coordinated with a parallel RTOP task entitled Lander Manipulators under the Telerobotics Program, which will design, fabricate, and test the mechanical structures (joints, actuators, links, end-effectors, etc.) needed to be controlled by the systems developed in this RTOP. The combined effort will lead to demonstration of Lander-based sample acquisition/evaluation approaches which include:<p>
<UL>
<LI>autonomous acquisition of samples from random locations about the Lander
<LI>operator-designated acquisition of samples from areas and objects of interest
<LI>coring of samples from selective strata beneath the Lander site
<LI>transfer of robotically acquired samples to Lander for sample analysis or return
<LI>automated sample preparation and in situ analysis within the module
<LI>coordination of the previous activities with rover sample acquisition
</ul>
The goal of this task is strategically coordinated advances in robotic mechanization, controls, and perception to enable Mars surface/sub-surface sampling in the near field of a miniature lander. This work will be carried out in mutually beneficial cooperation with manipulator technology developments of the NASA Code X Telerobotics Program. Specifically, the Mars Exploration Technology Program will emphasize perception and control functions for robust lander-based sampling operations and intelligent in situ sample analysis, while the Telerobotics Program will innovate sample acquisition devices consistent with the mass, power, volume, and cost constraints of Mars Surveyor-class science packages.<p>

The focus of the task is on mid-term Mars Surveyor science goals--the Mars 2001 Lander is representative, with evolution to Mars Sample Return a longer range task technology objective. R&D partnerships with the science community, NASA and outside, will be important to foster coherent sampling concepts, flight robotics technology insertion, and coupling to NASA strategic goals of cost-effective small-scale technologies. This task will therefore include strategic outside partnerships for in situ robotic science, for example coordinated robotic sample acquisition and spectroscopic sample analysis, with increasing miniaturization, autonomy, and data efficiency.<p>

There is an immediate opportunity to influence and perhaps contribute to Mars 1998 Lander science capabilities. Specifically, this task is making an accelerated effort in FY95 to define a relevant robotic sample acquisition subsystem for 1998 flight science integration. Progress in this work will be demonstrated through mid-FY95 laboratory technology concept demonstrations, broad communication of these capabilities to the Mars Science Working Group, and potential teaming relationships with interested science investigators for proposals into the $20M Mars 1998 Science AO package (this last effort to be conducted under separate funding). Consistent with primary funding goals of this task, the subject work will evolve to FY95-end new technology results in such areas as power-optimal sampling control strategies and volume-and-mass efficient deployable manipulator designs.<p>

The planned task developments in terms of yearly Level 1 Milestones are:<p>

<H4>FY95 Milestones</h4><p>
<UL>
<LI>Develop and demonstrate proof-of-concept for lander-based robotic sampling. Specifically, demonstrate capability for a robotic arm to reach out from a simulated lander platform to known near-field locations, scan and acquire samples of interest, and deposit a sample to a pre-specified lander location. The subject manipulator and controls development will provide a laboratory concept 3-d.o.f. serial arm of 2 meter (deployed) length--extensible to a replica flight implementation at 3.5 kg mass, 1.5 kg full extent payload, and 15x15x40 cubic-cm stowed volume.  As a derived product of this work, JPL proposed a robotic arm payload for the Mars 1998 Science AO (D. Paige, PI, UCLA/Mars Volatiles and Climate Surveyor) and was selected.
<LI>In the context of lander-based sampling, demonstrate flight-relevant innovations in control of the manipulator trajectories and sensor-referenced automated behaviors, with respective operations goals of minimizing power utilization for a given sampling objective and autonomously verifying task status & sampling system health during same.
</ul>
<H4>FY 96 Milestones</h4><p>
<UL>
<LI>In FY'95, the 3-d.o.f. Mars robotic arm prototype was operated under open loop control -- moving in free space, into abrupt contact, and through simulated soil/rocks based on programmed position controls only.  During FY'96, we will develop capabilities for sensor-based dexterous manipulation in closed-loop position and force.  This will enable such important science functions as commanding of the arm to an exact, operator designated location in the near field, a precision proximity camera scan of a sample surface, force-controlled emplacement of instruments and probes, and closed-loop position/force behaviors for trenching, sample grasp, and manipulation (e.g., flipping a rock over).  We will comparatively benchmark these new control-and-perception paradigms against FY'95 capabilities, using planned Mars Surveyor '98 lander task activities as reference studies.
<LI>Demonstrate capability of the lander-based sampling manipulator to autonomously place a simulated science sensor adjacent to an operator-selected location/object in the near field, thereby enabling a scan of immediate surroundings for information of geologic interest.
<LI>Develop, with science partners, lander-based Mars geological sample processing, utilizing an onboard instrument in-situ preparation-and-analysis of a simulated surface sample, e.g. material characterization by imaging spectroscopy.
<LI>Develop perceptual and algorithmic concepts for the lander-based intelligent automation of sample analysis, motivated by goals of down-link data compression and on-board science sample prioritization (extracting primary syntactic and semantic features of the sample data and ranking/classifying these relative to a particular training set or science-user defined attributes). Demonstrate this basic approach for discrimination and identification of basic Mars surface substrate materials by their characteristic visible and near-IR imaging spectra features.
</ul>
<H4>FY 97 Milestones</h4><p> 
<UL>
<LI>Develop an appropriate mechanization and sensor-referenced controls to enable sub-surface lander-based sampling up to depths of 1 meter in simulated Mars environments. Demonstrate retrieval of this sub-surface strata to a lander-based analysis, autonomously carrying out the sample acquisition, preparation, preliminary on-board analysis, and packaging (for hypothesized Mars sample return).
<LI>Develop and demonstrate an opportunistic science capability wherein a sensor of practical interest, used in coordination with thematic data obtained by a lander-mounted camera(s)/instrumentation, and carried by a lander-based robotic mechanism, scans the lander near-field proximity for objects of geologic interest, cataloguing its results (A science user will designate lander areas/objects of broad interest, and scanning will proceed semi-autonomously).
<LI>Develop and demonstrate sci-boom: a laboratory proof of concept for lander-based robotic science under extreme mass/volume/power/ cost constraints. This device concept is a telescopically-deployed (and prismatically-driven) mechanism that will carry integral end-of-arm microscopic viewing and point image spectroscopy sensors, and allow return of small quantity soil samples from at least a  hemisphere of the lander near field (flight targets: 3 meter reach, 1 kg mass, 3 watts power utilization, 10 cubic-cm sample volume, and 1M$).
<LI>Demonstrate and benchmark experiments for lander-based robotic science with on-board intelligent data analysis and compression. In this work, the goal is to evaluate science value and engineering efficiency of down-linking full, versus featurally-compressed sample data for a science instrument of major interest. Several different algorithmic approaches will be illustrated (drawn from statistical/fuzzy/heuristic decision criteria). The comparative accuracy and confidence of science sample analysis will be assessed, contrasting science users ability to achieve their goals using full versus compressed data sets. These experiments will be carried out as actual laboratory-simulated operations of a Mars science scenario, utilizing a lander-based robotic arm to retrieve user-designated blind samples from the near field. One candidate instrument is an on-board imaging spectrometer, and others will be utilized as science interest provides and motivates.
</ul>
<H4>FY 98 Milestones</h4><p> 
<UL>
<LI>Demonstrate generalized sampling operations wherein lander-based robotic mechanization (utilizing various and possibly exchangeable end-effector tooling/sensors), science instrumentation, and hierarchically structured on-board controls enable autonomous near-field scanning, multi-mode sample acquisition (viz., scrape, chip, drill), and in situ characterization/discrimination as to relative science value.
<LI>Based on this generalized sampling subsystem, show an automation capability to intelligently coordinate, prioritize and sequence a further set of opportunistic behaviors for high-yield, diversified in situ science. For example, if the initial scan of a nearby object is perceived interesting, then appropriately codified actions will be taken by the lander subsystem as might a field geologist performing analogous knowledge-based rudimentary analysis.
<LI>Supporting these advanced control capabilities, develop advanced machine perception functions to provide required robustness. Specifically: 1) computationally efficient means of visually localizing and servo in manipulator end-point trajectories to objects of interest; 2) visual and proximity sensing sufficient to verify in real-time sequence the action/success relative to a sampling objective (confirmed: the-designated-rock-is-grasped); 3) machine learning whereby a science user can interactively teach a set of basic sample acquisition primitives/behaviors for later semi-autonomous on-board execution
</ul>
<H4>FY 99 Milestones</h4><p> 
<UL>
<LI>Demonstrate a lander-based robotic sample acquisition subsystem operating in flexible autonomy with a nearby micro-rover. The basic scenario will be an initial visual mapping of the lander surround for science values of general interest (including any areas of explicitly designated by a science user), followed independent robot and rover collection/analysis of representative samples in the near and far field. Based on this initial determination of area science values, lander-based sampling (and on-board analysis) and micro-rover will coordinate their further control and perception for strategic area sample acquisition, processing, characterization, and packaging. Such scenarios may include deployment and collection of data from science instruments, sample hand-off from rover to robot, robot end-of-arm scans of rover-delivered specimens, etc. The general goal is to have this scenario proceed under high-level automation with temporal efficiency, achieving field geologist-like flexibility of sample collection and assessment.<p>
</ul>
<A HREF="Mars.html">Return to menu</a><p>
</DOC>
<DOC>
<DOCNO>WT01-B04-53</DOCNO>
<DOCOLDNO>IA080-000557-B035-104</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Isinstr.html 137.79.14.197 19970103071524 text/html 7489
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f33b.333@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:20:27 GMT
Last-Modified: Tuesday, 28-Nov-95 00:45:46 GMT
Content-type: text/html
Content-length: 7244
</DOCHDR>
<TITLE>In Situ Instruments</title>
<H3>In Situ Instruments</h3><p>
<H5>Point of Contact:  Sam Kim</h5><p>
<img src="NMR2.GIF"><p>
<H5>JPL-26198</h5><p>
The science goals of the Mars Exploration Program are: 1) Life (evidence of past or present); 2) Climate (weather processes and history); 3) Resources (environment and utilization).  The search for water (when, where, form and amount) acts as the common thread for three thrusts. In situ instruments have been identified as an important need by the Mars Exploration Office. A search was made of potential instruments (Ref. 15). With this great emphasis on water, it was decided to develop an instrument uniquely capable of detecting and characterizing water in different states, a miniature Magnetic Resonance Spectrometer (Ref. 21). Resonance instruments work on the principle that a magnetic field is applied to the sample, thus splitting the energy levels of either the nuclear or electronic spin states, and then energy is pumped into the states. Measurement is made of either the energy absorbed, or the re-emitted energy as a function of wavelength. Characteristic spectra reveal the composition of the sample. The advantages of magnetic resonance techniques are that<p>
<UL>
<LI>samples are tested under ambient conditions
<LI>minimal preparation or disruption of samples (gram to milligram)
<LI>analysis is not confounded by sample matrix
<LI>the spectrum is molecule-specific.
</ul>
The special features of Nuclear Magnetic resonance (NMR) are that it can detect:<p>
<UL>
<LI>presence of water in soil, minerals, rocks
<LI>free water in pores
<LI>adsorbed water on surfaces
<LI>chemically bound water
</ul>
The special features of EPR are that it can detect:<p>
<UL>
<LI>nature of oxidant in Martian soil
<LI>oxidation state of paramagnetic ions in soil (mineralogy)
<LI>characterization of volatiles (carbonates, sulfates)
<LI>radicals in icy samples (characterization at impurity level)
<LI>organics in subsoil
</ul>
Laboratory instruments use cw (change of impedance) or pulsed mode (observe re-emitted radiation). These instruments use large electromagnets to apply the magnetic field.  For a space instrument, a miniature permanent magnet system would be used (Ref. 24). The scanning method would depend on the application. Scanning at fixed magnetic field with variable frequency is relatively easy for NMR because circuitry to scan rf radiation is readily available. On the other hand, EPR requires scanning at microwave frequencies and this poses much more of a challenge.<p>

A goal of this task is to exploit prototype instrument probe systems for preliminary in-situ characterization of Martian surface chemistry, and to support the sample selection, and site selection objectives of this Task. The goal is to utilize innovative new technology in an external detection mode, which does not require separate sampling procedure for analysis. Since the search for water has been chosen as the theme for Mars exploration, initial emphasis in our program is on building and testing of a miniature Magnetic Resonance Spectrometer (MRS) with combined capabilities of Nuclear Magnetic Resonance (NMR) and Electron Paramagnetic Resonance (EPR). Conventional NMR and EPR systems in the laboratory  employ very large, heavy electromagnets and sweep the magnetic field to observe spectra. We plan to achieve miniaturization by using small permanent magnets, and use a tunable RF cavity to achieve a frequency sweep. It is projected that mass reduction of several hundred to one will be possible. This would provide a non-invasive analytical technique with a unique combination of capabilities such as detection of water, characterization of volatiles, active oxygen species, oxidation states of paramagnetic ions, and detection of possible organics from soil, minerals and rocks. All probes will be made compatible with the mechanisms and control systems developed under the SA/ET Task. The investigator under this task will also provide the team with insight into science needs for Mars surface missions.<p>
<img src="KIM.GIF">
<H5>P-46173 Cd</h5><p>
<H4>FY95 Accomplishments</h4><p>
<UL>
<LI>The miniature Nuclear Magnetic Resonance (NMR) spectrometer is being developed as a lander micro-instrument for the detection of water in the soil, minerals and rocks on Martian surface.  NMR can characterize different forms of water in the sample, such as adsorbed water (e.g., soil or clay), or chemically bound water in minerals (e.g., gypsum).  The analyses will be quantitative and require no modification of the sample.  Typical sample size is 0.1 - 1 gram.<p>
The picture shows the essential components of NMR; sample coil (probe), electronic detection and processing circuit, and the permanent magnet (Halbach).  Depending on mission requirements, such components can be deployed in several configurations as a penetrator, a lander or a rover sensor element.  It will be a compact, light weight (about 400 gram), low power (<0.5 W) instrument.<p>
In FY'95, we have developed miniature NMR electronics for two configurations, one which requires a sample to be placed inside the coil (conventional NMR) as shown in the first picture titled, "Digital Surface Mount NMR," and the other which can detect water externally by merely placing the NMR sensor over the sample surface (Inside-Out NMR."  The Inside-Out NMR circuit was tested with a laboratory electromagnet.  We obtained NMR spectra of adsorbed water in a clay sample as shown in the third picture.  Variation of the spectral intensity is shown, as expected, the NMR intensity decreases as the spacing between the sensor coil and the sample is increased.<p>
</ul>
<H4>FY96 Milestones</h4><p>
<UL>
<LI>Demonstrate a permanent magnet assembly to generate the Inside-Out field configuration for the miniature NMR spectrometer probe.  Demonstrate integration of the miniature NMR electronic circuit with the permanent magnet assembly, and optimize for  best performance as a system (target sensitivity, about 2 wt% H2O).  Design and fabricate a wideband mirowave sensor (scan range of 0.5 GHz - 5 GHz) for a miniature Electron Paramagnetic Resonance (EPR) spectrometer.<p>
<img src="inside-out.GIF"><p>
</ul>
<H4>FY 97 Milestones</h4><p>
<UL>
<LI>Microwave Antenna Technology for Geologic and Volatile Sample Detection. Build and test a microwave antenna for an EPR spectrometer and an EPR signal processing circuit with a solid state microwave source and demonstrate functionality of microwave antenna and EPR signal processing circuit using a laboratory electromagnet. Demonstrate integration of miniature antenna, miniature magnet assembly and EPR electronics and optimize for best performance as a system using standard and geologic samples (ppm level). EPR will detect the presence of other volatiles in the form of:  carbonates and sulfates; active oxygen species; oxidation states of paramagnetic ions for characterization of mineralogy.  
</ul>
<H4>FY98 Milestones</h4><p>
<UL>
<LI>NMR/EPR Probe Integrated with Sample Acquisition System. Demonstrate an integrated NMR and EPR probe with supporting electronics for use in the sample acquisition system developed under SA/ET.
</ul>
<A HREF="Mars.html">Return to menu</a><p>
</DOC>
<DOC>
<DOCNO>WT01-B04-54</DOCNO>
<DOCOLDNO>IA080-000557-B035-116</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Lowthide.html 137.79.14.197 19970103071533 text/html 7929
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f345.334@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:20:37 GMT
Last-Modified: Tuesday, 28-Nov-95 00:46:46 GMT
Content-type: text/html
Content-length: 7684
</DOCHDR>
<TITLE>Lo Temp, Hi Dens Elec</title>
<H3>Low Temperature, High Density Electronics</h3><p>
<H5>Point of Contact:  Nicholas  Moore</h5><p>
<img src="nchip.gif"><p>
The objective of this work is to assure that the new breakthroughs in high density electronic packaging now becoming available, which were designed for warm applications, can survive the Martian night in a state-of-the-art thermal enclosure.  The approach to survivable electronics will be to develop models for the physical processes that cause failure under thermal cycling, and to verify these through test.  This will allow us to assess the survivability of present designs under various thermal stresses, as well as to propose alternative designs for high density flight electronics that avoid these failure modes.<p>

This task will produce specific designs, including materials, for high density electronics that will survive on Mars or in other extreme temperature environments. Existing design/material combinations for high density electronics are being evaluated using a probabilistic physics of failure methodology to provide a point of departure from which to define new configurations that will survive in extreme temperature environments. An integral part of this effort is pioneering work in the characterization and modeling of failure mechanisms of high density electronics hardware.<p>

Miniaturized flight electronics are needed which can operate on the surface of Mars. Multi-Chip Modules (MCMs) are under development for warm electronics which will offer significant reductions in size and weight. There are two questions: (1) Will these electronic packages survive and function on the surface of Mars, and if not, (2) how can their design be modified to make them survivable.<p>

Conventional approaches to evaluating and controlling failure risk of electronic components are not effective for critical failure modes of Multi-Chip Modules (MCMs). It is not possible, by testing alone, to verify acceptable low failure risk for critical damage-accumulation failure modes that are indigenous to MCMs. However, failure risk due to damage-accumulation failure modes can be effectively evaluated and controlled using a Probabilistic Physics of Failure (P2oF) approach that incorporates both testing and analytical modeling based on fundamental analyses of the physics and mechanics of failure mechanisms.<p>

In P2oF, probabilistic models based on the physics of failure phenomena provide a framework for incorporating information from materials and component testing, inspection (NDE/NDI), and environmental characterization, even when such information is vague, approximate, sparse, or uncertain.<p>

MCM-D technology appears to be the most promising high density packaging technology for space applications, and it is being developed by a number of manufacturers, primarily for warm electronics applications. This technology takes several forms, such as metal/polymer based packages, and n-Chip (Al/SiO2 layered substrate). This will provide the starting point for our work.<p> 

MCM-D multi-chip module packaging technology will be evaluated to determine probabilities of failure when subjected to thermal cycling characteristic of the Mars surface, and specific failure modes and associated design aspects will be identified. The probabilities of failure will be determined as a function of the thermal variations to which the electronics are subjected. <p>

In the unlikely event that it will be found that the electronics (designed for warm environments) will function adequately in the Mars environment, nothing further need be done. In the more likely event that the probability of failure is too high to be acceptable, we will do two things:<p>

(i) Specify the maximum allowable range of thermal variation (as achieved by advanced thermal control) to meet adequate standards of reliability.<p>

(ii) Specify specific design changes in the multi-chip module packaging technology which will eliminate or significantly reduce the probability of major failure modes, thus significantly improving reliability in a Mars-like environment.<p>

<H4>FY 95 Achievements</h4><p> 
The major achievements of the task, "Low Temperature Survivability of High Density Electronics," during FY'95 were 1) the development of a general method for evaluating life of high density electronics packaging (HDEP) subjected to severe thermal cycling and 2) the application of that methodology to characterize stress and evaluate fatigue life of aluminum/silicon dioxide HDEP structures.  This thin film fatigue life evaluation method includes stress characterization by means of finite element modeling which incorporates x-ray rocking curve stress measurements.  In this method, a fatigue life simulation is carried out using a probabilistic fracture mechanics model which can consider average temperature, thermal cycle amplitude, geometry, material fracture mechanics properties, initial flaw size, and uncertainties about values of governing parameters and accuracy of stress and flaw growth models.  The probabilistic approach enables sensitivity analyses to be performed to identify the most important service life and failure risk drivers, so that development work can be focused more effectively to achieve life goals.<p>
The initial results of stress characterization and fatigue life simulation for the aluminum/silicon dioxide HDEP structure indicate that high residual stresses in the aluminum interconnect lines coupled with stress cycling due to thermal cycles drive the propagation of small initial flaws that result from void formation during stress relaxation and from manufacturing defects.  Design or manufacturing process changes that may improve thermal cycling fatigue life will be investigated in the ongoing work.
<H4>FY96 Milestones</h4><p> 
In FY'96, other materials and designs will be evaluated for use in extreme thermal environments.  This work will be focused on the investigation of the thermal cycling fatigue life of HDEP structures using copper/polymer substrate technology.  The evaluation of copper/polymer substrate technology will be conducted in a collaborative effort among Caltech/JPL, General Electric, Lockheed Martin, and Auburn University.
<H4>FY97 Milestones</h4><p>
<UL>
<LI>Develop probabilistic life prediction model for metal/polymer substrates based on the physics of low temperature failure mechanisms and processes characterized in FY96.   
<LI>Validate the metal/polymer physics-of-failure models in collaboration with industry.   
<LI>Formulate analysis procedure for evaluating life and failure risk of electronic systems containing multiple high density electronic modules, based on P2oF model output.
</ul>
<H4>FY98 Milestones</h4><p>
<UL>
<LI>Specify the thermal cycling limits that are required for  present metal/polymer based MCM-D designs to survive on  Mars.   
<LI>Define design sensitivities of metal/polymer based MCM-D  substrates using the P2oF model that includes substrate characterizations.   
<LI>Based on sensitivity analysis results, develop a recommended  metal/polymer substrate design(s) for survival on Mars.
</ul>
<H4>FY99 Milestones</h4><p>
<UL>
<LI>Evaluate alternative MCM-D technologies to identify those best suited for low-temperature survival.   
<LI>Assess life and failure risk of electronic systems consisting of multiple MCM-D units, based on aggregation of P2oF model results.   
<LI>Transfer to industry the technology and tools for design evaluation and life prediction of high density electronic packaging technology, including probabilistic physics-of-failure models.  
</ul>
<A HREF="Mars.html">Return to menu</a><p>
<p>
</DOC>
<DOC>
<DOCNO>WT01-B04-55</DOCNO>
<DOCOLDNO>IA080-000557-B035-137</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Thermcon.html 137.79.14.197 19970103071547 text/html 12070
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f351.335@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:20:49 GMT
Last-Modified: Thursday, 04-Jan-96 19:24:39 GMT
Content-type: text/html
Content-length: 11823
</DOCHDR>
<TITLE>Thermal Control</title>
<H3>Thermal Control</h3><p>
<H5>Point of Contact:  Ramachandra Manvi</h5><p>
The Martian environment imposes a very wide variation in ambient temperatures from  day to night.  Most electronics developed for Earth application require operating temperatures in the range 233 Kelvin to 313 Kelvin, and limits  for survival in extreme temperatures.  While it is hoped that some day, special electronics will be developed which can survive low temperatures and possibly even operate at low temperatures, the continuing pressure to drive costs down on space missions usually implies that low-cost standard electronics developed for room temperature operation will be employed on future Mars Landers.  We are working on the development of technology for low-temperature survivable electronics in a companion task in this RTOP. In addition, other components, particularly batteries lose performance as the temperature is lowered, and eventually become non-operable at very low temperatures.  Therefore, protecting electronics, batteries and other components from the low temperature Martian night environment is a critical need of Mars Lander missions.<p>

Future Mars Landers are expected to draw their power from photovoltaic (PV) arrays.  As a result, significant power will only be available during sunlit hours. While batteries can be used to provide minimal power over night, the power they can supply is limited, and furthermore, they must be protected from very low temperatures at night.  It is exactly when temperatures are lowest that the least power is available for heaters to maintain the warmth of key components<p>
     
In order to cope with this problem, the Mars Pathfinder and 98 Lander missions will house electronics and batteries within enclosures which are very effectively insulated, and which contain Radioisotope Heating Units (RHUs) which produce a considerable amount of heat  for their mass (~ 1 W per 50 g).  Because mass is always very scarce, lightweight enclosures have been developed using ultra-efficient insulation (Ref. 27).  However RHUs are no longer being produced and the 98 Mars Lander will have to depend on left-over spare RHUs from the Cassini mission.  It is expected that RHUs will probably not be available for Mars missions after the 1998 launch.<p>

Without RHUs to provide heat overnight, such warm electronics enclosures will go through very wide temperature swings during the diurnal cycle, despite the excellent warm electronics box (WEB) design developed by the Mars Pathfinder Program at JPL.  Therefore, post-1998 Mars Landers face a potential crisis in thermal control.  Based on recent modeling conducted under this RTOP, it is believed that the best way to provide thermal control in the absence of RHUs is to employ a scheme whereby heat is collected and stored during the day when the sun shines, and the heat is released at night to significantly reduce the diurnal temperature variation in an electronics/battery enclosure.  There is a ready source of heat during the day because the photovoltaic arrays associated with the lander generally operate above ambient temperature, and the structural members (frames or supports) for these PV arrays may be regarded as a substantial heat source for needs during the day.<p>

Heat can be stored efficiently in phase-change material (PCM), a material that undergoes repeated cycles of melting and resolidification when thermally cycled above and below its melting point.  Dodecane, with its melting point of about 263K, is an obvious choice for our application.  Heat can be transported from the PV arrays to the PCM within the enclosure by means of miniature heat pipes filled with a working fluid such as butane or propylene.<p> 
     
However, even though use of PCM is a very appealing approach on paper, the application of PCM for heat storage has been problematic for several reasons.  One is that it is necessary to supply and remove heat from all parts of the PCM, and this in turn requires good conduction heat transfer within the bulk of the PCM. Secondly, there is always a significant change in volume when a material melts or solidifies, and if the voids left by a previous solidification are not uniformly distributed, large stresses can build up locally upon subsequent melting if no voids are available to a region of PCM to accommodate the resulting volume change.  Thirdly, many materials tend to supercool below their melting points without solidification, unless nodes are present as nucleation sites to serve as solidification  starting points.<p>  
<img src="Manvi1.GIF"><p>
<CENTER>
<H4>Figure 1</h4>
</center>
The PCM composite materials are being developed by ESLI (A small business in San Diego) with SBIR funding, sponsored by the United States Air Force (Air Force Material Command, Phillips Laboratory, Kirtland AFB, New Mexico 87117-5777; Point of Contact:  Marko  Stoyanof, tel. 505-846-0775; Phase 1 Contract Number F29601-95-C-0098).  ESLI has developed a unique material which appears to overcome these three problems to using PCM as thermal capacitors.  It involves a network of high thermal conductivity carbon fibers (flocks) which occupy perhaps only 5% of a volume, as shown in Figure 1.  PCM is poured in to this matrix, which holds the PCM with capillary forces.  Heat transfer throughout the PCM region is rapid due to the network of carbon fibers.  Voids tend to collect at fiber tips and thus get distributed fairly uniformly throughout the bulk of the PCM.  Furthermore, the fibers also act as nucleation points for solidification, thus reducing supercooling.  This material is used to fabricate the MET warm electronics enclosure, as shown in Figure 2, for a highly efficient PCM heat storage.<p>
<img src="Manvi2.GIF><p>
<CENTER>
<H4>Figure 2</h4>
</center>
An additional challenge lies in the diode heat pipe design.  We must be assured that the heat pipe is a diode with very low reverse conductance so it can transfer heat efficiently during the day and not lose much heat at night.  The plan is to use the naturally occurring gravity and have the exterior end of the heat pipe lower than the interior end.  Thus, at night, the working fluid will condense out and remain outside.  The conductance of the walls of the heat pipe must be sufficiently low to produce reverse conductance values that are low.  Figure 3 shows the present design.<p> 
<img src="Manvi3.GIF><p>
<CENTER>
<H4>Figure 3</h4>
</center>
The initial effort in thermal control is to demonstrate the viability of a warm electronics/battery enclosure (WEE) using a PCM thermal capacitor, and including a diode heat pipe.  We will also attempt to use similar technology for energy saving in ISRU systems.<p> 
     
<H4>FY 95 Accomplishments</h4><p> 
<UL>
<LI>For missions to Mars without the use of Radioisotope Heater Units (RHUs), analysis of the MFEX Rover Warm Electronics Box (WEB) design showed that the aerogel only insulation design would not be adequate.  Analysis showed that the integration of Phase Change Material (PCM) panels with the aerogel insulation would meet the thermal requirements for diverse future Mars missions, including microrovers and power limited landers.  Carbon fiber flock PCM panels were developed and thermally cycled to show PCM panel concepts robustness. Miniature diode heat pipes were incorporated into the PCM panels and shown to have a high thermal efficiency.
<LI>Designed and fabricated PCM panels  into a Warm Electronic Enclosure (WEE)  with foam insulation. The WEE was tested at both  1 atmosphere  pressure and 10 torr ambient pressure for 3 diurnal temperature cycles (- 80 degrees to 0 degrees C) representative of the Mars Pathfinder landing site.  During the 10 torr testing, the WEE maintained the interior temperatures within  -10 to +20 degrees C for a  72 W-hr heater power duty and within -25 to -3 degrees C for a 57.6 W-hr heater power duty load.
</ul>
<H4>FY96 Milestones</h4><p>
<UL>
<LI>Further demonstrate Martian diurnal thermal cycle performance of a simple generic WEE structure incorporating improved aerogel/composite insulation, PCM energy storage capability at ~ 270 K and miniature diode heat pipes.  Optimize the design of composite PCM panels for thermal enclosures. Demonstrate improved mechanical performance while improving thermal performance by increasing PCM mass fraction and reducing structural  mass.
<LI>Demonstrate  a design for more realistic brassboard WEE's which provide thermal control during simulated earth operations, during simulated cruise, and after simulated landing on Mars.   Design  and build a brassboard WEE with application either for a Microrover or for use on a lander such as the Mars 98 or Mars 01 landers and evaluate its performance.  
</ul>
<H4>FY97 Milestones</h4><p>
<UL>
<LI>Perform long-term thermal cycling tests on realistic brassboard WEE's which provide thermal control during simulated earth operations, simulated cruise, and after simulated landing on Mars; one for use on a microrover, and the other for use on a lander.  Test in a vacuum and in a simulated Mars environment to ascertain creep, possible degradation in thermal performance, and structural load carrying capability. Characterize observations and document findings.
<LI>Demonstrate significantly improved performance of the realistic brassboard WEE's compared to the present state-of-the-art WEB which do not include RHUs.
</ul>
<H4>Accomplishments</h4>
During the FY'95, ESLI completed fabrication of a 6-inch side PCM (Dodecane) composite panels, and one special panel containing the Butane DHP.  Approximately 100 deep thermal cycling tests (-50 degrees C to +30 degrees C) were conducted on PCM panels, and 15 cycles on the DHP panel to assure that these performed as expected and were mechanically reliable .  A warm electronic enclosure (WEE) was then made by joining these panels and was fully instrumented with heaters and thermocouples and insulated with a 1-inch thick Rohacell insulation all around to undergo three deep thermal cycles at 1 atmosphere pressure, and approximating the Mars thermal environment.  The heater power (0 to 5 W ) was adjusted to mimic a typical payload duty cycle.  The warm electronic enclosure performed as expected by demonstrating that test results were repeatable as per design specifications.  They fully instrumented WEE assembly was then delivered to JPL for subsequent thermal vacuum tests.
<CENTER>
<H4>Figure 4</h4>
</center>
<img src="Manvi4&5.GIF">
<CENTER>
<H4>Figure 5</h4>
</center>
The WEE was tested at JPL in simulated 10-Torr Mars environment.  The WEE consisted of a 6-inch cubical box that included 5 Dodecane PCM panels and one Dodecane PCM panel with integrated butane diode heat pipe from Energy Sciences Laboratory (ESLI).  These panels were enclosed within a 1-inch thick Rohacell foam insulated box, as shown in Figure 5.  The test consisted of evaluating  the performance of the WEE and a reference thermal foam enclosure through three diurnal thermal cycles with heating applied to a simulated electronics mass to mimic a typical payload duty cycle.  Two duty cycles were evaluated, 8 watts maximum and 6.4 Watts maximum, for total heating of 72 W-hrs and 57.6 W-hrs.  The test showed reproducible phase transitions and maintained interior test temperatures within +20 degrees C and -25 degrees C.  These tests have demonstrated that the proposed WEE thermal control design is feasible.<p>
<img src="Manvi6.GIF">
<CENTER>
<H4>Figure 6</h4>
</center>
Finite element models (FEM) have been developed to perform transient thermal analyses of the WEE.  The models are well suited for investigating moving phase fronts, and for studying optimization of PCM mass, as shown in Figure 6.
<A HREF="Mars.html">Return to menu</a><p>
<p>
</DOC>
<DOC>
<DOCNO>WT01-B04-56</DOCNO>
<DOCOLDNO>IA080-000557-B035-156</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Hiplotb.html 137.79.14.197 19970103071610 text/html 9156
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f368.336@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:21:12 GMT
Last-Modified: Saturday, 03-Aug-96 00:10:34 GMT
Content-type: text/html
Content-length: 8910
</DOCHDR>
<TITLE>Hi Perf, Lo Temp Bat</title>
<H3>High Performance, Low Temperature Batteries</h3><p>
<H5>Points of Contact:  S. Surampudi, Chen-Kuo Huang, and M. Smart</h5><p>
The major goal of this program is to develop advanced batteries for future Mars Exploration Missions.  Mars Exploratory Missions can be broadly classified into four types:  orbiters, landers, rovers and penetraters.  These missions have some common performance requirements, such as high specific energy and energy density due to mass and volume limitations.  However, each of these missions have some unique promary performance drivers, such as, long cycle capability (orbiters) and ability to operate at low temperatures (landers, rovers and penetraters).  The orbiters require a cycle life greater than 10000 cycles at 20-30% depth of discharge with a specific energy > 100 Wh/kg.  The landers and rovers require batteries that can provide > 120 Wh/kg and operate at ttemperatures -20 to 30oC, whereas, the cycle life requirement is < 500 cycles (50-70% DOD).  Penetraters require batteries that can operate at temperatures lower than -60oC and withstand high shock levels.<p>
<img src="LOTBAT.GIF"><p>
The SOA Ni-Cd and Ni-H2 batteries are quite heavy and bulky and cannot meet mass and volume requirements of future Mars missions.  Furthermore, they have very poor low temperature performance capability as they use aqueous electrolytes.  Rechargeable lithium batteries offer significant weight, volume and cost advantages compared to SOA Ni-Cd and Ni-H2 batteries and are especially attractive for future Mars Missions.  The performance advantages include:  higher specific energy (2 to 3 times greater than Ni-Cd and Ni-H2), energy density (3-4 times greater than Ni-Cd and Ni-H2), higher cell voltage, coulombic and energy efficiency, low self-discharge rate, and lower battery costs compared to the SOA Ni-Cd and Ni-H2 batteries.  These advantages translate into several benefits for Mars Missions including: reduced weight and volume of the energy storage subsystem, improved reliability, extended mission life, and lower power system life cycle costs.<p>

the overall technical goal of this task is to develop advanced rechargeable lithium ion cells with improved cycle life and wide temperature performance capabilities for future Mars Exploratory Missions such as orbiters, landers, rovers, and penetraters.  The specific objectives of this task are: 1) Improve the cycle life performance of Lithium-ion cells and demonstrate the ability to meet life requirements of the Mars orbiters, 2) Improve the low temperature performance of lithium-ion cells and demonstrate their applicability to lander, rover and penetrater missions, 3) Design and fabricate higher capacity cells (> 10 Ah) with uniform capacity and predictable performance in association with US battery manufacturers, and 4) Establish effective charge methodology and reconditioning methods for on-board battery management.<p>

The proposed technical approach consists of three well defined subtasks:  1) chemistry and materials, 2) cell development, 3) testing and evaluation.  The prime objective of the chemistry and materials subtask is to develop advanced electrode materials and electrolytes that are capable of providing long cycle life and improved low temperature performance.  The objectives of the cell development subtask are:  a) develop methods for the fabrication of electrodes with uniform loading (to achieve cell matching and predictable performance), b) optimize cell design for improved cycle life and low temperature performance and c) fabricate higher capacity cells (5-20 Ah) for technology demonstration.  The objectives of the cell testing subtasks are: a) establish charge methods for effective battery management and b) determine the performance of cells at various mission operating and accelerated test conditions and demonstrate technological viability for various missions.  Assistance of an industrial patner will be sought for the fabrication of cell hardware.<p>
<img src="LithBat.GIF"><p>

<H4>FY 95Major Accomplishments To Date</h4><p>
<OL>
<LI>Identified baseline electrode materials and electrolytes for low temperature lithium ion cells (-20C) required for landers and rovers.
<LI>Identified baseline electrode  materials and electrolytes for long life lithium ion cells required for orbiter applications.
<LI>Determined the impact of key design variables on electrical and cycle life performance of ithium ion cells.
<LI>Fabricated AA size cylindrical and 5.0 Ah prismatic cells for establishing baseline performance.
<LI> Demonstrated 50% of nominal capacity and > 120 cycles (100% DOD) at -20C at C/3 discharge and C/6 charge rates.
<LI>Demonstrated more than 400 cycles at 100% DOD at RT with 0.04-0.08% /cycle capacity fade rate.
</ol>
<H4>FY 96 Milestones</h4><p>
(1)	Selection of materials and components for low temperature applications.<p>
<UL>
<LI>Evaluate and select electrolytes and electrode materials capable of extending the cell operation to temperatures as low as -20oC.
</ul>
(2)	Fabricate 1 Ah cells for low temperature (-20oC) applications.<p>
<UL>
<LI>Fabricate and test 1Ah cells for technology demonstration at low temperature (-20oC). 
<LI> Deliver 1 Ah cells to Rover Team for testing and demonstration.
</ul>
(3)	Demonstrate cycle life performance of room temperature cells.<p>
<UL>
<LI>Demonstrate > 500 cycles at high depths of discharge (> 80%) and 2000 LEO cycles at 20-30% DOD.
</ul>
(4)	Determine causes for limite dcycle life performance for SOA cells and identify strategies to improve the cycle life performance capability of the Li-ion cells.<p>
<UL>
<LI>Perform destructive physical analysis (DPA) of cells at different stages of cycle life and identify modes of degradation present in the cells.  Identify strategies to improve the cycle life performance.
</ul>
(5) Initiate studies to select optimum charge mathodology for Lithium-ion cells
<UL>
<LI>Initiate tests with commercial cells to optimize charge methodology.  Conduct tets at various fates and charge cut-off voltages as a function of temperature.
</ul>
<H4>FY 97 Milestones</h4><p>
(6) Demonstrate cell performance goals with 1 Ah cells at -20oC.
<UL>
<LI> Test the electrolytes and electrode materials with improved low temperature performance capable of operating at temperatures -40oC and below.
</ul>
(8) Select materials for second generation cells capable of delivering > 10,000 cycles at 40% DOD.
<UL>
<LI>Identify advanced anode materials, electrolytes with improved stabilty, and compatible cell components for improved cycle life performance.
</ul>
(9) Award contract for the fabrication of prototype cells for low temperature and cycle life demonstration.
<UL>
<LI>Award contract to a battery manufacturer to fabricate prototype cells for low temperature (5 Ah) and cycle life (10-20 Ah) demonstration.  It is proposed to develop cells in collaboration with an experienced battery manufacturer for space applictions.  The cell technology developed in-house will be transferred to the selected battery company.
</ul>
(10) Select charge methodology for efficient and safe battery management.
<UL>
<LI>Conduct tests at the battery level to confirm the findings obtained at the cell level.
</ul>
(11) Determine the safety of cells to ensure power system safety.
<UL>
<LI>conduct tests to evaluate the safety of the cells at various operating and inadvertent abuse conditions.
</ul>
<H4>FY 98 Milestones</h4><p>
(12) Fabricate cells for Technology demonstration
<UL>
<LI>Fabricate cells for cycle life (10-20 Ah) and low temperature (5 Ah) performance demonstration in association with a battery manufacturer.
</ul>
(13) Demonstrate > 5000 cycles at 25-40% DOD for orbiter applications.
<UL>
<LI>Conduct electrical and cycle life performance tests on 10-20 Ah cells to demonstrate 5000 cycles (25-40% DOD) at room temperature.
</ul>
(14) Demonstrate low temperature operation (-20oC) and > 300 cycles with 5-10 Ah size cells fo lander and Rover applications.
<UL>
<LI>conduct electrical and cycle life performance tests at -20oC to demonstrate the low temperature cycle life performance (at 100% DOD)
</ul>
<H4>FY 99 Milestones</h4><p>
(15) Demonstrate the suitability of Lithium-ion cells for low temperature applications, such as for rovers and landers, with 5-10 Ah prototype cells at -40oC.
<UL>
<LI>In association with a battery manufacturer, 5-10 Ah size cells will be fabricated and tested at -40oC to demonstrate the low temperature cycle life performance (at 100% DOD).
</ul>
(16) Demonstrate greater than 10,000 cycles for orbiter applications.
<UL>
<LI>Continue life tests at 25-40% DOD at room temperature for orbiter applications.
</ul>
(17) Transfer technology to JPL/NASA flight program offices and other aerospace corporations for flight validation studies.<p>
<A HREF="Mars.html">Return to menu</a><p>
<p>
</DOC>
<DOC>
<DOCNO>WT01-B04-57</DOCNO>
<DOCOLDNO>IA080-000557-B035-173</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Smldst.html 137.79.14.197 19970103071619 text/html 6669
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f374.337@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:21:24 GMT
Last-Modified: Tuesday, 28-Nov-95 00:49:06 GMT
Content-type: text/html
Content-length: 6424
</DOCHDR>
<H3>Small Deep Space Transponder</h3><p>
<H5>Point of Contact:  Steve Townes</h5><p>
<img src="Townes.GIF">
The object is to develop a miniature X-band deep space transponder, building upon the technology base established by the Pluto Fast Flyby Advanced Technology Insertion Activity. This involves two major technology developments, one being a digital X-band receiver using advanced GaAs Monolithic Microwave Integrated Circuit (MMIC) technology, and the other involves development of miniature high-frequency high-density electronic packaging technology. The combination of these two technology advances will enable a new miniature transponder with unsurpassed performance:<p>
<UL>
<LI>Narrow bandwidth Phase Lock Loop (<20Hz) with a carrier tracking threshold  of -158 dBm.
<LI>Wide dynamic range (>70 dB)
<LI>Command Detector functionality (for multi-user compatibility)
<LI>Total mass <2.5 kg.
</ul>
In the past, deep space telecommunication systems for spacecraft have been developed individually to fit the requirements of each spacecraft project. Since past spacecraft tended to be heavy, expensive, and power hungry, telecommunication systems based on past spacecraft designs are inappropriate for use on new miniaturized spacecraft. For Mars Landers launched from Med-Lite launch vehicles, mass, power and volume are precious commodities, and it is crucial that a truly miniaturized, high efficiency telecommunication system be developed for this kind of application. The Mars Exploration Office has defined such a development as their #1 technology need.<p>

Over the past couple of years, the Pluto Fast Flyby Advanced Technology Insertion (ATI) effort initiated the development of an advanced miniature X-Band digital receiver which is a major portion of a miniature telecommunication transponder. TRW won a competitive contract to develop this critical technology. However, they could not complete the work within the allocated funding and the effort was left unfinished. Nevertheless, the Pluto ATI effort successfully demonstrated the RF front-end functionality using advanced GaAs Monolithic Microwave Integrated Circuit (MMIC) technology. Also it was shown that the mass goal of less than one kilogram was indeed a feasible target. But the digital architecture was not completed nor was the integration of the miniature front-end with  advanced high-frequency multichip module (MCM) packaging. In our work, we will support advances in digital receiver and high frequency high density packaging technology to a prototype readiness level which will allow the Mars Exploration Office  to decide whether or not  to proceed with procurement of flight hardware.<p>
One part of the proposed program is completion of the digital architecture and integration of the miniature front-end with advanced high-frequency multichip module (MCM) packaging. The goal of this effort is to develop a state-of-the-art digital X-Band receiver technology which employs advanced GaAs MMIC and high-frequency packaging to achieve unsurpassed performance.<p>

The second part of the program involves the use of high density packaging technology to achieve miniaturization of the transponder. Although considerable effort and funds have been invested in high density packaging, very little of these resources are being invested in high frequency (> 200 MHz) applications and these packaging techniques are usually not suitable for use at high frequencies.  Consequently, NASA must lead and stimulate the development of miniature high-frequency high-density packaging technology.   Microelectronic packaging provides four basic functions: (1) Power Distribution, (2) Heat Dissipation, (3) Signal Distribution, and (4) Environmental Protection. High density electronic packaging implies incorporation of multiple integrated circuits, as bare die and passive components on a common interconnecting substrate. This format is commonly referred to as a multichip module (MCM).  Significant improvements in circuit density are attainable (10-30X), as compared with printed circuit board technology. For high density, high frequency (defined to be the microwave and millimeter wave range, covering 1 GHz to 100 GHz) packages) the performance requirements are much more stringent than for low frequency packaging for digital technology. Signal distribution becomes a major challenge as the frequency and packaging densities increase. Stray (RF) radiation in the form of cross-talk and package moding become limiting factors which must be addressed in order to preserve performance.  The interconnecting networks into and out of the package must have low loss characteristics and be matched to the impedances of the adjacent networks.  3D high density formats which use multi-layer materials systems and embedded components further complicate signal propagation characteristics and thermal management issues. Thermal management of Monolithic Microwave Integrated Circuits (MMICs) used for high frequency applications is a significant development issue in high density package design and can severely affect package reliability and performance. This task will include the development and demonstration of new cooling techniques which are critical for this application and while addressed mainly to high frequency applications, will be of benefit to all high density electronic packaging. The passive cooling approach will involve utilizing a very high thermal conductivity substrate to reduce the temperature of high power devices and the circuit in general by rapidly spreading and conducting the heat away. Methods for bonding the substrate to the devices will have to be developed. The performance and temperatures of various parts of the circuit will be compared to those obtained with a conventional substrate (such as alumina or Kovar).<p>
A single milestone occurs  on 10/1/95 when it is expected that the RF MCM will be demonstrated. This may or may not include the final form of the MCM including thermal control but the analysis for the final form will be done. The digital receiver will be demonstrated to the extent it can be depending on which contractor is selected. However, the technologies will be demonstrated at a readiness level which will allow the Mars Exploration Office to decide whether or not to include this innovative transponder in its plans for the 98 Lander mission.<p>

<A HREF="Mars.html">Return to menu</a>

</DOC>
<DOC>
<DOCNO>WT01-B04-58</DOCNO>
<DOCOLDNO>IA080-000557-B035-190</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/References.html 137.79.14.197 19970103071629 text/html 4668
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f37e.338@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:21:34 GMT
Last-Modified: Friday, 02-Jun-95 19:39:00 GMT
Content-type: text/html
Content-length: 4424
</DOCHDR>
<TITLE>References for Mars Page</title>
<H2>REFERENCES</h2><p>
<OL>
<LI> Concepts for a Small Sample Return Mission Using Microtechnology, JPL Report D-8822, October, 1991.
<LI>Mars Sample Return 1984 Study Report, JPL Report D-1845, Sept. 28, 1984.
<LI>Low Cost Mars Sample Return Study, Briefing for NASA HQ Code SL, R. A. Wallace, JPL, 15 November, 1994. Low Cost Mars Sample Return Study, Briefing for NASA HQ Code SL, R. A. Wallace, JPL, 13 February 1995. Mars Sample Return Final Report, Lockheed-Martin Corp. Report No. MCR 95-1301, Contract JPL-959902.
<LI>Autonomous Hazard Detection and Avoidance for Mars Exploration, H. Pien, AIAA Computing in Aerospace - 8 Baltimore, MD, 21-24 October 1991.
<LI>Achieving Safe Autonomous Landings on Mars Using Vision-Based Approaches, H. Pien, SPIE Advances in Intelligent Robotic Systems Conf. Cooperative Intelligent Robotics in Space II, Boston, MA, 11-15 November 1991.
<LI>Sensor Trade Study, Vol II: Autonomous Precision Landing, M. Trichel, et al., Final Report prepared for JSC, Erim, July 1990.
<LI>Planetary Terminal Descent Simulation with Autonomous Hazard Avoidance, J. Cuseo, C. Dallas, 27th AIAA Aerospace Sciences Mtg, Reno, NV, 9-12 Jan, 1989.
<LI>Planetary Lander Vehicles Utilizing LEAP Technology, 30th AIAA/ASME/SAE/ASEE Jt. Propulsion Conf., Indianapolis, IN, 27-29 June, 1994.
<LI>Feasibility of Rocket Propellant Production on Mars, R. L. Ash, W. Dowler, and G. Varsi, Acta Astronautica 5, 705-724 (1978)
<LI>Mass and Power Estimates for Martian In-Situ Propellant Production systems, R. Frisbee, JPL Report D-3648 (1986).
<LI>Recent Concepts in Missions to Mars: Extraterrestrial Processes, K. Ramohalli, E. Lawton and R. Ash, Jour. of Propulsion and Power 5, 181-187 (1989).
<LI>Martian Resource Utilization I. Plant Design and Transportation Selection Criteria, P. Kaloupis, P. Nolan and A. Cutler, Space Power 11, 343-375 (1992).
<LI>The Mars ISRU Sample Return Mission Study Report, M. Cerimele and J. Connolly, JSC Report, MISR Project, D. Kaplan, Manager, draft, October 1, 1994.
<LI>Mars Sample Return Mission Utilizing In-Situ Propellant Production, R. Zubrin and S. Price, Final Report of Study Conducted for JSC by Lockheed-Martin Corp., March 31, 1995.
<LI>Mars Surveyor Science Objectives and Measurements Requirements Workshop, Edited by D. J. McCleese, S. Squyres, S. Smrekar, and J. Plescia, JPL Technical report D12017, 1994.
<LI>Distribution of Rock Sizes at the Viking Sites for Purposes of Estimating Probability of a Hazardous Landing, preliminary manuscript, M. Golombek and D. Rapp, JPL, May 5, 1995.
<LI>Beyond-the-Horizon Mars Technology Study, JPL Report D12084, September 29, 1994.
<LI>Advanced Concepts, Miniconference on Thermal Control, JPL Miniconference Proceedings, January 24, 1995.
<LI>Satellite Thermal Control Handbook,  The Aerospace Corporation Press, 1994.
<LI>Characterization of Martian Surface Chemistry by a Miniature Magnetic Resonance Spectrometer, in Mars Surveyor Science Objectives and Measurements Requirements Workshop,  S. S. Kim and J. G. Bradley, Jet Propulsion Laboratory, Pasadena, CA, May 10-12, 1994, pp.93-94.
<LI>Novel NMR Apparatus for Investigating an External Sample, R.L. Kleinberg, A. Sezginer, D. D. Griffin and  M. Fukuhara, J. Mag. Res., 97, 466-485 (1992)
<LI>Remote (Inside-Out) NMR. III. Detection of Nuclear Magnetic Resonance in a Remotely Produced Region of Homogeneous Magnetic Field, J. A. Jackson, L. J. Burnett  and  F. Harmon, J. Mag. Res., 41, 411-421 (1980)
<LI>Portable ESR Spectrometer with NEOMAX (Nd-Fe-B) Permanent Magnet Circuit, A. Nakanishi, N. Sugahara and A, Furuse, Int. J. Rad. Appl. and Instrum., Part A, Appl. Rad. & Isotopes, 44, 357-360 (1993)
<LI>Sampling of Planetary Surface Solids for Unmanned In Situ Geological and Biological Analysis: Strategy, Principles and Instrument Requirmeents, D. B. Nash, NASA Technical Report 32-1225, November, 1967.
<LI>MESUR Lander Arm Study, Presentation to JPL, S. Price, Martin-Marietta Corp., Dec. 18, 1992.
<LI>Current State of Robotic End Effector Technology with respect to Planetary Surface Sample Acquisition Issues, JPL IOM, C. Moreno to B. Muirhead, February 8, 1989.
<LI>Integrated Lightweight Structure and Thermal Insulation for Mars Rover," G. S. Hickey, D. Braun, L. Wen and H. Eisen, JPL Division 35, to be submitted to ICES, 1995. 
</ol><p>

</DOC>
<DOC>
<DOCNO>WT01-B04-59</DOCNO>
<DOCOLDNO>IA080-000557-B035-204</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Menu.html 137.79.14.197 19970103071637 text/html 718
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f387.339@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:21:43 GMT
Last-Modified: Thursday, 20-Jul-95 23:16:18 GMT
Content-type: text/html
Content-length: 473
</DOCHDR>
<TITLE>Homepage Menu</title>
<CENTER>
<H2>Robotics & Mars Exploration Technology Program</h2>
<H1>HOMEPAGE MENU</h1><p>
<img src="Chuck.GIF">Charles R. Weisbin, Manager<p>
<img src="Lori.GIF">Lori Mooradian, Secretary<p>
</CENTER>
<p>
<p>
<img src="bullet.gif">Click here to access the <a href="TRProgram.html">Rover and Telerobotics Technology Homepage</a><p>

<img src="bullet.gif">Click here to access the <a href="mars.html">Mars Exploration Technology Homepage</a><p>
</DOC>
<DOC>
<DOCNO>WT01-B04-60</DOCNO>
<DOCOLDNO>IA080-000557-B035-275</DOCOLDNO>
<DOCHDR>
http://lmooradian.jpl.nasa.gov:80/Mars.html 137.79.14.197 19970103071722 text/html 2074
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aef1f3b2.344@lmooradian.jpl.nasa.gov.>
Date: Friday, 03-Jan-97 07:22:26 GMT
Last-Modified: Monday, 05-Aug-96 17:47:56 GMT
Content-type: text/html
Content-length: 1830
</DOCHDR>
<TITLE>MARS EXPLORATION TECHNOLOGY PROGRAM PLAN</TITLE>
<CENTER>
<H1>MARS EXPLORATION TECHNOLOGY PROGRAM</h1></c><p>
<H2>C. R. Weisbin, D. Rapp, G. Rodriguez</h2></c><p>
<H3>August 1996</h3></c><p>
</center>
<img src="met.GIF">
<H5>P-46312</h5><p>
<A HREF="emphsum.html"><h3>PROGRAM EMPHASIS AND SUMMARY</h3></a><p>
<A HREF="emphsum.html#Bkgrnd">Background</a><p>
<A HREF="emphsum.html#Progemph">Program Emphasis</a><p>
<A HREF="emphsum.html#Progcont">Program Content</a><p>
 <A HREF="emphsum.html#Strat">Strategy</a><p>
<A HREF="multistones.html"><h3>MULTIYEAR TASK OVERVIEWS AND MILESTONES</h3></a>
 <A HREF="multistones.html#Progmgmt">Program Management</a><p>
 <A HREF="multistones.html#Preclndg">Precision Landing</a><p>
 <A HREF="ISPP.html">In Situ Propellant Production (ISPP)</a><p>
 <A HREF="Sampacq.html">Sample Acquisition</a><p>
 <A HREF="Isinstr.html">In Situ Instruments</a><p>
 <A HREF="Lowthide.html">Low Temperature, High Density Electronics</a><p>
 <A HREF="Thermcon.html">Thermal Control</a><p>
 <A HREF="Hiplotb.html">High Performance, Low Temperature Batteries</a><p>
 <A HREF="Smldst.html">Small Deep Space Transponder</a><p>
<p>
<H3>ACKNOWLEDGEMENTS:</h3><p>
The contributions to this plan from the leaders for the individual tasks (and their colleagues) within the MET program were essential, and are gratefully acknowledged: S. Kim, R. Manvi, N. Moore,  D. Farless, S. Rao, and P. Schenker.  Valuable contributions from the Mars Exploration Program Office at JPL were also pivotal in determining the program contents and balance; acknowledgments here are due to: S. Bailey, L. Lowry, P. Sutton, J. B. Mc Namee, and D. Shirley.<p>


More information is available on the <A HREF="http://mpfwww.jpl.nasa.gov>Mars Pathfinder</a> homepage.

<A HREF="References.html"><H3>For reference information</h3></a><p>

</DOC>
<DOC>
<DOCNO>WT01-B04-61</DOCNO>
<DOCOLDNO>IA027-000290-B031-441</DOCOLDNO>
<DOCHDR>
http://applied-automation-ca.com:80/ 206.75.135.14 19970114042004 text/html 2788
HTTP/1.0 200 OK
Date: Tue, 14 Jan 1997 04:20:03 GMT
Server: Apache/1.1.1
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Applied Automation Canada Inc.</TITLE>
</HEAD>
<BODY BACKGROUND="back.jpg">
<P><CENTER><IMG SRC="logo.gif" WIDTH="312" HEIGHT="201" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
<B><FONT SIZE=+3>Applied Automation Canada Inc.</FONT></BR>
<TABLE>
<TD>
R.R. #6 - 501 Clyde Road<BR>
CAMBRIDGE, ON N1R 5S7<BR>
TEL: 519/622-4924<BR>
FAX: 519/622-5172<BR>
Email: 
<A HREF=mailto:info@applied-automation-ca.com>info@applied-automation-ca.com</A>
</TD>
</TABLE>
</CENTER>
<P>WELCOME TO OUR WEB SITE!<BR></B>
<BR>
APPLIED AUTOMATION CANADA INC. IS AN INDUSTRIAL AUTOMATION SYSTEM INTEGRATOR
AND A MANUFACTURER OF CUSTOM BUILT INDUSTRIAL AUTOMATION EQUIPMENT. <BR>
<BR>
We offer turn key solutions for a variety of automation needs. Our customers
range from single person shops to multi national corporations with world
wide locations. <BR>
<BR>
WE OFFER A WIDE RANGE OF SERVICES IN FOLLOWING AREAS: 
<UL>
  <LI><A HREF="sys.int.serv.html">System Integration Services </A>
  <LI><A HREF="design.manu.ind.equip.html">Design and Manufacturing of Industrial
Automation Equipment</A> 
  <LI><A HREF="des.manu.ics.html">Design and Manufacturing of Industrial
Control Systems</A> 
  <LI>PLC Software Development ( Allen Bradley, Siemens, Omron) 
  <LI>PC Software Development ( Visual Basic, C++, Forth, Assembler ) 
  <LI><A HREF="robotics.html">Robotics</A> 
  <LI>Automated and Robotic Welding 
  <LI>Stud Welding 
  <LI>Automated Assembly Equipment 
  <LI>Assembly and Production Lines 
  <LI>Material Handling and Part Feeding 
  <LI>Automated Testing and Data Acquisition 
  <LI>Field Installation and Post Implementation Support 
  <LI>Repair and Trouble Shooting of Industrial Equipment 
  <LI>Motion Control, Servo Systems and CNC implementation 
  <LI>Technical Product Support for Imported Equipment 
  <LI>Export / Import 
  <LI>Component Fabrication and Automatic Assembly Services 
</UL>
MAY WE ASSIST YOU IN PROVIDING SOLUTIONS TO YOUR AUTOMATION OR PRODUCTION
NEEDS?
<P>
PLEASE CONTACT OUR CUSTOMER SUPPORT TEAM AND LET US PROVIDE YOU WITH
A NO-OBLIGATION PROPOSAL.  Email us at <A HREF="supp@applied-automation-ca.com">supp@applied-automation-ca.com</A>!
<P>
<CENTER>
<TABLE>
<TD>
Email:
<BR>
<A HREF=mailto:les@applied-automation-ca.com>les@applied-automation-ca.com</A><BR>
<A HREF=mailto:andy@applied-automation-ca.com>andy@applied-automation-ca.com</A><BR>
<A HREF=mailto:witold@applied-automation-ca.com>witold@applied-automation-ca.com</A><BR>
<A HREF=mailto:agnieszka@applied-automation-ca.com>agnieszka@applied-automation-ca.com</A><BR>
<A HREF=mailto:pawels@applied-automation-ca.com>pawels@applied-automation-ca.com</A><BR>
</TD>
</TABLE>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-62</DOCNO>
<DOCOLDNO>IA027-000290-B032-21</DOCOLDNO>
<DOCHDR>
http://applied-automation-ca.com:80/sys.int.serv.html 206.75.135.14 19970114042036 text/html 1025
HTTP/1.0 200 OK
Date: Tue, 14 Jan 1997 04:20:42 GMT
Server: Apache/1.1.1
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>System Integration Services</TITLE>
</HEAD>
<BODY BACKGROUND="back.jpg">
<H2>System Integration Services</H2>
<BR>
We offer full application assistance and take total system responsibility
for the following: 
<UL>
  <LI>feasibility study 
  <LI>hardware selection 
  <LI>custom hardware design and fabrication (both mechanical and control) 
  <LI>control software development for any major PLC brand or Industrial
PC 
  <LI>control system and machine assembly 
  <LI>prototype testing
  <LI>field installation 
  <LI>system start - up, operator training, documentation 
  <LI>post - implementation support 
  <LI>custom built control panels 
  <LI>consulting services 
  <LI>electronic engineering, circuit design, and manufacturing of specific
electronic products ( microprocessor based controllers, interface devices
) 
</UL>
<HR><A HREF="index.html">...return to home page</A> 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-63</DOCNO>
<DOCOLDNO>IA027-000290-B032-46</DOCOLDNO>
<DOCHDR>
http://applied-automation-ca.com:80/design.manu.ind.equip.html 206.75.135.14 19970114042112 text/html 652
HTTP/1.0 200 OK
Date: Tue, 14 Jan 1997 04:21:05 GMT
Server: Apache/1.1.1
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Design and Manufacturing of Industrial Automation 
Equipment</TITLE> </HEAD>
<BODY BACKGROUND="back.jpg">
<H2>Design and Manufacturing of Industrial Automation Equipment</H2>
We design and fabricate a wide range of industrial automation equipment:
<UL>
  <LI>automated assembly systems
  <LI>automated machining systems and production tools
  <LI>custom made pick and place robots
  <LI>automatic welding systems
  <LI>automatic stud welding systems
</UL>
<HR><A HREF="index.html">...return to home page</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-64</DOCNO>
<DOCOLDNO>IA027-000290-B032-102</DOCOLDNO>
<DOCHDR>
http://applied-automation-ca.com:80/des.manu.ics.html 206.75.135.14 19970114042211 text/html 799
HTTP/1.0 200 OK
Date: Tue, 14 Jan 1997 04:22:00 GMT
Server: Apache/1.1.1
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Design and Manufacturing of Industrial Control Systems</TITLE>
</HEAD>
<BODY BACKGROUND="back.jpg">
<H2>Design and Manufacturing of Industrial Control Systems</H2>
<UL>
  <LI>PLC control systems based on major makes of PLC's
  <LI>implementing graphic operator interfaces, touch screens
  <LI>motion control systems
  <LI>CNC control
  <LI>PLC to PC platform interface
  <LI>PLC to motion control interface
  <LI>distributed control
  <LI>SCADA
  <LI>control panel design, and fabrication
  <LI>field installation, trouble shooting, repair
  <LI>modifications to third party built control systems
</UL>
<HR><A HREF="index.html">...return to home page</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-65</DOCNO>
<DOCOLDNO>IA027-000290-B032-128</DOCOLDNO>
<DOCHDR>
http://applied-automation-ca.com:80/robotics.html 206.75.135.14 19970114042242 text/html 346
HTTP/1.0 200 OK
Date: Tue, 14 Jan 1997 04:22:36 GMT
Server: Apache/1.1.1
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Robotics</TITLE>
</HEAD>
<BODY BACKGROUND="back.jpg">
<H2>Robotics</H2>
<UL>
  <LI>welding
  <LI>material handling
  <LI>assembly
  <LI>cutting
</UL>
<HR><A HREF="index.html">...return to home page</A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-66</DOCNO>
<DOCOLDNO>IA027-000290-B032-203</DOCOLDNO>
<DOCHDR>
http://applied-automation-ca.com:80/index.html 206.75.135.14 19970114042406 text/html 2788
HTTP/1.0 200 OK
Date: Tue, 14 Jan 1997 04:24:07 GMT
Server: Apache/1.1.1
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Applied Automation Canada Inc.</TITLE>
</HEAD>
<BODY BACKGROUND="back.jpg">
<P><CENTER><IMG SRC="logo.gif" WIDTH="312" HEIGHT="201" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
<B><FONT SIZE=+3>Applied Automation Canada Inc.</FONT></BR>
<TABLE>
<TD>
R.R. #6 - 501 Clyde Road<BR>
CAMBRIDGE, ON N1R 5S7<BR>
TEL: 519/622-4924<BR>
FAX: 519/622-5172<BR>
Email: 
<A HREF=mailto:info@applied-automation-ca.com>info@applied-automation-ca.com</A>
</TD>
</TABLE>
</CENTER>
<P>WELCOME TO OUR WEB SITE!<BR></B>
<BR>
APPLIED AUTOMATION CANADA INC. IS AN INDUSTRIAL AUTOMATION SYSTEM INTEGRATOR
AND A MANUFACTURER OF CUSTOM BUILT INDUSTRIAL AUTOMATION EQUIPMENT. <BR>
<BR>
We offer turn key solutions for a variety of automation needs. Our customers
range from single person shops to multi national corporations with world
wide locations. <BR>
<BR>
WE OFFER A WIDE RANGE OF SERVICES IN FOLLOWING AREAS: 
<UL>
  <LI><A HREF="sys.int.serv.html">System Integration Services </A>
  <LI><A HREF="design.manu.ind.equip.html">Design and Manufacturing of Industrial
Automation Equipment</A> 
  <LI><A HREF="des.manu.ics.html">Design and Manufacturing of Industrial
Control Systems</A> 
  <LI>PLC Software Development ( Allen Bradley, Siemens, Omron) 
  <LI>PC Software Development ( Visual Basic, C++, Forth, Assembler ) 
  <LI><A HREF="robotics.html">Robotics</A> 
  <LI>Automated and Robotic Welding 
  <LI>Stud Welding 
  <LI>Automated Assembly Equipment 
  <LI>Assembly and Production Lines 
  <LI>Material Handling and Part Feeding 
  <LI>Automated Testing and Data Acquisition 
  <LI>Field Installation and Post Implementation Support 
  <LI>Repair and Trouble Shooting of Industrial Equipment 
  <LI>Motion Control, Servo Systems and CNC implementation 
  <LI>Technical Product Support for Imported Equipment 
  <LI>Export / Import 
  <LI>Component Fabrication and Automatic Assembly Services 
</UL>
MAY WE ASSIST YOU IN PROVIDING SOLUTIONS TO YOUR AUTOMATION OR PRODUCTION
NEEDS?
<P>
PLEASE CONTACT OUR CUSTOMER SUPPORT TEAM AND LET US PROVIDE YOU WITH
A NO-OBLIGATION PROPOSAL.  Email us at <A HREF="supp@applied-automation-ca.com">supp@applied-automation-ca.com</A>!
<P>
<CENTER>
<TABLE>
<TD>
Email:
<BR>
<A HREF=mailto:les@applied-automation-ca.com>les@applied-automation-ca.com</A><BR>
<A HREF=mailto:andy@applied-automation-ca.com>andy@applied-automation-ca.com</A><BR>
<A HREF=mailto:witold@applied-automation-ca.com>witold@applied-automation-ca.com</A><BR>
<A HREF=mailto:agnieszka@applied-automation-ca.com>agnieszka@applied-automation-ca.com</A><BR>
<A HREF=mailto:pawels@applied-automation-ca.com>pawels@applied-automation-ca.com</A><BR>
</TD>
</TABLE>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-67</DOCNO>
<DOCOLDNO>IA060-000328-B017-169</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/index.html 206.86.13.106 19970115023456 text/html 5957
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:34:46 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5775
Last-modified: Fri, 10 Jan 1997 14:02:59 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Ethiolist</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="bkg1.gif" bgcolor="#FFFFFF" text="#FFFFFF"
link="#004080" vlink="#004080" alink="#004080">
<p align=center><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom wid








th=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom wid








th=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41>
<font color="#000040"><font size=6><strong><img src="logo4.gif" align=absmiddle width=225 height=50><img src="logo4.gif" align=absmiddle width=225 height=50><img src="logo4.gif" align=absmiddle width=225 height=50><img src="logo4.gif" align=absmiddle widt








h=225 height=50></strong></font></font></p>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<ul>
<li><h2 align=left><a href="welcome.htm"><font color="#000040"><font size=3><strong>Welcome</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="faq.htm"><font color="#000040"><font size=3><strong>FAQ</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="subscribe.html"><font color="#000040"><font
size=3><strong>Subscription</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
</ul>
</blockquote>
<blockquote>
<p align=left><font color="#000040"><font size=5><strong>Community Organizations</strong></font></font></p>
</blockquote>
<blockquote>
<ul>
<li><h2 align=left><a href="alem.htm"><font color="#000040"><font size=3><strong>Alem Children Support Organization (ACSO)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="ten.htm"><font color="#000040"><font size=3><strong>Trans Ethiopian Network (TEN)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="construc.htm"><font color="#000040"><font size=3><strong>Ethiopian Community Services (ESC)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a
href="http://www.ctr.columbia.edu/~nemo/ess"><font
color="#000040"><font
size=3><strong>Ethiopian Scientific Society (ESS)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="http://www.acctgandmgmt.com/stmary.htm"><font color="#000040"><font size=3><strong>Saint Mary's Orthodox Church Home page</strong></font></font></a><font color="#000040"><strong> </strong></font></h2>
</li>
</ul>
</blockquote>
<blockquote>
<p><font color="#000040"><font size=5><strong>News and Forums</strong></font></font></p>
</blockquote>
<blockquote>
<dir>
<li><h2 align=left><a href="clamp.htm"><font color="#000040"><font size=3><strong>Clampdown in Addis<br>
Ethiopia's Journalists at Risk</strong></font></font></a><font color="#000040"><font size=3><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="usstate.htm"><font color="#000040"><font size=3><strong>U.S. State Department Institutes Policy</strong></font></font></a><font color="#000040"><strong> </strong></font></h2>
</li>
</dir>

</blockquote>
</blockquote>
</blockquote>
<p align=left><font size=4>&#160;</font></p>
</blockquote>
</blockquote>
<img src="CORY/cnt.cgi"> 

<hr size=5 color="#008080">
<p align=left><font color="#004080"><font size=2><img src="posta4.gif" align=bottom width=100 height=62> Webmaster at</font></font></p>
<p align=left><a href="mailto:txt4@ethiolist.com"><font color="#408080"><font size=3>txt4@ethiolist.com</font></font></a></p>

<dl>
<div align=left>
<dt><font color="#400080"><font size=3><strong>Ethiolist Services </strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>3245 South White Road, Suite 155</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>San Jose CA, 95148-4056</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>408-531-8363</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>http://www.ethiolist.com/</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>Ethiolist-Request@ethiolist.com</strong> </font></font></dt>
</div>
<dd><font size=4>&#160;</font> <p>&#160; </p>
<p>&#160; </p>
</dd>
</dl>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-68</DOCNO>
<DOCOLDNO>IA060-000328-B015-62</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/welcome.htm 206.86.13.106 19970115022322 text/html 12627
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:23:24 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 12444
Last-modified: Tue, 07 Jan 1997 04:26:31 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Welcome</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="bkg1.gif" bgcolor="#FFFFFF" text="#000000">
<p><img src="logo4.gif" align=bottom width=225 height=50></p>
<p><font color="#000000"><font size=5><strong><blink>PLEASE READ THE FOLLOWING GUIDELINE . IF YOU DO NOT WANT TO FOLLOW 
THE GUIDELINE, PLEASE DO NOT SUBSCRIBE</blink></strong></font><font size=2><blink>.</blink></font></font></p>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h3><font color="#800040"><u>General Guidelines</u></font></h3>
<p><font color="#000000">Since 1994, Ethiolist Services has been an open communication medium for 
Ethiopians, friends of Ethiopia and interested subscribers. Since its inception, 
Ethiolist has been a vanguard proponent of OPEN communication. This tradition, 
which brings us all together WILL continue to be a celebrated privilege we all 
cherish. </font></p>
<p><font color="#000000">Our aim is to provide forums(s) that would be used for constructive, informational 
and educational purposes. Our main focus has been and continues to be to bring all 
Ethiopians and friends of Ethiopia together. For the most part, we have been 
successful! Our achievements would not have occurred without your participation. 
We are very thankful for your support. </font></p>
<p><font color="#000000">As you all know, the Ethiolist file and list server runs on a commercial service 
provider's platform. Ethiolist is not simply one list but it is rather a huge system 
capable of handling transactions of multiple lists and file services. Ethiolist operates 
based on its contractual obligations and its guidelines. Furthermore, the very nature 
of the INTERNET dictates the type of service we provide. </font></p>
<p><font color="#000000">As such, Ethiolist: </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<ul>
<li><font color="#000000">cannot and does not guarantee the delivery of each posting to its subscribers. 
We put in every effort to ensure that mails are distributed to all subscribers. 
Because of the routing mechanisms of e-mail distributions and the involved 
nodes in the path of the transmission of E-mails, we are unable to guarantee 
all distributions. </font></li>
</ul>
<ul>
<li><font color="#000000">promotes an open communication medium and free exchange of ideas. 
Therefore, Ethiolist cannot monitor where each e-mail has been forwarded. 
Our guidelines state that it is up to the individual to express a &quot;Copy Right&quot; 
disclaimer on the write-ups before the first distribution has been made. </font></li>
</ul>
<p><font color="#000000">As we mentioned earlier, Ethiolist is an open forum, however, we reserver the right 
to cancel, refuse or suspend subscription at any time with or without cause.</font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h3><font color="#800040"><blink>The following has been added to the Ethiolist guidelines/rules. </blink></font></h3>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p><font color="#000000"><strong><u>Cross postings. </u></strong></font></p>
<blockquote>
<p><font color="#000000">Cross-posting of threads that began at a different list are not 
allowed on any of the Ethiolist forums. </font></p>
</blockquote>
<p><font color="#000000"><strong><u>Mail forwarding </u></strong></font></p>
<blockquote>
<p><font color="#000000">Ethiolist does not permit the forwarding of mails from 
non-subscribers without the permission of the postmaster. 
Individuals (non-subscribers) who would like to have their 
messages forwarded to Ethiolist have to join the forums themselves. </font></p>
</blockquote>
<p><font color="#000000"><u>UPON REQUEST from Ethiolist postmaster, subscribers are required to identify 
themselves to the postmaster. Failure to comply with this guideline will result in 
automatic cancellation of subscription until such disclosure is made by the individual 
who recieved the request</u>. </font></p>
</blockquote>
<p>&#160;</p>
<ul>
<li><font color="#000000"><u>Upon Request from the Ethiolist Postmaster, diucussions of &quot;heated&quot; nature, personal attacks 
..etc will be diverted to off-line communication</u>. </font></li>
</ul>
<ul>
<li><font color="#000000"><strong><u>Ethiolist does not allow any dragetory, racial or ethnical postings that are intended 
to insult any group of people.</u></strong></font><blockquote>
<blockquote>
<ul>
<li><font color="#000000"><strong><u>Ethiolist reserves the right to deny subscription 
or change the rules and guidelines of its forums 
at any time</u></strong><u>.</u></font></li>
</ul>
</blockquote>
</blockquote>
</li>
</ul>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h4><font color="#000000">Ethiolist Services has the following forums available to subscribers. </font></h4>
<p><a href="ethforum.htm" title="EthioForum"><font color="#000000">EthioForum -</font></a><font color="#000000"> </font></p>
<blockquote>
<p><font color="#000000">News and Information forum regarding Ethiopia and Ethiopians .This is the global 
forum to which subscribers may send and receive news and information regarding 
Ethiopia and Ethiopians. News and information can be of different natures 
(example, Political, Cultural, Sports ..etc.). </font></p>
</blockquote>
<blockquote>
<p><font color="#000000">News of political nature may be sent to Ethioforum (the default forum), discussions 
are also encouraged. However, if subscribers request that the discussion be held in 
the political forum (EthioPolitics), then, involved parties are required to redirect 
their mails to the political forum. </font></p>
</blockquote>
<p><font color="#000000">When mails are sent to one of the forums, they are distributed ONLY to subscribers of that 
particular forum. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p><a href="ethbusines.htm" name="EthioBusiness" title="EthioBusiness"><font color="#000000">EthioBusiness</font></a><font color="#000000"> </font></p>
<blockquote>
<p><font color="#000000">Discussions of Business nature . ONLY legal and socially acceptable business 
discussions and advertisements are allowed. Advertisements and/or discussions 
involving the sale and purchase of narcotics or drugs, child adoptions for the 
purpose of profit making, prostitution and any other morally and socially 
unacceptable practices to our communities and the law of the land are NOT 
allowed. Ethiolist is not responsible for ANY transactions that come as result of 
discussions on the EthioBusiness forum.</font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p><a href="ethpoltk.htm" name="EthioPolitics" title="EthioPolitics"><font color="#000000">EthioPolitics:</font></a><font color="#000000"> </font></p>
<blockquote>
<p><font color="#000000">Discussions of political nature. Political discussions directed toward 
the well-being of Ethiopians are encouraged. </font></p>
</blockquote>
<p><a href="EthSports.htm" name="EthioSports" title="EthioSports"><font color="#000000">EthioSports:</font></a><font color="#000000"> </font></p>
<blockquote>
<p><font color="#000000">Discussions of Sports. </font></p>
</blockquote>
<p><a href="ethcult.htm" name="EthioCulture" title="EthioCulture"><font color="#000000">EthioCulture: </font></a></p>
<blockquote>
<p><font color="#000000">Discussions of various Ethiopian cultures (tradition, customs,food 
etc.) </font></p>
</blockquote>
<p><a href="ethmusic.htm" name="EthioMusic" title="EthioMusic" rel="Banner"><font color="#000000">EthioMusic: </font></a></p>
<blockquote>
<p><font color="#000000">Discussions of Ethiopian Music (traditional or modern) 
EthioScience: </font></p>
</blockquote>
<p><a href="ethmusic.htm" name="EthioMusic" title="EthioMusic" rel="Banner"><font color="#000000">Ethio</font></a><font color="#000000">Science</font></p>
<blockquote>
<p><font color="#000000">Discussions of scientific nature (researches, inventions, studies) This 
forum is intended to serve as a reach-out to the academic and 
professional Ethiopians. Discussions are encouraged to be subject 
oriented - Engineering, Chemistry, Biology, Economics .etc. </font></p>
</blockquote>
<p><a href="ethhistory.htm" name="EthioHistory" title="EthioHistory"><font color="#000000">EthioHistory:</font></a><font color="#000000"> </font></p>
<blockquote>
<p><font color="#000000">Discussion on Ethiopian History - ancient or modern history of 
Ethiopia.</font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p><font color="#000000"><font size=4>Other forums may be created in the future when and if the need 
arises. These available forums are experimental and may not cover 
all of the interests of subscribers. It may also be difficult to 
categorize a given write-up - meaning what some consider to be 
historical may also be political in nature. In cases like that 
subscribers are requested to make a reasonable judgement. 
Regardless of the difficulties though, we feel that we must start 
from a point and prepare ourselves to modify the guidelines as the 
needs come. </font></font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h4><font color="#800040"><u>HOW DO I SEND MY MAIL TO A PARTICULAR FORUM?</u></font></h4>
<p><font color="#000080"><strong>Simply address your mail to the particular forum. For example, to send mail 
to the EthioCulture forum, send your mail to: </strong></font></p>
<blockquote>
<p><font color="#000080"><strong>EthioCulture@ethiolist.com </strong></font></p>
</blockquote>
<p><font color="#000080"><strong>The same procedure applies to the other forums. </strong></font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<h4 align=center><font color="#000080"><font size=5><strong><u><blink>Subscribers who do not want their article(s) to be redistributed 
elsewhere should state so in their articles</blink></u></strong><strong><blink>.</blink></strong><strong> </strong></font></font></h4>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<h4 align=center><u>WHO TO CONTACT</u></h4>
<blockquote>
<blockquote>
<blockquote>
<p><font color="#000000">Contact the postmaster (Tadesse Tsegaye) with your questions 
and/or suggestion. The postmaster can be reached via 
</font><a href="txt4@ethiolist.com"><font color="#8000FF"><i>txt4@ethiolist.com</i></font></a><font color="#8000FF"><i> or </i></font><a href="txt4@necom.com"><font color="#8000FF"><i>txt4@netcom.com</i></font></a><font color="#8000FF"><i> </i></font><fon
t color="#000080">.</font></p>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<p align=center><font color="#400040"><strong>DISTRIBUTION OF COPY-RIGHTED MATERIAL(S) IS 
NOT PERMITTED WITHOUT A WRITTEN 
PERMISSION FROM THE AUTHOR AND THE 
POSTMASTER OF THIS ALIAS - ETHIOLIST. IN THE 
EVENT THAT SUCH RULE IS VIOLATED AND HAS 
COME TO THE ATTENTION OF THE POSTMASTER 
OR THE MANAGING TEAM OF ETHIOLIST 
SERVICES, THE POSTMASTER WILL TERMINATE 
THE MEMBERSHIP OF THE PARTY INVOLVED WITH 
OR WITHOUT FURTHER NOTIFICATION!</strong></font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<p align=center><font color="#000080">Please keep this mail for your reference, you may need it in the future. Thank You for joining Ethiolist and welcome again. </font></p>
</blockquote>
</blockquote>
<p><a href="contrbt.htm" name="Contribution" title="Contributin">Your Contribution is Welcome</a> </p>
<p><a href="index.htm" name="Ethiolist" title="Ethiolist Home">Go Back to Ethiolist Home</a> </p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-69</DOCNO>
<DOCOLDNO>IA060-000328-B015-96</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/faq.htm 206.86.13.106 19970115022352 text/html 13624
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:23:40 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 13441
Last-modified: Tue, 07 Jan 1997 04:13:53 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Ehiolist FAQ</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="bkg1.gif" bgcolor="#FFFFFF" text="#FFFFFF">
<p align=left><img src="logo4.gif" align=bottom width=225 height=50> </p>
<hr noshade>
<h1 align=center><font color="#000000"><font size=7><strong>FAQ</strong></font><strong> </strong></font></h1>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p><font color="#000000">Below is the Ethiolist FAQ (Frequently Asked Question) </font></p>
<h2><font color="#000000">1. How many forums are there on Ethiolist Server?</font></h2>
<p><font color="#000000">Ethiolist Services has the following forums : </font></p>
<ul>
<li><font color="#000000">EthioForum </font></li>
<li><font color="#000000">EthioPolitics </font></li>
<li><font color="#000000">EthioCulture </font></li>
<li><font color="#000000">EthioHistory </font></li>
<li><font color="#000000">EthioMusic </font></li>
<li><font color="#000000">EthioScience </font></li>
<li><font color="#000000">EthioBooks </font></li>
<li><font color="#000000">EthioBusiness </font></li>
<li><font color="#000000">EthioSports </font></li>
<li><font color="#000000">Ethio-Humor </font></li>
<li><font color="#000000">Ethio-Art </font></li>
<li><font color="#000000">EthioNews </font></li>
</ul>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2 align=left><font color="#000000">2. How would I post to these forums?</font></h2>
<p align=left><font color="#000000">First you need to subscribe to the Ethiolist Services by sending a request e-mail to 
Ethiolist-Request@Ethiolist.com. Once the subscription is processed, then posting 
to any one of the above forums is simple and direct. For example, to post to 
EthioMusic subscribers are requested to send their mails to 
EthioMusic@Ethiolist.com. And, to post EthioCulture the address to use is 
EthioCulture@Ethiolist.com. The domain name for all the forums is the same - 
@Ethiolist.com. The only thing that changes is the forum name. So, the format 
[forum name]@Ethiolist.com works for all postings. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">3. Why all these forums, is it not going to be 
confusing for subscribers?</font></h2>
<p><font color="#000000">The forums were designed to reflect different interest areas. For example, those 
interested in discussions of sports may send their messages to sports forum, and 
those interested in the Ethiopian culture will direct their postings to the EthioCulture 
forum. Having such kind of setup really benefits subscribers. As more Ethiopians 
get e-mail access, more postings will show, and it will be time consuming for a 
subscriber to sort through all the incoming mails. The current set-up can be used as 
a preliminary sorting method. If a subscriber does not want to get mails from a 
given forum he/she would unsubscribe from that particular forum while still being 
able to get information in other areas of interest (other forums). </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">4. What do I need to do to archive files?</font></h2>
<p><font color="#000000">Postings sent to Ethiolist server are automatically archived and can be accessed by 
sending a request to the request alias. The request alias for the Ethiolist services is : 
Ethiolist-Request@Ethiolist.com Since the archiving is done for each forum 
separately different commands should be used for each forum. However, all 
requests can be made in a single request mail. The following example shows how to 
use the request alias to get archive mails. The first thing you need to do is address 
your request to the proper alias. In the case, the request would be addressed to 
Ethiolist-Request@Ethiolist.com , so, the mail header would look like this: </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<pre><font color="#000000">

</font><font color="#000040"><strong>		To: Ethiolist-Request@Ethiolist.com
		From: Your address (this is entered automatically)
		Date: (This is automatic)
		Subject: (what ever you want it to be)

		SEND EthioForum
		SEND EthioMusic
		SEND EthioCulture
		SEND Ethio-Art
		SEND Ethio-Humor</strong></font><font color="#000000">

</font></pre>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p><font color="#000000">As you see, the command for retrieving archives is the SEND command. Other 
commands also follow the same format. We are currently working on adding more 
features onto the system . </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">5. If I send the an e-mail to all the forums at the 
same time, would subscribers get that many 
duplicate mails - provided that they have 
subscribed to all the forums?</font></h2>
<p><font color="#000000">If a mail is sent to ALL the forums at the SAME time, subscribers should not be 
getting multiple copies and , the incoming mail shows the tags indicating which 
forum the mail was sent to. If mails are sent at time intervals, then, subscribers might 
get multiple copies. So, if you want to reach ALL Ethiolist subscribers without 
sending duplicate mails, then, what you really need to do is, address your e-mail to 
one forum and carbon copy all the remaining forums. Since it is one mail 
composition, the server should not send SAME mail to the same person more than 
one time. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">6. Are there other commands that subscribers 
may use?</font></h2>
<p><font color="#000000">We are currently working on a set of commands that would grant list maintainers 
access to the Ethiolist server. As the needs comes we will be adding more 
commands that could also be utilzed by subscribers to get more information on their 
subscrption and also allow them to access the archives in a better efficient way. By 
design, the Ethiolist server would allow us to add more commands as the needs 
come in the future. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">7. What is the objective of Ethiolist?</font></h2>
<p><font color="#000000">Our objective is to open and strengthen an open electronic forum for Ethiopians 
and those who promote the interests of Ethiopians. We sincerely believe that open 
communication and exchange of diverse ideas is a prerequisite for a consensus on 
issues at hand. Hence, we encourage discussions on different issues to be open and 
sincere. The Ethiolist managing team has no political partisanship, however, we 
sincerely believe that our strength rests on our unity. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">8. Who pays for all these service? Is there any 
plan to share the cost?</font></h2>
<p><font color="#000000">This question was raised by a number of subscribers. Ethiolist is maintained by the 
postmaster and managed by a team of Ethiopians. There is a monthly fee that is 
paid to the service provider for access to their machine. That fee is ONLY for a 
limited use of the service provider's resources. For instance every time we exceed 
the limitation (disk space) we are required to pay extra money. This can happen 
very frequently considering the increasing number of subscribers. Every activity on 
the Ethiolist server is logged in addition to the actual e-mails that are also saved on 
the server. And that eats-up disk space. Ethiolist requests subscribers to share the 
burden. We will be asking for small contribution to continue the service. The 
subscription and start-up fee is a little over $2 per month per subscriber for a total 
of $25/year. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">9. Where would I send my contribution to?</font></h2>
<p><font color="#000000">Contributions to Ethiolist Services can be sent (in check or money order) to the 
following address: </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<dl>
<dt><font color="#000000"><strong>Ethiolist Services </strong></font></dt>
<dt><font color="#000000"><strong>3245 S. White Rd. Suite 155 </strong></font></dt>
<dt><font color="#000000"><strong>San Jose, CA 95148</strong></font></dt>
</dl>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p><font color="#000000">Check or money order payable to: Ethiolist. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">10. How &quot;OLD&quot; is Ethiolist?</font></h2>
<p><font color="#000000">Ethiolist came into being on March 14, 1994. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">11. How would I get a copy of the most recent 
FAQ?</font></h2>
<p><font color="#000000">FAQs can be obtained from the server via the request alias : 
Ethiolist-Request@Ethiolist.com. Address your mail to this alias and in the body of 
your request mail mail type SEND FAQ. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">12. File Transfer</font></h2>
<h2><font color="#000000"><i>VIA FTP</i></font></h2>
<p><font color="#000000">Some files on the Ethiolist Server can be accessed via the FTP mechanism. To 
download files via FTP, use ftp ftp.netcom.com directory /ftp/pub/tx/txt4. From the 
'txt4' directory you would more subdirectories for the forums we maintain. Go to 
the forum of your choise and check tha available file out (if any) </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000"><i>WITHOUT FTP</i></font></h2>
<p><font color="#000000">Ethiolist also has an E-mail based File Transfer service for binary files. These files 
can be saved on the server via e-mail remotely and can also be retrieved via e-mail 
remotely. Files and programs can be saved to AAU on the Ethiolist system and 
people in Ethiopia can access these files via e-mails. To use this feature interested 
parties need to contact the postmaster (txt4@Ethiolist.com). Due to limited disk 
space, this feature may not be available to all at this time. However, interested 
parties are encouraged to contact the postmaster. This feature is what was talked 
about on the AAU connectivity project. Well, it is here now. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<h2><font color="#000000">13. What is new?</font></h2>
<p><font color="#000000">-Three more forums have been added! </font></p>
<p><font color="#000000">Ethio-Art Ethio-Humor EthioNews </font></p>
<p><font color="#000000">The managing team has just added three more forums - Ethio-Art and 
Ethio-Humor. Ethio-Art is intended to enhance discussions related to Ethiopians 
arts, and Ethio-Humor serves as a forum for discussions regarding Ethiopian 
humors. Jokes that are not based on ethnicity and that are not divisive are very 
welcome. Homor and/or jokes that undermine the integrity of ANY of the 
Ethiopian ethnic groups are NOT allowed! EthioNews is a news forum that is 
directly from Ethiopia. Ethiolist has made arrangement with news providers in 
Ethiopia and the postings to this forum are obtained directly from these news 
sources. In the future the sources will be expanded and not limited to sources in 
Ethiopia only. EthioNews is a moderated forum. </font></p>
<p><font color="#000000">****** Ethiolist has aquired its new domain name - Ethiolist.com - in January 
1996. In addition to the new domain name Ethiolist also has its own Wbe page on 
the Internet. The URL for the Ethiolist WWW site is : 
http://www.ethiolist.com/welcome.html Please look us up for your information 
needs. </font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<p><img src="logo4.gif" align=bottom width=225 height=50></p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-70</DOCNO>
<DOCOLDNO>IA060-000328-B015-137</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/subscribe.html 206.86.13.106 19970115022438 text/html 1538
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:24:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1356
Last-modified: Wed, 08 Jan 1997 07:51:38 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>subscribe</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="../download/snow.jpg">
<dl>
<div align=left>
<dt><font color="#004000"><font size=4><img src="logo3.gif" align=texttop width=227 height=99></font></font></dt>
</div>
<dd><blockquote>
<blockquote>
<blockquote>
<blockquote>
<dl>
<div align=center><center>
<dt>&#160;</dt>
</center></div>
<div align=center><center>
<dt><font color="#004000"><font size=4>Subscription to Ethiolist is easy. Simply send e-mail to 
</font></font><a href="mailto:Ethiolist-request@Ethiolist.com">Ethiolist-Request@Ethiolist.com</a></dt>
</center></div>
<div align=center><center>
<dt><font color="#004000"><font size=4>and in the body of your mail type &quot;</font></font><font color="#800000"><font size=4>JOIN ETHIOFORUM</font></font><font color="#004000"><font size=4>&quot;</font></font></dt>
</center></div>
</dl>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<p align=center><font color="#004000"><font size=4><img src="roba.jpg" align=bottom width=331 height=363></font></font> </p>
<p>&#160; </p>
<p><a href="index.html"><img src="logo4.gif" align=bottom border=0 width=225 height=50></a> </p>
<p>&#160; </p>
</dd>
</dl>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-71</DOCNO>
<DOCOLDNO>IA060-000328-B015-194</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/alem.htm 206.86.13.106 19970115022504 text/html 4092
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:25:05 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3910
Last-modified: Wed, 08 Jan 1997 15:57:07 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>ALEM</title>
</head>

<body background="back1.gif" bgcolor="#FFFFFF" text="#000000">

<p align="center"><img src="alem.gif" width="624" height="103"></p>

<p align="center"><font color="#800000"><strong><u>TO WHOM IT MAY
CONCERN</u></strong></font></p>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <p><font color="#000000">Alem Children
                    Support Organization (<strong>ACSO</strong>)
                    is an indigenous, humanitarian and
                    non-governmental organization established to
                    help destitute children in Ethiopia. </font></p>
                    <p><font color="#000000">The organization was
                    founded by Ethiopian couple and was
                    registered with the Ethiopian government in <strong>1994</strong>
                    to undertake child focused rehabilitation and
                    development programs. </font></p>
                    <p><font color="#000000">However, <strong>ASCO</strong>
                    lacks direct access to International donors
                    to mobilize funds and other resources to
                    support its programs and we believe you will
                    be the right person. </font></p>
                    <p><font color="#000000">As we have now a
                    couple of projects going on any donations in
                    cash or in kind, from interested individuals,
                    groups or agency will be highly appreciated.
                    Your contact is: </font></p>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<dl>
    <div align="center"><center>
    <dt><font color="#FF0000" size="1"><strong>MISS LULIT
        BEZUAYEHU</strong></font> </dt>
    </center></div><div align="center"><center>
    <dt><font color="#FF0000" size="1"><strong>1507 KEESLING AVE
        #C</strong></font> </dt>
    </center></div><div align="center"><center>
    <dt><font color="#FF0000" size="1"><strong>SAN JOSE, CA 95125</strong></font>
    </dt>
    </center></div><div align="center"><center>
    <dt><font color="#FF0000" size="1"><strong>USA</strong></font>
    </dt>
    </center></div><div align="center"><center>
    <dt><font color="#FF0000" size="1"><strong>408-266-9565</strong></font>
    </dt>
    </center></div>
</dl>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <p><font color="#000000">If you have any
                    questions or seek additional information
                    please feel free to contact Miss Lulit
                    Bezuayehu - </font><a
href="mailto:LulitB@aol.com"><font
                    color="#000000">LulitB@aol.com</font></a></p>
                    <p><font color="#000000">We appreciate all
                    your cooperation and assistance accorded to
                    our organization. </font></p>
                </blockquote>
                <p><font color="#000000">&nbsp; </font></p>
                <blockquote>
                    <p><font color="#000000">Sincerely yours </font></p>
                </blockquote>
                <blockquote>
                    <p><font color="#000000">ALEM MOGES </font></p>
                </blockquote>
                <blockquote>
                    <p><font color="#000000">Managing Director</font>
                    </p>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<p><a href="alemback.htm">More information on ASCO</a></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-72</DOCNO>
<DOCOLDNO>IA060-000328-B015-238</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/ten.htm 206.86.13.106 19970115022529 text/html 8823
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:25:29 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8641
Last-modified: Wed, 08 Jan 1997 07:08:05 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>ten</title>
</head>

<body background="back1.gif" bgcolor="#FFFFFF">

<h2 align="center"><font color="#008000" size="7"><b>TRANS
ETHIOPIAN NETWORK</b></font></h2>
<div align="center"><center>

<table border="1" cellspacing="1" width="11%" bgcolor="#000000"
bordercolor="#FFFFFF">
    <tr>
        <td align="center" width="100%"><p align="center"><font
        color="#008000" size="7"><b><blink>T</blink></b></font><font
        color="#FFFF00" size="7"><b><blink>E</blink></b></font><font
        color="#FF0000" size="7"><b><blink>N</blink></b></font></p>
        </td>
    </tr>
</table>
</center></div>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <hr size="5" color="#008080">
                    <blockquote>
                        <h2><font color="#FF0000" size="5"><b>Background</b></font></h2>
                        <p><font size="2">Out of the need to
                        network in the community, Trans-Ethiopian
                        Network was conceived by a group of
                        individuals on September 17, 1990 and
                        became incorporated as a Non-profit
                        Organization on June 18, 1992.</font></p>
                        <h2><font color="#FF0000" size="5"><b>Mission
                        Statement</b></font></h2>
                        <p><font size="2">Trans-Ethiopian Network
                        is a networking forum for the exchange of
                        <i>information and resource sharing ,
                        promoting business opportunities, career
                        choices, and personal development </i>for
                        the benefit of its members by providing
                        guest speakers, seminars, workshops,
                        trade fairs, newsletters, and maintaining
                        a relevant database</font></p>
                    </blockquote>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <blockquote>
                        <p align="left"><font color="#FF0000"
                        size="5"><b>Goals</b></font></p>
                    </blockquote>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <blockquote>
                        <p align="left"><font color="#008080"
                        size="4"><strong><b>Information and
                        Resources</b></strong></font></p>
                        <p align="left"><font size="2">To
                        facilitate the flow of information
                        between members of TEN and other
                        community organizations. Members can
                        benefit by using resources such as books,
                        computer databases, and the wealth of
                        knowledge of TEN members and associates.</font></p>
                    </blockquote>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <blockquote>
                        <p align="right"><font color="#008080"
                        size="4"><strong><b>Business
                        Opportunities</b></strong></font></p>
                        <p align="right"><font size="2">To serve
                        as a facilitator for improving the
                        overall effectiveness of member-owned
                        businesses and pave the path for those
                        interested in starting up new business.
                        Seminars, trade fairs, and theme meetings
                        shall be used to promote business, share
                        expertise, and establish the necessary
                        contacts for joint business efforts. All
                        members benefit from a highly productive
                        business network and support framework.</font></p>
                    </blockquote>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <blockquote>
                        <blockquote>
                            <p align="left"><font color="#0000FF"
                            size="4"><b>Career Choices</b></font></p>
                            <p align="left"><font size="2">To
                            help members make career decisions,
                            TEN will invite guest speakers from
                            various professions. TEN will also
                            provide information on locations of
                            career resource centers.</font></p>
                        </blockquote>
                    </blockquote>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <blockquote>
                        <blockquote>
                            <p align="right"><font
                            color="#0000FF" size="4"><b>Personal/Self
                            Development</b></font></p>
                            <p align="right"><font size="2">To
                            assist members fulfill personal
                            needs, TEN will invite experts from
                            various fields such as:</font></p>
                            <p align="right"><font size="2">social
                            skills development, communication
                            skills, public speaking, physical
                            fitness, overcoming culture shock,
                            and time management.</font></p>
                            <hr>
                        </blockquote>
                    </blockquote>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<address>
    <font color="#000000" size="4"><b><u>Board Members</u></b></font>
</address>

<address>
    <font color="#000000" size="2">Nigusse Kassa, <i>Chairman</i></font>
</address>

<address>
    <font color="#000000" size="2">Dr. Tenagne Mekbib, <i>President</i></font>
</address>

<address>
    <font color="#000000" size="2">Meron Tedla, <i>Secretary</i></font>
</address>

<address>
    <font color="#000000" size="2">Daniel Wolde Selassie</font> 
</address>
<div align="left">

<address>
    <font color="#000000" size="2">Germa Aweke</font> 
</address>
</div>

<address>
    <font color="#000000" size="2">Lulit Bezuayehu</font> 
</address>

<p><font color="#000000" size="5"><i>Would you like more
information? Please send us e-mail - </i></font><font
color="#800000" size="5"><i>: </i></font><a
href="mailto:Ethio-Ten@Ethiolist.com"><font size="5"><i>Ethio-Ten@Ethiolist.com</i></font></a></p>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <blockquote>
                        <blockquote>
                            <blockquote>
                                <hr>
                            </blockquote>
                        </blockquote>
                    </blockquote>
                </blockquote>
            </blockquote>
        </blockquote>
        <p align="center"><font color="#008000" size="4">Trans-Ethiopian
        Network Inc.</font></p>
        <p align="center"><font color="#008000" size="4">3550
        Stevens Creek Blvd. Suite 310</font></p>
        <p align="center"><font color="#008000" size="4">Santa
        Clara Ca. 95050</font></p>
        <p align="center">&nbsp;</p>
    </blockquote>
</blockquote>

<hr>

<p align="left"><a href="index.html"><img
src="logo4.gif" border="0" width="225" height="50"></a></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-73</DOCNO>
<DOCOLDNO>IA060-000328-B015-307</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/construc.htm 206.86.13.106 19970115022617 text/html 530
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:26:01 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 349
Last-modified: Tue, 12 Nov 1996 14:47:30 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>construct</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body bgcolor="#000000" text="#008080">
<h2>Sorry. This page is under construction.........</h2>
<p>&nbsp;</p>
<p>&nbsp;</p>
<hr>
<p><a href="index.html">Ethiolist Home</a></p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-74</DOCNO>
<DOCOLDNO>IA060-000328-B015-373</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/clamp.htm 206.86.13.106 19970115022655 text/html 7889
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:26:58 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7707
Last-modified: Wed, 08 Jan 1997 07:06:57 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>ClampDown</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="bkg1.gif">
<p align=right>&#160;</p>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p>.<img src="zenaeth.gif" align=top width=326 height=86></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<dl>
<dt><br>
<strong>Clampdown in Addis<br>
Ethiopia's Journalists at Risk</strong><br>
<br>
by Kakuna Kerina<br>
<br>
After centuries of feudal rule, 17 years of communist dictatorship, almost<br>
three decades of civil war, and no tradition of an independent press before 1992, Ethiopia is<br>
at a crossroads. <br>
<br>
As one of the African continent's youngest exercises in democracy, Ethiopia can serve as an </dt>
<dt>example of a true democracy--one that does not sacrifice freedom of expression and human </dt>
<dt>rights as its leaders establish order. Or, it can join the ranks of neighbors whose leaders</dt>
<dt>assumed office promising respect for press freedom and other civil rights, but who have </dt>
</dl>
<dt>since broken these and other pledges.<br>
<br>
As things stand today, Ethiopia's independent journalists and the government of Meles Zenawi, </dt>
<dt>the country's first freely elected prime minister, eye each other with mutual suspicion and </dt>
<dt>distrust. Journalists labor under a restrictive press law and penal code, and, as a result, more </dt>
<dt>journalists have been jailed in Ethiopia in the past three years than in any other African country. </dt>
<dt>The Committee to Protect Journalists embarked on a fact-finding mission to Ethiopia in May </dt>
<dt>1996 to better understand how and why the press law and other legal measures are used </dt>
<dt>against journalists.</dt>
<dl>
<dt><br>
Following the fall of Col. Mengistu Haile Mariam's communist regime in 1991 and encouraged </dt>
<dd><dl>
<dt>by assurances of press freedom by the newly installed Transitional Government of Ethiopia </dt>
<dt>(TGE), a vociferous independent media exploded into existence, signaling what many hoped </dt>
<dt>would be the end of tight government control over information. <br>
<br>
One of the first acts of the TGE, led by then-President Meles*, was passage of the Press </dt>
<dt>Proclamation No. 34/1992 in October 1992. The law quickly put an end to the euphoria </dt>
<dt>that fueled the country's new era of free speech as journalists realized how vulnerable they</dt>
<dt>were under the proclamation, which is both restrictive and contradictory. The legislation </dt>
<dt>prohibits, among other things, the dissemination of information the government deems </dt>
<dt>dangerous, and requires the licensing of all journalists. Moreover, it classifies libel as both a </dt>
<dt>criminal and civil offense, demanding penalties of payment in the amount of twice the value of<br>
a publisher's assets.<br>
<br>
Criminal libel laws or indeed any statutes intended or used to insulate government officials<br>
from press criticism through the application of civil or criminal penalties have no place in<br>
democratic societies. The right to speak freely without fear of government<br>
reprisal is a core principle of democracy, and critical reporting must be tolerated and<br>
protected, not criminalized.<br>
<br>
In late 1993, reeling from criticism from a growing number of newspapers and magazines </dt>
<dt>about state policies and the political transition under way, the government cracked down on </dt>
<dt>the press, starting with the detention of Tefera Asmare, editor of the independent newspaper </dt>
<dt>Etiopis. In connection with an article titled &quot;There's War in Gondar,&quot; Tefera was charged </dt>
<dt>with &quot;inciting people against the government&quot; and &quot;disseminating false rumors,&quot; under Article </dt>
<dt>10, Section 2 of the Press Proclamation. Tefera was later charged with 11 counts of libel</dt>
<dt>under the press law; five counts were for the same story carried in different editions of </dt>
<dt>Etiopis. In March 1994, he was convicted of all charges and sentenced to a two-year prison </dt>
<dt>term. He was released on Sept. 27, 1995.<br>
<br>
The irony of Tefera's arrest was that he was legally carrying out his responsibilities as a </dt>
<dt>journalist according to the Press Proclamation's Art. 4, Sec. 2, which states that &quot;the press</dt>
<dt>gathers and disseminates news; expresses opinions on various issues; forwards criticisms on </dt>
<dt>various issues; participates in forming public opinion by employing various other methods;</dt>
<dt>[and] undertakes other activities necessary for the accomplishment of its purposes.&quot;<br>
<br>
Tefera's case is emblematic of the double bind imposed on independent Ethiopian<br>
journalists--he is one of more than 50 who have been imprisoned for their work since 1993.</dt>
<dt>By simultaneously using ambiguous articles of the Press Proclamation and provisions of the </dt>
<dt>civil, penal, and criminal codes, many of which were created in the 1950s, the Meles </dt>
<dt>government has put the media on notice that it will not hesitate to manipulate the laws to </dt>
<dt>suit its own ends.<br>
<br>
Ethiopia, which is a signatory to several regional and international charters guaranteeing press</dt>
<dt>freedom, such as the African Charter on Human and People's Rights and the International </dt>
<dt>Covenant on Civil and Political Rights (ICCPR), has rapidly become a country where reality </dt>
<dt>belies the government's public proclamations about the need for a free press. Contradictory</dt>
<dt>statements by government officials illuminate this gap between rhetoric and policy. &quot;A free </dt>
<dt>press is an essential ingredient of any democratic exercise [because it provides] information </dt>
<dt>to the public so they can make informed decisions,&quot; Prime Minister Meles told CPJ's mission. </dt>
<dt>During the same meeting, however, he also said that the government has to impose restrictions </dt>
<dt>on the media to stave off ethnic strife and threats to national security. <br>
<br>
The stance that Prime Minister Meles' administration chooses to adopt toward the<br>
independent press in the coming years will have significant repercussions.<br>
The existence of a free press in Ethiopia is dependent upon a clear commitment from the<br>
government to support the development of private media and to lift restrictions on reporting </dt>
<dt>and private-sector competition. Ethiopia cannot claim to be a genuine democracy, nor should </dt>
<dt>it be treated as one by Western donors such as the United States, unless the Meles government<br>
ceases its practice of subjecting independent journalists to repeated arrests, detention without </dt>
<dt>trial, and excessive fines.<br>
<br>
*On second reference, Ethiopians are referred to by the first of their names. <br>
<br>
<br>
(c) 1996 Committee Protect Journalists <br>
</dt>
</dl>
<hr>
<p align=center><br>
<br>
<strong>Ethiolist Services</strong><br>
EthioForum<br>
3245 South White Rd. Suite 155<br>
San Jose, CA 95148-4056<br>
Voice/Fax (408) 531-8363<br>
http://www.ethiolist.com/<br>
Mon Dec 30 13:12:10 PST 1996<br>
<br>
To subscribe to EthioForum, please send e-mail to<br>
Ethiolist-request@ethiolist.com, and in the body<br>
your mail type : JOIN EthioForum<br>
To unsubscribe type: LEAVE EthioForum </p>
<p align=center>&#160; </p>
<hr>
</dd>
</dl>
</blockquote>
</blockquote>
</blockquote>
<p><a href="index.html"><img src="logo4.gif" align=bottom border=0
width=225 height=50></a> </p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-75</DOCNO>
<DOCOLDNO>IA060-000328-B016-49</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/usstate.htm 206.86.13.106 19970115022734 text/html 5178
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:27:38 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4996
Last-modified: Wed, 08 Jan 1997 07:07:28 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>US State Department</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="bkg1.gif" link="#0000A0" vlink="#0000A0" alink="#FF0000">
<blockquote>
<p align=center>&#160;</p>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p align=left>.<img src="zenaeth.gif" align=top width=326 height=86></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<p align=left><font color="#000000"><strong>U.S. State Department Institutes Policy<br>
Change Toward Ethiopian Press During<br>
Christopher&#146;s Visit to Addis Ababa<br>
</strong><br>
Policy Change Enacted After Review of CPJ Report<br>
Revealing More Journalists Imprisoned in Ethiopia in Past<br>
Three Years Than in Any Other African Country<br>
<br>
New York&#139; U.S. Secretary of State Warren Christopher today declined the<br>
Ethiopian government&#146;s invitation to hold a joint press conference upon his<br>
arrival in Addis Ababa. This, in response to a report by the New York-based<br>
Committee to Protect Journalists (CPJ) detailing the legal harassment and<br>
imprisonment of Ethiopian journalists, and the government&#146;s systematic<br>
exclusion of the private press from official press conferences. State Department<br>
Spokesperson Nicholas Burns told the Committee&#146;s chair, Kati Marton, that<br>
CPJ&#146;s report Clampdown in Addis: Ethiopia&#146;s Journalists at Risk led to the<br>
policy change.<br>
<br>
In a public statement, Secretary of State Christopher told reporters,<br>
&#147;Ethiopia has made progress in human rights during the past five years, but the<br>
United States wants to see more. One of the areas of our concern is the<br>
freedom of the press and the treatment of journalists.&#148; <br>
<br>
CPJ&#146;s report is based on a fact-finding mission conducted last May by<br>
Africa Program Coordinator Kakuna Kerina, who wrote the report, and CPJ 
board<br>
member and Newsday U.N. bureau chief Josh Friedman, who wrote the<br>
report&#146;s introductory essay. Based on more than 50 interviews with<br>
government officials, journalists and other sources, the report demonstrates how<br>
independent journalists are regularly harassed, censored and jailed under the<br>
provisions of a restrictive press law enacted in 1992. The repressive climate exists<br>
despite promises of press freedom made by the Transitional Government of 
Ethiopia<br>
(TGE) in 1991 and by the recently elected Prime Minister Meles Zenawi, who<br>
served as TGE president. Clampdown in Addis, which was released on<br>
October 7 -- the day Ethiopia&#146;s Parliament reconvened to address key media<br>
issues -- made several recommendations to the Meles administration, and<br>
called on the United States and other Western countries to take a more<br>
aggressive role in encouraging the Ethiopian government to uphold guarantees of 
press<br>
freedom.<br>
<br>
&#147;Secretary of State Christopher&#146;s position is a welcome step toward<br>
what CPJ hopes will be a continued U.S. government commitment to press 
freedom and<br>
support for Ethiopia&#146;s independent journalists,&#148; said Kerina. &#147;We look<br>
forward to the time when the Ethiopian government views the private press as an<br>
ally, not an enemy, in the democratic process.&#148; <br>
<br>
To order copies of Clampdown in Addis: Ethiopia&#146;s Journalists at Risk,<br>
please call (212) 465-1004. <br>
<br>
CPJ documents and responds to press freedom abuses around the world. From<br>
its headquarters in New York, CPJ works to get detained journalists out<br>
of jail, directs international campaigns of protest against repressive<br>
governments, and provides practical safety information to reporters assigned to<br>
dangerous areas. CPJ is a nonpartisan, nonprofit organization, and does not accept 
any<br>
government funding.<br>
<br>
<br>
The information in this news alert may be freely copied and distributed provided 
that it is </font></p>
<p align=left><font color="#000000">properly attributed to the Committee to Protect Journalists. <br>
</font></p>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
</blockquote>
<hr>
<p align=center><font color="#000000"><strong>Ethiolist Services</strong><br>
EthioForum<br>
3245 South White Rd. Suite 155<br>
San Jose, CA 95148-4056<br>
Voice/Fax (408) 531-8363<br>
http://www.ethiolist.com/<br>
Mon Dec 30 13:09:06 PST 1996<br>
<br>
To subscribe to EthioForum, please send e-mail to<br>
Ethiolist-request@ethiolist.com, and in the body<br>
your mail type : JOIN EthioForum<br>
To unsubscribe type: LEAVE EthioForum<br>
<br>
A FORUM FOR NEWS, FREE EXPRESSION OF IDEAS, OPINIONS AND COMMENTS.</font><font color="#FFFF80"><br>
</font></p>
<hr>
<p align=left><br>
<a href="index.html"><img src="logo4.gif" align=bottom border=0 width=225
height=50></a><br>
</p>
</body>

</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-76</DOCNO>
<DOCOLDNO>IA060-000328-B017-106</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/contrbt.htm 206.86.13.106 19970115023336 text/html 1315
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:33:44 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1133
Last-modified: Wed, 03 Jul 1996 03:50:12 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<HTML>
<BODY><BODY BGCOLOR="CCFFFF" TEXT="000000"><HR> 
   <body background="../bk3.gif"> 
<H3>Your Contribution </H3>
<HR> 
<P>
Ethiolist Services is run on a commercial network and there is a cost associated
to these services. The cost is paid by the Ethiolist Managing Team. In order to
cover the cost of maintenance and usage of resources, Ethiolist accepts
financial support from subscribers. We feel contributions in the amount of
$25/year (U.S.) -a little over two dollars a month - would help us maintain the
existing systems and also help us to add more features which we have not been
able to bring due to limitations of resources.
</P>
<P>
<U>Please send your contributions to:</U>
</P>
<P>
    <B>Ethiolist Services </B>
</P>
<P>
<B>    3245 S. White RD. Suite 155 </B>
</P>
<P>
<B>    San Jose, CA 95148-4056</B>
</P>
<P>
Please make your checks or money orders payable to : Ethiolist Services or
Ethiolist. Thank you! </P>
<HR>
<HR> 
<P>
<A HREF="index.htm" TITLE="Ethiolist Home">Go to Ethiolist Home</A>
</P> 
</BODY></BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-77</DOCNO>
<DOCOLDNO>IA060-000328-B017-140</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/index.htm 206.86.13.106 19970115023413 text/html 5957
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:34:12 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5775
Last-modified: Fri, 10 Jan 1997 14:04:58 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Ethiolist</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="bkg1.gif" bgcolor="#FFFFFF" text="#FFFFFF"
link="#004080" vlink="#004080" alink="#004080">
<p align=center><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom wid








th=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom wid








th=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41>
<font color="#000040"><font size=6><strong><img src="logo4.gif" align=absmiddle width=225 height=50><img src="logo4.gif" align=absmiddle width=225 height=50><img src="logo4.gif" align=absmiddle width=225 height=50><img src="logo4.gif" align=absmiddle widt








h=225 height=50></strong></font></font></p>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<ul>
<li><h2 align=left><a href="welcome.htm"><font color="#000040"><font size=3><strong>Welcome</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="faq.htm"><font color="#000040"><font size=3><strong>FAQ</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="subscribe.html"><font color="#000040"><font
size=3><strong>Subscription</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
</ul>
</blockquote>
<blockquote>
<p align=left><font color="#000040"><font size=5><strong>Community Organizations</strong></font></font></p>
</blockquote>
<blockquote>
<ul>
<li><h2 align=left><a href="alem.htm"><font color="#000040"><font size=3><strong>Alem Children Support Organization (ACSO)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="ten.htm"><font color="#000040"><font size=3><strong>Trans Ethiopian Network (TEN)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="construc.htm"><font color="#000040"><font size=3><strong>Ethiopian Community Services (ESC)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a
href="http://www.ctr.columbia.edu/~nemo/ess"><font
color="#000040"><font
size=3><strong>Ethiopian Scientific Society (ESS)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="http://www.acctgandmgmt.com/stmary.htm"><font color="#000040"><font size=3><strong>Saint Mary's Orthodox Church Home page</strong></font></font></a><font color="#000040"><strong> </strong></font></h2>
</li>
</ul>
</blockquote>
<blockquote>
<p><font color="#000040"><font size=5><strong>News and Forums</strong></font></font></p>
</blockquote>
<blockquote>
<dir>
<li><h2 align=left><a href="clamp.htm"><font color="#000040"><font size=3><strong>Clampdown in Addis<br>
Ethiopia's Journalists at Risk</strong></font></font></a><font color="#000040"><font size=3><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="usstate.htm"><font color="#000040"><font size=3><strong>U.S. State Department Institutes Policy</strong></font></font></a><font color="#000040"><strong> </strong></font></h2>
</li>
</dir>

</blockquote>
</blockquote>
</blockquote>
<p align=left><font size=4>&#160;</font></p>
</blockquote>
</blockquote>
<img src="CORY/cnt.cgi"> 

<hr size=5 color="#008080">
<p align=left><font color="#004080"><font size=2><img src="posta4.gif" align=bottom width=100 height=62> Webmaster at</font></font></p>
<p align=left><a href="mailto:txt4@ethiolist.com"><font color="#408080"><font size=3>txt4@ethiolist.com</font></font></a></p>

<dl>
<div align=left>
<dt><font color="#400080"><font size=3><strong>Ethiolist Services </strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>3245 South White Road, Suite 155</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>San Jose CA, 95148-4056</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>408-531-8363</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>http://www.ethiolist.com/</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>Ethiolist-Request@ethiolist.com</strong> </font></font></dt>
</div>
<dd><font size=4>&#160;</font> <p>&#160; </p>
<p>&#160; </p>
</dd>
</dl>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-78</DOCNO>
<DOCOLDNO>IA060-000328-B017-203</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/alemback.htm 206.86.13.106 19970115023525 text/html 9943
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:35:21 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9761
Last-modified: Wed, 08 Jan 1997 07:08:49 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Background</title>
</head>

<body bgcolor="#FFFFFF" text="#000000">

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <p><font color="#000000" size="5"><strong><u>BACKGROUND</u></strong></font></p>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <p><font color="#000000">The Persistent
                    famine situation in Ethiopia coupled with
                    civil war and economic stagnation has been
                    very devastating.</font></p>
                    <p><font color="#000000">Children who were
                    the most vulnerable group become easy victim
                    of various diseases, malnutrition, death and
                    untold misery and suffering.</font></p>
                    <p><font color="#000000">Alem Children
                    Support Organization was established as an
                    indigenous and humanitarian NGO, to
                    contribute its share towards alleviating the
                    plight of the children in the country.</font></p>
                    <p><font color="#000000">ASCO was founded by
                    Ethiopian married couple and was registered
                    with the Ethiopian government in 1994 to
                    undertake child focused rehabilitation and
                    development programs.</font></p>
                    <p><font color="#000000">The organization is
                    superintended by a board of directors whose
                    membership is drawn from government and
                    non-government organizations. I is managed by
                    Mrs. Alemnesh MOgessie with the help of small
                    but diligent staff. There are now a couple of
                    professional people who have joined the
                    organization as paid staff.</font></p>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<p align="center"><font color="#000000" size="4"><strong><u>HIGHLIGHTS
OF ACTIVITIES</u></strong></font></p>

<blockquote>
    <blockquote>
        <blockquote>
            <blockquote>
                <blockquote>
                    <p><font color="#000000">Within the past
                    three years, efforts have been made to
                    provide basic and material support by the
                    founders and by few humanitarian individuals.</font></p>
                    <p><font color="#000000"></font>&nbsp;</p>
                </blockquote>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<blockquote>
    <blockquote>
        <blockquote>
            <p><font color="#008080"><strong><u>BENEFICIARIES -
            STREET AND DESTITUTE CHILDREN</u></strong></font></p>
            <blockquote>
                <ul>
                    <li><font color="#000000">Street and
                        destitute children numbering 200 from low
                        income families of the neighborhood are
                        being supported at a drop-in center in
                        Addis Ababa with the following:</font></li>
                </ul>
            </blockquote>
            <blockquote>
                <ul>
                    <li><font color="#000000">Provision of
                        supervised informal education through the
                        day care center.</font></li>
                </ul>
            </blockquote>
            <blockquote>
                <ul>
                    <li><font color="#000000">Supplementary
                        feeding program, i.e. offering one mean a
                        day at the drop-in center through out the
                        year.</font></li>
                </ul>
            </blockquote>
            <blockquote>
                <ul>
                    <li><font color="#000000">Recreational
                        facilities.</font></li>
                </ul>
            </blockquote>
            <blockquote>
                <ul>
                    <li><font color="#000000">Health referral and
                        clothing support.</font></li>
                </ul>
            </blockquote>
            <blockquote>
                <ul>
                    <li><font color="#000000">School supplies
                        such as exercise books and pencils are
                        issued for pre-school children and a few
                        primary school children.</font></li>
                </ul>
            </blockquote>
            <blockquote>
                <ul>
                    <li><font color="#000000">Providing monthly
                        financial support to very poor families
                        through the child sponsorship program.</font></li>
                </ul>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<blockquote>
    <blockquote>
        <blockquote>
            <p><font color="#008080"><strong><u>DESTITUTE MOTHERS</u></strong></font></p>
            <blockquote>
                <ul>
                    <li><font color="#000000">Provide cash loan
                        to 80 disadvantaged mothers of the
                        neighborhood to start small income
                        generating ventures.</font></li>
                    <li><font color="#000000">Assist another 60
                        poor women to earn income by involving
                        them in traditional cotton spinning
                        activity. The spun cotton will be used as
                        raw material to produce traditional
                        Ethiopian clothes. The weaving cottage
                        handicraft was set up within the compound
                        of the drop-in center as part of our
                        effort to reduce our dependence on
                        external assistance and promote self
                        reliance.</font></li>
                    <li><font color="#000000">Provision of basic
                        health education, including family
                        planning practice, child care and
                        nutrition.</font></li>
                </ul>
            </blockquote>
        </blockquote>
    </blockquote>
</blockquote>

<p><font color="#000080"><strong><u>MAJOR CONSTRAINTS</u></strong></font></p>

<blockquote>
    <ul>
        <li><font color="#000080"><strong>Lack of direct access
            to internatonal donors to mobilize funds and other
            organizational support.</strong></font></li>
    </ul>
</blockquote>

<blockquote>
    <ul>
        <li><font color="#000080"><strong>Lack of transport is a
            major constraint for carrying out planned activities
            on time.</strong></font></li>
    </ul>
</blockquote>

<blockquote>
    <ul>
        <li><font color="#000080"><strong>Shortage of qualified
            staff, office supplies and equipment.</strong></font></li>
    </ul>
</blockquote>

<blockquote>
    <ul>
        <li><font color="#000080"><strong>Frequent changes of
            government structure and policies</strong>.</font></li>
    </ul>
</blockquote>

<p><font color="#008080"><strong><u>FUTURE PLANS</u></strong></font></p>

<blockquote>
    <blockquote>
        <ul>
            <li><font color="#008080"><strong>Improving the
                facilities, management operation and the quality
                of manpower so as to promote effective
                performance.</strong></font></li>
        </ul>
    </blockquote>
</blockquote>

<blockquote>
    <blockquote>
        <ul>
            <li><font color="#008080"><strong>Increasing the
                number of beneficiary children by promoting child
                sponsorship programs.</strong></font></li>
        </ul>
    </blockquote>
    <blockquote>
        <ul>
            <li><font color="#008080"><strong>Providing revolving
                fund to street children and their mothers to
                initiate income generating schemes.</strong></font></li>
        </ul>
    </blockquote>
    <blockquote>
        <ul>
            <li><font color="#008080"><strong>Partnering with
                other NGOs to have a maximum positive impact from
                the programs.</strong></font></li>
        </ul>
    </blockquote>
    <blockquote>
        <ul>
            <li><font color="#008080"><strong>Initiating income
                generating activity or other alternative options
                that would reduce dependency on donation and
                promote self-reliance.</strong></font></li>
        </ul>
    </blockquote>
</blockquote>

<blockquote>
    <p><font color="#000000">It is to be noted, however, that the
    above plans are only major outlines reflecting our vision and
    intents. If you wish detailed plan and project proposals to
    participate in funding, we are ready to submit.</font></p>
    <p><font color="#000000">We will be glad to receive
    innovative ideas and practical experiences as well as
    assistance in the form of cash, material and man-power
    support.</font></p>
</blockquote>

<hr>

<p><a href="index.html"><img src="logo4.gif"
border="0" width="225" height="50"></a></p>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-79</DOCNO>
<DOCOLDNO>IA060-000328-B015-15</DOCOLDNO>
<DOCHDR>
http://www.ethiolist.com:80/ 206.86.13.106 19970115022307 text/html 5957
HTTP/1.0 200 OK
Date: Wed, 15 Jan 1997 02:22:58 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5775
Last-modified: Fri, 10 Jan 1997 14:02:59 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>
<title>Ethiolist</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
</head>

<body background="bkg1.gif" bgcolor="#FFFFFF" text="#FFFFFF"
link="#004080" vlink="#004080" alink="#004080">
<p align=center><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom wid








th=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom wid








th=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41><img src="Eth.gif" align=bottom width=70 height=41>
<font color="#000040"><font size=6><strong><img src="logo4.gif" align=absmiddle width=225 height=50><img src="logo4.gif" align=absmiddle width=225 height=50><img src="logo4.gif" align=absmiddle width=225 height=50><img src="logo4.gif" align=absmiddle widt








h=225 height=50></strong></font></font></p>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<blockquote>
<ul>
<li><h2 align=left><a href="welcome.htm"><font color="#000040"><font size=3><strong>Welcome</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="faq.htm"><font color="#000040"><font size=3><strong>FAQ</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="subscribe.html"><font color="#000040"><font
size=3><strong>Subscription</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
</ul>
</blockquote>
<blockquote>
<p align=left><font color="#000040"><font size=5><strong>Community Organizations</strong></font></font></p>
</blockquote>
<blockquote>
<ul>
<li><h2 align=left><a href="alem.htm"><font color="#000040"><font size=3><strong>Alem Children Support Organization (ACSO)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="ten.htm"><font color="#000040"><font size=3><strong>Trans Ethiopian Network (TEN)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="construc.htm"><font color="#000040"><font size=3><strong>Ethiopian Community Services (ESC)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a
href="http://www.ctr.columbia.edu/~nemo/ess"><font
color="#000040"><font
size=3><strong>Ethiopian Scientific Society (ESS)</strong></font></font></a><font color="#000040"><font size=4><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="http://www.acctgandmgmt.com/stmary.htm"><font color="#000040"><font size=3><strong>Saint Mary's Orthodox Church Home page</strong></font></font></a><font color="#000040"><strong> </strong></font></h2>
</li>
</ul>
</blockquote>
<blockquote>
<p><font color="#000040"><font size=5><strong>News and Forums</strong></font></font></p>
</blockquote>
<blockquote>
<dir>
<li><h2 align=left><a href="clamp.htm"><font color="#000040"><font size=3><strong>Clampdown in Addis<br>
Ethiopia's Journalists at Risk</strong></font></font></a><font color="#000040"><font size=3><strong> </strong></font></font></h2>
</li>
<li><h2 align=left><a href="usstate.htm"><font color="#000040"><font size=3><strong>U.S. State Department Institutes Policy</strong></font></font></a><font color="#000040"><strong> </strong></font></h2>
</li>
</dir>

</blockquote>
</blockquote>
</blockquote>
<p align=left><font size=4>&#160;</font></p>
</blockquote>
</blockquote>
<img src="CORY/cnt.cgi"> 

<hr size=5 color="#008080">
<p align=left><font color="#004080"><font size=2><img src="posta4.gif" align=bottom width=100 height=62> Webmaster at</font></font></p>
<p align=left><a href="mailto:txt4@ethiolist.com"><font color="#408080"><font size=3>txt4@ethiolist.com</font></font></a></p>

<dl>
<div align=left>
<dt><font color="#400080"><font size=3><strong>Ethiolist Services </strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>3245 South White Road, Suite 155</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>San Jose CA, 95148-4056</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>408-531-8363</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>http://www.ethiolist.com/</strong></font></font></dt>
</div>
<div align=left>
<dt><font color="#400080"><font size=2><strong>Ethiolist-Request@ethiolist.com</strong> </font></font></dt>
</div>
<dd><font size=4>&#160;</font> <p>&#160; </p>
<p>&#160; </p>
</dd>
</dl>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-80</DOCNO>
<DOCOLDNO>IA009-000096-B026-115</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/ 194.183.5.143 19970222162349 text/html 2564
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:24:01 GMT
Pragma: no-cache
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML> 
<META HTTP-EQUIV="Expires" CONTENT= "Tue, 20 Aug 1900 14:25:27 GMT"><BODY  BGCOLOR="#01004D" TEXT="#FFFF00" LINK="#FF0000" VLINK="#BFBFBF"><!-- BEGIN BODY HEADER SECTION --><HEAD><TITLE>Ziwin-go CyberCafe'</TITLE><!-- BEGIN MAIN BODY SECTION --><body>
<H1><CENTER><B><I><H1><B><I>Welcome to</I></B></H1> <H1><B>Ziwin-go Cybercafe'</B></H1></I></B>
</CENTER></HEAD></H1><p>
<CENTER><H4>Via della Meloria 78 (Ple. degli Eroi)
- ROMA</H4></CENTER><p>
<CENTER>Click <A HREF="italian.htm">here</A> for italian version</CENTER><P>

<body><center><IMG WIDTH=204 HEIGHT=255  SRC="images/logo.gif"></center><P><BR>

<CENTER><!-- Table Tag --><TABLE BORDER=2>
<TR><TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="info.html">INFO</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="services.html">SERVICES</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="picture.html">PICTURES</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="staff.html">STAFF</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="menu.html">MENU</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="http://www.pngroup.net/surfing/surfing_ita.htm">LINKS</A></TH></TR>
</TABLE></center><p><HR ALIGN=CENTER>
<H2 ALIGN=CENTER>Ziwin-go has been chosen for the new Levi's promotion!</H2>
<CENTER><A HREF="http://adserver.obsolete.com/scripts/adserv.dll?file=index1.html">
<IMG SRC="http://adserver.obsolete.com/mermaids/1.gif" BORDER=0 WIDTH=80
HEIGHT=54>
</A></CENTER>
<HR ALIGN=CENTER><P>


<CENTER><A HREF="armando/asic.htm">Personal Pages</A>   <IMG SRC="images/new.gif" BORDER=0 ></CENTER><P>

<CENTER><HR ALIGN=CENTER WIDTH=100% SIZE=2><p></CENTER>

<!-- BEGIN BODY FOOTER SECTION --><CENTER><H4>Open from June 20, 1996</CENTER>
<CENTER>8 pm - 2 am</CENTER>
<CENTER>Tel. 39735305</H4></CENTER><p>
<CENTER><H3>Air Conditioning</H3></CENTER>
<A HREF="http://www.pngroup.net/welcome_ita.htm"><IMG SRC="images/POWRBY1.gif"HEIGHT=43 WIDTH=114></A>
<A HREF="http://www.easymac.it"><IMG SRC="images/easymac.JPG"HEIGHT=43 WIDTH=114></A>
</BODY> 
</HTML> 


</DOC>
<DOC>
<DOCNO>WT01-B04-81</DOCNO>
<DOCOLDNO>IA009-000096-B026-140</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/italian.htm 194.183.5.143 19970222162403 text/html 2615
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:24:13 GMT
Last-modified: Friday, 14-Feb-97 19:40:20 GMT
Content-length: 2388
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML> 
<META HTTP-EQUIV="Expires" CONTENT= "Tue, 20 Aug 1900 14:25:27 GMT"><BODY  BGCOLOR="#01004D" TEXT="#FFFF00" LINK="#FF0000" VLINK="#BFBFBF"><!-- BEGIN BODY HEADER SECTION --><HEAD><TITLE>Ziwin-go CyberCafe'</TITLE><!-- BEGIN MAIN BODY SECTION --><body>
<H1><CENTER><B><I><H1><B><I>Benvenuti da</I></B></H1> <H1><B>Ziwin-go Cybercafe'</B></H1></I></B>
</CENTER></HEAD></H1><p>
<CENTER><H4>Via della Meloria 78 (Ple. degli Eroi)
- ROMA</H4></CENTER><p>
<body><center><IMG WIDTH=204 HEIGHT=255  SRC="images/logo.gif"></center><P><BR>

<CENTER><!-- Table Tag --><TABLE BORDER=2>
<TR><TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="info.html">INFO</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="services.html">SERVICES</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="picture.html">PICTURES</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="staff.html">STAFF</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="menu.html">MENU</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="http://www.pngroup.net/surfing/surfing_ita.htm">LINKS</A></TH></TR>
</TABLE></center><p><HR ALIGN=CENTER>
<H2 ALIGN=CENTER>Ziwin-go e' stato scelto tra i migliori 80 cybercafes nel mondo per la nuova promozione della Levi's jeans</H2>
<CENTER><A HREF="http://adserver.obsolete.com/scripts/adserv.dll?file=index1.html">
<IMG SRC="http://adserver.obsolete.com/mermaids/1.gif" BORDER=0 WIDTH=80
HEIGHT=54>
</A></CENTER>
<HR ALIGN=CENTER><P>


<CENTER><A HREF="armando/asic.htm">Pagine Personali</A>   <IMG SRC="images/new.gif" BORDER=0 ></CENTER><P>

<CENTER><HR ALIGN=CENTER WIDTH=100% SIZE=2><p></CENTER>

<!-- BEGIN BODY FOOTER SECTION --><CENTER><H4>Aperto dal 20 Giugno1996</CENTER>
<CENTER>8 pm - 2 am (weekend 15:30 - 2:00)</CENTER>
<CENTER>Tel. 39735305</H4></CENTER><p>
<CENTER><H3>Air Conditioning</H3></CENTER>
<A HREF="http://www.pngroup.net/welcome_ita.htm"><IMG SRC="images/POWRBY1.gif"HEIGHT=43 WIDTH=114></A>
<A HREF="http://www.easymac.it"><IMG SRC="images/easymac.JPG"HEIGHT=43 WIDTH=114></A>
</BODY> 
</HTML> 


</DOC>
<DOC>
<DOCNO>WT01-B04-82</DOCNO>
<DOCOLDNO>IA009-000096-B026-168</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/info.html 194.183.5.143 19970222162417 text/html 1446
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:24:31 GMT
Last-modified: Wednesday, 3-Jul-96 06:39:28 GMT
Content-length: 1217
</DOCHDR>
<HTML>
<HEAD>
<TITLE>ziwingo info</TITLE>
</HEAD>
<BODY BGCOLOR=#000080 TEXT=#FFFF00 LINK=#C0C0C0 VLINK=#FF0000>

<CENTER><H3>Ziwin-go CyberCafe'</H3> e' il circolo privato della</CENTER> 
<CENTER>Associazione Culturale "Citta' Possibile"</CENTER>

<P>Lo scopo della Associazione e' quello di sviluppare la comunicazione 
interpersonale attraverso la telematica. Ziwin-go e' un locale dove e' 
possibile (e piacevole) usare il computer come mezzo per stare insieme:
surfare su Internet, giocare in rete su velocissimi Pentium, o semplicemente
chiacchierare bevendo una birra od un caffe' sono tutte cose che si possono 
fare qui insieme a vecchi o nuovi amici. Nei nostri intenti il carattere 
"sociale" del locale dovra' essere mantenuto nel tempo con lo sviluppo di 
iniziative dei quali i soci saranno promotori.

<P>Ziwin-go sara' aperto dal 21 Giugno inizialmente con un orario solo serale
dalle 8PM alle 2AM (dal 10 Luglio sara' in vigore una apertura sperimentale a pranzo). <H4 ALIGN=none>L'ingresso e' riservato ai soci</H4> 
Associarsi costa pochissimo <B>10.000 lire</B> (fino al 31 Luglio) ed in questa quota e'<B> compreso
un indirizzo di posta elettronica! </B> 

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-83</DOCNO>
<DOCOLDNO>IA009-000096-B026-211</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/services.html 194.183.5.143 19970222162433 text/html 2315
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:24:45 GMT
Last-modified: Wednesday, 3-Jul-96 06:40:12 GMT
Content-length: 2086
</DOCHDR>
<HTML>
<BODY BGCOLOR="#0F0B75" TEXT="#FDFF33" LINK="#FF0000" VLINK="#BFBFBF">
</BODY>
<HEAD>
<TITLE>ziwingo services</TITLE>
</HEAD>
<BODY>
<H2 ALIGN=CENTER>I nostri servizi</H2>
<H3 ALIGN=none>Collegamento Internet:</H3> Ziwin-go in collaborazione con PRO.NET Internet
Access Provider fornisce collegamenti ad Internet su <B>linee preferenziali</B> 
con un massimo di 10 utenti/linea. Questo garantisce un servizio sempre efficientissimo.
Sono previsti 4 tipi di abbonamento:
<P><B>Utenza Privata:</B> 	
<BR>Canone annuo lit 220.000 + IVA comprende:	 	
	<BLOCKQUOTE>linea RTC 28.800Kbps<BR>
	casella E_mail<BR>
	Kit software shareware per Internet<BR>
	Assistenza e supporto telefonico o da Ziwin-go</BLOCKQUOTE>

<P><B>Utenza Affari:</B>
<BR>Canone annuo lit 520.000 + IVA comprende:
	<BLOCKQUOTE>Linea RTC 28.800Kbps<BR>
	3 caselle E_mail<BR>
	Kit software shareware per Internet<BR>
	Assistenza e supporto telefonico o da Ziwin-go</BLOCKQUOTE>

<P><B>Utenza Aziendale</B>
<BR>Canone annuo lit.3.000.000 + IVA comprende:
	<BLOCKQUOTE>linea ISDN 64Kbps<BR>
	3 caselle E_mail<BR>
	Kit software shareware per Internet<BR>
	Assistenza e supporto telefonico o da Ziwin-go</BLOCKQUOTE>

<P><B>Utenze con connessione su linea dedicata</B>			
<BR>Canone annuo da definire:
	<BLOCKQUOTE>Linea digitale dedicata 64Kbps o piu'<BR>
	Registrazione dominio Internet<BR>
	Assegnazioni indirizzi IP<BR>
	Software Internet<BR>
	Assistenza e supporto personalizzati</BLOCKQUOTE>

<P><H3 ALIGN=none>Internet Publishing:</H3><P>
<B>Realizzazione pagine WEB personali:</B>
<BLOCKQUOTE>testo e grafica forniti dal cliente: lit. 100.000<BR>
multimediali: circa lit. 300.000 (prezzo variabile) </BLOCKQUOTE>

<B>Realizzazione pagine WEB aziendali:</B>
<BLOCKQUOTE>testo e grafica forniti dal cliente: lit. 200.000<BR>
multimediali: circa lit. 400.000 (prezzo variabile) </BLOCKQUOTE>

<P><H3 ALIGN=none>Internet Hosting:</H3><P>
<BLOCKQUOTE>pagine personali: lit. 100.000/anno<BR>
pagine aziendali: da definire personalmente</BLOCKQUOTE>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-84</DOCNO>
<DOCOLDNO>IA009-000096-B026-236</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/picture.html 194.183.5.143 19970222162442 text/html 934
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:24:57 GMT
Last-modified: Thursday, 23-Jan-97 21:55:10 GMT
Content-length: 706
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML>
<HEAD><TITLE>picture1</TITLE>


</HEAD><BODY  BGCOLOR="#01004D" TEXT="#FFFF00" LINK="#11BFB1" VLINK="#EB0000"><!-- BEGIN BODY HEADER SECTION --><H2 ALIGN=CENTER>Some Views of ZIWIN-GO CyberCafe'</H2><!-- BEGIN MAIN BODY SECTION --><CENTER><IMG SRC="LOCALE1.JPG"ALT="picture1" HEIGHT=200 WIDTH=280></center><P>

<H2 ALIGN=CENTER>The President at Work</H2><P>

<A HREF="picture2.html">next</A><!-- BEGIN BODY FOOTER SECTION --></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-85</DOCNO>
<DOCOLDNO>IA009-000096-B026-259</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/staff.html 194.183.5.143 19970222162502 text/html 1270
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:25:06 GMT
Last-modified: Wednesday, 3-Jul-96 06:40:20 GMT
Content-length: 1041
</DOCHDR>
<HTML>
<HEAD>
<TITLE>ziwingo staff</TITLE>
</HEAD>
<BODY BGCOLOR="#0F0B75" TEXT="#FDFF33" LINK="#FF0000" VLINK="#BFBFBF">
<BODY>
<H2 ALIGN=CENTER>ZIWIN-GO's Staff
</H2>
<H4>Giuseppe Console </H4>
Presidente, ingegnere, buon vecchio programmatore fortran 
<P>
<H4 ALIGN=none>Bruno Pighetti </H4>
Vice-presidente, impiegato ministero interno, oste per vocazione, un po' cicciotto
<P>
<H4 ALIGN=none>Carlo Presutti </H4>
Tesoriere, biologo, capisci 'nternet, si sposa il 29 Giugno con =>
<P>
<H4 ALIGN=none>Loredana Verdone </H4>
Responsabile Bar, biologa, 
<P>
<H4 ALIGN=none>Antonello Ciccarelli </H4>
Responsabile Bar, insegnante,
<P>
<H4 ALIGN=none>Marco Mazzocchi </H4>
P.R., giornalista, capellone beat anni '60
<P>
<P> 
<H3 ALIGN=none>Special guests:</H3>
<H5>Paola Fragapane</H5> - La nostra cuoca<BR>
<H5 ALIGN=none>Costanza Filippucci</H5> - Architetto, ha progettato Ziwin-go CyberCafe'<BR>
<H5 ALIGN=none>Teresa Filippucci</H5> - Pubblicitaria, ha realizzato il logo, volantini, etc. 

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-86</DOCNO>
<DOCOLDNO>IA009-000096-B026-289</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/menu.html 194.183.5.143 19970222162512 text/html 1170
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:25:28 GMT
Last-modified: Friday, 9-Aug-96 13:37:40 GMT
Content-length: 945
</DOCHDR>
<ADDRESS></ADDRESS><!--   --><BLOCKQUOTE></BLOCKQUOTE><HTML> 
<HEAD><TITLE>ziwin-go menu</TITLE></HEAD> 
<BODY BGCOLOR="#B1B4ED" TEXT="#0000FF">
<!-- Graphic Tag --><IMG WIDTH=68 HEIGHT=85 ALIGN=RIGHT SRC="images/tazza.GIF">
<BR>

<H1 ALIGN=CENTER>ZIWIN-GO CyberC@fe' Menu</H1>
<BR>
<!-- Graphic Tag --><IMG WIDTH=450 HEIGHT=23  SRC="images/ruler4.gif"><P>
<BR>
<BR>
<!-- Table Tag --><TABLE BORDER=3>
<h2 ALIGN=CENTER><TR><TD VALIGN=MIDDLE><H2><!-- Link Tag --><A HREF="sandw.HTML">Sandwiches</A></H2></TD></TR>
<TR><TD VALIGN=MIDDLE><H2><!-- Link Tag --><A HREF="drinks.HTML">Drinks</A></H2></TD></TR>
<TR><TD VALIGN=MIDDLE><H2><!-- Link Tag --><A HREF="beers.HTML">Beers</A></H2></TD></TR>
<TR><TD VALIGN=MIDDLE><H2><!-- Link Tag --><A HREF="cakes.HTML">Cakes</A></H2></TD></TR>

<TR><TD VALIGN=MIDDLE><H2><!-- Link Tag --><A HREF="cock.HTML">Cocktails</A></H2></TD></TR><TR><TD></TD></TR>
</TABLE>


</BODY> 
</HTML> 
</DOC>
<DOC>
<DOCNO>WT01-B04-87</DOCNO>
<DOCOLDNO>IA009-000096-B027-13</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/armando/asic.htm 194.183.5.143 19970222162540 text/html 5127
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:25:51 GMT
Last-modified: Wednesday, 11-Dec-96 22:36:01 GMT
Content-length: 4897
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML><HEAD><TITLE>ASIC ASSISTED REPRODUCTION</TITLE>

</HEAD>
<BODY><!-- BEGIN BODY HEADER SECTION --><!-- BEGIN MAIN BODY SECTION --><BODY BACKGROUND="zzlogo.GIF">
<CENTER><TABLE BORDER=1 CELLSPACING=2 CELLPADDING=2>
<TR ALIGN=Center VALIGN=Middle>
	<TD><B><BIG>A.S.I.C. Assisted Reproduction Expertice<P>Directed by Dr. Gholami
<TR ALIGN=Center VALIGN=Middle>
	<TD><B>Rome, Italy</B><BR><BR>

Viale Aventino, 61  -  00153   Rome<BR>
Tel. 39 -6-5756396; 5756398; 535156.     Fax 39-6-5747730 <P></BIG></B>E-mail address:  <A HREF="mailto:gholami@pronet.it">gholami@pronet.it</A>
</TABLE></CENTER><HR>This page is also available in<P>
 <A HREF="ASIC_it.htm"><IMG ALIGN=Absmiddle SRC="italianonew.gif" WIDTH=50 HEIGHT=30><U> Italian </U></A>and<P>
 <A HREF="ASIC_Deutch.htm"><IMG ALIGN=Absmiddle SRC="flagdenew.gif" WIDTH=50 HEIGHT=30> German</A> language<P><HR>


The infertility centre A.S.I.C. has one of the largest and best IVF programs including:<BR>
<BR>
<CENTER><TABLE BORDER=4 CELLSPACING=3 CELLPADDING=1>
<TR>
	<TD><LI>I.V.F. (in vitro fertilization)<BR>
<TR>
	<TD><LI>I.C.S.I. (intracitoplasmic sperm injection)<BR>
<TR>
	<TD><LI>oocyte donation in early  and physiologic menopausal women<P>
</TABLE></CENTER>
<HR>
<B><U><CENTER>IN VITRO FERTILIZATION PROGRAM</CENTER></U></B><BR>

In order for pregnancy to occur, an egg has to be released from the ovary and unite with a sperm. Normally this union, called fertilization, occurs within the fallopian tube which joins the uterus to the ovary. However, in IVF the union occurs in laboratory after eggs and sperm have been collected. Embryos are then transferred to the uterus to continue growth.<BR>
<BR>
There are five major steps in the IVF and embryo transfer sequence:<BR><BR>

<FONT SIZE=2><LI>Monitor the development of ripening egg(s) in the ovaries.<LI>Collect eggs.<LI>Obtain sperm.
<LI>Put eggs and sperm together in the laboratory, and provide correct conditions for fertilization and early embryo growth.<LI>Transfer embryos in the uterus.
</FONT>
<P>
<CENTER><U><B>INTRACITOPLASMIC SPERM INJECTION PROGRAM<P></B></U></CENTER><P>
I.C.S.I. is indicated for severe male infertilities. Couples with infertilities related to lowered sperm counts or sperm motility or obstructive azoospermia (sperm failure to be ejaculated) usually have I.C.S.I.<BR>
The tecnique involves all the steps of the I.V.F. precedure exept for the fertilization step. In fact one sperm is directly injected in the egg cytoplasm with the aid of a microcapillary glass tube. This overcome the sperm failure to attach the egg zona and to penetrate the cytoplasm.<BR>
Embryos so obtained are then transferred into the uterus two days after.<P>

<CENTER><U><B>OOCYTE DONATION PROGRAM</B></U></CENTER><P>
Nowdays even women with premature ovarian failure of diverse origin (e.g. surgical menopause) can become pregnant with the aid of this tecnique. Morever, the procedure descripted below has been extended to physiological menopausal women up to 50 years of age.<BR>
The procedure consists on the collection of eggs from selected and healthy young donor women followed by in vitro  fertilization using the acceptor's husband semen.<BR>
Embryos so obtained are then transferred in the uterus of the acceptor woman.<P>
Please note that this tecnique leads to higher rate of achieved pregnancies compared with those obtained with conventional IVF.<HR>
For information contact us <A HREF="mailto:gholami@pronet.it"><IMG ALIGN=Absmiddle SRC="mail2.gif" WIDTH=40 HEIGHT=40> gholami@pronet.it</A><P>
<IMG SRC="waveline.gif" WIDTH=550 HEIGHT=16><B><CENTER><FONT SIZE=5><FONT COLOR="990099"><IMG ALIGN=Middle SRC="baby.jpg" WIDTH=48 HEIGHT=60>Favorite links</FONT></B></CENTER><P>
<CENTER><TABLE BORDER=1 CELLSPACING=2 CELLPADDING=1>
<TR ALIGN=Center>
	<TD><A HREF="http://ferti.net"><IMG ALIGN=Middle SRC="fertinet.gif" WIDTH=62 HEIGHT=24></A><BR>

	<TD><A HREF="http://www.multisoft.it/ricerca.htm"><IMG ALIGN=Middle SRC="multisoft.gif" WIDTH=100 HEIGHT=24></A><TD>

	<a href="http://www.queen.it/iwp"><IMG ALIGN=Middle SRC="queen.gif" WIDTH=80 HEIGHT=24></a>

	
	<TD><A HREF="http://www.stpt.com/"><IMG ALIGN=Middle SRC="startingp.gif" WIDTH=85 HEIGHT=24></A>
</TABLE><BR>
<A HREF="http://www.hon.ch/Conduct.html">
   </A>
    We subscribe to the <A HREF="http://www.hon.ch/Conduct.html">
    HONcode principles</A> of the  <A HREF="http://www.hon.ch/">
    Health On the Net Foundation</A>
</CENTER>
<IMG SRC="rainban.gif" WIDTH=550 HEIGHT=5><P>

<IMG SRC="coc_rb_s.gif"HEIGHT=50 WIDTH=45>
<!-- BEGIN BODY FOOTER SECTION --></BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-88</DOCNO>
<DOCOLDNO>IA009-000096-B027-27</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/picture2.html 194.183.5.143 19970222162549 text/html 808
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:26:05 GMT
Last-modified: Thursday, 23-Jan-97 21:55:27 GMT
Content-length: 580
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML>
<HEAD><TITLE>picture2</TITLE>


</HEAD><BODY  BGCOLOR="#01004D" TEXT="#FFFF00" LINK="#11BFB1" VLINK="#EB0000"><!-- BEGIN BODY HEADER SECTION --><!-- BEGIN MAIN BODY SECTION --><CENTER><IMG SRC="LOCALE2.JPG"ALT="picture2"></CENTER><P>

<A HREF="picture3.html">next</A><!-- BEGIN BODY FOOTER SECTION --></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-89</DOCNO>
<DOCOLDNO>IA009-000096-B027-57</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/armando/ASIC_it.htm 194.183.5.143 19970222162606 text/html 5774
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:26:21 GMT
Last-modified: Wednesday, 11-Dec-96 22:38:04 GMT
Content-length: 5544
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML><HEAD><TITLE>ASIC RIPRODUZIONE ASSISTITA</TITLE>

</HEAD>
<BODY><!-- BEGIN BODY HEADER SECTION --><!-- BEGIN MAIN BODY SECTION --><BODY BACKGROUND="zzlogo.GIF">
</BODY><CENTER><TABLE BORDER=1 CELLSPACING=2 CELLPADDING=2>
<TR ALIGN=Center VALIGN=Middle>
	<TD><B><BIG>A.S.I.C. Assisted Reproduction Expertice<P>Direttore Dott. Gholami
<TR ALIGN=Center VALIGN=Middle>
	<TD><B>Roma, Italia</B><BR><BR>

Viale Aventino, 61  -  00153   Rome<BR>
Tel. 39 -6-5756396; 5756398; 535156.     Fax 39-6-5747730 <P></BIG></B>E-mail address:  <A HREF="mailto:gholami@pronet.it">gholami@pronet.it</A>
</TABLE></CENTER><HR>Questa pagina &egrave; disponibile anche in lingua<P>
 <A HREF="ASIC.htm"><IMG ALIGN=Absmiddle SRC="flaguknew.gif" WIDTH=50 HEIGHT=30> Inglese</A> e<P>
 <A HREF="ASIC_Deutch.htm"><IMG ALIGN=Absmiddle SRC="flagde.gif" WIDTH=50 HEIGHT=30> Tedesca</A><P><HR>Il Centro A.S.I.C. per la cura delle infertilit&agrave; si avvale delle migliori tecniche quali:<P>
<TABLE BORDER=2 CELLSPACING=2 CELLPADDING=1>
<TR>
	<TD><LI>IVF (fecondazione in vitro e trasferimento di embrioni)<BR>
<TR>
	<TD><LI>ICSI (iniezione intracitoplasmatica dello spermatozoo<BR>
<TR>
	<TD><LI>ovodonazione per le donne in menopausa precoce o fisiologica
</TABLE><P><B><U><CENTER>FECONDAZIONE IN VITRO</CENTER></U></B><BR>

Perch&eacute; si verifichi una gravidanza &egrave; necessario che un ovocita venga espulso dall'ovaio e si unisca ad uno spermatozoo. Normalmente questo processo, detto fecondazione, avviene nelle tube di Falloppio che uniscono le ovaie all'utero.  Nella tecnica della IVF tale incontro avviene, invece, in laboratorio, dopo che sia gli ovociti che gli spermatozoi sono stati raccolti. Gli embrioni cos&igrave; ottenuti sono poi trasferiti nell'utero della donna per continuare lo sviluppo.<BR>
<BR>
La sequenza delle operazioni da compiere utilizzando questa tecnica  &egrave; la seguente:<BR><BR>

<FONT SIZE=2><LI>Monitoraggio ecografico dello sviluppo degli ovociti nelle ovaie.<LI>Prelievo degli ovociti.<LI>Raccolta del seme.
<LI>Manipolazione delle uova e degli spermatozoi in laboratorio per ottenere le migliori condizioni di fecondazione e di sviluppo degli embrioni.<LI>Trasferimento degli embrioni in utero.
</FONT>
<P>
<CENTER><U><B>INIEZIONE INTRACITOPLASMATICA DEGLI SPERMATOZOI (I.C.S.I.)<P></B></U></CENTER><P>
La tecnica detta "I.C.S.I."  &egrave; indicata per le infertilit &agrave; maschili gravi. Infatti essa viene usualmente applicata nel caso di coppie con infertilit&agrave; correlata ad una scarsa quantit&agrave; di spermatozoi o ad una loro scarsa capacit&agrave; di movimento oppure alla impossibilit&agrave; degli spermatozoi ad essere eiaculati.<BR>
Le operazioni che si compiono utilizzando tale tecnica sono le stesse della "Fecondazione in vitro" tranne che per le modalit&agrave; di fecondazione. Infatti, si inserisce direttamente uno spermatozoo nel citoplasma dell'uovo con l'aiuto di micropipette di vetro manovrate da un micromanipolatore. Ci&ograve; facendo si superano le incapacit&agrave; degli spermatozoi di raggiungere l'uovo e di penetrarvi.<BR>
Gli embrioni cos&igrave; ottenuti vengono trasferiti in utero dopo circa 48 ore.<P>

<CENTER><U><B>DONAZIONE DI UOVA</B></U></CENTER><P>
Attraverso questo tipo di intervento, anche donne con carenze ovariche premature di origine diversa (come, ad esempio, la menopausa chirurgica) possono ottenere una gravidanza. Tuttavia ci&ograve; pu&ograve; essere applicabile anche a donne in menopausa fisiologica (sotto i 50 anni di et&agrave;).<BR>
La procedura consiste nel prelievo delle uova da donne volontariamente donatrici, dopo un accurata scelta rispetto ad alcune caratteristiche tra cui lo stato di salute e l'et&agrave;. Si procede quindi ad inseminare in vitro le uova raccolte con il seme del partner della donna che ricever&agrave; gli embrioni.<BR>
Si fa notare che attraverso questa procedura la possibilit&agrave; di successo risulta maggiore di quella delle altre tecniche descritte (IVF ed ICSI).<HR>
Per ulteriori informazioni utilizzare questa casella postale elettronica <A HREF="mailto:gholami@pronet.it"><IMG ALIGN=Absmiddle SRC="mail2.gif" WIDTH=40 HEIGHT=40> gholami@pronet.it</A><IMG SRC="waveline.gif" WIDTH=550 HEIGHT=16><B><CENTER><FONT SIZE=5><FONT COLOR="990099"><IMG ALIGN=Middle SRC="baby.jpg" WIDTH=48 HEIGHT=60>I nostri siti favoriti</FONT></B></CENTER><P>
<CENTER><TABLE BORDER=1 CELLSPACING=2 CELLPADDING=1>
<TR ALIGN=Center>
	<TD><A HREF="http://ferti.net"><IMG ALIGN=Middle SRC="fertinet.gif" WIDTH=62 HEIGHT=24></A><BR>

	<TD><A HREF="http://www.multisoft.it/ricerca.htm"><IMG ALIGN=Middle SRC="multisoft.gif" WIDTH=100 HEIGHT=24></A><TD>

	<a href="http://www.queen.it/iwp"><IMG ALIGN=Middle SRC="queen.gif" WIDTH=80 HEIGHT=24></a>

	
	<TD><A HREF="http://www.stpt.com/"><IMG ALIGN=Middle SRC="startingp.gif" WIDTH=85 HEIGHT=24></A>
</TABLE><BR>
<A HREF="http://www.hon.ch/Conduct.html">
   </A>
    Noi aderiamo ai  <A HREF="http://www.hon.ch/Conduct.html">
  principi</A> della  <A HREF="http://www.hon.ch/">
    Health On the Net Foundation</A>
</CENTER>
<IMG SRC="rainban.gif" WIDTH=550 HEIGHT=5><P>

<IMG SRC="coc_rb_s.gif"HEIGHT=50 WIDTH=45>
</BODY>
</HTML>

<!-- BEGIN BODY FOOTER SECTION -->
</DOC>
<DOC>
<DOCNO>WT01-B04-90</DOCNO>
<DOCOLDNO>IA009-000096-B027-92</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/armando/ASIC_Deutch.htm 194.183.5.143 19970222162617 text/html 2831
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:26:29 GMT
Last-modified: Wednesday, 11-Dec-96 22:37:58 GMT
Content-length: 2601
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML><HEAD><TITLE>ASIC Home Page</TITLE>

</HEAD>
<BODY><!-- BEGIN BODY HEADER SECTION --><!-- BEGIN MAIN BODY SECTION --><BODY BACKGROUND="zzlogo.GIF">
</BODY>


<CENTER><TABLE BORDER=1 CELLSPACING=2 CELLPADDING=2>
<TR ALIGN=Center VALIGN=Middle>
	<TD><B><BIG>A.S.I.C. Assisted Reproduction Expertice<P>Direktor Dr. Gholami
<TR ALIGN=Center VALIGN=Middle>
	<TD><B>Rom, Italien</B><BR><BR>

Viale Aventino, 61  -  00153   Rom<BR>
Tel. 39 -6-5756396; 5756398; 535156.     Fax 39-6-5747730 <P></BIG></B>E-mail address:  <A HREF="mailto:gholami@pronet.it">gholami@pronet.it</A>
</TABLE></CENTER><HR> language  
 <A HREF="ASIC.htm"><IMG ALIGN=Absmiddle SRC="flaguknew.gif" WIDTH=30 HEIGHT=20></A>  <A HREF="ASIC_it.htm"><IMG ALIGN=Absmiddle SRC="italianonew.gif" WIDTH=30 HEIGHT=20></A><HR>

Wir sind eine IVF-Institut mit einen team von spezialisten mit schwerpunkt auf:<P>
IVF (in vitro fertilization) kunstliche Befruchtung<BR>
ICSI (f&uuml;r mannliche unfruktbarkeit)<P>
Oocyte donation program: Eizellen-spende f&uuml;r frauen in menopause.<P>
<HR>

Wir w&uuml;rden sie gerne baraten auf Deutche sprache und erwarten ihre kontaktaufname.<P>

<A HREF="mailto:gholami@pronet.it"><IMG ALIGN=Absmiddle SRC="mail2.gif" WIDTH=40 HEIGHT=40>  gholami@pronet.it</A>
</BODY><IMG SRC="waveline.gif" WIDTH=550 HEIGHT=16><B><CENTER><FONT SIZE=5><FONT COLOR="990099"><IMG ALIGN=Middle SRC="baby.jpg" WIDTH=48 HEIGHT=60>Favorite links</FONT></B></CENTER><P>
<CENTER><TABLE BORDER=1 CELLSPACING=2 CELLPADDING=1>
<TR ALIGN=Center>
	<TD><A HREF="http://ferti.net"><IMG ALIGN=Middle SRC="fertinet.gif" WIDTH=62 HEIGHT=24></A><BR>

	<TD><A HREF="http://www.multisoft.it/ricerca.htm"><IMG ALIGN=Middle SRC="multisoft.gif" WIDTH=100 HEIGHT=24></A><TD>

	<a href="http://www.queen.it/iwp"><IMG ALIGN=Middle SRC="queen.gif" WIDTH=80 HEIGHT=24></a>

	
	<TD><A HREF="http://www.stpt.com/"><IMG ALIGN=Middle SRC="startingp.gif" WIDTH=85 HEIGHT=24></A>
</TABLE><BR>
<A HREF="http://www.hon.ch/Conduct.html">
   </A>
    We subscribe to the <A HREF="http://www.hon.ch/Conduct.html">
    HONcode principles</A> of the  <A HREF="http://www.hon.ch/">
    Health On the Net Foundation</A>
</CENTER>
<IMG SRC="rainban.gif" WIDTH=550 HEIGHT=5>
<IMG SRC="coc_rb_s.gif"HEIGHT=50 WIDTH=45></BODY>
</HTML><!-- BEGIN BODY FOOTER SECTION -->
</DOC>
<DOC>
<DOCNO>WT01-B04-91</DOCNO>
<DOCOLDNO>IA009-000096-B027-114</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/picture3.html 194.183.5.143 19970222162625 text/html 799
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:26:41 GMT
Last-modified: Thursday, 23-Jan-97 21:55:36 GMT
Content-length: 571
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML>
<HEAD><TITLE>picture3</TITLE>


</HEAD><BODY  BGCOLOR="#01004D" TEXT="#FFFF00" LINK="#11BFB1" VLINK="#EB0000"><!-- BEGIN BODY HEADER SECTION --><!-- BEGIN MAIN BODY SECTION --><CENTER><IMG SRC="LOCALE3.JPG"></CENTER><P>


<A HREF="home.htp">home</A>



<!-- BEGIN BODY FOOTER SECTION --></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-92</DOCNO>
<DOCOLDNO>IA009-000096-B027-139</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/armando/ASIC.htm 194.183.5.143 19970222162634 text/html 5127
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:26:50 GMT
Last-modified: Wednesday, 11-Dec-96 22:36:01 GMT
Content-length: 4897
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML><HEAD><TITLE>ASIC ASSISTED REPRODUCTION</TITLE>

</HEAD>
<BODY><!-- BEGIN BODY HEADER SECTION --><!-- BEGIN MAIN BODY SECTION --><BODY BACKGROUND="zzlogo.GIF">
<CENTER><TABLE BORDER=1 CELLSPACING=2 CELLPADDING=2>
<TR ALIGN=Center VALIGN=Middle>
	<TD><B><BIG>A.S.I.C. Assisted Reproduction Expertice<P>Directed by Dr. Gholami
<TR ALIGN=Center VALIGN=Middle>
	<TD><B>Rome, Italy</B><BR><BR>

Viale Aventino, 61  -  00153   Rome<BR>
Tel. 39 -6-5756396; 5756398; 535156.     Fax 39-6-5747730 <P></BIG></B>E-mail address:  <A HREF="mailto:gholami@pronet.it">gholami@pronet.it</A>
</TABLE></CENTER><HR>This page is also available in<P>
 <A HREF="ASIC_it.htm"><IMG ALIGN=Absmiddle SRC="italianonew.gif" WIDTH=50 HEIGHT=30><U> Italian </U></A>and<P>
 <A HREF="ASIC_Deutch.htm"><IMG ALIGN=Absmiddle SRC="flagdenew.gif" WIDTH=50 HEIGHT=30> German</A> language<P><HR>


The infertility centre A.S.I.C. has one of the largest and best IVF programs including:<BR>
<BR>
<CENTER><TABLE BORDER=4 CELLSPACING=3 CELLPADDING=1>
<TR>
	<TD><LI>I.V.F. (in vitro fertilization)<BR>
<TR>
	<TD><LI>I.C.S.I. (intracitoplasmic sperm injection)<BR>
<TR>
	<TD><LI>oocyte donation in early  and physiologic menopausal women<P>
</TABLE></CENTER>
<HR>
<B><U><CENTER>IN VITRO FERTILIZATION PROGRAM</CENTER></U></B><BR>

In order for pregnancy to occur, an egg has to be released from the ovary and unite with a sperm. Normally this union, called fertilization, occurs within the fallopian tube which joins the uterus to the ovary. However, in IVF the union occurs in laboratory after eggs and sperm have been collected. Embryos are then transferred to the uterus to continue growth.<BR>
<BR>
There are five major steps in the IVF and embryo transfer sequence:<BR><BR>

<FONT SIZE=2><LI>Monitor the development of ripening egg(s) in the ovaries.<LI>Collect eggs.<LI>Obtain sperm.
<LI>Put eggs and sperm together in the laboratory, and provide correct conditions for fertilization and early embryo growth.<LI>Transfer embryos in the uterus.
</FONT>
<P>
<CENTER><U><B>INTRACITOPLASMIC SPERM INJECTION PROGRAM<P></B></U></CENTER><P>
I.C.S.I. is indicated for severe male infertilities. Couples with infertilities related to lowered sperm counts or sperm motility or obstructive azoospermia (sperm failure to be ejaculated) usually have I.C.S.I.<BR>
The tecnique involves all the steps of the I.V.F. precedure exept for the fertilization step. In fact one sperm is directly injected in the egg cytoplasm with the aid of a microcapillary glass tube. This overcome the sperm failure to attach the egg zona and to penetrate the cytoplasm.<BR>
Embryos so obtained are then transferred into the uterus two days after.<P>

<CENTER><U><B>OOCYTE DONATION PROGRAM</B></U></CENTER><P>
Nowdays even women with premature ovarian failure of diverse origin (e.g. surgical menopause) can become pregnant with the aid of this tecnique. Morever, the procedure descripted below has been extended to physiological menopausal women up to 50 years of age.<BR>
The procedure consists on the collection of eggs from selected and healthy young donor women followed by in vitro  fertilization using the acceptor's husband semen.<BR>
Embryos so obtained are then transferred in the uterus of the acceptor woman.<P>
Please note that this tecnique leads to higher rate of achieved pregnancies compared with those obtained with conventional IVF.<HR>
For information contact us <A HREF="mailto:gholami@pronet.it"><IMG ALIGN=Absmiddle SRC="mail2.gif" WIDTH=40 HEIGHT=40> gholami@pronet.it</A><P>
<IMG SRC="waveline.gif" WIDTH=550 HEIGHT=16><B><CENTER><FONT SIZE=5><FONT COLOR="990099"><IMG ALIGN=Middle SRC="baby.jpg" WIDTH=48 HEIGHT=60>Favorite links</FONT></B></CENTER><P>
<CENTER><TABLE BORDER=1 CELLSPACING=2 CELLPADDING=1>
<TR ALIGN=Center>
	<TD><A HREF="http://ferti.net"><IMG ALIGN=Middle SRC="fertinet.gif" WIDTH=62 HEIGHT=24></A><BR>

	<TD><A HREF="http://www.multisoft.it/ricerca.htm"><IMG ALIGN=Middle SRC="multisoft.gif" WIDTH=100 HEIGHT=24></A><TD>

	<a href="http://www.queen.it/iwp"><IMG ALIGN=Middle SRC="queen.gif" WIDTH=80 HEIGHT=24></a>

	
	<TD><A HREF="http://www.stpt.com/"><IMG ALIGN=Middle SRC="startingp.gif" WIDTH=85 HEIGHT=24></A>
</TABLE><BR>
<A HREF="http://www.hon.ch/Conduct.html">
   </A>
    We subscribe to the <A HREF="http://www.hon.ch/Conduct.html">
    HONcode principles</A> of the  <A HREF="http://www.hon.ch/">
    Health On the Net Foundation</A>
</CENTER>
<IMG SRC="rainban.gif" WIDTH=550 HEIGHT=5><P>

<IMG SRC="coc_rb_s.gif"HEIGHT=50 WIDTH=45>
<!-- BEGIN BODY FOOTER SECTION --></BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-93</DOCNO>
<DOCOLDNO>IA009-000096-B027-182</DOCOLDNO>
<DOCHDR>
http://www.ziwingo.it:80/home.htp 194.183.5.143 19970222162651 text/html 2564
HTTP/1.0 200 OK
Server: Purveyor / v1.2 Windows NT
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Sat, 22 Feb 1997 16:26:57 GMT
Pragma: no-cache
</DOCHDR>
<!-- THIS PAGE WAS CREATED WITH WORLD WIDE WEB WEAVER 2.0
IN ORDER TO SEPARATE THIS PAGE INTO MULTIPLE SECTIONS COMMENT TAGS HAVE BEEN PLACED AT SPECIFIC LOCATIONS. REMOVING OR EDITING THESE COMMENTS WILL CAUSE WEB WEAVER TO NOT RECOGNIZE SECTIONS --><HTML> 
<META HTTP-EQUIV="Expires" CONTENT= "Tue, 20 Aug 1900 14:25:27 GMT"><BODY  BGCOLOR="#01004D" TEXT="#FFFF00" LINK="#FF0000" VLINK="#BFBFBF"><!-- BEGIN BODY HEADER SECTION --><HEAD><TITLE>Ziwin-go CyberCafe'</TITLE><!-- BEGIN MAIN BODY SECTION --><body>
<H1><CENTER><B><I><H1><B><I>Welcome to</I></B></H1> <H1><B>Ziwin-go Cybercafe'</B></H1></I></B>
</CENTER></HEAD></H1><p>
<CENTER><H4>Via della Meloria 78 (Ple. degli Eroi)
- ROMA</H4></CENTER><p>
<CENTER>Click <A HREF="italian.htm">here</A> for italian version</CENTER><P>

<body><center><IMG WIDTH=204 HEIGHT=255  SRC="images/logo.gif"></center><P><BR>

<CENTER><!-- Table Tag --><TABLE BORDER=2>
<TR><TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="info.html">INFO</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="services.html">SERVICES</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="picture.html">PICTURES</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="staff.html">STAFF</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="menu.html">MENU</A></TH>
<TH ALIGN=CENTER VALIGN=MIDDLE><!-- Link Tag --><A HREF="http://www.pngroup.net/surfing/surfing_ita.htm">LINKS</A></TH></TR>
</TABLE></center><p><HR ALIGN=CENTER>
<H2 ALIGN=CENTER>Ziwin-go has been chosen for the new Levi's promotion!</H2>
<CENTER><A HREF="http://adserver.obsolete.com/scripts/adserv.dll?file=index1.html">
<IMG SRC="http://adserver.obsolete.com/mermaids/1.gif" BORDER=0 WIDTH=80
HEIGHT=54>
</A></CENTER>
<HR ALIGN=CENTER><P>


<CENTER><A HREF="armando/asic.htm">Personal Pages</A>   <IMG SRC="images/new.gif" BORDER=0 ></CENTER><P>

<CENTER><HR ALIGN=CENTER WIDTH=100% SIZE=2><p></CENTER>

<!-- BEGIN BODY FOOTER SECTION --><CENTER><H4>Open from June 20, 1996</CENTER>
<CENTER>8 pm - 2 am</CENTER>
<CENTER>Tel. 39735305</H4></CENTER><p>
<CENTER><H3>Air Conditioning</H3></CENTER>
<A HREF="http://www.pngroup.net/welcome_ita.htm"><IMG SRC="images/POWRBY1.gif"HEIGHT=43 WIDTH=114></A>
<A HREF="http://www.easymac.it"><IMG SRC="images/easymac.JPG"HEIGHT=43 WIDTH=114></A>
</BODY> 
</HTML> 


</DOC>
<DOC>
<DOCNO>WT01-B04-94</DOCNO>
<DOCOLDNO>IA027-000294-B024-76</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/index.html 206.86.175.106 19970120081709 text/html 5554
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:10:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5372
Last-modified: Thu, 19 Dec 1996 09:44:31 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Undersea Hunter... Cocos Island and more...</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center>
<IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>
<center><blink><b><font size=+1>Don't miss the boat for our Silverbanks trips.
Space still remaining. <br>Departing very soon.</b></font></blink></center>
<center><HR WIDTH="92%" SIZE="7"></center>


<center>
<br>
<table border=0>
<td rowspan=6 align=center><a href="images/001.jpeg"><IMG SRC="images/n001.gif"><br><font size=-1>M.V. Undersea Hunter</font></a></td>
<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>

<td><a href="cocos.html"><img src="images/3dbuttons/ussmallcocos.gif"></a></td>

<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>
<td rowspan=6 align=center><a href="images/021.jpeg"><IMG SRC="images/n021.gif"><br><font size=-1>M.V. Sea Hunter</font></a></td>

<tr>
<td><a href="silverbank.html"><img src="images/3dbuttons/ussmallsilverbank.gif"></a></td>
<tr>
<td><a href="techdiving.html"><img src="images/3dbuttons/ussmalltechnicaldiving.gif"></a></td>
<tr>
<td><a href="specialprojects.html"><img src="images/3dbuttons/ussmallspecialprojects.gif"></a></td>
<tr>
<td><a href="photography.html"><img src="images/3dbuttons/ussmallphotography.gif"></a></td>
<tr>
<td><a href="booking.html"><img src="images/3dbuttons/ussmallbooking.gif"></a></td>



</table>
</center>
<hr> 
<center>
<table border=0 width =90%>
<td><font size=+1><p>The <b>Undersea Hunter</b> and the <b>Sea Hunter</b> offer live-aboard experiences that focus on comfort and convenience. We take pride in providing excellent service, food and non-stop underwater excitement. 
<p>
From the distinctive and remote <b>Cocos Island</b> to visiting the Humpbacks of the <b>Silver Bank</b>, our vessels provide world-class diving experiences in complete comfort and safety. Join us for one of our adventures into the magnificent marine environment!
<p>
We also provide support vessel functions for underwater film productions, oceanographic research, small research submersibles, marine salvage, search and recovery, and supply and transport duties.</font>
</table>
</center>
<hr>
<center>
<table border=0>
<tr>
<th colspan=1><font size=+2><b>Undersea Hunter</b>&nbsp;&nbsp;</font></th>
<td></td>
<th colspan=1><font size=+2><b>Sea Hunter</b></b></font></th>
</tr>
<tr>
<td align=center><a href="underseahunter.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></a></td>
<td align=center><font size=+1><b>Description of Vessel</b></font></td>
<td align=center><a href="seahunter.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></td>
</tr>
<tr>
<td align=center><a href="underseahlayout.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></td>
<td align=center><font size=+1><b>Deck Plan of Vessel</b></font></td>
<td align=center><a href="sealayout.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></td>
</tr>
<tr>
<td align=center><a href="underseavesselspecs.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></td>
<td align=center><font size=+1><b>List of Specifications</b></font></td>
<td align=center><a href="seahuntertmp.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
</tr>
<tr>
<td align=center><a href="captlog1196.html"><IMG ALIGN=top SRC="images/3dbuttons/usnewfeature.gif"></a></td>
<td align=center><font size=+1><b>Captain's Log</b></font></td>
<td align=center><a href="captlog1196.html"><IMG ALIGN=top SRC="images/3dbuttons/usnewfeature.gif"></a></td>
</tr>
<tr>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
<td align=center><font size=+1><b>Newsletter</b></font></td>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
</tr>
<tr>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
<td align=center><font size=+1><b>Expedition Schedule</b></font></td>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
</tr>
<tr>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
<td align=center><font size=+1><b>Important Announcements</b></font></td>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
</tr>
</table>
</center>
<br><br>
<p>
<center>
<b>Let us know what you think of our site, use the email link below to send us your comments!</b>
<p>
<table border=0>
<td><a href="mailto:Info@underseahunter.com"><img src="images/3dbuttons/usemail.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/ushome.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usfrench.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usgerman.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usspanish.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usitalian.gif"></a></td>


</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-95</DOCNO>
<DOCOLDNO>IA027-000294-B020-63</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/cocos.html 206.86.175.106 19970120080143 text/html 4143
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 07:55:16 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3961
Last-modified: Mon, 28 Oct 1996 11:52:31 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Cocos Island</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/042.jpeg"><IMG SRC="images/042.gif"><br><font size=-1>Cocos above Water</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/052.jpeg"><IMG SRC="images/052.gif"><br><font size=-1>Cocos below Water</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<center>
<table border=0 width =90%>


<td><P align=center><font size=+2><b>If you are looking for adventure, it's here!</b></font>

<p><font size=+1>A distinctive and remote diving location, <b>Cocos Island</b> is for the serious diver. In the world-renowned waters surrounding Cocos Island you will dive with white tips and hammerhead sharks, marbled sting rays approaching 6' in diameter, manta rays up to 12' across, giant moray eels and an occasional whale shark! Additionally, you will see moorish idols, large schools of jacks and tuna, creole fish, lobsters, octopus and other various reef life. Silky sharks, silver tips, sailfish, marlin, and green turtles are also in the area. 

<p>The <a href="underseahunter.html"><b>Undersea Hunter</b></a> and the <a href="seahunter.html"><b>Sea Hunter</b></a> offer live-aboard expeditions to Cocos Island in comfort and safety. In addition our crews are experts on Cocos and it's surrounding waters so that you can experience the best Cocos has to offer!
</font>
</table>
</center>
<p>

<center>
<table border=0>
<tr>
<th colspan=4 align=center><font size=+2><b>Cocos Information</b></font></th>
<td></td>

</tr>
<tr>

<td align=right><a href="cocositinerary.html"><font size=+1><b>Sample Cocos Itinerary</b></a></font></td>
<td width=10%><IMG ALIGN=top SRC="images/bblue.gif"></td>

<td width=10% align=right><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><a href="cocosdive.html"><font size=+1><b>Diving at Cocos</b></a></font></td>

</tr>
<tr>
<td align=right><a href="cocostravel.html"><font size=+1><b>Travel Information</b></a></font></td>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>

<td align=right><IMG ALIGN=top SRC="images/bblue.gif"></td>

<td><a href="cocosboat.html"><font size=+1><b>On the Boat</b></a></font></td>
</tr>
<tr>
<td align=right><a href="cocospelagics.html"><font size=+1><b>Pelagic Life</b></a></font></td>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>

<td align=right><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><a href="cocosthere.html"><font size=+1><b>Getting to and from Cocos</b></a></font></td>
</tr>
</table>
</center>
<p>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="underseahunter.html">Undersea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:Info@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><b>Cocos Information</b></font></td>
<td><font size=+1><b>|</b> <a href="index.html">Home</a> <b>|</b></font></td>
<td><font size=+1> <a href="seahunter.html">Sea Hunter</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-96</DOCNO>
<DOCOLDNO>IA027-000294-B020-117</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/silverbank.html 206.86.175.106 19970120080221 text/html 4269
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 07:55:54 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4087
Last-modified: Thu, 19 Dec 1996 09:44:35 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Silverbank</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<td rowspan=6 align=center><a href="images/037.jpeg"><IMG SRC="images/n037.gif"><br><font size=-1>Silverbank above water</font></a></td>
<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>

<td><a href="cocos.html"><img src="images/3dbuttons/ussmallcocos.gif"></a></td>

<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>
<td rowspan=6 align=center><a href="images/040.jpeg"><IMG SRC="images/n040.gif"><br><font size=-1>Silverbank below water</font></a></td>

<tr>
<td><a href="silverbank.html"><img src="images/3dbuttons/ussmallsilverbank.gif"></a></td>
<tr>
<td><a href="techdiving.html"><img src="images/3dbuttons/ussmalltechnicaldiving.gif"></a></td>
<tr>
<td><a href="specialprojects.html"><img src="images/3dbuttons/ussmallspecialprojects.gif"></a></td>
<tr>
<td><a href="photography.html"><img src="images/3dbuttons/ussmallphotography.gif"></a></td>
<tr>
<td><a href="booking.html"><img src="images/3dbuttons/ussmallbooking.gif"></a></td>



</table>
</center>
<hr>
<blockquote> 
<font size=+1>
<p>
The Silverbank is the largest mating and calving ground for the North Atlantic
humpback whale. From January to March of each year, approximately three to five
thousand Atlantic humpbacks migrate to the Silverbank from as far away as Nova
Scotia, to birth and train their young. This area, which is north of the
Dominican Republic, is only one of a few areas where this activity happens each year,
and to swim with these mothers and calves while being escorted by many bulls is an
experience like no other a swimmer has ever witnessed.
<p>
The humpback is the most active of whales on the surface, and at this time
of year the action gets even more incredible. As you watch males compete for females,
you will see them finslapping and lobtailing. When you watch 50 ton male
leviathans as they breach completely out of the water and ram into each
other with incredible force, totally ignoring their surroundings, it is a sight that
humbles even the hard-core naturalists, and sets everybody's heart pounding.                 .
<p>
A whale expert will be present on every trip and during the night we will share
with you personal experiences with lectures, slide shows and hopefully videos
taken during the day. During the day we observe the whales from the comfort of
our large, stable skiffs. At the Silverbank, we don't only see the whales,
we also hear them. The humpback whale is famous for its haunting song, and during
mating season it is ever present. With our hydrophones you will be able to
listen in on every word, as we interpret it for you. The skiffs are provided with a
cover to protect you from the sun, and have a special area for protecting the camera
equipment. The skiffs also have bran-new, silent and fumeless engines in
order not to disturb the whales, since we are there solely to enjoy the splendor of
the whales, not to intrude on them. This is the experience of a lifetime you don't want
to miss.
<p>
<a href="mailto:Info@underseahunter.com">Contact us</a> for further information.
</font>
<blockquote> 
<br>
<center>
<p>
<table border=0>
<td><a href="mailto:Info@underseahunter.com"><img src="images/3dbuttons/usemail.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/ushome.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usfrench.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usgerman.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usspanish.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usitalian.gif"></a></td>


</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-97</DOCNO>
<DOCOLDNO>IA027-000294-B020-140</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/techdiving.html 206.86.175.106 19970120080237 text/html 3122
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 07:56:07 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2940
Last-modified: Mon, 28 Oct 1996 11:53:19 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Technical Diving</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/045.jpeg"><IMG SRC="images/045.gif"><br><font size=-1>Undersea Hunter</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/021.jpeg"><IMG SRC="images/l021.gif"><br><font size=-1>Sea Hunter</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<center>
<table border=0 width =90%>
<td><font size=+1><p>The Undersea Hunter team is working towards providing a safe and exciting environment for underwater exploration. To this end, we offer advanced technical diving facilities and training opportunities.</font>
</table>
</center>
<hr>
<center>
<h2>More detailed Technical Diving information coming soon!</h2>

<table border=0>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>UHT - The Undersea Hunter Team</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Technical Diving International</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Special Training Programs</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Rental Programs</b></font></td>
</tr><tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Equipment</b></font></td>
</tr><tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Special Mission Support</b></font></td>
</tr>
</table>
</center>
<p>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="mailto:TechDiving@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><a href="index.html">Home</a></font></td>
<td><font size=+1><b>|</b> <b>Technical Diving</b> <b>|</b></font></td>
<td><font size=+1> <a href="silverbank.html">Silver Bank</a> <b>|</b></font></td>
<td><font size=+1> <a href="cocos.html">Cocos</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-98</DOCNO>
<DOCOLDNO>IA027-000294-B020-171</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/specialprojects.html 206.86.175.106 19970120080302 text/html 2808
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 07:56:30 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2626
Last-modified: Mon, 28 Oct 1996 11:53:17 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Photography and Filming</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/001.jpeg"><IMG SRC="images/l001.gif"><br><font size=-1>Undersea Hunter</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/021.jpeg"><IMG SRC="images/l021.gif"><br><font size=-1>Sea Hunter</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<center>
<table border=0 width =90%>
<td><font size=+1><p>The <a href="underseahunter.html"><b>Undersea Hunter</b></a> and the <a href="seahunter.html"><b>Sea Hunter</b></a> are both truly global diving support vessels capable of many different types of commercial and research duties.</font>
</table>
</center>
<hr>
<center>
<h2>More detailed Special Projects information coming soon!</h2>

<table border=0>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Company History and Experience</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Special Missions/Expeditions</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Capcity to Adapt</b></font></td>
</tr>

</table>
</center>
<p>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="mailto:Booking@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><a href="index.html">Home</a></font></td>
<td><font size=+1><b>|</b> <b>Special Projects</b> <b>|</b></font></td>
<td><font size=+1> <a href="silverbank.html">Silver Bank</a> <b>|</b></font></td>
<td><font size=+1> <a href="cocos.html">Cocos</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-99</DOCNO>
<DOCOLDNO>IA027-000294-B020-194</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/photography.html 206.86.175.106 19970120080320 text/html 3061
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 07:56:53 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2879
Last-modified: Mon, 28 Oct 1996 11:53:04 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Photography and Filming</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/003.jpeg"><IMG SRC="images/003.gif"><br><font size=-1>Camera Deck Undersea Hunter</font></a></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/033.jpeg"><IMG SRC="images/033.gif"><br><font size=-1>Camera Deck Sea Hunter</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<center>
<table border=0 width =90%>
<td><font size=+1><p>Both the <a href="underseahunter.html"><b>Undersea Hunter</b></a> and the <a href="seahunter.html"><b>Sea Hunter</b></a> are capable of supporting the most demanding photography and filming support requirements.</font>
</table>
</center>
<hr>
<center>
<h2>More detailed Photography and Filming information coming soon!</h2>

<table border=0>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Special Support Facilities</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Experience</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Professional Filming</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Commercial Projects</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>IMAX  Support</b></font></td>
</tr>
<tr>
<td><IMG ALIGN=top SRC="images/bblue.gif"></td>
<td><font size=+1><b>Photo Gallery</b></font></td>
</tr>

</table>
</center>
<p>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="mailto:Photography@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><a href="index.html">Home</a></font></td>
<td><font size=+1><b>|</b> <b>Photography</b> <b>|</b></font></td>
<td><font size=+1> <a href="silverbank.html">Silver Bank</a> <b>|</b></font></td>
<td><font size=+1> <a href="cocos.html">Cocos</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-100</DOCNO>
<DOCOLDNO>IA027-000294-B023-26</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/underseahunter.html 206.86.175.106 19970120081248 text/html 3958
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:06:21 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3776
Last-modified: Mon, 28 Oct 1996 11:53:28 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Undersea Hunter</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/001.jpeg"><IMG SRC="images/l001.gif"><br><font size=-1>M.V. Undersea Hunter</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/002.jpeg"><IMG SRC="images/002.gif"><br><font size=-1>Aft-deck Undersea Hunter</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<center>
<table border=0 width =90%>
<td><font size=+1><p>The research vessel <b>Undersea Hunter</b> was built in Florida in 1968 for Perry Oceanographic and was used for twenty years as a submarine support vessel. Working primarily in the Bahamas and the Carribean, she completed hundreds of research and photographic missions including the Deep Rover Project with Dr. Sylvia Earle. Her closest brush with fame - so far - was her participation as support vessel for the James Bond movie <b>"License to Kill."</b>

<p>
We bought the Undersea Hunter in June, 1990, and spent five months refurbishing her from stem to stern. Already a capable and well-proven research vessel, the Undersea Hunter was modified to include six new cabins, complete will all the modern conveniences, to accommodate 14 passengers. She is now a rare hybrid combining the large working platform and powerful machinery of a functional work boat with the comfortable interior of a modern yacht. With fuel capacity of 40 tons and water tankage of 26 tons, her blue water capability is almost unlimited.

<p>
Under the guiding hands of Captains Avi Klafper and Yosy Naaman, the Undersea Hunter is dedicated to bringing civilized comfort to the delightfully uncivilized gems like <b>Cocos Island.</b> 

</td>
</table>
<p>
<table border=0 width=65%>
<th align=left>The undersea Hunter features these advantages not usually found on a vessel her size.</th>
<tr>
<td>- Extendable deck-mounted crane with 15 ton capacity</td>
<tr>
<td>- Large aft work deck measuring 38ft by 24ft</td>
<tr>
<td>- Two main generators, 40kw and 25 kw</td>
<tr>
<td>- Portable diesel 5kw generator mountable in either tender</td>
<tr>
<td>- Two heavy duty fiberglass tenders, 24ft and 22ft</td>
<tr>
<td>- Full workshop including electric welder, oxy-acetelene unit, drill press, and all other necessary tools</td>
</table>
</center>

<p></font>
</table>
</center>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <b>Undersea Hunter</b></font></td>
<td><font size=+1><b>|</b> <a href="mailto:UnderseaHunter@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><a href="index.html">Home</a></font></td>
<td><font size=+1><b>|</b> <a href="contact.html">Contact</a> <b>|</b></font></td>
<td><font size=+1> <a href="underseavesselspecs.html">Vessel Specifications</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-101</DOCNO>
<DOCOLDNO>IA027-000294-B023-53</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/seahunter.html 206.86.175.106 19970120081334 text/html 2917
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:06:44 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2735
Last-modified: Mon, 28 Oct 1996 11:53:09 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Sea Hunter</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/021.jpeg"><IMG SRC="images/l021.gif"><br><font size=-1>M.V. Sea Hunter</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/024.jpeg"><IMG SRC="images/024.gif"><br><font size=-1>Dive Deck Sea Hunter</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<center>
<table border=0 width =90%>
<td><font size=+1><p>The <b>Sea Hunter</b> is 115 feet of live-aboard comfort and convenience. Specialties of her itineraries include excellence in service, food, and incredible underwater excitement.

<p>She has eight cabins for a total capacity of 18 passengers (three double-bed staterooms with private bath, two triples with private bath, and three doubles with private bath). 

<p>Diver facilities are extremely well designed: a private dryer for clients' towels and bathing suits, private camera/strobe storage shelves with individual 110 volts AC power, individual gear storage, etc.

<p>
The chase boats are superb; two 24' fiberglass cruisers. <b>Sea Hunter</b> puts 9 or less divers in each chase boat.

<p>This is a superbly comfortable, stable and spacious vessel, with everything a serious diver/photographer could wish.

</td>
</table>
<p></font>
</table>
</center>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <b>Sea Hunter</b></font></td>
<td><font size=+1><b>|</b> <a href="mailto:SeaHunter@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><a href="index.html">Home</a></font></td>
<td><font size=+1><b>|</b> <a href="contact.html">Contact</a> <b>|</b></font></td>
<td><font size=+1> <a href="">Vessel Specifications</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-102</DOCNO>
<DOCOLDNO>IA027-000294-B023-81</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/underseahlayout.html 206.86.175.106 19970120081352 text/html 2692
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:07:25 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2510
Last-modified: Mon, 28 Oct 1996 11:53:25 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Undersea Hunter... Layout</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>
<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/001.jpeg"><IMG SRC="images/smushupperlayout.gif"><br><font size=-1>Upper Deck</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/001.jpeg"><IMG SRC="images/smushlowerlayout.gif"><br><font size=-1>Lower Deck</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 


<center><b>Please look for interactive deck layout feature coming soon!</b></center>
<center>
<br>
<table border=0>
<th colspan=2 align=center><font size=+2>Undersea Hunter Vessel Layout</font></th>
<tr><td colspan=2 align=center><font size=-1><b>|</b> <b>Horizontal Perspective</b> <b>|</b> <a href="undersealayout.html">Vertical Perspective</a> <b>|</b></font></td><tr>

<tr><tr>
<th align=center><font size=+1>Upper Deck</th><td><img src="images/ushhupperlayout.gif" border=1></td>
<tr><tr>
<th align=center><font size=+1>Lower Deck</th><td><img src="images/ushhlowerlayout.gif" border=1></td>
</table>
</center>

<p></font>
</table>
</center>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="underseahunter.html">Undersea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:UnderseaHunter@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><a href="index.html">Home</a></font></td>
<td><font size=+1><b>|</b> <a href="contact.html">Contact</a> <b>|</b></font></td>
<td><font size=+1> <b>Vessel Layout</b> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-103</DOCNO>
<DOCOLDNO>IA027-000294-B023-108</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/sealayout.html 206.86.175.106 19970120081413 text/html 2672
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:07:38 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2490
Last-modified: Mon, 28 Oct 1996 11:53:12 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Sea Hunter... Layout</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>
<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/021.jpeg"><IMG SRC="images/smshupperlayout.gif"><br><font size=-1>Upper Deck</font></a></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/024.jpeg"><IMG SRC="images/smshlowerlayout.gif"><br><font size=-1>Lower Deck</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 


<center><b>Please look for interactive deck layout feature coming soon!</b></center>
<center>
<br>
<table border=0>
<th colspan=3 align=center><font size=+2>Sea Hunter Vessel Layout</font></th>
<tr><td colspan=3 align=center><font size=-1><b>|</b> <a href="seahlayout.html">Horizontal Perspective</a> <b>|</b> <b>Vertical Perspective</b> <b>|</b></font></td><tr>
<th align=center><font size=+1>Upper Deck</th><th align=center><font size=+1>Main Deck</th>
<th align=center><font size=+1>Lower Deck</th><tr><tr>
<td><img src="images/shupperlayout.gif" border=1></td>
<td><img src="images/shmiddlelayout.gif" border=1></td>
<td><img src="images/shlowerlayout.gif" border=1></td>
</table>
</center>

<p></font>
</table>
</center>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="seahunter.html">Sea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:SeaHunter@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><a href="index.html">Home</a></font></td>
<td><font size=+1><b>|</b> <a href="contact.html">Contact</a> <b>|</b></font></td>
<td><font size=+1> <b>Vessel Layout</b> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-104</DOCNO>
<DOCOLDNO>IA027-000294-B023-135</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/underseavesselspecs.html 206.86.175.106 19970120081435 text/html 4976
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:08:07 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4794
Last-modified: Mon, 28 Oct 1996 11:53:33 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Undersea Hunter... Vessel Specifications</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>
<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/012.jpeg"><IMG SRC="images/012.gif"><br><font size=-1>Aft-deck Crane</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/008.jpeg"><IMG SRC="images/008.gif"><br><font size=-1>24ft Dive Tender</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 



<center>
<br>
<table border=0 width=65%>
<th colspan=2 align=left><font size=+1>Undersea Hunter Vessel Specifications</font></th>
<tr><tr>
<TD valign=top><b>Length:</b></td><td valign=top>	90 ft (28m)</td><tr></tr><tr>
<TD valign=top><b>Beam:</b></td><td valign=top>	24 ft (7.4m)</td><tr></tr><tr>
<TD valign=top><b>Draft:</b></td><td valign=top>	8 ft (2.5m)</td><tr></tr><tr>
<TD valign=top><b>Displacement:</b></td><td valign=top>	180 tons</td><tr></tr><tr>
<TD valign=top><b>Construction:</b></td><td valign=top>	steel with teak work deck</td><tr></tr><tr>
<TD valign=top><b>Engines:</b></td><td valign=top>	twin Caterpilar 240 hp</td><tr></tr><tr>
<TD valign=top><b>Speed:</b></td><td valign=top>	10 kts</td><tr></tr><tr>
<TD valign=top><b>Range:</b></td><td valign=top>	5,000 miles</td><tr></tr><tr>
<TD valign=top><b>Generators:</b></td><td valign=top>	60 kw, 40 kw and 5 kw portable</td><tr></tr><tr>
<TD valign=top><b>Available voltage:</b></td><td valign=top>	12-32 VDC, 11 0/220 VAC</td><tr></tr><tr>
<TD valign=top><b>Fuel tankage:</b></td><td valign=top>	10,000 gallons</td><tr></tr><tr>
<TD valign=top><b>Water tankage:</b></td><td valign=top>	6,400 gallons<br>
	1300 gallons/day water maker</td><tr></tr><tr>
<TD valign=top><b>Tenders:</b></td><td valign=top>	heavy duty fiberglass Privateers,<br>
	24 ft and 22 ft w/integral racks
	for scuba tanks</td><tr></tr><tr>
<TD valign=top><b>Scuba Compressors:</b></td><td valign=top>	2 Bauer K14, 14 cfm electric<br>
	1 Bauer 7.5 cfm diesel portable</td><tr></tr><tr>
<TD valign=top><b>Scuba tanks:</b></td><td valign=top>	25 aluminum 80 cu/ft tanks<br>
	1760 cu/ft high pressure storage
	bank</td><tr></tr><tr>
<TD valign=top><b>Electronics:</b></td><td valign=top>	Magellan G.P.S.<br>
	Magnavox 4102 Sat Nav<br>
	Furuno 72 and 36 mile radars<br>
	2 recording fathometers<br>
	2 VHF radios<br>
	3 handheld VHF radios<br>
	Icom Ham radio<br>
	SEA SBB radiotelephone<br>
	NTSC television and VCR<br>
	CD Stereo, Slide projector</td><tr></tr><tr>
<TD valign=top><b>Safety:</b></td><td valign=top>	full safety equipment as per USCG
	requirements<br>
	emergency first aid kit<br>
	emergency oxygen kit for 2 people</td><tr></tr><tr>
<TD valign=top><b>Miscellaneous:</b></td><td valign=top>	fully equipped workshop<br>
15 tons deck crane<br>
38 ft by 24 ft (I I m by 7.4m) work deck<br>
14 personal dive gear boxes<br>
14 personal camera lockers with stabilized and surge protected 110v outlets<br>
air conditioning throughout. <br>
sundeck and lounge chairs <br>
washing machine and dryer <br>
refrigerator and ice machine</td><tr></tr><tr>
<TD valign=top><b>Guest Acommodations:</b></td><td valign=top>	For 14 guests:<br>
4 double cabins<br>
2 triple cabins<br>
5 heads with showers</td><tr></tr><tr>

<TD valign=top><b> Crew Acommodations:</b></td><td valign=top>For 8 crew:<br>
3 crew cabins <br>
2 crew heads</td>

</table>
</center>

<p></font>
</table>
</center>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="underseahunter.html">Undersea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:UnderseaHunter@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><a href="index.html">Home</a></font></td>
<td><font size=+1><b>|</b> <a href="contact.html">Contact</a> <b>|</b></font></td>
<td><font size=+1> <b>Vessel Specifications</b> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-105</DOCNO>
<DOCOLDNO>IA027-000294-B023-165</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/seahuntertmp.html 206.86.175.106 19970120081458 text/html 2287
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:08:30 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2105
Last-modified: Tue, 17 Dec 1996 17:17:27 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Sea Hunter</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<td rowspan=6 align=center><a href="images/021.jpeg"><IMG SRC="images/l021.gif"><br><font size=-1>M.V. Sea Hunter</font></a></td>
<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>

<td><a href="cocos.html"><img src="images/3dbuttons/ussmallcocos.gif"></a></td>

<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>
<td rowspan=6 align=center><a href="images/024.jpeg"><IMG SRC="images/024.gif"><br><font size=-1>Dive Deck Sea Hunter</font></a></td>

<tr>
<td><a href="silverbank.html"><img src="images/3dbuttons/ussmallsilverbank.gif"></a></td>
<tr>
<td><a href="techdiving.html"><img src="images/3dbuttons/ussmalltechnicaldiving.gif"></a></td>
<tr>
<td><a href="specialprojects.html"><img src="images/3dbuttons/ussmallspecialprojects.gif"></a></td>
<tr>
<td><a href="photography.html"><img src="images/3dbuttons/ussmallphotography.gif"></a></td>
<tr>
<td><a href="booking.html"><img src="images/3dbuttons/ussmallbooking.gif"></a></td>



</table>
</center>

<hr> 
<center>
<h2>Detailed vessel specifications coming soon!</h2>
<p></font>
</table>
</center>
<center>
<p>
<table border=0>
<td><a href="mailto:Info@underseahunter.com"><img src="images/3dbuttons/usemail.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/ushome.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usfrench.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usgerman.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usspanish.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usitalian.gif"></a></td>


</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-106</DOCNO>
<DOCOLDNO>IA027-000294-B024-23</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/captlog1196.html 206.86.175.106 19970120081613 text/html 8907
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:09:26 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 8725
Last-modified: Tue, 17 Dec 1996 17:17:18 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Captain's Log</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>
<p>
<center>
<b><font size=+4>Not Quite the Blurb</b></font><br>
A <b>"Captain's Log"</b> by <b>David "PJ" Probert</b>, Captain of the <b>M/V Sea Hunter</b>
</center>
<hr>
<center>
<br>
<table border=0>


<td valign=top width=20%>
<font size=+2><b>In this Issue:</b></font>
<br><br>
<a href="captlog1196.html#humantoothpicks">Human Toothpicks</a><br>
<br>
<a href="captlog1196.html#hoffasboots">Jimmy Hoffa's Boots</a><br>
<br>
<a href="captlog1196.html#orcas">Orcas in the Soup</a><br>
<br>
<a href="captlog1196.html#hotchocolate">Hot Chocolate Fights</a><br>
<br>
<a href="captlog1196.html#mantathief">The Manta Thief</a><br>
<br>
<a href="captlog1196.html#quads">Quadruplets</a><br>
<br>
<a href="captlog1196.html#wizardry">Ladies and Wizardry</a><br>
<br>

</td>
<td valign=top width=3%></td>

<td valign=top>
<p><font size=+2><b>Bribery and Corruption Scandal at Cocos</b></font>

<p>
<b>I'll</b> bet you are just gagging to hear about the latest scandal to hit the diving community which shocked it right down to it's boots aren't you? Well I'm afraid you will just have to wait for my next edition of <b>"The Blurb"</b> to find out what it is all about. It should be coming to a mailbox near you soon.

<p>
What a great year this has been at <b>Cocos!</b> In fact, what a great two years this has been! It is difficult to believe that I am in my third year already and do you know what? <b>It gets better!</b>

<p>
Yes, after we came back from the <a href="silverbank.html">Silverbank</a> trips (Whale watching, Humpbacks, loads of them all over the place, between the Dominican Republic and Turks and Caicos but that's another story) Cocos was alive and well and living in the prehistoric era. At least that's what it feels like when you are there, such a beautiful place. Anyway this year was unbelievable (you can ask anyone who has been there, they will tell you. Go ask somebody).

<p><a name="humantoothpicks">
<b>Human Toothpicks</b></a><br>
For three months there was this amazing scene going on at Manuelita. Hammerheads by the score wandering in close to the rocks (I mean <b>really close</b>) to get their teeth cleaned by the King Angels and the Barber Fish. What a job! Imagine being a human toothpick, not to mention the other places they have to clean.

<p><a name="hoffasboots">
<b>Jimmy Hoffa's Boots</b></a><br>
Anyway there we were, face to face with these sometimes huge beasts. Some looked as if they had been shaving with an old razor blade, nicks and scratches and cuts all over their chins. It's an amazing feeling looking down the throat of a big old Hammerhead and seeing what they had for breakfast. This just went on and on. I'm sure I saw Jimmy Hoffa's boots one day.

<p>
<b>Bored Yet?</b><br>
Are you bored yet? Yes? Well listen to this then. We saw Whale Sharks four times on one trip and <b>Petra</b>, from <b>Sinai Divers</b> got her reward by seeing the <b>largest fish in the sea</b> on her last dive of the trip (her third, all the way from Egypt).

<p>
(I was keeping it in reserve because everything was so unbelievable)
<p>

Do you know what? I can't count the number of times that I have dived with <b>Dolphins</b> since I've been here. It's great to be in one of the pangas after someone has just swam or dived with a Dolphin for the first time. Sometimes they have enormous yellow fin tuna with them and very often silky sharks. There are a lot of firsts out here I can tell you. I know, I've witnessed them.

<p><a name="orcas">
<b>Orcas in the Soup</b></a><br>
What if I told you that I was doing a rebreather course and as soon as we left the surface Hugo, our panga driver, saw <b>three orcas</b> cruising "right over our heads" he said, but I think he was exaggerating (slightly). Anyway I was obviously paying too much attention to my student because I didn't see it at all. That fish on the reef was really freaking out, several divers got to see two. One luck guy had an eyeball encounter. Imagine that when you least expect it! You see never know what you might see!

<p>
That was also on the last dive of that trip. The orcas were seen again on the next trip also. <b>What an amazing place!</b>

<p><a name="hotchocolate">
<b>Hot Chocolate Fights</b></a><br>
You know, anyone can night dive. Every night if they wish and we encourage it, but I'm not really into it much anymore, I get all the excitement I need with the three major dives of the day but when the silkys show up at night around the back of the boat, as they do regularly these days, it's impressive. It is even more impressive seeing the divers jump into the water while there are about ten around (I just take another sip of my hot chocolate and try to remember where I put the Band-Aids). Yes, the excitement level is pretty intense here!
<p><a name="mantathief">
<b>The Manta Thief</b></a><br>
Did you here about one of our repeat guests who had his camera nicked by a manta? True story. <b>No really.</b> Well he was at dirty rock getting some superb shots of the manta's throat when the strobe cable got caught around the cephalic fin and the manta took off with $7000 worth of camera gear. <b>Winnie Persinger from Germany</b> was the unfortunate victim of this theft. The camera was never seen again. There were several witnesses, I might add. Poor manta.

<p>
Anyway, the great manta debate continues. Are <b>mobilas</b> mantas? I would say ask everyone who has seen them here what they think. To me they must be. I mean what else do they look like? You know we've regularly seen schools of twenty or more. What a fantastic place this is.

<p><a name="quads">
<b>Quadruplets</b></a><br>
  Do you know what else a diver saw? No? Well you know I'm going to tell you anyway, right? It was a white tip giving birth in the sand at Manuelita. I'm not surprised really, sometimes there are hundreds of the buggers swimming around courting. Anyway I'll bet you didn't know that they come out tail first. You did? Well, there you go then.

<p>
<b>Secret</b><br>
I'm afraid I can't tell you anymore because we are trying to keep <b>Cocos</b> one of the best kept secrets in the world. Well it's not really going to be a secret anymore once <b>Howard Hall's new special on Cocos</b> is released. He has some unbelievable stuff. So I hear has <b>Marty Snyderman</b> who was here a few months ago.

<p>
It was great to see all the new faces this year and to see lots of our old friends back again. When you come back next time you had better bring me some new jokes! One guy came for the seventh time this year (take that anyway you like).

<p><a name="wizardry">
<b>Ladies and Wizardry</b></a><br>
What else can I bore you with? I know, <b>Silverbanks.</b> It is between the Turks and Caicos and the Dominican Republic. A huge mating and calving area for humpbacks. We go there for three months, beginning in January and actually get to <b>swim with these fantastic mammals</b> and boy can I tell you (and girl too, it's just a figure of speech, we are definitely not sexist on our boats) where was I? Oh yes, looking one of these gigantic ladies in the eye, that, I bet you know everything, is unbelievable. So you had better get hold of <b>Alan</b> on the phone or fax or other electronic wizardry and book now. <b>Go on, do it, it's going to be great!</b>

<p>
Don't forget that while we are away the <b>Undersea Hunter</b> is still enjoying the thrill of <b>Cocos</b> and the weather is very nice at this time of year with more excursions to the south of the island. It's time to start seeing big schools of <b>Eagle Rays.</b> Although you can see groups of five or size year round. <b>It really is a great place.</b>




</table>



<br><br>
<p>
<center>
<b>Comments about "The Blurb?" Use the email link below to send us your comments!</b>
<p>
<table border=0>
<td><a href="mailto:Info@underseahunter.com"><img src="images/3dbuttons/usemail.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/ushome.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usfrench.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usgerman.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usspanish.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usitalian.gif"></a></td>


</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>

</DOC>
<DOC>
<DOCNO>WT01-B04-107</DOCNO>
<DOCOLDNO>IA027-000294-B024-46</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/comingsoon.html 206.86.175.106 19970120081644 text/html 2274
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:10:13 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2092
Last-modified: Tue, 17 Dec 1996 17:17:24 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Undersea Hunter</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<td rowspan=6 align=center><a href="images/001.jpeg"><IMG SRC="images/n001.gif"><br><font size=-1>M.V. Undersea Hunter</font></a></td>
<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>

<td><a href="cocos.html"><img src="images/3dbuttons/ussmallcocos.gif"></a></td>

<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>
<td rowspan=6 align=center><a href="images/021.jpeg"><IMG SRC="images/n021.gif"><br><font size=-1>M.V. Sea Hunter</font></a></td>

<tr>
<td><a href="silverbank.html"><img src="images/3dbuttons/ussmallsilverbank.gif"></a></td>
<tr>
<td><a href="techdiving.html"><img src="images/3dbuttons/ussmalltechnicaldiving.gif"></a></td>
<tr>
<td><a href="specialprojects.html"><img src="images/3dbuttons/ussmallspecialprojects.gif"></a></td>
<tr>
<td><a href="photography.html"><img src="images/3dbuttons/ussmallphotography.gif"></a></td>
<tr>
<td><a href="booking.html"><img src="images/3dbuttons/ussmallbooking.gif"></a></td>



</table>
</center>
<hr> 
<center>
<h2>This feature coming soon!</h2>
<p></font>
</table>
</center>
<center>
<p>
<table border=0>
<td><a href="mailto:Info@underseahunter.com"><img src="images/3dbuttons/usemail.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/ushome.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usfrench.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usgerman.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usspanish.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usitalian.gif"></a></td>


</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-108</DOCNO>
<DOCOLDNO>IA027-000294-B024-178</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/cocositinerary.html 206.86.175.106 19970120081841 text/html 4428
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:11:49 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4246
Last-modified: Mon, 28 Oct 1996 11:52:44 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Cocos Island Sample Itinerary</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/057.jpeg"><IMG SRC="images/057.gif"><br><font size=-1>"Cleopatra" the Snowflake Moray</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/059.jpeg"><IMG SRC="images/059.gif"><br><font size=-1>Red lip Batfish</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<br>
<center>
<table border=0 wifth=85%>


<td colspan=2><p align=center><font size=+2><b>Sample Cocos Itinerary</b></font>
<tr><tr>
<td valign=top width=15% align=right><font size=+1><b>Day 1:</b></font></td> <td valign=top> <font size=+1>Upon arrival in San Jose, Costa Rica, you will need to take a taxi to your hotel. There are plenty of taxies available, even big cars for those of you who carry a lot of gear. The same evening, an Undersea Hunter representative will call you to confirm your pick up time, the next day. Evening at your leisure.</font></td>
<tr>
<tr>
<tr>
<td valign=top align=right><font size=+1><b>Day 2:</b></font></td> <td valign=top> <font size=+1>You will be picked up before noon at your hotel and transferred by bus to Puntarenas, a seaport village where our boats board their passengers. That afternoon, you will begin the cruise to Cocos Island.</font></td>
<tr>
<tr>
<tr>
<td valign=top align=right><font size=+1><b>Day 3:</b></font></td> <td valign=top> <font size=+1>All day of travel. There will be ample time to arrange dive and camera gear. The cruise gives you an opportunity to get aquainted with the other divers.</font></td>
<tr>
<tr>
<tr>
<td valign=top align=right><font size=+1><b>Days 4 to 9:</b></font></td> <td valign=top> <font size=+1>Spent diving the pinnacles around the perimeter of Cocos Island. Divers usually average three dives per day at depths of 60-100' or more. Water temperature of approximately 78-82F (27-30C).</font></td>
<tr>
<tr>
<tr>
<td valign=top align=right><font size=+1><b>Day 10:</b></font></td> <td valign=top> <font size=+1>Make the last 3 dives before the cruise back to Costa Rica and reality!</font></td>
<tr>
<tr>
<tr>
<td valign=top align=right><font size=+1><b>Day 11:</b></font></td> <td valign=top> <font size=+1>All day to discuss the diving and to compare your adventures!</font></td>
<tr>
<tr>
<tr>
<td valign=top align=right><font size=+1><b>Day 12:</b></font></td> <td valign=top><font size=+1>Arrival in Puntarenas. Immediately after breakfast you will be transported back to San Jose, with a stop in Sarchi, a local scenic village along the way. There you may purchase local handicrafts and coffee. Upon arrival in San Jose you will need to spend an additional hotel night as airline departures are the following morning.</font></td>
</font>
</table>
</center>
<hr>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="underseahunter.html">Undersea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:Info@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><a href="index.html">Home</a></font></td>
<td><font size=+1><b>|</b> <a href="booking.html">Booking Information</a> <b>|</b></font></td>
<td><font size=+1> <a href="seahunter.html">Sea Hunter</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-109</DOCNO>
<DOCOLDNO>IA027-000294-B024-205</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/cocosdive.html 206.86.175.106 19970120081920 text/html 4476
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:12:48 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4294
Last-modified: Mon, 28 Oct 1996 11:52:41 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Diving at Cocos</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/048.jpeg"><IMG SRC="images/048.gif"><br><font size=-1>White tip sharks</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/051.jpeg"><IMG SRC="images/051.gif"><br><font size=-1>Sharks and Dolphins</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<br>
<center>
<table border=0 wifth=80%>

<td><font size=+2><p align=center><b>Cocos Diving</b></font>

<p><font size=+1>While diving Cocos Island is extraordinary and beautiful, the Cocos Island area is very remote.  It is not recommended for inexperienced divers because it is an open ocean destination that requires advanced open water diving skills.

<p>Every dive at Cocos is distinct.  Currents and visibility can be entirely different in just a few hours.  The diving among the rocky islets off the coast of the main island is very exciting.  The primary attraction are large pelagics, i.e., sharks, whales, rays, mantas, turtles and schooling fish.  Sightings of sailfish, marlin, bottlenose dolphins and whale sharks are often reported.  The bottom is volcanic rock, with prolific long-spine sea urchins.  Most of the action is at 60-80 feet but a dive computer is recommended as you will want the capability to go to 100 feet.  A safe limit of 110 feet is requested.  Visibility averages 80-100 feet.

<p>Diving will commence shortly after your arrival at Cocos Island.  There are three dives daily from one of the fiberglass skiffs.  You may choose your diving buddy or join the group which is guided by our dive master.

<p><b>Water Termperature:</b><br>
You will be diving in water about 78-83 F.

<p><b>Visibility:</b><br>
Visiblity averages 80-100' with ocassional extremes of 40 and 120'.


<p><b>Certification Cards:</b><br>
All divers must bring proof of certification by a national certifying agency.  The dive master will request to see your certification before you are allowed to dive.

<p><b>Dive Gear Suggestions:</b><br>
You will need the following gear:
1/8" to 3/16" wet suit, mask, fins, snorkel, regulator with visible pressure gauge, dive computer, buoyancy compensator, depth gauge, dive gloves, weight belt (without weights), dive knife and dive watch.  It is recommended that you mark each piece of gear with waterproof paint or tape.  We suggest you put all or most of the above items in a carry-on bag.

<p>There is ample storage space for your diving equipment, including your own personal locker.  We provide you with 80 cubic ft. tanks and weights.

<p><b>Underwater Photography:</b><br>
The diving around Cocos Island offers some of the most photogenic waters in the world.  Photographers will find reefs, fish life and visibility excellent for both stills and videos.

</font></td>
</font>
</table>
</center>
<hr>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="underseahunter.html">Undersea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:Info@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><b>Diving at Cocos</b></font></td>
<td><font size=+1><b>|</b> <a href="index.html">Home</a> <b>|</b></font></td>
<td><font size=+1> <a href="seahunter.html">Sea Hunter</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-110</DOCNO>
<DOCOLDNO>IA027-000294-B024-228</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/cocostravel.html 206.86.175.106 19970120081937 text/html 4829
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:13:10 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4647
Last-modified: Mon, 28 Oct 1996 11:52:58 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Cocos Travel Information</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/001.jpeg"><IMG SRC="images/001.gif"><br><font size=-1>MV Undersea Hunter</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/021.jpeg"><IMG SRC="images/021.gif"><br><font size=-1>MV Sea Hunter</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<br>
<center>
<table border=0 wifth=80%>

<td><font size=+2><p align=center><b>Travel Information</b></font>
<p><font size=+1><b>Health:</b><br>
No inoculations are required to travel to Costa Rica.  A well-equipped first aid kit including oxygen is on board.  You may want to bring anti-seasickness medicine if you feel you will need it.

<p>Please inform us and especially the dive guides if you are taking medication or suffer from allergies.

<p>There is no smoking allowed inside the boat.  Smoking is permitted on the sundeck only.


<p><font size=+1><b>Travel Documents:</b><br>
All passengers must have a valid passort for entry to Costa Rica. Non U.S. residents must check with the Costa Rican consulate if visas are necessary prior to travel.

<p><b>Clothing:</b><br>
We recommend casual and cool cotton attire while on board.  Nights can be chilly and/or drizzly.  A sweater, light jacket or windbreaker should be sufficient on a cool evening.  In San Jose dress is slightly more formal - long pants for men in the evening and a dress or pant suit for women is appropriate.  Puntarenas is generally very warm and shorts are acceptable.  We suggest packing in a soft duffle bag for easy luggage storage.

<p><font size=+1><b>Currency:</b><br>
Hotels and banks will accept and exchange US Dollars for Costa Rican Colones.  US dollars as well as travellers checks are accepted on the Undersea Hunter and Sea Hunter.  We do not accept personal checks.

<p><font size=+1><b>Baggage Limitations:</b><br>
Pack lightly since you will be dressing for warm tropical weather.  Airlines' baggage limitations can affect divers and photographers.  Domestic airlines limit passengers to two pieces of check-in luggage.  International flights also have a two piece limit and a limit of 70 lbs per bag.  You will be charged for an extra bag or overweight luggage.

<p><font size=+1><b>D.A.N. Insurance:</b><br>
We strongly urge all clients to obtain the inexpensive D.A.N. insurance designed to evacuate divers in the event of an accident.

<p>Cocos Island is a very remote area and the cost involved in evacuating a diver is very high.  The D.A.N. policy, priced at $52.00 per year is a vital protection to have.


<p><font size=+1><b>Insurance:</b><br>
We recommend the purchase of a short term cancellation insurance policy in case of unexpected changes in your plans.  Accident, medical and baggage insurance are also recommended.  The nearest recompression chamber is in Panama and the cost of evacuation is extremely high, we therefore recommend emergency evacuation insurance.

<p><font size=+1><b>National Park Fee:</b><br>
There is a National Park fee of $105.00 per person for seven days of diving.  This must be included with your final payment.



</font></td>
</font>
</table>
</center>
<hr>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="underseahunter.html">Undersea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:Info@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><b>Travel Information</b></font></td>
<td><font size=+1><b>|</b> <a href="index.html">Home</a> <b>|</b></font></td>
<td><font size=+1> <a href="seahunter.html">Sea Hunter</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-111</DOCNO>
<DOCOLDNO>IA027-000294-B025-4</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/cocosboat.html 206.86.175.106 19970120082032 text/html 4303
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:13:23 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4121
Last-modified: Mon, 28 Oct 1996 11:52:34 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Cocos Travel Information</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/001.jpeg"><IMG SRC="images/001.gif"><br><font size=-1>MV Undersea Hunter</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/021.jpeg"><IMG SRC="images/021.gif"><br><font size=-1>MV Sea Hunter</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<br>
<center>
<table border=0 wifth=80%>

<td><font size=+2><p align=center><b>On the Boat</b></font>
<p><font size=+1><b>Meals:</b><br>
The menu aboard offers a delicious combination of American and local cuisine.  Meals are varied and well balanced.  Food is abundant with plenty of fresh tropical fruit and salads.

<p>Please let us know of any special dietary needs or requests, but try to be lenient as storage and preparation space is limited.

<p><font size=+1><b>Beverages:</b><br>
Soft drinks: $1.00, Beer: $1.50, Bottle of wine: $8.00

<p>Hard liquor is not available on board and should be purchased by the guest prior to boarding.

<p><b>Entertainment:</b><br>
There is a variety of nightly entertainment available on board: slide shows, video movies, games and much more.  The crew especially love new VHS movies, musical cassettes and compact discs.  Please feel free to bring along your favorites.

<p><font size=+1><b>Crew:</b><br>
The Undersea Hunter crew consists of a unique combination of talents, offering the ultimate in service.  The dive master and two deck hands make sure you have the best possible diving adventure, while the chef and steward prepare our delicious meals and take care of your needs on board.

<p><font size=+1><b>E-6 Processing:</b><br>
Ektachrome and Fujichrome film is processed on the vessel at $10.00 per roll.


<p><font size=+1><b>Communications:</b><br>
The Undersea Hunter is in constant radio contact in the event of any emergency.  Your family and friends may contact you through our office at 011-506-289-7334 or 011 506-228-6535.  We are happy to let family and friends know how you are when they call our office.  Please understand, however, that you will be in a remote area and it is preferable that personal communications from the boat be limited to emergency use only.

<p><font size=+1><b>Tips:</b><br>
Since it is customary to tip crew members, many people ask us what an appropriate tip would be.  This is a very personal decision, for tips are your way of expressing satisfaction.  We do not include tips in the price of the cruise.  Generally, each guest tips the skipper and he distributes it among the crew.  Usually, each guest tips $15 $20 for each crew member.


</font></td>
</font>
</table>
</center>
<hr>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="underseahunter.html">Undersea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:Info@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><b>On the Boat</b></font></td>
<td><font size=+1><b>|</b> <a href="index.html">Home</a> <b>|</b></font></td>
<td><font size=+1> <a href="seahunter.html">Sea Hunter</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-112</DOCNO>
<DOCOLDNO>IA027-000294-B025-40</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/cocospelagics.html 206.86.175.106 19970120082111 text/html 2574
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:14:23 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2392
Last-modified: Mon, 28 Oct 1996 11:52:46 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Pelagics at Cocos</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/056.jpeg"><IMG SRC="images/056.gif"><br><font size=-1>Hammerhead</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/054.jpeg"><IMG SRC="images/054.gif"><br><font size=-1>Silky Shark</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<br>
<center>
<table border=0 wifth=80%>

<td><font size=+2><p align=center><b>Pelagics at Cocos Island</b></font>

<p><font size=+1>
Cocos Island offers one of the most unique marine environments to encounter many different varieties of pelagics. From hammerheads, white tips, and the occasional whale shark, to huges schools of jacks, tuna, pods of dolphins, groups of rays, and turtles, Cocos offers a plethora of opportunities to experience  some of the world's most exciting marine life in their native habitat.
</font></td>
</font>
</table>
</center>
<hr>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="underseahunter.html">Undersea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:Info@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><b>Pelagics at Cocos</b></font></td>
<td><font size=+1><b>|</b> <a href="index.html">Home</a> <b>|</b></font></td>
<td><font size=+1> <a href="seahunter.html">Sea Hunter</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-113</DOCNO>
<DOCOLDNO>IA027-000294-B025-73</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/cocosthere.html 206.86.175.106 19970120082147 text/html 4745
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 08:15:18 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4563
Last-modified: Mon, 28 Oct 1996 11:52:49 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Cocos Travel Information</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center><IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>



<center>
<br>
<table border=0>
<tr>
<td rowspan=2 align=center><a href="images/001.jpeg"><IMG SRC="images/001.gif"><br><font size=-1>MV Undersea Hunter</font></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td><a href="booking.html"><img src="images/nav/booking.gif" border=0></a><a href="cocos.html"><img src="images/nav/cocos.gif" border=0></a><a href="photography.html"><img src="images/nav/photo.gif" border=0></a></td>
<td rowspan=2></td><td rowspan=2></td><td rowspan=2></td><td rowspan=2></td>
<td rowspan=2 align=center><a href="images/021.jpeg"><IMG SRC="images/021.gif"><br><font size=-1>MV Sea Hunter</font></a></td>

<tr>
<td align=top><a href="specialprojects.html"><img src="images/nav/prcts.gif" border=0></a><a href="silverbank.html"><img src="images/nav/silver.gif" border=0></a><a href="techdiving.html"><img src="images/nav/tech.gif" border=0></a></td>
</tr>
</table>
</center>
<hr> 
<br>
<center>
<table border=0 wifth=80%>

<td><font size=+2><p align=center><b>Getting to and from Cocos</b></font>

<p><font size=+1>
It is important you notify our office of last minute changes in your flight arrival times or in any changes in your address or telephone (contact) numbers.

<p><b>Arrival in Costa Rica:</b><br>
We recommend that you fly to San Jose via direct flights from Miami, Houston or Dallas.  Passengers using other non-direct flights have experienced delays and luggage problems in Mexico City and San Salvador.  You must arrive one night prior to boat departure date.

<p>Upon arrival in San Jose, you will need to take a taxi to your hotel.  There are always taxies available at the airport, even minivans for those of you who carry a lot of gear.  We can arrange accommodations at several hotels in San Jose.  The same evening, an Undersea Hunter representative will call you to confirm your pick up time the next day.  The evening is at your leisure.  Hotel nights and meals pre- and post-cruise are not included in the charter.

<p>The following day, between 9:30 AM and 1:30 PM you will be picked up from your hotel and transferred by bus to Puntarenas, the seaport village where you will board the Undersea Hunter or the Sea Hunter.  The drive takes about 2 1/2 hours and gives you a chance to view the lush tropical forest and rich farmland of the region.

<p>Due to occasional low tides our boats may need to depart from the pier earlier in the day.  Should this occur, you will transferred by panga (skiff) to the Undersea Hunter.  When all passengers are boarded, the Undersea Hunter will take a 32-36 hour cruise out to Cocos Island.  Although at most times the cruise to the island is calm, it can, at times, be uncomfortable.  Precaution against motion sickness is advised.  At the end of the trip you will cruise back to Puntarenas and be transferred by bus to your hotel in San Jose.


<p><b>Land Arrangements:</b><br>
Costa Rica is a beautiful country with a wide range of land-based activities for the visitor.  Volcano tours, jungle adventures, visits to craft centers and white water rafting are among day trips available around San Jose.  We would be happy to arrange one day tours or longer trips to more remote areas.

<p><font size=+1><b>Transfer Fees:</b><br>
If for some reason you should need a transfer to or from Puntarenas, taxi service is available.  WARNING - Transfers other than the Undersea Hunter's can run in excess of $60.00 per person one way.

<p><font size=+1><b>Departures:</b><br>
You disembark in Puntarenas at 8:30 AM the morning of departure.  You will be transferred by bus to your hotel in San Jose.

</font></td>
</font>
</table>
</center>
<hr>
<center>
<p>
<table border=0>
<td><font size=+1><b>|</b> <a href="underseahunter.html">Undersea Hunter</a></font></td>
<td><font size=+1><b>|</b> <a href="mailto:Info@underseahunter.com">Email</a> <b>|</b></font></td>
<td><font size=+1><b>Getting There</b></font></td>
<td><font size=+1><b>|</b> <a href="index.html">Home</a> <b>|</b></font></td>
<td><font size=+1> <a href="seahunter.html">Sea Hunter</a> <b>|</b></font></td>

</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-114</DOCNO>
<DOCOLDNO>IA027-000294-B019-240</DOCOLDNO>
<DOCHDR>
http://www.underseahunter.com:80/ 206.86.175.106 19970120075937 text/html 5554
HTTP/1.0 200 OK
Date: Mon, 20 Jan 1997 07:53:11 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5372
Last-modified: Thu, 19 Dec 1996 09:44:31 GMT
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>Undersea Hunter... Cocos Island and more...</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BACKGROUND="images/waterbg.gif">

<center>
<IMG SRC="images/tlogo.gif"  ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
</center>
<center>
<HR WIDTH="92%" SIZE="7"></center>
<center><blink><b><font size=+1>Don't miss the boat for our Silverbanks trips.
Space still remaining. <br>Departing very soon.</b></font></blink></center>
<center><HR WIDTH="92%" SIZE="7"></center>


<center>
<br>
<table border=0>
<td rowspan=6 align=center><a href="images/001.jpeg"><IMG SRC="images/n001.gif"><br><font size=-1>M.V. Undersea Hunter</font></a></td>
<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>

<td><a href="cocos.html"><img src="images/3dbuttons/ussmallcocos.gif"></a></td>

<td rowspan=6></td><td rowspan=6></td><td rowspan=6></td><td rowspan=6></td>
<td rowspan=6 align=center><a href="images/021.jpeg"><IMG SRC="images/n021.gif"><br><font size=-1>M.V. Sea Hunter</font></a></td>

<tr>
<td><a href="silverbank.html"><img src="images/3dbuttons/ussmallsilverbank.gif"></a></td>
<tr>
<td><a href="techdiving.html"><img src="images/3dbuttons/ussmalltechnicaldiving.gif"></a></td>
<tr>
<td><a href="specialprojects.html"><img src="images/3dbuttons/ussmallspecialprojects.gif"></a></td>
<tr>
<td><a href="photography.html"><img src="images/3dbuttons/ussmallphotography.gif"></a></td>
<tr>
<td><a href="booking.html"><img src="images/3dbuttons/ussmallbooking.gif"></a></td>



</table>
</center>
<hr> 
<center>
<table border=0 width =90%>
<td><font size=+1><p>The <b>Undersea Hunter</b> and the <b>Sea Hunter</b> offer live-aboard experiences that focus on comfort and convenience. We take pride in providing excellent service, food and non-stop underwater excitement. 
<p>
From the distinctive and remote <b>Cocos Island</b> to visiting the Humpbacks of the <b>Silver Bank</b>, our vessels provide world-class diving experiences in complete comfort and safety. Join us for one of our adventures into the magnificent marine environment!
<p>
We also provide support vessel functions for underwater film productions, oceanographic research, small research submersibles, marine salvage, search and recovery, and supply and transport duties.</font>
</table>
</center>
<hr>
<center>
<table border=0>
<tr>
<th colspan=1><font size=+2><b>Undersea Hunter</b>&nbsp;&nbsp;</font></th>
<td></td>
<th colspan=1><font size=+2><b>Sea Hunter</b></b></font></th>
</tr>
<tr>
<td align=center><a href="underseahunter.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></a></td>
<td align=center><font size=+1><b>Description of Vessel</b></font></td>
<td align=center><a href="seahunter.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></td>
</tr>
<tr>
<td align=center><a href="underseahlayout.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></td>
<td align=center><font size=+1><b>Deck Plan of Vessel</b></font></td>
<td align=center><a href="sealayout.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></td>
</tr>
<tr>
<td align=center><a href="underseavesselspecs.html"><IMG ALIGN=top SRC="images/3dbuttons/usmain.gif"></td>
<td align=center><font size=+1><b>List of Specifications</b></font></td>
<td align=center><a href="seahuntertmp.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
</tr>
<tr>
<td align=center><a href="captlog1196.html"><IMG ALIGN=top SRC="images/3dbuttons/usnewfeature.gif"></a></td>
<td align=center><font size=+1><b>Captain's Log</b></font></td>
<td align=center><a href="captlog1196.html"><IMG ALIGN=top SRC="images/3dbuttons/usnewfeature.gif"></a></td>
</tr>
<tr>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
<td align=center><font size=+1><b>Newsletter</b></font></td>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
</tr>
<tr>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
<td align=center><font size=+1><b>Expedition Schedule</b></font></td>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
</tr>
<tr>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
<td align=center><font size=+1><b>Important Announcements</b></font></td>
<td align=center><a href="comingsoon.html"><IMG ALIGN=top SRC="images/3dbuttons/uscomingsoon.gif"></a></td>
</tr>
</table>
</center>
<br><br>
<p>
<center>
<b>Let us know what you think of our site, use the email link below to send us your comments!</b>
<p>
<table border=0>
<td><a href="mailto:Info@underseahunter.com"><img src="images/3dbuttons/usemail.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/ushome.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usfrench.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usgerman.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usspanish.gif"></a></td>
<td><a href="index.html"><img src="images/3dbuttons/usitalian.gif"></a></td>


</table>
</center>

<P><HR><FONT SIZE=-1>&copy; 1996 Undersea Hunter, Netilus. All rights reserved.
Reproduction without permission is strictly prohibited.</FONT>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-115</DOCNO>
<DOCOLDNO>IA077-000520-B048-11</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/ 207.112.150.94 19970124112310 text/html 6803
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:23:04 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 6632
Last-modified: Fri, 24 Jan 1997 08:01:09 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Drug Watch International Home Page</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" BACKGROUND="../Images/dwbckgrnd.GIF">
<P><CENTER><IMG SRC="../Images/DWlogo.GIF" WIDTH="233" HEIGHT="121" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><BR>
<BR>
<IMG SRC="../Images/dwbar.gif" WIDTH="468" HEIGHT="12" ALIGN="BOTTOM" NATURALSIZEFLAG=
"3"></CENTER>
<H4><CENTER>Summary</CENTER>
</H4>
Drug Watch International is a volunteer non-profit information network and
advocacy organization which promotes the creation of healthy drug-free cultures
in the world and opposes the legalization of drugs. The organization upholds
a comprehensive approach to drug issues involving prevention, education,
intervention/treatment, and law enforcement/interdiction. <BR>
<BR>
The purpose of Drug Watch is to provide the public, policymakers, and the
media with current drug information, factual research and expert resources,
and to counter measures aimed at drug legalization. <BR>
<BR>
Drug Watch International is comprised of a Board of Directors, Delegates
from countries from around the world, a Liaison Board of representatives
from international, national and state prevention and treatment organizations,
a Board of Advisors, and the International Drug Strategy Institute. 
<H4><CENTER>Mission Statement</CENTER>
</H4>
The illegal or harmful use of psychoactive or addictive drugs is a major
threat to all world communities and to future generations. Drug Watch International
is a network of prevention experts and community volunteers from a wide
range of professions whose mission is to help assure a healthier and safer
world through drug prevention efforts by: Providing accurate information
on both illicit and harmful psychoactive substances; Promoting sound drug
policies based on scientific research; and Opposing efforts to legalize
or decriminalize drugs. 
<H4><CENTER>International Drug Strategy Institute</CENTER>
</H4>
The International Drug Strategy Institute is a group of physicians, attorneys,
educators, law enforcement officials and drug prevention and treatment specialists
who provide expertise on national and international drug strategies. The
Institute pursues public policy on drug issues consistent with the mission
and goals as established by Drug Watch International. 
<H4><CENTER>Philosophy</CENTER>
</H4>
Drug abuse prevention is the most effective, humane, and cost effective
way of addressing the consequences of illegal, harmful and mind altering
drugs in our society. Prevention works and needs to be reinforced, enhanced,
and expanded. <BR>
<BR>
Effective prevention can take place only with positive societal norms which
embrace and support healthy drug-free attitudes, environment, and activities,
while reinforcing nonacceptance toward the presence of drugs and destructive
behavior. These societal norms must be reflected in the accountability and
enforcement of legal, medical, educational, community, and personal standards
<BR>
<BR>
AII parts of the local and global communities need to unite the strengths
of professional expertise, generational wisdom and individual commitment
to combat the drug problem as we strive together toward a healthier world.
<H4><CENTER>Principles</CENTER>
</H4>
<UL>
  <LI>Support clear messages and standards of no illegal use of alcohol,
tobacco and other drugs, (including &quot;no use&quot; under legal age)
and no abuse of legal drugs or substances for adults or youth. <BR>
<BR>
  <LI>Support comprehensive and coordinated approaches that include prevention,
education, law enforcement, and treatment in addressing issues regarding
alcohol, tobacco, and other drugs. 
  <LI>Support strong laws and meaningful legal penalties that hold users
and dealers accountable for their actions. <BR>
<BR>
  <LI>Support the requirement that any medical use of psychoactive or addictive
drugs meet the current criteria required of all other therapeutic drugs.
<BR>
<BR>
  <LI>Support adherence to the scientific research standards and ethics
that are prescribed by the world scientific community and professional associations
in conducting studies and reviews on alcohol, tobacco and other drugs (without
exception to illicit drugs). <BR>
<BR>
  <LI>Support efforts to prevent availability and use of drugs, and oppose
policies and programs that accept drug use based erroneously on reduction
or minimization of harm. <BR>
<BR>
  <LI>Support International Treaties and Agreements, including international
sanctions and penalties against drug trafficking, and oppose attempts to
weaken international drug policies and laws. <BR>
<BR>
  <LI>Support efforts to halt the legalization/decriminalization of drugs.
<BR>
<BR>
  <LI>Support the freedom and rights of individuals without jeopardizing
the stability, health, and welfare of society. 
</UL>
<P><CENTER><IMG SRC="../Images/dwbar.gif" WIDTH="468" HEIGHT="12" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><BR>
<BR>
To see a list of documents publicly accessible from Drug Watch click <A HREF="dw1.html">here.
</A><BR>
<BR>
<A HREF="dw1.html"><IMG SRC="../Images/DWlogo.GIF" BORDER="../Images/dwbckgrnd.GIF" WIDTH="233" HEIGHT="121"
ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A><BR>
<BR>
or visit the <A HREF="http://www.drugnet.org/">International Drug Strategy
Institute</A><BR>
<BR>
<A HREF="http://www.drugnet.org/"><IMG SRC="../Images/DSIlogo.GIF" BORDER="../Images/dwbckgrnd.GIF" WIDTH=
"240" HEIGHT="113" NATURALSIZEFLAG="0" ALIGN="BOTTOM"></A><BR>
<BR>
Visit <A HREF="http://www.hassela.se/hassela">Hassela Nordic Network and
Hassela</A>- a politically and religiously independent network for international
exchange of theoretical ideas and suggestions for practical action to maintain
a restrictive drugs policy and prevent the legalisation of illicit drugs.
<BR>
<BR>
<A HREF="http://www.hassela.se/hassela"><IMG SRC="../Images/hnnlogo.GIF" BORDER="../Images/dwbckgrnd.GIF" WIDTH="144" HEIGHT="145" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A><BR>
<BR>
<IMG SRC="../Images/dwbar.gif" WIDTH="468" HEIGHT="12" ALIGN="BOTTOM" NATURALSIZEFLAG=
"3"></CENTER>
<P>Drug Watch International suggests you also visit these non-government
web sites for accurate information on drug issues. <BR>
<BR>
<A HREF="http://www.halcyon.com/drugprev/">Drug Watch Pennsylvania</A><BR>
<A HREF="http://www.hassela.se/hassela">Hassela Nordic Network</A><BR>
<BR>
For more information or to send comments e-mail <A HREF="mailto:DrugWatch6@aol.com">Drug
Watch mail center</A>. <BR>
<BR>
There have been <IMG SRC="http://www.enteract.com/cgi-bin/Count.cgi?dd=A|df=dwi-tally.dat"
ALIGN="BOTTOM"> visitors to this page since November 1st, 1996. 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-116</DOCNO>
<DOCOLDNO>IA077-000520-B048-67</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/dw1.html 207.112.150.94 19970124112334 text/html 3635
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:23:26 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 3464
Last-modified: Sun, 19 Jan 1997 08:00:34 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Drug Watch International Documents Home Page</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF" LINK="#000062">
<P><CENTER><IMG SRC="../Images/DWlogo.GIF" WIDTH="233" HEIGHT="121" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"> </CENTER>
<H4><CENTER><STRONG>Public Access Documents Page</STRONG></CENTER>
</H4>
<P><CENTER><IMG SRC="../Images/dwbar.gif" WIDTH="468" HEIGHT="12" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"></CENTER>
<P>Please feel free to browse these documents. We will update this page
from time to time and appreciate any comments. Resources provided on request.
Kindly e-mail your fax number or your mailing address to Drug Watch. <BR>
<BR>
<IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN="MIDDLE"
NATURALSIZEFLAG="3"> <STRONG><A HREF="drugfx.html">Effects of Marijuana
and other Drugs</A></STRONG><BR>
<IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN="MIDDLE"
NATURALSIZEFLAG="3"> <B><A HREF="hr.html">Harm Reduction and Minimization</A></B><BR>
<IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN="MIDDLE"
NATURALSIZEFLAG="3"> <STRONG><A HREF="le.html">Law Enforcement</A></STRONG><BR>
<IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN="MIDDLE"
NATURALSIZEFLAG="3"> <STRONG><A HREF="mrr.html">Marijuana Research Reviews</A>
</STRONG><BR>
<IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN="MIDDLE"
NATURALSIZEFLAG="3"> <STRONG><A HREF="mm.html">Medical Marijuana<BR>
</A></STRONG><IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN=
"MIDDLE" NATURALSIZEFLAG="3"> <B><A HREF="general.html">Other Drug Issues
and Papers</A></B><BR>
<IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN="MIDDLE"
NATURALSIZEFLAG="3"> <STRONG><A HREF="pp.html">Position Papers<BR>
</A></STRONG><IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN=
"MIDDLE" NATURALSIZEFLAG="3"> <B><A HREF="rr.html">Research Reviews and
Updates</A></B><BR>
<IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN="MIDDLE"
NATURALSIZEFLAG="3"> <STRONG><A HREF="mr.html">Media Releases</A></STRONG><BR>
<IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN="MIDDLE"
NATURALSIZEFLAG="3"> <STRONG><A HREF="tl.html">Truth and Lies<BR>
</A></STRONG><IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN=
"MIDDLE" NATURALSIZEFLAG="3"> <STRONG><A HREF="press.html">World News and
Editorials<BR>
</A></STRONG><IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN=
"MIDDLE" NATURALSIZEFLAG="3"> <STRONG><A HREF="ftp://ftp.drugwatch.org/pub">Document
Index and FTP site</A></STRONG><BR>
<P><CENTER><IMG SRC="../Images/dwbar.gif" WIDTH="468" HEIGHT="12" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><BR>
<BR>
<A HREF="http://www.hassela.se/hassela"><IMG SRC="../Images/hnnlogo.GIF"
BORDER="../Images/dwbckgrnd.GIF" WIDTH="144" HEIGHT="145" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"></A></CENTER>
<P>Visit <A HREF="http://www.hassela.se/hassela">HASSELA NORDIC NETWORK
and HASSELA. </A>- a politically and religiously independent network for
international exchange of theoretical ideas and suggestions for practical
action to maintain a restrictive drugs policy and prevent the legalisation
of illicit drugs. <BR>
<P><CENTER><IMG SRC="../Images/dwbar.gif" WIDTH="468" HEIGHT="12" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"></CENTER>
<P>Click here to send E-mail to Drug Watch International: <A HREF="mailto:DrugWatch6@aol.com">Drug
Watch mail center</A><BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-117</DOCNO>
<DOCOLDNO>IA077-000520-B048-137</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/drugfx.html 207.112.150.94 19970124112414 text/html 563
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:23:58 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 393
Last-modified: Mon, 16 Dec 1996 23:32:31 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>The Effects of Marijuana and other Drugs</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>The Effects of Marijuana and other Drugs</CENTER>
</H1>
<BR>
<BR>
<A HREF="Documents/DWJL02.html"><IMG SRC="../Images/FIRE01.GIF" WIDTH="25"
HEIGHT="25" NATURALSIZEFLAG="0" ALIGN="MIDDLE"></A> Dr. Janet Lapey's Marijuana
Update 1996. <BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-118</DOCNO>
<DOCOLDNO>IA077-000520-B048-257</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/hr.html 207.112.150.94 19970124112506 text/html 1277
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:24:47 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 1106
Last-modified: Tue, 29 Oct 1996 17:31:54 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DW Harm Reduction Page</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>Harm Reduction and Minimization</CENTER>
</H1>
<BR>
<A HREF="Documents/HRVSHP.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Susan Kaplin's
paper, &quot;Harm Reduction VS. Effective Prevention&quot;.<BR>
<BR>
<A HREF="Documents/DWDN1.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> &quot;Harm Reduction:
The Deadly Lie&quot;. An essay on harm reduction by David S. Noffs.<BR>
<BR>
<A HREF="Documents/DWHRPOS.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Drug Watch International's
position paper on harm reduction/minimization. <BR>
<BR>
<A HREF="Documents/DWAM.html"><IMG SRC="../Images/FIRE01.GIF" WIDTH="24"
HEIGHT="24" NATURALSIZEFLAG="0" ALIGN="MIDDLE"></A> Needle Exchange Programs
are among the most heavily promoted applications of<BR>
&quot;Harm Reduction.&quot;  A paper by Alan Markwood.
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-119</DOCNO>
<DOCOLDNO>IA077-000521-B001-80</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/le.html 207.112.150.94 19970124112643 text/html 1307
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:25:56 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 1136
Last-modified: Tue, 29 Oct 1996 17:31:58 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DW Law Enforcement Page</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>Drug Law Enforcement</CENTER>
</H1>
<BR>
<A HREF="Documents/CNOA.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>The California Narcotics
Association rebuttal of medical marijuana claims.<BR>
<BR>
<A HREF="Documents/DWKK.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> &quot;Without Question&quot;.
A paper on drug legalization by Keith M. Kaneshiro, Prosecuting Attorney,
Honolulu, Hawaii.<BR>
<BR>
<A HREF="Documents/DWLH.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> &quot;CRIMINAL BEGINNINGS:
The Use of Drugs&quot;. A letter on Drug Abuse from Lois Haight, Superior
Court Judge, Los Angeles, California.<BR>
<BR>
<A HREF="Documents/BP1.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> PAE Reports Preview.
&quot;The Success of Tough Drug Enforcement&quot; by Bob Peterson. 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-120</DOCNO>
<DOCOLDNO>IA077-000521-B001-210</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/mrr.html 207.112.150.94 19970124112733 text/html 2513
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:27:11 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 2342
Last-modified: Fri, 17 Jan 1997 07:34:54 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Marijuana Research Reviews</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>Marijuana Research Reviews</CENTER>
</H1>
<H3><CENTER>Marijuana Research Review is a publication of Drug Watch Oregon.<BR>
<BR>
<IMG SRC="../Images/Blackbar.GIF" WIDTH="468" HEIGHT="12" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"></CENTER>
</H3>
<A HREF="Documents/MRR11.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 1, No.1 February, 1994. <BR>
<BR>
<A HREF="Documents/MRR12.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 1, No.2 July, 1994. <BR>
<BR>
<A HREF="Documents/MRR13.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 1, No.3 October, 1994. <BR>
<BR>
<A HREF="Documents/MRR21.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 2, No.1 January, 1995. <BR>
<BR>
<A HREF="Documents/MRR22.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 2, No.2 March, 1995. <BR>
<BR>
<A HREF="Documents/MRR23.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 2, No.3 June, 1995. <BR>
<BR>
<A HREF="Documents/MRR24.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 2, No.4 September, 1995.<BR>
<BR>
<A HREF="Documents/MRR31.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 3, No.1 March, 1996<BR>
<BR>
<A HREF="Documents/MRR32.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 3, No.2, June, 1996<BR>
<BR>
<A HREF="Documents/MRR33.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Marijuana Research
Review. Volume 3, No.3, October, 1996<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-121</DOCNO>
<DOCOLDNO>IA077-000521-B001-272</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/mm.html 207.112.150.94 19970124112805 text/html 2075
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:27:52 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 1904
Last-modified: Tue, 29 Oct 1996 17:31:59 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DW Medical Marijuana Page</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>About Medical Marijuana</CENTER>
</H1>
<BR>
<A HREF="Documents/DWJL01.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;Marijuana
as Medicine Refuted by NIH Scientists&quot;. Dr. Janet Lapey reports on
recent findings from the National Institutes of Health. Published in the
Best of IDEA, Illinois. Fall, 1993. <BR>
<BR>
<A HREF="Documents/DWMM.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>This article published
in the Best of IDEA shows that no credible organization has supported Medical
Marijuana use. <BR>
<BR>
<A HREF="Documents/MJforAIDS.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;Marijuana
for AIDS Patients?...Think Again.&quot; From Drug Watch Oregon.<BR>
<BR>
<A HREF="Documents/MJforGlaucoma.html"><IMG SRC="../Images/dwbutton.GIF"
WIDTH="24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;GLAUCOMA.
Is Marijuana a Safe and Effective Treatment?&quot; From Drug Watch Oregon.<BR>
<BR>
<A HREF="Documents/DWBrookoff.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;MARIJUANA
IS NOT MEDICINE. SOMEBODY HAD BETTER TELL YOUR DOCTOR!&quot; by Dan Brookoff,
M.D., Ph.D. This <STRONG>must read</STRONG> article gives the hard facts
about medical marijuana use and enlightens readers about why some Harvard
Medical School professors may have come out in favor of it. <BR>
<BR>
<A HREF="Documents/CAMJINIT.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Dr. Janet Lapey's
paper regarding the 1996 California Marijuana Initiative. <BR>
<P><CENTER></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-122</DOCNO>
<DOCOLDNO>IA077-000521-B001-320</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/general.html 207.112.150.94 19970124112834 text/html 5885
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:28:29 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 5714
Last-modified: Sat, 21 Dec 1996 05:09:27 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DW Other Drug Issues and Papers</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>Drug Watch Issues and Papers</CENTER>
</H1>
<A HREF="Documents/BP2.html"><IMG SRC="../Images/FIRE01.GIF" WIDTH="25"
HEIGHT="25" NATURALSIZEFLAG="0" ALIGN="BOTTOM"></A> Bob Peterson's response
to a young web surfer's queries about drug legalization.<BR>
<BR>
<A HREF="Documents/Nahas.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Gabriel Nahas' paper
on Hemp, Marijuana and the Law.<BR>
<BR>
<A HREF="Documents/DWJG1.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Dr. Jack Gilligan's
paper, &quot;A Fork in the Road; Toward a Drug Free Culture&quot;. <BR>
<BR>
<A HREF="Documents/DWJL.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Dr. Janet Lapey's paper
on &quot;Drug Induced Violence&quot;. <BR>
<BR>
<A HREF="Documents/DWMGEAC.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;Drug Legalization.
What if?&quot; A commentary on the consequences of legalizing drugs for
communities by the Maryland Governor's Executive Advisory Council.<BR>
<BR>
<A HREF="Documents/DWER.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>May 13, 1996. A European
report from Renee Wikesjo, Drug Watch Sweden Delegate.<BR>
<BR>
<A HREF="Documents/DWBC.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;Let's Get Real&quot;.
Illinois' Director of Department of Alcoholism and Substance Abuse, Barbara
Cimaglio's views on the legalization of drugs. <BR>
<BR>
<A HREF="Documents/DWSH.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;For the Sake of
Our Children&quot;, by Stephanie Haynes, President, Drug Watch International.
Ms. Haynes points out in this article that, contrary to opinions from the
pro-legalization movement, the War on Drugs has NOT been lost! <BR>
<BR>
<A HREF="Documents/DWWR.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;The Dumbing of
America&quot; by Prevention Specialist, Wayne Roques. <BR>
<BR>
<A HREF="Documents/DWWR01.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;No Stampedes,
Please&quot;. An article on needle exchange programs by Wayne Roques, Prevention
Specialist. <BR>
<BR>
<A HREF="Documents/DWAMR.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;No, Drugs
Can Leave you Dead&quot;. An article written by A.M. Rosenthal on Drug Legalization.
<BR>
<BR>
<A HREF="Documents/DWDB.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;The Drug Dealer
Liability Act&quot;. From The Best of IDEA, Illinois Winter, 1993 by Dan
Bent, Esq. <BR>
<BR>
<A HREF="Documents/DWmisc1.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;Legalization:
Flawed Logic&quot;. Various quotes from professionals against the legalization
of drugs.<BR>
<BR>
<A HREF="Documents/DWJG2.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;Societal Meltdown&quot;
by Jack Gilligan, PhD. <BR>
<BR>
<A HREF="Documents/SK1.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Susan Kaplin's paper
on research used to block the UK &quot;Royal Commission on Cannabis&quot;
May, 1994.<BR>
<BR>
<A HREF="Documents/DWEA.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;Criticism of the
Experiments on Medical Prescription of Narcotics in Switzerland&quot; by
Dr.(med) Ernst Aeschbach (Lecture held at the Drug Conference in San Patrignano,
October 14, 1995). <BR>
<BR>
<A HREF="Documents/DWRC.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH="24"
HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>The &quot;shadow pushers&quot;
are the aging marijuana users and advocates who try to legitimize their
drug of choice and perpetuate their crusade to legalize marijuana. They
have embraced slick marketing and promotional techniques that target a new
generation of potential marijuana advocates. A paper by Rosanna Creighton.
<BR>
<BR>
<A HREF="Documents/Nahas.html"><IMG SRC="../Images/FIRE01.GIF" WIDTH="25"
HEIGHT="25" NATURALSIZEFLAG="0" ALIGN="MIDDLE"></A> A Manual on Drug Dependence
by Gabriel Nahas. <BR>
<BR>
<A HREF="Documents/dyktam.html"><IMG SRC="../Images/FIRE01.GIF" WIDTH="25"
HEIGHT="25" NATURALSIZEFLAG="0" ALIGN="MIDDLE"></A> Do You Know This About
Marijuana? <BR>
<BR>
<A HREF="Documents/DWCFpress.html"><IMG SRC="../Images/FIRE01.GIF" WIDTH=
"25" HEIGHT="25" NATURALSIZEFLAG="0" ALIGN="MIDDLE"></A> Houston's Drug-Free
Business Director Fears Results of Lenient Drug Policy. A paper by Calvina
Fay. <BR>
<BR>
<A HREF="Documents/Benzo.html"><IMG SRC="../Images/FIRE01.GIF" WIDTH="25"
HEIGHT="25" NATURALSIZEFLAG="0" ALIGN="MIDDLE"></A> Benzopyrene. Lung cancer
causing carcinogen more prevalent in marijuana than in tobacco.<BR>
<BR>
<A HREF="Documents/mj.html"><IMG SRC="../Images/FIRE01.GIF" WIDTH="25" 
HEIGHT="25" NATURALSIZEFLAG="0" ALIGN="MIDDLE"></A> Comparative analysis
of mainstream smoke from marihuana and tobacco reference cigarette. A report
by the National Academy of Sciences, Institute of Medicine.<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-123</DOCNO>
<DOCOLDNO>IA077-000521-B001-403</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/pp.html 207.112.150.94 19970124112906 text/html 1696
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:28:50 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 1525
Last-modified: Fri, 17 Jan 1997 07:34:45 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DW Position Papers</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>Drug Watch Position Papers</CENTER>
</H1>
<BR>
<A HREF="Documents/DWTPOS.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Drug Watch International's
position paper on Drug and Alcohol Treatment.<BR>
<BR>
<A HREF="Documents/DWDTPOS.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>To read Drug Watch
International's position statement on drug testing click here. <BR>
<BR>
<A HREF="Documents/DWPDUA.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Drug Watch Position
Paper on Drug User Accountability. An enlightening perspective on International
Policies on Drug User Accountability. <BR>
<BR>
<A HREF="Documents/DWNEPP.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Drug Watch Position
Paper on Needle Handout programs and their effects. <BR>
<BR>
<A HREF="Documents/DWHRPOS.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Drug Watch International's
position paper on harm reduction/minimization. <BR>
<BR>
<A HREF="Documents/ATPOS.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>Drug Watch International's
position paper on Alcohol and Tobacco as gateway drugs.
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-124</DOCNO>
<DOCOLDNO>IA077-000521-B002-26</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/rr.html 207.112.150.94 19970124112935 text/html 752
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:29:25 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 582
Last-modified: Sun, 19 Jan 1997 08:00:22 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Drug Watch Research Reviews and Updates</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>Drug Watch Research Reviews and Updates</CENTER>
</H1>
<P><CENTER><IMG SRC="../Images/dwbar.gif" WIDTH="468" HEIGHT="12" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><BR>
</CENTER>
<P><A HREF="Documents/DWEA2.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A> On the Scientific
Value of the Research Studies Accompanying Heroin Distribution...<BR>
A Critique. by Ernst Aeschbach, M.D.
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-125</DOCNO>
<DOCOLDNO>IA077-000521-B002-86</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/mr.html 207.112.150.94 19970124113003 text/html 763
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:29:55 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 593
Last-modified: Tue, 29 Oct 1996 17:32:01 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DW Media Releases </TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>Media Releases</CENTER>
</H1>
<BR>
<A HREF="Documents/HNNPress87.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> HNN Sweden's media
release regarding medical marijuana sales at the Cannabis Buyers' Club.<BR>
<BR>
<A HREF="Documents/DWPress92.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Drug Watch media
release on the Cannabis Buyers' Club.<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-126</DOCNO>
<DOCOLDNO>IA077-000521-B002-268</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/tl.html 207.112.150.94 19970124113105 text/html 817
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:30:40 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 647
Last-modified: Tue, 29 Oct 1996 17:32:06 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DW Truth and Lies Page</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>Truth and Lies</CENTER>
</H1>
<BR>
<A HREF="Documents/Med_Marijuana_Paper.html"><IMG SRC="../Images/dwbutton.GIF"
WIDTH="24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Drug Watch
International's &quot;Truth and Lies&quot; about medical marijuana use.
<BR>
<BR>
<A HREF="Documents/DUATL.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Drug Watch International's
&quot;Truth and Lies&quot; about drug user accountability. <BR>
<P><CENTER></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-127</DOCNO>
<DOCOLDNO>IA077-000521-B002-430</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/press.html 207.112.150.94 19970124113156 text/html 1501
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:31:34 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 1330
Last-modified: Tue, 29 Oct 1996 17:32:05 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>World News and Editorials</TITLE>
</HEAD>
<BODY BACKGROUND="../Images/dwbckgrnd.GIF">
<H1><CENTER>World News and Editorials</CENTER>
</H1>
<A HREF="Documents/Reuters.html"><BR>
</A><A HREF="Documents/Reflections.html"><IMG SRC="../Images/FIRE01.GIF"
WIDTH="30" HEIGHT="30" NATURALSIZEFLAG="0" ALIGN="MIDDLE"></A> General David
Perlman's reflections on a lifetime of military service and the War on Drugs.
<A HREF="Documents/Reuters.html"><BR>
<IMG SRC="../Images/dwbutton.GIF" WIDTH="24" HEIGHT="24" ALIGN="MIDDLE"
NATURALSIZEFLAG="3"></A> The Dutch get tough on drugs...a report from Reuters.
<BR>
<BR>
<A HREF="Documents/VOTHED.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> Eric Voth's provocative
editorial in the New York Times about the drug legalization. movement.<BR>
<BR>
<A HREF="Documents/DSNTRIB.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A>&quot;Drug War Insights&quot;
An editorial by David Noffs published in the Chicago Tribune.<BR>
<BR>
<A HREF="Documents/TRIBMFUZ.html"><IMG SRC="../Images/dwbutton.GIF" WIDTH=
"24" HEIGHT="24" ALIGN="MIDDLE" NATURALSIZEFLAG="3"></A> &quot;Mental fuzziness
linked to marijuana&quot;, the Chicago Tribune reports.<BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-128</DOCNO>
<DOCOLDNO>IA077-000521-B003-196</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWJL02.html 207.112.150.94 19970124113313 text/html 7883
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:32:50 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 7712
Last-modified: Tue, 29 Oct 1996 17:29:36 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Marijuana Update 1996 by Janet D. Lapey, MD </TITLE>
</HEAD>
<BODY>
<H3><CENTER>MARIJUANA UPDATE 1996 by Janet D. Lapey, M.D.</CENTER>
</H3>
Marijuana causes many mental disorders, including acute toxic psychosis,
panic attacks, flashbacks, delusions, depersonalization, hallucinations,
paranoia, depression, and &quot;uncontrollable feelings of aggression.&quot;
(1) <BR>
<BR>
Increased aggressive behavior after smoking marijuana has been reported
in inner city males. (2) <BR>
<BR>
Marijuana has long been known to trigger attacks of mental illness, such
as bipolar (manic-depressive) psychosis and schizophrenia. It has been shown
that marijuana users are six times more likely to develop schizophrenia
than are non-users. (3) <BR>
<BR>
Marijuana use is associated with the development of Amotivational Syndrome.
(4) <BR>
<BR>
&quot;Often the relationship of impairments and symptoms to marijuana use
becomes evident only when the user is persuaded to stop, shows clear-cut
improvement in mood and behavior, and describes a feeling of coming out
of a fog.&quot; (5) <BR>
<BR>
Marijuana impairs perception, judgment, thinking, memory, and learning.
Memory defects may persist six weeks after last use. (6) <BR>
<BR>
Mental disorders caused by marijuana (cannabis) listed in the Diagnostic
and Statistical Manual of Mental Disorders (DSM) IV, published by the American
Psychiatric Association May 1994 include: Cannabis Dependence; Cannabis
Abuse; Cannabis Intoxication (impaired motor coordination, anxiety, impaired
judgment, sensation of slowed time, social withdrawal), often includes perceptual
disturbances; Cannabis Intoxication Delerium (memory deficit, disorientation);
Cannabis Induced Psychotic Disorder, Delusions; Cannabis Induced Psychotic
Disorder, Hallucinations; Cannabis Induced Anxiety Disorder; other Cannabis-Related
Disorders. <BR>
<BR>
Marijuana causes both dependence and addiction. &quot;Marijuana is an addictive
drug...Addictive use is defined by compulsive, repeated use in spite of
adverse consequences. Marijuanas effects include tolerance, leading to dependence,
and then inability to cease use.&quot; (7) <BR>
<BR>
In many parts of the country, there are more people admitted to drug treatment
centers because of marijuana addiction than heroin addiction. (8) <BR>
<BR>
A withdrawal syndrome occurs, consisting of &quot;anxiety, depression, sleep
and appetite disturbances, irritability, tremors, diaphoresis, nausea, muscle
convulsions, and restlessness.&quot; (9) <BR>
<BR>
Since marijuana impairs coordination, perception, and judgment, it is the
cause of many accidents. A study of 1023 trauma victims revealed that marijuana
had been used by 34.7%; alcohol had been used by 33.5%.(10) <BR>
<BR>
This is similar to a 36.8% incidence of marijuana use reported in fatally
injured drivers in California.(11) <BR>
<BR>
A study of 182 fatal truck accidents revealed that 12.8% of the drivers
had used marijuana, 12.5% alcohol, 8.5% cocaine, 7.9% stimulants. (12) <BR>
<BR>
A roadside study of reckless drivers not believed to be impaired by alcohol
found that 45% tested positive for marijuana. (13) <BR>
<BR>
The effects of marijuana, which is fat-soluble, persist much longer than
the effects of alcohol, which is water soluble. An experiment on pilots,
using a computerized flight simulator, showed that their ability to land
a plane was still impaired 24 hours after smoking a single marijuana cigarette.
(14) <BR>
<BR>
The use of marijuana during pregnancy is associated with babies of low birth
weight. (15) <BR>
<BR>
Also, there is evidence that such infants will show intellectual impairment
a decade or more later. (16) <BR>
<BR>
Children exposed to marijuana prenatally have increased behavioral problems;
they have decreased visual perception, language comprehension, attention
span and memory. (17) <BR>
<BR>
Babies born to mothers who use marijuana during pregnancy have an eleven-fold
increase in nonlymphoblastic leukemia. (18) <BR>
<BR>
In males, marijuana diminishes testosterone production and lowers sperm
counts. In females, marijuana disrupts hormone cycles. (19) <BR>
<BR>
Studies have shown that marijuana is mutagenic and impairs DNA synthesis.
(20) <BR>
<BR>
Marijuana smoke produces airway injury, acute and chronic bronchitis, lung
inflammation, and decreased pulmonary defenses against infection. Smoking
one marijuana cigarette leads to airway deposition of four times as much
cancer-causing tar as does tobacco smoke. (21) <BR>
<BR>
Recently, there have been cases of cancer reported in young marijuana smokers,
including cancer of the mouth, tongue, larynx, jaw, head, neck, and lungs.
(22) <BR>
<BR>
Marijuana causes impairment of the white blood cells which fight infections.
(23) <BR>
<BR>
Marijuana use decreases resistance to diseases such as herpes. (24)<BR>
<BR>
Marijuana smokers have increased outpatient visits for respiratory illnesses,
accidents, and other illnesses. (25) <BR>
<BR>
The use of marijuana tends to lead to the use of other drugs. 20% of persons
who use marijuana 3-10 times go on to use cocaine; 75% of persons who use
marijuana 100 or more times go on to use cocaine. (26) <BR>
<BR>
Non-marijuana users virtually never become cocaine users. In Alaska, when
marijuana use was decriminalized, use by Alaskan youth of both marijuana
and cocaine became the highest in the nation. The National Survey of High
School Seniors showed that whereas nationally 17% of seniors had used marijuana
in the past month, the Alaskan rate was 45%. The Alaskans then sensibly
recriminalized marijuana use in 1990. 
<DL>
  <DT>1. Schwartz RH. Pediatric Clinics of North America 34:305-317, 1987.
  <DT>2. Cherek DR et al. Psychopharmacology 111:163-168, 1993. 
  <DT>3. Andreasson S et al. Lancet 2:1483-1485, 1987. 
  <DT>4. Schwartz RH, op.cit. 
  <DT>5. Jaffe JH. Drug Dependence. In Kaplan HI, Saddock BJ eds, Comprehensive
Textbook of Psychiatry, Baltimore: Williams &amp; Wilkins, 1989. 
  <DT>6. Schwartz RH et al. Am J Dis Child 143:1214-1219, 1989. 
  <DT>7. Gold MS. Marijuana, NY:Plenum Medical Book Co., p. 227, 1989. 
  <DT>8. Office of National Drug Control Policy. Pulse Check, December 1994.
  <DT>9. Gold MS. op. cit. p. 103. 
  <DT>10. Soderstrom CA et al. Archives of Surg 123:733-737, 1988. 
  <DT>11. Williams AF et al. Public Health Report 100:19-25, 1985. 
  <DT>12. Department of Transportation. National Transportation Safety Board
Report, Washington DC, February 5, 1990. 
  <DT>13. Brookoff D et al. New Eng J Med 331:518-522, 1994. 
  <DT>14. Leirer VO et al. Aviat Space Environ Med 62:221-227, 1991. 
  <DT>15. Zuckerman B et al. New Eng J Med 320:762-768, 1989. 
  <DT>16. Shalala DE. Say No to Legalization of Marijuana. The Wall Street
Journal, August 18, 1995. 
  <DT>17. Fried PA. Life Sciences 56:2159-2168, 1995. 
  <DT>18. Robison LL et al. Cancer 63:1904-1910, 1989. 
  <DT>19. Gold MS. op. cit. p. 69-71. 
  <DT>20. Nahas G et al. Med J Austr 156:495-497, 1992. 
  <DT>21. Tashkin DP. West J Med 158:635-637, 1993. 
  <DT>22. Donald PJ Otolaryn Head &amp; Neck Surg 94:517-521, 1986. Ferguson
RP et al. JAMA 261:41-42, 1989. Taylor FM. South Med J 81:1213-1216, 1988.
Donald PJ. Adv Exp Med Bio 288:33-46, 1991. 
  <DT>23. Spector S et al. Adv Exp Med Bio 288:47-56, 1991. Djeu J et al.
Adv Exp Med Bio 288: 57-62, 1991. Watzl B et al. Adv Exp Med Bio 288: 63-70,
1991. Cabral GA et al. Adv Exp Med Bio 288: 93-105, 1991. 
  <DT>24. Cabral GA et al. Proc Soc Exp Bio Med 182:181-186, 1986. 
  <DT>25. Polen MR et al West J Med 158:596-601, 1993. 
  <DT>26. Kleber HD. J Clin Psych 49:2(Suppl), p. 3-6, 1988.
</DL>
From Drug Watch International September 1996 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-129</DOCNO>
<DOCOLDNO>IA077-000521-B004-2</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/HRVSHP.html 207.112.150.94 19970124113447 text/html 17216
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:34:37 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 17044
Last-modified: Tue, 29 Oct 1996 17:30:40 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> Harm Reduction VS. Harm Prevention </TITLE>
</HEAD>
<BODY>
<H3><CENTER>THE EFFECTS OF HARM REDUCTION VS HARM PREVENTION: AN INTERNATIONAL
ASSESSMENT </CENTER>
</H3>
<H4><CENTER>Susan Kaplin May, 1994 </CENTER>
</H4>
Although the term &quot;Harm Reduction&quot; is applied more generally,
it has its roots in and is applicable to treatment. Harm reduction has some
use in treatment; hopefully while working toward the goal of stopping drug
use. To attempt anything less is a disservice to individuals, families,
communities, and society. Although it is said that harm reduction covers
a continuum of approaches ranging from prohibition/abstinence to legalization,
most harm reduction approaches focus on the &quot;safer&quot; uses of drugs
where drug-taking behaviors fall on a continuum with differing levels of
danger. <BR>
<BR>
Therefore, harm reduction is not appropriate for use in primary prevention,
since primary prevention focuses on avoiding drug use since any use of drugs
affects the body, which can lead to harm. This includes both legal and illegal
drugs. It is especially important to remember that harm reduction is not
appropriate with young (underage) children since it is illegal for them
to get/use legal drugs (e.g. cigarettes and alcohol), in addition to illicit
drugs. <BR>
<BR>
There are four studies which have examined the effects of the &quot;harm
reduction&quot; policy of the Netherlands on drug taking: <BR>
<BR>
1. &quot;The Dutch Drug Policy: A Physician's Commentary&quot; (Karel Frederick
Gunning, M.D., 1993). Conclusions: The availability and sale of cannabis
in Dutch coffee shops has been associated with an increase in its social
acceptability and use among adolescents as a &quot;soft&quot; drug. The
&quot;harm reduction&quot; Dutch policy of containing heroin addiction through
distribution of free needles and syringes and through methadone distribution
has not prevented the spread of heroin addiction, curtailed drug-related
crime, nor has it proven to decrease the level of HIV infection. <BR>
<BR>
2. &quot;DrugReform: TheDutchExperience&quot; (RichardR. Schwartz, 1993).
Conclusions: The Dutch policy has been associated with a progressive increase
in cannabis use among 15-19 year olds (from 4% in 1984 to over 8% in 1989).
Between 1984 and 1988, the use of cannabis increased by almost 100% among
upper high school students in the Netherlands. The policy of &quot;harm
reduction&quot; has not prevented a steady and significant rise in drug
addiction (cannabis, cocaine and opiates) among 15-19 year olds and young
adults. <BR>
<BR>
[These two reports are presented in &quot;Cannabis: Physiopathology, Epidemiology,
Detection&quot; (CRC Press, London, 1993).] <BR>
<BR>
3. The Dutch Institute on Alcohol and Drugs questioned 8,000 young people
and also found that the percentage of students smoking cannabis has more
than doubled in four years (from 3% in 1984 to 7% in 1988). (Guardian, 9
November 1993). <BR>
<BR>
4. The Council of Europe, Pompidou Group Survey of 1990 showed that there
was a doubling of cannabis use among 15 and 16 year olds after the laws
were relaxed. The number of retail outlets or cafes, where cannabis products
are sold, has risen from 30 to 1,500. (Lambton Families in Action Newsletter,
Fall 1993) <BR>
<BR>
After visiting Amsterdam to learn more about the Dutch drug policy, the
Scottish Affairs Committee documented important problems with this policy.
Drug policy guidelines have been violated in many coffee shops selling cannabis:
stocking amounts over the 30 gms limit, selling alcohol and other (&quot;harder&quot;)
drugs and advertising (Scottish Affairs Committee, House of Commons &quot;Drug
Abuse in Scotland, Volume I, &quot; 1994). It was reported that &quot;the
guidelines are clearly being flouted despite the more rigorous enforcement
which was supposed to have taken place over the last year. Since May 1993,
we were told by the Justice Ministry officials that 60 coffee shops had
been closed down, 14 of them on the grounds that they permitted hard (sic)
drugs to be sold on the premises&quot;. <BR>
<BR>
The Scottish Committee also described Amsterdam as &quot;an important centre
for the import and export drugs of all categories and along with the Crown
Office, we believe that the Dutch toleration of soft (sic) drugs has had
a role to play in this unwelcome development&quot;. Recently, it has been
noted that a new type of cannabis (&quot;skunk&quot;) has been developed
in the Netherlands that has a much larger THC component and this has now
been found in the U.K. (Home Office, 1994). Amsterdam is seeing an increase
in crime and it has been written that it has one of the highest crime rates
among European cities. Police are experiencing difficulty in handling this
crime and the general increase in, and visibility of, other drug use such
as heroin. Citizens are also objecting to the increased visibility of heroin
use, especially those people who have children who are exposed to this sight.
<BR>
<BR>
Other countries have had an increase in drug use and related social problems
when drug laws and policies were made more lenient. In England, drug-related
crime has risen in regions adopting harm reduction strategies (including
cautions for some drug offenders, registration of addicts, methadone and
needle exchange programmer). For example, the cost of drug-related crime
in the Metropolitan Police area is 1.85 billion each year (1992). In Wigan,
England, it has been estimated that drug-related crime costs victims 7
million per year. More than half the crimes committed in the borough are
thought to be carried out by drug abusers in order to fund their addictions
(1993). U.K. government sources have stated that legalizing drugs will not
lower crime because those who desire drugs will still require the money
for these drugs. &quot;So those who currently resort to stealing will continue
to do so. Furthermore, since the drug would be more easily available, demand
would increase and so, arguably, would theft&quot;. (Kenneth Baker, &quot;Why
We Cannot Go Soft on Drugs,&quot; June 1991). <BR>
<BR>
In Liverpool, England, ten years ago, a small number of people were injecting
drugs. With the uncontrolled issuing of syringes, the number of people injecting
drugs increased dramatically. (South Liverpool Family Support Group). <BR>
<BR>
Spain's change to a lenient drug policy resulted in a tremendous increase
in drug use and crime, including trafficking (cocaine, heroin and other
drugs). <BR>
<BR>
Places that have tried decriminalization or legalization have either rescinded
liberalized laws or are currently rethinking them based on the increase
of crime and other social problems that appear to have occurred as a result
of more lenient laws regarding cannabis use. Police in Alaska supported
decriminalization in 1975 primarily because they believed that crime would
decrease. However, by monitoring the situation over time, in 1990 it was
shown that there was a major increase in cannabis use and problem use: up
to twice the national average in both categories. Use of all other drugs
increased. Health and social costs also increased drastically. Most importantly,
the main argument for decriminalization that is also occurring in the UK
(that crime would decrease) was disproved as crime increased. Whether or
not there was a direct cause and effect relationship between cannabis decriminalization
and the increase in crime, decriminalization was seen to have failed. In
seeing this failure, the police who had initially supported decriminalization
fully supported rescinding the law. (Drug Prevention: Just Sav Now, Stoker).
<BR>
<BR>
In early 1992, Zurich, Switzerland ended its four year experiment with designating
a park a &quot;police-free harm reduction area&quot;. In this park, drug
users were allowed to deal and use and dealers &quot;commuted&quot; from
Turkey and Lebanon. Drug users in the park increased dramatically and came
in from other parts of the world. Food and needles were distributed, as
many as 12,000 needles a day. However, three to four users died each night
and crime rose enormously. In one year, drug-related deaths doubled and
this city has one of the highest drug abuse and AIDS rates in Europe. Swiss
officials admitted that harm-reduction had failed and thus, this experiment
was ended. Although ended, there were still costs to the drug users and
society that remain after this four year period ended. (Stoker). <BR>
<BR>
In comparison, Sweden has by tradition had a restrictive drug policy. However,
there was once a short period (1965-1967) when a more permissive drug policy
was in operation. During this period, a number of doctors were allowed to
prescribe drugs (stimulants, opiates) to addicts. Though drugs were legally
obtained, this permissive policy was seen to increase the amount of drugs
on the black market and criminal activity among the addicts. Because of
this, the government returned to a restrictive drug policy by the end of
the 1960s. This policy has been maintained and reinforced since then. Swedish
studies have shown that there has been a steady decline in the proportion
of young people reporting that they have ever tried narcotics (from a maximum
of 15% in 1971 to 4% in 1991) (Allebeck). In 1988, Professor Nils Bejerot,
The Carnegie Institute, Stockholm reported that a restrictive drug policy
not only halts the spread of addiction but also makes considerable reductions
in the rate of current drug use. In contract, a permissive drug policy leads
to &quot;a rapid spread of drug use&quot; [Allebeck and Bejerot's reports
are presented in &quot;Cannabis: Physiopathology, Epidemiology, Detection&quot;
(CRC Press, London, 1993)]. <BR>
<BR>
Harm reduction, through its acceptance and &quot;normalization&quot; of
drug use actually sets in motion the increased use of drugs in society.
There are no studies showing that harm reduction has decreased drug use.
<BR>
<BR>
In the recent report from the Scottish Affairs Committee, House of Commons
(&quot;Drug Abuse in Scotland, Volume 1,&quot; 1994), it is clearly stated
that harm reduction should not be applied to schools and children indiscriminately
because it is not appropriate for them. It is believed that using a harm
reduction approach on all young people would be &quot;totally counter-productive&quot;.
<BR>
<BR>
The Committee also takes a firm stand on the proven harm of cannabis and
state that &quot;the lesson of history is that the dangers of a drug are
more often under-estimated than over-estimated&quot; (eg the harm of smoking
tobacco and that &quot;heroin itself was originally developed as a non-addictive
substitute for morphine&quot;). They also cite cannabis as a gateway drug
(as well as cigarettes and alcohol) and state that &quot;the greater the
prevalence of cannabis use, the greater the risk will be that more young
people will enter into a drug taking subculture and develop a serious drug
problem&quot;. <BR>
<BR>
Based on the Scottish Committees' experience in assessing the Dutch drug
policy (described earlier in this paper), they state &quot;we are totally
opposed to any experimentation with the Dutch approach to cannabis in Scotland&quot;.
They note that &quot;at a time when Scotland faces a massive drug problem
we believe that any move to decriminalize cannabis would send the wrong
signal to young people. As the Association of Directors of Social work put
it to us: There comes a point where you have to draw the line somewhere
and if you keep moving the line practice suggested that people's behavior
will move to wherever you draw the line&quot;. <BR>
<BR>
In fact, the Scottish Committee does not believe that the fight against
drug trafficking is being hampered by the diversion of police resources
to a vast number of minor cannabis offenses and that fiscal fines, when
applied to minor cannabis offenses, should act as credible deterrents. <BR>
<BR>
The socio-economic costs of drug use are high. For example, in the U.K.
in 1992, it was estimated that alcohol and other drug use costs industry
3 billion pounds each year (1992). <BR>
<BR>
However, the costs of providing prevention are low and the results of research
show that prevention, not harm reduction, works in halting potential drug
users. In the U.S.A. young people who have been the focus of prevention
programs were found to use less alcohol and other drugseachyearbetweenl979andl991.
(NIDA,199ISurvey). Twenty-fivemillionAmericans who will not use drugs in
the next month might have if it were not for prevention (&quot;Alcohol,
Tobacco and Other Drug Prevention and Prevalence: A White Paper,&quot; 1993,
Social and Health Services Inc.). The amount of money spent each year on
health care in the U.S.A. could be reduced by $90.4 billion if alcohol and
other drug problems were prevented (U.S. Department of Health and Human
Services, 1985). <BR>
<BR>
More than twenty research studies evaluating prevention programs based on
personal and social skills training have demonstrated significant reductions
in substance use (typically cigarettes). <BR>
<BR>
Reductions in the onset of smoking ranged from 42% - 75%. Alcohol and marijuana
use have also been significantly reduced. Results across studies were consistent
and effects generally lasted for at least two years aRer post-testing. <BR>
<BR>
Research into Life Skills Training has shown that it significantly reduces
the use of cigarettes, alcohol and marijuana (by 50% - 83%) when used with
12 and 13 year olds. The positive effects from this programming apply to
various population types and may last for at least two years after the conclusion
of the program. <BR>
<BR>
A study of drug prevention (Project Alert, aimed at cigarettes, alcohol
and marijuana) by the Rand Corporation (1990) tracked 6,500 12 year old
children from 30 schools over a period of three years. Students in the program
were one-third less likely to try marijuana than the control group students.
The number of children wo experimented with marijuana was reduced by 50%.
For students who tried cigarettes, the program reduced smoking from 30%
- 50%. <BR>
<BR>
In 1990, the long-term impact (over a period of eight years) of the &quot;I'm
Special&quot; (ISP) drug abuse prevention program for primary school students
(8-10 year olds) was assessed in America. The study showed that a lower
percentage of the ISP students used alcohol, cigarettes, marijuana and other
drugs. They also had a lower incidence of other problem behavior than did
non-ISP students. <BR>
<BR>
A long-term study looking at the PRIDE prevention program (for youth and
parents) over five years found that there has been a continuous decrease
in use of all substances by almost all age groups (the younger children
have smaller percentages of use and as such, the changes may not be statistically
significant). One example is that cannabis use by 16-17 year olds has decreased
from 45% to 30%. <BR>
<BR>
In the U.K., an evaluation of the Brigantia Smoking Prevention Prograrn
has shown a reduction in experimental smoking in 9-1 1 year olds. A study
of another UK program, the &quot;My Body Project&quot; also showed a reduction
in experimental smoking. <BR>
<BR>
A community program which included social resistance training and normative
influences modification with 10-13 year old was effective in reducing cigarette
and marijuana use prevalence. These effects are still very strong aRer three
years and during the ages when youth are more apt to use drugs. <BR>
<BR>
The school setting has also been shown to be an effective site for prevention
programs. Drug use risk factors have been reduced, while skills for coping
with social pressures/influences to smoke, drink or use other drugs have
increased. Programs in schools that include cognitive and behavioral skill
building have been successful in preventing the start of drug use. (Prevention
research information from &quot;Evaluation Studies Supporting the Successes
of Drug Prevention,&quot; October 1993. All reference materials are cited
in this report). <BR>
<BR>
Also, in Ontario, Canada prevention has had a major impact on adolescent
drug use which has declined steadily from 32% in 1979 to 14% in 1991. (Lambton
Families in Action, Newsletter, Fall 1993). <BR>
<BR>
With the widening chasm between treatment and prevention theories, a vacuum
has been created. This vacuum is increasingly being filled by applying treatment
theory's harm reduction strategy to the prevention field. Harm reductionists
have claimed that prevention and the &quot;war on drugs&quot; have not worked,
despite the multitude of studies which clearly show that prevention programs
for young people do work. Instead, harm reductionists believe drug use is
&quot;inevitable&quot; and young people need to be educated on ways to make
their own drug use &quot;safer&quot;. While it has been shown that prevention
does work, there is no evidence of the effectiveness of harm reduction.
<BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-130</DOCNO>
<DOCOLDNO>IA077-000521-B004-64</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWDN1.html 207.112.150.94 19970124113514 text/html 3789
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:35:06 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 3618
Last-modified: Tue, 29 Oct 1996 17:29:06 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> Harm Reduction: The Deadly Lie by David Noffs </TITLE>
</HEAD>
<BODY>
<H3><CENTER>HARM REDUCTION: THE DEADLY LIE</CENTER>
</H3>
<P><CENTER></CENTER>
<H4><CENTER>David S. Noffs Founder, Executive Director, Life Education Centers,
USA Founder, Past President, Drug Watch International </CENTER>
</H4>
A new and well organized group of drug pushers have taken to the streets
of some of the world's major cities in an apparent attempt to sustain a
drug market that has felt the impact of over a decade of prevention efforts
worldwide. They have engaged communities in debating the legal aspects of
drug use and skillfully avoided any discussion around the consequences,
whether physical, emotional, or spiritual, of the user or their family and
friends. In so doing, they have managed to recruit some well respected citizens
in their drug promotion efforts. <BR>
<BR>
These pushers of the '90s call themselves &quot;Harm Reductionists,&quot;
an appropriately Orwellian title, considering their main pastime is the
promotion of &quot;responsible&quot; drug use among the world's young people.
They believe that primary prevention programs have failed in their efforts
to prevent drug use among young people and that legislators have wrongfully
declared drug users criminals. To the Harm Reductionists, drug use is a
normal part of adolescence, has always been practiced by humans, and will
always be a human form of expression. They say, therefore, that we should
teach young people how to use drugs responsibly, rather than be endlessly
frustrated in our attempts to stop drug use. <BR>
<BR>
Harm Reductionists point to a range of symptoms from this intolerance to
drug use in our culture. Prohibition is their choice weapon to impress upon
us the futility and negative consequences of drug criminalization. They
believe organized crime, corruption, the spread of disease (in particular
AIDS), and the massive drug cartels are the fruits of our labor when we
make drugs illegal in our society. Their claims are convincing to many and
they back them up further with impressive sounding surveys and research
coming out of prestigious educational institutions, failing to explain that
they conducted the surveys themselves and that their research has been challenged
by the medical community, health organizations and research foundations.
<BR>
<BR>
Furthermore, Harm Reductionists believe drug use is actually beneficial
to individuals and is an essential part of an adolescent's initiation into
adulthood. To them, drug use is a positive expression of a young person's
individuality and freedom to explore the limits of their mental, physical,
and spiritual being. To Harm Reductionists, society should grant this right
to explore without fear of moral judgment or imprisonment, while teaching
young people how far they can go on this flight to freedom. <BR>
<BR>
Harm Reductionists ignore the human face of drug addiction. They do not
frequent AA or NA meetings, nor do they visit outpatient wards or drug crisis
centers. Their world is the conference podium, curriculum committee, or
an office somewhere far from those other &quot;uneducated&quot; drug pushers.
Tragically, Harm Reductionists target the innocence of children. <BR>
<BR>
Beware the Harm Reductionists or Minimizers or any other variations of these
clever drug pushers. When they come to your hometown, as they surely will,
challenge them. Above all, remember that, despite their arguments, prevention
is working . . . the Harm Reduction movement is proof! <BR>
<BR>
From The Best of IDEA, Illinois. Winter, 1993 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-131</DOCNO>
<DOCOLDNO>IA077-000521-B004-124</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWHRPOS.html 207.112.150.94 19970124113539 text/html 4142
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:35:32 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 3971
Last-modified: Tue, 29 Oct 1996 17:29:21 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> DW Position Statement on Harm Reduction </TITLE>
</HEAD>
<BODY>
<H2><CENTER>Drug Watch International Position Statement on Harm Reduction</CENTER>
</H2>
Prevention and the elimination of harm, not &quot;Harm Reduction,&quot;
has the best potential for effectively addressing the drug problem. &quot;Harm
Reduction&quot; is a theory promoted by pro-drug advocates who hold that
society must learn to accept levels of use of psychoactive or addictive
drugs by adults and youth and teach them the &quot;responsible use&quot;
of these drugs to reduce the harm. Drug Watch International opposes this
theory of &quot;harm reduction&quot; and believes that no level of use of
marijuana, cocaine, and other harmful and illicit substances is acceptable.
<BR>
<H4>Background:</H4>
The term &quot;Harm Reduction&quot; was &quot;coined&quot; in Great Britain
by a group of individuals attempting to make the use of illicit drugs acceptable
to society. The basic premise is that the personal use of illicit drugs
should be legal, and can be made manageable and less harmful to the user.
The goal of &quot;Harm Reduction&quot; according to proponents, is to decrease
the negative consequences of drug use, rather than to decrease the prevalence
of drug use. Abstinence, they say, may neither be a realistic nor desired
goal. Some have utilized this theory as a method attempting to &quot;reduce&quot;
the spread of hepatitis among IV drug users. The onset of HIV infection
has given major impetus to this flawed concept. The &quot;Harm Reduction&quot;
concept has been incorporated into some treatment programs which allow for
continued drug use rather than working towards no drug use. It has also
made inroads into health programs and school curricula in Great Britain,
Australia, and Canada. <BR>
<H4>Rationale:</H4>
&quot;Harm Reduction&quot; interpretations range from the legalization of
some drugs, to decriminalization, to the legalization of all drugs. The
fallacy of &quot;Harm Reduction&quot; is that dangerous and addictive drugs
can safely be used if &quot;properly&quot; managed by the user or regulated
by government. <BR>
<BR>
&quot;Harm Reduction&quot; has no place in drug prevention. &quot;Harm Reduction&quot;
includes educational strategies used to teach &quot;responsible use&quot;
of drugs and convey that drug use is tacitly, if not openly, acceptable
regardless of the harmful effects of drugs. <BR>
<BR>
The &quot;responsible use&quot; or &quot;harm reduction&quot; approach to
drug use was attempted in the U.S. in the 1970's. The result was record
levels of drug use by young people, many of whom became the middle-aged
addicts of today. <BR>
<BR>
&quot;Harm Reduction&quot; proponents falsely claim that education and prevention
have failed. Prevention (no first drug use) programs, policies, and strategies
have caused a positive change in public attitudes about illicit drugs and
a significant decline in drug use, especially by youth. A social context
in which drug use is not accepted is essential in decreasing drug use. <BR>
<BR>
&quot;Harm Reduction&quot; ignores the proven physiological effects of drug
use. &quot;Harm Reduction&quot; is counterproductive to individuals with
addictive behavior. The most successful treatment programs are abstinence-based.
<BR>
<BR>
&quot;Harm Reduction&quot; policies in Europe resulted in a dramatic increase
in the number of drug users in the United Kingdom, the Netherlands, Switzerland,
Sweden and other countries. As a result, a number of European countries
returned to a restrictive drug policy when it became clear that lenient
drug laws had a negative effect on society. <BR>
<BR>
&quot;Harm Reduction&quot; proponents consider that legalizing drugs would
be the ultimate &quot;harm reduction&quot; for the drug user. For them,
the right to the personal use of psychoactive and addictive drugs supersedes
what is beneficial and healthy for the rest of society. 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-132</DOCNO>
<DOCOLDNO>IA077-000521-B004-206</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWAM.html 207.112.150.94 19970124113607 text/html 7733
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:36:03 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 7562
Last-modified: Tue, 29 Oct 1996 17:28:45 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Drugs, Needles, and Harm by Alan Markwood</TITLE>
</HEAD>
<BODY>
<H2><CENTER>DRUGS, NEEDLES, AND HARM</CENTER>
</H2>
<P><CENTER>by Alan Markwood<BR>
June, 1996</CENTER>
<P>Needle Exchange Programs are among the most heavily promoted applications
of<BR>
&quot;Harm Reduction.&quot;  The theory of &quot;Harm Reduction&quot; is
that drug use can be made more<BR>
safe, as an alternative to drug abstinence.  Needle Exchange Programs (NEPs)
seek to<BR>
prevent HIV infection by providing clean needles to intravenous users of
illegal drugs.<BR>
<BR>
NEP advocates claim that NEPs save lives by lowering HIV infection rates.<BR>
 Evaluation studies have been equivocal.  NEP opponents state that any apparent
positive results<BR>
are flawed, and a  Montreal study indicates NEP participants had higher
rates of HIV infection<BR>
than non-NEP addicts.<BR>
<BR>
Three common flaws are:<BR>
<BR>
(1)  Failure to separate effects of NEPs from effects of concurrent<BR>
interventions such as drug treatment and HIV/AIDS education.<BR>
(2)  Failure to monitor sickness, injuries, and deaths resulting from<BR>
continuation of drug use among NEP participants.<BR>
(3)  Failure to compare NEP effects to alternatives known to be effective,<BR>
particularly aggressive outreach and drug treatment.<BR>
<BR>
The true effects of NEPs may take many years to sort out.  Based on the<BR>
current state of knowledge, even the best designed and best administered
NEPs will probably be<BR>
found to increase drug deaths more than they decrease HIV infection, particularly
in<BR>
comparison to outreach and drug treatment.<BR>
<BR>
Given this dismal scenario, why are proponents and opponents of NEPs so<BR>
concerned and vociferous?  The reason is ideology.  &quot;Harm reduction&quot;
in general, and NEPs<BR>
in particular, is a major battleground between those of us who believe illicit
drug use to be an<BR>
anti-social act (due to drug-induced health problems, violence, negligent
injury, negligent<BR>
parenting, and destruction of pro-social values) versus those who believe
that drug use is merely a<BR>
lifestyle issue.<BR>
<BR>
A stunning example of how fully the drug culture permeates &quot;harm reduction&quot;<BR>
and NEPs appeared in a recent day-long workshop given by Mr. Dan Bigg, who
operates a major NEP<BR>
in Chicago. Printed material composed and distributed by Mr. Bigg clearly
presents drug<BR>
use as acceptable, unlike drug abuse, which he defines as drug use that
produces &quot;unwanted<BR>
harm.&quot;  In other words, until the user perceives harm to self or others,
use is acceptable.<BR>
Similarly, he defines recovery as &quot;Any positive change as a person
describes it for her/himself.&quot;<BR>
<BR>
Mr. Bigg's handout sheet titled &quot;Essential Ingredients of a Harm Reduction<BR>
Program&quot; starts with, &quot;Orientation toward the person seeking help
as the expert in the direction<BR>
and intensity of their own positive change(s).&quot;  Again, harm is only
that which is perceived by the<BR>
drug user.  Accordingly, another &quot;essential ingredient&quot; is &quot;Definitions
of program<BR>
completion and success that include the continued use of alcohol and other
drugs.&quot;  The point is clear.<BR>
Drug use is not aproblem unless the user decides it's a problem.<BR>
<BR>
Another handout from Mr. Bigg is titled &quot;Some Comparisons Between Typical<BR>
Drug Treatment and Substance Use Management.&quot;  What are these comparisons?
 For &quot;process,&quot;<BR>
typical drug treatment uses &quot;coercion&quot; while substance use management
uses<BR>
&quot;clarification.&quot;  For employers,&quot; typical drug treatment
employs &quot;drug-free workers,&quot; while<BR>
substance use management employs &quot;drug-abuse free workers.&quot;  For
&quot;outcome,&quot; typical drug<BR>
treatment aims for a &quot;drug-free state,&quot; while substance abuse
management aims for a &quot;happy,<BR>
productive, stable existence regardless of drug use.&quot;<BR>
<BR>
Another handout created and distributed by Mr. Bigg is titled &quot;Typical
Goals<BR>
of Substance Use Management (as selected by the person seeking help).&quot;
 Of the three goals<BR>
listed, two are covered briefly:<BR>
<BR>
* &quot;Abstinence:  As people freely define it for themselves (may include
one or<BR>
more drugs and be permanent or of a limited period.)&quot;<BR>
<BR>
* &quot;Improved:  Health, Relationships, Job Performance . . .&quot;<BR>
<BR>
The third goal, &quot;Developing and Enacting a Safer Use Plan,&quot; is
more<BR>
extensively discussed.  Sub-headings include &quot;Practicing Safer Drug
Use,&quot;  &quot;Preparing Yourself for Use,&quot; and &quot;Creating a
Safer Drug Use Environment.&quot;<BR>
<BR>
Other material distributed by Mr. Bigg continues along the same lines, as
did<BR>
comments he made in the course of the presentation.  A slide show included
demonstrations of<BR>
how to find good veins to inject, how to cook heroin, etc.<BR>
<BR>
This is all very disturbing, but perhaps most disturbing is the acceptance
of<BR>
&quot;harm reduction&quot; and NEPs by legitimate authorities.  Mr. Bigg
presented this material in Peoria,<BR>
Illinois on May 22, 1996, at a presentation sponsored by the local Health
Department, and widely<BR>
promoted by that department.  The presentation was accredited by the Illinois
Chapter of the<BR>
National Association of Social Workers, and by the Illinois Alcohol and
Other Drug Abuse<BR>
Professional Certification Association!  When I wrote to these three organizations,
I received no<BR>
response except from the credentialing association.  The Executive Director
pointed out that the<BR>
organization, &quot;doesn't endorse, support or approve the content of any
training.&quot;  The Director has<BR>
received &quot;numerous calls from Association members complaining about
his (Mr. Bigg's)<BR>
presentations and disagreeing with the content.&quot;  Still, they feel
the absurdity of the ideas speak for<BR>
themselves, without need for censorship by the Association.<BR>
<BR>
&quot;Harm reduction&quot; and NEPs are publicly promoted as having pragmatic
value,<BR>
but Mr. Bigg's presentation demonstrated that the defining characteristic
here is not a<BR>
concern for effective results, but a firm belief that drug use is fine.
 <BR>
<BR>
I would encourage all responsible persons and groups to disavow any support<BR>
for this.  I particularly believe that support for this so-called &quot;harm
reduction&quot;<BR>
movement is absolutely incompatible with legitimate drug abuse prevention
and treatment entities.<BR>
Because of the support &quot;harm reduction&quot; has already received,
active opposition is needed<BR>
from those of us who believe that illegal drug use IS an anti-social act.<BR>
<BR>
 * * * * * * * * * *<BR>
<BR>
Alan Markwood has been an InTouch Prevention Area Coordinator since 1987,<BR>
serving nine Illinois counties as part of the statewide prevention coordinating
system.<BR>
He was trained as a School Psychologist.  He earned  his M.A. from Alfred
University in 1977 and<BR>
worked in School Psychology in Illinois and Massachusetts until coming to
InTouch.  He earned<BR>
a Certificate of Advanced Graduate Study at Boston University's School of
Education and is a<BR>
Nationally Certified School Psychologist.<BR>
<BR>
 * * * * * * * * * *<BR>
<BR>
The above article is printed with permission of the author, whose research,<BR>
expertise, and viewpoint is being communicated as a public service.<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-133</DOCNO>
<DOCOLDNO>IA077-000521-B004-319</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/CNOA.html 207.112.150.94 19970124113657 text/html 11246
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:36:26 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 11074
Last-modified: Tue, 29 Oct 1996 17:28:36 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>CNOA Position Paper</TITLE>
</HEAD>
<BODY>
The following document has been written by the California Narcotics Officers
Association. Drug Watch International supports the efforts of Californians
to defeat the California Marijuana Initiative 1996.<BR>
<H3><CENTER>Position Paper</CENTER>
</H3>
<H1><CENTER>Use of Marijuana as a &quot;Medicine&quot;</CENTER>
</H1>
<BR>
There currently exists some controversy concerning smoking marijuana as
a medicine. Many well-intentioned leaders and members of the public have
been misled by the well-financed and organized pro-drug legalization lobby
into believing there is merit to their argument that smoking marijuana is
a safe and effective medicine. A review of the scientific research, expert
medical testimony, and government agency findings shows this to be erroneous.
There is <B>no</B> justification for using marijuana as a medicine<BR>
<BR>
The California Narcotic Officers' Association consists of over 7,000 criminal
 justice professionals who are dedicated to protecting the public from the
devastating effects of substance abuse, whether cocaine, methamphetamine,
or marijuana. We have seen first hand the debilitating and often tragic
results, both psychologically and physically, of those who choose intoxication
as part of their lifestyle. We have studied the medicinal use of marijuana
issue, compiling information from medical experts to present to those we
are sworn to protect. It is our firm belief that any movement that liberalizes
or legalizes substance abuse laws would set us back to the days of the '70s
when we experienced this country's worst drug problem and the subsequent
consequences. In the '80s, through the combined and concerted efforts of
law enforcement, prevention and treatment professionals, illicit drug use
was reduced by 50  percent. Teenagers graduating from the class of 1992
had a 50  percent less likely chance of using drugs than those who graduated
in the class of 1979.<BR>
<BR>
Substance abuse rises whenever public attitude is more tolerant toward drugs.
i.e.. they are safe and harmless. Other factors that contribute to a rise
in use include increased availability, reduced risk associated with using
or selling, and lower prices. In 1993, for the first time after 12 years
of steady decline, illicit drug use rose and continues to climb. A major
contributing factor is a message that drugs  &quot;aren't so bad.&quot;
 To counter this &quot;just say yes&quot; campaign, we feel compelled to
provide the facts on the use of smoking marijuana as a medicine. These well-documented
facts will prove beyond a doubt that <B>MARIJUANA IS NOT MEDICINE</B>.<BR>
<BR>
<HR><BR>
FACT: The movement to legitimize smoking marijuana as a medicine is NOT
encouraged by the pharmaceutical companies, Federal Food and Drug Administration,
health and medical associations, or medical experts; but instead by groups
such as the National Organization for the Reform of Marijuana Laws (NORML)
and the Drug Policy Foundation (DPF). These organizations have little medical
expertise and favor various forms of legalizing illicit drugs.<BR>
<BR>
FACT: Pro legalization organizations have admitted that their strategy to
legalize marijuana begins with legitimizing smoking marijuana as a medicine.
As reported in High Times magazine, the Director of NORML expressly stated
that the medicinal use of marijuana is an integral part of the strategy
to legalize marijuana. Tony Serra, a criminal defense attorney associated
with the prolegalization groups, stated that medicinal marijuana is the
&quot;chink in the administration's armor&quot; that will lead to society
seeing pot's mystical effects of peace, sisterhood and brotherhood. He is
also the one who said, &quot;If you kill a cop, I'll pay to take the case;&quot;
and &quot;My sustenance is drugs and murder.&quot; A former director of
NORML, Keith Stroup, told an Emory University audience that NORML would
be using the issue of medicinal marijuana as a red herring to give marijuana
a good name. The director of NORML, Dick Cowan, is quoted, &quot;The key
is medical access. Because once you have hundreds of thousands of people
using marijuana under medical supervision, the whole scam is going to be
brought up...then we will get medical, then we will get full legalization.&quot;
Is there any doubt about their true motive while they play this cruel hoax
on people with legitimate illnesses?<BR>
<BR>
FACT: A leader of the medicinal use of manj uana movement, Dr. Lester Grinspoon
is an associate professor of psychiatry at Harvard as well as chairman of
the board of NORML. He has made absurd claims such as marijuana, like aspirin,
is &quot;unusually safe;&quot; using cocaine two or three times a week &quot;creates
no serious problems;&quot; and &quot;Chronic cocaine abuse usually does
not appear as a medical problem.&quot; He wrote a book called 'Marihuana:
The Forbidden Medicine', which is the bible for pro-marijuana advocates.<BR>
<BR>
FACT: The studies cited by the marijuana advocates have been found to be
either unscientific, poorly researched, or involved pharmaceutical THC,
not marijuana. One of their &quot;experts&quot; who testified at the 1987
federal hearings to reschedule marijuana was a wellness counselor at a health
spa who admitted under oath to using every illegal mind altering drug he
ever studied. Another &quot;expert'' admitted he had not kept up with new
medical or scientific information on marijuana for over 18 years. Another
doctor claimed there was voluminous medical research on the effectiveness
of marijuana but under oath, when asked to cite the number of the studies,
he replied, &quot;I would doubt very few.&quot; The fact is that there is
not one reliable scientific study that shows smoking marijuana to be a safe
and effective drug.<BR>
<BR>
FACT: The majority of the marijuana advocates' &quot;evidence&quot; comes
from unscientific, nonscrutinized or analyzed anecdotal statements from
people with a variety of illnesses. It is unknown whether these individuals
used marijuana prior to their illness or are using marijuana in combination
with other medicines. It is also unknown whether they have had recent medical
examinations, are justifying their use of marijuana, experiencing a placebo
effect, or experiencing the intoxicating effect of smoking marijuana.<BR>
<BR>
FACT: The main psychoactive ingredient in marijuana (THC) is already legally
available in pharmaceutical capsule form by prescription from medical doctors.
This drug, Marinol, is less often<BR>
prescribed because of the potential adverse effects, and there are more
effective new medicines currently available. Marinol differs from the crude
plant marijuana because it consists of one pure, well-studied, FDA-approved
pharmaceutical in stable known dosages. Marijuana is an unstable mixture
of over 400 chemicals including many toxic psychoactive chemicals which
are largely unstudied and appear in uncontrolled strengths.<BR>
<BR>
FACT: The manufacturers of Marinol, Roxane Laboratories Incorporated, do
not agree with the pro-marijuana advocates that THC is safe and harmless.
In the Physician's Desk Reference, a good portion of the description of
Marinol includes warnings about the adverse effects..<BR>
<BR>
FACT: Comnon sense dictates that it is not good medical practice to allow
a substance to be used as a medicine if that product is: <BR>
<BR>
1) not ADA approved <BR>
2) ingested by smoking <BR>
3) made up of hundreds of different chemicals <BR>
4) not subject to product liability regulations <BR>
5) exempt from quality control standards <BR>
6) not governed by daily dose criteria <BR>
7) offered in unknown strengths (THC) from 1 to 10 +percent <BR>
8) self-prescribed and self-administered by the patient.<BR>
<BR>
FACT: The federal govemment, over the last 20 years involving a number of
administrations from both political parties has determined that smoking
marijuana has no redeeming medicinal value, and is, in fact, harmful to
health. These governmental agencies include the Drug Enforcement Administrations,
the Food and Drug Administration, and the U.S. Public Health Service. Their
latest finding, as recently as 1994, was affirmed in a decision by the U.S.
Court of Appeals in Washington, D.C.<BR>
<BR>
FACT: Since the pro-marijuana lobby has been unsuccessful in dealing with
the federal govemment, they have targeted state and local govemments to
legitimize smoking marijuana as a medicine. A careful examination of their
legislative and/or ballot proposals reveals they are written to effectively
neutralize tile enforcement of most marijuana laws. Crude, intoxicating
marijuana under their proposals would be easier to obtain and use than even
the most harmless, low level prescription drug.<BR>
<BR>
FACT: Major medical and health organizations, as well as the vast majority
of nationally recognized expert medical doctors, scientists and researchers,
have not accepted smoking marijuana as a safe and effective medicine. These
organizations include: the American Medical Association, the American Cancer
Society, National Sclerosis Association, the American Glaucoma Association,
American Academy of Ophthalmology, National Eye Institute. National Cancer
Institute, National Institute for Neurological Disorders and Stroke, National
Institute of Dental Research, and the National Institute on Allergy and
Infectious Diseases.<BR>
<BR>
FACT: There are thousands of studies available documenting the harmful physical
and psychological effects of smoking marijuana. The harmful consequences
include but are not limited to premature cancer, addiction, coordination
and perception impairment, a number of mental disorders including depression.
hostility and increased aggressiveness, general apathy, memory loss, reproductive
disabilities, impairment to the immune system, numerous airway injuries,
and other general problems associated with intoxication.<BR>
<BR>
FACT: The medicinal marijuana movement and its media campaign have helped
contribute to the changing attitude among our youth that marijuana is harmless,
therefore contributing to the increase of marijuana use among our young
people afler 12 years of steady decline.<BR>
<BR>
The overriding objective behind this movement is to allow a minority (less
than five percent) of our society to get &quot;stoned&quot; with impunity.
This small minority is willing to put our citizens at risk from all the
negative and disastrous effects caused to and by those who are intoxicated.
What we don't need in this society is more intoxicated people on our highways,
in workplaces, schools, colleges, or in our homes.<BR>
<BR>
We ask you, as concerned citizens, to join us in spreading the truth and
countering the lies propagated by those who want to legalize drugs. If you
would like more information, call the CNOA office at (805) 287-0195.<BR>
<BR>
This position paper may be reproduced without the permission of the California
Narcotic Officers' Associatien.<BR>
<BR>
Revised 06/17/1996<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-134</DOCNO>
<DOCOLDNO>IA077-000514-B011-413</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWKK.html 207.112.150.94 19970124113836 text/html 1892
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:37:54 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 1721
Last-modified: Tue, 29 Oct 1996 17:29:38 GMT
</DOCHDR>
<TITLE> Without Question </TITLE>
<CENTER>
<H3>WITHOUT QUESTION</H3>
<DL>
<DT>Keith M. Kaneshiro, Prosecuting Attorney
<DT>Honolulu, Hawaii
</DL>
</CENTER>
Without question, drug abuse in our society has been a major cause of crime
and social disruption.  The drug problem has been so enormous that some in our community, misguided by frustration, are listening to the beguiling arguments to legalize or decriminalize drugs.
<P>
The solution to the drug problem is not to repeal drug laws.  The solution
requires commitment to a balanced strategy of drug education, prevention, treatment and law enforcement. Softening our drug laws would be a terrible mistake.  Research information and data clearly show the problem is not drug prohibition, but drug use. When drugs are cheap, plentiful and legal, more people will use them.  It is a frightening scenario that envisions more of our citizens, juveniles and adults, using mind-altering substances that not only adversely affect their own behavior and health, but also endanger innocent people.
<P>
Experience has already shown a link between illegal drug use and crime; that
even the mythical "victimless" use of marijuana can cause a disproportionate amount of serious accidents; and that countries (such as South Korea and Taiwan) learned that tolerating drug abuse only allowed it to grow to intolerable levels among their citizens.
<P>
Those who do not learn from experience are damned to repeat it.  We cannot
afford to do this with the drug problem.  At stake are the lives of too many of our people in this generation and the next.  As Honolulu's Prosecuting Attorney, I ask for your strong commitment to fight--and not surrender--in the war against drugs.       
</DOC>
<DOC>
<DOCNO>WT01-B04-135</DOCNO>
<DOCOLDNO>IA077-000514-B012-209</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWLH.html 207.112.150.94 19970124114013 text/html 5273
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:39:06 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 5102
Last-modified: Tue, 29 Oct 1996 17:29:41 GMT
</DOCHDR>
<TITLE>Lois Haight's "The Use of Drugs"</TITLE>
<CENTER>
<H3>CRIMINAL BEGINNINGS: The Use of Drugs</H3>
<H4>Lois Haight, Superior Court Judge, Los Angeles, California</H4>
</CENTER>
<P>
In my courtroom, as in others across California, illegal drugs erode the
foundation of our society.  Drug-addicted parents breed drug-addicted babies who grow up severely handicapped, physically and emotionally.  They later become drug-addicted juveniles who commit serious violent crime as the influence of drugs reduces inhibitions, undermines judgement, clouds
perceptions, and eliminates conscience.
<P>
Since most drug users are in the child-bearing years, the cycle continues
and drug-compromised adults face the crucial job of child-rearing, while at the same time dealing with the consequences and the side effects of hallucinations, anxiety, paranoia, physical aggression, impulsive behavior, memory loss and depression.  These factors include good parenting.  Drug
using parents who come before me are routinely diagnosed as having
amphetamine or cocaine induced delusional disorders, as being gravely disabled, or unable to provide self and family with food and clothing.  They are a danger to themselves and others, and they often have 4 to 6 children.
<P>
The description of cocaine or methamphetamine addicted babies most often
reads something like this:  incessant crying, respiratory breathing problems,
rigidity of limbs, blindness, lack of muscle control, inability to sit up or crawl, developmentally disabled, and sometimes retardation.  I have watched these children go back and forth between the homes of addict parent
and new foster homes where they try to care for the severely handicapped
child and often give up. This child then grows up how? -- abused? molested? neglected?  Is it any wonder that these youngsters turn to drugs and crime?  Without values, without consistency of love and care, they have learned to use and to abuse.
<P>
Approximately 90% of abused, neglected, abandoned and molested children in
Los Angeles alone are the result of substance abuse.  These are dysfunctional
families in the real meaning of the word.  This is a phenomenon that we as a state cannot afford. People who use drugs undermine not just their own lives, but make victims of us all as they destroy future generations, overrun our hospital and health care facilities, cause carnage on our highways, and
destroy our cities and neighborhoods as they join gangs, commit crimes and
victimize law-abiding citizens.
<P>
We have laws to ensure some minimum level of behavior that is universally
recognized as being essential for a civilized society.  It is a futile exercise to suggest that crime can somehow be eliminated or the behavior of a drug user changed by redefining it as legal -- as if a criminal act had no inherent danger other than the fact that it has been placed in the law books of our nation.  To legalize this behavior is to condone it and undisputably increase the behavior.  This we cannot tolerate!  More importantly, laws are the reflection of the values of society.  The seriousness with which we hold those values is measured by the penalty imposed when those values are violated. Therefore, I ask you, how do we value our children when illegal drug use is not viewed as the destroyer it is when the penalties for drug use are insignificant?  How can we expect a minimum level of behavior in our children, when we send the message that drug use is not harmful or wrong?
<P>
Drug treatment has not been a panacea, with less than a 25% success rate.
We must do everything in our power to prevent and deter the use of drugs, because the high is extremely powerful, and the desire for it almost impossible to stop.
<P>
In 1988, I chaired the White House Conference on a Drug-Free America.  That
conference held hearings throughout the United States with five thousand principals and over one thousand recovering addicts participating.  Every drug user gave the same heartfelt message, "Make it difficult, very difficult to use, because if you don't, the lure and seductiveness of the "high" will prevail."
<P>
There must be a down to drug use.  We must always consider and encourage
treatment and recovery, but sanctions should be commensurate with and reflect the harm drug use does to society.  We live in a democracy with freedom to make a choice and freedom to choose consequences.  Those who use drugs make their own choices.  For some, the choices are more difficult than for others, but there are many free-will choices made before one becomes an addict. There must be sanctions for drug use.  When people are considering that choice, considering giving their lives over to drugs, the penalties for the use must have a significant impact on that decision.
<P>
Drug use is clearly the beginning of crime for the users and the abused who
become the next generation of users and abusers.  Stop the use of illegal drugs, and we will stop much of the crime in California.
<P>
(Permission to reprint given provided source listed: Committees of Correspondence/Drug Watch International)
</DOC>
<DOC>
<DOCNO>WT01-B04-136</DOCNO>
<DOCOLDNO>IA077-000514-B012-397</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/BP1.html 207.112.150.94 19970124114136 text/html 9120
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:41:15 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 8949
Last-modified: Tue, 29 Oct 1996 17:28:28 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> BP1.html </TITLE>
</HEAD>
<BODY>
<H1><CENTER>PAE Reports Preview</CENTER>
</H1>
<P><CENTER><HR></CENTER>
<H2><CENTER>The Success of Tough Drug Enforcement </CENTER>
</H2>
Strong drug enforcement in the United States is correlated with reductions
in crime, drug use, and drug addiction growth rates. The impact of tougher
drug sanctions has been overshadowed by a prevalent myth that U.S. drug
enforcement has become &Ocirc;too punitive' or is a failed approach that
should be replaced with a &Ocirc;public health' strategy by diverting enforcement
resources into treatment programs. <BR>
<BR>
This myth has been packaged and promoted by the multi-million dollar pro-drug
legalization lobby, civil libertarians, and misguided academic researchers
to the media and public with limited critical review and challenge. Historical
experience warns that weakening drug enforcement leads to increased societal
costs and problems. <BR>
<BR>
Attacks on drug enforcement efforts often hold law enforcement to impossible
and changing performance standards. Law enforcement, treatment, and prevention
complement one another. None of the credit for a dramatic twelve year decline
in drug use among our children is attributed to law enforcement, yet recent
increases in drug use are cited as evidence of enforcement's failure. <BR>
<H2><CENTER>The Slough of Drug Permissiveness </CENTER>
</H2>
The prevailing myth is that the U.S. has taken a progressively tougher drug
enforcement stance for the past 30 years and that this punitive approach
has not been successful or beneficial. <BR>
<BR>
The basic premise that the U.S. has taken a progressively more punitive
policy on drugs is inaccurate and based on faulty measures. When toughness
is re-defined from arrest and incarceration numbers to reflect the proportion
of drug arrestees actually incarcerated, one finds that the nation entered
a period of drug permissiveness beginning in 1960 and ending in 1980. <BR>
<BR>
It is during this period of drug permissiveness and weak punitive sanctions
that a dramatic rise in crime and violence swept across America. The decline
in drug offender incarceration rates was steep and sudden. In 1960, the
incarceration rate for drug offenders was over 90 per 1000 arrests, by 1980
that figure reached a low point of only 19 of every 1000 offenders being
incarcerated. <BR>
<BR>
As drug incarceration rates fell 374% from 1960-1980: 
<UL>
  <LI>Serious crimes increased 215%, on average up 11% per year. 
  <LI>Property crime increased 210 %, on average up 11% per year 
  <LI>Violent crime increased 252%, on up average 13 % per year 
  <LI>Drug use among teens (% who use) climbed 27% from just 1974-1980 
  <LI>Murders increased 100%, an average 5 % per year. 
  <LI>Burglary increased 230 %, an average 12 % per year. 
  <LI>Drug addiction rates also rose, with heroin use climbing 900% 
</UL>
As drug incarceration rates rose 447% from 1980-1994: 
<UL>
  <LI>Serious crimes declined 8% 
  <LI>Number of teens who used drugs declined 193% 
  <LI>Property crime declined 12 % 
  <LI>Murders declined 7% 
  <LI>Burglary declined 35% 
  <LI>Violent crime rate growth slowed from 13 to 2% per year 
  <LI>Heavy cocaine use fell 11% and heavy heroin use 17% from 1988 
</UL>
The entire 215% rise in crime rates experienced during the past three decades
in the U.S. transpired when drug incarceration rates fell below the 1960
level during a period of declining incarceration rates for drug offenders.
This permissive period also is correlated with rising drug use. <BR>
<BR>
Historical experience indicates that arresting drug offenders is not an
effective policy, offenders have to be incarcerated and risk facing consequences
to have an impact. It is only when the U.S. abandoned a permissive treatment
dominated drug policy that the growth in drug use and crime was abated.
<BR>
<H2><CENTER>The Impact of Increasing Drug Incarceration Rates </CENTER>
</H2>
The peak year for murder and property crime in the U.S. was 1978-1980. Drug
incarceration rates reached their lowest ebb during these years. After 1980,
crime rates began to stabilize and have declined overall as drug incarceration
rates increased. It was not until 1990, that drug incarceration rates reached
the level the nation was at in 1960. The crime rate began falling again
in 1992, as drug incarceration rates reached record levels. Estimates for
1994 are that violent crime dropped another 4% and murder, rape, and burglary
dropped 5%. <BR>
<BR>
U.S. police chiefs believe that the number one way to reduce crime is to
reduce drug use. The imposition of mandatory minimum drug penalties in 1988
was followed by the nation's largest decrease in drug use. The proportion
of murders related to narcotics also has fallen with tougher drug sentencing
practices and the imposition of mandatory minimum laws. <BR>
<BR>
Young black males are seven times as likely to be murdered as their white
counterparts. This racial discrepancy rose during the drug permissive 1970's
and peaked in 1972, when black males were more than 11 times as likely to
be murdered than white males. <BR>
<H2><CENTER>Are We Tough Enough On Drugs? </CENTER>
</H2>
<STRONG>Myth:</STRONG> Too many non-violent first time minor drug offenders
are in prison. <BR>
<BR>
<STRONG>Fact:</STRONG> The most comprehensive study ever of U.S. prisoners
by the U.S. Department of Justice found the following: 
<UL>
  <LI>1. 93.5% of state prisoners were either violent or repeat offenders,
two thirds are currently in prison for a violent crime (violent crime makes
up only 9% of all crime). 
  <LI>2. Only 1.3% of state drug prisoners are not repeat or violent offenders
of the 6.5% in this category. 
  <LI>3. Only .6% of state prisoners were in prison for marijuana possession
(with unknown quantity) and only 2% were in for marijuana trafficking. 
  <LI>4. In federal prison the average amount of marijuana a trafficker
was involved with was 3.5 tons and cocaine traffickers averaged 183 pounds
of cocaine. 
  <LI>5. Only 1.3% of federal prisoners are in prison for drug possession
charges (average pot possession is 105 pounds). 
  <LI>6. A large number of federal prisoners are aliens and their prior
criminal record may not reflect their entire criminal history. 
</UL>
<STRONG>Myth:</STRONG> Drug arrests are increasing and threaten to overwhelm
the criminal justice system if alternatives to the criminal justice approach
are not undertaken. <BR>
<BR>
<STRONG>Fact:</STRONG> Drug arrests are declining and the criminal justice
system is not about to be overwhelmed by drug cases. 
<UL>
  <LI>1. Drug arrests have been decreasing since 1989 and only make up 8%
of all arrests nationwide. 
  <LI>2. Federal prosecutors have declined to prosecute an increasing proportion
of drug cases. 
  <LI>3. Alternative sentences are being used and growing. 
  <LI>4. Court caseloads for drug offenses have declined the past few years
and court and prison staff have generally kept pace with increased drug
caseloads. 
  <LI>5. Decriminalization would result in more drug related arrests, alcohol
related arrests far outnumber drug arrests, with more teens arrested for
underage drinking than drug offenses. 
</UL>
<STRONG>Myth:</STRONG> Drug sentences are too harsh and mandatory minimums
should be repealed. <BR>
<BR>
<STRONG>Facts: </STRONG>Drug incarceration rates plummeted through 1980
and stronger incarceration and mandatory minimum terms are the result of
public demanded. There is evidence that drug sentencing is still inadequate.
<BR>
<MENU>
  <LI>1. Despite lengthy terms on paper, the average federal drug possessor
imprisoned served only 8 months. 
  <LI>2. Those convicted of a federal drug possession offense were less
likely to be incarcerated than those convicted of liquor law or motor carrier
regulatory violations. 
  <LI>3. The proportion of drug offenders who are traffickers has increased
as drug possession convictions and incarceration declined since the late
1980's. 
</MENU>
<HR><STRONG>PAE Reports:<EM> The Success of Tough Drug Enforcement </EM></STRONG>exposes
many of the myths and misunderstandings about the impact of tougher drug
enforcement and warns against turning back to the drug permissive policy
of the 1970's. The report covers in detail, the success of mandatory minimum
terms, the truth about race and drug laws, the increased efficiency and
effectiveness of drug enforcement agencies, actual sentencing practices,
drug treatment through tough drug policy, and the facts behind murder, youth
violence and drugs. <BR>
<BR>
This report includes presentation ready graphics, numerous charts and tables,
and extensive original source citations. To order a full copy of this report,
send a written request with your name and address to: <A HREF="mailto:DrugWatch6@aol.com">DrugWatch@lec.org
</A><BR>
<BR>
PAE Services Robert E. Peterson P.O. Box 1184 Vestal, NY 13850-1184 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-137</DOCNO>
<DOCOLDNO>IA077-000514-B013-2</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR11.html 207.112.150.94 19970124114210 text/html 7192
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:42:06 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 7021
Last-modified: Tue, 29 Oct 1996 17:31:00 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> MRR vol1 no.1 </TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW </CENTER>
</H1>
<H4><CENTER>A publication of Drug Watch Oregon. Volume 1, No. 1, February
1994| </CENTER>
</H4>
<P><CENTER><HR></CENTER>
<H2><CENTER>Marijuana absent in 1993 scientific review of glaucoma treatment
</CENTER>
</H2>
G!aucoma treatment was thoroughly reviewed in the New England Journal of
Medicine, Vol. 328, p. 1103, 1993, by Quigley. Marijuana was not mentioned
in the review of effective medications for treatment of this disorder. For
precise control of the intraocular pressure usually associated with this
disease, frequent monitoring of patients receiving a drug that delivers
uniform doses is necessary. <BR>
<BR>
<STRONG>Commentary:</STRONG> Except in rare instances glaucoma is a symptomless
disease until loss of eyesight begins. Most, but not all patients afflicted
with glaucoma, experience increased intraocular pressure which, if left
untreated, will lead to blindness. Since there are many effective medications,
and since doses of marijuana by smoking cannot be controlled, using smoked
marijuana to treat glaucoma is potentially dangerous. <BR>
<BR>
Because the baseline (normal) pressure varies from individual to individual,
this disease and its treatment must be carefully monitored and tailored
to each patient. Though marijuana, like alcohol, can reduce intraocular
pressure, the dose cannot be controlled and risk of damage due to either
excessive or inadequate lowering of pressure could lead to blindness. Further,
the side effects associated with marijuana use, such as impairment of motor
skills, are not present with currently available approved therapies. To
assure the best outcome for this disease, frequent monitoring of patients
receiving a drug that delivers uniform doses is necessary. <BR>
<H2><CENTER>Suppository form of Delta 9 THC better than oral form for treating
appetite loss</CENTER>
</H2>
Struwe et al, in the Annals of Pharmacotherapy, vol. 27, pp. 827-831, 1993,
reported a double-blind, randomized placebo-controlled crossover trial with
two 5-week treatment periods separated by a 2-week washout period. Patients
received dronabinol (Marina) 5 mg twice daily before meals, or a placebo.
Twelve HlV-infected patients who had lost at least five pounds participated
in the study. Only five patients were able to complete the protocol because
of various side effects of delta 9 THC. In the subjects who completed the
study, there was no statistically significant weight gain, increased serum
proteins, or improved appetite. <BR>
<BR>
<STRONG>Commentary:</STRONG> Smoking marijuana has been alleged to be good
for the loss of appetite seen in AIDS patients. Because inhallation of irritants
(which potentially could be contaminated with fungi) poses a needless and
serious endangerment to the already compromised immune systems of AIDS patients,
this practice would appear risky. <BR>
<BR>
Oral delta 9 THC, the synthetic form of the most active cannabinoid in marijuana,
would seem to be a better choice, but recent research on its efficacy was
disappointing. Thus, in a selected group of HIV infected patients, a controlled
study failed to support any effect of delta 9 THC to increase appetite.
<BR>
<BR>
Perhaps the recent report by Mattes and associates, in the journal, Pharmacology,
Biochemistry, and Behavior, vol. 44, pp. 745-747, 1993, of a rectal form
of THC which was well-tolerated, would be of benefit. This drug produced
higher and more sustained plasma levels which should enhance its efficacy
as an anti-vomiting drug in chemotherapy and, perhaps, as an appetite stimulant.
This would completely avoid the necessity to have a smoked form of the drug
in which a variable amount of active drug is delivered with each cigarette
and further compromises damaged immune systems. <BR>
<H2><CENTER>Marijuana carries serious risk for those under treatment for
mental illness </CENTER>
</H2>
Tardive dyskinesia is a condition in which abnormal involuntary movements
develop, producing serious necrologic disability. Some patients treated
for schizophrenia with drugs such as chlorpromazine, develop this serious
condition as a side effect of therapy. New research published by Zaretsky
in the journal, Schizophrenia Research, Vol. 11, pp. 3-8, 1993, shows that
a major risk factor for development of this complication of neuroleptic
therapy is current or past use of cannabis. A study of 51 chronic neuroleptictreated
outpatients with diagnoses of schizophrenia showed that current use of cannibis
far outdistanced any other risk factor such as cigarette smoking, caffeine,
or alcohol use. The authors concluded that even &quot;recreational&quot;
use of marijuana or hashish in patients treated with these drugs was dangerous
. <BR>
<BR>
<STRONG>Commentary:</STRONG> This study adds to the current literature confirming
that up to 60% of schizophrenic patients use non-prescription psychoactive
drugs. O <BR>
<H2><CENTER>Marijuana components damage the ability of human immune cells
to function. </CENTER>
</H2>
Recent work by Watzl et al, Drugs of Abuse Immunity and Immunodeficiency,
1991, and Djeu et al, published in the same journal, showed that the major
psychoactive component of marijuana, delta 9 tetrahydrocannabinol (THC)
is able to interfere with the function of white blood cells taken from humans.
Both neutrophils, which fight bacterial infection, and mononuclear cells
of the immune system, which fight viruses, were suppressed by various concentrations
of THC. <BR>
<BR>
Schwartz, in the Journal of Hospital and Community Psychiatry, Vol. 38,
p. 531, May 1987, pointed out that marijuana use is a factor in preparing
the ground for HIV infection and that in the list of risk-reducing behaviors
for patients with HIV, a significant preventative step might be to discourage
the use of marijuana among those at risk. <BR>
<BR>
It is of interest, as pointed out by Pillia, in the Archives of Toxicology,
Vol. 65, pp. 609-617, 1991, that drugs of abuse, as well as alcohol, have
immunotoxic properties which include marked changes in the cellular, humoral,
and other components of the immune defense mechanism. <BR>
<BR>
<STRONG>Commentary: </STRONG>Applying this work to human beings would suggest
that marijuana smoke would depress those immune cells which protect the
body from viral or bacterial infections. This would be particularly dangerous
in patients with already compromised immune systems, such as those with
AIDS. <BR>
<BR>
Thus, since a large majority of people with AIDS have a well-established
history of drug and alcohol abuse, Such a compromise of the immune system
can render the body more susceptible to the development of AIDS after HIV
infection. <BR>
<P><CENTER><HR>Material used in this publication has been reviewed and commented
on by William M. Bennett, M.D., Professor, Chief of Nephrology, Clinical
Pharrnacology and Hypertension at Oregon Health Sciences University, Portland,
Oregon. </CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-138</DOCNO>
<DOCOLDNO>IA077-000514-B013-194</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR12.html 207.112.150.94 19970124114327 text/html 7211
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:43:17 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 7040
Last-modified: Tue, 29 Oct 1996 17:31:04 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>MRR vol.1 No.2 </TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW </CENTER>
</H1>
<H4><CENTER>A publication of Drug Watch Oregon. Volume 1, No. 2, July 1994
</CENTER>
</H4>
<P><CENTER><HR></CENTER>
<H2><CENTER>Fungal sinus infection associated with marijuana use </CENTER>
</H2>
Marijuana smoke is often contaminated by the fungus, aspergillus, (Kagen
et al, Journal of Allergy and Clinical Immunology, vol. 71, pp. 389-393,
1983). A report by these authors showed that 11 of 12 samples they tested
demonstrated various species of the fungus, aspergillus. It then was of
great interest when Brummund, in the Journal of the American Medical Association,
vol. 256, pp. 3249-3253, 1986, reported cases of allergic sinus infection
with the same fungus from the recreational use of contaminated marijuana.
<BR>
<BR>
<STRONG>Commentary:</STRONG> Fungal sinus infections can be very difficult
to treat and can lead to destruction of the sinuses with involvement of
the brain and central nervous system. 
<H2><CENTER>Marijuana implicated in fatal fungal infection </CENTER>
</H2>
A 34-year-old man who had undergone a bone marrow transplant for chronic
leukemia was reported to have developed a fatal disseminated fungal infection
associated with a contaminated batch of marijuana cigarettes used heavily
for several weeks prior to his admission to the hospital (Chestvol. 94/2,
pp. 432-433, 1988). <BR>
<BR>
<STRONG>Commentary:</STRONG> Noting that &quot;Invasive aspergillosis has
become a significant cause of death in immunosuppressed patients&quot; The
authors, Hamadeh and associates, reported the case so that physicians would
be aware of this potentially lethal complication of marijuana use in compromised
hosts such as patients with AIDS or malignancies. <BR>
<BR>
Aspergillus spores are found throughout the environment in soil, air, and
vegetable matter, including tobacco and marijuana. However, smoking contaminated
plant material, puts a concentration of the fungi directly into the lungs
and blood stream placing smokers/ patients without intact immune systems
at extreme risk. 
<H2><CENTER>Marijuana use impairs function in all areas </CENTER>
</H2>
Psychological tests measuring intelligence, memory, and other mental functions,
were given to 26 heavy cannabis users and compared with a control group
by Varma reported in the journal Drug and Alcohol Dependence, vol. 21, pp.
147-152, 1988. A heavy cannabis user was defined as a person consuming cannabis
for five years, 20 or more times per month, with a daily intake equivalent
to 150 mg of delta-9 THC, 3 to 5 joints depending on the concencentration.
<BR>
<BR>
<STRONG>Commentary:</STRONG> These authors found that the cannabis users,
with an average of 6.8 years of use, were found to react very slowly in
performing motor tasks, but more importantly, suffered disability in personal,
social, and vocational areas. They also indicated a higher score for neurotic
and psychotic behavior. This is consistent with several other recent studies
linking marijuana smoking to behavioral problems. 
<H2><CENTER>Marijuana smoking linked to increased lung damage </CENTER>
</H2>
Marijuana smoke is known to be as irritating as tobacco smoke. Research
by Barbers and associates American Review of Respiratory Marijuana Research
Review, Volume 1, No.2, July 1994 <BR>
<BR>
Diseases, vol. 135, pp. 1271 -1275, 1987, showed that smoking of both marijuana
and tobacco caused the small oxygen exchanging parts of the lung to shed
inflammatory cells. The smoking of marijuana and tobacco together increased
this reaction significantly above smoking either drug alone, and marijuana
caused an adverse effect on the lungs that was independent of and additive
to that of tobacco. 19 healthy non-smokers and 43 healthy smokers of tobacco
and/or marijuana took part in the study. <BR>
<BR>
<STRONG>Commentary:</STRONG> None of these individuals had any previous
history of chronic lung disease. These lung inflammatory changes are early
findings in individuals who go on to develop malignancy, chronic infection,
and emphysema in their lungs. 
<H2><CENTER>Pre-employment screening for marijuana use makes good economic
sense </CENTER>
</H2>
Zwerling and associates, in the Journal of the American Medicine Association,
vol. 264, pp. 2639-2643, 1990, present a prospective controlled study of
the association between pre-employment drug screening tests and adverse
employment outcomes in 2,537 postal employees. &quot;This was a blind study:
the employees, hiring officials, medical personnel and management officials
did not know the results of the urine drug screens at any time during the
study. The study was designed to detect and measure any association between
the presence of marijuana and/or or cocaine on a preemployment drug screen
and employment outcomes such as employee turnover, absenteeism, accidents,
injuries, and discipline.&quot; <BR>
<BR>
<STRONG>Commentary:</STRONG> The purpose of the study was to substantiate
or disprove claims that drug-abusing employees have substantially more accidents
at work, many more compensable injuries, and use significantly more sick
leave than those who do not use illicit drugs. <BR>
<BR>
The study showed that marijuana users had &quot;55% more industrial accidents,
85% more injuries and a 78% increase in absenteeism.&quot; It also showed
that cocaine users had a 145% increase in absenteeism and an 85% increase
in injuries. The mean absence rate from the job was 7.1% for marijuana users
compared to 4% for non-users. <BR>
<BR>
The study showed that pre-employment drug screens positive for marijuana
and cocaine were associated with significant adverse employment outcome
supporting the use of such screening for economic and health reasons. 
<H2><CENTER>Marijuana continues to be available for scientific research
</CENTER>
</H2>
Since the 1970's more than 10,500 scientific studies have been conducted
on marijuana. The marijuana (cannabis) used in the studies is obtained from
the Research Institute of Pharmaceutical Sciences at the University of Mississippi,
who produce a standardized marijuana specifically for research. Material
to be used in clinical trials is shipped to Research Triangle Institute
in North Carolina where it is processed into marijuana cigarettes. It is
then made available for Researchers following proper protocol and paperwork
filed with the National Institute on Drug Abuse, in that form. Questions
regarding the availability of marijuana should be directed to Dr. Rao Rapaka
or Dr. Paul Hillery at NIDA (301-443-4250). <BR>
<BR>
<CITE>Per Mahmoud A. ElSohly, Ph.D., Project Director, NIDA Marijuana Project.
4/1/93 <BR>
<P><CENTER></CITE>Material used in this publication has been has been reviewed
and commented on by William M. Bennett, M.D., Professor, Chief of Nephrology,
Clinical Pharrnacology and Hypertension at Oregon Health Sciences University,
Portland, Oregon. <HR>Drug Watch Oregon, P.O. Box 5853, Portland, Oregon.
97228-5853 </CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-139</DOCNO>
<DOCOLDNO>IA077-000514-B014-138</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR13.html 207.112.150.94 19970124114644 text/html 7085
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:43:54 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 6914
Last-modified: Tue, 29 Oct 1996 17:31:07 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> MRR Vol.1 No.3 </TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW </CENTER>
</H1>
<H4><CENTER>A publication of Drug Watch Oregon. Volume 1, No. 3, October
1994 </CENTER>
</H4>
<P><CENTER><HR></CENTER>
<H2><CENTER>Dangerous side effects of cocaine are amplified when used in
conjunction with marijuana </CENTER>
</H2>
Drug-using volunteers were used in a study to determine the effect that
marijuana smoking had on their subsequent use of cocaine. Lukas and colleagues
(Pharmacology, Biochemistry and Behavior, Vol 48:715721, 1994). The study
found that the increase in heart rate due to cocaine was markedly enhanced
if preceded by smoking marijuana, and that the time to the cocaine high
was reduced from two minutes to one minute. Most importantly there was double
the amount of drug absorption evident when marijuana use preceded cocaine
use. <BR>
<BR>
<STRONG>Commentary:</STRONG> Many drug users use two or more drugs at the
same time. In analyses of polydrug use, marijuana is the most heavily used
illicit drug. Because it enhances the cocaine experience, it is commonly
used in combination with this drug. <BR>
<BR>
People snorting cocaine after smoking marijuana are at greater risk of overdose
and more severe cardiovascular effects from the cocaine. Variability in
the nasal effects of both drugs makes dosing unpredictable and dangerous.
<BR>
<H2><CENTER>Study on use of THC to treat HlV-wasting syndrome shows no weight
gain. </CENTER>
</H2>
A review of the current treatment for the HIV-wasting syndrome reported
on studies with dronabinol, which has an approved use for anorexia in AIDS
patients. Schroeder, Hart, and Lynch (Annals of Pharmacotherapy, Vol 28:595-597,
1993). Dronabinol, a synthetic form of THC, the active ingredient in marijuana,
was approved by the FDA based on a double-blind placebo-controlled clinical
trial involving 139 AIDS patients in 18 centers. <BR>
<BR>
Patients with a five-pound weight loss, no active infection, and no marijuana
use for 30 days were included in the study. Dronabinol was given in a dose
of 2.5 mg orally twice a day to the treatment group with a placebo control
group. Patients reported an increase in appetite after six weeks of therapy.
However, there was less than a half-pound weight gain in treated patients
which was not statistically different from the one-pound weight loss in
the placebo group at the end of the six week period. <BR>
<BR>
The authors conclude that the efficacy of dronabinol in reversing the wasting
process associated with AIDS is yet to be determined, and that the subjective
increase in appetite did not necessarily correspond to increased body weight.
<BR>
<BR>
<STRONG>Commentary:</STRONG> AIDS wasting is a devastating complication
of infection with the AIDS virus. The drug megestrol has been recently approved
by the FDA and is far more effective than dronabinol in the studies to date.
<BR>
<BR>
Likewise, no scientific studies have confirmed a benefit of the use of crude
marijuana on HlV-wasting syndrome. Additionally, for the AIDS patient, smoking
a substance with fungal and bacterial contamination, as well as the inherent
damage by the smoke to lungs already predisposed to infection, would be
counterproductive. <BR>
<H2><CENTER>Review of anti-nausea drugs show restricted use for synthetic
cannabinoids </CENTER>
</H2>
Grunder and Hesketh (New England Journal of Medicine, Vol. 329:1790-1795,
1993) recently reviewed current therapies for chemotherapy-induced vomiting
control. The authors discuss the vomiting response and the neural pathways
involved in mediating that response. Regarding the use of cannabinoids,
the authors state that dronabinol and nabilone, the two cannabinoids that
have been evaluated most thoroughly, are active only in patients receiving
mild, not severely, emetogenic chemotherapy. <BR>
<BR>
The authors state that these drugs have serious side effects, however, including
dysphoria, vertigo, hallucinations, sedation, and disorientation, and are
seldom selected as first-line anti-emetic therapy. They point out that while
these drugs have limited usage, some synthetic cannabinoids with no psychotropic
activity have anti-emetic properties, suggesting that there are separate
sites of action for the anti-vomiting and the psychotropic activity. <BR>
<BR>
<STRONG>Commentary:</STRONG> With the availability of newer anti-emetic
drugs which are more potent, more effective and have less side effects in
reversing nausea and vomiting associated with chemotherapy, the use of drugs
with major side effects should be avoided. <BR>
<BR>
One common assumption about taking anti-emetics orally is that the patients
are already vomiting and cannot keep the medication down. However, all anti-emetic
therapy is given prior to administration of chemotherapy drugs, before the
onset of nausea and vomiting. Further, if the need for additional anti-emetic
medication were indicated it could be administered in suppository form.
<BR>
<H2><CENTER>Study looks at immunologic impact of tobacco and marijuana smoke
on the lungs </CENTER>
</H2>
Wallace and associates, in Chest, Vol. 105:847-852, studied the effect of
heavy, habitual marijuana use and compared it with tobacco smoking on the
composition of cells in the peripheral blood and small airways of the lung.
<BR>
<BR>
Cell samples from 14 non-smokers were compared to samples from 14 tobacco
smokers, 19 heavy habitual marijuana smokers, and 9 patients who smoked
both substances. The tobacco smokers had lower percentages of cells in their
small airways that had the marker for the CD4 or helper T-cells. Marijuana
use had the opposite effect of lowering the CD8 positive cells, so-called
suppressor cells, at the expense of CD4 cells. The authors concluded that
tobacco and marijuana have effects on immune cells and blood lymphocyte
populations that differ from each other, both in type and magnitude. <BR>
<BR>
<STRONG>Commentary:</STRONG> These data are further examples of information
from the group of Tashkin et al which show the effects of tobacco and marijuana
smoke on the intrinsic cells in the lung and the immunologic defenses of
the lungs. A combination of tobacco and marijuana would be devastating in
terms of exposure of patients to carcinogens, and also in damaging the immune
response to foreign particles, bacteria, and viruses. Immunologic alterations
that were observed in the study were of potential importance because they
correlated with the adverse health effects of smoking either substance,
alone or in combination. <BR>
<P><CENTER><HR>Material used in this publication has been reviewed and commented
on by William M. Bennett, M.D., Professor of Medicine, Division of Nephrology,
Clinical Pharmacology and Hypertension at Oregon Health Sciences University,
Portland, Oregon. <HR>Drug Watch Oregon, P.O. Box 5853, Portland, Oregon.
97228-5853</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-140</DOCNO>
<DOCOLDNO>IA077-000514-B014-246</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR21.html 207.112.150.94 19970124114740 text/html 7718
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:47:13 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 7547
Last-modified: Tue, 29 Oct 1996 17:31:11 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> MRR Volume 2, No.1 </TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW </CENTER>
</H1>
<H4><CENTER>A publication of Drug Watch Oregon. Volume 2, No. 1, January
1995 </CENTER>
</H4>
<P><CENTER><HR></CENTER>
<H2><CENTER>Study shows MS patients further impaired by smoking low-THC
marijuana. </CENTER>
</H2>
Greenburg et al, in their paper in Clinical Pharmacology and Therapeutics,
Vol. 55:324-328, 1994, performed a double-blind, randomized, placebo-controlled
study of inhaled marijuana smoke on balance and coordination responses in
ten adult patients with spastic multiple sclerosis, and normal volunteers
who were matched for age, sex, and weight. A sophisticated computer controlled
video system was used to identify responses. The study showed that marijuana
smoking enhanced the abnormalities already present in MS patients and that
smoking just one marijuana cigarette containing 1.5% delta-9 THC increased
the objective errors in these responses. The authors concluded that marijuana
smoking impairs coordination and balance in patients with spastic MS. <BR>
<BR>
<STRONG>Commentary:</STRONG> This is an objective and well done controlled
study which strongly refutes anecdotes suggesting that marijuana is beneficial
for patients with multiple sclerosis. In the absence of data showing any
benefit, this documentation of an adverse effect is disturbing and should
be heeded by those who would consider using smoked marijuana for treatment
of this disorder. <BR>
<H2><CENTER>Low doses of THC found to cause learning deficits </CENTER>
</H2>
Kamine et al, in their article in Behavior of Pharmacology, Vol 5:71-78,
1994, studied the effects of delta-9 tetrahydrocannabinol (THC) on the learning
and performance ability of eight healthy subjects (19-32 years of age) all
of whom had occasionally used marijuana, as well as other psychoactive drugs,
but were not perceived to be drug dependent. Subjects were given placebo
capsules, and 10 mg. and 20 mg. capsules of THC, (&quot;...roughly equivalent
to smoking a marijuana cigarette containing 2.3-3.6% THC&quot;) <BR>
<BR>
Oral THC caused measurable learning deficits which, the authors concluded,
might be disasterous in some environments, such as operating &quot;the cab
of a speeding locomotive.&quot; They pointed out that the &quot;learning
deficit from a single dose might become quite relevant if it accumulates
over time.&quot; <BR>
<BR>
<STRONG>Commentary:</STRONG> In regular marijuana users, the presence of
a learning deficit with a single dose of drugs and five hours of post-therapy
monitoring is sobering. In view of the greatly increased potentcy of marijuana
over the past decade and the recent rise in its use by teenagers and pre-adolescent
children, this should be particularly alarming to parents and educators.
This report contributes to the body of evidence showing that &quot;recreational
use of marijuana is not a benign habit in terms of intellectual performance.&quot;
<BR>
<H2><CENTER>Marijuana's implication in a number of chronic diseases reflects
its harmful impact on the immune system. </CENTER>
</H2>
Immune defenses against fungal organisms are triggered by natural killer
cells. If this system is upset, the susceptibility to fungal infections
is enhanced. Cusher et al, in their report in Cellular Immunology (Vol 154:99-108,
1994) incubated human large granular lymphocytes (human immune cells) with
varying concentrations of THC (delta-9 tetrahydrocannabinol). The concentrations
used mirrored what would be obtained in the blood of people smoking marijuana
or taking the drug dronabinol. They found that low levels of THC inhibited
tumor necrosis factor thereby weakening the killing activity of lymphocytes
against tumor cells. <BR>
<BR>
<STRONG>Commentary:</STRONG> It is well-known that substance abuse may compromise
immune response to a variety of infectious agents. Marijuana, a widely abused
drug around the world, and its components, have adverse effects on the immune
system. This study is another of a series showing that, in the test tube,
concentrations of the major psychoactive metabolites of marijuana are capable
of impairing the ability of human immune cells to kill tumors and destroy
fungal cells. The importance of this report is that the relatively low concentrations
which mimic drug use in humans, cause these profound depressions of immune
activity. <BR>
<H2><CENTER>Marijuana not listed in latest review of beneficial treatment
for Multiple Sclerosis </CENTER>
</H2>
Because of frequent claims that smoking marijuana provides therapeutic benefit
to victims of multiple sclerosis, the extensive and well documented review
of all the effective therapies for treatment of this disease, by G. C. Eber,
The Lancet, Vol 343, January 29, 1994, is included in this publication.
<BR>
<BR>
Eber notes in his review that multiple sclerosis (MS) &quot;...is unpredictable,
being characterized by a tendency to relapse and remission and/or to stabilisation
without treatment.&quot; He notes that the natural history of the disease
is well-defined and states that trial and error can no longer be reasonably
applied to the search for effective therapies. Eber concludes that although
clinical symptoms and anecdotes are valuable, highly sensitive objective
methods are now available in the form of serial MRI scans to document improvement
of the disease with such exciting therapies as beta-interferon. <BR>
<BR>
<STRONG>Commentary:</STRONG> This extremely complete review of multiple
sclerosis therapy puts to rest any contention that smoked marijuana is good
for this disorder and can be given without side effects. There simply are
no data to support the safe or effective use of either smoked marijuana
or dronabinol for treatment of MS. Eber's warning of the need for objective
data when judging a therapy for this complex disease is well worth heeding.
<BR>
<H2><CENTER>Marijuana use linked to homicide </CENTER>
</H2>
In terms of life-time use, marijuana was reported to be the most common
illicit drug used by a sample of 268 murderers incarcerated in New York
State correctional facilites, for homicides that occurred in 1984. Spunt
et al (&quot;The Role of Marijuana in Homicide,&quot; International Journal
of the Addictions, Vol. 29:195-213,1994) <BR>
<BR>
About one-third of prisoners who had used marijuana, had used it in the
24-hour period before the homicide, and three-quarters of those said they
experienced some kind of effect from the drug when the homicide occurred.
The authors speculate that drugs and violence may be linked in a variety
of complex ways. <BR>
<BR>
<STRONG>Commentary:</STRONG> It is clear that abnormal behavior induced
by the use of psychoactive drugs plays a significant role in violent crimes
which are completely unrelated to either drug profits or trafficking. Many
of the murderers interviewed for this study stated they felt that marijuana
use was a factor in their crimes. Recent well-publicized violent murders,
such as the tragic rape and murder of 12 year-old Polly Klaus, were also
committed by people who admitted to being under the influence of marijuana
at the time of their homicides. <BR>
<P><CENTER><HR><BR>
Material used in this publication has been reviewed and commented on by
William M. Bennett,M.D., Professor of Medicine, Division of Nephrology,
Clinical Pharmacology and Hypertension at Oregon Health Sciences University,
Portland, Oregon <BR>
<BR>
Drug Watch Oregon. P.O. Box 5853, Portland, Oregon 97228-5853 </CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-141</DOCNO>
<DOCOLDNO>IA077-000514-B014-376</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR22.html 207.112.150.94 19970124114831 text/html 7251
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:47:59 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 7080
Last-modified: Tue, 29 Oct 1996 17:31:14 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> MRR Vol. 2 No. 2 </TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW </CENTER>
</H1>
<H4><CENTER>A publication of Drug Watch Oregon. Volume 2, No. 2. March l995
</CENTER>
</H4>
<P><CENTER><HR></CENTER>
<H2><CENTER>Cannabis use found to increase frequency of relapse in patients
with schizophrenia </CENTER>
</H2>
The literature examining the relationship between marijuana use and schizophrenic
symptoms among patients with schizophrenic disorders has been conflicting.
The purpose of this study by Linzen et al (Archives General Psychiatry,
Vol. 51, pg. 273-279, 1994), was to compare cannabis-using schizophrenic
patients with schizophrenic non-users. There were 11 mild and 13 heavy cannabis
users compared to 69 non-users in a prospective study which lasted one year.
The authors found that significantly more and earlier psychotic relapses
occurred in the cannabis-using group, particularly as use increased. No
other factors could be found to explain this including other street drugs.
<BR>
<BR>
Fourteen of the cannabis-using patients, who were experiencing clinical
remission from their schizophrenia, reported an immediate increase in psychiatric
symptoms after using cannabis again. <BR>
<BR>
In all but one of the patients cannabis use also preceded the onset of their
first psychotic symptom. Over the one-year period only 20 percent of the
non-using subjects had a psychotic relapse, as compared to 46 percent for
those who used cannabis . <BR>
<BR>
<STRONG>Commentary:</STRONG> This study helps to clarify the relationship
between cannabis use and schizophrenia. While studies such as this cannot
prove cause-and-effect relationships, it is clear that use of cannabis can
cause patients with psychiatric disorders, such as schizophrenia, to have
more frequent relapse of symptoms compared to non-users of cannabis. An
important feature of this study was that the groups were matched for variables,
such as the use of other street drugs or alcohol, making these factors not
relevant in interpretation of the results. Findings of this study are consistent
with the observations of prior studies showing that cannabis use prior to
illness was an independent risk factor for schizophrenic symptoms. <BR>
<H2><CENTER>Smoking Tobacco or Marijuana Reduces Antioxidant Levels in HlV-lnfected
Patients </CENTER>
</H2>
Miguez-Verbano and colleagues from the University of Miami School of Medicine
reported at the American College of Clinical Pharmacology meeting in 1994
that anti-oxidant status was negatively impacted in 60 non-symptomatic HlV-infected
marijuana smokers. <BR>
<BR>
Vitamin E levels were significantly lower in marijuana users, as well as
cigarette smokers, compared to non-smoking HIV infected subjects. Subjects
who used both tobacco and marijuana exhibited frank vitamin E deficiency,
although vitamin E intake did not differ significantly among the groups.
<BR>
<BR>
These findings show that marijuana and tobacco smoking have a detrimental
effect on vitamin E status of HlV-infected individuals. This is of concern
in light of the important role of vitamin E in immune processes, including
inhibition of viral activation. <BR>
<BR>
<STRONG>Commentary:</STRONG> This well done study shows further evidence
that smoking marijuana contributes to defects in the immune system. The
issue of smoking marijuana for an HlV-infected patient makes absolutely
no sense in terms of preserving immune function to fight the virus that
causes the disease. Antioxidant levels also have an important effect on
preventing cardiovascular disease and cancer, both of which would be important
in HlV-infected individuals. <BR>
<H2><CENTER>Study examines the use of psychoactive and addictive drugs by
physicians </CENTER>
</H2>
Lutsky et al studied the current use of psychoactive drugs of abuse by physicians
specializing in medicine, surgery, and anesthesia, all of whom had trained
at the same academic institution. (Canadian Journal of Anaesthesia 1994/41:7/pp561-7)
1624 questionnaires were sent with a response rate of 58 percent. <BR>
<BR>
Difference in impairment rate among the physicians was not significant:
in surgery 14 percent, medicine 20 percent, and anesthesia 17 percent. Substance
abuse was clearly associated with a family history of substance abuse. Increased
stress at various career stages did not appear to increase substance abuse.
Substances most frequently abused were marijuana 55 percent, amphetamines
33 percent, and benzodiazepines 25 percent. <BR>
<BR>
A number of respondants reported that the use of alcohol and drugs by faculty
role models during their medical training was an important part of their
own personal use. Drug counseling programs and diversion programs were judged
inadequate by most respondents. <BR>
<BR>
<STRONG>Commentary:</STRONG> No subset of society is immune from substance
abuse in a modern social context. Obviously, better detection and treatment
programs are necessary for the prevention and control of this problem, which
impairs medical judgment and places patients interests at great risk. <BR>
<BR>
In the United States, only 3 percent of practicing physicians are anesthesiologists,
yet 13 percent of physicians being treated for drug dependency are anesthesiologists,
presumably because of the ease of access to these substances in this medical
specialty. <BR>
<BR>
The data from this survey pointed out that most drug use started prior to
entry into medical school. The authors suggested that programs aimed at
deterrents failed at least partially because there are no universally acceptable
drug screening methods, and because penalties for drug use are insufficiently
severe. Substance abuse by faculty represented another setback to any prospect
for deterring physicians in training. <BR>
<H2><CENTER>Study shows two marijuana cigarettes as harmful as 28 of tobacco.
</CENTER>
</H2>
This study by Starr et al followed 25 non-tobacco smoking surfers, in excellent
physical condition, who smoked an average of two marijuana joints per day.
The control was 25 male urban smokers from the San Francisco area and 25
non-smoking male Mormons from the Silicon Valley area. Damage and irritation
to the lung cells of the marijuana smokers was comparable to those who smoked
a mean of 28 tobacco cigarettes per day. (Medical Tribune, page 17,1994)
<BR>
<BR>
<STRONG>Commentary:</STRONG> Tobacco smoke is the most widespread factor
associated with premature death due to cancer and cardiovascular disease
in the USA. This study shows that cellular damage to the lungs produced
by daily use of two marijuana cigarettes is similar to that seen in those
who smoke nearly a pack and a half of tobacco cigarettes a day. <BR>
<P><CENTER><HR><BR>
Material used in this publication has been reviewed and commented on by
William M. Bennett,M.D., Professor of Medicine, Division of Nephrology,
Clinical Pharmacology and Hypertension at Oregon Health Sciences University,
Portland, Oregon. <BR>
<BR>
Drug Watch Oregon. P.O. Box 5853, Portland, Oregon 97228-5853 </CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-142</DOCNO>
<DOCOLDNO>IA077-000514-B014-433</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR23.html 207.112.150.94 19970124114855 text/html 7435
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:48:46 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 7264
Last-modified: Tue, 29 Oct 1996 17:31:17 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> MRR Vol. 2 No. 3 </TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW </CENTER>
</H1>
<H4><CENTER>A Publication of Drug Watch Oregon. Volume 2, No. 3, June 1995
</CENTER>
</H4>
<P><CENTER><HR></CENTER>
<H2><CENTER>Increase in unprotected sex in urban minority youth blamed on
use of alcohol or marijuana </CENTER>
</H2>
It is now established that regular condom use can decrease the spread of
AIDS. A recent study by Ford and Norris (Journal of the Acquired Immune
Deficiency Syndrome, Vol 7:389-396, 1994), studied the effects of the use
of alcohol and marijuana in the context of sexual relationships and the
impact of these substances on the consistency of condom use by urban minority
youth. <BR>
<BR>
The sample design and field work were conducted by the Survey Research Center
of the Institute for Social Research at the University of Michigan. A total
of 1435 interviews were obtained from Hispanic and African-American young
adults, ages 15-24, residing in low-income areas in Detroit. <BR>
<BR>
Results indicated that when alcohol and marijuana were used with a sexual
partner, the consistency of condom use decreased even when other variables
related to sexual history were controlled. Alcohol use had a greater negative
effect on condom use for Hispanic men, and marijuana for African-American
women, than it did for Hispanic women and African-American men. <BR>
<BR>
The authors concluded that safe sex intervention programs for urban low
income minority youth need to emphasize the risk of AIDS virus exposure
that results from substance use, casual sex, and sex with multiple partners.
<BR>
<BR>
<STRONG>Commentary:</STRONG> Aside from the many obvious adverse side effects,
use of alcohol and marijuana among teenagers may contribute to the spread
of AIDS. <BR>
<BR>
Clearly, it is counter-productive to give a safe sex message without also
pointing out that the behavior produced by the use of alcohol and marijuana
lessens the likelihood that safe sex will be performed. This factor is often
overlooked in drug prevention programs and sexual eduation courses when,
in fact, these things should be considered together. <BR>
<H2><CENTER>Delta 9 THC affects metabolism in human blood cells </CENTER>
</H2>
Delta 9 THC is known to inhibit a variety of immune functions. Diaz and
colleagues, in their paper in the Journal of Pharmacology and Experimental
Therapeutics, 268:1289-1296, 1994, show that THC, when incubated with cells
from the blood of normal humans, caused increased release of a variety of
metabolites that stimulate acute inflammation. These metabolites are potent
agents that can cause asthma, and which enhance the activity of other cells
which suppress immune defense against virus and other infectious agents.
<BR>
<BR>
<STRONG>Commentary:</STRONG> This paper is one of the first to show that
normal human cells, when incubated with concentrations of THC equivalent
to that found in the blood of regular smokers of marijuana, cause immune
cells to release compounds which promote inflammation within the lungs,
and at the same time, suppress the natural defenses against external bacterial
and viral agents that cause disease. <BR>
<BR>
While these studies are conducted in the test tube, the implications for
smoking marijuana in humans, particularly those who smoke or with a tendency
towards asthma or respiratory disease are obvious. <BR>
<H2><CENTER>Attempt made to use marijuana to treat Tourette's Syndrome </CENTER>
</H2>
A nurse consultant and a visiting psychiatrist reported on a single case
of Tourette's Syndrome treated successfully with smoked marijuana (Hemming
and Yellowlees, Journal of Psychopharmacology 7-4 1993 pp. 389-391 ). <BR>
<BR>
Tourette's Syndrome is a disorder characterized by multiple motor and vocal
tics. The tics occur many times daily and may include obscenities and other
strange behaviors. Untreated, the disorder tends to be a lifelong disease
characterized by remissions and relapses. Haloperidol (Haldol) is the drug
of choice in the treatment of this disorder. <BR>
<BR>
The patient they reported started to smoke marijuana at age 35 to get relief
while he continued his Haldol. The anecdotal improvement prompted the case
report. There was no stopping of the drug to see if symptoms returned, and
no rechallenge with marijuana. <BR>
<BR>
<STRONG>Commentary:</STRONG> This report is the type of anecdote used to
support claims for the use of smoked marijuana to treat disease. It is interesting
that the standard treatment of Haldol was continued throughout the period
of marijuana use with this patient, and there was no placebo control or
rechallenge involved. There are ways of using drugs in single patients,
known as the &quot;n of 1&quot; method. Efficacy as well as side effects
can be monitored using this method in a single patient. This was not done
here. It is also of interest that there is no objective documentation of
improvement in Tourette's Syndrome in the patient. Neither of the authors
has any expertise in neurologic diseases. Nicotine is also known to potentiate
the effects of Haldol in improving motor tics in this disorder. It is possible
that any one of the 4000 components found in marijuana smoke provided beneficial
effects, if, in fact, they did occur. <BR>
<H2><CENTER>Study finds self-reporting of Illicit drug use differs greatly
from actual test results. </CENTER>
</H2>
Self-reporting by users, of the frequency of their drug use, is the measure
used In a variety of studies regarding prevention strategies, needle exchange
programs, and effects of treatment interventions, to indicate the success
rate of these programs. <BR>
<BR>
The report by Hindin in the International Journal of the Addictions, 29:771-789,
1994, highlights the fact that when an objective measurement is done, such
as an assay of hair for actual determination of cocaine, heroine, and marijuana
use, the indication is far greater than that reported by the user. <BR>
<BR>
Among a group of patients followed up post-treatment, only 51 percent of
cocaine positive people and 67 percent of heroin positive people gave an
accurate history by their own self report. The correlation with marijuana
was even weaker. <BR>
<BR>
<STRONG>Commentary:</STRONG> The study emphasizes the folly of depending
on self reporting as an outcome variable in any study regarding the efficacy
of treatment and prevention programs. <BR>
<BR>
Objective measures of exposure need to be done because of the notorious
inaccuracy of self reporting. This self reporting, with its obvious pitfalls,
is, however, currently being used to prove &quot;efficacy&quot; of needle
exchange programs which claim to limit the spread of HIV by providing &quot;clean&quot;
needles to addicts. The purported success of these programs is based, in
part, on self reporting by the addict of whether or not they shared needles.
O <BR>
<P><CENTER><HR><BR>
Material used in this publication has been reviewed and commented on by
William M. Bennett,M.D., Professor of Medicine, Division of Nephrology,
Clinical Pharmacology and Hypertension at Oregon Health Sciences University,
Portland, Oregon <BR>
<BR>
Drug Watch Oregon. P. O. Box 5853 . Portland, Oregon 97228-5853 </CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-143</DOCNO>
<DOCOLDNO>IA077-000514-B014-497</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR24.html 207.112.150.94 19970124114931 text/html 6922
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:49:30 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 6751
Last-modified: Tue, 29 Oct 1996 17:31:21 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Marijuana Research Review Doc 1 </TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW</CENTER>
</H1>
<H4><CENTER>A Publication of Drug Watch Oregon Volume 2, No.4, September
1995</CENTER>
</H4>
<P><CENTER><HR></CENTER>
<H3><CENTER>Use of marijuana and other illicit drugs may play role in increase
of genital abnormalities and infertility in males </CENTER>
</H3>
A report by Auger et al., New England Journal of Medicine. 332:281 -285,
1995, shows that in some countries, during the past 20 years, there was
a decline in the quality of sperm of fertile men which correlated with an
increase in genital abnormalities such as cancer and cryptorchidism. This
effect was independent of the age of the men. In the same issue of the New
England Journal of Medicine, Howards, page 312, pointed out that male infertility
is often related to lifestyle factors such as the use of marijuana, anabolic
steroids, and cocaine. <BR>
<BR>
<STRONG>Commentary:</STRONG> While associations such as these do not prove
cause and effect, it is of interest that illicit drug use could be a major
factor in the decline of fertility among men over the past two decades.
The authors of the original paper admit to not having another explanation
and acknowledge that environmental or lifestyle factors could be playing
a major role. <BR>
<P><CENTER><HR></CENTER>
<H3><CENTER>Lower IQ in Toddlers Linked to Prenatal Exposure to Marijuana.
</CENTER>
</H3>
Researchers (Day et al. Neurotoxicology and Teratology 16, 169-175, 1994),
found ''significant negative effects of prenatal marijuana exposure on the
performance&quot; of both African-American and Caucasian children in standard
intelligence tests. This negative effect on the child was related to marijuana
exposure during the first and second trimester of pregnancy. On average,
children exposed prenatally to marijuana will have a lower IQ compared to
children who are not exposed, even when the effects of various environmental
factors are adjusted for. <BR>
<BR>
<STRONG>Commentary:</STRONG> The children involved in this study were tracked
from birth to three years. The study, which included an equal number of
Caucasian and African-American women, most of whom were single and of lower
socioeconomic status, suggesting that marijuana, not race or other prenatal
factors, accounts for these changes. <BR>
<P><CENTER><HR></CENTER>
<H3><CENTER>Sleeping Problems Found in Toddlers Exposed to Marijuana </CENTER>
</H3>
Prenatal exposure to marijuana showed impairment in sleep pattern and more
awake time after sleep onset in exposed children, at age three, compared
to control children (Dahl and colleagues in the journal, Archives of Pediatric
and Adolescent Medicine, 149:145-150, 1995). Sleep deprivation is frequently
associated with emotional and behavioral difficulties and reduced attention
span, symptoms which could be associated with other psychiatric problems
as well. Marijuana directly impacts the part of the brain that regulates
sleep and arousal, causing concern that prenatal use of marijuana could
affect the development of that part of the brain, resulting in permanent
changes in sleeping patterns. <BR>
<BR>
<STRONG>Commentary: </STRONG>While studies of prenatal marijuana exposure
and long-term follow-up of children so exposed are rare, the weight of the
evidence suggests that this exposure is not without adverse consequences
for the child. <BR>
<P><CENTER><HR></CENTER>
<H3><CENTER>Substance use during Vietnam conflict associated with nine times
higher mortality rate than that for civilians </CENTER>
</H3>
Price et al., from Washington University School of Medicine, presented long
term follow-up studies on a group of Vietnam veterans, now in their mid-40's,
compared to civilian controls who did not serve in Vietnam. Veterans who
tested positive for drugs upon their return from Southeast Asia, had a nine
times higher death rate than that of the civilian controls. The death rate
for veterans who tested negative for drugs was still four times higher.
The authors concluded that substance use in the Vietnam experience played
a key role in the increased mortality. <BR>
<BR>
This is a culmination of a landmark study started in 1972 and consists of
900 soldiers who had come home from Vietnam the year before. All had been
tested for drug use. Three year follow-up interviews were conducted in 1974
when civilian controls were also added to the sample. The current study
tracks the original participants. <BR>
<BR>
Available data in the present study show that a sizeable percentage of deceased
veterans who tested positive for drugs died of drug and/or alcohol related
causes according lo death certificates. Of the deceased drug positive veterans
37 percent had alcohol or drug related causes of death, and 14 percent were
found to be homicide victims. <BR>
<BR>
While these men tested positive in one single drug test, the authors noted
that it was interesting that this one test seemed to have predicted both
the high mortality and a high risk of certain causes of death. The authors
noted that drug use was not the only statistically significant predictor
of premature death, since veterans who tested negative for drugs still had
a four times higher death rate than men of similar age and background who
did not go to Vietnam. <BR>
<BR>
<STRONG>Commentary:</STRONG> This important study should carry major alarm
messages for those who advocate casual drug use and minimalize the impact
on the medical and psychiatric health of the population. <BR>
<P><CENTER><HR></CENTER>
<H3><CENTER>Toxic Psychosis Produced by Marijuana Smoking While on Antabuse
</CENTER>
</H3>
A 36-year-old man who was on Antabuse alcohol treatment smoked marijuana
as a substitute for alcohol. He immediately developed an acute toxic psychosis
with disorientation, lack of reality, and a manic psychosis. This lasted
for 48 hours. The manufacturers of Antabuse have had one previous report
of this type of drug interaction (Lacoursiere et al., American Journal of
Psychiatry, 140:242-244, 1983.) <BR>
<BR>
<STRONG>Commentary:</STRONG> People attesting to a relative safety of marijuana
forget that there are interactions between many drugs that may lead to adverse
reactions. This example of an acute toxic psychosis in someone under treatment
for alcohol abuse emphasizes the potential for marijuana interactions with
prescription and non-prescription substances. <BR>
<P><CENTER><HR><EM><STRONG>Material used in this publication has been reviewed
and commented on by William M. Bennett M.D. Professor of Medicine, Division
of Nephrology, Clinical Pharmocology and Hypertension at Oregon Health Sciences
University, Portland, Oregon.</STRONG></EM> </CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-144</DOCNO>
<DOCOLDNO>IA077-000514-B015-44</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR31.html 207.112.150.94 19970124115001 text/html 10015
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:49:53 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 9844
Last-modified: Tue, 29 Oct 1996 17:31:25 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Marijuana Research Review Volume 3, No.1 March, 1996</TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW<BR>
<IMG SRC="../../Images/Blackbar.GIF" WIDTH="468" HEIGHT="12" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"></CENTER>
</H1>
<P><CENTER><B>	A publication of Drug Watch Oregon	                   Volume
3, No. 1, March 1996<BR>
</B><HR></CENTER>
<P>
<H3>Damaging effects of prenatal marijuana use show up in older children</H3>
<BR>
Subjects of this investigation by Fried P A, reporting on the effects of
marijuana used during pregnancy since 1978 (Life Sciences, 56:2159-2168,
1995) were primarily middle class, low-risk women who entered the study
in their early pregnancy. The offspring have been assessed repeatedly during
the neonatal period and at least annually up unto the i age of 6. While
earlier reports of children to age 3 did not reveal an association between
defects associated with in utero exposure to marijuana (memory, language
development, visual perceptual functioning), later follow-up could distinguish
between marijuana exposed children and control children.<BR>
<BR>
Prenatal marijuana exposure showed that at age 4 and older children showed
increased behavioral problems and decreased performance on visual perceptual
tasks, language comprehension sustained attention and memory. The author
concluded that the nature and the timing of the appearance of these deficits
was consistent with the notion that prenatal marijuana exposure adversely
affected behavior that is goal-directed which includes planning, organized
search, and impulse control. These findings suggested to the author that
chronic marijuana use impacted on functioning of the prefrontal lobe in
the brain.<BR>
<BR>
<B>Commentary: </B>This study documents that the adverse effects of prenatal
exposure may not become apparent until the child grows old enough to perform
high level tests such as those termed executive functioning. The danger
of drawing short-term conclusions from effects that, while introduced in
utero may take a generation to discover, have been amply documented for
other poisons ingested by expectant mothers such as lead, cocaine, and alcohol.
Some authors have suggested that differences in the functioning of children
exposed in utero to marijuana to nonexposed children often disappear by
age 2-3. However, effects of marijuana cannot be determined until enough
time has passed so that the children are expected to perform. Then, and
only then, can their performance be accurately assessed. This prospective
study provides valuable insights into the many insidious problems associated
with the use of marijuana. <BR>
<H3>Prenatal use of tobacco and marijuana by adolescent mothers causes increased
damage to infants</H3>
<BR>
Cornelius et al. studied the effects of tobacco and marijuana use during
pregnancy on length of gestation, growth, and formation of 310 children
of adolescent mothers (Pediatrics 95:738-743). The subjects were interviewed
at mid-pregnancy and after delivery to obtain information on their use of
tobacco, marijuana, and other substances before and during pregnancy. The
infants were examined by physicians 24-36 hours after birth. The average
maternal age was 16.<BR>
<BR>
Prenatal tobacco use was associated with reduced birthweight, length, and
circumferences of head and chest, but not the gestational age or the number
of physical abnormalities of the baby. Prenatal marijuana smoking was associated
with increased premature birth. Additionally, some physical abnormalities
were associated with the use of marijuana during the first trimester among
the white participants in the study These effects of prenatal tobacco and
marijuana smoke were prominent despite the lower levels of exposure in these
offspring as compared with the offspring of mothers of adult age. The authors
concluded that the risk of adverse effects from use of tobacco or marijuana
during pregnancy may be increased for offspring of adolescent mothers.<BR>
<BR>
<B>Commentary: </B>Under the best of circumstances, infants of adolescent
mothers are 2-6 times more likely to be of low birthweight compared to infants
of adult women, and these infants are at increased risk for prematurity,
complications, and infant mortality. During the first year of life, the
mortality of children born to teenagers is 2-3 times that of infants born
to older mothers, and there is a 6-told increase of Sudden Infant Death
Syndrome, Hectman L. Teenage mothers and their children: risks and problems:
A review, Canadian Journal of Psychiatry, 34:569-575, 1989. The current
study points out that the use of tobacco or marijuana can be associated
with adverse effects on newborns. The authors found that adolescent mothers
who smoked tobacco during pregnancy were more likely to binge on alcohol
and use other illicit drugs in the first trimester. Mothers who smoked heavily
had significantly lower pre-pregnancy weight. Similarly, teenagers who used
marijuana tended to use more tobacco and drink more alcohol, particularly
in the crucial first trimester when the fetal organs are being formed. It
is clear that preventive efforts aimed at eliminating the use of marijuana
and tobacco would correlate with reduction of alcohol intake, further reducing
the risk of adverse effects to the children of these adolescent mothers.
<BR>
<H3>Attention impaired by marijuana use</H3>
<BR>
If attention processes were impaired through chronic use of marijuana, this
would be important to understanding decreases in work performance, memory
learning, and every day tasks, such as driving. Previous research has shown
that cannabis use impairs attention while the user is intoxicated, but the
long-term effects of chronic use had not previously been studied. Subjects
in this study by Solowji et al (Biol Psychiatry, 37:731-739, 1995) were
recruited from the general community through advertising. The minimum requirement
for participation as a cannabis user was regular use at least once a month
for 3 years. By criteria established by the American Psychiatric Association,
all subjects could be labeled as cannabisdependent or cannabis abusers.
The control group of non-users were selected to cover the range of the age,
years of education, and sex distribution in the user group. The subjects
were excluded if they had a history of any psychiatric or neurologic disorders,
head injury, or the use of any other drugs more than once a month, or alcohol
abuse. The ability to focus attention and filter out irrelevant information
was measured and was found to be impaired progressively by the number of
years of marijuana use, but was unrelated to the frequency of use. With
increasing frequency of use the speed of information processing was delayed
significantly but was unaffected by the duration of use. The results suggested
that a chronic build-up of cannabinoid produces both short- and long-term
impairments of brain function compared to control subjects.<BR>
<BR>
<B>Commentary: </B>The data from this well-done study provide an outstanding
demonstration that marijuana use effects brain function, and documents in
an objective way what has been observed for decades, namely that marijuana
produces an attention deficit. This study was controlled for alcohol use,
educational level, and l.Q. scores. No subject involved in other illicit
drug activity was included in the sample so that these data are from individuals
who consume marijuana by smoking alone. The data developed in this study
provide evidence that iincreasing duration of cannabis use leads to progressively
impaired information processing which could lead to distractibility and
impairment in any situation where concentration and focus attention are
essential. <BR>
<H3>Passive exposure to cocaine and marijuana impacts children</H3>
<BR>
In a study by Bhushan et al (American Journal of Public Health, 84:675-686,
1994) over 7,700 infants and young children visiting the pediatric emergency
room of a New York City hospital for six months in 1992 were screened for
evidence of byproducts of marijuana and cocaine in their urine. Of the approximately
15% who were given a routine urinalysis 245 were randomly selected for further
testing. The criteria recommended by NIDA for testing exposure to drugs
was applied in 100 of the cases and no metabolites were detected. However,
when more sensitive measures for cocaine and marijuana byproducts were used
to test the remaining 145 specimens, 11 % tested positive for cocaine or
marijuana metabolites. Since these children were all age 8 and under, the
most likely avenue of ingestion is by passive exposure to smoked forms of
the drugs. There is some indication that passive low level exposure may
be cumulative in children.<BR>
<BR>
<B>Commentary: </B>Low level exposures to toxins in the environment can
only be detected by changing the detection threshold to a highly sensitive,
but still specific level. This study shows that use of NIDA limits for exposure
would not have picked up the passive exposure of children whose mothers
use smoked marijuana and cocaine in their presence. Symptoms consistent
with cocaine toxicity have been described previously in infants and toddlers
exposed to smoke of cannabinoids and free base cocaine, by Moreland, et
al., Journal of Forensic Sciences 30:997-1002, 1985. Though these children
have no substance use problems themselves their exposure may predisposed
them to such problems in the future as well as other negative physiological
consequences. <BR>
<P><CENTER>Material used in this publication has been has been reviewed
and<BR>
commented on by William M. Bennett M.D., Professor of Medicine,<BR>
Division of Nephrology, Clinical Pharmacology and Hypertension at<BR>
Oregon Health Sciences University. Portland. Oregon.</CENTER>
<P><BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-145</DOCNO>
<DOCOLDNO>IA077-000514-B015-124</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR32.html 207.112.150.94 19970124115020 text/html 10126
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:50:20 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 9955
Last-modified: Tue, 29 Oct 1996 17:31:31 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Marijuana Research Review, Volume 3, No.2, June 1996</TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW<BR>
<IMG SRC="../../Images/Blackbar.GIF" WIDTH="468" HEIGHT="12" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"></CENTER>
</H1>
<P><CENTER><B>A publication of Drug Watch Oregon Volume 3, No.2, June, 1996<BR>
</B><HR></CENTER>
<H3>Marijuana smoking associated with kidney damage</H3>
<BR>
The authors, Lambrecht et al, in Nephron, 70:494496, 1995, report on a 29-year-old
man admitted to the hospital with severe pain in his back. He had smoked
marijuana for 10 years, and just prior to admission had smoked several marijuana
cigarettes and consumed several bottles of beer. No other psychotropic drugs
were used. An area of damage in the right kidney resulting from a block
in the major branch of the right kidney artery was detected. Toxicology
screening on the urine revealed cannabinoids. All other causes of acute
kidney infarction were excluded. The world's literature on cannabis effects
on the kidney was reviewed by the authors.<BR>
<BR>
<B>Commentary: </B>This report is the first one showing clotting off of
an artery to the kidney resulting from acute marijuana smoking. The cardiovascular
effects of marijuana are well-known and include dilation of peripheral blood
vessels resulting in blood pressure changes and reflex, speeding up of the
heart rate. If the heart rate is inadequate, there may be drops in blood
flow to organs such as the kidney with resulting thrombosis of small arteries.
Marijuana is known to be associated with myocardial infarction and stroke
(Zachariah SB, Stroke 22:406-409, 1991; Charles et al. Clinical Toxicology
14:433-438, 1979). It is also possible that the marijuana damaged the blood
vessels directly, as has been suggested for other drugs of abuse, such as
amphetamines (Baden et al. New England Journal of Medicine, 284:111-113,
1971). It is clear from this case report, however, that a previously healthy
male with acute ingestion of marijuana can clog the blood vessels of a major
organ.
<H3>British study illuminates negative aspects of regular marijuana use</H3>
A self-reporting study of the behavior of marijuana users attending a community
drug and alcohol climic was reported on by McBride in Drug and Alcohol Dependence
39:29-32, 1995. One hundred consecutive users were interviewed. All were
Caucasian and 85% were male. The mean age was 28 and their cannabis use
had been ongoing for approximately 12.5 years. No one in the sample was
employed. All were receiving state benefits. Eighty percent smoked tobacco
cigarettes as well. The author found that the average consumption of cannabis
in the week preceding the interview was 10.5 grams with 60% of interviewees
smoking daily. The average cannabis cigarette comprised 3 cigarette papers,
the tobacco from three-quarters of a king-sized cigarette, and 0.35 grams
of cannabis resin. Only 26% of the sample smoked tobacco in the absence
of cannabis. Only 5% of the population took cannabis by oral ingestion.
The amount of money spent on the cannabis averaged &#163;35.00 or approximately
$50.00 per week at current exchange rates. The author concluded that the
high doses of cannabis used, the frequency of use, and the expenditure on
the drug relative to income raised questions about the assumed benign effects
of cannabis among those attending such clinics.<BR>
<BR>
<B>Commentary: </B>Heavy use of cannabis was documented in patients attending
drug and alcohol clinics for which cannabis was not the primary reason for
referral to the clinic. Amphetamines, alcohol, opioids, and benzodiazepines
comprised 94% of the cases referred. This data shows the frequency of cannabis
use in combination with tobacco. This makes it very difficult to interpret
self-reporting data about the health effects of tobacco alone. It is clear
that drug-seeking behavior, even in patients undergoing treatment for drug
and alcohol abuse, is not completely gone since other drugs are being used
at the same time. Perhaps the difficulty in obtaining a higher level of
treatment success relates to this fact. It is also startling to note the
amount of money being spent on cannabis by a population supported by the
government and in whom tremendous healthcare resources are being expended.
<H3>Marijuana cigarette triggers severe hyperthermia</H3>
The symptoms of heatstroke include a body temper-ature of 104&#176; F or
greater, and delirium, coma, or seizures. Many drugs and chemicals have
been associated with heatstroke, including amphetamines, cocaine, LSD, and
PCP. Walter and associates, in Clinical Toxicology, 34:217-221, report a
case of life-threatening hyperthermia associated with the use of marijuana
alone. A 24 year-old man with a history of smoking one marijuana cigarette
twice a month for many years left his office immediately after smoking one
marijuana cigarette. He was acclimatized to the environment but had been
jogging for only one week. The temperature was 84&#176; F with a low relative
humidity. He had no preexisting medical conditions. After jogging for 15
minutes, he became acutely ill and collapsed. Paramedics were called who
noted a hot, red, dry skin and an agitated combative condition. They took
him to an emergency department where his rectal temperature was recorded
at 107&#176; F. He required aggressive cooling and a tracheal tube for assisted
breathing. It took him 16 hours to return to his usual mental state. All
tests were negative except for urine and blood toxicology screens, which
showed cannabinoids. No other drugs associated with hyperthermia were detected.<BR>
<BR>
<B>Commentary: </B>This case report fits with animal studies and some human
data showing that marijuana interferes with normal temperature control.
In animal studies, marijuana has been shown to produce a condition known
as poikilothermia, which is a loss of the ability to regulate temperature
control. Marijuana is known to increase heat production in humans (Hanna
et al. Aviation Space Environmental Medicine, 47:634-639, 1976, Rosenberg
et al. Cntical Care Medicine, 14:964-969, 1986). Thus, people who smoke
marijuana in environments of high temperature and exert themselves are excessively
predisposed to hyperthermia, which can be lifethreatening. The smoker feels
less hot than they really are because of constriction of skin blood vessels
and diminished sweating. The impaired ability to feel overheated produces
a greater chance of developing heatstroke.
<H3>THC causes abnormalities in immune molecules</H3>
Zhu and colleagues continue a series of investigations into the mechanism
of the immunological effects of the active ingredient in marijuana smoke,
tetrahydrocannabinol (The Journal of Pharmacology and Experimental Therapeutics,
274:10011007, 1995). These authors had previously reported that interleukin
2, a potent substance released by activated immune cells (which are necessary
for a proper immune response) is suppressed by ingredients in marijuana
smoke. The current studies use a line of cloned natural killer cells of
the immune system which are mixed with varying concentrations of THC. These
cells were blocked in their ability to display this important molecule.
The authors suggest that this effect may account in part, at least, for
the THC suppression of the immune response.<BR>
<BR>
<B>Commentary: </B>Further studies by the active immunology group of Klein,
et al, at the University of South Florida, has further explained the way
in which the active ingredient of marijuana can suppress the immune response.
Somewhat surprisingly, the liberation of an important molecule by lymphocytes
was not reduced, but instead, the place where it attaches on activated cells
was suppressed. The result of this abnormality is that a cloned cell line
of natural killer cells could not function in their ability to attack invading
foreign molecules. Although these results are done in a test tube, it is
frightening to think what the implications of this work is for patients
already immunosuppressed by the viral disease, AIDS, where part of the viral
infection is impairment of the immune system. Smoking marijuana in this
setting would further depress the body's ability to fight those invading
organisms which, ultimately, are the cause the death of most AIDS patients.
<H3>Rectal THC effective as an appetite stimulant</H3>
One potential use of delta-9 THC (dronabinol) is as an appetite stimulant
in patients with cancer or AIDS. Mattes et al., Pharmacologic Pharmacology
Biochemistry, and Behavior, 49:187-195, 1994, reviewed the subject of cannabinoids
and appetite stimulation. They noted that most but not all prior studies
showed marijuana to have some appetite stimulating property. In this study
eleven subjects, all of whom were casual marijuana cigarette users, were
observed. The authors compared oral THC with administration by a rectal
suppository. Mean daily food intake was significantly increased when the
patient was routinely using the rectal suppository, but this did not occur
with either an oral capsule or dissolving an oral dose under the tongue.<BR>
<BR>
<B>Commentary: </B>This study confirms the efficacy of rectal suppositories
in appetite stimulation. The drug absorption from the rectal suppository
was adequate to accomplish the therapeutic goal compared to oral or inhalation
routes. There was no correlation between drug efficacy and the age, gender,
the dnug &quot;high,&quot; or plasma drug levels. This study further supports
the possibility of developing a rectal suppository form of delta-9 THC for
use in appetite stimulation in chronically ill patients. <BR>
<P><CENTER>Material used in this publication has been reviewed and commented
on<BR>
by William M Bennett, M.D., Professor of Medicine, Division of<BR>
Nephrology, Clinical Pharmacology and Hypertension at Oregon Health<BR>
Sciences University, Portland, Oregon</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-146</DOCNO>
<DOCOLDNO>IA077-000514-B015-225</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MRR33.html 207.112.150.94 19970124115049 text/html 8518
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:50:34 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 8347
Last-modified: Fri, 17 Jan 1997 07:33:55 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Marijuana Research Review Volume 3. No. 3. October, 1996</TITLE>
</HEAD>
<BODY>
<H1><CENTER>MARIJUANA RESEARCH REVIEW<IMG SRC="../../Images/Blackbar.GIF"
WIDTH="468" HEIGHT="12" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></CENTER>
</H1>
A publication of Drug Watch Oregon	                                    
     Volume 3, No. 3, October 1996
<P><CENTER><HR></CENTER>
<P>
<H3>Study cites marijuana as factor in increased crime and emergency room
episodes</H3>
<BR>
&quot;A substantial proportion of the US population has used illicit drugs,
resulting in increased risk of injury, disease, and death,&quot; (BA Rouse,
Clinical Chemistry 42:8(B) 1330-1336, 1996). From this perspective, Rouse
examined the National Institute of Justice Drug Use Forecasting (DUF) system
and two studies from the Substance Abuse and Mental Health Services Administration,
i.e., the National Household Survey on Drug Abuse and the Drug Abuse Warning
Network (DAWN), to chart the role of illegal or nonmedical drug use in emergency
room episodes and interactions with the criminal justice system.<BR>
<BR>
The DAWN report showed marijuana use had increased significantly in all
age groups and that in emergency room treatment &quot;most marijuana related
episodes also included mentions of other drugs, particularly alcohol and
cocaine.&quot; Nonetheless, marijuana use alone was a significant factor
in emergency room visits.<BR>
<BR>
<B>Commentary:</B> In the DUF study on the relationship between drugs and
crime it was noted that since an arrest may occur long after an offence
has taken place, determination as to whether or not drugs were a factor
is often minimised. Additionally, only the most serious offence for which
a person was booked was reflected. That being the case, it is highly likely
that drug offences are under reported.<BR>
<H3>Marijuana users incur Increased health care costs</H3>
<BR>
Marijuana smoke contains carcinogens and more tars than tobacco smoke. However,
little epidimeologic evidence has identifled marijuana smoking as a risk
factor for health. Polen et al (Westem Journal of Medicine, Vol. 158, pp
596601, 1993) studied the health effects of smoking<BR>
marijuana by comparing daily marijuana smokers who never smoked tobacco
(452 patients) with a demographically similar group of non-smokers of either
substance (450 patients). Daily marijuana smokers had a 19% increased risk
of out patient visits for respiratory illnesses, a 32% increased risk of
inury, and a 9% increased risk of other illnesses compared to non-smokers.
They also had a 50% increased risk of being admitted to the hospital. These
results were adjusted for sex, age, race, education, marital status, and
alcohol consumption.<BR>
<BR>
<B>Commentary: </B>Daily marijuana smoking, even in the absences of tobacco,
appears to be associated with an elevated risk of adverse health outcomes,
including an excessive use of health care resources. Many marijuana smokers
also smoke tobacco and the adverse health consequences of using these two
substances together are likely to be multiplied. <BR>
<H3>Lung cancer causing carcinogen more prevalent in marijuana than tobacco</H3>
<BR>
A breakthrough report published in the journal Science, October 18, 1996,
provides the first true molecular evidence conclusively linking components
in tobacco smoking to lung cancer. A chemical found in tobacco smoking,
benzopyrene, causes genetic damage in lung cells that is identical to the
damage observed in the DNA of most malignant tumors of the lungs.<BR>
<BR>
Although scientists have been convinced in the past that smoking causes
lung cancer, the strong statistical associations did not provide absolute
proof. This paper absolutely pinpoints that mutations in lung cancer cells
are caused by benzopyrene. An average marijuana cigarette contains 30 nanograms
of this carcinogen compared to 21 nanograms in an average tobacco cigarette
(Marijuana and Health, National Academy of Sciences, Institute of Medicine
report, 1982). This potent carcinogen suppresses a gene that controls growth
of cells. When this gene is damaged the body becomes more susceptible to
cancer. This gene, P53, is related to half of all human cancers and as many
as 70% of lung cancers.<BR>
<BR>
<B>Commentary: </B>Clearly marijuana smoke contains more of the potent carcinogen
benzopyrene than tobacco smoke. Furthermore, the technique of smoking marijuana
by inhaling deeply and holding the smoke within the lungs presents a chance
of much greater exposure than a conventional tobacco cigarette.<BR>
<H3>Marijuana interferes with brain's ability to metabolize glucose</H3>
<BR>
Marijuana is the most widely used illicit drug in the United States, but
its short and long term effects on brain metabolism are not clearly understood.
Volkow et al (Psychiatry Research: Neuroimaging, Vol 67, pp 29-38, 1996)
studied brain glucose metabolism in daily marijuana users at baseline and
during marijuana intoxication. They used the sophisticated technique of
positron emission tomography (PET scan) which gives a visual picture of
the actively metabolizing brain.<BR>
<BR>
The results of eight chronic marijuana users were compared with age and
sex matched normal subjects. They found that THC, the main psychoactive
component of marijuana, produced lower glucose metabolism in the cerebellar
part of the brain. A single THC dose in a chronic user increases metabolism
in other specific parts of the brain. This does not occur in the non-using
controls. The activation of chemical metabolism pathways in the brains of
users, as compared to the controls, could lead to the drive and compulsion
to self-administer the drug observed in addicted individuals.<BR>
<BR>
<B>Commentary: </B>This sophisticated use of PET scanning which illustrates
individual regions of the brain and their abilities to metabolise glucose,
the main energy source of the brain, documents an abnormality in chronic
users of marijuana. The location of the abnormality in the cerebellum could
account for the motor defects and lack of coordination previously reported
in these subjects. This has obvious implications for public safety and operation
of motor vehicles by marijuana users. <BR>
<H3>Researcher calls for more studies of impact of marijuana on brain</H3>
<BR>
In an editorial (JAMA 996;275:521-527) Robert I. Block, Ph.D, discusses
a study by Pope &amp; Yurgelun-Todd in the same issue relative to marijuana
use and brain function. Dr. Block laments that there is &quot;so little
scientific information to communicate about adverse effects of chronic marijuana
use on human cognition or brain function&quot; He cites the Pope &amp; Yurgelun-Todd
study, which &quot;shows impairment in mental flexibility and abstraction,
as well as some aspects of leaming&quot; in frequent marijuana users, and
adds that &quot;With continued use of marijuana...the impairments might
increase over the years.&quot;<BR>
<BR>
Block notes that there is evidence of cognitive deficits &quot;persisting
for prolonged periods following cessation of marijuana use, consistent with
marijuana-induced brain alterations,&quot; and says that the recent increase
in marijuana use by US youth is a &quot;compelling motivation&quot; to conduct
more rigorous testing using the most modern detection techniques.<BR>
<BR>
<B>Commentary:</B> The editorialist feels that far too few studies have
been done on this aspect of marijuana use and praised the Pope and Yurgelun-Todd
study for &quot;incorporating a rigorously supervised, 19-hour abstinence
period before testing.&quot; His suggestion that matched studies must be
done to measure intellectual ability prior to the onset of drug use is seemingly
impractical in that it would require being able to predetermine who would
use illicit drugs. However, more well designed and controlled studies in
this area would certainly be useful. <BR>
<P><CENTER><HR></CENTER>
<P>
<P><CENTER>Material used in this publication has been reviewed and<BR>
commented on by William M. Bennett M.D., Professor<BR>
of Medicine, Division of Nephrology, Clinical<BR>
Pharmacology and Hypertension at Oregon Health<BR>
Sciences University, Portland, Oregon</CENTER>
<P>
<P><CENTER><HR></CENTER>
<P>
<P><CENTER>DrugWatch Oregon &#183; P. O. Box 5853 &#183; Portland, Oregon
97228-5853</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-147</DOCNO>
<DOCOLDNO>IA077-000514-B015-310</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWJL01.html 207.112.150.94 19970124115119 text/html 3793
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:51:05 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 3622
Last-modified: Tue, 29 Oct 1996 17:29:33 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> Medical Marijuana Refuted by Janet Lapey </TITLE>
</HEAD>
<BODY>
<H3><CENTER>MARIJUANA AS MEDICINE REFUTED BY NIH SCIENTISTS by Janet D.
Lapey, M.D.</CENTER>
</H3>
In June 1991, the U.S. Public Health Service ordered a study of the issue
of medical marijuana by the nation's top scientists at the National Institutes
of Health. In March 1992, at the completion of their long thorough review,
the NIH scientists issued a report stating that there were better, safer
drugs available than marijuana cigarettes. The report contained specific
factsheets concerning cancer chemotherapy, the AIDS wasting syndrome, multiple
sclerosis, pain, and glaucoma. <BR>
<BR>
These factsheets stated that &quot;Marijuana cigarette smoke contains a
complex mixture of over 400 compounds including polyareomatic hydrocarbons
which are carcinogenic. This would be a concern for anyone, but especially
for patients with chronic disorders and/or impaired immune systems.&quot;
<BR>
<BR>
The National Eye Institute factsheet on the Therapeutic Use of Marijuana
for Glaucoma states that the NEI did research on marijuana from 1978 to
1988, and &quot;none of the studies demonstrated that marijuana or any of
its components could safely and effectively lower intraocular pressure enough
to prevent optic nerve damage from glaucoma.&quot; Undesirable side effects
were produced by smoking marijuana, such as elevated blood pressure and
dry eye. It was noted that these patients would also be at risk for respiratory
damage. Furthermore, marijuana smoking is not an optimal drug delivery system,
lacking a standardized product and method of assuring the bioavailability
of its active ingredients. There are 24 FDA approved drugs for the treatment
of glaucoma. In conclusion, &quot;there is no scientifically verifiable
evidence that marijuana or its derivatives are safe and effective in the
treatment of glaucoma.&quot; <BR>
<BR>
The National Cancer Institute factsheet noted that the FDA has approved
synthetic THC (Marinol) and a related synthetic drug, Cesamet, for use in
chemotherapy patients who have failed to respond to other anti-nausea agents.
However the NCI scientists believe that marijuana-related compounds probably
are not as effective as certain other antiemetics or combinations of emetics
in controlling nausea and vomiting. Moreover, inhaling marijuana smoke is
a health hazard. Other antiemetic agents such as ondansetron, metoclopramine,
droperidol, etc. have been shown to be more useful than marijuana-related
compounds as first line therapy. <BR>
<BR>
The National Institute of Neurological Disorders and Stroke factsheet stated
that there is no evidence that marijuana is effective in modifying the course
of multiple sclerosis and that only anecdotal reports of benefit have been
reported. The report mentioned that a suppository formulation of THC is
being tested on human beings and that this promises better bioavailability
than the oral form. <BR>
<BR>
The National Institute of Dental Research factsheet reported that no controlled
studies of the effects of marijuana on acute or chronic pain exist, thus
there is insufficient evidence to recommend marijuana as treatment for pain.
<BR>
<BR>
The National Institute on Allergy and Infectious Diseases factsheet reports
that studies of the effect of oral THC on the HIV-wasting syndrome are underway.
Also the suppository THC is being tested in normal volunteers. Again it
is mentioned that marijuana cigarette smoke would be a concern for patients
with compromised immune systems. <BR>
<BR>
From the Best of Idea. Fall, 1993.
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-148</DOCNO>
<DOCOLDNO>IA077-000514-B015-377</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWMM.html 207.112.150.94 19970124115144 text/html 2946
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:51:34 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 2775
Last-modified: Tue, 29 Oct 1996 17:29:48 GMT
</DOCHDR>
<TITLE> Marijuana Has No Medical Use </TITLE>
<CENTER>
<H3>MARIJUANA HAS NO CURRENTLY ACCEPTED MEDICAL USE
</H3></CENTER>

Relying on the same scientific standards used to judge all other drugs, FDA
experts repeatedly rejected marijuana for medicinal use.  
<P>
Is marijuana good medicine for illnesses we all fear?  The answer might seem obvious based simply on common sense.  Smoking causes lung cancer and other deadly diseases. Americans take their medications in many different forms, but never by smoking.  No medicine prescribed for us today is smoked.
<P>
<DL>
<DT>*  Marijuana's chemistry is neither fully known, nor reproducible.
<DT>*  Adequate safety studies have not been done.
<DT>*  There are no adequate, well-controlled scientific studies proving
marijuana is effective for anything.
<DT>*  Marijuana is not accepted for medical use in treatment by even a
respectable minority.
<DT>*  The published scientific evidence is not adequate to permit experts to
fairly and responsibly conclude that marijuana is safe and effective for use in humans.
</DL>
<P>
Beyond a shadow of a doubt, the claims that marijuana is medicine are false
and dangerous.  It is a cruel hoax to offer false hope to desperately ill
people.  Sick people can be fooled by false claims and waste precious time
experimenting with marijuana while neglecting approved medications for their specific illness.
<P>
Not one American health association accepts marijuana as a medicine.
<DL>
<DT>*  Not the American Medical Association
<DT>*  Not the National Multiple Sclerosis Society
<DT>*  Not the American Glaucoma Society
<DT>*  Not the American Academy of Ophthalmology
<DT>*  Not the American Cancer Society
<DD>
</DL>
There are over 10,000 documented scientific research papers on file at the
University of Mississippi, and not one gives marijuana a clean bill of
health.  By any modern standard, marijuana is no medicine.
<P>
Using lay testimonials, impressions of physicians, isolated case studies,
random clinical experience, reports so lacking in details they cannot be
scientifically evaluated, anecdotal proof, and statistically flawed studies,
pro drug legalization advocates have sought to establish credibility through
the medical marijuana issue.
<P>
Unfortunately, many who have limited or no medical background and politicians with little time to learn the issue have been influenced by the drug culture statements presented by the media.  In many cases, the media has ignored contrary data in thousands of research papers and opinions of highly respected medical researchers.  The result, if not the intent, of this type of irresponsible reporting is that society is being misled with an untrue and very dangerous message.    
<P>
From the Best of Idea, Illinois. Winter 1993.
</DOC>
<DOC>
<DOCNO>WT01-B04-149</DOCNO>
<DOCOLDNO>IA077-000514-B015-426</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MJforAIDS.html 207.112.150.94 19970124115215 text/html 2901
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:52:05 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 2730
Last-modified: Tue, 29 Oct 1996 17:30:53 GMT
</DOCHDR>
<TITLE> Marijuana for AIDS Patients...Think Again </TITLE>
<CENTER>
<H3>MARIJUANA TO TREAT AIDS PATIENTS?
...THINK AGAIN!
</H3></CENTER>
In The December 1993 issue of High Times Magazine, a reader who signed himself "Doper Professor," complained that after ingesting marijuana-laced "space cakes" he and his wife became "frighteningly high...accompanied by a lot of vomiting...combined with passing in and out of consciousness...which seemed potential life-threatening," adding that a doctor had to be called to give them Valium "to counteract the reaction..."
<P>
High Times responded by informing Doper Professor that "determining the desired dose is much harder if one is eating cannabis.  It is not unusual to have a panic reaction."  This would certainly appear to invalidate the claims made by San Francisco's Brownie Mary that her sole reason for possessing 200 pounds of marijuana was that she gives marijuana-laced brownies to AIDS patients to help ease their nausea and vomiting.
<P>
One of the world's leading specialists on medical quackery, Victor Herbert, M.D., J.D., of Mount Sinai and Bronx Veterans Affairs Medical Centers, wrote of this phenomenon in JAMA in October 1993.  "In some cases," he wrote, "the patient never had the disease.  In others the disease was cured or a remission was induced by genuine therapy, but the quack remedy also given was credited.  In other cases the patient died but was represented as cured.  Sometimes the patient had a spontaneous remission that was publicized as a success, but the proponents failed to keep score and publicize all the failures before and after each 'success.'  The difference between promoters of quack remedies and promoters of legitimate remedies is that only the latter keep score."
<P>
An abstract of a recent study on the Impact of tobacco and marijuana use on antioxidants in HIV-1 infected patients by Miguez-Burbano, G Shor-Posner and MK Baum at the Department of Epidemiology and Public Health at the Univ. Miami School of Medicine, in the Journal of Clinical Pharmacology 1994;34:1031, showed that vitamin E levels were significantly lower in marijuana users and cigarette smokers relative to non-users, stating that "The results of this study indicate that both marijuana and cigarettes have a detrimental effect on vitamin E status of HIV-1 infected individuals. These findings are of particular concern in light of the important role of vitamin E in immune processes, inhibition of viral activation, and the death of immune cells."
<P>
THOUSANDS OF SCIENTIFIC STUDIES ON MARIJUANA HAVE FAILED TO SUBSTANTIATE CLAIMS BY THE PRO-DRUG LOBBY THAT MARIJUANA IS SAFE OR EFFECTIVE FOR ANY MEDICAL INDICATION.  
<P>
Drug Watch Oregon. November 15, 1994
</DOC>
<DOC>
<DOCNO>WT01-B04-150</DOCNO>
<DOCOLDNO>IA077-000514-B016-257</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/MJforGlaucoma.html 207.112.150.94 19970124115352 text/html 3953
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:52:56 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 3782
Last-modified: Tue, 29 Oct 1996 17:30:57 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> Marijuana for Glaucoma? </TITLE>
</HEAD>
<BODY>
<H3><CENTER>GLAUCOMA Is Marijuana a Safe and Effective Treatment? </CENTER>
</H3>
What is Glaucoma: Glaucoma, a leading cause of blindness, in the United
States, afflicts nearly 2 million Americans, about 60,000 of whom are legally
blind. <BR>
<BR>
Open angle closure glaucoma: In the vast majority of cases this type of
glaucoma is without symptoms. It is associated with mild elevation of intraocular
pressure that produces chronic damage to the optic nerve. Open angle closure
glaucoma is treated medically with drugs that reduce aqueous humor formation.
<BR>
<BR>
Acute angle closure glaucoma: This rare form of the disease, which may include
pain, blurring of vision, halos around lights, etc., is treated with laser
or surgery. <BR>
<BR>
Although elevated intraocular pressure is a common symptom of glaucoma,
nearly 20 percent of those who have the disease do not experience elevated
pressure. For these the traditional screening tests may miss the diagnosis
and, since glaucoma patients &quot;almost never have symptoms,&quot; damage
will continue to progress in their eyes. <BR>
<BR>
Medical treatment for Open Angle Closure Glaucoma: Because the level of
pressure that causes damage varies from person to person a target &quot;normal&quot;
pressure must be determined for each patient and the treatment carefully
adjusted. &quot;Daily variations in pressure complicate the assessment of
treatment, since eyes affected by glaucoma tend to have larger fluctuations
than normal eyes.&quot; (New England Journal of Medicine, 328:1103,1993)
<BR>
<BR>
Prostaglandins:These drugs are being developed to improve aqueous humor
outflow and are believed to &quot;hold much greater promise for the hypotensive
therapy of glaucoma.&quot; <BR>
<BR>
Beta blockers: At least four are marketed in the United States and being
used sucessfully in the treatment of intraocular pressure associated with
glaucoma. According to researchers there is &quot;little motivation to develop
new inhibitors of aqueous humor formation since the market is relatively
saturated with such drugs.&quot; <BR>
<BR>
In the latest scientific evaluation of glaucoma treatment, as reported in
the New England Journal of Medicine, 328:1103,1993, marijuana was not mentioned
as having any role whatsoever. <BR>
<BR>
What about marijuana?: The country's leading ophthalmologists are &quot;chagrined&quot;
and &quot;disturbed&quot; to hear that claims are being made touting marijuana
as a treatment for glaucoma. Because of wide fluctuations in intraocular
pressure, and a numerous other factors which affect the course of this disease,
doctors agree that using marijuana as a treatment is likely to mask problems
and increase the risk of blindness. <BR>
<BR>
William T. Shults, M.D., recognized in the publication &quot;The Best Doctors
in America,&quot; for his work in ophthalmology at the Devers Eye Institute
in Portland, Oregon, noted that alcohol can also lower intraocular pressure
if one has ingested enough to be intoxicated. He added that no one would
propose using alcohol for that purpose, however, because of its many adverse
side effects. Shults stated &quot; I can see no compelling reason whatsoever
for the use of marijuana by patients with glaucoma, and believe that to
propose such a use works a cruel hoax on the public and especially those
with a chronic ocular disease for which many other better treatments are
currently available.&quot; <BR>
<BR>
Even Judge Francis Young, the DEA administrative judge often quoted by advocates
of medical use of marijuana, stated that he found insufficient evidence
to show that marijuana is an accepted treatment for glaucoma. <BR>
<BR>
(Drug Watch Oregon. 1/21/94) 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-151</DOCNO>
<DOCOLDNO>IA077-000514-B017-140</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWBrookoff.html 207.112.150.94 19970124115551 text/html 15926
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:54:27 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 15754
Last-modified: Tue, 29 Oct 1996 17:28:56 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DWBrookoff.html </TITLE>
</HEAD>
<BODY>
<H2><CENTER>MARIJUANA IS NOT MEDICINE. SOMEBODY HAD BETTER TELL YOUR DOCTOR!
</CENTER>
</H2>
<H4><CENTER>by Dan Brookoff, M.D., Ph.D. </CENTER>
</H4>
<DL>
  <DT>I give people dangerous drugs. 
  <DT>I am responsible for a lot of people using narcotics. 
  <DT>I am an oncologist. 
  <DT>I do not recommend marijuana. 
</DL>
<H3><CENTER>IS MARIJUANA A MEDICATION?</CENTER>
</H3>
My definition of a medication is a drug treatment that is aimed at one of
the following three goals:<BR>
<BR>
1. the prolongation or preservation of life, <BR>
2. the support of functioning or <BR>
3. the relief of discomfort. <BR>
<BR>
<STRONG>The use of drugs for other purposes is not medicine.</STRONG> <BR>
<BR>
My guiding principle in caring for a patient is that any medication that
I use must be the best available treatment for that particular situation.
Because of this, marijuana cannot be considered a medication. <BR>
<H3><CENTER>IS MARIJUANA NOT A MEDICATION BECAUSE IT IS TOXIC?</CENTER>
</H3>
Some of the drugs we use in the medical treatment of cancer have toxic side
effects. The toxic effects of a drug don't necessarily disqualify it as
a medication. Sometimes it is worth using a very toxic medication if the
potential benefits are great. For example, many cases of leukemia can be
cured but at the cost of severe side effects. In some cases, the severe
side effects are not a risk -- they are a certainty. <BR>
<H3><CENTER>IS MARIJUANA NOT A MEDICATION BECAUSE IT IS UNCONVENTIONAL?</CENTER>
</H3>
Just because a treatment is not &quot;conventional&quot; doesn't disqualify
it as a medication, either. Sometimes, there are no conventional treatments
available for a particular problem. After weighing the risks and benefits
of an unusual treatment, my patient may feel that he or she wants to undergo
an alternative therapy. If I am sure that my patient is fully informed,
is not forgoing a treatment that has a better potential for success, and
is not exposing himself or herself to needless risk, I (and many physicians)
will help the patient gain access to that treatment. I have certainly recommended
alternative medical treatments for several of my patients with AIDS and,
frankly, I am glad that I did; however, marijuana is neither an acceptable
medical treatment nor an alternative medical treatment for any illness.
<BR>
<H3><CENTER>BUT MARIJUANA CAN RELIEVE CHEMOTHERAPY-INDUCED NAUSEA; ISN'T
THAT AN IMPORTANT PROBLEM? </CENTER>
</H3>
When one of my patients has a cancer problem that can be helped by treatment
with chemotherapy medications, I will recommend that we proceed with treatment.
Many of these drugs have serious side effects that we must take into consideration
and be prepared to manage. Often, I will also recommend the use of medications
to alleviate symptoms caused by the cancer (such as the judicious use of
narcotic medications for the relief of pain). I will also use medications
to relieve the symptoms caused by chemotherapy treatments, such as nausea.
<BR>
<BR>
Whenever I recommend that a patient undergo chemotherapy treatment, I always
make sure that we have a lot of time to discuss the effects of a particular
treatment and how they will be managed. I find that the word &quot;chemotherapy&quot;
usually evokes a lot of anxiety. People facing the prospect of chemotherapy
invariably know of someone who underwent cancer treatment and suffered a
great deal of discomfort. The most frightening symptom that people associate
with chemotherapy is not pain, but rather uncontrollable nausea and vomiting.
While this is not a problem with many types of chemotherapy treatments,
it has been common enough over the years to give rise to a lot of legitimate
fear. The good news is that within the last 10 years, safe and effective
treatments for chemotherapy-induced nausea and vomiting have made this fear
a thing of the past. <BR>
<H3><CENTER>IS THERE EVER A CIRCUMSTANCE IN WHICH MARIJUANA IS THE BEST
AVAILABLE TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING? </CENTER>
</H3>
I never recommend that my patients use marijuana. I want to explain why
in the most balanced and compassionate way I can. To understand why I feel
the way I do, it is important to understand some of the medical details
about chemotherapy-induced nausea and vomiting. <BR>
<BR>
Chemotherapy drugs cause nausea by stimulating an area of the brain called
the chemoreceptor trigger zone. Typically, nausea and vomiting begin 90
minutes to three hours after the administration of the chemotherapy and
can last for up to six hours. For certain chemotherapy medications, such
as platinum and intravenous cyclophosphamide, the onset of nausea may be
delayed for up to 18 hours and may have a somewhat more prolonged course
of up to four days. <BR>
<BR>
Patients whose nausea and vomiting have been poorly controlled can become
conditioned into developing anticipatory nausea, which can begin even before
the treatment begins. Since there are several different chemical receptors
in the brain which control the sensation of nausea, several different types
of drugs have proven effective in its treatment. All of these medications
need only be used for very limited periods of time. <BR>
<BR>
The most successful group of anti-nausea drugs has been the recently introduced
medications which block serotonin receptors in the chemoreceptor trigger
zone, such as ondansetron. These medications have proven to be safe and
effective for both adults and children and generally have only mild side
effects. <BR>
<BR>
Another group of drugs which has proven safe and effective for the treatment
of chemotherapy-induced vomiting are medications which block dopamine receptors,
such as metoclopramide and haloperidol. Other dopamine-blocking medications
as the phenothiazine medications (which include Thorazine and Compazine)
are somewhat effective but are inferior and remain &quot;third choice&quot;
medications. <BR>
<BR>
Other medications, such as certain steroids and minor tranquilizers, have
proven safe and effective for the treatment of chemotherapy-induced nausea
and vomiting, usually when used in conjunction with another anti-nausea
drug. <BR>
<H3><CENTER>WHAT ABOUT DRUGS DERIVED FROM MARIJUANA? </CENTER>
</H3>
A class of drugs derived from marijuana called the cannabinoids has also
been shown to have some anti-nausea effects, but this activity is no greater
than that of third-choice drugs. <BR>
<BR>
Cannabinoids also cause more side effects than the other anti-nausea drugs
(sedation, dizziness, low blood pressure, and an unpleasant sensation called
dysphoria). A purified form of the cannabinoid Delta-9 THC has been available
on the American market for eight years under the brand name Marinol. Despite
its availability it has found limited use, because it generally doesn't
work. If you look at the advertisements for Marinol placed in the medical
journals by its manufacturer (Roxane Laboratories), it is touted as &quot;more
effective than Compazine,&quot; which is a third-choice medication for the
treatment of chemotherapy-induced nausea and vomiting. <BR>
<H3><CENTER>IS MARIJUANA MORE EFFECTIVE THAN THE DERIVATIVES THAT ARE CURRENTLY
ON THE MARKET? </CENTER>
</H3>
Every few years, the lay press brings up the issue of using inhaled marijuana
for the treatment of chemotherapy-induced nausea. For physicians, this issue
was settled 10 years ago when Dr. M. Levitt and colleagues conducted a randomized
double-blind comparison of Delta-9 THC and marijuana for the treatment of
chemotherapy-induced nausea and vomiting. (This is published in the 1984
Proceedings of the American Society of Clinical Oncology, volume 3, page
91.) What they found was that neither agent was particularly useful (75
percent of patients in both groups suffered significant nausea and vomiting),
and among patients expressing a preference, Delta-9 THC was chosen the best
agent. Inhaled marijuana has nothing to add to the limited benefits of purified
Delta-9 THC. It does carry added risks due to its method of delivery and
its impurity. This includes toxic effects on the lungs, additional side
effects, and the danger of infection from fungus which is often found in
marijuana cigarettes. Marijuana is never the best available treatment for
a patient, and that is why it is not a medication. <BR>
<H3><CENTER>IF MARIJUANA ISN'T A MEDICATION, WHY AREN'T PHYSICIANS UP IN
ARMS ABOUT THE CURRENT MOVEMENT TO LEGALIZE ITS USE FOR CANCER PATIENTS?
</CENTER>
</H3>
Most physicians are unaware that this is really an issue; for them the issue
was settled years ago. Years ago, when there were no effective medications
on the market for the treatment of chemotherapy-induced nausea and vomiting,
the American Medical Association considered the therapeutic potentials and
hazards of marijuana. As they examined its emerging therapeutic possibilities,
they found more and more evidence that marijuana was hazardous to health.
(Journal of the AMA, Oct. 16, 1981, volume 246, pages 1823-1827.) <BR>
<BR>
Nonetheless, many physicians (including me) had patients who participated
in treatment trials using inhaled marijuana in the late 70s and early 80s
because, at the time, there was no better alternative. With the therapeutic
potential of marijuana eclipsed by safer and more effective drugs, we have
come to the conclusion that there is no therapeutic use for marijuana. All
we are left with are the hazards. These include lung disease, cardiac dysfunction,
brain damage, genetic damage, immune disorders and psychomotor impairment.
<BR>
<H3><CENTER>HOW CAN PHYSICIANS' NON-RESPONSE TO THE ISSUE OF THE MEDICINAL
USE OF MARIJUANA BE EXPLAINED? </CENTER>
</H3>
I have to admit that when I was first confronted with the issue of &quot;medical
marijuana&quot; by my friends in the prevention field, I couldn't get very
excited about it. I felt that the facts obviously showed that there was
no medicinal use for inhaled marijuana and, as such, it was not a subject
worthy of serious concern. As I mentioned to a friend, I classed the medical
use of marijuana right up there with the issue of therapeutic bathing in
Drano! I was against that too, but I couldn't see that anybody could seriously
be in favor of it. <BR>
<H3><CENTER>HASN'T THERE BEEN RECENT SCIENTIFIC EVIDENCE TO SHOW THAT MARIJUANA
CAN BE USEFUL AS A MEDICATION? </CENTER>
</H3>
If you look up &quot;marijuana&quot; in the last few years of the journal
used by most clinical oncologists (Journal of Clinical Oncology) you'll
find only one mention of marijuana (a sign that it's not a hot topic for
us). That mention is made in an article by Richard Doblin and Mark Kleiman,
of Harvard University, that reports a survey that they conducted of physicians
and that purports to &quot;suggest that support for rescheduling marijuana
is indeed present in at least a significant minority of our population (oncologists).&quot;
<BR>
<BR>
The report, which appears in the Journal of Clinical Oncology volume 9,
pages 1314-1319, does not mention how the authors selected doctors to respond
to their survey, and it also doesn't mention the authors' affiliation with
any of the pro-marijuana organizations to which they belong (no bias there?).
While this article did not have much of an impact on oncologists, mention
of it was made in letters to many medical journals -- letters written by
Doblin and Kleiman. <BR>
<BR>
These letters were generally ignored by physicians. This would almost be
funny if all these references weren't being used by pro-marijuana forces
to convince ill-informed government officials that there is medical evidence
to support the use of marijuana. <BR>
<H3><CENTER>WHAT ABOUT THE BOOK ON MARIJUANA WRITTEN BY A PROFESSOR AT HARVARD
MEDICAL SCHOOL? </CENTER>
</H3>
Another source cited as evidence of the therapeutic effects of marijuana
is a book that was recently written by Dr. Lester Grinspoon of the Harvard
Medical School (&quot;Marihuana, the Forbidden Medicine&quot;). The book
is poorly written, unscientific, and makes some absolutely bizarre claims
for the use of marijuana. (For example, Dr. G. says it promotes safe driving!)
<BR>
<BR>
Many people in the prevention field were justifiably angered when they read
this book. I read the book, and I found it very disturbing. I must say that
my predominant emotional reaction was to feel sorry for Dr. Grinspoon. <BR>
<BR>
Dr. Grinspoon was obviously moved to write this book because of his experience
with his young son Danny. Danny had leukemia, and his treatments caused
severe nausea and vomiting that did not respond to the medications that
were available at that time. Danny could barely tolerate his chemotherapy
treatments, and I'm, sure that his parents could barely stand to watch him
suffer. Nonetheless, they must have thought that the chemotherapy treatments
held some potential benefit for Danny, so they urged him to continue. <BR>
<BR>
In 1971, Danny found that smoking marijuana helped him tolerate his treatments.
His doctors, feeling that this was the best available treatment, supported
Danny's smoking and conducted research which eventually led to the development
of Marinol. Dr. Grinspoon writes that, during the remaining year of his
life, Danny used marijuana before his chemotherapy treatments and because
of his marijuana use, Danny and his parents were all much more comfortable.
Because of this, Dr. Grinspoon must have some strong positive associations
with marijuana, and he has become an advocate for its use as a medication.
<BR>
<BR>
Marijuana is not a medication. Marijuana was a medication when Danny used
it. At the time it was the best available treatment, and he used it in a
medical, life-affirming way. He did not use it to escape his life. He used
it to help him undergo treatment so that he could continue his life. <BR>
<BR>
I am sure that Dr. Grinspoon would not recommend that people undergo the
same leukemia treatment that Danny underwent over 20 years ago. There are
now new treatments that are more effective and safer. (These days most children
with the type of leukemia that Danny had are cured.) I think that the same
holds true for Danny's anti-nausea treatment. These days, no oncologist
would recommend marijuana, because there are safer and more effective treatments.
<BR>
<H3><CENTER>IS MEDICAL MARIJUANA A SERIOUS ISSUE?</CENTER>
</H3>
The thing that really frightens me is that some people will use Dr. Grinspoon's
tragedy to construct an even larger tragedy. I worry that the well-financed
advocates of the recreational use of marijuana -- e.g. the people that want
to sell it to my kids -- are using this wedge of false medical evidence
to open the door for the legalization and wider recreational use of marijuana.
The glibness with which our new (and obviously uninformed) Surgeon General
has come out in favor of using inhaled marijuana is scary and shows that
even some doctors (though I'm sure it's very few) don't always think before
they speak. This is a serious issue, and I am worried that most doctors
won't get involved until it is too late. <BR>
<H3><CENTER>SOMEBODY HAD BETTER TELL YOUR DOCTOR!</CENTER>
</H3>
<HR>(Fall 1993) Daniel Brookoff, M.D., Ph.D., is certified by the American
Board of Internal Medicine with a Subspecialty Certification in Medical
Oncology. He is a member of the American College of Physicians, American
Medical Association, American College of Emergency Physicians, American
Pain Society and Society for Academic Emergency Medicine. He has published
numerous papers on hematology-oncology, pain management, emergency medicine
and drug complications. Dr. Brookoff is a member of the International Drug
Strategy Institute. <BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-152</DOCNO>
<DOCOLDNO>IA077-000514-B018-47</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/CAMJINIT.html 207.112.150.94 19970124115836 text/html 4289
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:57:04 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 4118
Last-modified: Tue, 29 Oct 1996 17:28:31 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DW CA Marijuana Initiative, August 1996 </TITLE>
</HEAD>
<BODY>
<H2><CENTER>Statement Against California Marijuana Initiative 1996</CENTER>
</H2>
<BR>
It is not compassionate, and should never be legal, to provide a harmful
addictive drug which<BR>
has never been scientifically proven safe or effective as required by Federal
consumer<BR>
protection laws.<BR>
<BR>
This initiative creates a giant loophole to grow and deal marijuana, endangering
the health and<BR>
safety of all, and it puts California in conflict with Federal law.  This
initiative falsely implies<BR>
that marijuana cigarettes alleviate disease; however, there is no scientific
proof that marijuana<BR>
is safe or effective for ANY illness.  Its use masks symptoms, discouraging
ill people from<BR>
seeking medical care, often causing them direct harm.<BR>
<BR>
In 1994, a US Court of Appeals ruled marijuana remain a Schedule I drug:
highly addictive,<BR>
no medical usefulness.  The court noted that the pro-marijuana physicians
had relied on non-<BR>
scientific evidence.  The Food and Drug Administration (FDA) has approved
THC, marijuana's major ingredient, for limited medical use.  Pure synthetic
THC, marketed as Marinol, is available by prescription in pill form for
treatment of nausea in some cancer chemotherapy patients and as an appetite
stimulant for AIDS Wasting Syndrome.<BR>
<BR>
The FDA has NOT approved crude marijuana, which has more than 425 chemicals
converting to thousands when smoked; many are toxic and cancer-causing.
Smoking is harmful; no medicine is administered by smoking.<BR>
<BR>
<STRONG>AIDS: </STRONG> Scientific studies indicate marijuana cigarettes
damage the immune system, causing further peril to already weakened immune
systems.  HIV-positive smokers progress to full-blown AIDS twice as fast
as non-smokers and have an increased incidence of bacterial pneumonia.<BR>
<BR>
<STRONG>CANCER: </STRONG> Marijuana contains many cancer-causing substances;
some are present in higher concentrations in marijuana smoke than in tobacco
smoke.  Studies have linked marijuana to a number of cancers in young marijuana
smokers, including cancer of the mouth, tongue, larynx, jaw, head, neck,
and lungs.<BR>
<BR>
<STRONG>GLAUCOMA: </STRONG> Marijuana does NOT prevent blindness due to
glaucoma.<BR>
<BR>
Marijuana is harmful to lungs, heart, immunity, and reproduction.  Recent
studies have shown<BR>
numerous abnormalities, including low birthweight, behavioral disorders,
lower IQ, and an<BR>
eleven-fold increase in childhood leukemia in offspring of mothers who smoked
marijuana during pregnancy. Since marijuana impairs mental functioning,
it is a known cause of many motor vehicle and industrial accidents.<BR>
<BR>
Marijuana is currently up to 25 times more potent than it was in the 1960s.
It remains in the bodys fat cells for months. Marijuana is a major cause
of addiction, often requiring rehabilitation/treatment. Research links marijuana
to the use of cocaine and other drugs. The number of young users of marijuana
is rising because of the marijuana as medicine propaganda.<BR>
<BR>
The initiative bypasses laws designed to protect the public from unscrupulous
snake oil salesmen.  With no restrictions or regulations, this initiative
encourages cultivation and use of marijuana, allowing any physician, including
those in the marijuana lobby, to verbally approve marijuana for any condition.
 What has not been made clear to the public is that this initiative will
bypass FDA regulations designed to protect the public.<BR>
<BR>
A leading activist for marijuana legalization said pro legalization advocates
would use &quot;The<BR>
medical model as spearheading a strategy for the legalization of marijuana
by 1997.&quot;  The<BR>
California Marijuana Initiative 1996 is blatant legalization of marijuana;
it is medical quackery<BR>
and makes a mockery of the law.  <BR>
<HR><BR>
Janet Lapey, M.D., International Drug Strategy Institute<BR>
Carla Lowe, California Delegate, Drug Watch International<BR>
Telephone       916 965-4825  Fax             916 536-9733
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-153</DOCNO>
<DOCOLDNO>IA077-000514-B018-238</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/BP2.html 207.112.150.94 19970124120034 text/html 9468
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 11:59:35 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 9297
Last-modified: Sat, 21 Dec 1996 05:09:06 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Peterson's letter 12/13/96</TITLE>
</HEAD>
<BODY>
December 13, 1996<BR>
<BR>
Dan S.<BR>
New York<BR>
<BR>
Dear Dan:<BR>
<BR>
Thank you for your letter to Drug Watch International about the drug<BR>
legalization issue.  My name is Bob Peterson and I have been asked to respond<BR>
on behalf of our organization.<BR>
<BR>
I have enclosed a pamphlet about Drug Watch.  We are a group of volunteers,<BR>
both professional and lay persons ( I am an attorney), who are dedicated
to<BR>
preventing drug use and ensuring that the facts about drugs are known. 
None<BR>
of us are paid for our Drug Watch work, but all of us share a deep concern<BR>
for young people and are committed to drug prevention.  We also have no<BR>
affiliation with any government agency.  Drug Watch leaders include parents,<BR>
drug treatment professionals, medical doctors, attorneys, educators, and<BR>
community prevention experts.   <BR>
<BR>
You asked what Drug Watch does and what kind of people Drug Watch helps?
 Our<BR>
information, training, and advice has been tapped by a broad range of<BR>
individuals, from high school students (such as yourself) to national and<BR>
international government leaders.  We have helped parents find treatment
for<BR>
their children; helped communities discover resources and ideas to close
drug<BR>
houses; and, we have provided medical, scientific, and legal advice and<BR>
updates to professionals and community based groups.  Mainly, we have helped<BR>
counter the huge barrage of pro-drug propaganda that dominates the Internet,<BR>
the media, and the entertainment industry.  Millions of dollars has been<BR>
poured into the pro-drug legalization movement over the past few years and<BR>
almost no money has been spent to balance it.  While we cannot counter the<BR>
funding we do provide a balance to their barrage of misinformation.<BR>
<BR>
Why do we feel that controlling drugs is the right thing to do?  For many<BR>
reasons, but the top reason is probably to protect children.  All of us
lived<BR>
through the 1970's when drug legalization was a popular idea and even the<BR>
President talked of decriminalizing pot.  Our nation's attitude was very<BR>
permissive toward drugs and although drug arrests were made, the<BR>
incarceration rate for drugs went down dramatically.  The result was record<BR>
drug use among high school students and among adults as well.  In 1979,<BR>
nearly one in ten high school seniors was stoned on pot every day of the
week<BR>
and drug incarceration rates were at an all time low point - support for
drug<BR>
legalization was at an all time high.<BR>
<BR>
Drug prevention combined with tougher drug control in the 1980's brought<BR>
about a less permissive attitude and less acceptance of drugs.  This resulted<BR>
in cutting the use of drugs in half from 1980-1992, especially among young<BR>
adults and children.  Support for drug legalization fell also and drug<BR>
incarceration rates rose for the first time since the year 1960.  However,
in<BR>
the past few years things have begun to change again.  The pro-drug<BR>
legalization movement grew by millions of dollars and support for drug<BR>
legalization went up again.  The use of drugs, especially pot, has doubled<BR>
among teens in just four years!<BR>
<BR>
Legalizing drugs would not solve any of our social problems.  You mentioned<BR>
prison overcrowding.  There is a lot of propaganda about this issue.  Did
you<BR>
know that 93% of prisoners are repeat or violent offenders and that first<BR>
time non-violent marijuana offenders make up only 1/10th of 1% of the prison<BR>
population (and these might have been dealers who pled down).  Alcohol is<BR>
legal and yet there are three times as many alcohol related arrests than<BR>
there are drug arrests.  If drugs were legal there would likely be a 300%<BR>
increase in drug arrests, not a decrease! <BR>
<BR>
From 1960-1980 the drug incarceration rate (the % of drug convicts actually<BR>
locked up) dropped by 374% and violent crime and property crime skyrocketed.<BR>
 The murder rate peaked the year that drug incarceration rates were at an
all<BR>
time low point.  Nearly all of the drug prisoners are hardcore criminals
who<BR>
make their living out of crime, when you lock up the drug dealer you also<BR>
have locked up the mugger and the burglar!  From 1980-1994 the drug<BR>
incarceration rate rose swiftly and crime of all types went down - especially<BR>
property crimes that victimize the most people.  I have enclosed a few pages<BR>
of my book on this topic for you.<BR>
<BR>
You mentioned the cost of drug regulation.  Of course if drugs are legal
they<BR>
would be even more regulated.  There would be government regulations on
drug<BR>
imports, drug purity, drug types, drug farms, and security and taxes and<BR>
sales and age limits.  The cost of tobacco and alcohol warn us that tax<BR>
revenues can never make up enough to pay their way.  The increased health<BR>
care costs would hurt us all.  Most police time is spent on petty crime
and<BR>
disturbances and if drugs are cheaper and easier to get, there will be far<BR>
more demands on police time.  Drug testing of drivers and workers also would<BR>
have to be expanded and our civil rights would diminish.<BR>
<BR>
Lastly, you state that you believe that drugs are a personal choice and
many<BR>
legalization advocates hold that viewpoint as well.  We greatly respect<BR>
individual liberty and personal freedom.  We respect it for the person who<BR>
does not use drugs as well.  It is our view that drugs do not only affect
the<BR>
person that is using them and, like other hazardous substances, they are
a<BR>
danger to innocent non-users.  <BR>
<BR>
The most hideous violence in society is perpetrated against children by<BR>
adults through child abuse and neglect.  If drugs were legal, cheaper, and<BR>
easier to get, would there be more crack addicted babies born, or fewer?<BR>
 With more fathers and mothers stoned, more often, would there be less child<BR>
abuse, or more?  In some cities over 80% of child abuse killings are related<BR>
to the use of cocaine, yet only 2-3% of adults use cocaine regularly.<BR>
<BR>
When a person uses drugs they use them to get intoxicated and once the brain<BR>
is impaired people do not make good decisions about driving, child care,
or<BR>
workplace safety.  It is our ability to reason and to think clearly that<BR>
enables us to make choices freely.  All of society is at risk from drug
use,<BR>
not just the user.  Among big rig truckers killed in accidents, as many
had<BR>
pot in their system as had alcohol, even though there are five times as
many<BR>
regular drinkers.  If pot were legal, even more accidents would occur. 
Have<BR>
you ever been to a high school or public event and seen an intoxicated person<BR>
annoy others or start fights.  That is an intrusion on your rights caused
by<BR>
intoxicating drugs.  Legalization will not improve the situation.<BR>
<BR>
Most of us in Drug Watch have seen the damage drugs cause firsthand.  Some<BR>
have wept with mothers who have lost their son or daughter to addiction
or to<BR>
drug related accidents.  Some have gone through it with their own children.<BR>
 Some have treated the abused children of addicts.  Some have tried to patch<BR>
up the broken bones and bodies in emergency rooms.  Some have watched healthy<BR>
happy teens withdraw into bitter rebellion and loneliness.  Some have seen<BR>
drugs steal the best and brightest minds.  Some have helped others work<BR>
through the family, financial, and legal wreckage.  Some regularly visit
the<BR>
gravestones of people they loved dearly.<BR>
<BR>
None of us can imagine what problems legalizing drugs can ever solve and
how<BR>
it would benefit children.  None of us have ever seen someone become a better<BR>
person by taking mind numbing intoxicants.  None of us plan to let that<BR>
happen while we are alive.<BR>
<BR>
I am very happy that you wrote and that you want to hear what &quot;our&quot;
side has<BR>
to say about this issue.  I am most pleased that you do not use drugs and
I<BR>
hope that you never do.  They have nothing to offer.  You have been hit
with<BR>
a lot of propaganda from the pro-drug legalization side.  MTV, Rolling Stone,<BR>
music bands, and mass media have worked hard to promote this legalization<BR>
idea.  In fact, recently one billionaire gave over $15 million to the<BR>
legalization cause.  I hope that you can sift through the myths and the
facts<BR>
on this issue.  It seems that many of the legalizers are a bit older than
I<BR>
am and white and from fairly wealthy homes.  They only relate drugs to their<BR>
60's experience or their ivy league college times and from that perspective<BR>
they may sound convincing.  <BR>
<BR>
Drug Watch believes that we have to protect the poor, as well as the rich,<BR>
and people of all races and gender. Our focus should be on the needs of<BR>
children - not the desires of a few selfish adults.  People are more<BR>
important than ideas and theories.  Our experience in life teaches us that<BR>
drug legalization is not good for people.<BR>
 <BR>
<BR>
Kindest regards,<BR>
Robert E. Peterson<BR>
Vice Chairman, Drug Watch International Drug Strategy Institute
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-154</DOCNO>
<DOCOLDNO>IA077-000514-B018-276</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/Nahas.html 207.112.150.94 19970124120104 text/html 1691
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:00:49 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 1520
Last-modified: Tue, 29 Oct 1996 17:31:33 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Nahas Book Page</TITLE>
</HEAD>
<BODY>
<H1><CENTER>Nahas Book Now Available!</CENTER>
</H1>
<P><CENTER></CENTER>
<H2><CENTER>A MANUAL ON DRUG DEPENDENCE by Gabriel G. Nahas, M.D., Ph.D.,
DSc</CENTER>
</H2>
A summary of the basic scientific data available on this vast subject. The
unique design and compact size of this comprehensive reference guide provides
easy access to critical information. It is must reading for prevention,
treatment, and education professionals. M.D.s will find the content extremely
useful in making decisions regarding patient care. This valuable book includes
tables, figures and detailed information related to: 
<UL>
  <LI>Properties Common to All Drugs 
  <LI>The Targets of Drugs of Dependence 
  <LI>Opiates and Opioids 
  <LI>Detoxification 
  <LI>Management 
  <LI>Drugs and the Law 
  <LI>and much, much more. 
</UL>
Dr. Gabriel Nahas, Research Professor of Anesthesiology at New York University
Medical Center, received his medical degree from the University of Toulouse
Medical School and his Ph.D. from the University of Minnesota (Mayo Foundation
Fellow). He has published more than 600 scientific publications and 27 books,
many of which deal with research on marijuana and cocaine. <BR>
<BR>
Cost per copy -- $15 (Includes postage and handling) Please print your name
and address and send a check or money order payable to: 
<DL>
  <DD>Treasurer 
  <DD>Drug Watch International 
  <DD>P.O. Box 80616 
  <DD>Valley Forge, PA 19484 
</DL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-155</DOCNO>
<DOCOLDNO>IA077-000514-B019-110</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWJG1.html 207.112.150.94 19970124120313 text/html 7481
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:01:52 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 7310
Last-modified: Tue, 29 Oct 1996 17:29:25 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>A Fork in the Road</TITLE>
</HEAD>
<BODY>
<H2><CENTER>A FORK IN THE ROAD: Toward a Drug Free Culture</CENTER>
</H2>
<DL>
  <DD><CENTER>John F. Gilligan, Ph.D. </CENTER>
</DL>
&quot;No!&quot; Now, that's a word difficult to say these days. Parents
of teenagers fear it, educators seldom use it, and elected officials avoid
it. Take for example: &quot;Just Say No To Drugs.&quot; It evokes laughter
among teenagers and comments by adults that this is just too simple to work.
It's the root causes of drug abuse that first must be addressed, goes the
argument. For drug abuse, some say, is only a symptom of a deeper social
pathology; just telling kids to say &quot;no&quot; will never work. <BR>
<BR>
Of course, if everyone did say : No!&quot; to illegal drugs, there wouldn't
be a problem. In the last analysis, anyone's cure from drug use and alcohol
abuse will require a firm and resolute &quot;No!&quot; for we are all responsible
for our own actions and the consequences that follow. <BR>
<BR>
So, what's the problem with the campaign &quot;Just Say No To Drugs&quot;
first initiated by Mrs. Reagan? Why hasn't it been more successful? There
are several reasons. First, it takes courage -- guts -- to say &quot;No!&quot;
This is particularly true when it goes against the tide of social pressure.
It requires a strength of character not yet fully developed in adolescents.
That's why strong parental and adult guidance is required during this critical
and final period of character formation. (The assumption is that adults
do have the convictions and moral strength of character to also say &quot;No!&quot;)
<BR>
<BR>
Next, too many educators are ambivalent about the illegal status of drugs
in our society and tolerant of underage drinking. Now, if adult leadership
has difficulty providing a clear and unequivocal &quot;No!&quot; to the
illegal use of drugs and alcohol, what may we reasonably expect from the
youth of America? A few quotations from a widely used text in universities
and high schools will illustrate this second point. In the book From Chocolate
to Morphine: Everything You Need to Know About Mind-Altering Drugs, the
authors state that &quot;. . .we are not going to argue for or against drugs
and will not side with either those who endorse them or those who oppose
them.&quot; <BR>
<BR>
What a clear and unequivocal position on nothing! Yet, the authors do have
a position: &quot;to teach people how to form good relationships with drugs
so that if they choose to use drugs, they will continue to be users and
never become abusers.&quot; This must be very comforting for parents to
know that their sons and daughters are learning how to form &quot;good relationships
with drugs.&quot; <BR>
<BR>
The authors then go on to give &quot;advice&quot; on the use of the following:
Stimulants: &quot;limit your frequency of use;&quot; Marijuana: &quot;Do
not use marijuana on the job or at school;&quot; Solvents and Inhalants:
&quot;Only inhale nitrates when you are in a comfortable sitting or lying
position;&quot; Hallucinogenic Drugs: &quot;if you are trying one of the
hallucinogenic drugs for the first time, take it with an experienced companion.&quot;
<BR>
<BR>
Isn't it good to know that our youth are learning to make wise choices about
when and how to use illegal drugs? <BR>
<BR>
So thank the authors and the educators who order these books for contributing
to a culture that is tolerant of illegal drug use. Apparently, they believe
what the authors stated in their opening chapter: &quot;Drugs Are Here To
Stay.&quot; And, the only course of action is to make the best of it and
teach our children how to make wise choices. But, what about just plain
&quot;No!&quot; <BR>
<BR>
Rape, theft, and murder are also with us. Are we to now start educating
students on how to make &quot;wise decisions&quot; about date-rape, theft,
and murder? Is there anything to decide? Can't anyone just say &quot;it's
wrong?&quot; Can't anyone just say &quot;No!&quot; <BR>
<BR>
All of which brings us to the final point of why the &quot;Just Say no To
Drugs&quot; message has trouble playing in America. It's called relativism.
Assertions about what is good or bad and what is right or wrong and what
is true or false are quickly becoming only matters of subjective opinion.
If there are no objective criteria, the moral code is reduced to such relativistic
and inane aphorisms as &quot;a man's gotta do what a man's gotta do&quot;
and the recommendation of inner guidance &quot;to do your own thing.&quot;
At last, something is now certain: &quot;You should do your own thing.&quot;
<BR>
<BR>
Some things are good, some things are true, some things are right, and some
things are just. Likewise, there are some things that are bad, some things
that are false, some things that are wrong, and some things that are unjust.
To assert otherwise is to cast aside 2500 years of Western Civilization's
accumulated wisdom, knowledge, and experience. To accept that no judgments
can be made and that all is relative is not only the end of human discourse
but the demise of society itself. <BR>
<BR>
In a world of relativism, all values and truths cancel each other out. According
to this view, the evils embodied in the Holocaust could never be called
evil. Evil would only be a matter of opinion. In such a world, there can
be no justice, no mercy, no loyalty, no honor, and no freedom. And society
will be reduced to the world of the &quot;Road Warrior&quot; or &quot;Terminator.&quot;
<BR>
<BR>
In so far as illegal drugs are concerned, a culture that not only tolerates
but legalizes them will be different from one that does not. It would be
the final surrender to all restraints on the human impulse to feel good
now. In addition to opening a societal black hole of self-centeredness,
it would sabotage society's ability to develop any sense of obligation and
duty among its citizens to promote the well-being of the human community.
<BR>
<BR>
The question is: Should we, as American citizens, tolerate illegal drug
use in practice, policy, or law? We are at a fork in the cultural road.
Do we want a drug free culture or one that is tolerant of drugs? The answer
will yield one culture that is much different from the other. And some cultures
are clearly better than others. <BR>
<BR>
So, let's say &quot;No!&quot; to drugs. Why? Because they are wrong. They
pollute both body and spirit. They destroy family and community. They destroy
strength of will and character, both for the individual and the nation.
Their sole effect is to intoxicate beyond redemption. This is why we have
made them illegal in the first place. <BR>
<BR>
&quot;If men were angels, no laws would be necessary,&quot; said James Madison,
father of our Constitution. So, let's keep our laws against illegal drugs
and strenuously enforce the laws on the illegal use of alcohol. Our salvation
-- at least in this kingdom -- may depend upon it. <BR>
<BR>
<CITE><STRONG>Dr. John F. Gilligan, President of Fayette Companies and its
subsidiaries: Human Service Center, White Oaks Companies of Illinois, and
Behavioral Health Advantages, Inc. He is a member of Drug Watch International
whose mission is to create drug free cultures in the world community.</STRONG></CITE><STRONG>
</STRONG>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-156</DOCNO>
<DOCOLDNO>IA077-000514-B023-52</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWJL.html 207.112.150.94 19970124121124 text/html 3284
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:11:09 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 3113
Last-modified: Tue, 29 Oct 1996 17:29:30 GMT
</DOCHDR>
<TITLE> Drug Induced Violence </TITLE>
<CENTER>
<H3>Drug Induced Violence</H3>
by Janet D. Lapey, M.D.
</CENTER>
<P>
Currently there is an epidemic of violence in the U.S., and it is related in
large part to the epidemic of drugs, since drug alcohol usage to violence is
well-documented in Pediatric Clinics of North America: 37:881-903, 1990, where Jan Bays, M.D. writes that "Intoxicated adults can become violent, paranoid, and less constrained about injuring, molesting, or neglecting their children . . . Cocaine, methamphetamine, and PCP use causes anxiety and
fearfulness, distrust of others, hallucinations, and physical aggressiveness
. . . Violence is increased in families that abuse alcohol or drugs . . . Abuse or murder of a spouse is more likely when both partners are intoxicated . . . One half of all child abuse and neglect cases in New York City in 1987 were linked to parental substance abuse.  If alcohol abuse was included, the incidence rose to 64% . . . An Oregon study documents a 93% increase in incidents of child abuse and neglect between 1981 and 1987 attributed the increase
largely to parental substance abuse."
<P>
Too often we hear people claim that legalizing drugs would end violence when
the truth is that legalizing drugs would actually increase violence, since it
would increase the use of drugs.  Consider the well-publicized case of New York defense attorney Joe Steinberg, who was convicted of beating his little daughter Lisa to death while he was snorting cocaine.  He certainly did not kill her to get money for drugs, or because she was a rival drug dealer;
cocaine use had tragically changed his behavior.
<P>
Other drugs are also increasingly connected to violent behavior.  Anabolic
steroids cause "roid rage," i.e., steroid-induced violent aggressive behavior.  In general, mind-altering drugs cause users to lose control of their behavior.  The Physicians' Desk Reference  (p. 2076, 1993) states that "Marinol," which is THC, the main active ingredient in marijuana, causes "decreased ability to control drives and impulses."  A recent study by Dr. Don R. Cherek in  Psychopharmacology  111:163-168, 1993, showed that smoking marijuana
caused increased aggressive behavior in inner-city males.  Furthermore, it is
know that marijuana use tends to lead to the use of other drugs, such as cocaine, which are strongly associated with violent behavior.  Herbert Kleber, M.D. in the Journal of Clinical Psychiatry 49:2  (Suppl), p. 3-6, 1988, reported that 20% of those who used marijuana 3-10 times went on to use cocaine.  75% of those who used marijuana 100 times went on to use cocaine.  In
Alaska, when marijuana was decriminalized, use among the youth of both
marijuana and cocaine skyrocketed, becoming by far the highest in the nation.  Alaskans then repealed their lenient laws in the fall of 1990.
<P>
Thus, any discussion of the violence prevalent in society today must take
into account the fact that drug and alcohol use cause violent behavior.  
<P>
People who promote drug legalization are promoting drug use and thus
increasing violence in our society.
</DOC>
<DOC>
<DOCNO>WT01-B04-157</DOCNO>
<DOCOLDNO>IA077-000514-B024-18</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWMGEAC.html 207.112.150.94 19970124121255 text/html 1721
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:12:05 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 1550
Last-modified: Tue, 29 Oct 1996 17:29:43 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>What if?</TITLE>
</HEAD>
<BODY>
<H3><CENTER>WHAT IF?</CENTER>
</H3>
What if a tiny but stubborn group of people continue to promote legalization
of now- illegal drugs? We cannot afford to permit these few misguided people,
some possibly with ulterior motives, to succeed. There is a need for factual
information to counter the Drug Policy Foundation (DPF) and others who would
create a nation of zombies and destroy America. <BR>
<BR>
This nation's most precious resource is our children, the future generation.
Our legacy to them must be a society that gives them the best possible chance
to live useful, healthy lives in safe communities that are free of crime
and drugs. <BR>
<BR>
What if ... we left our children in communities with even more crime and
violence than there is now? Drug-related crime generates much of the increasing
violence in our schools and neighborhoods. <BR>
<BR>
What if ... more drugs were legalized? What kinds of communities would we
leave? <BR>
<BR>
What if ... the legalizers succeed? <BR>
<BR>
Who loses? 
<UL>
  <LI>Our children 
  <LI>Families 
  <LI>Neighborhoods 
  <LI>Communities 
  <LI>All of us!! 
</UL>
Who gains? 
<UL>
  <LI>Drug producers 
  <LI>Drug sellers 
  <LI>Criminals 
  <LI>Addicts 
  <LI>Money launderers 
</UL>
All of us need to take a stand, to do something before we lose even more
of our children to drugs and violence. <BR>
<BR>
<CITE><STRONG>Drug Legalization. What if? 
Maryland Governor's Executive Advisory Council 
December 1994</STRONG></CITE> </BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-158</DOCNO>
<DOCOLDNO>IA077-000514-B024-138</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWER.html 207.112.150.94 19970124121351 text/html 4730
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:13:34 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 4559
Last-modified: Tue, 29 Oct 1996 17:29:16 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>European Report May 13, 1996</TITLE>
</HEAD>
<BODY>
<H2><CENTER>A European Update from Renee Wikesjo, Drug Watch Sweden Delegate
</CENTER>
</H2>
<H4><CENTER>May 13, 1996</CENTER>
</H4>
<STRONG>HOLLAND</STRONG> <BR>
<BR>
* * * * * The prime minister of Holland, Wim Kok, some weeks ago on the
radio denied all the criticism about the failures of Dutch Drug Policy.
He feels that Holland has the right to solve their problems their own way.
<BR>
<BR>
* * * * * There are no known health records or scientific research work
in the field of cannabis abuse in the Netherlands. Dutch people in general
hate statistics and insight in their private life. <BR>
<BR>
* * * * * The HIV/AIDs is a big problem. Statistics are not known, but there
are many institutions to help HIV patients and abusers survive. <BR>
<BR>
* * * * * An urgent appeal from &quot;Concerned Citizens&quot; (LCD) in
the Netherlands -- The situation in the Netherlands is quite desperate,
and they have every right to cry out for help. On June 5th, 1996, LCD will
hold a conference meeting at Congrescentrum Rolduc, not far from the German
and Belgian border. Anyone wishing more information please contact: <BR>
<BR>
<H4>Dr. L.P. Dorenbos, co-ordinator Fax + 31-35-624-9141</H4>
<BR>
<BR>
(If you cannot attend, please fax a letter of support to &quot;Concerned
Citizens.&quot; Letters from around the world showing our support will be
extremely important.) <BR>
<BR>
* * * * * The Dutch drug liberals will recede more into the background as
their opponents get stronger and stronger. <BR>
<BR>
<STRONG>ICELAND</STRONG> <BR>
<BR>
&quot;Equal Education&quot; (Jafningja Fraesla) is a project involving age
16- 20. Young people point out how life can be fun without drugs, to make
it uncool to use drugs, to turn the spotlight on the positive things young
people are doing. <BR>
<BR>
For more information contact: <BR>
<BR>
Kristinn Aspelund -- aspel@cemtrum.is <BR>
<BR>
<STRONG>INTERPOL</STRONG> <BR>
<BR>
Mr. Raymond Kendal, Secretary General of Interpol, France, is well known
for his drug permissive ideas. He has been invited to speak at the 7th International
Conference on the Reduction of Drug Related Harm, March 2-7, 1996, in Australia.
<BR>
<BR>
<STRONG>EU</STRONG> <BR>
<BR>
On the 17th of April the European Parliament voted about drug prevention
for the second time in 6 months. There was strong debate. The drug liberals
were thoroughly beaten. It was a tremendous breakthrough for a restrictive
drug policy for the whole of Europe. No money can be used for decriminalization
activities, no money for methadone prescriptions or programs, no money for
free needle exchange, no money for &quot;harm reduction.&quot; <BR>
<BR>
<STRONG>EURAD</STRONG> <BR>
<BR>
The chairman of Europe Against Drugs, Mrs. Grainne Kenny, has lobbied academics
and parent leaders throughout Europe and America to support Dr. Nahas, who
has given us all such great support on our work down the years. Good luck
the 25th of May! <BR>
<BR>
Renee asked for information about Khat. She has a presentation in the late
summer about KHAT in the world. Please send information to: <BR>
<BR>
<H4>Renee Wikesjo Box 139 234 23 LOMMA Sweden</H4>
<BR>
<BR>
<HR>
<P><CENTER></CENTER>
<H2><CENTER>Update from Renee -- May 16, 1996 Information about Holland.</CENTER>
</H2>
<P><CENTER></CENTER>
<P>a) as from influx of cannabis into the Netherlands in the sixties an
increase to 675,000 regular cannabis users; number of young cannabis users
between 12 and 18 were estimated in 1992 on 60,000: young people start using
cannabis at an younger age; schools are more and more the target; <BR>
<BR>
b) from 1984 to 1992 cannabis use in the age from 12-18 has tripled; <BR>
<BR>
c) percentage cannabis users in the age from 11-18 has more than doubled
from 1990-1995 (from 7 to 17 %), in the age from 11-13 it was quadrupled
in that time (from 1 -4 %) <BR>
<BR>
d) coffeeshops selling cannabis increased in the eighties to 1200 in the
strict sense with an additional 800 affiliate sales points; the separation
of markets on which the concept of tolerance versus coffeeshops was based
is in reality wishful thinking, an illusion; <BR>
<BR>
e) a-d are especially worrying, cannabis being a dangerous drug: (death
of some persons followed); <BR>
<BR>
g) the 1995 annual report of the International Narcotics Control Boards
mentions the Netherlands as a significant producer of cannabis cultivated
indoors and as the major supplier of hallucinogenic amphetamines in Europe.
<BR>
<BR>
-end- 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-159</DOCNO>
<DOCOLDNO>IA077-000514-B024-280</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWBC.html 207.112.150.94 19970124121442 text/html 2614
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:14:03 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 2443
Last-modified: Tue, 29 Oct 1996 17:28:49 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> Let's Be Realistic </TITLE>
</HEAD>
<BODY>
<H2><CENTER>Let's Be Realistic</CENTER>
</H2>
<DL>
  <DT><CENTER>by Barbara A. Cimaglio </CENTER>
  <DD><CENTER>Director, Illinois Department of Alcoholism and Substance
Abuse (DASA) </CENTER>
  <DT><CENTER><HR></CENTER>
</DL>
Let's be realistic. Legalizing marijuana is a terrible idea which would
have serious negative side-effects. <BR>
<BR>
Proponents of legalization are making false arguments that may sound good,
but are often simplistic and short-sighted. Legalization may lessen the
violence surrounding drug dealing. But the real problem is violence resulting
from drug use, and this must be addressed with strong law enforcement, substance
abuse treatment, prevention and a commitment to cultural change. <BR>
<BR>
Do we need marijuana as medicine, as some legalizers claim? Not according
to many medical experts who say marijuana is neither safe to use nor effective
for medical use. <BR>
<BR>
And marijuana users are fooling themselves if they think smoking pot isn't
harmful. The active ingredient, THC, is addictive, and users can get hooked
just as they can on alcohol or cocaine. More than 5,000 Illinoisans listing
marijuana as their drug of abuse were treated at state-funded programs last
year. Many pot smokers also suffer serious health problems and are a threat
to others when they're high. <BR>
<BR>
Any tax revenue resulting from legalization would be minimal compared to
the social costs of addiction. Legalization would create even more clients
for an already overburdened treatment system -- at a much higher cost. But
treatment is only part of the price we pay. We also pay for marijuana users
increased health problems, reduced productivity, injuries from accidents,
auto crashes, and crime. All the media hype over legalization of marijuana
is particularly scary when you think of the impact on our young people.
Marijuana is the most widely used illicit drug among Illinois teens. Thirteen
percent of students have tried it. The good news is marijuana use is down
slightly according to a recent state survey. We must send strong and consistent
messages to our youth about what society considers appropriate behavior.
A message that it is &quot;OK to get high&quot; is not a message that stresses
healthy relaxation and coping with problems in a mature manner. The majority
of Americans believe legalization is not the answer.
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-160</DOCNO>
<DOCOLDNO>IA077-000514-B025-106</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWSH.html 207.112.150.94 19970124121516 text/html 3571
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:14:54 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 3400
Last-modified: Tue, 29 Oct 1996 17:30:11 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> For The Sake of Our Children. by Stephanie Haynes </TITLE>
</HEAD>
<BODY>
<H3><CENTER>&quot;FOR THE SAKE OF OUR CHILDREN&quot; by Stephanie Haynes,
President, Drug Watch International </CENTER>
</H3>
America must not be deceived by the voices of despair and doom crying out
for the legalization of drugs. Some say the drug problem is overwhelming,
inevitable, hopeless and that the &quot;war on drugs&quot; is lost and the
only solution is to legalize drugs. <BR>
<BR>
Some of these people are national leaders who are making headlines. They
may be well-intentioned but are very misguided, because there is no sound
medical, legal, or social evidence that drug legalization would be a solution
to the drug problem. To the contrary, scientific research, history, and
common sense tells us that if drugs are made easily available, drug use
will increase, drug addiction will increase, and society's problems will
increase. <BR>
<BR>
There are also others who are self-servingly promoting drug use, who are
members of the Washington based Drug Policy Foundation, NORML, and the ACLU,
&quot;children of the 60's:, the so called &quot;intellectuals&quot; of
today. These people, who now wear suits and ties instead of sandals and
beards, are working hard to shape public opinion in the media on recent
television and talk shows, and in popular magazines, and to influence lawmakers
and public policy. Their agenda is the same as it was in the 60's and 70's.
They believe they should have the right to alter their own consciousness
through drug use, ignoring the harm it would do to society in general if
drugs were legal, available and socially acceptable. <BR>
<BR>
I was a teenager in the late 60's, and now as the mother of two teenagers,
for their sake, I do not want to go back to that time when the drug culture
with its pot-heads, psychedelic mind-trips, and depraved lifestyles demoralized
the nation. Society is paying a heavy price for the permissive drug use
of that era, which has left in its wake problems of the homeless, child
abuse, crack babies, the HIV epidemic, loss of productivity on the job,
and crime-ridden communities. Drug legalization now would only deepen the
problem by increasing the number of drugged, addicted individuals on our
streets, on the job, and in our hospitals. <BR>
<BR>
Now is not the time to surrender. Attitudes are changing. Drug use is no
longer considered &quot;chic;&quot; people in public housing are taking
a stand against drug dealing; others are &quot;reclaiming&quot; their neighborhoods
and tearing down crack houses; and statistics show that drug use is down
among young people. <BR>
<BR>
We have a long way to go. We did not get here over night, but we are on
the right track. We must be convinced that a society and an environment
free of the overwhelming problems associated with drug use are once again
attainable. As a nation, we must be committed to providing safe, drug-free
and healthy environments where parents can parent, children can grow, teachers
can teach, and all of us can travel on our streets and live in neighborhoods
with the feeling of security <BR>
<BR>
For the sake of our children and grandchildren, we must keep our standards
high. We must never give in and risk the increase in drug use which legalization
would surely bring. <BR>
<BR>
From the Best of IDEA, Illinois Fall 1992.
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-161</DOCNO>
<DOCOLDNO>IA077-000514-B025-243</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWWR.html 207.112.150.94 19970124121615 text/html 2109
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:15:56 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 1938
Last-modified: Tue, 29 Oct 1996 17:30:19 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> The Dumbing of America. by Wayne Roques </TITLE>
</HEAD>
<BODY>
<H2><CENTER>THE DUMBING OF AMERICA </CENTER>
</H2>
<H3><CENTER></CENTER>
</H3>
<H4><CENTER>by Wayne Roques, Prevention Specialist </CENTER>
</H4>
Regular drug use can cause a condition known as the delayed emotional development
syndrome. At whatever age the condition begins, the emotional development
of the user arrests. Hence, we find 40 year old people (some with excellent
jobs, others unemployed) demonstrating irresponsible adolescent behaviors.
Unfortunately, the enormous increase in drug use in the sixties and seventies
has led to a large adult cohort of drug users. <BR>
<BR>
Some adults have devoted their lives to advocating their drugs of choice,
demanding that we legitimize their choices and behavior. They deny the effects
of drug use on their health, families, and society. They run pro-drug advocacy
groups, magazines, web sites, etc. They deny the science that reflects the
harm that their drugs of choice cause, claiming that the government and
scientists are lying to them. Pro- drug advocacy groups send out by mail
and via the internet materials disputing scientific claims of the harm that
marijuana does and making outlandish claims of its benefits. Sadly, denial
and lying are as much a part of drug use as getting high. <BR>
<BR>
Psychoactive drugs reduce inhibitions and self control, impair judgment
and decision-making skills. Those under the influence make high risk decisions,
e.g., driving while impaired, having unsafe sex with inappropriate partners,
overreacting to stressful situations, and generally engaging in behaviors
that are highly likely to have negative consequences. Society is now reaping
the bitter fruits of increasing adolescent violence and anti-social behavior
as the pre and post-natally damaged children of the drug users of the seventies
and eighties come of age. <BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-162</DOCNO>
<DOCOLDNO>IA077-000514-B026-12</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWWR01.html 207.112.150.94 19970124121652 text/html 3420
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:16:38 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 3249
Last-modified: Tue, 29 Oct 1996 17:30:21 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> No Stampedes Please by Wayne Roques </TITLE>
</HEAD>
<BODY>
<H2><CENTER>NO STAMPEDES, PLEASE </CENTER>
</H2>
<H3><CENTER></CENTER>
</H3>
<H4><CENTER>W. Roques, Drug Prevention Specialist </CENTER>
</H4>
There is no verified information that needle distribution reduces the incidence
of HIV seroprevalence (positives) among intravenous drug users. There is
only self-reporting, anecdotal information. <BR>
<BR>
There are a number of international experiences that have been less than
satisfactory. The rate of HIV infections among addicts involved in heroin
maintenance programs in Switzerland ranges from 40% to 50% positive, despite
distribution of free, clean needles for at least 8 years. Italy and Spain
have a 70% rate of HIV prevalence among its heroin addicts, and needle sales
have never been restricted in those countries. The number of heroin addicts
and needle sales have never been restricted in those countries. The number
of heroin addicts per capita in Switzerland, Italy, and Spain is several
times that of the U.S. Sweden has run a needle exchange study since 1987,
and there is no statistical difference in the rate of HIV seroprevalence
in the cities where the needles are distributed and the non-participating
cities. A needle distribution program in Montreal reflects a four times
higher HIV seroconversion rate among participants, than non- participant
addicts. <BR>
<BR>
Distribution of clean needles cannot prevent overdose deaths or protect
the injector's immune system from being compromised by the drugs, causing
greater vulnerability to HIV, hepatitis, and other opportunistic diseases.
It does enable the addict to continue this harmful behavior. Clearly, drug
use (particularly intravenous use) is illogical and self-destructive. Advocating
the concept of needle exchange as a perceived method of reducing the risks
associated with needle- sharing is predicated on the theory that intravenous
drug users will make a rational decision to delay fulfilling their need
for their drug, while they seek out a clean needle to insure their safety!
<BR>
<BR>
It is an act of extraordinary faith to believe that people engaged in such
ultimately self-destructive behavior can or will make rational, healthy
decisions while fighting the ravages of withdrawal. The well- meaning activists
for needle exchange project their own thoughtful evaluation of the risk
of needle-sharing onto the dysfunctional thought processes of intravenous
drug users, a classic error. <BR>
<BR>
Needle use is not the only method of HIV transmission that affects drug
users. Prostitution and promiscuity are also high risk factors. Witness
the explosion of HIV positives among non-needle using crack addicts. Needle
exchange programs do not show any change in such dangerous sexual practices.
<BR>
<BR>
Federal funding of needle exchange programs is inappropriate and premature.
The science regarding the efficacy of needle exchange programs falls far
short of normal standards. Further scientific examination is called for
and should be used to determine the wisest course for us to follow. <BR>
<BR>
We must not be stampeded by fear and politically correct advocates whose
compassion clouds their judgement. 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-163</DOCNO>
<DOCOLDNO>IA077-000514-B026-294</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWAMR.html 207.112.150.94 19970124121835 text/html 4174
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:17:42 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 4003
Last-modified: Tue, 29 Oct 1996 17:28:48 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> No, Drugs Can Leave You Dead. by A.M. Rosenthal </TITLE>
</HEAD>
<BODY>
<H2><CENTER>NO, DRUGS CAN LEAVE YOU DEAD </CENTER>
</H2>
<H3><CENTER></CENTER>
</H3>
<H4><CENTER>By A. M. Rosenthal</CENTER>
</H4>
New York -- He strolled out of his apartment in Manhattan. He knew where
to get what he wanted, no problem. He was back soon with his packages, the
way some husbands come home with ice cream or flowers. <BR>
<BR>
He took some of the contents, and so did his wife. She died. The two children
were asleep. They found out in the morning. <BR>
<BR>
Happens all the time -- heroin overdose, dead on arrival. But he was a young
magazine publisher and she a stockbroker -- both up and coming and everything
to live for. How could they do this to themselves and the kids? <BR>
<BR>
Soon somebody wrote a letter to The New York Times explaining how it happened.
US. antidrug polices are to blame. The &quot;demoniztion&quot; of drugs
prevented people from learning how much heroin at what potency was O.K.
for holding good jobs without dropping dead. That failure to acknowledge
the enduring appeal of drugs is the &quot;larger tragedy.&quot; <BR>
<BR>
This was from a professor. He also is a senior fellow at one of those pro-legalization
groups supported by tax-free foundation money. This column is not directed
to people like that. They make their reputations and living by being professional
legalization pushers; they are gone, goodbye. <BR>
<BR>
It is addressed to other people, in academia, or journalism, some lawyers,
who simply believe that making drugs legally available would reduce drug
crime and save the billions spent on fighting drugs. They are worth arguing
with because they are people of influence. Their activities, writing, their
money to pro-drug foundations, help create a casualness, an acceptance,
toward drugs that increases their use. <BR>
<BR>
I ask them to rethink the consequences of what they do. Start by calling
the Center on Addiction and Substance Abuse -- (212) 841-5227 -- to get
its new report, &quot;Legalization: Panacea or Pandora's Box?&quot; I have
read myself groggy with studies on drugs. This one by the center -- at Columbia
University and headed by Joseph a. Califano Jr. -- is one of the most valuable.
<BR>
<BR>
These are some of its points: 
<UL>
  <LI>The drug war has made substantial progress that would have been impossible
without laws and public support. The number of &quot;current&quot; users
-- those who used drugs within the last month -- has dropped from 24.8 million
in 1979 to 13 million last year, nearly 50 percent -- but not evenly in
all cities and neighborhoods. The number of hard addicts has stayed steady
at 6 million. Wrestling with them is the job ahead. 
  <LI>Marijuana is the growing enemy of US youth. Teenagers who use it are
85 times more likely also to use cocaine than those who do not. Youngsters
also say that the major deterrent to the use of marijuana and other drugs
is legal penalty. 
  <LI>More access to drugs through legalization or permissiveness will hugely
increase consumption and addiction. That will cost far more than the $13
billion spent to fight drugs -- in increased hospital costs, spread of disease,
and drop in economic productivity and student learning abilities. 
  <LI>Drug-gang crimes would decrease only if drugs could be bought almost
everywhere by grown-ups and kids, wiping out all black markets. Even so,
crime would increase -- by drug-related crimes not related to the drug trade,
like murder, rape and assault. 
  <LI>Experiments in legalization or permissiveness have failed. In the
Netherlands, adolescent marijuana use has increased 250 percent. Registered
harder-drug addicts have increased by 22 percent. 
</UL>
Reading this report should be the ticket to talking about legalization.
Go argue with it. If you still want more access to drugs, stroll down to
buy a few packets for yourself and your wife, while the children sleep.
No problem. 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-164</DOCNO>
<DOCOLDNO>IA077-000522-B038-284</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWDB.html 207.112.150.94 19970124122100 text/html 5587
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:18:57 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 5416
Last-modified: Tue, 29 Oct 1996 17:29:03 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> Drug Dealer Liability Act by Dan Bent </TITLE>
</HEAD>
<BODY>
<H3><CENTER>DRUG DEALER LIABILITY ACT by Dan Bent, Esq. </CENTER>
</H3>
Why shouldn't illegal drug dealers pay for the harm they cause? . . . In
America, sellers of legitimate products that are defective can be forced
to pay for the injuries they cause. Courts force such payments regularly
in civil suits brought by those injured, or their parents, against those
who profited from the distribution of the harmful product. High punitive
damages are often imposed by courts and juries in civil judgments against
product distributors who sell their product even though they know of the
potential harm. Third parties, such as insurance companies and hospitals,
can recover their costs of treatment either directly or indirectly from
those responsible for harmful products. <BR>
<BR>
Doesn't it strike you as &quot;out of whack&quot; that millions of dollars
are paid by legitimate business that negligently produce or distribute harmful
products, yet personal injury suits against dealers of the ultimate harmful
product, illegal drugs, are virtually unheard of? . . . If so, the Drug
Dealer Liability Act should get your active support in your state. It has
already passed in Michigan, Illinois, Hawaii, Oklahoma, and Arkansas and
is pending in California, New York, Pennsylvania, and Florida. The Act fills
a vacuum in the laws against illegal drug trade. It imposes civil liability
on anyone who is intentionally involved in trafficking illegal drugs. <BR>
<BR>
Who can recover damages under the Drug Dealer Liability Act? . . . Parents,
hospitals, employers, insurance companies, county health departments and
others who suffer a financial burden as a result of illegal drug sales in
their community. All can recover damages, including punitive damages, from
any drug dealer in that community. For example, let's say &quot;Bob&quot;
is a cocaine dealer who also has a successful dry cleaning business that
is independent of his drug trafficking. Even if Bob gets arrested and convicted
of drug dealing, his dry cleaning business cannot be forfeited, since it
is neither proceeds of, nor used to facilitate Bob's drug deals. However,
a parent of a teen in drug treatment in Bob's community could bring suit
against Bob to pay for the treatment. Bob could even be forced by the court
to sell his business to pay for drug treatment for kids in his community.
Moreover, county hospitals that care for drug babies at public expense could
bring suits against drug dealers who may have assets, including wages that
can be garnished. <BR>
<BR>
&quot;Wait!&quot; you say. Aren't most drug dealers &quot;street dealers&quot;
who are often inner city people without bank accounts, legitimate businesses
or garnisheable wages?. . . Many are . . .but most are not. Let's look at
the statistics. <BR>
<BR>
A national survey of household drug use by the National Institute on Drug
Abuse showed that 67% of all drug users are employed. Workplace dealers
may be the majority of retail dealers. Moreover, this group may be deterred
by threat of civil suit in which they could lose their savings, retirement
funds, home and other assets and have their wages garnished. <BR>
<BR>
In fact, experts on drugs in the workplace acknowledge that the major problem
is the &quot;accommodation dealer,&quot; the employee who happens to have
a &quot;source&quot; and accommodates his or her friends by making drug
purchases as a middle man. <BR>
<BR>
But is it reasonable to expect that an accommodation dealer would be deterred
by a potential civil suit, when they aren't being deterred by the possibility
of criminal charges? . . . The criminal prosecution of workplace dealers,
particularly accommodation dealers, is virtually non-existent. Workplaces
are difficult, if not impossible, for undercover operations to penetrate.
Management is loath to call the police and publicize their company's drug
problem. Workplace dealers feel relatively safe dealing drugs to fellow
employees whom they have known for years. Furthermore, prosecutors are too
busy with wholesale dealers to focus much attention on retail dealers who
don't strike the community's attention. <BR>
<BR>
Does the Drug Dealer Liability Act have a potential for significant impact?
. . . You bet it does. Markets respond to economic pressure. When some retail
drug dealers, even accommodation dealers, have to give up their assets to
pay for drug treatment facilities, many will be less likely to enter the
market. With fewer retailers promoting drugs to prospective customers, there
will be fewer customers and fewer retail sales. When retail sales decrease,
markets decline. <BR>
<BR>
We have been concentrating on the major dealers; now it is time to confront
the retail dealers. What's more, the Drug Dealer Liability Act doesn't require
more prosecutors and police officers to have its impact. <BR>
<BR>
Peter Bensinger, a former head of the Federal Drug Enforcement Administration,
has said that the Drug Dealer Liability Act has the potential to have as
much impact as the major drug forfeiture laws passed by Congress in the
1970s. It has been adopted by the American Legislative Exchange Council,
an organization of over 2,000 legislators nationwide, as its model legislation.
<BR>
<BR>
For more information contact: Dan Bent, Esq. at <EM>DanBent@counsel.com</EM>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-165</DOCNO>
<DOCOLDNO>IA077-000522-B039-189</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWmisc1.html 207.112.150.94 19970124122222 text/html 2289
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:21:49 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 2118
Last-modified: Tue, 29 Oct 1996 17:29:46 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> Legalization: Flawed Logic </TITLE>
</HEAD>
<BODY>
<H3><CENTER>LEGALIZATION: FLAWED LOGIC</CENTER>
</H3>
<P><CENTER></CENTER>
<H4><CENTER>From The Best of IDEA, Winter/Spring, 1993 </CENTER>
</H4>
&quot;Legalization is a flawed concept. Those who support it are only looking
at the issue of drug abuse from a financial standpoint. The notion that
somehow legalization will take the underworld element out of the drug trade
and result in lower drug prices is ludicrous. To think that this will somehow
reduce the drug problem is flawed logic. <BR>
<BR>
In fact, drug use would become far more widespread and rampant. Our models
on this are alcohol and tobacco. They represent extremely serious health
hazards. Why should we add cocaine, marijuana, etc., to this spectrum of
potential physical and psychological disaster? <BR>
<BR>
Marijuana is clearly addictive, is responsible for behavioral, intellectual
and cognitive deficits, and is responsible for severe side-effects to the
pulmonary, reproductive and immune systems as well.&quot; (E. Voth, M.D.,
FACP) <BR>
<BR>
&quot;Pro-legalization advocates appeal to emotion, not reason. Legalization
or decriminalization is not drug reform; it is drug retardation, taking
us back to the lax drug policy of the 70's.&quot; (R. Peterson, Esq.) <BR>
<BR>
&quot;Those who would legalize drugs fall into two categories -- Pollyannas
who are incredibly naive or uninformed, or children playing with matches.
Legalization is a Pandora's box, which if opened would unleash a tide that
will sweep away prevention and treatment.&quot; (D. Risley, Esq.) <BR>
<BR>
&quot;The greatest danger of legalization is to our youth. Adolescents are
the most difficult to diagnose and treat. Many slip through the cracks.
The window for learning is gone; opportunities are lost. It is impossible
to regain those years -- too late to become an engineer, astronaut, physicist.
The legalization debate is sparked by marijuana, and inherent in marijuana
use is denial. Some Harvard individuals are selling their denial.&quot;
(D. Spencer, M.D.) <BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-166</DOCNO>
<DOCOLDNO>IA077-000522-B039-267</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWJG2.html 207.112.150.94 19970124122253 text/html 3109
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:22:37 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 2938
Last-modified: Tue, 29 Oct 1996 17:29:27 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> Societal Meltdown by Jack Gilligan </TITLE>
</HEAD>
<BODY>
<H1><CENTER>SOCIETAL MELTDOWN</CENTER>
</H1>
<P><CENTER></CENTER>
<H4><CENTER>J.F. Gilligan, Ph.D. International Drug Strategy Institute Director,
International Delegates<BR>
<HR> </CENTER>
</H4>
It's time for a change in America. Eight out of 10 Americans polled believe
that the country is headed in the wrong direction. <BR>
<BR>
The questions are -- how did this happen, and what's to be done about it?
<BR>
<BR>
Answers: We have tolerated too much, and it's time to stop! <BR>
<BR>
The innumerable problems facing our nation were not born overnight. We originally
tolerated them in their harmless infancy. Now that they have grown dangerous,
society decries them. We want someone to blame. Yet, we are that society.
We are responsible for what is. <BR>
<BR>
Let's look at how it all happens. <BR>
<BR>
It is human nature to adjust, accommodate and readily tolerate slow and
incremental changes in life. This capacity to adapt has great survival value,
but it is also humanity's Achilles' heel. For we can learn to tolerate almost
anything, even to the point of our own undoing. <BR>
<BR>
The founders of America recognized this tendency when they wrote in the
Declaration of Independence that &quot;. . . all experience has shown that
mankind are more disposed to suffer, while evils are sufferable, than to
right themselves by abolishing the forms to which they are accustomed.&quot;
<BR>
<BR>
What an insightful but also alarming sentence. There is this human tendency
to tolerate the evils around us and a hesitancy to take action against them.
Yes, we have a wonderful ability to adapt to and tolerate most anything.
It is in our nature. But, this capacity must be governed by forethought,
self-discipline and the courage to challenge, or it will slowly and incrementally
result in self- destruction. <BR>
<BR>
Take crime, for example. Look at how well society has passively adjusted
to living with it: deadbolt locks, Mace, attack dogs, whistles, handguns
-- 60 million legal ones -- and lots of protective barriers. Security guard
have become one of the leading employment opportunities in the United States.
We have become accustomed to hourly crime as the reality of American life.
<BR>
<BR>
Through this slow and incremental process, society can become tolerant of
and habituated to the very behaviors that can destroy it. Here is a sample
of behaviors to which we have grown accustomed: In addition to crime in
the street, we tolerate poor manners, disrespectful youth, poor performance
in the classroom and workplace, litter on the side of our roads and underage
drinking. <BR>
<BR>
How does tolerating such apparently minor misbehaviors affect the national
character? Easily. Once a critical mass of citizens engage in them, societal
meltdown is soon to follow. <BR>
<BR>
From The Best of IDEA, Illinois. Winter, 1993. 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-167</DOCNO>
<DOCOLDNO>IA077-000522-B041-58</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/SK1.html 207.112.150.94 19970124122730 text/html 13052
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:26:50 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 12880
Last-modified: Tue, 29 Oct 1996 17:31:44 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> SK1.html </TITLE>
</HEAD>
<BODY>
<H1><CENTER>Cannabis and Legalization Issues in the United Kingdom:</CENTER>
</H1>
<P><CENTER><HR></CENTER>
<H2><CENTER>Research Used in Blocking the Proposed &quot;Royal Commission
on Cannabis&quot; </CENTER>
</H2>
In February, 1994, a &quot;Royal Commission on Cannabis&quot; was proposed
to &quot;review the prohibition of the use of cannabis and to examine alternative
options for control of the drug within the law&quot;. It was noted in this
proposed motion that there is a &quot;growing body of evidence which testifies
to the medicinal and therapeutic properties of cannabis and its relative
safety compared with other legalized drugs&quot;. <BR>
<BR>
However, an amendment was made and passed stating that increased penalties
for possession of cannabis set by the government were welcomed &quot;in
the light of overwhelming medical evidence that cannabis leads to poor short-term
memory and learning problems, lung damage and cancer risks that are 50-70
per cent greater than those associated with tobacco use, reduced immunity
producing cells, and impairment of heart function: (it is noted that) cannabis
causes greater organic brain damage than any other drug with the possible
exception of PCP and the end stages of alcoholism; and that the effect of
one cannabis cigarette lasts five or six times as long as one unit of alcohol&quot;.
It was then stated that &quot;(this House) deplores any moves towards the
legalization of cannabis, based on the experience in Alaska where such a
move was abandoned in 1990, having led to the increased use of both soft
(sic) and hard (sic) drugs, increased drug related crime and increased health
care costs&quot;. <BR>
<BR>
A letter from a pro-legalization organization questioning the facts of this
passed amendment was sent to the Member of Parliament responsible for its
draft. This paper sets out to address these questions by citing recent relevant
research findings. <BR>
<BR>
The effects of cannabis in the amendment are not &quot;falsified&quot; nor
are they a &quot;form of outdated propaganda (laid) onto people.... &quot;.
In addition, the information on the harmful effects of cannabis are not
based on &quot;biased newspaper reports&quot;. In fact, in reviewing the
newspapers over the past three years, there has not been a true factual
representation of the harmful effects of cannabis nor the potential dangers
in legalizing or decriminalizing it. Instead, pro-cannabis individuals and
groups have been able to use the newspapers as a forum for their &quot;cause&quot;
to the exclusion of factual information on cannabis and its effects. <BR>
<BR>
The facts on cannabis are not a &quot;form of outdated propaganda&quot;.
It should be pointed out that most of the studies cited in the pro-legalization
letter are outdated - documenting the evidence that &quot;no detrimental
effects (of cannabis) can be proved,&quot; when examining reference 1-13,
eight of these are from the 1970s, one is from 1982, two are from the l990s
(both of these sources, High Times and HEMP, &quot;Help Eliminate Marijuana
Prohibition,&quot; are pro-cannabis) and two are listed as &quot;1893-4&quot;
and &quot;1944&quot;. The majority of the research cited in the letter,
therefore, is outdated. This is a major problem because medical research
in general has advanced technically since the 1970s. The &quot;long-term&quot;
studies cited in the letter are from 1977 (Greek study) and 1975 (Jamaican
study). It should be noted that recent studies are able to assess the longer
term effects of cannabis, using more advanced research techniques (see below
for examples). In addition, the study cited in the letter which examined
the effect of cannabis on the immune system was from 1976. This is before
AIDS was discovered. More recent studies on the immune system (how it works
and what affects it) have occurred since 1976 and these studies show the
impairing effect cannabis has on the immune system (see below for more detail).
<BR>
<BR>
The following are some examples of more recent research to counter the research
claims mentioned in the letter: <BR>
<UL>
  <LI><STRONG>Effects on memory:</STRONG> a carefully controlled study by
Richard Schwartz; Georgetown University; Washington D.C. directly studied
the effect of cannabis on memory (and examined other studies) and concluded
that the use of cannabis &quot;impairs short term memory well beyond the
period of intoxication&quot;. (Cannabis: Phvsiopathologv. Epidemiology Detection
1993), not solely during the period of intoxication, as written in the letter
(based on information from 1973). <BR>
<BR>
  <LI><STRONG>Cardiovascular/respiratory and carcinogenic effects:</STRONG>
numerous studies on humans which examined the effects of marijuana on lung
cell tissue have indicated that the adverse effects of marijuana smoke in
various contents equal or surpass the similar effects of tobacco smoke (&quot;Government's
Supplemental Memorandum Re: Health Effects of Marijuana,&quot; in the United
States District Court for the District of Hawaii by the U. S. Attorney in
Hawaii, 1992). This report also documents that marijuana contains a total
of 421 chemicals, which include a variety of toxins and cancer-inducing
chemicals. This finding was replicated after the United States Public Health
'Service ordered a study by the nations' top scientists at the National
Institute of Health. A one year review of data concluded &quot;marijuana
cigarette smoke contains a complex mixture of over 400 compounds including
polyareomatic hydrocarbons which are carcinogenic&quot; (1992) (The letter
states that there are other ways to ingest cannabis than smoking it, however,
the majority of cannabis users smoke it). <BR>
<BR>
  <LI>The U. S. Attorney in Hawaii's report also included citation of studies
showing that marijuana has substantial adverse health effects not previously
suspected - including impairing effects on brain tissue and psychological
functioning and damage to reproductive and immunological systems which are
also cited in this document. <BR>
<BR>
  <LI><STRONG>Immunity:</STRONG> In 1993, Virginia Medical College (USA)
found that THC damages the immune system and reduces the ability to fight
disease (including AIDS). Also last year, Cabral and Vasquez from the Department
of Microbiology and Immunology (Medical College of Virginia, USA) reported
that cellular immunity and pulmonary immunity are impaired and it is now
documented that there is an impaired ability to fight infections in humans.
<BR>
<BR>
  <LI><STRONG>The metabolism of cannabis:</STRONG> the metabolism of cannabis
is not &quot;similar to alcohol&quot; as written in the letter. It has been
found that cannabinoid urinary metabolites may be detected 3-5 days after
occasional smoking and up to 77 days after chronic use (5 cigarettes a day)
(Paul Latargue, Institut de Recherche Criminelle de la Gendarmerie, France,
1993). Marijuana differs substantially from alcohol and other drugs which
are water soluble - marijuana is fat soluble and as such accumulates in
the brain, adrenal glands, liver, kidneys, heart, and sexual organs. Being
fat soluble, THC and other cannabinoids tend to remain in the body long
after the mind-altering effects of the drug have ceased, unlike water-soluble
alcohol (&quot;Government's Supplemental Memorandum Re: Health Effects of
Marijuana,&quot; in the United States District Court for the District of
Hawaii by the U.S. Attorney in Hawaii, 1992). <BR>
<BR>
  <LI><STRONG>The long-term effects of cannabis:</STRONG> in contrast to
the statements in the letter that harmful long term effects of cannabis
use have not been found, the Center for Brain Research in California (Gilkeson)
and Oxford University (Paton) have found that the long term presence of
the fat soluble molecules of cannabis do cause damage to the brain. Cell
damage has also been found (University of Toulouse, University of Utah and
University of Toronto). It is therefore not accurate to state, as noted
in the letter, that &quot;all effects are reversible&quot;. Also, as stated
before, lung damage occurs from smoking. 
</UL>
<STRONG>In regard to Alaska</STRONG>, cannabis was decriminalized, not legalized,
through the Alaska Supreme Court and through the initial support of police
primarily because they first thought crime would decrease. However, cannabis
use and problem use went up (with heavy increases in health and social costs).
An important factor in rescinding decriminalization was the response of
the police, who saw first hand the problems caused by decriminalization.
Whether or not there was a direct cause and effect relationship between
cannabis decriminalization and the increase in crime, decriminalization
was seen to have failed. In seeing this failure, the police who had initially
supported decriminalization fully supported rescinding the law. <BR>
<BR>
&quot;Legalization could provide significant benefits to society,&quot;
as claimed in the letter, is not true when examining cities that tried decriminalization.
In addition to Alaska's experience with decriminalization, when examining
the effects of their lenient cannabis laws, the Dutch policy has been associated
with a progressive increase in cannabis use among 15- 19 year old (from
4% in 1984 to over 8% in 1989). Between 1984 and 1988, the use of cannabis
increased by almost 100% among upper high school students in the Netherlands.
The policy of &quot;harm reduction@' has not prevented a steady and significant
rise in drug addiction (cannabis, cocaine and opiates) among 15-19 year
olds and young adults. (&quot;Drug Reform: The Dutch Experience,&quot; Richard
H. Schwartz, 1993). The Dutch Institute on Alcohol and Drugs recently questioned
8,000 young people and also found that the percentage of students smoking
cannabis has more than doubled in four years (from 3% in 1984 to 7% in 1988).
(Guardian 9 November 1993). <BR>
<BR>
It should also be noted that references in the letter to support the claim
that &quot;legalization could provide significant benefits to society&quot;
included three sources of information from the 1970s. In addition, the two
1993 resources are by pro-cannabis, and thus, biased, authors. <BR>
<BR>
Finally, in contrast to the 1993 report, cited in the letter, on the decreased
health costs and lower absenteeism of drug-using employees in Utah Power
and Light and Georgia Power (originally appearing in High Times, a pro-cannabis
and therefore, biased publication), it should be noted that over 85% of
the largest employers in the USA use urinalysis drug testing as a means
of preventing illegal drug use on and off the job. Several studies have
been conducted that examine work performance of employees using illegal
drugs compared with those who have tested negatively for such drugs. <BR>
<BR>
For example, at the U.S. Postal Service, the biggest employer in the USA,
300 people who tested positively for illegal drugs were compared with non-drug
users who started work at the same time. After eight months, accident rates,
injury, absenteeism, and disciplinary problems were found to be far higher
for the illegal drug users than for non-drug users. (Supervisors did not
know which employees tested positive for drugs). Those who tested positive
had higher termination and turnover rates than the no-drug user. After 16
months, absenteeism, termination, and turnover rates increased even more
for the drug-users. The U. S. Postal Service has decided to do pre-employment
drug testing to save 62 million dollars a year and decrease absenteeism,
turnover, and accidents (&quot;Testing for Illicit Drugs in the Workplace,&quot;
Peter Bensinger, Former Director, Drug Enforcement Administration, Washington
D.C.) (Cannabis: Physiopathology. Epidemiology, Detection, 1993). In addition,
it was recently found (March 1994) that drug use and resulting disciplinary
problems by some Chicago postal employees has resulted in the nondelivery
of nearly 10,000 pieces of mail, some of which was dumped and burned. This
problem has had a major effect on the people and business in the areas affected.
<BR>
<BR>
In conclusion, it is clear that the defeat of the proposed &quot;Royal Commission
on Cannabis&quot; is based on factual and recent research and is a positive
move to support prevention. <BR>
<BR>
<HR>For further information: <BR>
<BR>
&quot;Information on Cannabis,&quot; 1993. &quot;Issues in the Prevention
Field: The Definition of Prevention, Prevention Research and Legalisation
of Cannabis,&quot; 1993. &quot;The Effects of Drug Laws on Crime and Other
Social Problems in the UK,&quot; 1993. &quot;The Effects of Harm Reduction
and Prevention: An International Assessment,&quot; 1994. <BR>
<BR>
Susan Kaplin. Senior Researcher, International Drug Strategy Institute.
May, 1994 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-168</DOCNO>
<DOCOLDNO>IA077-000522-B041-192</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWEA.html 207.112.150.94 19970124122823 text/html 8649
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:27:45 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 8478
Last-modified: Tue, 29 Oct 1996 17:29:13 GMT
</DOCHDR>
<TITLE> DWEA.html </TITLE>
<CENTER>
<H1>Criticism of the Experiments on
Medical Prescription of Narcotics in Switzerland
</H1>
<H4>Dr.(med) Ernst Aeschbach
</H4>
<H4>(Lecture held at the Drug Conference in San Patrignano, October 14, 1995)
</H4>
</CENTER>
First I want to thank the organizers for the invitation and the opportunity
to give you a short presentation of the heroin distribution projects carried
out in Switzerland.
<P>
For about eight years now, we have witnessed a gradual shift from a
restrictive to a more and more liberal drug policy in Switzerland. This
eventually led to the big open drug scene at the Platzspitz and later at the
Lettensteg in Zurich. Because of the reduced law enforcement, drugs became
more and more available. At that time, the distribution of heroin as a
measure of help for drug addicts was put on the political agenda.
<P>
In my presentation, I'll shortly explain the attitude of the Swiss Government
on drug policy. Then, after a presentation of the heroin projects, I will
focus on the scientific insufficiencies of these experiments.
<P>
<H3>The Swiss Federal Government</H3>
In February 1991 the Swiss Federal Government demanded measures to stabilize the number of drug addicts by 1993 and to reduce it by 20% until 1996. It demanded further efforts in the field of prevention and therapy as well as assistance and support for addicts. At that time, a scientifically
accompanied pilot project on the distribution of narcotics to addicts was
taken into consideration; the distribution of heroin, however, should be
excluded in any case. This was in 1991: definitely no heroin distribution.
<P>
Nevertheless, the Federal Government - under strong political pressure -
agreed upon a scientifically accompanied project on the medical prescription
of narcotics including heroin in May 1992. In October 1993, the responsible
authority, the Federal Office of Public Health, approved on 7 submitted
projects in bigger cities of Switzerland.
<P>
<H3>Aims of the experiments</H3>
In the experimental design the general objective of the experiments is
described as follows:
<P>
<BLOCKQUOTE>"Projects on the medical prescription of narcotics to drug addicts are
defined as scientific experiments aimed at examining the success of this kind
of  therapy as one step towards drug abstinence."
</BLOCKQUOTE>
Thus, the success of the projects should be determined by the number of
participants who become drug abstinent.
<P>
Further aims are:
<UL>
<LI>Improvement of the physical and/or mental health of the addicts
<LI>Improvement of their social integration (e.g. reduction of delinquency)
<LI>Improvement of their responsible behaviour concerning the risk of
HIV-infection
</UL>
<H3>Research questions of the experimental plan</H3>
The experimental plan includes a number of questions, for instance about
general well-being, ability to work, contacts with the drug scene, delinquent
behaviour, risk behaviour, subjective effects of drugs, preference of drugs
and ways of application, to mention only some of them. The data come from
questionnaires and interviews with the participants.
<P>
<H3>Types of projects</H3>
The participants get either iv heroin, iv morphine or iv methadone. They also
get other substances like oral methadone, benzodiazepines or
anti-depressants. The experiment is conducted in five different types of
projects. They deal with different target groups or contextual conditions. In
three of the project types the decision which drug is given to which addict
is made by the doctor who asks the addict for his preferences. Two projects
started with a randomized allocation one of them is also double blind. This
double blind project, however, was soon abandoned. The addicts may now choose the substance themselves.
<P>
<H3>Number of participants and changes of the project design</H3>
Originally, the experimental groups (heroin, methadone, morphine) were
supposed to be of the same size, 250 subjects each. For heroin being the drug
of choice of most of the addicts, the heroin groups were filled much faster
than the other two groups. So in December 1994, there was a first extension
of the heroin group up to 500 subjects. In May 1995 a second extension was
decided upon. The number of heroin places was then increased up to 800.
Additionally, the project design was changed in that the heroin distribution
projects were to be integrated into existing methadone maintenance programs
and the prescription of narcotics should be extended to patients with
psychiatric disorders and to prisoners. The next steps which are discussed
are the possibilities to take drugs home, to make cocaine available and to
further extent the inclusion criteria (NZZ 16.8.95). This means they want to
make it easier for the addicts to participate in the projects.
<P>
<H3>Actual size of the groups</H3>
By April 1st, 1995, there were 286 participants in the heroin group, 28 in
the morphine group and 41 in the methadone group. Of the possible number of
988 places, only 355 are filled.
<P>
<H3>Criticism</H3>
From a scientific point of view, those narcotics distribution projects in
Switzerland and their scientific evaluation have to be criticized for a lot
of reasons. 
<P>
First of all, I think that the distribution of heroin to drug addicts has to
be rejected for ethical reasons. Human beings should not be misused as
experimental rabbits! Negative effects on the whole society, an increase of
the drug problem, an increase of delinquency and of the HIV epidemic have to
be expected.  The devastating effects of such projects were already
demonstrated in different countries at different times. 
<P>
Let us continue with the research questions. They are partly formulated in a
very general and unspecific way. The answers to this questions will be based
on questionnaires and interviews done with addicts who know that their future depends on their answers, and taken by professionals whose professional future depends on the outcome of these projects. A lot of energy is wasted and questions such as drug tolerance, side effects and withdrawal symptoms could have been answered easily by referring to the existing scientific literature.
<P>
Unfortunately, the most controversial questions are not examined: The effect
of the projects on the drug scene, the effect on drug related delinquency and
the effect on the AIDS epidemic. 
<P>
A fact which will result in a very difficult scientific problem is that the
project design was changed several times in different ways. The number of
subjects was changed, the number of experimental groups was changed, the type of drug allocation was changed.
<P>
A major criticism has to focus on the different group size of the heroin and
the other groups. You get into serious statistical trouble if you try to get
significant results from a comparison of two groups if the number of subjects in one group is ten times higher than the number in the other group. Being aware of this forthcoming problem, the director of the experiment decided just not to compare the three groups. For my understanding, this is one further step away from a scientific approach. 
<P>
Another basic deficiency of the project design is that there is no drug free
control group.
<P>
And above all, the polydrug use is a major pitfall of the evaluation of the
heroin projects. According to Prof. Uchtenhagen, the director of the
experiment, only 10% of the participants are pure heroin consumers, whereas
about 80% additionally consume cocaine and/or other drugs. The participants
are not required to take only the drugs they get in the projects and there is
no systematic testing on drugs.
<P>
Obviously, the politicians who favoured this type of project and evaluation
do not really believe in what is said in the general objective of the
experiment itself, namely that this kind of therapy should be one step
towards drug abstinence. 
<P>
I think it is generally questionable if such a controversial issue like
giving heroin to heroin addicts is to be evaluated by means of a project
which is not designed according to scientific standards. The term scientific
just refers to the "accompanying scientific evaluation". Ladies and
Gentlemen, such a kind of scientific evaluation cannot compensate for the
weaknesses of the project design and for the soft and biased data. 
<P>
<HR>
Please address any comments on the above paper to Dr.Ernst Aeschbach directly at (e-mail) <STRONG>76057.1653@compuserve.com</STRONG> 
</DOC>
<DOC>
<DOCNO>WT01-B04-169</DOCNO>
<DOCOLDNO>IA077-000522-B041-350</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWRC.html 207.112.150.94 19970124122920 text/html 14110
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:29:03 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 13938
Last-modified: Tue, 29 Oct 1996 17:30:09 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Marijuana Marketing by R. Creighton</TITLE>
</HEAD>
<BODY>
<H2><CENTER>THE MARKETING OF MARIJUANA <BR>
THE SHADOW PUSHERS TARGET AMERICA'S YOUTH</CENTER>
</H2>
<DL>
  <DT><CENTER>by Rosanna Creighton</CENTER>
</DL>
The &quot;shadow pushers&quot; are the aging marijuana users and advocates
who try to legitimize their drug of choice and perpetuate their crusade
to legalize marijuana. They have embraced slick marketing and promotional
techniques that target a new generation of potential marijuana advocates.
Media blitzes, billboard and print advertising, celebrity endorsements and
promotion, logo merchandising, mainstream outlet distribution, religious
and environmental sensitivities, and compassion for the ill and suffering;
all of these techniques have been used. Their most potent weapon is subterfuge.
Keep the masses ignorant of the facts, and manipulate and distort the truth.
<BR>
<BR>
They try desperately to separate marijuana from the other dangerous mind-altering
drugs. They call it hemp! They call it medicine! They portray themselves
as caring and compassionate. They do whatever they can to get attention
and sound rational; they conceal their true agenda - complete LEGALIZATION
OF MARIJUANA. They target America's youth by going to college campuses in
an attempt to recreate themselves and their own college experiences of spacing
out, promoting peace and free love while rebelling against the establishment.
They desperately need new recruits to emulate their ideals and their lifestyle.
<BR>
<BR>
But unlike the 60's and 70's, smoking pot and legalizing marijuana is not
well received by the general public today, so the shadow pushers have disguised
their intent and turned to promoting hemp to save the environment and promoting
medical marijuana to end pain and suffering. Richard Cowan, former director
of NORML (National Organization for the Reform of Marijuana Laws) and Drug
Policy Foundation Board of Advisors clarifies their point of view, &quot;Medical
marijuana is....our strongest suit. It is our point of leverage which will
move us toward the legalization of marijuana for personal use.&quot;1 <BR>
<P><CENTER><STRONG>STRATEGY NUMBER ONE - MARIJUANA, THE MEDICAL MAGIC BULLET</STRONG></CENTER>
<P>Let's look at what the shadow pushers mean by medical marijuana. They
insist pot smoking will help America's sick and terminally ill. No credible
medical or scientific data supports such an outrageous claim, but they say
it, and the media prints or broadcasts it. In 1979, Emory University students
were told that NORML would help reclassify marijuana as medicine for chemotherapy
patients, &quot;as a red herring to give marijuana a good name....&quot;
2 A synthetic form of THC (the only chemical in marijuana identified as
therapeutic) is available by prescription, but that is not good enough for
the shadow pushers. If they acknowledge that a pharmaceutical preparation
is already legal and available, they can't push for growing and using pot
without legal restriction. They would lose their political agenda and their
profit potential. <BR>
<BR>
So they push the need to smoke pot by exploiting the fears and desperation
of sick people and their families. The shadow pushers do not tell the public,
and the media rarely includes scientific fact with the marijuana propaganda,
that smoking marijuana can weaken and damage the immune system. Crude leaf
marijuana can irritate the lungs and introduce bacteria and fungal organisms
that can lead to infection and upper respiratory arrest. <BR>
<BR>
To successfully market an idea or a product, the promoter would never want
the target audience to know that the product is not proven safe or effective.
The truth is, AIDS and chemotherapy patients have an extremely weakened
immune system, and smoking pot can be extremely dangerous to them and other
ailing Americans. But the shadow pushers cleverly conceal the potential
dangers of smoking marijuana. Why do they conceal the dangers? Because they
would risk losing their legalization goal! Why don't the media reveal the
risks to sick people smoking pot as &quot;medicine&quot;? Because they rarely
know or believe the truth, and the shadow pushers use the media to their
advantage. Marijuana advocates have been carefully trained. In a media workshop
at the 1985 NORML conference advocates were instructed to, &quot;stroke
the egos of reporters. They like to be courted, they like to have attention
paid to them.&quot;3 These advocates are not concerned about substantiating
claims because, most of their press releases get publicized anyway. <BR>
<BR>
Case in point: in 1985 NORML head Kevin Zeese sent out a press release claiming
that marijuana had become the largest cash crop in the country. This information
was never verified. There was no real way to substantiate such a claim,
but this &quot;fact&quot; was publicized all over the country in major newspapers.4
<BR>
<BR>
Wow, what a break for the shadow pushers! They can tell lies, distort the
truth, exaggerate, or fantasize. It doesn't matter if what they say is not
proven by reputable scientific fact -- they just say what they want, and
it usually gets printed. In the last few months, their ideas and fantasies
have received increasing attention on major television networks. Nonscientific
claims with no solid base of medical evidence have been printed and broadcast
repeatedly until Americans, young and old, believe what they hear and read.
The marketing is effective, appallingly effective. <BR>
<BR>
The medical marijuana scam has reached our youth! Young people believe the
propaganda, repeat the misconceptions, and tell themselves and each other
that marijuana is natural, that God created it, that it is less harmful
than tobacco and alcohol, and that it couldn't be bad because it is used
for medicine. <BR>
<BR>
So smoking crude leaf marijuana for medicine becomes a successful marketing
tool for the shadow pushers. The truth doesn't reach the public and the
legalizers become the winners; the kids, their parents, the community, the
country, and especially the sick and the vulnerable, become the losers.
<BR>
<BR>
This marketing strategy has unfortunately gotten a boost from the tragic
HIV/AIDS epidemic. As stated in High Times Greatest Hits, &quot;Due in large
part to the growing AIDS crisis, the fight for medical marijuana has become
the most important issue in the battle for legalization.&quot;5 <BR>
<P><CENTER><STRONG>STRATEGY NUMBER TWO - HEMP FOR VICTORY</STRONG></CENTER>
<P>The marketing of hemp fabric and novelty products started out as a cottage
industry targeting the counterculture; but by calling marijuana or pot &quot;hemp&quot;,
a new twist for respectability and mainstreaming became available to the
shadow pushers. <BR>
<BR>
Direct from High Times Greatest Hits comes insight into this marketing strategy.
&quot;Hemp Clothing Is Here! Suddenly, out of nowhere came Stoned Wear,
a new line of hemp clothing and products.... High Times editors were skeptical,
as the clothing samples sent were only 55% hemp and 45% cotton. Is this
the real thing or not, we asked? <BR>
<BR>
Then we met Matthew Cheng and Alex Shum, the two men who are importing the
hemp fabric. Matthew and Alex feel that the way to legalize marijuana is
to sell marijuana legally. When you can buy marijuana in your neighborhood
shopping mall, IT'S LEGAL! So, they are going to produce every conceivable
thing out of hemp: hemp shirts, hemp pants, hemp jackets, hemp hats, hemp
oven mittens, hemp towels, hemp pot holders, hemp books, hemp comics, hemp
scratch pads, and hemp stationery. Anything and everything you can think
of will be made of hemp.&quot;6 <BR>
<BR>
And it is all coming true. Hemp is being promoted as a fabric, a fiber,
an environmental savior; a true marketing find for the shadow pushers. Even
Adidas has joined the counterculture's marketing of hemp to America's youth
by introducing a sport shoe called &quot;The Hemp&quot; with hemp tops and
hemp shoelaces. Everyone is cashing in! But the cash is often coming from
our children's pockets, and the hemp hype is promoting a strong psychoactive
drug - marijuana. Hemp, as a word, is confusing, which adds to the benefits
of the marijuana legalization efforts. Marijuana (pot, weed, reefer, bud,
chronic, blunt, dope, ganja, etc.) is generally called Cannabis Indica or
Indian Hemp or Cannabis sativa. &quot;True hemp&quot; is Cannabis sativa
L. There are other fibers that are referred to by the generic name &quot;hemp&quot;,
which can be Manila hemp or abaca, sisal hemp or henequen, New Zealand hemp,
jute and others.7 Only the &quot;true hemp&quot; comes from the cannabis
plant, the same plant as the psychoactive drug, marijuana. <BR>
<BR>
Whether &quot;true hemp&quot; or a generic hemp fiber, the shadow pushers
just call it &quot;hemp&quot;. They interchange hemp and the word marijuana
whenever they want and whenever it suits their purpose. They market &quot;hemp&quot;
as an environmentally sound fiber, and just like the smoking marijuana for
&quot;medicine&quot; strategy, their claims about &quot;hemp&quot; being
the environmental magic bullet gets printed and repeated with no scientific
proof. Remember, they have learned they do not have to substantiate their
claims; it gets printed anyway. <BR>
<BR>
The kids buy into the marijuana propaganda hook, line, and sinker; so do
many adults. America's environmental idealism gets exploited just like the
sick and terminally ill get exploited. The marketing strategies are working.
<BR>
<BR>
In the September 1993 issue of Madamoiselle, Rob Buchanan writes, &quot;To
the antidrug lobby, the medical marijuana argument is a cynical attempt
by recreational users to capitalize on sympathy for the ill, just as the
industrial-use argument tries to cash in on the sympathy for the environment....&quot;
That premise is supported by the very actions of the marijuana promoters
and the words of their leaders. &quot;It's the 'leaky bucket' strategy,&quot;
says Eric Sterling, marijuana promoter and president of the Criminal Justice
Foundation. &quot;Legalize it (marijuana) in one area, and sooner or later
it will trickle down into the others.&quot;8 <BR>
<BR>
Yes, the shadow pushers know what they are marketing. They are marketing
the legalization of marijuana and they are targeting America's youth. Besides
marijuana leaf logo clothes and novelty items, besides &quot;hemp&quot;
clothes and products, they have utilized the most powerful youth spell binder
available -- rock music and rap groups! <BR>
<P><CENTER><STRONG>STRATEGY NUMBER THREE - LOSE YOURSELF IN THE MUSIC AND
THE BEAT</STRONG></CENTER>
<P>Hempilation (1995 Capricorn Records), a CD featuring a variety of rock
bands, vividly demonstrates this marketing approach. This album was produced
to benefit NORML, and it shamelessly promotes pot smoking. This album includes:
<BR>
<DL>
  <DD>I Wanna Get High by Cypress Hill 
  <DD>I Want To Take You Higher by Blues Traveler 
  <DD>Don't Step On The Grass, Sam by Gov't Mule 
  <DD>Champagne & Reefer by Ian Moore 
  <DD>Sweet Leaf by Sacred Reich 
  <DD>Who's got The Herb by 311 
  <DD>I Like Marijuana by David Peel And The 360's 
  <DD>High Time We Went by The Screamin' Cheetah Wheelies 
  <DD>Smokin' Cheeba Cheeba by High Fidelity 
  <DD>Pot Head Pixies by Raging Slab 
  <DD>Legalize It by Sublime 
  <DD>Homegrown by Gus 
  <DD>And It Stoned Me by Widespread Panic 
</DL>
High Times magazine promotes this album in a full-page ad offering hempilation
T-shirts and hemp baseball hats. When asked about their special support
of NORML, High Times replied: &quot;High Times' founder Tom Forcade worked
closely with NORML, and the magazine will continue to support the group
until legalization is realized.&quot;9 <BR>
<BR>
In High Times Greatest Hits the editors say, &quot;In 1993, rock and rap
stars moved to the forefront of the legalization movement.&quot; Cyprus
Hill's Sen Dog states, &quot;in all our demos, we rhymed about gettin' high.
It's just something that comes natural to us.&quot;10 The shadow pushers
tell America's youth, be hip -- do drugs--be like us. Marijuana is OK, it's
healthy, and it's good for the environment. <BR>
<BR>
Marketing marijuana, marketing illicit drug use, marketing lies for profit
and political gain; the shadow pushers know no shame. <BR>
<BR>
At the Hempfest in Seattle, Sarah Ferguson writes, &quot;...with the late-summer
sun came crowds, thousands upon thousands of ganja fans, hemp fanatics,
medical marijuana crusaders, and stoned-out rockers, ready to fete the herb
in all its glory.&quot;11 <BR>
<BR>
Our young people flock to these hemp/marijuana/pot festivals, they learn
to glorify the herb, glorify hemp, and glorify the mind-altering drug -
marijuana. <BR>
<BR>
The shadow pushers say: <BR>
<DL>
  <DT><CENTER>MARIJUANA 
  <DT>can 
  <DT>reduce 
  <DT>stress, 
  <DT>increase 
  <DT>creativity, 
  <DT>enhance 
  <DT>sensual 
  <DT>activities, 
  <DT>improve 
  <DT>health, 
  <DT>create 
  <DT>laughter, 
  <DT>and stimulate 
  <DT>good feelings 
  <DT>*********** 
  <DT>Hard drugs 
  <DT>like heroin, 
  <DT>cocaine and PCP 
  <DT>CAN KILL you. 
  <DT>Don't do </CENTER>
  <DT><CENTER>hard drugs.</CENTER>
</DL>
<P><CENTER><STRONG>AND.....America's kids listen and believe!</STRONG> </CENTER>
<P>February 1996 <HR>
<H3><CENTER>ABOUT THE AUTHOR</CENTER>
</H3>
Rosanna Creighton is a founder of Drug Watch International and serves as
their Special Advisor on Public Policy . She was executive director and
public policy specialist for Citizens For A Drug Free Oregon from 1987-1995.
For over fourteen years Ms. Creighton has served as a specialist in drug
prevention/education. Cited by President Ronald Reagan for her drug prevention
efforts, she has served as a consultant to the National Institute on Drug
Abuse, U. S. Department of Education, and the State of Oregon. 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-170</DOCNO>
<DOCOLDNO>IA077-000522-B041-408</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/dyktam.html 207.112.150.94 19970124122954 text/html 9159
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:29:38 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 8988
Last-modified: Tue, 29 Oct 1996 17:30:26 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE></TITLE>
</HEAD>
<BODY>
<H2><CENTER>DO YOU KNOW THIS ABOUT MARIJUANA?</CENTER>
</H2>
<BR>
* * * Babies born to mothers who use marijuana during <BR>
pregnancy have eleven times the risk of getting childhood leukemia. These
<BR>
children are the innocent victims of their parents marijuana use. Based
on <BR>
research by Dr. L. Robison in the publication Cancer and Dr. J. Buckley
in <BR>
Cannabis: Physiopathology, Epidemiology, Detection.<BR>
        <BR>
* * * Marijuana smoke produces airway injury, acute and <BR>
chronic bronchitis, lung inflammation, and decreased pulmonary defences
<BR>
against infection. Smoking one marijuana cigarette leads to airway <BR>
deposition of four times as much cancer-causing tar as does tobacco smoke.
<BR>
Based on research by by Dr. D. Tashkin as reported in the Western Journal
of <BR>
Medicine.<BR>
        <BR>
* * * Cases of cancer, including cancer of the mouth, <BR>
tongue, larynx, jaw, head, neck, and lungs have been reported in young <BR>
marijuana smokers that would not occur in tobacco smokers until much later
<BR>
in life. Based on research by reported in Otolaryngology, Head &amp; Neck
<BR>
Surgery, the Journal of the American Medical Association and Southern <BR>
Medical Journal. <BR>
        <BR>
* * * A 1995 study of blood samples taken from one <BR>
thousand four hundred and forty-one dead or impaired drivers across Canada
<BR>
found marijuana present in 38% of these samples. Based on research by of
Dr. <BR>
Wayne Hindmarsh, Dean, Faculty of Pharmacy, University of Manitoba and Wayne
<BR>
Jeffery, R.C.M.P. Police Forensic Laboratory.<BR>
        <BR>
* * * Marijuana has long been known to trigger attacks <BR>
of mental illness, such as bipolar (manic-depressive) psychosis and <BR>
schizophrenia. It has been shown that marijuana users are six times more
<BR>
likely to develop schizophrenia than are non-users. Based on research by
of <BR>
Dr. S. Andreasson published in Britain's The Lancet.<BR>
        <BR>
* * * The use of marijuana leads to the use of other <BR>
drugs. Of those who use marijuana 3 to 10 times, 20% go on to use cocaine.
<BR>
Of those who use marijuana one hundred or more times, 75% go on to use <BR>
cocaine. Based on research by as reported in the Journal of Clinical<BR>
Psychiatry.<BR>
<BR>
* * * Marijuana causes both dependence and addiction. <BR>
Addictive use is defined by compulsive repeated use in spite of adverse
<BR>
consequences. Marijuana's effects include tolerance leading to dependence
<BR>
and inability to cease use. Based on research by of Dr. Mark Gold published
<BR>
in his book Marijuana.  <BR>
<BR>
* * * It's not just alcohol that caused impaired <BR>
accidents. A roadside study of reckless drivers who were not impaired by
<BR>
alcohol, showed that 45% of these drivers tested positive for marijuana.
<BR>
Based on research by of Dr. Dan Brookoff, published in the New England <BR>
Journal of Medicine.<BR>
        <BR>
* * * The effects of marijuana persist much longer than <BR>
the effects of alcohol. Using a computerized flight simulator, an experiment
<BR>
on pilots showed that their ability to land a plane was still impaired 24
<BR>
hours after smoking one marijuana cigarette. Based on research by of  Dr.
V. <BR>
Leirer in Aviation, Space &amp; Environmental Medicine.<BR>
        <BR>
* * * Children exposed to marijuana prenatally have <BR>
increased behavioural problems, and they have decreased visual perception,
<BR>
language comprehension, attention span and memory. These children are the
<BR>
innocent victims of their parents marijuana use.  Based on research by of
<BR>
Dr. Peter Fried of the Ottawa Prenatal Prospective Study.<BR>
        <BR>
* * * In males marijuana use diminishes testosterone <BR>
production and lowers sperm count. In females, marijuana use disrupts <BR>
hormone cycles.  Marijuana is mutagenic, fetotoxic (poisonous to the fetus)
<BR>
and impairs RNA and DNA synthesis.  Based on research by of Dr. Mark Gold
in <BR>
his book Marijuana and Drs. Latour and Nahas in the Medical Journal of <BR>
Australia.<BR>
        <BR>
* * * Marijuana impairs the white blood cells which <BR>
fight infection. Marijuana also causes decreased resistance to diseases
such <BR>
as herpes. Marijuana smokers have increased outpatient visits for <BR>
respiratory illnesses, accidents and other illnesses. Based on research
by <BR>
of Drs. Spector, Djeu, Watzl and Cabral in Advances in Experimental Medicine
<BR>
&amp; Biology and the Western Journal of Medicine.<BR>
        <BR>
* * * Children prenatally exposed to marijuana <BR>
experienced more than two times the number of sleep arousals at night and
<BR>
more awake time after each sleep arousal than children not prenatally <BR>
exposed to marijuana. Based on research by published in The Archives of
<BR>
Pediatric and Adolescent Medicine.<BR>
        <BR>
<BR>
* * * Cases of cancer from marijuana use are now well <BR>
documented. In one California study 90% of young cancer patients are <BR>
marijuana smokers compared with 40% of young people in California as a <BR>
whole. Based on research by by Dr. P. Donald in Otolaryngology, Head and
<BR>
Neck Surgery .<BR>
<BR>
* * * HIV positive marijuana smokers have increased <BR>
incidence of bacterial pneumonias in comparison to non-smokers. HIV positive
<BR>
smokers develop full-blown AIDS twice as fast as non-smokers. Based on <BR>
research by in the journal, AIDS Weekly 1993, and Dr. Neiman, in the <BR>
journal, AIDS 1993.<BR>
        <BR>
* * * In a survey of one hundred and fifty marijuana <BR>
using students, 59% surveyed report they sometimes forget what a <BR>
conversation is about before it has ended. 41% report that if they read
<BR>
while stoned they remembered less of what they had read hours later. Based
<BR>
on research by of Dr. Richard Schwartz, Vienna Pediatric Associates in <BR>
Psychiatric Annals. <BR>
        <BR>
* * * Long-term use of marijuana may cause irreversible <BR>
memory problems. Marijuana users find it more difficult to separate <BR>
irrelevant information from the relevant, their reaction times are longer
<BR>
and electrical activity of the brain is slowed. Based on research by from
<BR>
Macquarie University, Sydney in conjunction with Australia's National Drug
&amp; <BR>
Alcohol Research Centre.<BR>
        <BR>
* * * Marijuana impairs perception, judgment, thinking, <BR>
memory and learning. Memory defects may persist for 6 weeks after last <BR>
marijuana use. Based on research by of Dr. Richard Schwartz, Vienna <BR>
Pediatrics Associates in the American Journal of Diseases of Children.<BR>
        <BR>
* * * There are significant negative effects of <BR>
prenatal marijuana exposure on the performance of children in standard <BR>
intelligence tests. On average children exposed prenatally to marijuana
will <BR>
have a lower IQ compared to children who are not exposed. Based on research
<BR>
by of Dr. Day et al, in Neurotoxicology and Teratology.<BR>
        <BR>
* * * A cannabis (marijuana)-state-dependent effect in <BR>
users includes weaknesses in analytic and synthetic skills. This includes
<BR>
having difficulty sorting out information, synthesizing and classifying
<BR>
information correctly and understanding subtle shades of meaning. Based
on <BR>
research by of Dr. Lundqvist in Life Sciences.<BR>
        <BR>
* * * Fetal Marijuana Symptoms are similar to Fetal <BR>
Alcohol Syndrome are two diseases children are born with that are totally
<BR>
preventable. One of the leading specialists in cellular heredity, Dr. Akira
<BR>
Morishima of Columbia University, has said that in his 20 years of research
<BR>
on human cells he has never found any other drug, including heroin, which
<BR>
comes close to the DNA damage caused by marijuana.<BR>
        <BR>
* * * Saying nobody ever died from smoking marijuana is <BR>
like saying nobody ever died from smoking tobacco. Marijuana contains the
<BR>
same cancer causing chemicals as tobacco. Marijuana contains acetone, <BR>
hydrogen cyanide, ammonia, carbon monoxide, benzene, benzo pyrene, <BR>
nitrosamines and many other cancer causing pollutants. Based on research
by <BR>
of G. Huber in Pharmacology Biochemistry and Behavior.<BR>
<BR>
* * * Who is really killing our rain forests? The <BR>
United Nations reports that in Jamaica growers of marijuana plant their
<BR>
crops on isolated mountain slopes disturbing fragile forest soils. Growers
<BR>
clear cut and destroy the forests exposing fertile soil to runoff and <BR>
erosion causing permanently damages forests. <BR>
        <BR>
* * * Marijuana causes many mental disorders, including <BR>
acute toxic psychosis, panic attacks, flashbacks, delusions, <BR>
depersonalization, hallucinations, paranoia, depression and &quot;uncontrollable
<BR>
feelings of aggression&quot;. Based on research by of Dr. Richard  Schwartz,
<BR>
Vienna Pediatrics Associates in Pediatric Clinics of North America.<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-171</DOCNO>
<DOCOLDNO>IA077-000522-B042-49</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWCFpress.html 207.112.150.94 19970124123048 text/html 4864
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:30:07 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 4693
Last-modified: Tue, 29 Oct 1996 17:28:59 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>DWCFPress.html</TITLE>
</HEAD>
<BODY>
Press Release Issued by Houston's Drug-Free Business Initiative Houston
(July 9, 1996)<BR>
<H2><CENTER>COMING TO A STREET CORNER NEAR YOU?      </CENTER>
</H2>
<P><CENTER>Houston's Drug-Free Business Director Fears Results of Lenient
Drug Policy</CENTER>
<P> <BR>
Federally-funded heroin distribution clinics on the corner.  Methadone<BR>
maintenance programs gone awry.  Needles and condoms openly distributed
to<BR>
minors.  Frustrated police officials with little control.  With results
such<BR>
as these raging through the streets of Switzerland, the dangers of a lenient<BR>
drug-control policy were made abundantly evident last week to Calvina Fay,<BR>
Executive Director of Houston's Drug-Free Business Initiative.<BR>
 <BR>
 &quot;As I stood and watched young addicts inject themselves with heroin
as<BR>
though this was normal behavior, I realized that no attempt is made to<BR>
intervene on behalf of the addict and get him or her into treatment,&quot;
Fay<BR>
observed.  &quot;The objective of the Swiss law seems to be to assist the
addicts,<BR>
not get them off the drug.&quot;<BR>
 <BR>
 Switzerland's current drug-control policy, while outlawing consumption,
is<BR>
also a futile attempt to reduce the harms associated with use by taking<BR>
certain drugs off the street and putting them in the control of government
distribution clinics.<BR>
One frequently heard argument against the adoption of a similar law in the<BR>
United States centers around the concern that such a policy would serve
only<BR>
to magnify drug usage, rather than eliminate it.  And according to Fay,
her<BR>
observations of the situation in Switzerland only support such an argument.<BR>
 <BR>
 &quot;The alarming thing about the state of affairs in Switzerland is that
this<BR>
did not occur overnight,&quot; Fay said.  &quot;This situation emerged over
a 10-year<BR>
period and was slowly created through a process that I see evolving here
in<BR>
the United States.&quot;<BR>
 <BR>
 Switzerland's lenient environment, according to Fay, began with inadequate<BR>
controls to enforce the law.  Consumption and trafficking of drugs such
as<BR>
marijuana, cocaine and heroin are illegal.  However, all that enforcement
can<BR>
do to prevent such crimes is give the offender a ticket; imprisonment comes<BR>
only after a multitude have been issued.  Hence, officials are powerless
to<BR>
effectively control what Fay sees as a growing problem.<BR>
 <BR>
 The situation was furthered with the development of the government-subsidized
<BR>
programs designed to monitor current drug addicts and limit access to certain
drugs.  <BR>
Such efforts, in addition to free heroin distribution clinics and methadone
distribution <BR>
centers, include needle  exchange programs in the name of AIDS prevention
and public <BR>
shooting galleries, where street addicts are provided with a room, food,
condoms, and<BR>
clean needles.<BR>
 <BR>
 &quot;What they are doing to these addicts is absolutely criminal.  The<BR>
government has given up on them and thrown them away,&quot; Fay said.  &quot;I
fear<BR>
that we will see the same situation in our country in just a few years.&quot;<BR>
 <BR>
 As expert in workplace drug prevention, Fay returned from Switzerland last<BR>
week, where she addressed employers about the impact of drug abuse in the<BR>
workplace.<BR>
 <BR>
Fay's presentation, requested by Swiss employers concerned about safety
and<BR>
productivity implications of the lenient drug policy, detailed the findings<BR>
of a recent research study she directed through HDFBI in collaboration with<BR>
the University of Houston - Clear Lake.  The study, which gathered employers'<BR>
attitudes about drug control strategies, such as mandatory drug testing
and<BR>
employee assistance programs in the workplace, attempted to measure the<BR>
impact of such methods on workplace productivity.<BR>
 <BR>
 HDFBI is a non-profit organization dedicated to eliminating alcohol and
drug<BR>
abuse in the workplace by providing information and assistance to the<BR>
business community.  Founded in 1985 after the Strategic Planning Committee<BR>
of the Houston Chamber of Commerce asked for business sector involvement
in<BR>
the community's anti-drug activities, the organization is supported by the<BR>
FBI, Drug Enforcement Administration, Houston Crackdown, Texans' War on
Drugs<BR>
and the U.S. Attorney's office. <BR>
<BR>
Calvina Fay<BR>
Executive Director<BR>
Houston's Drug-Free Business Initiative<BR>
713-676-7275<BR>
                                        <BR>
                                                  <BR>
<BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-172</DOCNO>
<DOCOLDNO>IA077-000522-B042-330</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/Benzo.html 207.112.150.94 19970124123252 text/html 2502
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:32:21 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 2331
Last-modified: Wed, 13 Nov 1996 22:19:07 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Benzopyrene Doc.</TITLE>
</HEAD>
<BODY>
<H2><CENTER>Lung cancer causing carcinogen<BR>
more prevalent in marijuana<BR>
than in tobacco.</CENTER>
</H2>
<BR>
A breakthrough report published in the journal Science, October 18, 1996,<BR>
provides the first true molecular evidence conclusively linking components
in<BR>
tobacco smoking to lung cancer. A chemical found in tobacco smoking,<BR>
benzopyrene, causes genetic damage in lung cells that is identical to the<BR>
damage observed in the DNA of most malignant tumors of the lungs.<BR>
<BR>
Although scientists have been convinced in the past that smoking causes
lung<BR>
cancer, the strong statistical associations did not provide absolute proof.<BR>
This paper absolutely pinpoints that mutations in lung cancer cells are
caused by<BR>
benzopyrene. <BR>
<BR>
An average marijuana cigarette contains 30 nanograms of this carcinogen,<BR>
compared to 21 nanograms in an average tobacco cigarette <A HREF="mj.html">(Marijuana
and<BR>
Health, National Academy of Sciences, Institute of Medicine report, 1982)</A>.<BR>
This potent carcinogen suppresses a gene that controls growth of cells.
When this<BR>
gene is damaged, the body becomes more susceptible to cancer. This gene,<BR>
P53, is related to half of all human cancers and as many as 70% of lung<BR>
cancers.<BR>
<BR>
Clearly marijuana smoke contains more of the potent carcinogen benzopyrene<BR>
than tobacco smoke. Furthermore, the technique of smoking marijuana by<BR>
inhaling deeply and holding the smoke within the lungs presents a chance
of<BR>
much greater exposure than a conventional tobacco cigarette.<BR>
<BR>
* * * * * * * * * *<BR>
<BR>
This material has been reviewed and commented on by William M. Bennett,
M.D.,<BR>
Professor of Medicine, Division of Nephrology, Clinical Pharmacology and<BR>
Hypertension at Oregon Health Sciences University, Portland, Oregon.<BR>
<BR>
Dr. Bennett, who is listed in &quot;BEST DOCTORS IN AMERICA,&quot; states,
&quot;The idea of<BR>
using smoked marijuana containing these carcinogens as medicine, particularly<BR>
for patients who have suppressed immune systems like those with AIDS, should<BR>
be unthinkable. Thus, prior to considering marijuana as medicine, one must<BR>
abide by the old edict, &quot;first do no harm.&quot;<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-173</DOCNO>
<DOCOLDNO>IA077-000522-B043-32</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/mj.html 207.112.150.94 19970124123338 text/html 4470
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:33:16 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 4299
Last-modified: Wed, 13 Nov 1996 22:19:16 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Marihuana and Tobacco Analysis</TITLE>
</HEAD>
<BODY>
<P><CENTER><B>COMPARATIVE ANALYSIS OF MAINSTREAM SMOKE FROM<BR>
MARIHUANA AND TOBACCO REFERENCE CIGARETTE.<BR>
(Average weight: 1.110 mg; Length: 85 mm)</B><BR>
<HR>Measurements ------------------------Marihuana Cigarette -----------------------------Tobacco
Cigarette <HR></CENTER>
<P><I><STRONG>Gas phase <BR>
<P><CENTER></STRONG></I>Carbon monoxide, vol.% --------------------------------------3.99
--------------------------------------4.58 <BR>
Carbon dioxide, vol.% -----------------------------------------8.27 --------------------------------------9.38
<BR>
Ammonia, &#181;g --------------------------------------------------228 ---------------------------------------199
<BR>
HCN, &#181;g --------------------------------------------------------532
---------------------------------------498<BR>
Cyanogen (CN)2, &#181;g -----------------------------------------19 -----------------------------------------20<BR>
Isoprene, &#181;g ----------------------------------------------------83
-----------------------------------------310 <BR>
Acetaldehyde, &#181;g ----------------------------------------------1,200
-------------------------------------980 <BR>
Acetone, &#181;g ----------------------------------------------------443
---------------------------------------578 <BR>
Acrolein, &#181;g --------------------------------------------------92 -----------------------------------------85<BR>
Acetonitrile, &#181;g ------------------------------------------------132
---------------------------------------123 <BR>
Benzene, &#181;g ---------------------------------------------------76 ----------------------------------------67<BR>
Toluene, &#181;g -----------------------------------------------------112
--------------------------------------108 <BR>
Vinyl chloride, ng* ---------------------------------------------5.4 --------------------------------------12.4
<BR>
Dimethylnitrosanline, ng* -----------------------------------75 ---------------------------------------84
<BR>
Methylethylnitrosamine, ng* -------------------------------27 ---------------------------------------30<BR>
<BR>
</CENTER>
<P><I><STRONG>Particulate phase
<P><CENTER></STRONG></I>Total particulate matter, dly, mg ---------------------------22.7
--------------------------------------39<BR>
Phenol, &#181;g -------------------------------------------------------76.8
-------------------------------------138.5 O-Cresol, &#181;g -------------------------------------------------17.9
--------------------------------------24 <BR>
m- and p- Cresol, &#181;g ----------------------------------------54.4 --------------------------------------65
<BR>
Dimethylphenol, &#181;g ------------------------------------------6.8 ---------------------------------------14.4
<BR>
Catechol, &#181;g ---------------------------------------------------188---------------------------------------328<BR>
<B>Cannabidiol</B>, &#181;g ----------------------------------------190
--------------------------------------- <BR>
<B>Delta-9-tetrahydrocannabinol</B>, &#181;g ------------------820------------------------------------------<BR>
<B>Cannabinol</B>, &#181;g ------------------------------------------400
----------------------------------------<BR>
Nicotine, &#181;g ------------------------------------------------------------------------------------------------2,850<BR>
N-Nitrosonornicotine, ng* - ---------------------------------------------------------------------------390<BR>
Naphthalene, &#181;g -----------------------------------------------3 ----------------------------------------1.2<BR>
1-Methylnaphthalene, &#181;g -------------------------------------6.1 --------------------------------------3.65<BR>
2-Methylnaphthalene, &#181;g ------------------------------------3.6 ---------------------------------------1.4<BR>
Benz(a)anthracene, ng* -------------------------------------75 ---------------------------------------43<BR>
Benzo(a)pyrene, ng* ------------------------------------------31 ---------------------------------------21.1<BR>
<BR>
<HR>* indicates known carcinogens.<BR>
<BR>
From Marihuana and Health, National Academy of Sciences, Institute of Medicine<BR>
Report, Washington, D.C. 1982. </CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-174</DOCNO>
<DOCOLDNO>IA077-000522-B043-79</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWTPOS.html 207.112.150.94 19970124123401 text/html 5763
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:33:54 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 5592
Last-modified: Tue, 29 Oct 1996 17:30:15 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Drug Watch Position on Drug and Alcohol Treatment</TITLE>
</HEAD>
<BODY>
<H4><CENTER>Drug Watch International's</CENTER>
</H4>
<H2><CENTER>POSITION STATEMENT ON DRUG AND ALCOHOL TREATMENT</CENTER>
</H2>
<STRONG>Introduction:</STRONG> <BR>
<BR>
Drug treatment is an effective means of recovering from drug use and maintaining
a drug-free lifestyle for those who are addicted to alcohol and other drugs.
Programs must be accountable and able to demonstrate drug-free outcomes.
Drug treatment can be cost effective in that it reduces other related health
care costs and costs associated with the criminal justice system such as
courts, legal prosecution and defense, and incarcerations. Drug treatment
should be made available, accessible, and accountable to those addicted
to alcohol and other drugs. <BR>
<BR>
<STRONG>Background:</STRONG> <BR>
<BR>
Substance abuse is the number one health problem in America. More deaths,
illness, and disabilities derive directly from substance use than from any
other preventable health condition. The financial costs of substance abuse,
according to the Center on Addiction and Substance Abuse at Columbia University,
approach $400 billion annually. This does not include all the personal life
tragedies incurred by the individuals addicted and the sufferings borne
by their families, children, and friends. Almost 30% of all prisoners were
under the influence of drugs at the time of their offense. Furthermore,
in a sample of 23 American cities, 70% of all female arrestees tested positive
for drugs, and 30% to 78% of male arrestees likewise tested positive for
drugs. <BR>
<BR>
<STRONG>Rationale:</STRONG> <BR>
<BR>
Drug treatment has multiple goals: maintaining a drug-free lifestyle; reducing
the demand for illegal drugs; reducing street crime; changing users' personal
values; developing educational and vocational capabilities; improving the
user's overall health; reducing fetal exposure to drugs. <BR>
<BR>
Different modalities of treatment have been demonstrated to be effective
to varying degrees in achieving, to some degree, the aforementioned treatment
goals. Furthermore, significant savings, in terms of court costs and imprisonment,
are achieved as a result of participating in drug treatment. Health care
costs are likewise reduced as a function of drug treatment. For every $1.00
expended in drug treatment, there is a cost offset of up to $4.00 saved
in related health care expenditures. <BR>
<BR>
By making treatment more available, making it a priority within the health
care delivery system, and insisting on it whenever possible, the costs of
criminal justice and health care systems that are mushrooming out of control
can be reduced. More importantly, an addicted person can have the opportunity
to engage in a life of recovery and make a positive contribution to his
or her community. An appropriate criticism of the current treatment framework
involving criminal addicts is the &quot;revolving door&quot; phenomenon.
Criminal addicts often receive treatment as an afterthought, but then cycle
through the criminal justice system with repeated relapses. <BR>
<BR>
A possible alternative to currently available treatment of criminal addicts
could include intensively supervised extended treatment, which also involves
an intensive overhaul of the addict's social and personal factors, while
integrating treatment into the criminal justice system. Thus, criminal addicts
could not use treatment as a means to reduce their sentences. Rather, sentences
would be spent in a treatment environment, and addicts would risk going
to criminal prison or remaining incarcerated if they continue to use drugs.
<BR>
<BR>
When it is said that treatment works, this doesn't mean that it works in
each and every instance. There are few medical interventions that work all
the time. For some, treatment is a framework for life that will never be
acceptable or applicable. For others, treatment is embraced and is a successful
way of life. Relapse occurs in many of those who finish treatment, but may
often be handled by short relapse focused refreshers. A great emphasis is
now placed on the eventuality of relapse and how to prevent it. <BR>
<BR>
Some treatment programs are more effective than others. Treatment is a continuum
of processes which on one hand may include only self help measures, and
at the other extreme may be extensive long term institutional processes.
It is also important to recognize coexistent conditions which reduce the
potential long term effectiveness of treatment. Effective programs must
incorporate the entire family system, relapse prevention, and aftercare
subsequent to the primary treatment program. The effectiveness of treatment
should be documented by drug testing and outcomes monitoring. <BR>
<BR>
The challenge to treatment professionals, then, is to identify those differences
in order to establish more effective and cost efficient treatment for society.
Every treatment program should also be able to demonstrate its effectiveness
and cost effectiveness to both the public and private payers. <BR>
<BR>
<STRONG>Conclusion:</STRONG> <BR>
<BR>
Drug use and addiction is a complex human and societal problem. It must
be addressed from at least a threefold perspective: interdiction, prevention
and treatment. None of these interventions is by itself sufficient, but
in combination they are effective. They do reduce the amount of drugs that
are available, they do prevent initial use, and they do result in addicts
becoming drug free. <BR>
<BR>
December, 1995 
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-175</DOCNO>
<DOCOLDNO>IA077-000522-B043-114</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWDTPOS.html 207.112.150.94 19970124123419 text/html 2869
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:34:18 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 2698
Last-modified: Tue, 29 Oct 1996 17:29:08 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE> DW Drug Testing Position Paper </TITLE>
</HEAD>
<BODY>
<H2><CENTER>Drug Watch International Position Statement on Drug Testing</CENTER>
</H2>
<UL>
  <LI>Drug testing is an effective and humane method to deter and to detect
drug 
  <LI>use. 
  <LI>Drug testing is an important tool to reduce health and workplace costs
and to 
  <LI>monitor criminal offenders. 
  <LI>Drug testing enhances safety for workplaces, schools, and transportation.
</UL>
<H4>Background:</H4>
Drug-related health costs, crime, and erosion of worker productivity costs
billions of dollars annually. Drug testing is a useful tool in combating
these problems. The aim of responsible drug testing is to deter drug use
and to rehabilitate those who need help in overcoming drug problems. The
1994 American Management Association Workplace Drug Testing Survey stated
there is no doubt that drug testing is an effective method of identifying
drug users and deterring drug use in the workplace. <BR>
<H4>Rationale:</H4>
Health care costs have risen dramatically in the last decade. The escalating
epidemic of drug use has contributed to these costs. Drug-free workplace
programs reduce health care costs. Drug testing is essential to the success
of workplace programs and is a useful tool in drug treatment. Drug testing
helps break denial and disrupts addiction. <BR>
<BR>
Workers support drug-free workplace programs which include drug testing
and provide firm and compassionate education and rehabilitation. Drug testing
is effective in deterring drug use, and it has been overwhelmingly supported
by the courts. Studies indicate broad public support for workplace drug
testing. In an employment context, all positive screening tests should be
confirmed by gas chromatography/mass spectrometry (GC/MS). <BR>
<BR>
Voluntary drug testing in schools has proven to be effective as part of
comprehensive drug prevention programs, which include education, intervention
and counseling. <BR>
<BR>
Drug testing aids law enforcement by adding new levels of flexibility and
accuracy to the detection and monitoring of drug-using offenders. Treatment
programs and probation and parole officers use drug testing to therapeutically
confront offenders. <BR>
<BR>
Drug testing is used to detect and reduce incidents of crime and drugged
driving. <BR>
<BR>
The accuracy of on-site drug testing has been well established. It has been
approved by the American Probation and Parole Association Drug Testing Guidelines.
<BR>
<BR>
Both laboratory and on-site testing are valuable tools in implementing drug
prevention, treatment, and enforcement programs, and in protecting the health
and safety of society.
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-176</DOCNO>
<DOCOLDNO>IA077-000522-B043-157</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWPDUA.html 207.112.150.94 19970124123447 text/html 17177
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:34:35 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 17005
Last-modified: Tue, 29 Oct 1996 17:29:59 GMT
</DOCHDR>
<HTML>
<CENTER>
<TITLE>Drug Watch Position on Drug User Accountability</TITLE>
<H4>Drug Watch International:</H4><H2>Position Statement on Drug User Accountability</H2>
</CENTER>
Drug users, like any other members of society, must be held accountable for
their actions. Illicit drug use should bring swift and cost effective
consequences which will benefit the user and society at large. Every segment
of society must send the message that drug use and drug use behavior will not
be tolerated. Drug user accountability must be a cornerstone of national and
international drug policy.
<P>
<STRONG>Background:</STRONG>
<P>
<STRONG>In Australia and New Zealand :</STRONG> Social Policy Advisors to the Australian and
New Zealand Governments have pushed the Harm Reduction model exclusively.  More liberal laws exist in Australia than in New Zealand.  However, contrary to news media reports, most Australian states have not decriminalized marijuana. The National Organisation for the Reform of Marijuana Laws (NORML) is very active in both countries. The focus of their thrust seems to be the Universities.  In July 1995 the students of Auckland University voted against decriminalisation, which was quite a setback for NORML.  The editor of the student magazine, who described the student common room as a drug
"supermarket," is now in hiding. His life has been threatened.  
<P>
Both New Zealand and Australia have seen dramatic increases in methadone and morphine maintenance programmes, free needles, condoms, with accent on
behaviour modification, ie: teaching children and adolescents how to use
drugs safely, "The Merseyside Model" and teaching alcoholics how to drink
safely. The good news is that the New Zealand Health Minister issued a
proclamation "Cannabis Causes Harm," which contradicts the present liberal
philosophies.
<P>
<STRONG>In Canada: </STRONG>Illicit drug use began its climb in Canada in the 1960's and
reached its peak in the mid 1970's.  Initially the response was almost
entirely enforcement oriented.  However, it was soon recognized that
prevention efforts would have to be increased. The most successful strategy
consisted of three initiatives: enforcement, prevention and treatment. Using
this formula, a downward trend of drug use among the student population was
enjoyed until approximately 1992/1993, when the trend began to climb.
 Analysis of this shift revealed the topic of substance abuse had dropped off
the political agenda of all levels of government, and therefore few resources
were dedicated to it.
<P>
Presently, in Canada, there exists an organized campaign to re-direct
resources from strategies designed to eliminate inappropriate drug use to those strategies directed at the symptoms of drug use. These strategies come under the umbrella of "Harm Reduction" which is difficult to criticize given the converse position is to increase harm. A closer look at this concept allows us to realize there are two types of movements utilizing the term "Harm Reduction." The first is a genuine compassion for the addicted 
person which employs harm reduction strategies as part of a treatment program where  the ultimate goal is to rid the person of drug dependency. The second type of "harm  reduction" movement supports the liberalization of drug laws and or/legalization of the drugs themselves. This concept accepts a level of and actually promotes drug use.
<P>
<STRONG>In England: </STRONG>The Government's position is clearly against legalisation and for
prevention, education and treatment.  Prime Minister John Major recently
wrote, "Drugs are a menace to our society.  They can wreck the lives of
individuals and their  families.  They are a frequent cause of crime.  That is why we have toughened laws against drugs and why we have given the police and Customs the powers
and the resources to enforce those laws effectively.  Those efforts are
delivering  results.  Strong enforcement action has gone hand in hand with
measures to reduce demand. Since 1990, the Home Office Drugs Prevention
Initiative has supported over 1,000 projects to help local communities tackle
the drugs problem.  Drug education is part of the National Curriculum.
 Health authorities spend over 25 million pounds a year on treatment and
rehabilitation services for drug misusers."
<P>
Since the mid 1980s, the Government has pursued action to tackle drug misuse
on five main fronts:
<UL>
<LI>international cooperation 
<LI>enforcement 
<LI>deterrence
<LI>prevention 
<LI>treatment 
</UL>
However, the numbers of young people experimenting
with drugs, notified addicts and drug offenders have increased in recent
years.
<P>
The Government proposes to introduce a new strategy for the period 1995-98,
which, while fully maintaining the emphasis on law enforcement and reducing
supply, recognizes the need for stronger action on reducing the demand for
illegal drugs.
The new strategy will emphasize three areas: crime, young people, and public
health. 
Vigorous law enforcement and a new emphasis on education and prevention will
be the focus. The principal objective of treatment policies will be to assist
drug misusers to achieve and maintain a drug free state. 
<P>
<STRONG>In The Netherlands:</STRONG> In 1973 the Dutch National Board of Drug Prevention
formed in
response to a trend in Dutch governmental circles to trivialize the harm of
Cannabis.  The policy of tolerance started officially with the amended Opium
Law in 1976, mitigating the penal consequences of the possession of Cannabis
products.  
<P>
A policy of increasing tolerance was started. There followed an enormous
increase in the use of cannabis, especially among young people. From 1983 to
1992 cannabis use among pupils increased by 250%.  Coffee shops, where
Cannabis is sold openly, now number some 1500 to 2000.      
<P>
The situation in the Netherlands reveals that, by a tolerated possession of
cannabis for private usage and the absence of judicial prosecution of their
sale, the number of abusers will grow steadily.  Though the number of
coffee shops is still increasing and the population is becoming more and more
critical, the Dutch government keeps telling the world that everybody should
follow their beautiful example!  The "responsible use" of drugs does not
exist.  Drugs destroy. And things that destroy must never be made legal.  If
we allow drugs to be legalized, nothing will stem the progress of evil. 
<P>
<STRONG>In Sweden:</STRONG> Sweden has a restrictive drug policy, but this has not always been
the case. In the mid-1950s, the number of drug abusers in Sweden was
estimated at 100.  A few years into the 1960s, the figure ran into thousands.
 Police action alone could 
not stem the tide of drug abuse.  And a liberalisation of drug policy
followed.  To limit the harmful effects of drugs to the user and to help
reduce crime, in 1965 drugs were legally prescribed to addicts and treatment
was offered. However, the addicts supplied their friends with free drugs and
crime increased.  The project was curtailed in 1967.
<P>
In 1965, drug abuse developed into a major social problem, simultaneously
with a rapid growth of juvenile cannabis abuse. There followed a series of
restrictive drug policies and laws.  During the 1970s drug policy was
intensely debated, and a permissive drug policy was again instituted.  In the
mid-1970s, the advent of heroin among drug abusers resulted in a more
restrictive drug policy.  From about 1980 onwards, drug use declined
noticeably among young persons, and continues its decline today.  
<P>
Today, drug prevention measures have high priority within the police, the
customs service, the public prosecution service, the prison and probation
service, social services, schools and various leisure activities.    
<P>
Experimental use of cannabis and other drugs is very low in Sweden, and for
many years drug use among young people has been very limited.  Our aim is a
society in which drug abuse remains a socially unaccepted form of behaviour,
a society in which drug abuse remains a marginal phenomenon.  The essential
prerequisite of a successful drug policy is for people of all ages to
dissociate themselves from drugs and drug abuse.
<P>
<STRONG>In Switzerland: </STRONG>Federal Law regulates the medical use of narcotic substances
and
prohibits all production, trafficking, possession and consumption of drugs
for non-medical purposes.  Opium, heroine, hallucinogens and cannabis are
explicitly banned for all purposes and may only be used for scientific
research.  However, the pro legalization lobby is attempting to circumvent
the law through a well organized network and an intensive media strategy. 
<P>
In 1985 needle exchange programs were initiated. In 1989, Needle Park opened
in Zurich, allowing addicts free rein in a specified location under official
surveillance.  About 300 syringes were distributed daily.  By September 1991
the number of syringes distributed in Needle Park had increased to 12,000 to
15,000 per day.  In 1992, squads of police were sent to close down the park.
Dealers and addicts simply moved about a mile away to Letten, a deserted
train station, where more than 1,000 addicts and dealers gathered daily and
stupefied addicts lay slumped on a carpet of blood-spattered syringes, cotton
swabs and refuse, while others bought and sold cocktails of drugs. 
<P>
After a string of murders and violence, Zurich closed Letten Station in
February 1995.  The experiment in "harm reduction" had grown into a grotesque
sordid spectacle and public menace that bore no resemblance to the clinical,
carefully supervised venture promised by those who led the campaign in its
favor in 1988. 
<P>
In 1987 a well-structured methadone program was liberalized.  There were 300
methadone addicts in the Canton of Zurich before 1987, and more than 2,000 in
1991, according to police.  
<P>
In 1991, the Federal Government decided to intensify its commitment in this
field.  The Swiss Government pursues a four-pronged strategy to prevent the
individually and socially damaging effects of drug misuse:
<UL>
<LI>Criminal prosecution of illicit production, trafficking, possession and
consumption of all legally defined substances. 
<LI>Financially support to cantonal and private projects aimed at prevention.
<LI>Support to cantonal and private projects for a variety of treatment and
reintegration programmes for drug addicts.  It has authorized and is supporting scientific studies of medically prescribed narcotics to destitute drug addicts.
<LI>Support of "harm reduction" measures to enable the immediate survival of
the drug addicts and also to prevent the spreading of HIV, such as needle
distribution.
</UL> 
<P>
A National People's Referendum for a "Youth Without Drugs," has been
sponsored by Jugend ohne Drogen in support of abstinence oriented drug policy
in the Federal Constitution. In June, 1995 on the occasion of the United
Nations Day Against Drug Abuse and Trafficking (June 26th) a Resolution was
addressed to the Swiss Federal Government by VPM Verein Zur Forderung Der
Psychologiscen Menschenkenntnis calling for abstinence oriented and
restrictive drug policy.
<P>
<STRONG>In the United States :</STRONG> Throughout the 1970's, marijuana was decriminalized in
11 states; drug addicts were viewed as victims; and cocaine decriminalization
was proposed.  The largest increase of youth using drugs in the history of
the U.S. followed this permissive attitude. Crime and drug-related social
problems threatened the health and well being of all citizens.
<P>
In the early 1980's the public and law enforcement applied pressure to hold
drug users accountable for their illegal drug use and their role in
facilitating the illegal drug trade.  And drug use was reduced by over 50%.
<P>
Drug legalization advocates initiated a sophisticated public relations
campaign aimed at weakening thepublic's aversion towards illegal drug use.
Drug user lobbyists and organizations and other drug apologists assailed user
accountability measures as infringement of one's "personal right" to use
drugs, exaggerated the cost of user accountability policies, and ignored the
benefit of 12.6 million fewer drug users.
<P>
In the early 1990s, the drug issue began to lose national focus, and thus
momentum.  Once again, anti-drug messages and social attitudes started to
soften, the media and music began to reglamorize drug use, and drug use among
school children began to climb (teen marijuana use doubling over a three year
span), after a 12 year decline.
<P>
<STRONG> Rationale:</STRONG>
<P>
Drug use is not a victimless crime. Drug users place non-drug-users at risk
and cause
considerable societal harm. Drug users harass and disrupt the public peace,
commit crimes under the influence of drugs, cause accidents, and create
unhealthy conditions.  They destroy families and take rights and freedom from
law abiding citizens.
<P>
Recreational drug users, as well as hard core users, are the foundation of
the international drug cartel trade and the source of funds for drug kingpins
and terrorists. The drug trade exists solely because drug users keep it
alive. Drug users who are not yet addicted are perhaps the most culpable for
their drug use.
<P>
Holding drug users accountable early in their drug use pattern can prevent
abuse and addiction problems. For those already addicted, swift and certain
negative consequences for drug use can modify drug use behavior and lead to
recovery through treatment or individual initiative. 
<P>
Research clearly indicates that social norms and user accountability laws are
key factors in preventing drug use and decreasing problem behavior.  In the
justice system, user accountability need not rely on lengthy prison
incarceration, but on a broad continuum of responses such as community
service, asset forfeiture, tough mandatory fines, civil liabilities for all
damages, drug abstinence enforced through frequent drug testing of offenders
with immediate, progressive consequences, loss of federal and state benefits,
loss of driving and other license privileges, automobile impoundment, and
restitution payments. 
<P>
In the workplace, programs must protect employers and non-drug using
employees. 
Workplaces should communicate clear rules and consequences.  In the
community, schools, and homes clear anti-drug norms and values must be stated
and applied.  Tough, but fair, user accountability sanctions should be
enacted.
<P>
Drug user accountability should be a cornerstone of drug strategy. Directing
policies, funding, and energies towards effectively reducing the demand for
drugs is true compassion for the drug user and is in the best interest of
society.
<P>
<STRONG>U.S. EXPERIENCE:</STRONG>
<P>
Throughout the 1970's, United States drug policy exhibited tolerance for drug
users and focused enforcement on heroin traffickers.  Marijuana was
decriminalized in 11 states; drug addicts were viewed as victims; and cocaine
decriminalization was proposed. The largest increase of youth using drugs in
the history of the U.S. and perhaps in the world followed this permissive
attitude by government and society.
<P>
In 1979, approximately 24 million Americans had tried an illicit drug, and
one in ten high school seniors was using marijuana every day of the week.
Drug incarceration rates reached an all time low and crime and drug-related
social problems threatened the health and well being of all citizens.
<P>
In the early 1980's, non-drug users became acutely aware of the negative
impact that drug use was having on their families and communities. The public
and law enforcement applied pressure to hold drug users accountable for their
illegal drug use and their role in facilitating the illegal drug trade after
a decade of lenient drug policy.  
<P>
Zero tolerance of drug use led to a dramatic shift in attitudes and to major
declines in drug use.  In 1992, a child was half as likely to use illegal
drugs as his or her counterpart from 15 years previous, and adults were even
less likely to use. Social intolerance to drug use resulted in 12.6 million
fewer Americans using drugs. Drug user accountability had been applied by law
enforcement, schools, families, workplaces, and the media.
<P>
Drug legalization advocates initiated a sophisticated public relations
campaign aimed at weakening the public's aversion towards illegal drug use.
Drug user lobbyists and organizations and other drug apologists assailed user
accountability measures as infringement of one's "personal right" to use
drugs, exaggerated the cost of user accountability policies, and ignored the
benefit of 12.6 million fewer drug users.
<P>
In the early 1990s, the drug issue began to lose national focus, and thus
momentum.  Once again, anti-drug messages and social attitudes started to
soften, the media and music began to reglamorize drug use, and drug use among
school children began to climb (teen marijuana use doubling over a three year
span), after a 12 year decline.
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-177</DOCNO>
<DOCOLDNO>IA077-000522-B043-374</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWNEPP.html 207.112.150.94 19970124123616 text/html 6298
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:35:11 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 6127
Last-modified: Tue, 29 Oct 1996 17:29:52 GMT
</DOCHDR>
<HTML>
<TITLE>Drug Watch Position Paper on Needle Handouts to Addicts</TITLE>
<CENTER>
<H3>DRUG WATCH POSITION STATEMENT ON NEEDLE HANDOUTS TO ADDICTS</H3> 
</CENTER>
Providing needles to addicts for injection of illegal drugs should cease. 
No funds should be spent on needle exchange programs unless it can be
scientifically proven that such programs are safe and effective. Studies
based on scientific protocols show no evidence that needle exchange
programs (NEPs) decrease HIV infection rates, and these studies fail to
prove that NEPs do not encourage drug use.  The practice actually
facilitates and enables illegal drug use, which puts the drug user at
continual risk of exposure and results in unpredictable behavior, crime,
violence, rising medical costs, drug impaired newborns, and other societal
problems. 
<P>
<STRONG>Background:</STRONG>
<P>
Needle exchange programs began in 1984 in Amsterdam, the Netherlands,
started by a drug-user advocacy group called the Junkie Union. Subsequent
programs were started in 1988 in Tacoma, Washington and San Francisco,
California; and in 1990 in  New Haven, Connecticut and New York City.
Currently, many illegal programs are operating in the U.S.  In Switzerland, liberal drug policies and the drug tolerant atmosphere they created, brought about the open drug scenes, where large numbers of needles were distributed to addicts, and caused a dramatic increase in drug addiction, crime, and violence.
<P>
<STRONG>Rationale:</STRONG>
<P>
Needles provided for the injection of illegal drugs encourage and perpetuate
drug use and unsafe sex that spreads AIDS and other sexually transmitted diseases (STDs).  The most effective approach to address the causal role of drugs with regard to AIDS is to prevent or intervene in the drug using behavior that leads to AIDS. Scientific studies show that drug use impacts the immune system and speeds the growth of the HIV virus which causes AIDS.  Reducing drug use would also decrease the incidence of risky sexual behavior while under the influence of drugs, a major factor in the spread of HIV infection, hepatitis and other STDs. 
<P>
Aggressive outreach/education efforts have resulted in decreased
seroconversion
rates of HIV/AIDS without providing needles to the population.  Treatment
programs have resulted in markedly reduced rates of HIV/AIDS.  The HIV
prevalence rate in addicts stabilized in NYC in 1983, well before needle
programs
began.  The Greater Los Angeles area has a lower prevalence of AIDS-infected
drug users than any major metropolitan area in the nation due to the
non-existence
of government sanctioned needle exchange programs, coupled with aggressive
prevention efforts and low cost treatment.  Funds currently being used for
NEPs
would be better spent if directed toward expansion and improvement of drug
abuse treatment.
There is no valid scientific evidence that providing needles has resulted in
any
additional lowering of HIV/AIDS rates, according to the U.S. Center for
Disease
Control report.  Furthermore, as shown in a recent Montreal study,
seroconversion rates, i.e. the percentage of persons who contract the AIDS
virus,
are many times higher in needle exchange participants than in addicts offered
outreach alone.
<P>
Current studies of needle exchange programs are flawed and inconclusive.
 Many
use insufficient sample size, do not conduct objective tests, do not use
valid
comparisons,  and use program staff, rather than independent evaluators, to
conduct client interviews.  A common failing of these studies is that they
fail to
control for the many variables involved.    
<P>
In Switzerland, first a limited number of needles were made available, then
the
supply was increased as the number of addicts increased.  Later heroin was
provided to addicts.  The open drug scenes, which have since been closed, 
became a magnet for foreign addicts.  Currently, needles are distributed at
multiple, smaller sites.  In the past, narcotic laws were very effective in
getting
addicts to enter treatment, since addicts were given the choice of treatment
or
prison.  The threat of prison serves as an incentive to stay in treatment and
off
drugs.
<P>
The problems associated with liberal drug policies, the distribution of
needles to
addicts, and the resultant rise in addiction, crime, and violence, which have
occurred in Switzerland, are now being replicated in the United States
through
NEPs.  Police are instructed not to enforce the anti-drug paraphernalia laws
when
persons possess a Pilot Needle Exchange Program Card.   Persons who
previously would have been ordered into treatment by the criminal justice
system
are given the means (needles, syringes, "cookers," and the NEP card) to
continue
their addiction.  Only a small minority (16%) of addicts in NEPs enter
treatment. 
Residents in the neighborhoods where needles are distributed complain that
giving addicts needles to inject illegal drugs interferes with community
goals of
clearing drug users and dealers from their neighborhoods.  Addicts inject
drugs in
broad daylight, and residents report an increase of crime and violence.
<P>
Providing needles to inject illegal drugs is in violation of U.S. Federal
law.  Federal
funds may not be used for such programs, since they have not been shown to
decrease the spread of AIDS without increasing drug use.   Anti-drug
paraphernalia laws, which are circumvented by NEPs, were passed to decrease
drug use and have proved to be effective.
<P>
An active pro-drug lobby promotes needle exchange programs and the
unscientific "studies" alleging the effectiveness of NEPs in reducing
HIV/AIDS
rates.  The needle exchange issue is a priority for drug-legalization groups,
who
lobby for permissive drug policies and programs promoting so-called "safer"
use
of illicit drugs.
<P>
The most compassionate and humanitarian approach for the addict, the drug
user,
and society is prevention, intervention and treatment. Needle handouts to
addicts
facilitate and increase drug use, enslaving the user and promoting
promiscuous
sexual behavior which spreads AIDS.
<P>
1996 Drug Watch International 
</DOC>
<DOC>
<DOCNO>WT01-B04-178</DOCNO>
<DOCOLDNO>IA077-000522-B044-62</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/ATPOS.html 207.112.150.94 19970124123738 text/html 7626
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:36:56 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 7455
Last-modified: Fri, 17 Jan 1997 07:33:41 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Alcohol and Tobacco Position Statement</TITLE>
</HEAD>
<BODY>
<H1><CENTER>Drug Watch International</CENTER>
</H1>
<P><CENTER>POSITION STATEMENT<BR>
ALCOHOL AND TOBACCO: TWO DANGEROUS GATEWAY DRUGS</CENTER>
<P><B>The use of alcohol and tobacco has taken a great toll on youth and
society and is a predictor of future alcohol abuse and addiction, as well
as the use of other drugs. Therefore, Drug Watch International supports
all efforts to prevent use of these drugs by youth and supports efforts
to restrict advertising of them to the general public.<BR>
<BR>
Background:</B><BR>
Alcohol and nicotine are legal drugs for adults in many countries. Even
though these dangerous and addictive drugs are &quot;socially acceptable&quot;
for adults, they are, to one degree or another, controlled substances for
youth throughout the world. Many cultures try to limit their young from
using alcohol or tobacco. Efforts to prevent the use of alcohol and tobacco
by youth should not be confused with efforts to prohibit adult use of either
of these drugs. However, it is time adults looked at their own alcohol and
tobacco use, if they want to influence young people.<BR>
<BR>
In North America and other countries, alcohol is the number one drug used
by teens. It's use is also the number one contributing factor in youthful
deaths. In the U.S., the use of alcohol is associated with at least one-half
of all car crashes, suicides, drownings, crimes of violence, unplanned sex,
poor school performance, and other trauma among youth.<BR>
<BR>
Alcohol and tobacco kill more people annually than all other drugs combined.
Alcohol alone is associated with at least one-fourth of all hospital visits
in the United States. Nicotine is one of the most addictive and harmful
of all drugs.<BR>
<BR>
There is a false perception that if a drug is legal it must cause less problems.
In many countries and cultures, the use of alcohol and/or tobacco is so
deeply woven into the cultural fabric of those countries that neither is
acknowledged as a drug or even as a problem.<BR>
<BR>
<B>Rationale:</B><BR>
In July 1995, the U.S. Food and Drug Administration (FDA) concluded for
the first time that nicotine is a drug and that it should be regulated as
a controlled substance. Regulations were proposed restricting access to
tobacco products and restricting attempts to make these products appealing
to children and adolescents. Indeed, if alcohol and tobacco were new products
seeking FDA clearance today, each would likely be rejected as hazardous
and addictive.<BR>
<BR>
A recent study by Columbia University's Center on Addiction and Subst,ance
Abuse, states that the earlier children use the gateway drugs tobacco or
alcohol or marijuana, the more likely they are to move on to other drugs.
Youth who drank alcohol were 50 times more likely to use cocaine, and those
who smoked tobacco cigarettes were 19 times as likely to use cocaine. Nearly
90% of cocaine users had smoked tobacco or drank alcohol or used marijuana
first. The study, based on 30,000 American households, established a clear
progression that began with use of the gateway drugs of alcohol, tobacco
or marijuana and led to use of other drugs.<BR>
<BR>
Dr. John Slade reported at the 1989 National Conference on Nicotine Dependence
in San Diego, California, that tobacco smoking teaches drug acquisition
skills to the youth. He said, &quot;For the most part, they're illegal for
kids to buy. In addition, kids who smoke get firsthand experience in using
a substance to adjust emotional states.&quot; Slade reports that tobacco
use teaches drug-taking skills and that tobacco use promotes an attitude
that fosters other drug taking behaviors.<BR>
<BR>
Compounding the problem is the relative ease with which youth can access
alcohol and tobacco. Both drugs are widely available, inexpensive and heavily
marketed, making them especially attractive to youth, who are the most price-sensitive
consumer age group.<BR>
<BR>
The right of adults to consume either of these drugs is a notion heavily
promoted by the alcohol and tobacco industries. This argument is meaningless
for many young people who have reached the legal age for use with no real
choice left, because they are already addicted. They have been seduced into
use of both drugs by slick marketing targeted at youth long before they
have had their first drink or used tobacco for the first time.<BR>
<BR>
Youth are bombarded daily with alluring advertising and marketing techniques.
Because new alcohol or tobacco users are rarely adults, images which imply
sexual prowess, athletic ability, popularity, freedom and escape from problems
are especially appealing to young people. Children grow up thinking that
they cannot have a good time without alcohol or tobacco. They don't realize
that many adults choose not to drink.<BR>
<BR>
Alcohol can kill or cause serious problems any time a young person uses
it. Yet, some youth are convinced that drinking alcohol or using tobacco
does not cause immediate problems in their lives, and most are certain that
they could quit at any time. The average teen smoker had his/her first whole
cigarette by 13 and became a daily smoker by age 14.5.<BR>
<BR>
Drug Watch International recognizes and supports the various efforts of
many concerned drug preventionists who are attempting to prevent the use
of alcohol and tobacco by youth. Many Drug Watch members are local and national
leaders in this aspect of prevention. We must never retreat in our efforts
to prevent drug use by youth.<BR>
<BR>
Drug Watch International supports the many promising practices and strategies
aimed at preventing youthful alcohol and tobacco use, including: changing
social acceptance of use by youth, increasing law enforcement efforts for
those who provide or procure these drugs for youth, increasing excise taxes,
Eating more meaningful and effective consequences for those who provide
alcohol or tobacco to adolescents, increasing prevention programs, restricting
advertising and marketing, and supporting legislation and public policy
that limits the lobbying practices of the alcohol and tobacco industries.<BR>
<H6><CENTER>COPYRIGHT Permission is granted to reproduce this article provided
credit is given to Drug Watch International as the source.</CENTER>
</H6>
<P><CENTER><HR><BR>
<BR>
<B>References: Alcohol &amp; Tobacco</B></CENTER>
<P>Comprehensive National Analysis Between &quot;Gateway&quot; Drug Use
and Other Illicit Drug Use, Center on Addiction and Substance Abuse, Columbia
University. October 27, 1994<BR>
<BR>
Andrew Golub, Ph.D., Bruce D. Johnson, Ph.D., &quot;The Shining Importance
of Alcohol and Marijuana as Gateway Substances among Serious Drug Abusers,&quot;
National Development and Research institutes. Joumal of Studies on Alcohol,
September 1994.<BR>
<BR>
Robert L. DuPont, Jr., M.D., &quot;Getting Tough On Gateway Drugs.&quot;
American Psychiatric Press, Inc., 1984.<BR>
<BR>
Ontario Ministry of the Attorney General Drinking/Driving Counterrneasurers,
July 8, 1991.<BR>
<BR>
P.R.I.D.E., People to Reduce Impaired Driving Everywhere, Official Chapter
of MADD.<BR>
<BR>
Canada's Epidemic, Death on the Highway, Insurance Bureau of Canada. 1982.<BR>
<BR>
Ian L. Reid, C.M., M.D., F.R.C.S., &quot;Raising The Drinking Age.&quot;
PRIDE Selkirk.<BR>
<BR>
John Slade, M.D., as reported at the National Conference on Nicotine Dependence,
San Diego, CA, 1989.
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-179</DOCNO>
<DOCOLDNO>IA077-000522-B044-229</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/DWEA2.html 207.112.150.94 19970124123838 text/html 21479
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:37:49 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 21307
Last-modified: Mon, 20 Jan 1997 02:13:12 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Heroin Distribution Research Review by Ernst Aeschbach, M.D.</TITLE>
</HEAD>
<BODY>
<H2><CENTER>On the Scientific Value of the Research Studies Accompanying
Heroin Distribution<BR>
A Critique . . .</CENTER>
</H2>
<P><CENTER>Ernst Aeschbach, M.D.</CENTER>
<P>For the past eight to ten years, the Citizens of the German speaking
sector of Switzerland have been witnessing a highly questionable change
of drug policy: open drug scenes, toleration of rising crime rates, and
pursuit of &quot;survival aid measures,&quot; sometimes known as &quot;harm
reduction.&quot; These &quot;measures&quot; facilitate addictive behavior
instead of behavior which favors the abandonment of drug use and positive
perspectives on life.<BR>
<BR>
Though the failure of Swiss drug policy seems obvious, nevertheless, models
are still being proposed which more or less advocate the free availability
of all drugs. One of these models calls for the distribution of heroin.
The common denominator of all these models is the theory that drugs themselves
are not dangerous, but rather the way they are used.<BR>
<BR>
Two prerequisites are necessary for the political endorsement of these models.
First, the media must disseminate the mistaken notion that drugs themselves
are not dangerous, but only the way they are used. And second, the &quot;heroin
experiment&quot; must be presented as a &quot;scientific study.&quot;<BR>
<BR>
There is no scientific interest or reason for this heroin experiment. The
hazards of heroin use have long been proven. Indeed, for the heroin experiment,
the term &quot;scientific study&quot; is being used as a subterfuge. This
is the only way available for proponents to introduce the broad distribution
of heroin in Switzerland.<BR>
<BR>
Federal Council of Switzerland 1992: Drug Abstinence as Primary Goal in
May of 1992, the Federal Council of Switzerland voted, under massive political
pressure, to allow a temporary experiment to distribute heroin to addicts.
It should be noted that the conduct of the experiment contradicted the prevailing
narcotics law. <BR>
<BR>
In its implementing decree of October 21, 1992, the Federal Council of Switzerland
stipulated that scientific research must accompany drug prevention measures,
so that improvements in the health and living conditions of drug addicts,
as well as their integration into society, may be analyzed. Drug abstinence
was still the primary goal of the prevention and welfare measures. This
decree forms the legal and substantive basis of the General Experimentation
Plan, published by the Federal Office of Public Health. The Experimentation
Plan delineates the binding guidelines for the establishment and implementation
of the heroin experiment. It also explicitly states that drug abstinence
is the primary goal, thereby setting forth the primary criteria for evaluating
the results. The first project applications for the experiment were submitted
by several cities and organizations and approved by the Federal Office of
Public Health in the Fall, 1993. The first experiment began in early December
1993, in Zurich. One of the major components of the project was the trial
prescription of heroin. This is an essential factor for determining scientifically
the possible basis for permanent distribution of heroin in the future. Since
the distribution of heroin to addicts represents a fundamental deviation
from hitherto proven principles of treatment, it is imperative that a critical
analysis of this experiment be undertaken.<BR>
<BR>
<B>Scientific Objectivity:</B><BR>
<BR>
Scientific research demands objective behavior in the formulation of experimentation
concepts, as well as in practical procedure. Pre judgment on the part of
those responsible could lead to biased results and may later cause erroneous
political decisions. When massive political pressure exists, as is the case
with this heroin experiment, then at least those who evaluate the individual
projects should be neutral. However, in this particular case, the evaluators'
neutrality is highly questionable.<BR>
<BR>
As early as 1991, the director of the current heroin project ZokL2, A. Seidenberg,
stated the following: &quot;A medicalization of the drug problem, as seen
in this experiment, does not represent a definitive solution to the drug
problem. Instead, it represents a partial step towards normalization....Even
before a broad distribution has been implemented, it is possible to enter
into a discussion concerning additional market-deregulating measures.&quot;1<BR>
<BR>
Continuous opposition to the Experimentation Plan has stated:<BR>
* The Experimentation Plan is based on drug-policy, not scientific reasoning.<BR>
* There is a call for broad distribution of opiates to drug addicts.<BR>
* There are exceptionally premature &quot;success reports&quot; by project
managers<BR>
and evaluators.<BR>
<BR>
Making unequivocal drug policy claims, and then trying to substantiate them
scientifically, can lead to only seeing what advocates want to see. Internationally
accepted scientific standards appear to have been violated.<BR>
<BR>
<B>Flaws in the Federal Office of Public Health's General Experimentation
Plan:</B><BR>
<BR>
The design of the General Experimentation Plan contains methodological flaws
and critical errors, some of which are presented below:<BR>
<BR>
1. A major omission is the lack of a control group of drug addicts, to whom
narcotics are not prescribed, but who nonetheless receive the same welfare
measures. Having a control group would have allowed an analysis of the results,
to determine whether the results are due to heroin prescription or welfare
measures. Without such a control group, positive results can be due to the
quality of counseling and supervision given, and can occur without regard
to the prescription of heroin. The use of control groups is a scientific
standard which all serious researchers include in order to insure recognition
of their work.<BR>
<BR>
2. A major limitation is the unreliability of data collected. Details of
physical and mental health, as well as social circumstances, were primarily
taken from interviews. This procedure is not in itself invalid, yet a scientist
must assure the reliability of collected data by hard facts and field surveys.
Without such reliable data, conclusions can only be speculative. In this
case, such supporting information has not been verified. In addition, the
collected data are not corroborated by reports from third parties, such
as relatives, employers, police, etc. Moreover, easily subjective data have
not been collected systematically. For example: although physical examinations
were given when participants entered the project, a preliminary report of
November 1995, shows that apparently not even systematic laboratory tests
were given to determine such important parameters as HIV-status and hepatitis
infections.<BR>
<BR>
3. A major contradiction is that quantitative conclusions cannot be drawn
from the ambiguous formulation of many questions. For example: according
to the General Experimentation Plan, risk behavior with regard to HIV must
be examined. However, the criteria for measuring risk behavior remains completely
unclear. Since the participants were not required to take routine HIV-tests,
no conclusion can be drawn with respect to the frequency of initial HIV
infections, not to mention those which may have occurred during the time
of participation in the experiment.<BR>
<BR>
4. A major concern is that the majority continued actively in the drug scene
and consumed additional narcotic substances during the experiment. Since
no records were kept of the drug types and amount consumed, no conclusions
can be deemed valid about the relationship between health and consumption
behavior or changes in social circumstances during the experiment. This
problem could have been avoided by prohibiting participants from taking
drugs outside of the experiment and introducing controls such as obligatory
random drug tests. Here the Experimentation Plan once again failed to maximize
the reliability of the data required for objective evaluation.<BR>
<BR>
5. Some critics, since the beginning of the heroin experiment, have raised
the following questions:<BR>
* Could the experiment have various negative effects on the drug scene?<BR>
* Could a general increase in drug consumption lead to increased drug-induced
delinquency?<BR>
* Could HIV infection spread further?<BR>
<BR>
According to the General Experimentation Plan, precisely these questions
will not be examined in the evaluation. In addition, cooperation by the
police has been categorically rejected, and this insures that the impact
of the experiment on public safety will not be appropriately verified.<BR>
<BR>
<B>Dubious Changes in the Experimentation Plan:</B><BR>
<BR>
In its decree of October 21, 1992 the Federal Council of Switzerland designated
abstinence as the primary goal of the experiment. Moreover, it limited drug
prescription to the end of 1996, except for the oral intake of methadone.
It authorized only 5 projects with a maximum of 50 participants each, thus
setting a ceiling of 250, so that the &quot;scientific experiment with human
beings not exceed certain bounds.&quot;<BR>
<BR>
These limitations have been attacked by various advocates of the experiment.
These advocates essentially called for: (1) an increase in the number of
participants; (2) authorization of prescriptions for other drugs, for example,
cocaine (U. Locher, Neue Zrcher Zeitung (NZZ), August 16, 1995); and, (3)
less controlled distribution conditions, i.e., such as the ability to take
drugs home (M. Stocker, NZZ, August 16, 1995). These criticisms should be
construed as an indication that the advocates themselves do not consider
the projects to be scientific research, but rather the means to implement
drug policy measures. Unfortunately, the Federal Council of Switzerland
succumbed to pressure from the experiment's advocates, and in October 1994,
one year after it began, the Council voted to allow the first change in
the General Experimentation Plan. The number of participants eligible for
heroin prescription was raised from 250 to 500, with those for morphine
reduced from 250 to100 and methadone reduced from 200 to 100. The reason
given was that heroin, in contrast to morphine and methadone, was more readily
accepted by heroin addicts. <BR>
<BR>
Another rationale for changing the ratio of heroin, morphine and methadone
subjects was that initially fewer side effects and incidents were reported
with heroin. By greatly increasing the number of heroin subjects and reducing
the number of other participants, the results of the study could be artificially
altered. This example shows very clearly that the experiment is not based
on scientific criteria. Instead, it was designed to accommodate the preferences
of heroin addicts. <BR>
<BR>
It is of considerable interest to note that no important successes have
been recorded with regard to the experiments' official primary goal, drug
abstinence -- the one factor which might have justified any eventual changes
in the Experimentation Plan. It seems that the real reason for the change
was based on the preference of heroin addicts to take heroin.<BR>
<BR>
The second change in the General Experimentation Plan was made in May 1995.
This time, the number of participants was increased to 800. With this change,
the following three additional research areas were added to the study. The
contribution of each one to the scientific validity of the experiment is
questionable:<BR>
<B>(1) Drug distribution to mentally ill addicts . . . </B><BR>
This proposal was made even though clinical evidence demonstrates that providing
drugs to such patients is particularly dangerous to their health.<BR>
<B>(2) Drug distribution in prison . . . </B><BR>
This proposal contradicts policy designed to motivate prisoners to accept
long term therapy toward abstinence after physical withdrawal has been completed.<BR>
<B>(3) Heroin distribution to patients in already existing ambulatory methadone
programs and other therapy centers . . . </B>This proposal undermines the
essence of the methadone programs and mixes heroin and methadone recipients
in the same facilities. This is inconsistent with the objective of helping
methadone patients stay away from the drug scene and encouraging them to
participate in abstinence oriented therapy. Once heroin programs are combined
with methadone programs, those receiving methadone face a greater danger
of becoming de-motivated in<BR>
overcoming their drug addiction.<BR>
<BR>
<B>Preliminary Results Justify Abandoning the Experiment:</B><BR>
<BR>
Within the scientific community, it is customary to publish results in scientific
journals and thus make them available for verification and discussion. Non-compliance
with this discipline violates important scientific procedures. Announcing
results for the first time at a press conference is a most unusual procedure
among researchers. But this is precisely what the Federal Office of Public
Health and the experiment's directors did in November 1995, when they presented
the first results at the press conference and deemed them predominantly
positive. The feasibility of the experiment and the accessibility of participants
within target groups were emphasized. Considering drug addicts' desire for
heroin and the very low demands made on them in the experiment, this is
not surprising.<BR>
<BR>
The preliminary report indicates that the General Experimentation Plan's
designated goal of abstinence2 has been replaced by a new goal &quot;...to
test new approaches in the treatment of drug addicts.&quot; This means that
the experiment violates the letter and intent of the original 1992 decree
of the Federal Council of Switzerland.<BR>
<BR>
<B>Analysis of the individual results presented by the Federal Office of
Public Health and the directors of the experiment indicates the following
specific failures of the experiment:<BR>
</B><BR>
1. Improvements in health did not occur within 6 months of the entrance
of a participant in the experiment. Physical symptoms such as insomnia,
loss of appetite, tiredness and loss of energy (a decrease from 47% to 46%!),
nocturnal sweating, dry throat, etc., improved only by a small percentage
during the first 6 months -- not enough to meet minimum objectives anticipated
for improvement of the participants' health. Indeed, the biggest improvement
reported reflects only a better &quot;injection technique&quot;, which astonishingly
has been included in the list of physical symptoms.<BR>
<BR>
Based on the data provided, improvements in physical health are more probably
the result of care given than narcotics prescribed. In addition, no comparison
was made of the results among the various groups receiving different narcotics.
Hence, it is completely inconceivable that researchers could arrive at an
optimistic conclusion based on such incomplete data.<BR>
<BR>
2. The amount of narcotics consumed stabilized after about a month. A significant
reduction in dosage and frequency of consumption was therefore not achieved.<BR>
<BR>
3. Improvements in living and working conditions of the participants, as
well as their social environment, are to be welcomed. However, it is more
likely that these results are due to psycho-social welfare measures rather
than to the supply of heroin. The inclusion of control groups would most
probably have substantiated this conclusion.<BR>
<BR>
4. The research directors gave great importance to the high retention rate
among the participants -- 73% until June 1995, with 82% participating for
at least 6 months. Such continuing participation in the program, with continuous
access to heroin, must be deemed a failure in light of the goal of abstinence
set for the project. <BR>
<BR>
There is little or no information provided about how far the experiment
has been able to attain the goal of abstinence, or the extent to which a
controlled narcotics prescription program can help drug addicts quit the
vicious circle of addiction (NZZ, November 24, 1995).<BR>
<BR>
5. The high retention rate in the experiment in comparison to in-patient
therapy centers was especially emphasized by A. Uchtenhagen, but this comparison
is invalid and implies erroneous conclusions. A high retention rate in heroin
distribution programs is, on the contrary, not an accomplishment if drug
abstinence is the ultimate goal.<BR>
<BR>
6. The reported decrease in illegal activities from 53% to 13% is based
on information provided exclusively by the addicts who participated in the
heroin experiment. Therefore, it cannot be considered as objective proof
of the impact of the heroin project on criminal behavior, as alleged by
A. Seidenberg (NZZ, No. 228). This data has no value.<BR>
<BR>
Conclusions on delinquent behavior can only be based on verified police
records. In the semi-annual report of the Federal Police Bureau of Switzerland,
the central narcotics task force noted that &quot;validated scientific findings
are lacking, and the only limited information available is based on certain
anecdotal observations of the drug scene....&quot; This has occurred primarily
because the police have not been included in the heroin projects. Zurich's
cantonal police force has also expressed its concern that the evaluation
of the experiment will turn out to be biased.<BR>
<BR>
<B>Consequences of Heroin Distribution:</B><BR>
<BR>
The real objective of the Swiss heroin experiment is to introduce a definitive
program to distribute heroin to addicts as soon as possible. The planned
revision of the narcotics law and the introduction of a new pharmaceutical
law will provide the necessary legal framework for achieving this objective.
However, the political, social and therapeutic consequences associated with
a departure from proven and accepted principles of drug therapy have been
ignored to date. <BR>
<BR>
In this connection the following considerations warrant careful attention.
<BR>
* The implications of such a major change in Switzerland's drug policy has
not been appreciated beyond its borders. <BR>
* Nothing similar is being undertaken anywhere else in the world. <BR>
* Even in the United Kingdom, heroin distribution has had universally negative
results, reflected by an increase in the number of drug addicts, an increase
in the death rate, and extensive health problems.<BR>
<BR>
Any program distributing narcotics is full of perils. A. Uchtenhagen, director
of the Swiss evaluation team acknowledged this when he stated, &quot;The
distribution of narcotics to addicts is being undertaken with great caution
and restraint throughout the world. In certain cases temporary and very
structured methadone programs have been provided as a bridge toward abstinence-oriented
treatment.&quot; (A. Uchtenhagen, Zrichsee-Zeitung, March 30, 1995).<BR>
<BR>
Caution in the distribution of narcotics is based on experience. On a societal
level and by the addicts themselves, such measures are perceived as acts
of resignation. Trust in established abstinence-oriented treatments decreases.
The danger involved in changing this mind set of an addict is frequently
not recognized. Often addicts will more willingly fulfill the conditions
needed to receive heroin in a distribution program than decide on a treatment
process which is considered to be arduous. Thus, motivation to enter therapy
is easily destroyed, and with it the hope for a life without drugs. The
negative consequences of drug use have represented the most important reason
for an addict to give up drugs. Easy access to drugs and belittling the
consequences of drug use, instead of abstinence-oriented treatment, are
counterproductive measures that facilitate drug use and encourage distribution
projects.<BR>
<BR>
One of the reasons for launching the Swiss referendum &quot;Youth Without
Drugs&quot; in December 1992, was the initiators' concern that the Swiss
heroin experiment could be misused to promote the liberalization/legalization
of drugs. If the referendum is enacted, heroin projects would be forbidden.
At the same time, appropriate and necessary measures would be implemented
to aid drug addicts.<BR>
<BR>
It is crucial that a broad and knowledgeable discussion be held on the scientific
value of the heroin experiment. For this purpose, the World Health Organization's
(WHO) current evaluation of the experiment is too limited. Scientists and
doctors beyond Switzerland should be invited to join in a critical professional
assessment of this experiment.<BR>
<P><CENTER><HR></CENTER>
<P>1 The translations which appear in this article have been prepared by
the author.<BR>
<BR>
2 The original statement in the General Experimentation Plan, BAG, November
1, 1993: &quot;The experiments involving the medical prescription of narcotics
to drug addicts are defined as scientific experiments aimed at investigating
the success of the therapy delineated here as a step towards drug abstinence.&quot;<BR>
<P><CENTER><HR></CENTER>
<P>Ernst Aeschbach, M.D., specialist for Psychiatry &amp; Psychotherapy
FMH<BR>
Dr. med. Ernst Aeschbach, Spezialarzt FMH for Psychiatrie und Psychotherapie<BR>
Susenbergstr. 53<BR>
CH - 8044 Zurich<BR>
Switzerland<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-180</DOCNO>
<DOCOLDNO>IA077-000522-B044-312</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/HNNPress87.html 207.112.150.94 19970124123922 text/html 8763
HTTP/1.0 200 OK
Date: Fri, 24 Jan 1997 12:38:58 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 8592
Last-modified: Tue, 29 Oct 1996 17:30:32 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>HNN Press Release 8/7/96</TITLE>
</HEAD>
<BODY>
Hassela Nordic Network<BR>
<BR>
Press release August 7, 1996 
<H3><CENTER>MARIJUANA SMOKERS AND THEIR ALLIED SO-CALLED 'SCIENTISTS' USE
ILL<BR>
PEOPLE TO GET THEIR POT - HNN EDITORIAL<BR>
<HR></CENTER>
</H3>
<BR>
The Cannabis Buyers' Club in San Fransisco is the Californian version of
the Dutch coffee shop topped with bogus-scientific auspices. The results
of the recent bust of the Cannabis Buyers' Club in San Fransisco clearly
revealed how junkies and their allied so-called 'scientists' are trying
to promote the idea of &quot;medicinal marijuana&quot; to promote marijuana.
Without any scientific proof whatsoever these harm productive groups claim
the beneficial results from using marijuana. Without referring to any of
the results of thousands of scientific reports on the damaging effects of
marijuana, even newspapers have bought the arguments. In a 'USA Today' recent
debate article, the headline of 'Our View' reads 'Anti-drug focus keeps
marijuana from the ill'. Among some of the 'arguments' in the article we
find &quot;Marijuana is one of the least toxical compunds in the world.
It poses far fewer pulmonary risks than tobacco and is less addictive than
alcohol. It is even less deadly than aspirin which causes at least 1,000
deaths a year.&quot; The arguments are so bad and show such a lack of knowledge,
one might think the author of the piece was advised by Philip Morris, the
tobacco company which recently, in a European advertising campaign, claimed
it was more dangerous to eat biscuits than being exposed to second-hand
smoking.<BR>
<BR>
Is this science? - NO. It is sheer campaigning. The advocates of Medicinal
marijuana&quot; are campaigning for it as if it was just a matter of launching
a new product - like Pepsi - the choice of a new generation&quot; - Marijuana
- the choice of a terminally ill generation&quot;. The tragedy is that the
advocates take advantage of ill people to support their claims for &quot;medicinal
marijuana&quot;, which obviously makes the whole issue somewhat difficult
for some people as being against medication for ill people might seem a
bit odd. In that respect the strategy of the junkies and their allied so-called
'scientists' is superficially clever. Very much in the same way as those
promoting so-called harm reduction have managed to shut up some of their
critics by asking &quot;Are you against harm reduction?&quot; It is most
advisable to reject so-called 'harm reduction' when it includes legalization
of marijuana, legal distribution of opiates, injection rooms, low threshold
methadone programmes etc. In the same way it is most advisable to reject
manjuana as the choice of a terminally ill generation.<BR>
<BR>
The following fact sheet information about the Cannabis Buyers' Club in
San Fransisco ought to make it very clear that what is going on there has
nothing to do with &quot;medicinal use&quot; based on science.<BR>
<BR>
CANNABIS BUYERS' CLUB FACT SHEET<BR>
<BR>
While claiming to be for the benefit of people who are terminally ill, the
Cannabis Buyers' Club was in fact a major drug distribution center for the
city of San Fransisco. The Club regularly sold marijuana to children, allowed
children and even infants to breathe second-hand marijuana smoke in its
'smoking areas', often sold marijuana without a doctors note or accepted
obviously forged doctor s notes for marijuana sales, and large multi-pound
marijuana deals with undercover agents without asking any medical reason
for the usage.<BR>
<BR>
At the Cannabis Buyers' Club in San Fransisco, officials seized<BR>
<BR>
* More than 150 pounds of marijuana valued from $750,000 to over $1 million<BR>
* More than $60,000 in cash<BR>
* More than 400 growing marijuana plants<BR>
* Undercover surveillance films show dozens of infants and small children
(many under the age of 10) inhaling large amounts of marijuana smoke in
the Club. Undercover videos also show the Club selling marijuana to teenagers
and persons who have not provided any medical excuse.<BR>
<BR>
* The Cannabis Buyers' Club claims to serve more than 10,000 members. The
members are purportedly only able to purchase marijuana for Personal use.'
The Club's own rules state remembers cannot buy more than is required for
personal use - &quot;usually not more than 1/4 ounce&quot;. All of the members
are supposed to have a letter from their doctor claiming they suffer from
one or more specific illnesses such as: <BR>
<BR>
HIV<BR>
Cancer<BR>
Multiple sclerosis<BR>
Glaucoma<BR>
Intractable pain<BR>
<BR>
* Undercover agents made a number of buys inside the Cannabis Buyers' Club
and were able to purchase as much as two pounds at a time. In one videotaped
case, the sale was made to an agent who clearly was not sick and who was
never asked by the Club's President for any kind of medical excuse. Undercover
agents alse seized several deliveries of marijuana headed for the Club.<BR>
<BR>
* Drug seizures from street delaers in other areas of San Fransisco have
included a number of baggies with marijuana apparently being re-sold from
the Cannabis Buyers' Club. Some street dealers would even state to their
customers the marijuana must be good since it has the Cannabis Buyers' Club
sticker on the bag.<BR>
<BR>
* Some of the &quot;doctors' notes&quot; used by undercover agents gave
phony doctors' names and addresses which the Cannabis Buyers' Club never
verified. Other notes were even written on scrap paper, without any type
of letterhead. Undercover agents from several law enforcement agencies were
able to purchase marijuana for such&quot;medical uses&quot; as:<BR>
<BR>
vaginal yeast infections <BR>
sore backs <BR>
insomnia <BR>
&quot;low back syndrome&quot; <BR>
colitis<BR>
sciatica<BR>
<BR>
* The Cannabis Buyers' Club is estimated to have sold up to a hundred pounds
of marijuana a week, based on former employee interviews and undercover
surveillance.<BR>
<BR>
* The estimated street value of one pound of marijuana is from $3,900 to
over $10,000 depending upon the grade.<BR>
<BR>
* Health and Safety Code Section 11359 dearly states that &quot;Every person
who possesses for sale any marijuana, except otherwise provided by law,
shall be punished by imprisonment in the state prison.&quot;<BR>
<BR>
It is important to infomm the general public about the pro-legalizers~ attempt
to legalize the sale of marijuana to critically ill people, as that initiative,
called Proposition 215 or the 'Medical Marijuana Initiative' is on California's
november ballot.<BR>
<BR>
Hassela Nordic Network would like to know since when the practice of approving
a substance for Medicinal use&quot; was transferred to a referendum which
could be the consequence if the Medicinal use&quot; of marijuana is approved
in California's November ballot. Before any other drug can be put on the
market, it must undergo rigorous development and testing to prove that it
is effective and safe, a procedure under the responsibility of the Food
and Drug Administration (FDA). Usually laboratories of phammaceutical companies
synthesize new chemicals thought to be effective. The drugs are then screened
using nonhumans to detemmine whether they are toxic and then whether they
have effects similar to known therapeutically useful drugs. When, and if,
the new drug appears to be safe, it goes to phase 1 of human testing, which
should assess the toxicity and side effects of the drug on healthy human
volunteers. Phase 2 involves testing on patients under very carefully supervised
conditions. If these two phases show that the drug has minimal toxic effects
AND a therapeutic effect, it goes to phase 3 with expanded clinical trials.
If phase 3 turns out to be successful the drug is licensed and marketed.<BR>
<BR>
The process does not stop here though. In phase 4 data are accumulated on
the success, or lack of success, of the drug as used in the clinic and attempts
to identify adverse effects not apparent in the short-term testing in earlier
phases. The above procedure has not been applied.to the distribution of
marijuana at the Cannabis Buyers' Club in San Fransisco. The Californian
Club is just another version of the Dutch coffee shop topped with bogus-scientific
auspices. We are pleased to note that action has been taken against this
hamm productive establishment.<BR>
<BR>
[HNN and Hassela Homepage]<BR>
&copy; Copyright HNN and Medstroms Multimedia AB<BR>
<BR>
<HR><BR>
<P><CENTER>For more information contact:<BR>
<A HREF="mailto:DrugWatch6@aol.com">DrugWatch@aol.com</A></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-181</DOCNO>
<DOCOLDNO>IA034-000688-B034-348</DOCOLDNO>
<DOCHDR>
http://drugwatch.org:80/Documents/Med_Marijuana_Paper.html 207.112.150.94 19970209080923 text/html 6102
HTTP/1.0 200 OK
Date: Sun, 09 Feb 1997 08:09:23 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 5931
Last-modified: Tue, 29 Oct 1996 17:30:44 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Medical Marijuana Paper Truth and Lies</TITLE>
</HEAD>
<BODY>
<H4><CENTER>Medical Marijuana</CENTER>
</H4>
<H1><CENTER>TRUTH AND LIES</CENTER>
</H1>
<H3><CENTER><HR></CENTER>
</H3>
<STRONG>Lie: </STRONG>Marijuana is an effective medication for nausea associated
with cancer chemotherapy. <BR>
<BR>
<STRONG>Truth: </STRONG>Oncologists overwhelmingly reject the idea of prescribing
smoked marijuana. Crude marijuana contains over 400 different chemicals
THC, the main active ingredient in crude marijuana, is available as the
prescription drug Marinol, for the treatment of nausea associated with medications
are available and preferred by oncologists. <BR>
<BR>
<HR><STRONG>Lie: </STRONG>Marijuana is a beneficial treatment for glaucoma.
<BR>
<BR>
<STRONG>Truth:</STRONG> There is no scientific evidence that marijuana prevents
the progression of visual loss in glaucoma. While marijuana, as well as
alcohol and a host of other substances, can lower intraocular eye pressure,
the medication must be carefully tailored to the individual to prevent further
eye damage. Besides numerous adverse side effects of smoking marijuana,
the dose cannot be controlled. <BR>
<BR>
<HR><STRONG>Lie: </STRONG>Crude marijuana is effective in treating the wasting
syndrome associated with AIDS. <BR>
<BR>
<STRONG>Truth: </STRONG>Smoking marijuana compromises the immune system
and puts AIDS patients at significant risk for infections and respiratory
problems. Current scientific studies show that Marinol (oral THC), which
is available to treat AIDS wasting syndrome, is effective in increasing
appetite but is ineffective in increasing weight gain. <BR>
<BR>
<HR><STRONG>Lie: </STRONG>The government is withholding important medicine
from suffering patients by not allowing the prescribing of marijuana. <BR>
<BR>
<STRONG>Truth: </STRONG>Crude marijuana does not meet the scientific requirements
for efficacy, quality, purity and safety necessary to be considered medicine.
It is neither compassionate nor medically responsible to prescribe harmful
impure substances to ill people. <BR>
<BR>
<HR><STRONG>Lie:</STRONG> Smoking marijuana reduces the spasticity associated
with multiple sclerosis. <BR>
<BR>
<STRONG>Truth:</STRONG> In a recent double-blind scientific study, the latest
hi- tech electronic monitoring equipment was used to determine if smoked
marijuana had any benefit in treating spasticity in patients with MS. The
study found that all patients receiving marijuana rather than placebo perceived
their spasticity to be lessened, when in actuality, it was made worse. <BR>
<BR>
<HR><STRONG>Lie:</STRONG> Many doctors want crude marijuana available so
they can prescribe it to their patients. <BR>
<BR>
<STRONG>Truth: </STRONG>Most doctors want the best medicine possible for
their patients. Although synthetic marijuana (THC) in a pure and standardized
form is available by prescription, it is often the last choice of doctors,
because many better medicines are available. The American Medical Association,
the Federal Drug Administration, the National Multiple Sclerosis Society,
the American Glaucoma Society, the American Academy of Ophthalmology, and
the American Cancer Society have all rejected the use of smoked marijuana
as a medicine. Marijuana is not recognized as a medicine in generally accepted
pharmacopeia, medical references or textbooks. <BR>
<BR>
<HR>
<H3><CENTER>BY ANY MODERN MEDICAL STANDARD, MARIJUANA IS NO MEDICINE. </CENTER>
</H3>
<H2><CENTER>Drug Watch International Position Statement on Medical Marijuana
Use. </CENTER>
</H2>
Leaf marijuana is not medicine. It is a harmful psychoactive drug, composed
of over 400 different chemicals, which should not be used by anyone, especially
by people who are ill. <BR>
<BR>
BACKGROUND: <BR>
<BR>
In the last several years, the public has seen the issue of the therapeutic
applications of leaf marijuana reach the level of discussions of public
policy. This movement has been fueled by the forces seeking to legalize
marijuana. By having marijuana listed as medicine, they hope to &quot;legitimize&quot;
marijuana use. <BR>
<BR>
RATIONALE:<BR>
<BR>
Smoked marijuana is neither an acceptable medical treatment nor an alternative
medical treatment for any illness. <BR>
<BR>
Marijuana use has serious health consequences. Concentration, motor coordination,
memory, lungs, reproductive and immune systems are all adversely impacted
by marijuana use; marijuana is addictive. <BR>
<BR>
Physicians who treat people for cancer, AIDS, glaucoma and other diseases
do not favor the use of marijuana. <BR>
<BR>
Not one American health organization accepts marijuana as medicine. These
include the American Medical Association, National Multiple Sclerosis Society,
American Glaucoma Society, American Academy of Ophthalmology and American
Cancer Society. <BR>
<BR>
FDA/DEA have repeatedly rejected marijuana for medicinal use Marijuana fails
to meet any of the Drug Enforcement Administration's requirements or Federal
Drug Administration's eight criteria for approving drugs for medical use.
<BR>
<BR>
Even Marinol, a synthetic form of THC (tetrahydrocannabinol), available
by prescription for treating nausea, has far more negative health effects
than other available agents. <BR>
<BR>
There are numerous safer and more effective anti-nausea agents These include
prochlorperazine (Compazine), metaclopramide (Reglan), lorazepam, corticosteroids,
thiethylperazine (Torecan), ondansetron (Zofran), promethazine (Phenergan),
perphenazine (Trilafon), and chlorpromazine (Thorazine). <BR>
<BR>
The pro-drug lobby exploits the suffering of patients with chronic illness
with false promises about marijuana as a medicine. They have stated that
they are pushing marijuana as medicine and using it as a &quot;red herring&quot;
as part of a strategy to legalize marijuana for general use. <BR>
<BR>
&copy; 1995 Drug Watch International<BR>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-182</DOCNO>
<DOCOLDNO>IA039-000740-B041-161</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/index.htm 198.78.22.165 19970210073527 text/html 936
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Friday, 3-Feb-95 15:42:40 GMT
Last-modified: Tuesday, 5-Mar-96 22:7:21 GMT
Content-length: 682
</DOCHDR>
<HTML>
<TITLE>Resources for VE Teachers</TITLE></head>
<body>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees3.HTM">Next section</A>]  [<A HREF="tofc.htm">Table of Contents</A>]   [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<H3>Search for Words in the  Varying Exceptionalities Manual</H3><p>
<HR>
<H5>You can use AND, OR, and NOT between words to find information in the VE Manual.</H5>
<H5>Please enter the term(s) to search for.</H5>
<isindex>
</body>
</HTML>







</DOC>
<DOC>
<DOCNO>WT01-B04-183</DOCNO>
<DOCOLDNO>IA039-000740-B041-132</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees3.HTM 198.78.22.165 19970210073512 text/html 5473
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:39:56 GMT
Last-modified: Tuesday, 5-Mar-96 22:1:50 GMT
Content-length: 5217
</DOCHDR>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 --><TITLE>Resources for VE Teachers</TITLE></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees4.HTM">Next section</A>]    [<A HREF="tofc.htm">Table of Contents</A>]    [<A HREF="cover.HTM">Resources for VE Teachers</A>]<P>
<HR>
<h1>Preface</h1><P>
<HR>

This manual has been created in response to the needs expressed by many
varying exceptionalities(VE) teachers in Florida.  Over the past 20 years, the
use of the varying exceptionalities delivery model has increased.  Various task
forces have been formed to examine the issues and concerns and to recommend
practices and policies to ensure appropriate uses of the model. <P>

In 1991, representatives from the Florida Teaching Profession/National
Education Association (FTP/NEA) urged the Department of Education to review the
current policies and practices.  Surveys and interviews were used to gather
input from VE teachers from 17 school districts over two years.<P>  

This manual<i>, Resources for VE Teachers, </i>was developed at the
recommendations of the advisory group formed in response to the FTP/NEA
inquiry.  It is intended to provide information about the use of the VE model
in Florida and to share classroom practices that teachers have found to be
successful.  In Fall, 1992, VE teachers were asked to submit ideas for
inclusion in this manual.  The members of the writing team that met in Spring,
1993. provided valuable input and insight into the contents of this manual and
their special contributions are gratefully acknowledged.  Debbie Houston,
Program Specialist in the Bureau for Education of Exceptional Students, and her
secretary, Myra Orange, also deserve recognition for their facilitation of this
entire effort.<P>

<H4>Writing Team</H4>


<pre>Phil Carlson		ESE Teacher			Palm Beach County
<>Daris Dew		Principal			Sumter County
Kay Dorsey		ESE Teacher			Citrus County
Madaline McFatter	ESE Teacher			Holmes County
Jan Weiss		ESE Teacher			Hillsborough County
Vicki Emo		ESE Teacher			Leon County
Ted Grosse		ESE Supervisor			Polk County
Bill Elkin		ESE Supervisor			Lee County
Marsha Kufel 		Director, FDLRS/Alpha		Palm Beach County
Debbie Stump		ESE Teacher			Okaloosa County
Greg Charles		ESE Teacher			Pinellas County</pre>
<P>
<H4>Thanks, VE Teachers</H4>

This is a list of the teachers and administrators who submitted many
additional ideas that have been incorporated in this manual.  We greatly
appreciate your time and effort.<P>
<b>PreKindergarten</b>
<PRE>Pat Gillette		Lopez Elementary		Hillsborough
Heidi Martin		School not identified		Hillsborough
</PRE>
<P><B>Elementary</B>
<PRE>Lynn Barbieri		Inverness Primary 		Citrus
Sheree Preston	Homosassa Elementary		Citrus
Gwen Dunaway		Pleasant Grove Elementary	Citrus
Marianna Reeves	Crystal River Primary		Citrus
Pat Bush		Poplar Springs Elementary	Holmes
Janet Reynolds	Littleton Academy		Lee
M. Wolf		Ocala Springs Elementary	Marion
Kerry Jones		Shady Hill Elementary		Marion
Catherine Altman	Shady Hill Elementary		Marion
Jodie Watts		South Ocala Elementary		Marion
Terri Partlow		Orange Center Elementary       	Orange
Trina Cassidy		Mollie Ray Elementary 		Orange
Liz Flickinger	Waterbridge Elementary		Orange
Phil Carlson		Grove Park Elementary		Palm Beach
David Frasier		Polk City Elementary		Polk
Barbara Christian	Bethune Elementary		Polk
Lora Lindsey		Garner Elementary		Polk
Kelly Maratea		Snively Elementary		Polk
Sherri Evans		Lake Panasoffkee Elementary	Sumter
Peggy Boyatt 		Bushnell Elementary		Sumter
</PRE>
<b>Middle School</b>
<PRE>
Pam Pate		Crystal River Middle 		Citrus
Vicki Emo		Raa Middle 			Leon
Ann Campbell		Raa Middle 			Leon
Tommi Stetson		Osceola Middle 			Marion
Maureen Fentross	S. Sumter Middle 		Sumter</PRE>
<b>High School</b>
<PRE>
Ellen Smith		Buckingham Except. Stud. Center Lee
Donald L. Payne	Buckingham Except. Stud. Center Lee
Doris Wayte		Dunellon High			Marion
Nancy R. English	Dunellon High			Marion
Ken Campbell		NMHS				Marion
E. Laverne Williams 	Dr. Phillips 9th Grade Center	Orange
Sheila Hoffman	Countryside High 		Pinellas
Nanette Standfast	Osceola Senior High 		Pinellas
Cindy Maschino	Osceola Senior High 		Pinellas
Michael Novarra	Dunedin High 			Pinellas
Charlotte Fox		Tarpon Springs Senior		Pinellas
P. Ross		Seminole Voc. Educ. Center 	Pinellas</PRE>

<b>District</b>
<PRE>
Fay Clark		ESE				Broward
Karl Amundson		ESE				Citrus
Paige French		ESE				Duval
Elsie Parker		Guidance			Escambia
Connie Tzvorras	ESE				Highlands
Roger Landers		ESE				Hernando
Sandi Serventi	ESE				Leon
Janet Morgan		ESE				Manatee
Jean Morris		ESE				Putnam
Carol Robbins		ESE				St. Johns
</PRE>
<HR>
<P>[<A HREF="bees4.HTM">Next section</A>]    [<A HREF="tofc.htm">Table of Contents</A>]    [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>





















</DOC>
<DOC>
<DOCNO>WT01-B04-184</DOCNO>
<DOCOLDNO>IA039-000740-B040-434</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/tofc.htm 198.78.22.165 19970210073135 text/html 1750
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:21 GMT
Last-modified: Tuesday, 5-Mar-96 22:22:51 GMT
Content-length: 1493
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head>
<!-- This document was created from RTF source by rtftohtml version 2.7.4 -->
<BODY BACKGROUND="beige.gif">
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<TITLE>Resources for VE Teachers</TITLE></head>
<body>

<A NAME = "Home"></A>
<H1>Table of Contents</H1><p>
<DL><A HREF = "bees3.htm"><H3>Preface</H3></A><p>
<A HREF = "BEES4.HTM"><H3>Introduction</H3></A><p>
<A HREF = "BEES5.HTM">
<H3>General Information</H3></A><p>
<A HREF = "BEES6.HTM">
<H3>Uses of the Varying Exceptionalities Model<p></H3></A>
<A HREF = "BEES7a.HTM"><H3>Effective Practices for Varying Exceptionalities Classes</H3></A>
<A HREF = "BEES8.HTM">
<H3>Staffing Considerations for Placement in Varying Exceptionalities Classes</H3></A>
<A HREF = "BEES9.HTM">
<H3>Support for Teachers</H3></A>
<A HREF = "REFEREN.HTM"><H3>References</H3></A></DL><P>
[<A HREF="dtofc.htm">Click here for the Detailed Table of Contents</A>]  <P>
[<A HREF="bees3.HTM">Next section</A>]  [<A HREF="#Home">Table of Contents</A>]   [<A HREF="cover.HTM">Resources for VE Teachers</A>]<P>
[<A HREF="index.htm">Click here to Search for words in the Varying Exceptionalities Resource Manual</A>]  
</body></html>






































</DOC>
<DOC>
<DOCNO>WT01-B04-185</DOCNO>
<DOCOLDNO>IA039-000740-B041-144</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/cover.HTM 198.78.22.165 19970210073519 text/html 2298
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:11 GMT
Last-modified: Tuesday, 5-Mar-96 22:1:13 GMT
Content-length: 2042
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><BODY BACKGROUND="ccla/paper3.gif">
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<!-- This document was created from RTF source by rtftohtml version 2.7.2 --></head>
<A NAME = "Home"></A>
<A HREF = "TOFC.HTM">
<TITLE>Resources for VE Teachers</TITLE>
<H2><Center>
A Resource Manual
For The Development And
Evaluation of Special Programs
For Exceptional Students<P>
</H2>
<H2>Volume 11-L: Varying Exceptionalities</H2></A>
<hr>
<H3>
Florida Department of Education<P>
Division of Public Schools<P>
Bureau of Education for Exceptional Students<P>
</H3>
<hr>
<H4>1994</H4></Center><p>
This manual was developed by <A HREF ="mailto:beechm@cet.fsu.edu">Dr. Martha C. Beech </A> through an Administrative
Services Grant to Florida Atlantic University, funded by the State of Florida
Department of Education, Division of Public Schools, Bureau of Education for
Exceptional Students, through federal assistance under the Individuals with
Disabilities Education Act (IDEA), Part B.<p>
HTML (Hypertext Markup Language) encoding and Web page design by The College Center for Library Automation<A HREF = "ccla.htm"> CCLA</A> through an SGML (Standard Generalized  Markup Language) Research Grant from the Schoolyear 2000 Initiative.
<P>
<I>Copyright</I><P>
State of Florida<P>
Department of State<P>
&copy 1994<P>
Authorization for reproduction is hereby granted to the state system of public
education as defined in Section 228.041 (1), Florida Statutes.  No
authorization is granted for distribution or reproduction outside the state
system of public education without prior approval in writing,<p>
[<A HREF="#Home">Resources for VE Teachers</A>]  <p>
<HR><P>
 [<A HREF="tofc.htm">Table of Contents</A>]  <P>
</body></html>


























</DOC>
<DOC>
<DOCNO>WT01-B04-186</DOCNO>
<DOCOLDNO>IA039-000740-B041-179</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees4.HTM 198.78.22.165 19970210073537 text/html 3279
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:39:57 GMT
Last-modified: Tuesday, 5-Mar-96 22:2:15 GMT
Content-length: 3023
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 -->
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<TITLE>Resources for VE Teachers</TITLE></head><body>

<A Name ="Introduction"></A>

<P>[<A HREF="bees3.HTM">Previous section</A>]   [<A HREF="bees5.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>

<h1><a name="RTFToC1">Introduction</a></h1>


<i><A HREF = "cover.HTM">Resources for VE Teachers</i></A> is designed to provide information about the
use of the varying exceptionalities model and to share ideas and practices that
teachers can use with their students.  <p>
<p>
The first section, <i><A HREF = "bees5.HTM">General Information,</A></i> includes the definition and
State Board of Education rules which apply to the model, as well as brief
descriptions on the history and rationale.<p>
<p>
The second section, <i><A HREF = "bees6.HTM">Uses of the Varying Exceptionalities Model,</A></i> provides
examples of guidelines and policies which have been developed in various
school districts for programs at the prekindergarten, elementary, middle, and
high school level.  Recommendations from previous task forces are summarized in
the description of "Best Practices."<p>
<p>
The third section, <i><A HREF = "bees7a.HTM">Effective Practices in Varying Exceptionalities Classes,
</i></A> is intended to share the practices that many teachers have found to be
effective in meeting the diversity of student needs.  This includes a brief
description of the characteristics of exceptional students,  and suggestions
for scheduling, grouping, and managing the educational environment.  In
response to the many concerns raised by VE teachers, information is also
included on managing behavior and using assistants in the classroom.<p>
<p>
The fourth section, <i><A HREF = "bees8.HTM">Staffing Considerations for Placement in Varying
Exceptionalities Classes,</i></A> is designed to guide the staffing process.  Key
questions and sources of information can be used by teachers to make sure that
all important factors are considered.<p>
<p>
The fifth section, <i><A HREF = "bees9.HTM">Support for Teachers,</i></A> is intended to help teachers
access support at both the state and district level.  The information for the
district level should be added to the appropriate spaces.<P>

[<A HREF="#Introduction">Introduction</A>]<p>

<HR>

<P>[<A HREF="bees3.HTM">Previous section</A>]   [<A HREF="bees5.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]

</body></html>











</DOC>
<DOC>
<DOCNO>WT01-B04-187</DOCNO>
<DOCOLDNO>IA039-000740-B041-113</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/dtofc.htm 198.78.22.165 19970210073503 text/html 5148
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:21 GMT
Last-modified: Tuesday, 5-Mar-96 22:8:12 GMT
Content-length: 4892
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 --><TITLE>Resources for VE Teachers</TITLE></head>
<BODY BACKGROUND="beige.gif">
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<A NAME="Table of Contents"></A>

<P>[<A HREF="bees3.HTM">Next section</A>]     [<A HREF="tofc.htm">Table of Contents</A>]   [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<H1>Detailed Table of Contents</H1><p>
<p>
<p>
<A HREF = "bees3.htm"><H3>Preface</H3></A><p>
<p>
<A HREF = "BEES4.HTM"><H3>Introduction</H3></A><p>
<p>
<A HREF = "BEES5.HTM">
<DL Compact><H3><DT>General Information</H3></A><p></DL><DL>

<DD><A HREF = "BEES5.HTM#Definition">Definition</A>
<DD><A HREF = "BEES5.HTM#History">History of the Varying Exceptionalities Model</A>
<DD><A HREF = "BEES5.HTM#Why Use">Why Use the Varying Exceptionalities Model?</A>
<DD><A HREF = "BEES5.HTM#State Board of Education Rule">State Board of Education Rule</A>
<DD><A HREF = "BEES5.HTM#Certification Requirements">Certification Requirements for Teachers</DL></A>

<A HREF = "BEES6.HTM">
<DL Compact><H3><DT>Uses of the Varying Exceptionalities Model<p></H3></A></DL>
<DL>
<DD><A HREF = "BEES6.HTM#Best Practices">Best Practices in Providing Educational Services in a VE Delivery Model
<DD><A HREF = "BEES6.HTM#Sample District Guidelines">Sample District Guidelines for Varying Exceptionalities<DL>
<DD><A HREF = "BEES6.HTM#Prekindergarten Programs"><B>Prekindergarten Programs</B>
<DD><B><A HREF = "BEES6.HTM#Elementary School">Elementary School</B><DL>
<DD><A HREF = "BEES6.HTM#Elementary School">Resource Programs
<DD><A HREF = "BEES6.HTM#ESelf-Contained Programs">Self-Contained Programs</DL>
<DD><A HREF = "BEES6.HTM#Middle School"><B>Middle School</B></DL><DL>
<DL><DD><A HREF = "BEES6.HTM#MResource Programs">Resource Programs
<DD><A HREF = "BEES6.HTM#MSelf-Contained Programs">Self-Contained Programs</DL>
<DD><A HREF = "BEES6.HTM#High School"><B>High School</B></DL><DL>
<DL><DD><A HREF = "BEES6.HTM#High School Resource Programs">Resource Programs
<DD><A HREF = "BEES6.HTM#Self-Contained Programs">Self-Contained Programs for Special Diplomas
<DD><A HREF = "BEES6.HTM#Vocational Education">Vocational Education Programs</DL></DL></DL></DL></DL>

<A HREF = "BEES7a.HTM"><H3>Effective Practices for Varying Exceptionalities Classes</H3></A>
<DL Compact>
<DD><A HREF = "BEES7a.HTM#Organizing and Managing">Organizing and Managing Diversity in Instruction<DL>
<DD><A HREF = "BEES7a.HTM#Characteristics of Exceptional">Characteristics of Exceptional Students
<A HREF = "BEES7b.HTM"><DD>Scheduling</A>
<DL>
<DD><A HREF = "BEES7b.HTM#General Suggestions">General Suggestions
<DD><A HREF = "BEES7b.HTM#Elementary Programs">Elementary Programs
<DD><A HREF = "BEES7b.HTM#Secondary Programs">Secondary Programs</DL></DL><DL>
<DD><A HREF = "BEES7b.HTM#Grouping for Instruction">Grouping for Instruction
<DL>
<DD><A HREF = "BEES7b.HTM#Independent Learning">Independent Learning
<DD><A HREF = "BEES7b.HTM#One-on-One Instruction">One-on-One Instruction
<DD><A HREF = "BEES7b.HTM#Large and Small Groups">Large and Small Groups
<DD><A HREF = "BEES7b.HTM#Students in the Mainstream">Students in the Mainstream</DL></DL>
<DL>
<DD><A HREF = "BEES7b.HTM#Managing the Classroom">Managing the Classroom Environment
<DL>
<DD><A HREF = "BEES7c.HTM#Managing Behavior">Managing Behavior
<DD><A HREF = "BEES7d.HTM#Using Aides">Using Aides, Volunteers, and Peer Support
<DD><A HREF = "BEES7d.HTM#Teacher Aides">Teacher Aides
<DD><A HREF = "BEES7d.HTM#Volunteers">Volunteers
<DD><A HREF = "BEES7d.HTM#Peer Support">Peer Support</DL></DL>

<A HREF = "BEES8.HTM">
<H3>Staffing Considerations for Placement in Varying Exceptionalities Classes</H3></A>
<DL>
<DD><A HREF = "BEES8.HTM#Individual Educational Plans">Individual Educational Plans:  Identifying Individual Student Needs
<DD><A HREF = "BEES8.HTM#Supporting the Placement">Supporting the Placement of Students
<DD><A HREF = "BEES8.HTM#Ongoing Review">Ongoing Review and Monitoring of Placement
<DD><A HREF = "BEES8.HTM#Dealing with Parental">Dealing with Parental Concerns</DL>

<A HREF = "BEES9.HTM">
<H3>Support for Teachers</H3></A>
<DL Compact>
<DD>District List of Contact Persons and Consultation and Training Resources</DL></DL>
<A HREF = "REFEREN.HTM"><H3>References</H3></A>
<HR>
[<A HREF="#Table of Contents">Detailed Table of Contents</A>]  <P>

<P>[<A HREF="bees3.HTM">Next section</A>]     [<A HREF="tofc.htm">Table of Contents</A>]       [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>



























</DOC>
<DOC>
<DOCNO>WT01-B04-188</DOCNO>
<DOCOLDNO>IA039-000740-B041-197</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees5.HTM 198.78.22.165 19970210073545 text/html 13867
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:39:58 GMT
Last-modified: Tuesday, 5-Mar-96 22:2:49 GMT
Content-length: 13610
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version 2.7.2 --></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<TITLE>Resources for VE Teachers</TITLE>
<A NAME = "General Information"></A>
<P>[<A HREF="bees4.HTM">Previous section</A>]   [<A HREF="bees6.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>


<H1>General Information</H1>
<br>
<DL>
<LI><A HREF = "#Definition">Definition</A>
<LI><A HREF = "#History">History of the Varying Exceptionalities Model</A>
<LI><A HREF = "#Why Use">Why Use the Varying Exceptionalities Model?</A>
<LI><A HREF = "#State Board of Education Rule">State Board of Education Rule</A>
<LI><A HREF = "#Certification Requirements">Certification Requirements for Teachers</DL></A>
</DL><P>

The use of the varying exceptionalities class as a delivery model for
exceptional student education has a long history in the State of Florida.
Currently, teachers of this class comprise the largest group of teachers in
exceptional student education classes in this state.  The model provides
flexibility that enables districts to ignore categorical lines when serving
exceptional students who have similar needs.<p></DL>

<pre>



















</pre>
<A NAME = "Definition"><h2>Definition</h2></A><P>
<DL Compact><i><B><DT>Varying Exceptionalities (VE) Classes:</B></i><P>
The setting that provides for the assignment of students of<P>
<UL>
<DD><LI>more than one exceptionality to one teacher per instructional class period,<P> or<P>
<DD><LI>more than one exceptionality to one teacher during the school week.</DL>
</UL>
<p>

<i><B>Categories of Exceptionalities:  </B></i><P>
For purposes of defining a varying exceptionalities class, the following categories of exceptionalities may be
combined:<p>
<DL>
<LI>Specific Learning Disabilities
<LI>Mentally Handicapped (Educable Mentally Handicapped; Trainable Mentally 
	Handicapped; and Profoundly Mentally Handicapped)
<LI>Emotionally Handicapped (Emotionally Handicapped and Severely Emotionally 
	Disturbed)
<LI>Physically Impaired
<LI>Speech and Language Impaired
<LI>Visually Impaired
<LI>Hearing Impaired
<LI>Gifted
<LI>Profound  (including Autistic; Deaf-Blind; Profoundly Mentally Handicapped;
and Severely Emotionally Disturbed)<P>
</DL>
Please note that each school district determines which exceptionalities may be
served in a varying exceptionalities class.  The list above indicates that
certain categories of exceptional students may be grouped in classes that are
not considered to be varying exceptionalities classes.  For example, if
emotionally handicapped and severely emotionally disturbed students are in the
same class, this class is not designated as varying exceptionalities.<P>

[<A HREF="#General Information">General Information</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<A NAME = "History"><h2>History of the Varying Exceptionalities Model</h2></A>
<P>
<DL><DT><H6><B>1947</B></H6><DD>Rule established.  "Where it is not practical nor feasible because of too
few pupils to assign special teachers for each type of exceptional child, combination units will be approved."  (Concept deleted a short time later.)</DL><p>
<p>
<DL><DT><H6><B>1962</B></H6><DD>Rule revised.  "Varying exceptionalities -- For the employment of a teacher to serve children with varying exceptionalities as defined in these regulations in rural and sparsely populated areas, one unit may be allowed." (Rule repealed in 1974 with the adoption of the Florida Education Finance Program.)</DL><p>
<p>
<DL><DT><H6><B>1970s</B></H6><DD>Use of VE model increases somewhat as a result of school-based
management, implementation of PL 94-142 and the concept of least restrictive
environment, and the high cost of transportation.</DL><p>
<p>
<DL><DT><H6><B>1980-81</B></H6><DD> <i>Task Force on Varying Exceptionalities.  </i>Responding to a
request of the internal auditors, the task force met and made recommendations
regarding definition, class composition, and teacher competencies to be
incorporated into State Board of Education Rules.</DL><p>
<p>
<DL><DT><H6><B>1980s</B></H6><DD> VE use doubles with increased populations and changes in secondary
requirements.  </DL><p>
<p>
<DL><DT><H6><B>1985-86</B></H6><DD>  <i>Subcommittee on Varying Exceptionalities (State Advisory
Committee).  </i>Site visits were made to 12 districts, and VE teachers were
surveyed to identify issues related to the use of the VE model.
Recommendations were made regarding the composition and organization of the
class, placement decisions, class size, support services, and teacher
competencies.</DL><p>
<p>
<DL><DT><H6><B>1986-87</B></H6><DD>  <i>Task Force on the Education of Exceptional Students (Varying
Exceptionalities).  </i>As a result of issues raised by teacher organizations
and the Florida Association for Children with Learning Disabilities (FACLD), a
legislative task force was convened.  Recommendations were made regarding
certification requirements; VE class size, composition, and staffing patterns;
parent involvement; and general policies.  In addition, nine best practices
were identified to assist districts.</DL><p>
<p>
<DL><DT><H6><B>1990s</B></H6><DD>VE use increases.  Prekindergarten programs increase and show preference
for a VE model.</DL><p>
<p>
<DL><DT><H6><B>1991-93</B></H6><DD>  <i>Varying Exceptionalities Advisory Committee.  </i>At the urging of
the Florida Teaching Profession/National Education Association (FTP/NEA), the
Bureau of Education for Exceptional Students funded a study to look at the use
of the VE model in 17 districts and established an advisory committee.  The
results of the study were widely disseminated and a resource manual for VE
teachers was developed.</DL><P>

[<A HREF="#General Information">General Information</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<A NAME = "Why Use"><h2>Why Use the Varying Exceptionalities Model?</h2></A>

<i><B>Enables ESE students to be served in their home schools.</B></i><p>
Serving ESE students in the least restrictive environment requires that
consideration be given to providing the services in the school that the child
would normally attend.  <p>
<p>
<i><B>Allows ESE students to be grouped by program or curricular needs.</B></i><p>
A VE model facilitates the grouping of students according to their
program or curriculum needs.   For example, in some districts, a VE model is
used to provide programs for students on Special Pupil Progression Plans.   In
other districts, a VE model is used for the students in resource classes who
are served in ESE on a part-time basis.  <p>
<p>
When a school has more than one ESE teacher, the use of a VE model allows the
children to be grouped by age as well as curriculum needs.  Thus, an elementary
school may be able to staff both primary and intermediate units.  A VE model
may also be used where the majority of students are the same exceptionality and
only a few children have a different classification.  Many school districts
determine the number of teaching units allocated to a school based on the
number of ESE students and the FTE generated by them, and allow the teachers at
the school to determine how the students will be grouped in classes.  <p>
<p>
<i><B>Provides flexibility in providing services for small populations of ESE students.</B></i><p>
In addition to the options described above, a VE model provides for ESE
students in low prevalence categories.  Students with physical impairments or
mild sensory impairments often can be appropriately served in a VE model.<p>
<p>
<i><B>Focuses the educational program on the individual needs of the students,
rather than on the label of the child.</B></i><p>
The flexibility associated with the use of a VE model can be seen as an asset
when providing appropriate programs for exceptional students.  When parents
want  their child to be served in the neighborhood school, a VE model can be
used to accommodate that preference.  ESE teachers in secondary schools can use
the model to departmentalize and group students by functional levels.  <p>
<p>
While a VE model sometimes carries a reputation as being a "dumping ground," in
fact, it can remove artificial barriers.  <i>What is important, however, is
that the program provided in a VE model have an identity, i.e., a clear sense
of purpose.</i>   Whether a VE model is seen as the program for special diploma
students at the high school, the prekindergarten program for high functioning
students, or the program at the elementary school that enables all of the
exceptional students to attend their neighborhood school,  the teachers in VE
classes need to understand and support the purposes of their programs.<p>

[<A HREF="#General Information">General Information</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<A NAME = "State Board of Education Rule"><h2>State Board of Education Rule</h2></A>
<P>
In 1983, Rule 6A-6.0311, Florida Adminstrative Code, (FAC), Special Programs
and Procedures for Exceptional Students, was amended to include requirements
for varying exceptionalities classes.<p>

<DL><DT><H6><B>(3)  Varying Exceptionalties.</B></H6><DD>If a school district elects to use a varying
exceptionalities class, it shall be used only to a limited extent in order to
provide special programs for exceptional students.<p>
<p>
<DL><DT><H6><B>(a)</B></H6><DD>  A varying exceptionalities class is the setting which may provide for
assignment of students of more than one (1) exceptionality to one (1) teacher
per instructional class period, or more than one (1) exceptionality to one (1)
teacher during the school week.<p>
<p>
<DT><H6><B>(b)</B></H6><DD> If a school district establishes varying exceptionalities classes,
procedures for the program shall be set forth in district procedures as
required by Rule 6A-6.0311, FAC.<p>
<p>
<DT><H6><B>(c)</B></H6><DD>  Eligible exceptional students served in varying exceptionalities classes
shall be reported for full-time equivalent membership in accordance with Rule
6A-6.1.451(7)(8), FAC.<p>
<p>
<DT><H6><B>(d)</B></H6><DD> Parents shall be notified, as provided in Rule 6A-6.0311, FAC, when the
student is assigned to a varying exceptionalities class with other
exceptionalities.</DL></DL><p>

[<A HREF="#General Information">General Information</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<p>
<A NAME = "Certification Requirements"><h2>Certification Requirements for Teachers</h2></A>
<P>
The required certification for teachers in VE classes is identified annually in
the Course Code Directory.  Teachers in VE classes must have one of the
following certification areas:<p>
<DL>
<LI>Varying Exceptionalities
<LI>Specific Learning Disabilities
<LI>Mentally Handicapped
<LI>Emotionally Handicapped.</DL>
<p>
The requirements for the Varying Exceptionalities certification have recently
been revised and became effective July 1, 1992. <P>
They are as follows:<p>
<p>
<I>A bachelor's or higher degree with a major in exceptional student education
which includes courses in the instructional strategies for emotionally
handicapped, mentally handicapped, and specific learning disabilities.</I><p>
<p>
or<p>
<p>
<I>A bachelor's or higher degree with thirty six (36) semester hours in
exceptional student education including the following areas:</I><p>

<DL>
<LI>Foundations of exceptional student education
<LI>Language development and disorders
<LI>Assessment of exceptional students
<LI>Educational management
<LI>Teaching social and personal skills
<LI>Methods and materials for teaching reading
<LI>Teaching skills and concepts of mathematics
<LI>Methods and content for teaching language arts
</DL>
<p>
Characteristics of  mildly handicapped students (EH, EMH, SLD)<p>
<DL>
<LI>Instructional strategies for teaching students who are mentally handicapped
<LI>Instructional strategies for teaching students who are emotionally handicapped
<LI>Instructional strategies for teaching students with specific learning disabilities
</DL>
<p>
In addition, teachers already certified in the areas of mentally handicapped,
specific learning disabilities, emotionally handicapped, or physically
impaired, may qualify for VE certification by adding the appropriate additional
requirements in terms of the characteristics and instructional strategies
courses specified in the last section. <p>

[<A HREF="#General Information">General Information</A>]<p>
<HR><P>
<P>  [<A HREF="bees4.HTM">Previous section</A>]  [<A HREF="bees6.HTM">Next section</A>]             [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]

</body></html>


















</DOC>
<DOC>
<DOCNO>WT01-B04-189</DOCNO>
<DOCOLDNO>IA039-000740-B041-237</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees6.HTM 198.78.22.165 19970210073638 text/html 26483
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:0 GMT
Last-modified: Tuesday, 5-Mar-96 22:3:15 GMT
Content-length: 26227
</DOCHDR>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 --></head><body>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<a name = "Uses of the Varying"><TITLE>Resources for VE Teachers</TITLE></a><br>
<P>[<A HREF="bees5.HTM">Previous section</A>]   [<A HREF="bees7a.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>

<h1>Uses of the Varying Exceptionalities Mode</h1>
<p>
<DL>
<LI><A HREF = "#Best Practices">Best Practices in Providing Educational Services in a VE Delivery Model</A>
<LI><A HREF = "#Sample District Guidelines">Sample District Guidelines for Varying Exceptionalities</A>
<LI><A HREF = "#Prekindergarten Programs">Prekindergarten Programs</A>
<LI><A HREF = "#Elementary School">Elementary School Resource Programs</A>
<LI><A HREF = "#ESelf-Contained Programs">Self-Contained Programs</A>
<LI><A HREF = "#Middle School">Middle School</A>
<LI><A HREF = "#MResource Programs">Resource Programs</A>
<LI><A HREF = "#MSelf-Contained Programs">Self-Contained Programs</A>
<LI><A HREF = "#High School">High School</A>
<LI><A HREF = "#High School Resource Programs">Resource Programs</A>
<LI><A HREF = "#Self-Contained Programs">Self-Contained Programs for Special Diplomas</A>
<LI><A HREF = "#Vocational Education">Vocational Education Programs</A>
</DL><P>
<HR>
<pre>


























</pre>
<h3>
<a name="Best Practices">Best Practices in Providing Educational Services in a VE Delivery Model</a></h3>
<P>
Several state level task forces and advisory groups have studied the issues and
practices in regard to the VE model.  In 1986-87,  the Task Force on Education
of Exceptional Students (Varying Exceptionalities) developed a list of best
practices to assist districts.  Recent surveys of VE teachers have indicated
that the majority of teachers feel that these best practices are being
implemented in school districts.  <p>
<p>
<i>1.	</i> <i>A VE model should be used for specific educational
programs.</i><p>
	The Task Force recommended that a VE model may be best utilized at the
prekindergarten or high school level.  Districts have found a VE model
effective for programs such as community-based instruction, vocational
programs, and special diploma programs.<p>
<p>
<i>2.	 A VE model is best utilized for classes and programs where students have
more common curricular needs.</i><p>
<i>	</i>The class size, composition, and educational demands must be taken into
account when using a VE model at any level.  Consideration of the behavior and
academic functioning of students will be critical to the successful use of a VE
model.<p>
<p>
<i>3.</i>	<i>Prior to a student's placement in the VE delivery model, the
potential receiving teacher(s) should have the opportunity to observe the child
in his or her current educational setting or to become familiar with the
child's educational needs.   </i><p>
<i>	</i>This may include access to the student's records, phone conferences, or
other methods of communication when direct observation is not possible.  When
the receiving teacher is well-informed about the needs of the new student,
support services and other accommodations can be provided.<p>
<p>
<i>4.	After a student is placed in a VE class, the appropriateness of the
placement is reviewed within a reasonable amount of time or whenever
requested.</i><p>
<i>	</i>Monitoring the effectiveness of a student's placement should be an
ongoing process.  The review may evaluate the appropriateness of the placement,
given the child's educational needs.  Whenever requested, the staffing team may
reconsider a placement decision and recommend a more appropriate educational
program.<p>
<p>
<i>5.	To the extent possible, full-time and part-time students should be served
in separate classes.</i><p>
<i>	</i>Consideration must be made regarding the educational impact of
combining self-contained students with part-time resource students, who enter
and exit the classroom at differing times during the course of the school
day.<p>
<p>
<i>6.	Instructional aides are provided as needed.  These may include volunteer
assistants as well as paid paraprofessionals.</i><p>
<i>	</i>Teachers need to understand the district policies and procedures for
providing teacher aides.  In addition, participation in the school volunteer
program can be a ready source of help.<p>
<p>
<i>7.	Adequate supplies are provided within existing guidelines to maintain the
quality of the program.</i><p>
<i>	</i>In districts where money for supplies is managed at the school level,
the ESE teachers should become a part of the decision making team.  <p>
<p>
<i>8.	Adequate support services are provided within district guidelines to
maintain the quality of the program.  </i><p>
<i>	</i>Support services should include administrative assistance and related
service personnel, including school psychologists and social workers.<p>
<p>
<i>9.	Parents are well informed about the circumstances in the VE class.</i><p>
<i>	</i>There should be a close working relationship between the parents of an
ESE student in a VE class and the VE teacher.  The parents should be aware of
the characteristics of the class (e.g., class size, functional levels of the
students, etc.) and the availability of support and appropriate services for
their child.  <p>

<i>10.	School or district administrative staff monitor the effectiveness of the
program for students on an individual basis.</i><p>
<i>	</i>The effectiveness of a VE delivery model should be evaluated by looking
at key indicators such as the accomplishments of the students, discipline,
participation in the mainstream, etc. <p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h2>
<a name="Sample District Guidelines">Sample District Guidelines for Varying Exceptionalities</a></h2> 

<p>
Local school districts determine how a VE model is to be used to deliver
exceptional student education programs.  In small districts, due to the small
number of students, a VE model may be used to provide a wide range of services.
In middle and large-sized districts in Florida, a VE model may be used either
broadly or only for specific programs or populations.  District policy and
philosophy determine the particular application.  <p>
<p>
In VE classes that are seen as successful, students are grouped according to
similar academic and behavior functioning and needs.  Effective teachers in a
VE model will need to have a strong curriculum background and will also need to
be well-organized, open-minded, flexible, and creative. They must be able to
present knowledge and skills from many different perspectives.  <p>
<p>
The descriptions in this section are provided as illustrations of the ways that
districts have elected to use a VE model in the prekindergarten, elementary,
middle, and secondary programs.    Recommendations regarding the
characteristics of children, provision of aides, or pupil/teacher ratio are
included only as guidelines and are not intended to serve as requirements or
official state policy.  The districts that provided the guidelines are named at
the end of the descriptions.<p>
<p>
<p>
<!--insert graphic depicting school buildings-->

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h4>
<a name="Prekindergarten Programs">Prekindergarten Programs</a></h4>

<p>
The primary purpose for using the VE model in the prekindergarten program is to
keep students as close to home as possible.  This eliminates long bus rides and
provision of services on an itinerant basis.  The model provides more cost
effective services.<p>
<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Students can be grouped by ability or functioning level, rather than
exceptionality.  Prekindergarten children can be exposed to better role models
in skill areas which may not be their strengths.  They more readily develop
social and language skills from interaction with their peers. <p>
<p>
Children who are 3-5 years of age and developmentally delayed are often
considered for placement in a VE model.  The disability of the child may be
directly interfering with social interaction, and the child may need to be in a
program with children of his or her own age.  The family may benefit from
parent training provided along with the program for the child.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 8:1 with a full-time paraprofessional or aide is
considered best practice for students in this age group.  The class size should
also consider the needs of the students.  Students who require a great deal of
care and personal support will need to be placed in classes with an even
smaller pupil/teacher ratio or additional teacher aides. <p>
<p>
The classroom program should be staffed by a teacher who is certified in
exceptional student education or early childhood education (as indicated in the
Course Code Directory).   Speech/language pathologists, physical therapists, or
occupational therapists should provide programs and services for children as
appropriate.  The school psychologists and social worker may serve in an
evaluative and consultative capacity and assist parents in accessing local
agencies, if needed. <p>
<p>
<i>Program</i><p>
<p>
Planned activities are designed to increase functional skills in all six
developmental areas:  fine motor, gross motor, language, cognitive, self-care,
and social skills.  Skill development is encouraged through
multi-sensory-stimulation and activities such as dressing, pre-speech and
feeding, use of music to facilitate language and movement, and manipulation of
materials for improvement of fine motor skills.  An interdisciplinary team
approach is used in the classroom to support the goals and objectives
formulated in the Individual Educational Plan (IEP) of each child.  <p>
<p>
(from Manatee County Guidelines)<P>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4>
<a name="Elementary School">Elementary School <P>Resource Programs</a></h4>

<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Children are grouped in a VE class with other children who have comparable
needs.  They may exhibit delays in individual areas such as language arts,
reading, math, motor skills, and social and personal behaviors.  These students
are mainstreamed for the majority of the school day, and the VE class serves to
provide intervention in the area of the child's greatest need and to provide
support to successful performance in the mainstream class.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
For a resource room, the number of students will be based on the number of
hours each student is seen.  In most cases, 20-30 students can be served in a
resource room.  Sometimes additional students who are fully mainstreamed are
assigned to the ESE teacher for consultation services only.  Each district sets
the caseload requirements for a teaching unit, and actual numbers of students
vary considerably from these recommendations.  Support services are available
from the Florida Diagnostic and Learning Resources System (FDLRS), program
supervisors, school psychologists, social workers, school guidance personnel,
and curriculum resource personnel in the school. <p>
<p>
<i>Program</i><p>
<p>
The schedule in a VE class is determined according to the particular needs of
the students assigned to the class and must be arranged to accommodate the the
schedule of the mainstream classes. In some schools, the VE teacher is using a
team teaching model to provide services in the context of the regular
classroom.<p>
<p>
Cooperative Consultation (Reigel, 1988)  can enhance the success of the
mainstreaming experience of all ESE students.  Through this model, exceptional
education teachers and basic or vocational education teachers join together to
plan needed support and accommodations for exceptional students in mainstream
classes.  Through regular conferences and monitoring, the likelihood of success
of the student is greatly enhanced.  This is particularly critical at the start
of a new school year or when the ESE students are first being included in
mainstream programs.  <p>
<p>
(from Polk County Guidelines)<p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<p>
<H4>Elementary School</H4><p>

<h4><a name="ESelf-Contained Programs">Self-Contained Programs</a></h4>
<P>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Children are grouped in a VE class with other children who have comparable
needs.  They may exhibit delays in multiple areas such as language arts,
reading, math, motor skills, and social and personal behaviors.  Participation
in mainstream classes is generally limited to art, music, and physical
education for most students.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
For a self-contained class, a 12:1 pupil/teacher ratio  with a full-time aide
or paraprofessional is considered best practice for students in this age group.
Support services are available from FDLRS, program supervisors, school
psychologists, social workers, school guidance personnel and curriculum
resource personnel in the school. <p>
<p>
<i>Program</i><p>
<p>
The schedule is determined based on the functioning levels and subject areas
needs of the students as well as the scheduling of students for mainstream
classes.  In many programs, ESE students participate in the music, art, and
physical education programs with their chronological peers.  <p>
<p>
In schools with more than one ESE unit, students can be grouped by age range or
by program needs.  Teachers generally feel that emotionally handicapped
students who require full-time services should be placed together. (Polk County
Guidelines)<p>
<p>
<!--insert graphic showing teacher and several elementary age students-->


[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4>
<a name="Middle School">Middle School </a></h4>
<h4>
<a name="MResource Programs">Resource Programs</a></h4>
<P>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
This program is usually designed for mildly handicapped students who do not
require services in all academic areas or intensive related services or therapy
for behavior or emotional handicaps.<p>
<p>
Middle school programs are departmentalized or organized by grade level teams.
Students typically receive instruction from a number of different teachers,
including  those in the exploratory subjects.  The VE teacher may provide
instruction in basic academic classes such as English and mathematics, but
generally the content areas and special areas are taken in the mainstream for
students in resource programs.   If the school has sufficient students and ESE
teachers, faculty assignments may be made by subject area specialization or to
grade level teams.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class period is considered best
practice for students in this age group.  Aides and volunteers may be essential
if the class sizes are large or if the students need a lot of personal
attention.  Support services should be available from FDLRS, program
supervisors, school psychologists, social workers, school guidance personnel,
and curriculum resource personnel in the school. <p>
<p>
<i>Program</i><p>
<p>
The schedule is organized by grade level, subject area, and in some subjects,
by functional level.  The number of VE teachers in the school will affect the
flexibility of the scheduling.  <p>
<p>
In middle schools with grade level teams, VE teachers are sometimes organized
as a separate department, and students are scheduled in their classes on a
pull-out basis.  Other middle schools have found success with placing the VE
teacher on one of the teams and enrolling the ESE students on that team. <p>
<p>
Cooperative Consultation (Reigel, 1988) can enhance the success of the
mainstreaming experience of all ESE students.  (See Elementary School:
Resource Programs for a description of Cooperative Consultation.)<p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<H4>Middle School</H4><p>

<h4>
<a name="MSelf-Contained Programs">Self-Contained Programs</a></h4>
<p>
<i> Characteristics of Students Who Are Served in This Model</i><p>
<p>
This program is usually designed for exceptional students who require services
in the major academic areas and may need some related services or intensive
therapy.  <p>
<p>
Students in self-contained programs are taught  the academic content areas  in
VE classes.  If the school has sufficient students and ESE teachers, faculty
assignments may be by subject area specialization within the ESE department.
Students may be mainstreamed for art, music, physical education and vocational
exploration.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class period is considered best
practice for students in this age group.  Aides and volunteers may be essential
if the class sizes are large or if the students need a lot of personal
attention.  Support services should be available from FDLRS, program
supervisors, school psychologists, social workers, school guidance personnel,
and curriculum resource personnel in the school. <p>
<p>
<i>Program</i><p>
<p>
The schedule is generally organized by grade level, subject area, and in some
subjects, by functional level.  If there is only one self-contained unit in a
middle school, the content area subjects may rotate on a three year cycle, to
schedule the courses more efficiently.  The number of VE teachers in the school
will affect the flexibility of the scheduling.  <p>
<p>
<!---insert graphic showing several middle school students working together with a map or globe-->

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><a name="High School">High School </a></h3><P>

<h4><a name="High School Resource Programs">Resource Programs</a></h4>
<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
This program is designed for mildly handicapped students who are served on a
resource basis and do not require intensive related services or therapy.<p>
<p>
High school programs are usually departmentalized.  Students receive
instruction from a number of different teachers.  The VE teacher may provide
instruction in basic classes such as English and mathematics, or in support
areas such as learning strategies, social skills or unique skills.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class period is considered best
practice for students in this age group.  Support services should be available
from FDLRS, program supervisors, school psychologists, social workers, school
guidance personnel, and curriculum resource personnel in the school.   Job
placement specialists and vocational education services are an important aspect
of the high school program.  Because of the needs for transition services,
other agencies such as Vocational Rehabilitation may become involved at this
level.<p>
<p>
<i>Program</i><p>
<p>
The schedule is generally organized by grade level, subject area, and in some
subjects, by functional level.  Team teaching has been used successfully in
many districts to support ESE students in mainstream classes.  In this model,
the ESE teacher and the mainstream teacher work as a team to deliver a class.<p>
<p>
Cooperative Consultation (Reigel, 1988)  can enhance the success of the
mainstreaming experience of all ESE students.  (See Elementary School Programs:
Resource Programs for a description of Cooperative Consultation.)<p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<H4>High School</H4><p>

<h4><a name="Self-Contained Programs">Self-Contained Programs for Special Diplomas</a></h4>
<p>
The exceptional students who require full-time placement at the high school
level in many districts are those who are working towards a special diploma.
The full-time students would receive credit in VE classes to meet the
requirements of a special diploma. <p>
<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Districts may establish guidelines to assist in the recommendation of
exceptional students for participation in a functional life skills curriculum
and a special diploma.  Low academic levels, particularly low reading ability,
are commonly used indicators. <p>
<p>
In some districts, this determination is made as a part of the eighth grade
planning process.  The district program specialist may review recommended
students with teachers and other school personnel.  The parent and students may
participate in an IEP review in the spring to make the actual decisions.<p>
<p>
<i> Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class period is considered best
practice for students in this age group.  Aides and volunteers may be essential
if the class sizes are large or if the students need a lot of personal
attention.  Support services should be available from FDLRS, program
supervisors, school psychologists, social workers, school guidance personnel,
and curriculum resource personnel in the school.   Most special-diploma-seeking
students should be involved with a vocational program.  Because of the needs
for transition services, other agencies such as Vocational Rehabilitation may
become involved at this level.<p>
<p>
<p>
<i>Program</i><p>
 <p>
The functional life skills curriculum emphasizes career awareness, social
skills, and pre-employment habits and attitudes necessary for successful work
adjustment.  Basic skills and problem-solving techniques are presented in a
real-life context to prepare students to function independently as adults. <p>
<p>
(from Palm Beach County Guidelines)<p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<p>
<H4>High School</H4><p>

<h4><a name="Vocational Education">Vocational Education Programs</a></h4>
<p>
The purpose of vocational programs at the high school level is to enable
students to develop the ability to communicate appropriately with peers and
adults, to demonstrate the skills and attitudes essential for employment, and
to help students set realistic career goals.  Students are involved in job
preparatory programs to develop specific occupational skills.<p>
<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Students should enroll in vocational programs based on their interest and
aptitude.  Work experience may be provided either on or off campus.  ESE
students may enroll in regular vocational programs or in specially designed
programs.  The VE class generally serves to support the academic and job
training requirements of the program.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class is conisdered best practice for
students in this age group.  Occupational specialists, vocational
rehabilitation counselors, and ESE specialists and evaluators are needed to
support this program.  For more severely disabled students, job coaches may be
required. <p>
<p>
<i>Program</i><p>
<p>
The program is organized to support the course needs to meet graduation and
vocational program requirements.  The student's work schedule may occur during
the school day or may be arranged in off hours.  Districts may provide the
vocational program through the offerings at a comprehensive high school or in
an area vocational-technical program.<p>
<p>

<!--insert graphic showing high school students working on a car, or working in a retail outlet with adults-->
[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]  <P>

<HR>
<P>[<A HREF="bees5.HTM">Previous section</A>]   [<A HREF="bees7a.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>





















</DOC>
<DOC>
<DOCNO>WT01-B04-190</DOCNO>
<DOCOLDNO>IA039-000740-B041-266</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees7a.HTM 198.78.22.165 19970210073651 text/html 29381
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:1 GMT
Last-modified: Tuesday, 5-Mar-96 22:3:46 GMT
Content-length: 29125
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 -->
<A NAME = "Effective Practices"><TITLE>Resources for VE Teachers</TITLE></A></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<br>
<P>[<A HREF="bees6.HTM">Previous section</A>]   [<A HREF="bees7b.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>

<h1>Effective Practices for Varying Exceptionalities Classes</h1><P>
<DL>
<LI><A HREF = "#Organizing and Managing">Organizing and Managing Diversity in Instruction</A>
<LI><A HREF = "#Characteristics of Exceptional">Characteristics of Exceptional Students</A>
<DL>
<LI><A HREF= "#Autistic">Autistic</A>
<LI><A HREF= "#Dual Sensory Impaired">Dual Sensory Impaired</A>
<LI><A HREF= "#Emotionally Handicapped">Emotionally Handicapped and Severely Emotionally Disturbed</A>
<LI><A HREF= "#Gifted">Gifted</A>
<LI><A HREF="#Hearing Impaired">Hearing Impaired</A>
<LI><A HREF="#Mentally Handicapped">Mentally Handicapped</A>
<DL>
<LI> <A HREF="#Educable Mentally Handicapped (EMH)">Educable Mentally Handicapped (EMH)</A>
<LI> <A HREF="#Trainable Mentally Handicapped (TMH)">Trainable Mentally Handicapped (TMH)</A>
<LI> <A HREF="#Profoundly Mentally Handicapped (PMH)">Profoundly Mentally Handicapped (PMH)</A>
</DL>
<LI><A HREF="#Physically Impaired">Physically Impaired</A>
<LI><A HREF="#Specific Learning Disabilities">Specific Learning Disabilities</A>
<LI><A HREF="#Speech and Language Impaired">Speech and Language Impaired</A>
<LI><A HREF="#Visually Impaired">Visually Impaired</A>
</DL>
</DL><P>
<HR>
<pre>





























</pre>
<A NAME = "Organizing and Managing"><h3>Organizing and Managing Diversity in Instruction</h3></A>
<P>
<br>
<p>Teachers in VE classes frequently comment that the biggest problem they
encounter in the class is managing the diversity of instructional needs of
their students.  Consideration must be given to the characteristics and needs
of the students, the scheduling of students during the day, the way students
are grouped for instruction, and  the management of  the learning environment.
This section provides a variety of suggestions that may help the VE teacher.
<br>
<!--Insert a drawing of a busy classroom --><br><P>

[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "Characteristics of Exceptional">Characteristics of Exceptional</A> Students</h3>
<P>
<br>
<p>As identified in the first section of this document, all categories of
exceptional students may be served in a VE class.  The following descriptions
have been developed by the Bureau of Education for Exceptional Students
(<i>Educating Exceptional Students</i>, 1993) and are provided to define and
describe educational characteristics related to each exceptionality.
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<br>
<h4><A NAME = "Autistic">Autistic</A></h4><br>
<P>
<i>Student Characteristics</i><br>
<br>
<p>Autism is a behaviorally-defined syndrome characterized by severe
problems in learning, communication, and social interaction.  Although autism
is a lifelong disability for which there is no known cure, persons with this
disorder can make substantial progress through intervention programs in
education, speech and language therapy, and other disciplines.<br>
<br>
<p>The term "autism" refers to a collection of behavioral symptoms which normally
are diagnosed during infancy or early childhood and may have more than one
cause.  Behavioral characteristics may vary significantly among individuals
with autism.  These characteristics include cognitive, behavioral, social, and
communication deficits.  <br>
<br>
<i>Educational Characteristics</i><br>
<br>
<ul>
<li>Cognitive levels of functioning vary dramatically within this
population.  Levels may range from the profoundly disabled who display a number
of physical problems, to high functioning individuals who are socially
integrated with the community.<br>
<br>
<li>Many individuals show unevenness in their developmental profile.  Splinter
skills within and between academic areas often evidence this uneven skill
development.<br>
<br>
<li>Most individuals evidence speech which is noncommunicative and language skills
which are dysfunctional.  There may be markedly abnormal nonverbal
communication, such as lack of eye contact or inability to refocus attention as
the situation changes.  There may be marked impairment in the ability to
initiate or sustain a conversation.<br>
<br>
<li>Many individuals may ignore the presence of others and remain aloof and
indifferent to social contact.  Interest in objects may be greater than
interest in people. Some may show an inability to make friends with others in
the classroom.<br>
<br>
<li>Some individuals may lack appropriate affect in relation to environmental
stimulation.  They may become extremely upset without obvious provocation,
resulting in tantrumming behavior of considerable duration or intensity.<br>
<br>
<li>Hypo- or hyper-sensitivity are often characteristic reactions to stimuli.
Individuals with autism may demonstrate insensitivity or lack of response to
pain, or they may overreact to a common environmental noise such as a school
bell.
</ul><P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<br>
<A NAME = "Dual Sensory Impaired"></A><h4>Dual Sensory Impaired</h4><br>
<P>
<P>

<i>Student Characteristics</i>
<p>Students with "dual sensory impairments" have both a vision and a hearing loss
and are sometimes referred to as "deaf-blind."  The combination of sensory
losses creates severe communication and other developmental and learning needs
that require special education and related services.  Communication and
mobility are the most seriously affected areas for students with dual sensory
impairments.<br>
<br>
<br>
<i>Educational Characteristics</i><br>
<ul>
<li>Students communicate through facial expression, body movement, and
various vocalizations that may seem unintelligible.  Staff should acknowledge
and expand communication attempts so that students can develop effective means
of communication.<br>
<br>
<li>Students with little functional use of their vision or hearing are often
unable to understand what is going to happen to them. Staff should develop
touch cues (specific signals of events or requests) and use them consistently
in daily routines.<br>
<br>
<li>Students with severe impairments react more positively to a stranger if
approached using a gentle touch to the shoulder as a cue.<br>
<br>
<li>Students must be taught appropriate touch, tolerating touch, and exploration
strategies.
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<br>
<h4><A NAME = "Emotionally Handicapped">Emotionally Handicapped and Severely Emotionally Disturbed</A></h4><br>
<P>

<i>Student Characteristics</i><br>
<br>
<p>The student who has an emotional handicap exhibits one or more of the
following characteristics, to the extent that he or she is unable to take
advantage of or participate in the regular education program:<br>
<br>
<ul>
<li>Inability to learn cannot be explained by intellectual, sensory, or health
factors.<br>
<br>
<li>Demonstrates inappropriate types of behaviors or feelings under normal
circumstances.<br>
<br>
<li>General mood is one of unhappiness or depression.<br>
<br>
<li>Tendency to develop physical symptoms, pain, or fears associated with personal
or school problems.<br>
<br>
<li>Unable to build or maintain satisfactory interpersonal relationships with
peers or teacher.<br>
<br>
<li>Demonstrates a variety of excessive behaviors, ranging from hyperactive and
aggressive responses to severe depression and withdrawal.<br>
<br>
</ul>
<p>All student characteristics must be examined as they are impacted by the
context of educational settings (academic and social), home, and community.<br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>Students should be provided with a structured learning environment to provide
for skill acquisition in behavior control strategies, academic achievement, and
socialization.<br>
<br>
<li>Classroom rules for group control and structure for targeting behaviors should
be key elements in the learning environment.<br>
<br>
<li>Many have academic problems, particularly in reading comprehension, social
studies, and math problem solving.  These areas should be emphasized in the
curriculum.<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Gifted">Gifted</A></h4><br>
<P><br>
<p>Gifted students are rarely served in a VE model.  However, students with other
exceptionalities occasionally exhibit characteristics associated with
giftedness, and these may be used as clues to appropriate learning
interventions.<br>
<br>
<br>
<i>Student Characteristics</i><br>
<br>
<p>There is no one type of giftedness; therefore, no single instructional
modification is effective for all gifted students.  Most effective teaching
strategies emphasize flexibility and sensitivity to the characteristics of
gifted students, and provision of opportunities to experience the breadth of a
concept to match the student's curiosity.<br>
<br>
<br>
<i>General Characteristics</i><br>
<br>
<ul>
<li>Learn skills efficiently, with little practice.<br>
<br>
<li>Interpret nonverbal cues and draw inferences independently.<br>
<br>
<li>Work independently at an earlier age and for longer periods of time.<br>
<br>
<li>Often have wildly eclectic interests and are intensely focused.<br>
<br>
<li>Have seemingly boundless energy; may be misdiagnosed as hyperactive.<br>
<br>
<li>Are able to relate well to adults and older children.<br>
<br>
</ul>
<i>Learning Characteristics</i><br>
<br>
<ul>
<li>Show keen powers of observation; have an eye for important details.<br>
<br>
<li>Prefer structure, organization, and consistency in their environment.<br>
<br>
<li>Are often skeptical, critical, and evaluative.<br>
<br>
<li>Have a ready grasp of underlying principles; can make generalizations.<br>
<br>
<li>Can attack complicated material and analyze it systematically.<br>
<br>
<li>Have well developed common sense.<br>
<br>
</ul>
<i>Behavioral Characteristics</i><br>
<br>
<ul>
<li>Are often well organized, goal-directed, and efficient.<br>
<br>
<li>Exhibit intrinsic motivation to learn, find out, and explore.<br>
<br>
<li>Have a highly developed moral and ethical sense.<br>
<br>
<li>Can integrate opposing impulses.<br>
<br>
<li>Often seem to be daydreaming.<br>
<br>
<li>May seek to conceal their abilities.<br>
<br>
<li>Have a well developed sense of self and realistic ideas about their
capabilities.<br>
<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Hearing Impaired">Hearing Impaired</A></h4><br>

<P>
<i>Student Characteristics</i><br>
<br>
<p>The term "hearing impaired" refers to people with all types of hearing
disabilities, ranging from a very slight loss to profound deafness.  Whether
the hearing loss occurred before or after the student acquired language often
determines the type of support services the individual student will need in
order to succeed. <br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<p>The diversity of manifestations makes it necessary to consider each
student as an individual with unique characteristics and educational needs.<br>
<br>
<ul>
<li>Some students have difficulty accepting their hearing loss and are
inconsistent in wearing their hearing aids.  Hearing aids only partially
compensate for an individual's hearing impairment.  Individual students may
exhibit speech, language, and communication problems.<br>
<br>
<li>Some students communicate orally; others use speech and sign language.
Students may need the assistance of an interpreter or notetaker.  Sign language
interpreters may sign and speak at the same time.  Oral interpreters voice
without using signs.<br>
<br>
<li>Optimum acoustical conditions must be provided for students with hearing
impairments.  Any extraneous noise makes it more difficult for students to
interpret oral language.  To reduce reverberation, the classroom should be
equipped with sound-absorbing materials such as carpet, cloth curtains, and
acoustical ceiling tile.<br>
<br>
<li>Adequate lighting is needed to help with the comprehension of information
through speech reading and visual aids.  In addition, amplification is needed
to assist students in understanding what is being said.  Students may have
difficulty processing both the visual information and the classroom
conversation at the same time.<br>
<br>
</ul>
<i>Suggestions for Classroom Routines</i><br>
<br>
<ul>
<li>Speak normally when talking; hearing aids increase the loudness of sounds.<br>
<br>
<li>Write assignments on the board.<br>
<br>
<li>Encourage students to ask for statements to be repeated.  Rephrase the
statements, if they do not understand.<br>
<br>
<li>Students may fatigue more readily because of the continuous visual and
auditory strain of keeping up with the classroom activity.<br>
<br>
<li>Allow students to sit where they can have direct eye contact with the speaker
and interpreter.<br>
<br>
<li>Avoid standing in front of windows and other light sources when speaking to
students.<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Mentally Handicapped">Mentally Handicapped</A></h4><br>
<P>
<i>Student Characteristics</i><br>
<br>
<p>People with a mental handicap develop at a below-average rate and
experience difficulty in learning and social adjustment.  "Mentally retarded
means significantly subaverage general intellectual functioning, existing
concurrently with deficits in adaptive behavior and manifested during the
developmental period, that adversely affects a student's educational
performance" (<i>Individuals with Disabilities Education Act--IDEA</i>).<br>
<br>
<p>In educational settings, students with mental handicaps may be determined
eligible for one of three groups based on their ability to learn and their
ability to be independent and socially responsible:<br>
<br>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<ol>
<LI><A NAME = "Educable Mentally Handicapped (EMH)">Educable Mentally Handicapped (EMH)</A>
<P>
<P>
<p>Students are mildly impaired in intellectual and adaptive behavioral skills.
IQ is approximately 55-70 and assessed adaptive behavior falls below age and
cultural expectations.  These students can learn about 50% to 75% of what a
typical student can learn and understand.  They usually have a short attention
span and do not retain information readily.<br>

<i>Educational Considerations</i><br>

<ul>
<li>Teachers may  need to use many clear, unambiguous verbal cues; prompts;
physical guidance; and modeling to help these students learn at a more
efficient rate.  Students need frequent feedback and reinforcement.  <br>
<br>
<li>Students can learn a broad range of subjects including basic skills, social
studies, science, and health and personal care.  An important component is
preparation for a vocation and community living. <br>
<br>
</ul>
<br>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<LI> <A NAME = "Trainable Mentally Handicapped (TMH)">Trainable Mentally Handicapped (TMH)</A>
<P>
Students identified as TMH are moderately or severely impaired in intellectual
and adaptive behavior and have a reduced rate of learning.  IQ is approximately
25-55 and assessed adaptive behavior falls significantly below age and cultural
expectations.  Students can learn about 25% to 50% of what a typical student
can learn and understand.  In addition, they may have cardiac or neurological
sensory disorders.<br>
<i>Educational Considerations</i><br>
<ul>
<li>Students may require many services provided through an interdisciplinary team
approach.<br> 
<li>Curriculum should include activities of daily living, preparation and
participation in a supported employment program, and transition services for
life after school.<br>
<br>
</ul>
<br>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<LI> <A NAME = "Profoundly Mentally Handicapped (PMH)">Profoundly Mentally Handicapped (PMH)</A><P>

<p>Students identified as PMH are profoundly impaired in intellectual and adaptive
behavior and have a reduced rate of learning.  IQ is approximately 25 or below
and assessed adaptive behavior falls very significantly below age and cultural
expectations.  Students have little response to most social stimuli and limited
awareness of their environment.  Communication is very limited, and they may
display temper tantrums, self-injurious behaviors, self-stimulation, and
seizures.  Many have other serious conditions as well, such as cerebral palsy
or blindness.<br>
<i>Educational Considerations</i><br>
<ul>
<li>Students benefit from social stimulation and communication training.<br>
<br>
<li>Many students require assistive technology for ambulation, self-care, and
health maintenance.<br>
<br>
<li>Teachers need to work with the adult agencies to which these students may
transition after graduation and help the students develop the appropriate
behavioral skills for this transition.<br>
</ul>
</ol>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Physically Impaired">Physically Impaired</A></h4><P>
<P>
<i>Student Characteristics</i><P>
<br>
<p>A physical impairment is a physically disabling condition resulting from
a health impairment, an orthopedic condition, or a traumatic brain injury which
requires an adaptation to the student's school environment or curriculum.
Physical impairments include physical problems present at birth as well as
physical problems resulting from other causes.  Neurological problems, such as
cerebral palsy, may be included in this category.<br>
<br>
<p>Health impairments may result in reduced efficiency in school work because of
temporary or chronic lack of strength, vitality, or alertness.  Asthma, cardiac
conditions, leukemia, and Acquired Immune Deficiency Syndrome (AIDS) are
examples of health impairments that could interfere with a student's
education.<br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>The effect of a physical impairment can vary from little or none to a
complete restructuring of daily life.  Severely involved students may require
intensive health care and educational assistance.<br>
<br>
<li>Physical impairments may interfere with the student's motor functioning,
communication, learning skills, or social development.<br>
<br>
<li>Physical, occupational, and speech and language therapy are often central to
the education of students with physical impairments.  The greatest progress is
achieved when therapy suggestions are consistently applied in the student's
home as well as throughout the school environment.<br>
<br>
<li>Programs may need to be made assessible by  structural changes (adding ramps
or elevators) or schedule or location changes.<br>
<br>
<li>Physical impairments can affect the student's emotional and social
development.  Avoid overprotection and encourage students to participate within
limits of safety and health.<br>
<br>
<li>Adaptive equipment can be used to enable students with physical impairments to
function more normally.<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Specific Learning Disabilities">Specific Learning Disabilities</A></h4><P>
<P>
<i>Student Characteristics</i><P>
<br>
<p>A specific learning disability is a condition which affects one of the
basic psychological processes involved in understanding or using language.  A
psychological process is considered to be the combined operations involved in
gathering, storing, or retrieving information through sensory channels.  The
disability can appear in areas such as listening, thinking, reading, talking,
writing, or arithmetic.  Learning disabilities cannot be attributed to a
vision, hearing, or motor disability, a mental handicap, an emotional
disturbance, or environmental deprivation.<br>
<br>
<p>Specific learning disability delays are typically in spoken language or
listening skills, error patterns in written language (including reading),
difficulty in grasping math concepts or performing basic arithmetic operations,
and difficulty in applying organizational skills.  These characteristics may be
evident in several areas of performance.  Identification of specific learning
disabilities is possible when a discrepancy exists between a student's
estimated ability and actual performance level. <br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>The disability can have a mild to severe impact on students' academic
performance.<br>
<br>
<li>Classroom organization providing a high level of structure, defined routines,
and clearly stated rules and assignments are helpful to many students.<br>
<br>
<li>Flexibility in allotment of time to complete assignments and in the use of
classroom space and equipment provides students an increased opportunity to be
successful.<br>
<br>
<li>Modifications in instructional methods, such as activities to support lessons
(study guides or advance organizers), assist students to master key concepts
and content.<br>
<br>
<li>Instructional materials can be modified by compressing or paraphrasing texts,
developing additional practice materials, or reducing the number of items
required to show proficiency.<br>
<br>
<li>Assessment procedures that allow alternative presentation of questions and
responses can enable students to demonstrate competencies.  Clear instructions
and expectations must be provided.<br>
<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Speech and Language Impaired">Speech and Language Impaired</A></h4><P>
<P>
<i>Student Characteristics</i><P>
<br>
<p>Speech and language impairments refer to problems in communication,
i.e., the ability to understand or appropriately use speech and language
systems.  Such disorders may range from simple sound repetitions or occasional
misarticulations to the absence of the ability to use speech and language for
communication.  A language impairment is the inability to use the symbols of
language through proper use of words and their meanings, appropriate
grammatical patterns, and proper use of speech sounds.  A speech impairment is
difficulty in producing speech sounds (articulation), maintaining speech rhythm
(fluency), and controlling vocal production (voice).<br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>Students with a communication disorder may have difficulty learning
basic academic subjects.<br>
<br>
<li>As students progress through school, increased demands in the language of
learning can result in great difficulty for students with speech or language
impairments.<br>
<br>
<li>Some students may encounter isolation in educational, vocational, social, and
emotional areas.<br>
<br>
<li>Technology can assist students whose physical condition makes communication
difficult.  The use of augmentative or assistive communication devices allows
limited-speaking or nonspeaking students to engage in meaningful
communication.<br>
<br>
</ul>
<P>

[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Visually Impaired">Visually Impaired</A></h4><br>
<P>
<i>Student Characteristics</i><br>
<br>
<dl>
<dt>"Partially sighted" 
<dd>refers to students who have corrected vision between 20/200
and 20/70 and who may require the use of special materials for learning.<br>
<br>
<br>
<dt>"Low vision" 
<dd>refers to students who may be partially sighted or legally blind
and who require adaptations that may include Braille.<br>
<br>
<br>
<dt>"Legally blind" 
<dd>refers to students who have corrected vision of less than
20/200 or a very limited field of vision and who require the use of special
materials for learning.<br>
<br>
<br>
<dt>"Totally blind" 
<dd>refers to students who have no light perception and who require
Braille or other nonvisual media for learning.<br>
<br>
</dl>
<p>The effect of visual problems on a student's development depends on the
severity and type of loss, the age of onset, and the overall functioning level
of the child.  Many children who have multiple handicaps may also have visual
impairments which result in further motor, cognitive, and/or social
developmental delays.  Many children who have a visual impairment are not
motivated to explore their environment because of lack of visual stimuli.  They
may appear uninterested, overprotected, and antisocial due to the impact of
their visual impairment.<br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>Special materials, including Braille, large print, and taped textbooks and
supplemental reading materials; special technology, including adaptive
computers, low-vision optical aids, and print-enlarging equipment; and
modifications to curricula may be necessary for students with visual
impairments.<br>
<br>
<li>Students may require special instruction in daily living skills, social
skills, orientation and mobility (independent movement in the environment),
communication (Braille), or vocational/career options.<br>
<br>
<li>Students with visual impairments are typically mainstreamed and receive
special instruction in Braille, daily living skills, and social behaviors.
</ul>
<br><P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]  
<HR><P>

Information on <A HREF = "bees7b.HTM"> Scheduling</a> is also available.

<P>[<A HREF="bees6.HTM">Previous section</A>]   [<A HREF="bees7b.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>

















</DOC>
<DOC>
<DOCNO>WT01-B04-191</DOCNO>
<DOCOLDNO>IA039-000740-B041-339</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees7b.HTM 198.78.22.165 19970210073739 text/html 25276
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:2 GMT
Last-modified: Tuesday, 5-Mar-96 22:4:10 GMT
Content-length: 25020
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 --><A NAME = "Scheduling"><TITLE>Resources for VE Teachers</TITLE></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees7a.HTM">Previous section</A>]   [<A HREF="bees7c.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<h1>Effective Practices for Varying Exceptionalities Classes</h1><P>
<DL><h2><A NAME = "#Scheduling">Scheduling</A></h2>
<DL>
<LI><A HREF = "#General Suggestions">General Suggestions</A>
<LI><A HREF = "#Elementary Programs">Elementary Programs</A>
<LI><A HREF = "#Secondary Programs">Secondary Programs</A>

</DL><P>

<h2>
<A NAME = "#Grouping for Instruction">Grouping for Instruction</A>
</h2>
<DL>
<LI><A HREF = "#Grouping for Instruction">Grouping for Instruction</A>
<LI><A HREF = "#Independent Learning">Independent Learning</A>
<LI><A HREF = "#One-on-One Instruction">One-on-One Instruction</A>
<LI><A HREF = "#Large and Small Groups">Large and Small Groups</A>
<LI><A HREF = "#Students in the Mainstream">Students in the Mainstream</A>
</DL><P>

<h2>
<A NAME = "Managing the Classroom Environment">Managing the Classroom Environment</A>
</h2>
<DL>
<LI><A HREF = "#Managing the Classroom">Managing the Classroom Environment</A>
<LI><A HREF = "#Planning the Environment">Planning the Environment</A>
<LI><A HREF = "#Arranging the Furniture">Arranging the Furniture</A>
<LI><A HREF = "#Organizing Instructional Materials and Supplies">Organizing Instructional Materials and Supplies</A>
</DL></DL><P>
<HR>
<pre>





























</pre>
<h3>
<A NAME = "General Suggestions">Scheduling</A>
</h3>
<h4>General Suggestions</h4>

<br>
<!-- insert graphic re: scheduling depict a matrix with students names down
one column and time periods across top --><br>
<br>
<p>Many VE teachers have raised concerns about the way that students are
scheduled into their classes.  They feel that they have to work around the
demands of all other programs in the school.  A proactive approach is needed to
facilitate appropriate scheduling.  The following list provides a number of
suggestions that may assist the VE teacher in developing the classroom schedule
at the beginning of the school year.<br>
<br>
<ul>
<li>Try not to remove ESE students from their homeroom time.  Wait until
announcements are finished.
<br>
<li>Allow time in the weekly or semester schedule for non-instructional duties,
such as paperwork, testing, conferencing with parents and teachers, and
planning.
<br>
<li>Be firm and assertive about scheduling for the time specified on the student's
IEP.
<br>
<li>If you must teach more than one subject at a time, make sure you have the
support you need.  For some students and subjects, an integrated and
interdisciplinary approach to instruction works very well.
<br>
<li>Make individual plans for students that could be used for a period of time.
Students could keep track of accomplishments and check off work as they
complete it.  Assignments may be posted on the bulletin board and students can
be responsible for tracking their completion.
<br>
<li>Stress day-by-day organization which is as critical as the weekly or yearly
plan.  Students need to know exactly what to do each day and the rules should
be consistently applied.
<br>
<li>Be aware of practices like Friday testing in the regular classroom.  Correlate
your activities as appropriate.
<br>
<li>Provide lesson plans for aides and volunteers so they will know what to do.
<br>
</ul><P>

[<A HREF="#Scheduling">Scheduling</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h4>
<A NAME = "Elementary Programs">Elementary Programs</A></h4>
<p>The following suggestions are intended to help teachers in elementary
schools whose ESE students regularly participate in mainstream programs.
<P>
<ul>
<li>Use the school's master schedule to identify times when all ESE students are
in mainstream programs, such as music, art, and physical education; include
lunch and other common times.
<br>
<li>Coordinate with the regular teacher's classroom schedule.  Where possible and
appropriate, the ESE student should remain in the regular classroom for classes
and activities in which they can experience success.
<br>
<li>Try to schedule students in the VE class for the subject or area identified on
the IEP at the same time their regular class has this scheduled.  Arrange the
VE schedule so that students can be grouped by academic or social needs, not
necessarily by grade level or by exceptionality.
<br>
<li>Sometimes, you may find that the all of the regular classes offer the targeted
subjects, like reading, at the same time of day.  The VE schedule becomes
overloaded at certain times during the day and very light at others.  The ESE
teacher may be able to negotiate with the regular teacher or the school
administrator to adjust the schedule or to accommodate the ESE students in the
regular class.
<br>
<li>If you have both part-time and full-time students in the class, try to
schedule students so that they can be grouped by functional level.
<br>
</ul>
<P>
[<A HREF="#Scheduling">Scheduling</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4>
<A NAME = "Secondary Programs">Secondary Programs</A>
</h4>
<p>The following suggestions are intended for teachers in middle and high
schools.<br>
<br>
<ul>
<li>ESE students should be hand-scheduled or scheduled first if a computer program
is used to ensure that appropriate courses and instructors are selected.  This
will help to avoid  placing students in inappropriate classes.
<br>
<li>Providing a consistent structure can assist students in meeting requirements
of many different teachers.  Daily reviews of expectations in each class will
promote improved behavior.
<br>
<li>Help students who are new to the school find their way around.  Older students
can be assigned to help new students for the first few weeks.
<br>
</ul>
<P>
[<A HREF="#Scheduling">Scheduling</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>


































</pre>
<h2>
<A NAME = "Grouping for Instruction">Grouping for Instruction</A></h2><br>

<br>
<p>After the schedule has been set for the VE class, the teacher must determine
how the students will be grouped for instruction.  The effective use of
grouping techniques can result in a classroom that functions as a real learning
community.  The following section provides descriptions of major types of
grouping techniques, with guidelines for determining the benefits of each type
of grouping, and recommendations and cautions for effective use of the grouping
technique.<br>
<br>
<i>Although each exceptional student has an Individual Education Plan and
should be provided individualized instruction and assessment, students can
benefit from participation in group instruction and group work.  </i><br>
<br>
<!-- insert graphics of 1-1, independent, small and large groups of students--><br>
<P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "Independent Learning">Independent Learning</A>
</h3><br>
<br>
<!-- insert graphic of independent learner--maybe with computer--><br>
<i>What does this accomplish?</i><br>
<br>
<p>Independent learning provides opportunities for students in VE classes
to practice needed skills, promote responsibility and individual effort, and
build time management skills and self-directed work habits. 
<br>
<br>
<i>Who benefits?</i><br>
<br>
<p>All students in VE classes can benefit from independent learning activities.
Even prekindergarten students in play activities are learning independently.
Older students requiring drill and practice for skill development and
reinforcement may use this method.  In self-guided learning activities,
students can work at their own pace. <br>
<br>
<i>How do you make this work?</i><br>
<br>
<b>Select the activities.</b> The types of activities used for
independent learning do not have to be limited to paper-and-pencil worksheets.
Activity centers can be created in which students can work on interesting
tasks.  Creative centers promote self-expression.  The computer is a natural
tool for an independent learning activity center.<br>
<br>
<b>Provide a management routine.</b> Students will need to be able to perform
the expected behaviors and outcomes of independent learning activities.
Students should be able to select, retrieve, and return all needed equipment
and materials.  The more you can rely on students to do things for themselves,
the more they will gain from the activities.<br>
<br>
<b>Provide feedback on performance.</b> Even though the activities are
independent, students will need direct feedback on their performance.  Many ESE
students benefit from clear evidence of their progress.<br>
<br>
<br>
<i>Any cautions?</i><br>
<br>
<b>Selection of activities.</b> Teachers in VE classes must provide the
structure for independent learning activities.  Activities should be carefully
selected so that they are appropriate for the students.  They should neither be
too difficult nor too easy.  Independent learning activities must be
sufficiently challenging and even more important, they must be interesting to
the students.<br>
<br>
<b>Arranging the learning environment.</b>The learning environment in the VE
class must be arranged so that students can easily locate the materials
themselves.  Students also should learn how to get help in ways that do not
disrupt the rest of the classroom activities.  Silent signals and learning
buddies are two methods that have worked in many classrooms.<br>
<P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "One-on-One Instruction">One-on-One Instruction</A>
</h3>
<P>
<!--insert graphic with one on one instruction--><br>
<br>
<i>What does this accomplish?</i><br>
<br>
<p>One-on-one instruction is used to provide the most intensive kind of
instruction.  Modeling, prompting, and feedback can be individualized to
anticipate and respond directly to the learner's needs.<br>
<br>
<br>
<i>Who benefits?</i><br>
<br>
<p>Students requiring personal contact for information to be processed will
require one-on-one instruction.  All students in a VE class may require
one-on-one instruction from time to time.  Students who are most likely to need
this type of instruction include the following:<br>
<br>
<ul>
<li><b>New Students</b>--Students who do not know the classroom routine do not
know how to get help independently.<br>
<br>
<li><b>Students in Crisis</b>--Students who temporarily lack self-control need
much direct support and structure.<br>
<br>
<li><b>Students Learning a New Skill</b>--Students learning new skills require
careful attention to the modeling and feedback provided by the teacher.
Sometimes this is most efficiently delivered on a personalized basis.<br>
<br>
<li><b>Students with Sensory Impairments</b>--Students whose ability to receive
information is impaired may require personal contact.  Some dual sensory
impaired students need to have the sign language transmitted in their hand.<br>
<br>
</ul>
<i>How do you make this work?</i><br>
<br>
<p>The most successful use of one-on-one instruction necessitates careful
planning.  When the VE teacher anticipates the need for this approach, the
appropriate conditions can be arranged.  A classroom management program is
needed for the other students and could involve peer tutoring, independent task
completion routines, and use of assistants and volunteers.  One-on-one
instruction may require the classroom teacher for delivery, but it may also be
provided by teacher assistants or through computer-assisted instruction.  In
some cases, the teacher can get the process started, then move aside as other
support mechanisms take over.<br>
<br>
<i>Any cautions?</i><br>
<br>
<p>As in any ESE class, teachers need to keep the goal of independent learning at
the forefront. In VE classes, students often need a lot of one-on-one
instruction at first.  Plan to fade some of the direct assistance as the child
becomes acclimated to the classroom or more proficient in practicing the new
skill.  Where groups of students must be instructed together, shift back and
forth from whole group participation to individual instruction and response.
When students in VE classes are taught how to be independent learners, they can
become partners in the process.<br>
<br>
<br>
<!--insert graphics with large groups and cooperative groups-->
<P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "Large and Small Groups">Large and Small Groups</A>
</h3><P>
<i>What does this accomplish?</i><br>
<p>For students with similar learning needs, group instruction provides an
efficient method for demonstrations, information presentations, and modeling.
For students with more diverse learning needs, group instruction can be used to
provide shared experiences.  Many VE classrooms use cooperative learning groups
to accommodate the diversity of student learning needs.<br>
<br>
<i>Who benefits?</i><br>
<p>Students of all ages can benefit from group learning experiences.  Very
young students may require smaller groups and activities that are relatively
short.  Older students will need activities that are well paced and easy to
follow.  Students with disabilities may need to learn how to participate in
group activities.<br>
<br>
<i>How do you make this work?</i><br>
<b>Keep grouping flexible. </b> Planning for instruction in a VE class requires
the teacher to consider the needs of  all students in the class.  Students may
be grouped for specific skill learning or for concept development.  Because of
the diversity within a VE class, teachers often must group and regroup students
throughout the day.  Most students can adjust to this type of flexibility as
long as it is predictable.  Students can follow a task card, with symbols
representing where they are to be.  A timer in the classroom can help to signal
change in activities.  <br>
<br>
<b>Use media to enhance presentations. </b> When information must be presented
to a group of students, visual and auditory aids are particularly useful.
These aids can reinforce the key points.   Concrete examples are generally the
most effective presentation aids.<br>
<br>
<b>Keep students actively involved.  </b>Learning requires active involvement.
Listening is rarely sufficient for students in VE classes to gain the
information and understanding provided through verbal instruction.  Use a lot
of cues to focus the student's attention.  Students can also participate in
group instruction in a variety of ways.  Assign each student a different role
or expectation, then have them collaborate to complete a related task.<br>
<br>
<b>Combine a variety of activities.  </b>Many teachers find group instruction
successful when they combine several activities within a class period.  Begin
the lesson with an advanced organizer that "sets the stage" and provides an
overview of the lesson or a link to what was done in previous lessons.  The
lesson can easily combine whole-group, small-group, and individual activities.
Don't forget to end the lesson with a summary or post-organizer.<br>
<br>
<i>Any cautions?</i><br>
<p>Monitoring student response to group instruction is the key to its
effectiveness.  Students will be processing information at different rates and
varying in their participation.  The teacher must always check for
understanding.  Group feedback can be effective for some activities.  However,
individual feedback may also be required.<br><P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Students in the Mainstream">Students in the Mainstream</A></h3>
<P>
<i>What does this accomplish?</i><br>
<br>
<p>To the extent appropriate, exceptional students should be provided education in
the least restrictive environment.  For the majority of ESE students, this
means participation in mainstream programs with their peers. <P>

<i>Who benefits?</i><br>

<p>ESE students can benefit from both the instructional and socialization
opportunities available through placement in regular classes.  For some,
accommodations may need to be provided  in terms of instructional methods,
communication modes, and assessment procedures.<br>
<br>
<br>
<i>How do you make this work?</i><br>
<br>
<p>A structured process has been widely used in Florida to promote the
successful integration of exceptional students in mainstream classes.
Cooperative Consultation (Riegel, 1988) provides a set of easy to use
checklists and forms through which exceptional education and mainstream
teachers can assess needs and plan realistic alternatives for students
encountering difficulty in the school setting.  The process facilitates open
communication among the professionals and with the students.  The result is a
shared responsibility for implementing alternatives and monitoring the outcomes
for the student.  The process requires the following steps:  <br>
<br>
<ul>
<li>Assess the ESE student's educational needs.<br>
<br>
<li>Assess the demands of the mainstream environment.<br>
<br>
<li>Determine any modifications or accommodations needed for the ESE
student.<br>
<br>
<li>Monitor the implementation of the modifications and the progress of the ESE
student.<br>
<br>
</ul>
<i>Any cautions?</i><br>
<br>
<p>Mainstreaming works well when the mainstream teacher, the ESE teacher,
and the ESE student have clearly communicated and agreed upon their
expectations and responsibilities.  When success is left to chance, results are
generally uneven.  <P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h2><A NAME = "Managing the Classroom">Managing the Classroom Environment</A></h2>
<P>
<p>The way you organize your classroom will contribute to the management of
instruction.  Furniture arrangement, access to equipment and materials, and
organization of materials all play key roles in managing the classroom
environment.<P>
[<A HREF="#Scheduling">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Planning the Environment">Planning the Environment</A></h3><p>

As you begin to think about organizing your classroom, here is a list of
things you may want to consider.<br>
<br>
<i>Take stock of what you will need.</i><br>
<br>
<ul>
<li>How many students will be in the classroom at a time?<br>
<br>
<li>Will there be an aide or volunteers?<br>
<br>
<li>What equipment and furniture is assigned to the room?<br>
<br>
<li>What instructional materials are available?<br>
<br>
<li>How can I get furniture, equipment, or materials I need?<br>
<br>
</ul>
<br>
<i>Organize your space.</i><br>
<br>
<ul>
<li>What kinds of working spaces will be needed?<br>
<br>
<li>How can the space be divided to accommodate the different kinds of
instructional activities that are used?<br>
<br>
<li>How can the furniture be used to create different areas in the room?<br>
<br>
</ul>
<cite>From <i>VE Teacher Handbook, </i>Polk County, draft, 1993</cite><br>
<P>
[<A HREF="#Scheduling">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Arranging the Furniture">Arranging the Furniture</A></h3>
<P>
Because of the wide variability in classroom size and location, no
single arrangement for desks and centers will work in all VE classrooms.  The
following arrangements are provided to represent the typical types of
classrooms and the advantages and disadvantages are listed to help teachers
decide which arrangement works best for them (adapted from <i>The Solution
Book</i>, SRA).<br>
<br>
<b>CLASSROOM STYLE</b><br>
<br>
<br>
<IMG align=center SRC="DOC71.gif"><br>
<br>
<u>Benefits</u><br>
<p>This arrangement has been the traditional arrangements in classrooms for
many years.  It places the teacher at the head of the classroom and faces all
students to the center of instruction.  It is an efficient use of space, and
may be used to keep individual desks away from learning centers, computers, or
other special features in the classroom.  When large group instruction and
presentation by the teacher is the most frequently used format, this style is
preferred.<br>
<br>
<u>Problems</u><br>
<p>When students are arranged in rows, the students at the back of the
classroom may have difficulty seeing the chalkboard or other visual aids in the
front of the room.  Students also may be too close together for independent
work, and behavior problems may result.  <br>
<b>CLUSTER STYLE</b><br>
<br>
<br>
<IMG align=center SRC="DOC72.gif"><br>
<u>Benefits</u><br>
<p>Grouping desks in clusters can be used in classes to support cooperative
learning activities, and team work.  In many VE classes, there are small groups
of students who are working on the same level, and this classroom arrangement
could facilitate their instruction.  Praise can be delivered to groups of
students as well as to individuals.  <br>
<br>
<u>Problems</u><br>
<p>This arrangement may require more classroom space and leave little room
for learning centers or other special classroom areas.  Because students are
facing each other, behavior problems sometimes occur during independent work
time.  Dividers may need to be used to partition the workspace.  When whole
group instruction is used, students may not all be facing the same direction.
<br>
<br>
<b>BOARDROOM STYLE</b><br>
<br>
<IMG align=center SRC="DOC73.gif"><br>
<br>
<u>Benefits</u><br>
<p>Grouping desks is sometimes necessary when classroom space is limited.
This works well when students are all working together on the same project or
when students can work well independently.<br>
<br>
<u>Problems</u><br>
<p>Like cluster style, the arrangement sometimes results in behavior
problems during independent work because students are facing each other.
Students may also have difficulty receiving individual help from the
teacher.<P>
[<A HREF="#Scheduling">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Organizing Instructional Materials and Supplies">Organizing Instructional Materials and Supplies</A></h3>
<P>
Think about how you will arrange and file your instructional materials
so that you, your assistants, and your students can easily access what is
needed.<br>
<br>
<ul>
<li>Where and how will you store textbooks, workbooks and other materials that are
being used?  What about the things you don't need right now?<br>
<br>
<li>How will worksheets be filed?<br>
<br>
<li>How will supplies be stored?<br>
<br>
</ul><P>
[<A HREF="#Scheduling">Managing the Classroom Environment</A>] <P>
<HR>
<p>Information on <A HREF = "BEES7C.HTM"><i>Storing Textbooks, Workbooks, and Other Materials</i></A> is also available.<P><P>
<P>[<A HREF="bees7a.HTM">Previous section</A>]   [<A HREF="bees7c.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<pre>








</pre>
</body></html>




























</DOC>
<DOC>
<DOCNO>WT01-B04-192</DOCNO>
<DOCOLDNO>IA039-000740-B042-166</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees7c.HTM 198.78.22.165 19970210073912 text/html 23286
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:4 GMT
Last-modified: Tuesday, 5-Mar-96 22:4:29 GMT
Content-length: 23030
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 --><A NAME = "Home"><TITLE>Resources for VE Teachers</TITLE></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees7b.HTM">Previous section</A>]   [<A HREF="bees7d.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<A NAME = "#Storing"><h1>Effective Practices for Varying Exceptionalities Classes</A></h1>
<HR>
<DL>
<h2>Managing the Classroom Environment</h2>
<DL>
<LI><A HREF = "#Storing">Storing Materials</A>
<LI><A HREF = "#Filing Worksheets">Filing Worksheets</A>
<LI><A HREF = "#Learning Centers">Learning Centers</A>
</DL></DL><P>

<DL><h2><A NAME = "#Managing Behavior">Managing Behavior</A></h2>
<DL>
<LI><A HREF = "#Managing Behavior">Managing Behavior</A>
<LI><A HREF = "#Behavior Management System">Behavior Management System</A>
<LI><A HREF = "#Establishing Classroom Rules">Establishing Classroom Rules</A>
<LI><A HREF = "#Implementing Classroom Rules">Implementing Classroom Rules</A>
<LI><A HREF = "#Maintain the Momentum">Maintain the Momentum</A>
</DL></DL><P>

<DL><h2>Other Management Techniques</h2>
<DL>
<LI><A HREF = "#RR for Students">R &amp; R for Students</A>
<LI><A HREF = "#Keeping Track of the Students">Keeping Track of the Students</A>
<LI><A HREF = "#Silent Signals">Silent Signals</A>
<LI><A HREF = "#Rewards Consequences">Rewards &amp; Consequences</A>
<LI><A HREF = "#Another Level System">Another Level System</A>
<LI><A HREF = "#Token Economies">Token Economies</A>
<LI><A HREF = "#More Reward Systems">More Reward Systems</A>
</DL></DL><P>
<HR>
<pre>




























</pre>
<H3><A NAME = "Storing">Storing Textbooks, Workbooks, and Other Materials</H3><P>

For books that must be easily available, teachers have found it helpful to
arrange areas on bookshelves.  By placing dividers about every 12 inches, books
can be easily put into the "cubbyholes."  Use plastic colored tape to code the
books by level or by subject area, so that matching their storage locations is
easy.  This same coding system could be used in other ways, perhaps to identify
materials for individual students.<P>
 
Workbooks with soft covers will survive longer if placed in plastic report
covers or if their covers are laminated.  Some report folders have a clear
front and solid back with a three-ring holder.  Have three holes drilled in the
workbooks so that they can be inserted in the folders easily.<P>

Books that are not currently needed are best stored out of the classroom.  It
may be possible to find a colleague who needs them.
<P>

[<A HREF="#Home">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Filing Worksheets">Filing Worksheets</A></h3><P>

Having access to a variety of worksheets can save the VE teacher a lot
of time.  But the key time-saver is having a system for filing so that the
worksheets can easily be retrieved.<br>
<i>Here's a system that works!  </i><br>
<br>
<p>Collect all loose worksheets and place all duplicate copies together in
individual files.  Take the original or best copy of each and number it
sequentially, so that each unique worksheet has a different number and there is
a numbered corresponding file folder with the duplicates.  <br>
<br>
<p>The originals can then be sorted by topic or skill and placed in three ring
notebooks.   You will have notebooks of worksheets for math skills, spelling
practice lessons, science concepts, etc. that you can scan easily to find just
the right one.  With the numbering system, you can go to your files and, by
matching the number, locate enough copies of the worksheets for your
students.<br>
<br>
<p>If you find that a worksheet fits in more than one category, just make enough
"originals" to place it in all appropriate notebooks.  If you are concerned
about putting holes in your originals to place them in the notebooks, put them
in the plastic sleeves that can be put in notebooks.</h3><P>

[<A HREF="#Home">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Learning Centers">Learning Centers</A></h3><P>

<p>Most teachers think of learning centers for elementary schools, but many
secondary teachers also find the concept very useful.  Learning centers are
used primarily to provide independent activities for students.  They can
provide a structured exploration of a specific subject, topic, skill, or
interest area.  The following are characteristics of a learning center:<br>
<br>
<ul>
<li>A learning center is self-instructional.  When designed properly, no direct
supervision of a teacher is required.<br>
<li>A learning center can present activities on a variety of levels of
difficulty.<br>
<li>A learning center should have clear objectives.<br>
<li>A learning center must include some method of record keeping for student
participation and accomplishment.<br>
<li>Students need to be taught how to use a learning center.<br>
<li>A learning center should be considered as a place where learning occurs, not
as a place for recreation.  <br>
(From <i>VE Teachers Handbook, </i>Polk County, draft, 1993)<br></UL><P>

[<A HREF="#Home">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Managing Behavior">Managing Behavior</A></h3><P>

<p>The VE teacher must be able to manage the behavior of the diverse group of
students in the class.  <i>Behavior management is a system, method or technique
that enables students to understand and respond appropriately to school and
teacher expectations</i>.  A behavior management plan also helps students
become aware of their own need to belong by choosing appropriate behaviors to
achieve a special place in the classroom.<br>
<br>
<p>The purpose of establishing a sound behavior management plan in the classroom
is to enable students to be successful intellectually, socially and
emotionally.  Guiding and nurturing students in these areas enable children to
grow up to become independent, creative, problem-solving citizens.<P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Behavior Management System">Behavior Management System</A></h3><P>


<i>How do you develop a behavior management system?</i><br>
<br>
<p>To develop a successful behavior management system, several steps should be
followed.  They include the establishment of a set of classroom rules,
guidelines for implementation, and, if needed, a well-defined set of rewards
and consequences.<P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Establishing Classroom Rules">Establishing Classroom Rules</A></h3><P>

<i>How to Establish Classroom Rules</i><br>
<br>
<ol>
<li>Develop a maximum of five rules for your classroom.  Be sure they
correlate with school and district codes of conduct.<br>
<li>State the classroom rules positively.<br>
<li>Post the classroom rules in all four corners of the room on the first day of
school.<br>
<li>Include the classroom rules in a letter to parents and have parents sign and
return it to indicate their understanding and full cooperation for their
child's success.<br>
<li>Teach the classroom rules directly and review them for seven days, stating
the rationale and life value of each.<br>
<p>Some instructional activities that can be used include role playing or
dramatization, drawing pictures to illustrate the classroom rules, or
teacher-directed instruction to make sure that students can recognize and
demonstrate behaviors that follow the rules.  You may also find it helpful to
make sure that students recognize behaviors that do <i>not</i> follow the
rules.<br>
<li>Here are some examples of classroom rules:  <br>
</ol>
<pre>
	Give your best effort daily.
	Listen when the teacher or someone is talking.
	Raise your hand if you have something to say or to ask.
	Cooperate and get along with others.
	Complete all of your work. </pre><P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "Implementing Classroom Rules">Implementing Classroom Rules</A></h3><P>
<i>How to Implement Classroom Rules</i><br>
<br>
<ol>
<li>Be consistent.  Set standards and expectations and follow them.<br>
<li>Follow through with rewards and consequences that are realistic and
appropriate.<br>
<li>Provide both positive and corrective feedback to students and parents.<br>
<li>Provide ongoing parent/teacher communication on a daily or regular basis
depending on the severity of problems and needs of individual students. <br>
<li>As needed, go back to "square one."  Reteach the classroom rules directly
and review them for several days stating the rationale and life value of
each.</OL><P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Maintain the Momentum">Maintain the Momentum</A></h3><P>

<i>How to Maintain the Momentum (or How do I survive in this classroom?)</i><br>
<br>
<ul>
<li>Whenever a student breaks a rule, use <i>verbal correction</i>.<P>
Example:  "Carol, I see you talking.  What's the rule about talking?"  Wait
for response.  "What will you do in the future if you want to talk?  Repeat
that one more time." (Student verbalizes rule three times.)  If student says
she forgot, child should read rule from the chart and write that rule three
times.  <br>
<li>Whenever a student breaks a rule and refuses to comply with your directions,
use the <i>broken record</i> technique.  The teacher repeats the rule concisely
until student cooperates. <br>
<li>Whenever the "broken record" technique doesn't work, use the <i>choice
technique</i>.  Offer the student a choice of two things he may do, both of
which are acceptable to the teacher. It's recommended that one of the choices
be obviously more appealing to the student.<br>
<li>Whenever choice does not work, remove the student from the group until he or
she can act appropriately.  This is a form of <i>time out</i> that keeps the
student in the classroom.  Advance the student through the steps only as
necessary.<br>
	Step 1: Move chair away from the group, but facing the group so the student
can observe appropriate behavior.<br>
<br>
	Step 2: Leave the student where he or she is but turn the chair facing away
from the group.<br>
<br>
	Step 3: Isolate the student from the group but within view of adult.<br>
	Step 4: Have student draw or write responses to three questions:<br>
<br>
<i>		What did I do that put me in time out?</i><br>
<br>
<i>		What am I going to do in the future so this won't happen again?</i><br>
<br>
<i>		What did I miss as a result of being in time out?</i><br>
<li>Assess the student's needs, interests, and behavior patterns and
jointly construct a behavioral contract that specifically states what is
expected of the student.<br>
<li>Contact the parents and get them to sign and support contract agreement.<br>
<li>As a last resort, send student to the office where another alternative may be
considered. <br><P>
</ul></UL></DL><P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "RR for Students">R&amp; R for Students</A></h3><P>

To ensure a safe learning environment for all students, you may wish to
institute R&amp;R for students.  An area of the classroom is designated as
R&amp;R -- Rest and Return -- and is available to any students who feel the
need to cool down and collect their thoughts when their behavior has gotten out
of control.  Generally a two-minute stay in R&amp;R is sufficient for this
purpose.<br>
<br>
<p>If the student won't voluntarily go to the R&amp;R area, he or she is asked by
the teacher to put his head down on the desk for a specified time (e.g., three,
five, or ten minutes). <br>
<br>
<p>If the behavior persists or worsens, the student may be asked to leave the
classroom for a brief time and return when ready to participate.  If this is
required, it is recommended that someone, an aide or responsible student,
accompany the student to the alternative area.  Make sure that arrangements
have been made ahead of time for this type of crisis intervention.<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>


<h3><A NAME = "Keeping Track of the Students">Keeping Track of the Students</A></h3><P>

<p>On a paper attached to a magnetic board, the names of class members are listed.
When a student leaves the classroom, he or she places a single magnet next to
his/her name to indicate the reason for being out of the classroom for a short
period. These reasons may include restroom, mainstream class, therapy, etc.
When the child returns, the magnet is placed at the bottom of the list
indicating re-entry to the classroom.  This places the responsibility on the
students to manage their own coming and going in the classroom.  Additional
contingencies could be set up: for example, limiting the number of students
going out to the restroom at one time.<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<P>
<h3><A NAME = "Silent Signals">Silent Signals</A></h3><P>

Sign language can be used for general requests in the classroom.  There is a
signal students may use to sharpen their pencils, get a drink of water, or go
to the bathroom.  This decreases the problem of being interrupted while
conducting a lesson.  You can signal to the child to go ahead without stopping
your lesson with the individual group.  If you don't know sign language,
contact your district coordinator for hearing-impaired programs or your local
FDLRS Center.<P>

(from <i>Lynn Barbieri, Citrus County</i>)<br>
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Rewards Consequences">Rewards &amp; Consequences</A></h3><P>

A <i>level system</i> can be used for behavior management.  The system must be
developed in conjunction with the classroom rules and behavioral expectations
for the students.  Positive reinforcement is provided for behavior that follows
the rules and meets the expectations.  <br>
<p>In most level systems, a <i>point system</i> is developed to provide concrete
indicators to students.  Points are awarded to students on a regularly
scheduled basis throughout the day or week.  For example, the classroom day may
be divided into 30-minute intervals and a timer set to notify the teacher and
students.  In secondary schools, regular class periods serve as convenient
intervals.  <P>

<p>Points may be awarded for each classroom rule a student follows, and
percentages may be calculated to determine how well the student is doing.  For
some students, the percentages may be calculated to show what percent of time
the student is following each rule.  For other students, the percentages may be
calculated to show what percent of the rules are being followed.   The rewards
are based on the percentages: the higher the percentage, or the higher the
number of days the percentage was reached, the higher the level of reward.
Generally, the levels and rewards are determined once a week, although a daily
schedule may be needed for some students.<br>
<br>
<p>Most teachers identify several behavioral levels for reinforcement.  The levels
are defined in terms of privileges that the student earns.  Privileges can be
adjusted according to the student's interests.  <br>
<br>
Level 1.  Student's behavior is appropriate less than 80 percent of the time.
<br>
	No privileges.  Student has no choice in activity or free time.  Student may
not attend outside activities or field trips.<br>
	<br>
Level 2.  Student maintains appropriate behavior 80 percent of the time.<br>
	Student may select art or music centers, manipulatives, computers, or other
free-time activity.  Student may attend outside activities and field trips.<br>
<br>
Level 3.  Student maintains appropriate behavior 90 percent of the time.<br>
	Privileges are the same as for Level 2, plus student may go to media center,
run errands, or be a peer tutor. <P>
(from <i>Phil Carlson, Palm Beach County</i>)
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Another Level System">Another Level System</A></h3><P>

Students "make their day" by earning a certain percentage of points.  Once they
make ten days, students earn a reward (snack out of classroom school store).
Students advance to the next level after earning ten days on the current level.
They are also able to earn pro-social points for appropriate pro-social
behaviors.  Each pro-social point is worth $.05 which can be spent in the
classroom store.  <br>
<br>
<p>Individual point sheets are developed for each student with targeted short term
objectives from student's IEP.  These sheets are updated every two months.
This helps the teachers, aides, parents, and students stay focused on the
instructional objectives.  Points are posted daily and discussed. Points are
tallied daily and recorded on a point sheet that is sent home for parent
signature and returned the next day.  <P>
(from <i>Ann Campbell and Vicki Emo, Leon County</i>)<br>
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Token Economies">Token Economies</A></h3><P>

<p>Token economies are often used in connection with level systems for behavior
management.  However, they can stand alone.  Here are some examples of
economies that have worked in VE classes.<br>
<br>
<p>Students <i>earn play money for following classroom rules</i>,
<i>participation, completing assignments, etc</i>.  Students may also be fined
when rules are broken.  If they don't have enough money to pay their fines,
they receive chips from the teacher.  The chips serve as an IOU.  A red chip
equals $1.00.  A black chip equals $5.00.  As students earn money later in the
day or the week, a student must first pay off his/her fines.  The classroom
bank is displayed on one bulletin board.  "Baggies" are kept on this bulletin
board with students' names on them to hold deposits and IOU chips.   Money can
be used to purchase items from classroom store which is displayed on another
bulletin board.  Money could also be used for classroom or department auctions,
McDonald's Certificates, or earning privileges.<P>
(from <i>M. Wolf, Marion County</i>)<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "More Reward Systems">More Reward Systems</A></h3><P>


<b>More Reward Systems</b><P>
<p>Students earn $20 of<i> "good behavior money"</i> for every 10 minutes they
stay on task within the hour in the classroom.  An activity period is allotted
on Friday for good behavior money earned.  Good behavior dollars are produced
in neon colors in different currencies and bear the school logo. <br>
<br>
(from <i>Nanette Standfast, Pinellas County</i>)<P>
<p>To promote a positive behavior management system, students are given an<i>
A,B,C certificate</i> for good academics, behavior, or citizenship on which
they write their names.  At the end of class, students fold their awards in
half and place them in a box.  At least once a week a name is drawn from the
box.  This lucky student can exchange the A,B,C certificate for a tangible
award such as a small game, juice box, etc.  The A,B,C certificates reinforce
specific behaviors immediately and give students an opportunity to be drawn as
a chosen ticket.  The more A,B,C certificates earned, the better the student's
chances in the ticket drawing.  <br>
<br>
(from <i>Terri Partlow, Orange County</i>)<P>
<p><i>"Kind Acts and Good Deeds Jar" </i> Students have 10 - 15 name cards in an
envelope at their desk.  Whenever they do a kind act or good deed, they are
allowed to place their name in the jar.   This can also be used to reward
appropriate responses to bad situations.  Whenever they do their best to
respond to a negative situation in a positive manner, they whisper the
situation to the teacher and explain how they have tried to handle the
situation positively.  Examples:  ignoring rude comment, not hitting back after
being hit first, etc.  The teacher then asks students to place their names in
the jar for positive behavior responses.  Each Friday 3-5 names are selected
from the can for special recognition or reward.<P>
(from <i> Trina Cassidy, Orange County</i>)<P>

[<A HREF="#Home">Other Management Techniques</A>]   <P>

Information on <A HREF = "bees7d.HTM"> Using Aides, Volunteers, and Peer Support</a> is also available.<P>

<HR><P>
<P>[<A HREF="bees7b.HTM">Previous section</A>]   [<A HREF="bees7d.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]

<pre>









</pre>
</body></html>





















</DOC>
<DOC>
<DOCNO>WT01-B04-193</DOCNO>
<DOCOLDNO>IA039-000740-B042-24</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees7d.HTM 198.78.22.165 19970210073750 text/html 9912
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:5 GMT
Last-modified: Tuesday, 5-Mar-96 22:4:49 GMT
Content-length: 9657
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 --><A NAME = "Home"><TITLE>Resources for VE Teachers</TITLE></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees7c.HTM">Previous section</A>]   [<A HREF="bees8.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<h1>Effective Practices for Varying Exceptionalities Classes</h1><P>
<DL><A NAME = "#Using Aides"><h2>Other Management Techniques</A></h2>

<DL>
<LI><A HREF = "#Using Aides">Using Aides, Volunteers, and Peer Support</A>
<LI><A HREF = "#Common Concerns">Common Concerns</A>
<LI><A HREF = "#Teacher Aides">Teacher Aides</A>
<LI><A HREF = "#Volunteers">Volunteers</A>
<LI><A HREF = "#Peer Support">Peer Support</A>
</DL></DL><P>
<HR>
<pre>





























</pre>
<h3><A NAME = "Using Aides">Using Aides, Volunteers, and Peer Support</a></h3><P>

<p>An extra hand is always needed in a VE class.  Many teachers are fortunate
to have aides or paraprofessionals assigned to their classes.  Some teachers
use the school volunteer program to lend a hand.   Students can also be a
welcome source of assistance to teachers.  This section provides some
recommendations for ensuring success with assistants in the classroom.</i>
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Common Concerns">Common Concerns</A></h3><P>

<i>Who's in charge?  </i>The most common problem faced when bringing aides and
volunteers into the classroom involves their authority.  Often the students in
a VE class do not respect the direction provided by someone other than their
teacher.  VE teachers must show the students that aides and volunteers have
their complete support.<P>

<i>Recognition for Effort  </i>It is strongly suggested that aides, volunteers
and peer support receive recognition on a regular basis. These individuals
should be reinforced for their efforts.  They should know that their efforts
have been valuable and have contributed to the development and progress of the
children they have helped.<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Teacher Aides">Teacher Aides</A></h3><P>

Teacher aides are members of the instructional staff at the school.  Some
districts use different titles for this job, but generally the aide's job is to
assist the teacher.  Duties may include administrative and clerical tasks,
arranging the classroom environment for learning, instruction-related
responsibilities, and supervisory activities with students.  <br>
<br>
<p>The teacher aide will need both knowledge and skill training to work
effectively in a VE classroom.  The school district, often in collaboration
with the regional FDLRS center, can make training available to teacher aides.
It is suggested that the aide be involved in an inservice training prior to
working with the  students in VE classes. This training should involve a basic
understanding of child growth and development and a general knowledge of
educational approaches to learning.  They will need to have an understanding of
the basic causes and characteristics of handicapping conditions for students
with whom they work.  They must understand the purpose of Individual
Educational Plans and how they are developed and carried out. <br>
<br>
<p>The specific duties of teacher aides varies from district to district.  Certain
restrictions may be placed on the range of duties assigned based on the source
of funding.  If aides are paid from federal IDEA funds, they may not provide
services to students who are not eligible for exceptional student education,
nor may they work with gifted students.  <P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Volunteers">Volunteers</A></h3><P>

Volunteers are recruited from the community to assist in classrooms.  Most
districts and schools have an organized program to facilitate this effort.
However, volunteer programs may not always be utilized in VE classes.
Sometimes ESE teachers feel that volunteers may not be suited for their
programs.  This is certainly not true.  What is needed, is volunteer selection
and preparation procedures that insures their awareness of the characteristics
of the students in VE classesand their readiness to respond appropriately.

<p>In many situations, volunteers may have duties that are similar to those of the
teacher aides.  However, they usually have not been specifically trained for
their role and the time they have to spend in the classroom is generally more
limited.  The volunteer may assist with preparing materials for the classroom,
filing student work, and providing important personal contact with students.<br>

<p>It is suggested that volunteers spend some time in the classroom before
committing to the job. Training is also recommended to prepare volunteers to
work with the students appropriately.
<P>
<i>Where can volunteers be found?</i><P>

If you don't have a ready source of volunteers for your classroom, try
these sources:<P>
<ul>
<li>Church groups and service clubs in the community<P>
<li>Business partnerships who provide release time for employees to serve as
mentors and volunteers in school programs<<P>
<li>Senior-citizen groups<P>
<li>Community college and university training programs<<P>
</ul><P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Peer Support">Peer Support</A></h3><P>

The use of students to provide assistance in the VE classroom benefits both the
ESE students and the student volunteers.  In some districts, older students
from nearby schools may earn credit by assisting in these classrooms.  Peer
support can also involve students from within the VE classroom or from regular
education classrooms in the school. The student assistant can provide
instructional assistance and be a positive social influence.<P>

<H4>Selection of Students for Peer Support</H4><P>

Peer support students can be selected by an interest survey and teacher
recommendation.  Some high school service clubs may be interested in sponsoring
a student assistance program.  It may be possible to recruit peer support
students from within the VE classroom.  Older, more mature students can serve
as respected role models.  Students will need structure and training to serve
effectively as a peer support.  The teacher should carefully select these
students. The factors that should be considered include reliability,
compatibility, behavior, and willingness to make a commitment.<P>

The following are examples of peer support programs that teachers in Florida
have used.<P>

<H4>Reading Buddies</H4><P>

Once a week ESE students meet with their reading buddies from first grade.
Each pair or threesome take turns reading their book to the other students.
This stimulates students' interest in reading as they have a direct, interested
audience. <P>

(from <i>Trina Cassidy, Orange County</i>)<P>

<H4>Mentors for Visually Impaired Students</H4><P>

Regular-education students are enrolled in a specially designed program
to assist visually impaired students in the mainstream setting.  As mentors,
they help the vision teacher by working with visually impaired high school
students and also travel to middle schools to provide reader services, large
print work, graphic details, and personal life experiences.  The regular
education students earn credit for their work.  Such a program can easily be
adapted for all types of students with disabilities. <P>

(from <i>Sandi Serventi, Leon County</i>) <P>

<H4>Peer Facilitators for the ESE Reading Program</H4><P>

A partnership between peer facilitators, ESE students, and teachers is
established to assist in the ESE reading program.  The peer facilitators are
specially chosen for patience, willingness, academic levels, character, and
dependability and work under the supervision of the guidance counselor.  ESE
students are chosen by reading level, desire to improve, and basic need, and
work under the supervision of the ESE teacher.  Peer facilitators and ESE
students work together to practice reading skills and enhance reading
abilities.  <P>

(from <i>Kay Dorsey, Citrus County</i>)<P>
[<A HREF="#Home">Other Management Techniques</A>] <P>

Information on <A HREF = "bees8.HTM"> Staffing Considerations for VE Placement </a> is also available.
<P>
<HR>
<P>[<A HREF="bees7c.HTM">Previous section</A>]   [<A HREF="bees8.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]

</body></html>























</DOC>
<DOC>
<DOCNO>WT01-B04-194</DOCNO>
<DOCOLDNO>IA039-000740-B041-296</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees8.HTM 198.78.22.165 19970210073708 text/html 24871
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:6 GMT
Last-modified: Tuesday, 5-Mar-96 22:5:16 GMT
Content-length: 24615
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 --></head>
<TITLE>Resources for VE Teachers</TITLE>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<A NAME = "Home">

<P>[<A HREF="bees7d.HTM">Previous section</A>]   [<A HREF="bees9.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<h1><A NAME = "#Staffing Considerations">Staffing Consideration for Placement in Varying Exceptionalities Classes</A></h1>
<DL>
<LI><A HREF = "#Individual Educational Plans">Individual Educational Plans</A>
<LI><A HREF = "#Supporting the Placement">Supporting the Placement of Students</A>
<LI><A HREF = "#Ongoing Review">Ongoing Review and Monitoring of Placement</A>
<LI><A HREF = "#Dealing with Parental">Dealing with Parental Concerns</A>
</DL><P>
<HR>
<pre>




























</pre>

<h3><A NAME = "Individual Educational Plans">Individual Educational Plans:  Identifying Individual Student Needs</A></h3><P>

In developing Individual Educational Plans (IEPs) for students with
disabilities, a variety of factors are taken into consideration to determine
which regular and special education services are needed by the individual
student.  The same factors are used for placement in a VE class.  This section
provides a brief description of the factors.  These factors can be readily
translated into guidelines appropriate to the specific use of the VE model in a
district or school.<P>

<h4>What are the factors? </h4><P>
<b>At what level is the child currently functioning?</B><P>

<h4>Functional level/Curriculum Needs</h4>
<p>
Review the child's level of achievement or           
functioning for all of the specific developmental    
                          domains, and academic or vocational areas.  Use      
                          both standardized test scores and reports of         
                          classroom teachers.  Only current test results       
                          that are considered to be a valid reflection of      
                          the child's achievement should be used to            
                          determine the functional level.  Frequently,         
                          group-administered achievement tests do not          
                          accurately reflect the capabilities of exceptional   
                          students.  
<p>
Observations of classroom behavior and    
                          input from the child's current teachers can          
                          provide critical information.  A review of both      
                          regular and special education classroom              
                          performance should be taken into account.            
                          Determine how well the student functions in a        
                          large group situation; how well the student can      
                          meet the demands of homework, independent            
                          assignments, and the social and behavioral           
                          expectations of the environment.
<P>
<h4>Curriculum needs and Pupil-Progression Plan</h4>
<p>
Determine if the child's needs are best met through the requirements of the regular              
                          pupil-progression plan or through the special        
                          pupil-progression plan for exceptional students.     
                          This will involve selecting the type of curriculum   
                          and, for secondary students, selecting the type of   
                          diploma.   Generally, the academic curriculum has    
                          been effective for exceptional students who are      
                          considered high-functioning or mildly handicapped.   
                          The functional life-skills curriculum is generally   
                          selected for low functioning students.               
<P>
<h4>Medical needs/Physical Impairment</h4>
<P>   
Determine need for any support services for medical needs or accessibility requirements due to   
                          physical limitations.                                
<P>
<h4>Behavior and Independence</h4>              
<P>
Consider the child's capacity for functioning independently in the school;  review the child's     
                          history in terms of self-regulation and behavior     
                          control.  

<p>Can a behavior management plan be          
                          reasonably implemented in the targeted setting?      
                          How will the child's behavior impact the others      
                          already in the classroom?  

<p>Can the child make        
                          appropriate decisions independently?  Is a crisis    
                          intervention teacher needed?                         
<P>
<h4>Social Skills</h4>             
<p>
Determine the child's capacity for functioning in    
                          a social environment;  review the child's            
                          relationships with peers and adults.  

<p>
Is a  separate social skills class appropriate for the  student?                                             
<P>
<h4>Long-range Career Plans</h4>   
<P>
For high school students, review career goals and    
 objectives to determine appropriateness of  secondary school placement.                          
<P>
<h4>Parent and Student Input</h4>  
<P>
Input should be obtained from both parents and       
                          students regarding these factors.  Both can          
                          provide information regarding their perceptions of   
                          the student's readiness for the proposed placement. 
<P>
<b>What special services are needed?</b>

<P>
<h4>Related Services</h4>
<P>          
Determine if any related services are required.      
                          This may include counseling, medical services, or    
                          other educationally related services.                
<P>
<h4>Course Modifications</h4>      
<p>
Review the need for course modifications,            
                          including modifications to time, communication       
                          modes, instructional techniques, or assessment       
                          procedures.   
<p>
Determine if needed technology is      
                          available to support the performance of the          
                          student.   
<p>
Consider the use of the Mainstream Cost   
                          Factor to suport consultation between regular        
                          education and ESE teachers.                          

<P>
<h4>Multiple Program Needs</h4>    
<p>
Consider the need for services from exceptional      
                          student education programs, such as speech,          
                          physical or occupational therapy, as well as other   
                          educational programs including Chapter 1, English    
                          for Speakers of Other Languages (ESOL), or           
                          vocational education.                                
<P>
<h4>Transition Services</h4>       
<p>
For high school students, review transition plans.   
                          This may include involvement of other agencies,      
                          such as Developmental Services from Health and       
                          Rehabilitative Services, and Vocational              
                          Rehabilitation from the Department of Labor.         
<P> <b>What are the placement options?                                                  </b>
<P>
<h4>Least Restrictive Environment</h4>        
<P>
Select the most normal educational setting in        
which the exceptional student can profit from the    
                          instruction.   To the maximum extent appropriate,    
                          exceptional students should be educated with         
                          nonexceptional students.  Encourage attendance at    
                          the student's home school, if possible.              
<P><h4>Availability of Delivery Models</h4>
<P>
Review the continuum of delivery models currently    
 available in the district.    
<P>
<h4>Availability of Support Personnel</h4>
<p>
Input may be           
                          obtained from the potential receiving teacher(s)     
                          and district staff.  This should include a           
                          description of the delivery models and               
                          characteristics of students served in each.          
                          Information regarding the  availability of           
                          curriculum and support services should be            
                          provided.                                            
<p>
Determine the ease of providing support personnel,                    if needed, in the targeted setting.                  
<P>

[<A HREF="#Home">Staffing Consideration for Placement</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Supporting the Placement">Supporting the Placement of Students</A></h3>
<P>
An important part of the placement decision made by the staffing committee is
the determination of the ongoing support needed to ensure the success of the
student in the classroom.  The student may require support in a variety of
areas. <P>

<B>Does the student require any specialized equipment?</B><P>

<h4>Adaptive/Assistive Devices</h4>
<P>
Generally provided to students with physical,       
 visual, or hearing impairments.                     
<P>
<h4>Augmentative Communication Devices</h4>
<P>
Check with speech and language personnel for        
availability and appropriateness for individual     
students.  
<P>                             
<h4>Computerized Instructional Systems</h4>
<P>
 Determine if integrated learning system is          
appropriate and available.
<P>
<h4>Electronic</h4>
<P>
 Determine if an electronic tool (word processor, draw program) is essential to        
 student's performance.                              
<P>
<B>Are appropriate textbooks and other resource materials available?</B><P>

<h4>Braille or large-print materials</h4>     
<P>Materials are available through Florida             
Instructional Materials Center and Division of     
                           Blind Services.                                     
<P>
<h4>Materials available through county textbook inventories</h4>        
<br>
<p>Determine if supplementary texts can be provided    
through the district inventory.  Also check the     
Florida Diagnostic Learning Resource Center for     
                           materials on loan.
<br>                                  
<h4>High interest/low vocabulary texts</h4>         
<br>
<p>For students with low reading abilities,            
alternative textbooks might be needed.  Check       
                           availability in other schools or on district        
                           inventory.  
<br>
<p>Materials for developing specific       
                           skills or materials compatible with the regular     
                           curriculum should be sought.                        
<br>
<h4>Hands-on/real life materials</h4>       
<br>
Authentic learning materials may be obtained from   
a variety of sources, including volunteer           
                           services, business partners, etc.  
<br>
<p>These            
                           materials may be critical to meet vocational and    
                           occupational objectives.                            
<br>
<h4>Learning centers</h4>           
<br>
<p>Primarily used in elementary schools, learning      
                           centers may be shared among teachers or schools.
<br>    
<h4>Interactive activities</h4>    

<p>These activities may include an affective           
                           curriculum designed to promote social skills and    
                           decision-making.                                    
<P>
<b>Does the teacher have access to necessary information and skills to work with this student?</b><P>
<h4>Accessibility to student records</h4>          
<p>
Teachers should have access to the   
student records so that all appropriate information is made          
                          available.                                           
<P>
<h4>Parent input</h4>              
<p>
Open lines of communication must be maintained to    
                          ensure parent support.  When parents have input      
                          into the process, they will be more likely to work   
                          in a partnership with the school.                    
<P>
<h4>Staff development programs/Inservice training</h4>
<p>
This may be provided through district level          
program specialists or resource teachers.  A         
support system is needed to help teachers meet the   
                          increasing demands of their classrooms. 
<P>     
<h4>FDLRS library/public library</h4>
<p>
The availability of information through the          
                  library system is a real asset for the exceptional   
                          student teacher.                                     
<P>
<h4>Community Services</h4>
<p>
Teachers must know how to reach community services   
                          including Deaf Services, Division of Blind           
                          Services, Job Training and Placement Agency,         
                          Vocational Rehabilitation, Florida Instructional     
                          Materials Center, Library for the Blind and          
                          Physically Handicapped, Public Health Department,    
                          Social Services.                                     
<P>
<h4>Service Clubs</h4>
<p>
For example, Sartoma, Lions Club, Kiwanis.
<P>
<h4>SpecialNet, FIRN</h4>
<p>
Electronic communication through SpecialNet or       
FIRN can open many networks to the exceptional       
student teacher.                                     
<P>
<h4>University personnel/programs</h4>
<p>Resources available in the university programs can   
be very helpful.  Contact the special education      
                          department or other related areas for assistance. 
<P>   
<h4>District school psychologist, social worker</h4>
<P>
Information and skills can sometimes be provided     
 through district level support personnel.  <P>

[<A HREF="#Home">Staffing Consideration for Placement</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Ongoing Review">Ongoing Review and Monitoring of Placement</A></h3>
<P>
After a placement decision, provision should be made to allow members of the
staffing team to review a student's progress in the new setting within a
reasonable amount of time.   This review may evaluate the appropriateness of
the placement given the child's educational needs and the characteristics of
the class in which the child is placed.
<p>
Whenever requested, the staffing team may reconsider a placement decision and
recommend a more appropriate educational program. <P>
<b>What procedures or guidelines are recommended?</b><P>

Periodic reviews need to be scheduled in order to maintain the
effectiveness of the delivery model. Reviews may occur as often as once a month
with school-based personnel to discuss progress of the student. Parents need to
be included at all levels of review.<P>

Items for Review (Teacher Review)<P>
<ul>
<li>Updated academic information<P>

<li>Classroom observations <P>

<li>Social skills - appropriateness<P>
<li>Behavior management plan<P>
</ul>
If, at any time, the parents, the classroom teacher(s), or school-based
personnel feel the placement is not meeting the child's educational needs, a
staffing review may be conducted. Additional testing may be warranted; support
services or curriculum adjustments may be required; or a new IEP may be
needed.<P>
<b>Who is responsible?</b><P>

The ESE teacher should accomplish these tasks:<P>
<ol>
<li>Review IEP and assess appropriateness of the plan.
<li>Conduct ongoing classroom observations.
<li>Conduct academic assessment.
<li>Review appropriateness of schedule.
<li>Consider motivational factors of the student.
<li>Monitor behavior of the student.
<li>Monitor attendance.
<li>Consult with mainstream teachers, if appropriate.
<li>Communicate with parents, if necessary.
</ol>
<P>
The mainstream teachers should accomplish these tasks:<P>
<ol>
<li>Review course modifications/adaptations.<br>
<br>
<li>Monitor test scores and grades.<
<li>Identify the demands of the setting.
<li>Monitor classroom participation and behavior.
<li>Monitor attendance.
<li>Assess the appropriateness of the curriculum.
</ol>
<P>
The school administration and other support personnel should accomplish
these tasks:<P>
<ol>
<li>Provide support for the various VE delivery models.
<li>Support flexible, innovative instructional models.
<li>Assist with implementation of behavior management plans.
<li>Communicate with parents.<
<li>Follow procedural safeguards when placing students in programs.
</ol>
<P>
The district administration should accomplish these tasks:<P>
<ol>
<li>Review files for current information.
<li>Keep informed about the school situations.
<li>Conduct classroom observations, if requested.
<li>Be available for consultation, curriculum assessments, etc.
</ol>
<P>
The parents should share assessment of home situation, including:<P>
<ol>
<li>behavior at home and in the community
<li>social interaction with peers and siblings
<li>study habits<
<li>changes in routine
<li>after-school activities
<li>motivation
<li>change in career plans
<li>health problems.
</ol>
<P>
The exceptional student should accomplish these tasks:<P>
<ol>
<li>Share perceptions of the classroom situation.
<li>Monitor his or her own academic standing/progress in class.
<li>Assess satisfaction with the program.
<li>Interact appropriately with peers.
<li>Conduct career assessment or make future plans.
</ol>
<P>
<!--insert a graphic of an IEP meeting with several adults and a teen sitting
around a table--><P>

<h3>Conducting Successful Annual IEP Reviews</h3>
<p>
The following suggestions are provided to exceptional student education
teachers to help them prepare for successful IEP review meetings.<P>
<ul>
<li>Come with <i>recommendations</i> for proposed goals and objectives.
<li>Greet parents with a smile and tell them why you have called this meeting
(i.e., to set educational goals for their student for the next year).<br>
<li>Have all participating teachers make positive comments about the student's
past performance.<P>
<li>Have each participating teacher explain the proposed goals for the student.
Make sure the parents and student understand the goals and give them the
opportunity to add others.
<li>If this is the first time the student's placement is in a VE setting, make
sure parents are aware of the configuration of the classroom and the rationale
for placing their student in this setting.
<li>Listen carefully to what the parents and student are saying.  Add additional
information, if appropriate.  You may recommend strategies you have found
successful that can be used at home.
<li>Express any concerns you have in a positive manner.
<li>Thank the parent and student for attending and end the conference with a
positive comment about the student.
<li>Remember:  Follow through on any promises that were made at the conference. 
</ul>
<P>
(Adapted from <i>VE Teacher's Handbook, </i>Polk County, draft, 1993)
<P>

[<A HREF="#Home">Staffing Consideration for Placement</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3>
<A NAME = "Dealing with Parental">Dealing with Parental Concerns</A></h3><P>

The State Board of Education Rule requires parental notification when a student
is assigned to a VE class. Beyond that, there should be a close working
relationship between the parents of an exceptional student and the teacher in a
varying exceptionalities class. The parents should be informed about the
characteristics of and the circumstances within the class, including the class
size, the functional levels of the students, and how this may relate to the
progress of the child.  <P>
<b>How can participation of the parents be encouraged?</b>
<p>
Frequent conferences should be held to discuss the student's progress, and the
parent should always be requested to attend. Parents need an opportunity to
share their ideas and concerns with the school.  If face-to-face conferences
are not possible, telephone conversations may be used.  Stay away from written
communication only.  Keep communication positive in nature.  Keep parents
informed about opportunities for participation in school activities.  They may
be interested in attending group functions such as:<P>
<ul>
<li>Parent Information Night
<li>Field Trips
<li>PTO/PTA participation
<li>School Advisory Councils<
<li>Parent Advisory Councils
</ul>
<p>
Here's a program that works to keep parents involved in the instruction of their children.
<p>
Call the parents of each student in the class at least once before
Thanksgiving.  By dividing up the students by class periods, all parents can be
contacted within a 3-5 day period. If a student has no phone, use a handwritten
letter to communicate.  The calls concentrate on the child's strengths.   The
teacher asks about the student's interests, hobbies and special
accomplishments.  Areas for improvement are then discussed.  Parents can make
excellent suggestions and certainly appreciate the communication.  Laying the
positive background makes it much easier to deal with concerns that might
occur. <P>
(from <i>Doris Wayte, Pinellas County</i>)<P>

<b>How can parents' concerns about the varying exceptionalities class be
addressed?</b><P>
<ul>
<li>Invite the parents to visit the VE classroom.
<li>Encourage parents to spend time talking about the class with the students and
the teacher.
<li>Encourage the parent to talk with other parents of students already in the
class.
<li>Make all curriculum materials available for parental review.<
<li>Create brochures explaining the different types of delivery models.
<li>Present  various delivery models at the parent support group meetings to
foster a smooth working relationship with parents.
<li>Create a parent library.
<li>Ask the parent to serve as a volunteer.
<li>Suggest that they seek advice from local or state parent support groups.
<li>Refer them to the Bureau of Education for Exceptional Students/Clearinghouse
Information Center or their local FDLRS center for resources and information.</UL></DL><P>

<P>

[<A HREF="#Home">Staffing Consideration for Placement</A>]  <p>

<P>Information on <A HREF = "bees9.HTM">Contact Persons and Consultation and Training Resources</a> is also available.
<P>
<HR>
[<A HREF="bees7d.HTM">Previous section</A>]   [<A HREF="bees9.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>





















</DOC>
<DOC>
<DOCNO>WT01-B04-195</DOCNO>
<DOCOLDNO>IA039-000740-B041-321</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees9.HTM 198.78.22.165 19970210073726 text/html 1779
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:8 GMT
Last-modified: Tuesday, 5-Mar-96 22:5:36 GMT
Content-length: 1524
</DOCHDR>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 --></head>
<TITLE>Resources for VE Teachers</TITLE>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<A NAME = "Home"></A>
<P>[<A HREF="bees8.HTM">Previous section</A>]   [<A HREF="referen.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<h1><a name="RTFToC1">Support for Teachers</a></h1>
<P>
<h2><a name="RTFToC2">List of Contact Persons and Consultation and Training Resources</a></h2>
<P>
These are potential sources of information for personnel, consultation and training related to varying exceptionalities.  Contact the appropriate personnel in your district.<P>
<ul>
<li>District
<li>Teachers' Union
<li>FDLRS Center
<li>Cooperative Consultation Contact Person
<li>Strategies Intervention Model Contact Person
<li>University Resource
<li>Bureau of Education for Exceptional Students<br>
</ul><P>
<HR>
[<A HREF="#Home">Support for Teachers</A>]  <p>
<HR>
<P>[<A HREF="bees8.HTM">Previous section</A>]   [<A HREF="referen.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]   [<A HREF="cover.HTM">Resources for VE Teachers</A>]

</body></html>
















</DOC>
<DOC>
<DOCNO>WT01-B04-196</DOCNO>
<DOCOLDNO>IA039-000740-B042-47</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/referen.HTM 198.78.22.165 19970210073758 text/html 1939
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:20 GMT
Last-modified: Tuesday, 5-Mar-96 22:7:40 GMT
Content-length: 1683
</DOCHDR>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 -->
<TITLE>Resources for VE Teachers</TITLE></head>
<body>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<A NAME = "Home"></A>
<P>[<A HREF="bees9.HTM">Previous section</A>]             [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<P>
<H1><a name="RTFToC1">References</a></H1>
<p>
Bureau of Education for Exceptional Students, 1987. <i>Florida, A Report of the
Task Force on the Education of Exceptional Students (Varying
Exceptionalities)</i>. Tallahassee:  Department of Education.<p>
<p>
Bureau of Education for Exceptional Students, 1993. <i>Educating Exceptional
Students, Creating Schools for Florida's Future.  </i> Tallahassee:  Department
of Education.<p>
<p>
Pinellas County, (1992) Handbook for VE Teachers, Clearwater, Florida.<p>
<p>
Polk County, 1993. <i>VE Teachers Handbook</i>, (draft)., Bartow, Florida.<p>
<p>
Reigel, R.H., 1988.  <i>A Guide to Cooperative Consultation. </i>Novi,
Michigan:  RHR Consultation Services, Inc.<p>
<p>
Sprick, Randall, "Small group instruction and independent seatwork,"<i> in The
Solution Book,</i> Science Research Associates<p>

[<A HREF="#Home">References</A>]  <p>

<HR>
<P>[<A HREF="bees9.HTM">Previous section</A>]             [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>














</DOC>
<DOC>
<DOCNO>WT01-B04-197</DOCNO>
<DOCOLDNO>IA039-000740-B040-364</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/ 198.78.22.165 19970210072951 text/html 2298
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:11 GMT
Last-modified: Tuesday, 5-Mar-96 22:1:13 GMT
Content-length: 2042
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><BODY BACKGROUND="ccla/paper3.gif">
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<!-- This document was created from RTF source by rtftohtml version 2.7.2 --></head>
<A NAME = "Home"></A>
<A HREF = "TOFC.HTM">
<TITLE>Resources for VE Teachers</TITLE>
<H2><Center>
A Resource Manual
For The Development And
Evaluation of Special Programs
For Exceptional Students<P>
</H2>
<H2>Volume 11-L: Varying Exceptionalities</H2></A>
<hr>
<H3>
Florida Department of Education<P>
Division of Public Schools<P>
Bureau of Education for Exceptional Students<P>
</H3>
<hr>
<H4>1994</H4></Center><p>
This manual was developed by <A HREF ="mailto:beechm@cet.fsu.edu">Dr. Martha C. Beech </A> through an Administrative
Services Grant to Florida Atlantic University, funded by the State of Florida
Department of Education, Division of Public Schools, Bureau of Education for
Exceptional Students, through federal assistance under the Individuals with
Disabilities Education Act (IDEA), Part B.<p>
HTML (Hypertext Markup Language) encoding and Web page design by The College Center for Library Automation<A HREF = "ccla.htm"> CCLA</A> through an SGML (Standard Generalized  Markup Language) Research Grant from the Schoolyear 2000 Initiative.
<P>
<I>Copyright</I><P>
State of Florida<P>
Department of State<P>
&copy 1994<P>
Authorization for reproduction is hereby granted to the state system of public
education as defined in Section 228.041 (1), Florida Statutes.  No
authorization is granted for distribution or reproduction outside the state
system of public education without prior approval in writing,<p>
[<A HREF="#Home">Resources for VE Teachers</A>]  <p>
<HR><P>
 [<A HREF="tofc.htm">Table of Contents</A>]  <P>
</body></html>


























</DOC>
<DOC>
<DOCNO>WT01-B04-198</DOCNO>
<DOCOLDNO>IA039-000740-B040-418</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/ccla.htm 198.78.22.165 19970210073043 text/html 2190
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Thursday, 8-Feb-96 16:49:44 GMT
Last-modified: Tuesday, 5-Mar-96 22:6:19 GMT
Content-length: 1933
</DOCHDR>
<html>
<head>
<BODY BACKGROUND="blue.gif">
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
   <title>The College Center for Library Automation</title>
   <meta name="GENERATOR" content="Mozilla/2.0GoldB1 (Win32)">
</head>
<body>

<div align=center><p><img src="ccla2.gif" border=0  height=90 width =640 align=top ></p></div>

<p>[<a HREF="http://screamer/Cover.HTM">Return to Resources for VE Teachers</a>]
[<a HREF="http://screamer/tofc.htm">Table of Contents</a>] 
<hr></p>

<p>The <b>College Center for Library Automation</b> (CCLA) was created
by the Florida Legislature to enhance and improve the community college
educational experience by providing statewide access to shared library
resources. This access is available via the Library Information Network
for Community Colleges <a HREF="http://bilbo.ccla.lib.fl.us">[LINCC]</a>,
an automated information system connecting Florida's 28 community colleges
and their associated 60 libraries.</p>

<p>CCLA is also working in collaboration with the Schoolyear 2000 (SY2000)
Initiative to create the Knowledge Database. The Knowledge Database is
one component of the SY2000 Electronic System. The SGML Research Grant
is the second phase of the collaborative effort. For more information on
this work, please contact <a HREF="mailto:marvin@lincc.ccla.lib.fl.us">Marvin
Pollard </a>(marvin@lincc.ccla.lib.fl.us) or <a HREF="mailto:janette@coe.uga.edu">Janette
Hill</a> [janette@coe.uga.edu).</p>

<p>[<a HREF="http://screamer/ccla.htm#Home">The College Center for Library
Automation</a>] </p>

<p>[<a HREF="http://screamer/Cover.HTM">Return to Resources for VE Teachers</a>]
[<a HREF="http://screamer/tofc.htm">Table of Contents</a>] </p>

<p>
<hr></p>

</body>
</html>


</DOC>
<DOC>
<DOCNO>WT01-B04-199</DOCNO>
<DOCOLDNO>IA039-000740-B040-392</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/TOFC.HTM 198.78.22.165 19970210073017 text/html 1750
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:21 GMT
Last-modified: Tuesday, 5-Mar-96 22:22:51 GMT
Content-length: 1493
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head>
<!-- This document was created from RTF source by rtftohtml version 2.7.4 -->
<BODY BACKGROUND="beige.gif">
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<TITLE>Resources for VE Teachers</TITLE></head>
<body>

<A NAME = "Home"></A>
<H1>Table of Contents</H1><p>
<DL><A HREF = "bees3.htm"><H3>Preface</H3></A><p>
<A HREF = "BEES4.HTM"><H3>Introduction</H3></A><p>
<A HREF = "BEES5.HTM">
<H3>General Information</H3></A><p>
<A HREF = "BEES6.HTM">
<H3>Uses of the Varying Exceptionalities Model<p></H3></A>
<A HREF = "BEES7a.HTM"><H3>Effective Practices for Varying Exceptionalities Classes</H3></A>
<A HREF = "BEES8.HTM">
<H3>Staffing Considerations for Placement in Varying Exceptionalities Classes</H3></A>
<A HREF = "BEES9.HTM">
<H3>Support for Teachers</H3></A>
<A HREF = "REFEREN.HTM"><H3>References</H3></A></DL><P>
[<A HREF="dtofc.htm">Click here for the Detailed Table of Contents</A>]  <P>
[<A HREF="bees3.HTM">Next section</A>]  [<A HREF="#Home">Table of Contents</A>]   [<A HREF="cover.HTM">Resources for VE Teachers</A>]<P>
[<A HREF="index.htm">Click here to Search for words in the Varying Exceptionalities Resource Manual</A>]  
</body></html>






































</DOC>
<DOC>
<DOCNO>WT01-B04-200</DOCNO>
<DOCOLDNO>IA039-000740-B040-447</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/bees3.htm 198.78.22.165 19970210073154 text/html 5473
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:39:56 GMT
Last-modified: Tuesday, 5-Mar-96 22:1:50 GMT
Content-length: 5217
</DOCHDR>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 --><TITLE>Resources for VE Teachers</TITLE></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees4.HTM">Next section</A>]    [<A HREF="tofc.htm">Table of Contents</A>]    [<A HREF="cover.HTM">Resources for VE Teachers</A>]<P>
<HR>
<h1>Preface</h1><P>
<HR>

This manual has been created in response to the needs expressed by many
varying exceptionalities(VE) teachers in Florida.  Over the past 20 years, the
use of the varying exceptionalities delivery model has increased.  Various task
forces have been formed to examine the issues and concerns and to recommend
practices and policies to ensure appropriate uses of the model. <P>

In 1991, representatives from the Florida Teaching Profession/National
Education Association (FTP/NEA) urged the Department of Education to review the
current policies and practices.  Surveys and interviews were used to gather
input from VE teachers from 17 school districts over two years.<P>  

This manual<i>, Resources for VE Teachers, </i>was developed at the
recommendations of the advisory group formed in response to the FTP/NEA
inquiry.  It is intended to provide information about the use of the VE model
in Florida and to share classroom practices that teachers have found to be
successful.  In Fall, 1992, VE teachers were asked to submit ideas for
inclusion in this manual.  The members of the writing team that met in Spring,
1993. provided valuable input and insight into the contents of this manual and
their special contributions are gratefully acknowledged.  Debbie Houston,
Program Specialist in the Bureau for Education of Exceptional Students, and her
secretary, Myra Orange, also deserve recognition for their facilitation of this
entire effort.<P>

<H4>Writing Team</H4>


<pre>Phil Carlson		ESE Teacher			Palm Beach County
<>Daris Dew		Principal			Sumter County
Kay Dorsey		ESE Teacher			Citrus County
Madaline McFatter	ESE Teacher			Holmes County
Jan Weiss		ESE Teacher			Hillsborough County
Vicki Emo		ESE Teacher			Leon County
Ted Grosse		ESE Supervisor			Polk County
Bill Elkin		ESE Supervisor			Lee County
Marsha Kufel 		Director, FDLRS/Alpha		Palm Beach County
Debbie Stump		ESE Teacher			Okaloosa County
Greg Charles		ESE Teacher			Pinellas County</pre>
<P>
<H4>Thanks, VE Teachers</H4>

This is a list of the teachers and administrators who submitted many
additional ideas that have been incorporated in this manual.  We greatly
appreciate your time and effort.<P>
<b>PreKindergarten</b>
<PRE>Pat Gillette		Lopez Elementary		Hillsborough
Heidi Martin		School not identified		Hillsborough
</PRE>
<P><B>Elementary</B>
<PRE>Lynn Barbieri		Inverness Primary 		Citrus
Sheree Preston	Homosassa Elementary		Citrus
Gwen Dunaway		Pleasant Grove Elementary	Citrus
Marianna Reeves	Crystal River Primary		Citrus
Pat Bush		Poplar Springs Elementary	Holmes
Janet Reynolds	Littleton Academy		Lee
M. Wolf		Ocala Springs Elementary	Marion
Kerry Jones		Shady Hill Elementary		Marion
Catherine Altman	Shady Hill Elementary		Marion
Jodie Watts		South Ocala Elementary		Marion
Terri Partlow		Orange Center Elementary       	Orange
Trina Cassidy		Mollie Ray Elementary 		Orange
Liz Flickinger	Waterbridge Elementary		Orange
Phil Carlson		Grove Park Elementary		Palm Beach
David Frasier		Polk City Elementary		Polk
Barbara Christian	Bethune Elementary		Polk
Lora Lindsey		Garner Elementary		Polk
Kelly Maratea		Snively Elementary		Polk
Sherri Evans		Lake Panasoffkee Elementary	Sumter
Peggy Boyatt 		Bushnell Elementary		Sumter
</PRE>
<b>Middle School</b>
<PRE>
Pam Pate		Crystal River Middle 		Citrus
Vicki Emo		Raa Middle 			Leon
Ann Campbell		Raa Middle 			Leon
Tommi Stetson		Osceola Middle 			Marion
Maureen Fentross	S. Sumter Middle 		Sumter</PRE>
<b>High School</b>
<PRE>
Ellen Smith		Buckingham Except. Stud. Center Lee
Donald L. Payne	Buckingham Except. Stud. Center Lee
Doris Wayte		Dunellon High			Marion
Nancy R. English	Dunellon High			Marion
Ken Campbell		NMHS				Marion
E. Laverne Williams 	Dr. Phillips 9th Grade Center	Orange
Sheila Hoffman	Countryside High 		Pinellas
Nanette Standfast	Osceola Senior High 		Pinellas
Cindy Maschino	Osceola Senior High 		Pinellas
Michael Novarra	Dunedin High 			Pinellas
Charlotte Fox		Tarpon Springs Senior		Pinellas
P. Ross		Seminole Voc. Educ. Center 	Pinellas</PRE>

<b>District</b>
<PRE>
Fay Clark		ESE				Broward
Karl Amundson		ESE				Citrus
Paige French		ESE				Duval
Elsie Parker		Guidance			Escambia
Connie Tzvorras	ESE				Highlands
Roger Landers		ESE				Hernando
Sandi Serventi	ESE				Leon
Janet Morgan		ESE				Manatee
Jean Morris		ESE				Putnam
Carol Robbins		ESE				St. Johns
</PRE>
<HR>
<P>[<A HREF="bees4.HTM">Next section</A>]    [<A HREF="tofc.htm">Table of Contents</A>]    [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>





















</DOC>
<DOC>
<DOCNO>WT01-B04-201</DOCNO>
<DOCOLDNO>IA039-000740-B040-462</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES4.HTM 198.78.22.165 19970210073230 text/html 3279
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:39:57 GMT
Last-modified: Tuesday, 5-Mar-96 22:2:15 GMT
Content-length: 3023
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 -->
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<TITLE>Resources for VE Teachers</TITLE></head><body>

<A Name ="Introduction"></A>

<P>[<A HREF="bees3.HTM">Previous section</A>]   [<A HREF="bees5.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>

<h1><a name="RTFToC1">Introduction</a></h1>


<i><A HREF = "cover.HTM">Resources for VE Teachers</i></A> is designed to provide information about the
use of the varying exceptionalities model and to share ideas and practices that
teachers can use with their students.  <p>
<p>
The first section, <i><A HREF = "bees5.HTM">General Information,</A></i> includes the definition and
State Board of Education rules which apply to the model, as well as brief
descriptions on the history and rationale.<p>
<p>
The second section, <i><A HREF = "bees6.HTM">Uses of the Varying Exceptionalities Model,</A></i> provides
examples of guidelines and policies which have been developed in various
school districts for programs at the prekindergarten, elementary, middle, and
high school level.  Recommendations from previous task forces are summarized in
the description of "Best Practices."<p>
<p>
The third section, <i><A HREF = "bees7a.HTM">Effective Practices in Varying Exceptionalities Classes,
</i></A> is intended to share the practices that many teachers have found to be
effective in meeting the diversity of student needs.  This includes a brief
description of the characteristics of exceptional students,  and suggestions
for scheduling, grouping, and managing the educational environment.  In
response to the many concerns raised by VE teachers, information is also
included on managing behavior and using assistants in the classroom.<p>
<p>
The fourth section, <i><A HREF = "bees8.HTM">Staffing Considerations for Placement in Varying
Exceptionalities Classes,</i></A> is designed to guide the staffing process.  Key
questions and sources of information can be used by teachers to make sure that
all important factors are considered.<p>
<p>
The fifth section, <i><A HREF = "bees9.HTM">Support for Teachers,</i></A> is intended to help teachers
access support at both the state and district level.  The information for the
district level should be added to the appropriate spaces.<P>

[<A HREF="#Introduction">Introduction</A>]<p>

<HR>

<P>[<A HREF="bees3.HTM">Previous section</A>]   [<A HREF="bees5.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]

</body></html>











</DOC>
<DOC>
<DOCNO>WT01-B04-202</DOCNO>
<DOCOLDNO>IA039-000740-B040-478</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES5.HTM 198.78.22.165 19970210073250 text/html 13867
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:39:58 GMT
Last-modified: Tuesday, 5-Mar-96 22:2:49 GMT
Content-length: 13610
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version 2.7.2 --></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<TITLE>Resources for VE Teachers</TITLE>
<A NAME = "General Information"></A>
<P>[<A HREF="bees4.HTM">Previous section</A>]   [<A HREF="bees6.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>


<H1>General Information</H1>
<br>
<DL>
<LI><A HREF = "#Definition">Definition</A>
<LI><A HREF = "#History">History of the Varying Exceptionalities Model</A>
<LI><A HREF = "#Why Use">Why Use the Varying Exceptionalities Model?</A>
<LI><A HREF = "#State Board of Education Rule">State Board of Education Rule</A>
<LI><A HREF = "#Certification Requirements">Certification Requirements for Teachers</DL></A>
</DL><P>

The use of the varying exceptionalities class as a delivery model for
exceptional student education has a long history in the State of Florida.
Currently, teachers of this class comprise the largest group of teachers in
exceptional student education classes in this state.  The model provides
flexibility that enables districts to ignore categorical lines when serving
exceptional students who have similar needs.<p></DL>

<pre>



















</pre>
<A NAME = "Definition"><h2>Definition</h2></A><P>
<DL Compact><i><B><DT>Varying Exceptionalities (VE) Classes:</B></i><P>
The setting that provides for the assignment of students of<P>
<UL>
<DD><LI>more than one exceptionality to one teacher per instructional class period,<P> or<P>
<DD><LI>more than one exceptionality to one teacher during the school week.</DL>
</UL>
<p>

<i><B>Categories of Exceptionalities:  </B></i><P>
For purposes of defining a varying exceptionalities class, the following categories of exceptionalities may be
combined:<p>
<DL>
<LI>Specific Learning Disabilities
<LI>Mentally Handicapped (Educable Mentally Handicapped; Trainable Mentally 
	Handicapped; and Profoundly Mentally Handicapped)
<LI>Emotionally Handicapped (Emotionally Handicapped and Severely Emotionally 
	Disturbed)
<LI>Physically Impaired
<LI>Speech and Language Impaired
<LI>Visually Impaired
<LI>Hearing Impaired
<LI>Gifted
<LI>Profound  (including Autistic; Deaf-Blind; Profoundly Mentally Handicapped;
and Severely Emotionally Disturbed)<P>
</DL>
Please note that each school district determines which exceptionalities may be
served in a varying exceptionalities class.  The list above indicates that
certain categories of exceptional students may be grouped in classes that are
not considered to be varying exceptionalities classes.  For example, if
emotionally handicapped and severely emotionally disturbed students are in the
same class, this class is not designated as varying exceptionalities.<P>

[<A HREF="#General Information">General Information</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<A NAME = "History"><h2>History of the Varying Exceptionalities Model</h2></A>
<P>
<DL><DT><H6><B>1947</B></H6><DD>Rule established.  "Where it is not practical nor feasible because of too
few pupils to assign special teachers for each type of exceptional child, combination units will be approved."  (Concept deleted a short time later.)</DL><p>
<p>
<DL><DT><H6><B>1962</B></H6><DD>Rule revised.  "Varying exceptionalities -- For the employment of a teacher to serve children with varying exceptionalities as defined in these regulations in rural and sparsely populated areas, one unit may be allowed." (Rule repealed in 1974 with the adoption of the Florida Education Finance Program.)</DL><p>
<p>
<DL><DT><H6><B>1970s</B></H6><DD>Use of VE model increases somewhat as a result of school-based
management, implementation of PL 94-142 and the concept of least restrictive
environment, and the high cost of transportation.</DL><p>
<p>
<DL><DT><H6><B>1980-81</B></H6><DD> <i>Task Force on Varying Exceptionalities.  </i>Responding to a
request of the internal auditors, the task force met and made recommendations
regarding definition, class composition, and teacher competencies to be
incorporated into State Board of Education Rules.</DL><p>
<p>
<DL><DT><H6><B>1980s</B></H6><DD> VE use doubles with increased populations and changes in secondary
requirements.  </DL><p>
<p>
<DL><DT><H6><B>1985-86</B></H6><DD>  <i>Subcommittee on Varying Exceptionalities (State Advisory
Committee).  </i>Site visits were made to 12 districts, and VE teachers were
surveyed to identify issues related to the use of the VE model.
Recommendations were made regarding the composition and organization of the
class, placement decisions, class size, support services, and teacher
competencies.</DL><p>
<p>
<DL><DT><H6><B>1986-87</B></H6><DD>  <i>Task Force on the Education of Exceptional Students (Varying
Exceptionalities).  </i>As a result of issues raised by teacher organizations
and the Florida Association for Children with Learning Disabilities (FACLD), a
legislative task force was convened.  Recommendations were made regarding
certification requirements; VE class size, composition, and staffing patterns;
parent involvement; and general policies.  In addition, nine best practices
were identified to assist districts.</DL><p>
<p>
<DL><DT><H6><B>1990s</B></H6><DD>VE use increases.  Prekindergarten programs increase and show preference
for a VE model.</DL><p>
<p>
<DL><DT><H6><B>1991-93</B></H6><DD>  <i>Varying Exceptionalities Advisory Committee.  </i>At the urging of
the Florida Teaching Profession/National Education Association (FTP/NEA), the
Bureau of Education for Exceptional Students funded a study to look at the use
of the VE model in 17 districts and established an advisory committee.  The
results of the study were widely disseminated and a resource manual for VE
teachers was developed.</DL><P>

[<A HREF="#General Information">General Information</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<A NAME = "Why Use"><h2>Why Use the Varying Exceptionalities Model?</h2></A>

<i><B>Enables ESE students to be served in their home schools.</B></i><p>
Serving ESE students in the least restrictive environment requires that
consideration be given to providing the services in the school that the child
would normally attend.  <p>
<p>
<i><B>Allows ESE students to be grouped by program or curricular needs.</B></i><p>
A VE model facilitates the grouping of students according to their
program or curriculum needs.   For example, in some districts, a VE model is
used to provide programs for students on Special Pupil Progression Plans.   In
other districts, a VE model is used for the students in resource classes who
are served in ESE on a part-time basis.  <p>
<p>
When a school has more than one ESE teacher, the use of a VE model allows the
children to be grouped by age as well as curriculum needs.  Thus, an elementary
school may be able to staff both primary and intermediate units.  A VE model
may also be used where the majority of students are the same exceptionality and
only a few children have a different classification.  Many school districts
determine the number of teaching units allocated to a school based on the
number of ESE students and the FTE generated by them, and allow the teachers at
the school to determine how the students will be grouped in classes.  <p>
<p>
<i><B>Provides flexibility in providing services for small populations of ESE students.</B></i><p>
In addition to the options described above, a VE model provides for ESE
students in low prevalence categories.  Students with physical impairments or
mild sensory impairments often can be appropriately served in a VE model.<p>
<p>
<i><B>Focuses the educational program on the individual needs of the students,
rather than on the label of the child.</B></i><p>
The flexibility associated with the use of a VE model can be seen as an asset
when providing appropriate programs for exceptional students.  When parents
want  their child to be served in the neighborhood school, a VE model can be
used to accommodate that preference.  ESE teachers in secondary schools can use
the model to departmentalize and group students by functional levels.  <p>
<p>
While a VE model sometimes carries a reputation as being a "dumping ground," in
fact, it can remove artificial barriers.  <i>What is important, however, is
that the program provided in a VE model have an identity, i.e., a clear sense
of purpose.</i>   Whether a VE model is seen as the program for special diploma
students at the high school, the prekindergarten program for high functioning
students, or the program at the elementary school that enables all of the
exceptional students to attend their neighborhood school,  the teachers in VE
classes need to understand and support the purposes of their programs.<p>

[<A HREF="#General Information">General Information</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<A NAME = "State Board of Education Rule"><h2>State Board of Education Rule</h2></A>
<P>
In 1983, Rule 6A-6.0311, Florida Adminstrative Code, (FAC), Special Programs
and Procedures for Exceptional Students, was amended to include requirements
for varying exceptionalities classes.<p>

<DL><DT><H6><B>(3)  Varying Exceptionalties.</B></H6><DD>If a school district elects to use a varying
exceptionalities class, it shall be used only to a limited extent in order to
provide special programs for exceptional students.<p>
<p>
<DL><DT><H6><B>(a)</B></H6><DD>  A varying exceptionalities class is the setting which may provide for
assignment of students of more than one (1) exceptionality to one (1) teacher
per instructional class period, or more than one (1) exceptionality to one (1)
teacher during the school week.<p>
<p>
<DT><H6><B>(b)</B></H6><DD> If a school district establishes varying exceptionalities classes,
procedures for the program shall be set forth in district procedures as
required by Rule 6A-6.0311, FAC.<p>
<p>
<DT><H6><B>(c)</B></H6><DD>  Eligible exceptional students served in varying exceptionalities classes
shall be reported for full-time equivalent membership in accordance with Rule
6A-6.1.451(7)(8), FAC.<p>
<p>
<DT><H6><B>(d)</B></H6><DD> Parents shall be notified, as provided in Rule 6A-6.0311, FAC, when the
student is assigned to a varying exceptionalities class with other
exceptionalities.</DL></DL><p>

[<A HREF="#General Information">General Information</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<p>
<A NAME = "Certification Requirements"><h2>Certification Requirements for Teachers</h2></A>
<P>
The required certification for teachers in VE classes is identified annually in
the Course Code Directory.  Teachers in VE classes must have one of the
following certification areas:<p>
<DL>
<LI>Varying Exceptionalities
<LI>Specific Learning Disabilities
<LI>Mentally Handicapped
<LI>Emotionally Handicapped.</DL>
<p>
The requirements for the Varying Exceptionalities certification have recently
been revised and became effective July 1, 1992. <P>
They are as follows:<p>
<p>
<I>A bachelor's or higher degree with a major in exceptional student education
which includes courses in the instructional strategies for emotionally
handicapped, mentally handicapped, and specific learning disabilities.</I><p>
<p>
or<p>
<p>
<I>A bachelor's or higher degree with thirty six (36) semester hours in
exceptional student education including the following areas:</I><p>

<DL>
<LI>Foundations of exceptional student education
<LI>Language development and disorders
<LI>Assessment of exceptional students
<LI>Educational management
<LI>Teaching social and personal skills
<LI>Methods and materials for teaching reading
<LI>Teaching skills and concepts of mathematics
<LI>Methods and content for teaching language arts
</DL>
<p>
Characteristics of  mildly handicapped students (EH, EMH, SLD)<p>
<DL>
<LI>Instructional strategies for teaching students who are mentally handicapped
<LI>Instructional strategies for teaching students who are emotionally handicapped
<LI>Instructional strategies for teaching students with specific learning disabilities
</DL>
<p>
In addition, teachers already certified in the areas of mentally handicapped,
specific learning disabilities, emotionally handicapped, or physically
impaired, may qualify for VE certification by adding the appropriate additional
requirements in terms of the characteristics and instructional strategies
courses specified in the last section. <p>

[<A HREF="#General Information">General Information</A>]<p>
<HR><P>
<P>  [<A HREF="bees4.HTM">Previous section</A>]  [<A HREF="bees6.HTM">Next section</A>]             [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]

</body></html>


















</DOC>
<DOC>
<DOCNO>WT01-B04-203</DOCNO>
<DOCOLDNO>IA039-000740-B041-16</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES6.HTM 198.78.22.165 19970210073300 text/html 26483
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:0 GMT
Last-modified: Tuesday, 5-Mar-96 22:3:15 GMT
Content-length: 26227
</DOCHDR>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 --></head><body>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<a name = "Uses of the Varying"><TITLE>Resources for VE Teachers</TITLE></a><br>
<P>[<A HREF="bees5.HTM">Previous section</A>]   [<A HREF="bees7a.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>

<h1>Uses of the Varying Exceptionalities Mode</h1>
<p>
<DL>
<LI><A HREF = "#Best Practices">Best Practices in Providing Educational Services in a VE Delivery Model</A>
<LI><A HREF = "#Sample District Guidelines">Sample District Guidelines for Varying Exceptionalities</A>
<LI><A HREF = "#Prekindergarten Programs">Prekindergarten Programs</A>
<LI><A HREF = "#Elementary School">Elementary School Resource Programs</A>
<LI><A HREF = "#ESelf-Contained Programs">Self-Contained Programs</A>
<LI><A HREF = "#Middle School">Middle School</A>
<LI><A HREF = "#MResource Programs">Resource Programs</A>
<LI><A HREF = "#MSelf-Contained Programs">Self-Contained Programs</A>
<LI><A HREF = "#High School">High School</A>
<LI><A HREF = "#High School Resource Programs">Resource Programs</A>
<LI><A HREF = "#Self-Contained Programs">Self-Contained Programs for Special Diplomas</A>
<LI><A HREF = "#Vocational Education">Vocational Education Programs</A>
</DL><P>
<HR>
<pre>


























</pre>
<h3>
<a name="Best Practices">Best Practices in Providing Educational Services in a VE Delivery Model</a></h3>
<P>
Several state level task forces and advisory groups have studied the issues and
practices in regard to the VE model.  In 1986-87,  the Task Force on Education
of Exceptional Students (Varying Exceptionalities) developed a list of best
practices to assist districts.  Recent surveys of VE teachers have indicated
that the majority of teachers feel that these best practices are being
implemented in school districts.  <p>
<p>
<i>1.	</i> <i>A VE model should be used for specific educational
programs.</i><p>
	The Task Force recommended that a VE model may be best utilized at the
prekindergarten or high school level.  Districts have found a VE model
effective for programs such as community-based instruction, vocational
programs, and special diploma programs.<p>
<p>
<i>2.	 A VE model is best utilized for classes and programs where students have
more common curricular needs.</i><p>
<i>	</i>The class size, composition, and educational demands must be taken into
account when using a VE model at any level.  Consideration of the behavior and
academic functioning of students will be critical to the successful use of a VE
model.<p>
<p>
<i>3.</i>	<i>Prior to a student's placement in the VE delivery model, the
potential receiving teacher(s) should have the opportunity to observe the child
in his or her current educational setting or to become familiar with the
child's educational needs.   </i><p>
<i>	</i>This may include access to the student's records, phone conferences, or
other methods of communication when direct observation is not possible.  When
the receiving teacher is well-informed about the needs of the new student,
support services and other accommodations can be provided.<p>
<p>
<i>4.	After a student is placed in a VE class, the appropriateness of the
placement is reviewed within a reasonable amount of time or whenever
requested.</i><p>
<i>	</i>Monitoring the effectiveness of a student's placement should be an
ongoing process.  The review may evaluate the appropriateness of the placement,
given the child's educational needs.  Whenever requested, the staffing team may
reconsider a placement decision and recommend a more appropriate educational
program.<p>
<p>
<i>5.	To the extent possible, full-time and part-time students should be served
in separate classes.</i><p>
<i>	</i>Consideration must be made regarding the educational impact of
combining self-contained students with part-time resource students, who enter
and exit the classroom at differing times during the course of the school
day.<p>
<p>
<i>6.	Instructional aides are provided as needed.  These may include volunteer
assistants as well as paid paraprofessionals.</i><p>
<i>	</i>Teachers need to understand the district policies and procedures for
providing teacher aides.  In addition, participation in the school volunteer
program can be a ready source of help.<p>
<p>
<i>7.	Adequate supplies are provided within existing guidelines to maintain the
quality of the program.</i><p>
<i>	</i>In districts where money for supplies is managed at the school level,
the ESE teachers should become a part of the decision making team.  <p>
<p>
<i>8.	Adequate support services are provided within district guidelines to
maintain the quality of the program.  </i><p>
<i>	</i>Support services should include administrative assistance and related
service personnel, including school psychologists and social workers.<p>
<p>
<i>9.	Parents are well informed about the circumstances in the VE class.</i><p>
<i>	</i>There should be a close working relationship between the parents of an
ESE student in a VE class and the VE teacher.  The parents should be aware of
the characteristics of the class (e.g., class size, functional levels of the
students, etc.) and the availability of support and appropriate services for
their child.  <p>

<i>10.	School or district administrative staff monitor the effectiveness of the
program for students on an individual basis.</i><p>
<i>	</i>The effectiveness of a VE delivery model should be evaluated by looking
at key indicators such as the accomplishments of the students, discipline,
participation in the mainstream, etc. <p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h2>
<a name="Sample District Guidelines">Sample District Guidelines for Varying Exceptionalities</a></h2> 

<p>
Local school districts determine how a VE model is to be used to deliver
exceptional student education programs.  In small districts, due to the small
number of students, a VE model may be used to provide a wide range of services.
In middle and large-sized districts in Florida, a VE model may be used either
broadly or only for specific programs or populations.  District policy and
philosophy determine the particular application.  <p>
<p>
In VE classes that are seen as successful, students are grouped according to
similar academic and behavior functioning and needs.  Effective teachers in a
VE model will need to have a strong curriculum background and will also need to
be well-organized, open-minded, flexible, and creative. They must be able to
present knowledge and skills from many different perspectives.  <p>
<p>
The descriptions in this section are provided as illustrations of the ways that
districts have elected to use a VE model in the prekindergarten, elementary,
middle, and secondary programs.    Recommendations regarding the
characteristics of children, provision of aides, or pupil/teacher ratio are
included only as guidelines and are not intended to serve as requirements or
official state policy.  The districts that provided the guidelines are named at
the end of the descriptions.<p>
<p>
<p>
<!--insert graphic depicting school buildings-->

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h4>
<a name="Prekindergarten Programs">Prekindergarten Programs</a></h4>

<p>
The primary purpose for using the VE model in the prekindergarten program is to
keep students as close to home as possible.  This eliminates long bus rides and
provision of services on an itinerant basis.  The model provides more cost
effective services.<p>
<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Students can be grouped by ability or functioning level, rather than
exceptionality.  Prekindergarten children can be exposed to better role models
in skill areas which may not be their strengths.  They more readily develop
social and language skills from interaction with their peers. <p>
<p>
Children who are 3-5 years of age and developmentally delayed are often
considered for placement in a VE model.  The disability of the child may be
directly interfering with social interaction, and the child may need to be in a
program with children of his or her own age.  The family may benefit from
parent training provided along with the program for the child.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 8:1 with a full-time paraprofessional or aide is
considered best practice for students in this age group.  The class size should
also consider the needs of the students.  Students who require a great deal of
care and personal support will need to be placed in classes with an even
smaller pupil/teacher ratio or additional teacher aides. <p>
<p>
The classroom program should be staffed by a teacher who is certified in
exceptional student education or early childhood education (as indicated in the
Course Code Directory).   Speech/language pathologists, physical therapists, or
occupational therapists should provide programs and services for children as
appropriate.  The school psychologists and social worker may serve in an
evaluative and consultative capacity and assist parents in accessing local
agencies, if needed. <p>
<p>
<i>Program</i><p>
<p>
Planned activities are designed to increase functional skills in all six
developmental areas:  fine motor, gross motor, language, cognitive, self-care,
and social skills.  Skill development is encouraged through
multi-sensory-stimulation and activities such as dressing, pre-speech and
feeding, use of music to facilitate language and movement, and manipulation of
materials for improvement of fine motor skills.  An interdisciplinary team
approach is used in the classroom to support the goals and objectives
formulated in the Individual Educational Plan (IEP) of each child.  <p>
<p>
(from Manatee County Guidelines)<P>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4>
<a name="Elementary School">Elementary School <P>Resource Programs</a></h4>

<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Children are grouped in a VE class with other children who have comparable
needs.  They may exhibit delays in individual areas such as language arts,
reading, math, motor skills, and social and personal behaviors.  These students
are mainstreamed for the majority of the school day, and the VE class serves to
provide intervention in the area of the child's greatest need and to provide
support to successful performance in the mainstream class.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
For a resource room, the number of students will be based on the number of
hours each student is seen.  In most cases, 20-30 students can be served in a
resource room.  Sometimes additional students who are fully mainstreamed are
assigned to the ESE teacher for consultation services only.  Each district sets
the caseload requirements for a teaching unit, and actual numbers of students
vary considerably from these recommendations.  Support services are available
from the Florida Diagnostic and Learning Resources System (FDLRS), program
supervisors, school psychologists, social workers, school guidance personnel,
and curriculum resource personnel in the school. <p>
<p>
<i>Program</i><p>
<p>
The schedule in a VE class is determined according to the particular needs of
the students assigned to the class and must be arranged to accommodate the the
schedule of the mainstream classes. In some schools, the VE teacher is using a
team teaching model to provide services in the context of the regular
classroom.<p>
<p>
Cooperative Consultation (Reigel, 1988)  can enhance the success of the
mainstreaming experience of all ESE students.  Through this model, exceptional
education teachers and basic or vocational education teachers join together to
plan needed support and accommodations for exceptional students in mainstream
classes.  Through regular conferences and monitoring, the likelihood of success
of the student is greatly enhanced.  This is particularly critical at the start
of a new school year or when the ESE students are first being included in
mainstream programs.  <p>
<p>
(from Polk County Guidelines)<p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<p>
<H4>Elementary School</H4><p>

<h4><a name="ESelf-Contained Programs">Self-Contained Programs</a></h4>
<P>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Children are grouped in a VE class with other children who have comparable
needs.  They may exhibit delays in multiple areas such as language arts,
reading, math, motor skills, and social and personal behaviors.  Participation
in mainstream classes is generally limited to art, music, and physical
education for most students.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
For a self-contained class, a 12:1 pupil/teacher ratio  with a full-time aide
or paraprofessional is considered best practice for students in this age group.
Support services are available from FDLRS, program supervisors, school
psychologists, social workers, school guidance personnel and curriculum
resource personnel in the school. <p>
<p>
<i>Program</i><p>
<p>
The schedule is determined based on the functioning levels and subject areas
needs of the students as well as the scheduling of students for mainstream
classes.  In many programs, ESE students participate in the music, art, and
physical education programs with their chronological peers.  <p>
<p>
In schools with more than one ESE unit, students can be grouped by age range or
by program needs.  Teachers generally feel that emotionally handicapped
students who require full-time services should be placed together. (Polk County
Guidelines)<p>
<p>
<!--insert graphic showing teacher and several elementary age students-->


[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4>
<a name="Middle School">Middle School </a></h4>
<h4>
<a name="MResource Programs">Resource Programs</a></h4>
<P>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
This program is usually designed for mildly handicapped students who do not
require services in all academic areas or intensive related services or therapy
for behavior or emotional handicaps.<p>
<p>
Middle school programs are departmentalized or organized by grade level teams.
Students typically receive instruction from a number of different teachers,
including  those in the exploratory subjects.  The VE teacher may provide
instruction in basic academic classes such as English and mathematics, but
generally the content areas and special areas are taken in the mainstream for
students in resource programs.   If the school has sufficient students and ESE
teachers, faculty assignments may be made by subject area specialization or to
grade level teams.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class period is considered best
practice for students in this age group.  Aides and volunteers may be essential
if the class sizes are large or if the students need a lot of personal
attention.  Support services should be available from FDLRS, program
supervisors, school psychologists, social workers, school guidance personnel,
and curriculum resource personnel in the school. <p>
<p>
<i>Program</i><p>
<p>
The schedule is organized by grade level, subject area, and in some subjects,
by functional level.  The number of VE teachers in the school will affect the
flexibility of the scheduling.  <p>
<p>
In middle schools with grade level teams, VE teachers are sometimes organized
as a separate department, and students are scheduled in their classes on a
pull-out basis.  Other middle schools have found success with placing the VE
teacher on one of the teams and enrolling the ESE students on that team. <p>
<p>
Cooperative Consultation (Reigel, 1988) can enhance the success of the
mainstreaming experience of all ESE students.  (See Elementary School:
Resource Programs for a description of Cooperative Consultation.)<p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<H4>Middle School</H4><p>

<h4>
<a name="MSelf-Contained Programs">Self-Contained Programs</a></h4>
<p>
<i> Characteristics of Students Who Are Served in This Model</i><p>
<p>
This program is usually designed for exceptional students who require services
in the major academic areas and may need some related services or intensive
therapy.  <p>
<p>
Students in self-contained programs are taught  the academic content areas  in
VE classes.  If the school has sufficient students and ESE teachers, faculty
assignments may be by subject area specialization within the ESE department.
Students may be mainstreamed for art, music, physical education and vocational
exploration.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class period is considered best
practice for students in this age group.  Aides and volunteers may be essential
if the class sizes are large or if the students need a lot of personal
attention.  Support services should be available from FDLRS, program
supervisors, school psychologists, social workers, school guidance personnel,
and curriculum resource personnel in the school. <p>
<p>
<i>Program</i><p>
<p>
The schedule is generally organized by grade level, subject area, and in some
subjects, by functional level.  If there is only one self-contained unit in a
middle school, the content area subjects may rotate on a three year cycle, to
schedule the courses more efficiently.  The number of VE teachers in the school
will affect the flexibility of the scheduling.  <p>
<p>
<!---insert graphic showing several middle school students working together with a map or globe-->

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><a name="High School">High School </a></h3><P>

<h4><a name="High School Resource Programs">Resource Programs</a></h4>
<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
This program is designed for mildly handicapped students who are served on a
resource basis and do not require intensive related services or therapy.<p>
<p>
High school programs are usually departmentalized.  Students receive
instruction from a number of different teachers.  The VE teacher may provide
instruction in basic classes such as English and mathematics, or in support
areas such as learning strategies, social skills or unique skills.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class period is considered best
practice for students in this age group.  Support services should be available
from FDLRS, program supervisors, school psychologists, social workers, school
guidance personnel, and curriculum resource personnel in the school.   Job
placement specialists and vocational education services are an important aspect
of the high school program.  Because of the needs for transition services,
other agencies such as Vocational Rehabilitation may become involved at this
level.<p>
<p>
<i>Program</i><p>
<p>
The schedule is generally organized by grade level, subject area, and in some
subjects, by functional level.  Team teaching has been used successfully in
many districts to support ESE students in mainstream classes.  In this model,
the ESE teacher and the mainstream teacher work as a team to deliver a class.<p>
<p>
Cooperative Consultation (Reigel, 1988)  can enhance the success of the
mainstreaming experience of all ESE students.  (See Elementary School Programs:
Resource Programs for a description of Cooperative Consultation.)<p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<H4>High School</H4><p>

<h4><a name="Self-Contained Programs">Self-Contained Programs for Special Diplomas</a></h4>
<p>
The exceptional students who require full-time placement at the high school
level in many districts are those who are working towards a special diploma.
The full-time students would receive credit in VE classes to meet the
requirements of a special diploma. <p>
<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Districts may establish guidelines to assist in the recommendation of
exceptional students for participation in a functional life skills curriculum
and a special diploma.  Low academic levels, particularly low reading ability,
are commonly used indicators. <p>
<p>
In some districts, this determination is made as a part of the eighth grade
planning process.  The district program specialist may review recommended
students with teachers and other school personnel.  The parent and students may
participate in an IEP review in the spring to make the actual decisions.<p>
<p>
<i> Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class period is considered best
practice for students in this age group.  Aides and volunteers may be essential
if the class sizes are large or if the students need a lot of personal
attention.  Support services should be available from FDLRS, program
supervisors, school psychologists, social workers, school guidance personnel,
and curriculum resource personnel in the school.   Most special-diploma-seeking
students should be involved with a vocational program.  Because of the needs
for transition services, other agencies such as Vocational Rehabilitation may
become involved at this level.<p>
<p>
<p>
<i>Program</i><p>
 <p>
The functional life skills curriculum emphasizes career awareness, social
skills, and pre-employment habits and attitudes necessary for successful work
adjustment.  Basic skills and problem-solving techniques are presented in a
real-life context to prepare students to function independently as adults. <p>
<p>
(from Palm Beach County Guidelines)<p>

[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<p>
<H4>High School</H4><p>

<h4><a name="Vocational Education">Vocational Education Programs</a></h4>
<p>
The purpose of vocational programs at the high school level is to enable
students to develop the ability to communicate appropriately with peers and
adults, to demonstrate the skills and attitudes essential for employment, and
to help students set realistic career goals.  Students are involved in job
preparatory programs to develop specific occupational skills.<p>
<p>
<i>Characteristics of Students Who Are Served in This Model</i><p>
<p>
Students should enroll in vocational programs based on their interest and
aptitude.  Work experience may be provided either on or off campus.  ESE
students may enroll in regular vocational programs or in specially designed
programs.  The VE class generally serves to support the academic and job
training requirements of the program.<p>
<p>
<i>Pupil/Teacher Ratio and Support Staff</i><p>
<p>
A pupil/teacher ratio of 12 students per class is conisdered best practice for
students in this age group.  Occupational specialists, vocational
rehabilitation counselors, and ESE specialists and evaluators are needed to
support this program.  For more severely disabled students, job coaches may be
required. <p>
<p>
<i>Program</i><p>
<p>
The program is organized to support the course needs to meet graduation and
vocational program requirements.  The student's work schedule may occur during
the school day or may be arranged in off hours.  Districts may provide the
vocational program through the offerings at a comprehensive high school or in
an area vocational-technical program.<p>
<p>

<!--insert graphic showing high school students working on a car, or working in a retail outlet with adults-->
[<A HREF="#Uses of the Varying"><I>Uses of the Varying Exceptionalities Mode</I></A>]  <P>

<HR>
<P>[<A HREF="bees5.HTM">Previous section</A>]   [<A HREF="bees7a.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>





















</DOC>
<DOC>
<DOCNO>WT01-B04-204</DOCNO>
<DOCOLDNO>IA039-000740-B041-56</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES8.HTM 198.78.22.165 19970210073410 text/html 24871
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:6 GMT
Last-modified: Tuesday, 5-Mar-96 22:5:16 GMT
Content-length: 24615
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 --></head>
<TITLE>Resources for VE Teachers</TITLE>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<A NAME = "Home">

<P>[<A HREF="bees7d.HTM">Previous section</A>]   [<A HREF="bees9.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<h1><A NAME = "#Staffing Considerations">Staffing Consideration for Placement in Varying Exceptionalities Classes</A></h1>
<DL>
<LI><A HREF = "#Individual Educational Plans">Individual Educational Plans</A>
<LI><A HREF = "#Supporting the Placement">Supporting the Placement of Students</A>
<LI><A HREF = "#Ongoing Review">Ongoing Review and Monitoring of Placement</A>
<LI><A HREF = "#Dealing with Parental">Dealing with Parental Concerns</A>
</DL><P>
<HR>
<pre>




























</pre>

<h3><A NAME = "Individual Educational Plans">Individual Educational Plans:  Identifying Individual Student Needs</A></h3><P>

In developing Individual Educational Plans (IEPs) for students with
disabilities, a variety of factors are taken into consideration to determine
which regular and special education services are needed by the individual
student.  The same factors are used for placement in a VE class.  This section
provides a brief description of the factors.  These factors can be readily
translated into guidelines appropriate to the specific use of the VE model in a
district or school.<P>

<h4>What are the factors? </h4><P>
<b>At what level is the child currently functioning?</B><P>

<h4>Functional level/Curriculum Needs</h4>
<p>
Review the child's level of achievement or           
functioning for all of the specific developmental    
                          domains, and academic or vocational areas.  Use      
                          both standardized test scores and reports of         
                          classroom teachers.  Only current test results       
                          that are considered to be a valid reflection of      
                          the child's achievement should be used to            
                          determine the functional level.  Frequently,         
                          group-administered achievement tests do not          
                          accurately reflect the capabilities of exceptional   
                          students.  
<p>
Observations of classroom behavior and    
                          input from the child's current teachers can          
                          provide critical information.  A review of both      
                          regular and special education classroom              
                          performance should be taken into account.            
                          Determine how well the student functions in a        
                          large group situation; how well the student can      
                          meet the demands of homework, independent            
                          assignments, and the social and behavioral           
                          expectations of the environment.
<P>
<h4>Curriculum needs and Pupil-Progression Plan</h4>
<p>
Determine if the child's needs are best met through the requirements of the regular              
                          pupil-progression plan or through the special        
                          pupil-progression plan for exceptional students.     
                          This will involve selecting the type of curriculum   
                          and, for secondary students, selecting the type of   
                          diploma.   Generally, the academic curriculum has    
                          been effective for exceptional students who are      
                          considered high-functioning or mildly handicapped.   
                          The functional life-skills curriculum is generally   
                          selected for low functioning students.               
<P>
<h4>Medical needs/Physical Impairment</h4>
<P>   
Determine need for any support services for medical needs or accessibility requirements due to   
                          physical limitations.                                
<P>
<h4>Behavior and Independence</h4>              
<P>
Consider the child's capacity for functioning independently in the school;  review the child's     
                          history in terms of self-regulation and behavior     
                          control.  

<p>Can a behavior management plan be          
                          reasonably implemented in the targeted setting?      
                          How will the child's behavior impact the others      
                          already in the classroom?  

<p>Can the child make        
                          appropriate decisions independently?  Is a crisis    
                          intervention teacher needed?                         
<P>
<h4>Social Skills</h4>             
<p>
Determine the child's capacity for functioning in    
                          a social environment;  review the child's            
                          relationships with peers and adults.  

<p>
Is a  separate social skills class appropriate for the  student?                                             
<P>
<h4>Long-range Career Plans</h4>   
<P>
For high school students, review career goals and    
 objectives to determine appropriateness of  secondary school placement.                          
<P>
<h4>Parent and Student Input</h4>  
<P>
Input should be obtained from both parents and       
                          students regarding these factors.  Both can          
                          provide information regarding their perceptions of   
                          the student's readiness for the proposed placement. 
<P>
<b>What special services are needed?</b>

<P>
<h4>Related Services</h4>
<P>          
Determine if any related services are required.      
                          This may include counseling, medical services, or    
                          other educationally related services.                
<P>
<h4>Course Modifications</h4>      
<p>
Review the need for course modifications,            
                          including modifications to time, communication       
                          modes, instructional techniques, or assessment       
                          procedures.   
<p>
Determine if needed technology is      
                          available to support the performance of the          
                          student.   
<p>
Consider the use of the Mainstream Cost   
                          Factor to suport consultation between regular        
                          education and ESE teachers.                          

<P>
<h4>Multiple Program Needs</h4>    
<p>
Consider the need for services from exceptional      
                          student education programs, such as speech,          
                          physical or occupational therapy, as well as other   
                          educational programs including Chapter 1, English    
                          for Speakers of Other Languages (ESOL), or           
                          vocational education.                                
<P>
<h4>Transition Services</h4>       
<p>
For high school students, review transition plans.   
                          This may include involvement of other agencies,      
                          such as Developmental Services from Health and       
                          Rehabilitative Services, and Vocational              
                          Rehabilitation from the Department of Labor.         
<P> <b>What are the placement options?                                                  </b>
<P>
<h4>Least Restrictive Environment</h4>        
<P>
Select the most normal educational setting in        
which the exceptional student can profit from the    
                          instruction.   To the maximum extent appropriate,    
                          exceptional students should be educated with         
                          nonexceptional students.  Encourage attendance at    
                          the student's home school, if possible.              
<P><h4>Availability of Delivery Models</h4>
<P>
Review the continuum of delivery models currently    
 available in the district.    
<P>
<h4>Availability of Support Personnel</h4>
<p>
Input may be           
                          obtained from the potential receiving teacher(s)     
                          and district staff.  This should include a           
                          description of the delivery models and               
                          characteristics of students served in each.          
                          Information regarding the  availability of           
                          curriculum and support services should be            
                          provided.                                            
<p>
Determine the ease of providing support personnel,                    if needed, in the targeted setting.                  
<P>

[<A HREF="#Home">Staffing Consideration for Placement</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Supporting the Placement">Supporting the Placement of Students</A></h3>
<P>
An important part of the placement decision made by the staffing committee is
the determination of the ongoing support needed to ensure the success of the
student in the classroom.  The student may require support in a variety of
areas. <P>

<B>Does the student require any specialized equipment?</B><P>

<h4>Adaptive/Assistive Devices</h4>
<P>
Generally provided to students with physical,       
 visual, or hearing impairments.                     
<P>
<h4>Augmentative Communication Devices</h4>
<P>
Check with speech and language personnel for        
availability and appropriateness for individual     
students.  
<P>                             
<h4>Computerized Instructional Systems</h4>
<P>
 Determine if integrated learning system is          
appropriate and available.
<P>
<h4>Electronic</h4>
<P>
 Determine if an electronic tool (word processor, draw program) is essential to        
 student's performance.                              
<P>
<B>Are appropriate textbooks and other resource materials available?</B><P>

<h4>Braille or large-print materials</h4>     
<P>Materials are available through Florida             
Instructional Materials Center and Division of     
                           Blind Services.                                     
<P>
<h4>Materials available through county textbook inventories</h4>        
<br>
<p>Determine if supplementary texts can be provided    
through the district inventory.  Also check the     
Florida Diagnostic Learning Resource Center for     
                           materials on loan.
<br>                                  
<h4>High interest/low vocabulary texts</h4>         
<br>
<p>For students with low reading abilities,            
alternative textbooks might be needed.  Check       
                           availability in other schools or on district        
                           inventory.  
<br>
<p>Materials for developing specific       
                           skills or materials compatible with the regular     
                           curriculum should be sought.                        
<br>
<h4>Hands-on/real life materials</h4>       
<br>
Authentic learning materials may be obtained from   
a variety of sources, including volunteer           
                           services, business partners, etc.  
<br>
<p>These            
                           materials may be critical to meet vocational and    
                           occupational objectives.                            
<br>
<h4>Learning centers</h4>           
<br>
<p>Primarily used in elementary schools, learning      
                           centers may be shared among teachers or schools.
<br>    
<h4>Interactive activities</h4>    

<p>These activities may include an affective           
                           curriculum designed to promote social skills and    
                           decision-making.                                    
<P>
<b>Does the teacher have access to necessary information and skills to work with this student?</b><P>
<h4>Accessibility to student records</h4>          
<p>
Teachers should have access to the   
student records so that all appropriate information is made          
                          available.                                           
<P>
<h4>Parent input</h4>              
<p>
Open lines of communication must be maintained to    
                          ensure parent support.  When parents have input      
                          into the process, they will be more likely to work   
                          in a partnership with the school.                    
<P>
<h4>Staff development programs/Inservice training</h4>
<p>
This may be provided through district level          
program specialists or resource teachers.  A         
support system is needed to help teachers meet the   
                          increasing demands of their classrooms. 
<P>     
<h4>FDLRS library/public library</h4>
<p>
The availability of information through the          
                  library system is a real asset for the exceptional   
                          student teacher.                                     
<P>
<h4>Community Services</h4>
<p>
Teachers must know how to reach community services   
                          including Deaf Services, Division of Blind           
                          Services, Job Training and Placement Agency,         
                          Vocational Rehabilitation, Florida Instructional     
                          Materials Center, Library for the Blind and          
                          Physically Handicapped, Public Health Department,    
                          Social Services.                                     
<P>
<h4>Service Clubs</h4>
<p>
For example, Sartoma, Lions Club, Kiwanis.
<P>
<h4>SpecialNet, FIRN</h4>
<p>
Electronic communication through SpecialNet or       
FIRN can open many networks to the exceptional       
student teacher.                                     
<P>
<h4>University personnel/programs</h4>
<p>Resources available in the university programs can   
be very helpful.  Contact the special education      
                          department or other related areas for assistance. 
<P>   
<h4>District school psychologist, social worker</h4>
<P>
Information and skills can sometimes be provided     
 through district level support personnel.  <P>

[<A HREF="#Home">Staffing Consideration for Placement</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Ongoing Review">Ongoing Review and Monitoring of Placement</A></h3>
<P>
After a placement decision, provision should be made to allow members of the
staffing team to review a student's progress in the new setting within a
reasonable amount of time.   This review may evaluate the appropriateness of
the placement given the child's educational needs and the characteristics of
the class in which the child is placed.
<p>
Whenever requested, the staffing team may reconsider a placement decision and
recommend a more appropriate educational program. <P>
<b>What procedures or guidelines are recommended?</b><P>

Periodic reviews need to be scheduled in order to maintain the
effectiveness of the delivery model. Reviews may occur as often as once a month
with school-based personnel to discuss progress of the student. Parents need to
be included at all levels of review.<P>

Items for Review (Teacher Review)<P>
<ul>
<li>Updated academic information<P>

<li>Classroom observations <P>

<li>Social skills - appropriateness<P>
<li>Behavior management plan<P>
</ul>
If, at any time, the parents, the classroom teacher(s), or school-based
personnel feel the placement is not meeting the child's educational needs, a
staffing review may be conducted. Additional testing may be warranted; support
services or curriculum adjustments may be required; or a new IEP may be
needed.<P>
<b>Who is responsible?</b><P>

The ESE teacher should accomplish these tasks:<P>
<ol>
<li>Review IEP and assess appropriateness of the plan.
<li>Conduct ongoing classroom observations.
<li>Conduct academic assessment.
<li>Review appropriateness of schedule.
<li>Consider motivational factors of the student.
<li>Monitor behavior of the student.
<li>Monitor attendance.
<li>Consult with mainstream teachers, if appropriate.
<li>Communicate with parents, if necessary.
</ol>
<P>
The mainstream teachers should accomplish these tasks:<P>
<ol>
<li>Review course modifications/adaptations.<br>
<br>
<li>Monitor test scores and grades.<
<li>Identify the demands of the setting.
<li>Monitor classroom participation and behavior.
<li>Monitor attendance.
<li>Assess the appropriateness of the curriculum.
</ol>
<P>
The school administration and other support personnel should accomplish
these tasks:<P>
<ol>
<li>Provide support for the various VE delivery models.
<li>Support flexible, innovative instructional models.
<li>Assist with implementation of behavior management plans.
<li>Communicate with parents.<
<li>Follow procedural safeguards when placing students in programs.
</ol>
<P>
The district administration should accomplish these tasks:<P>
<ol>
<li>Review files for current information.
<li>Keep informed about the school situations.
<li>Conduct classroom observations, if requested.
<li>Be available for consultation, curriculum assessments, etc.
</ol>
<P>
The parents should share assessment of home situation, including:<P>
<ol>
<li>behavior at home and in the community
<li>social interaction with peers and siblings
<li>study habits<
<li>changes in routine
<li>after-school activities
<li>motivation
<li>change in career plans
<li>health problems.
</ol>
<P>
The exceptional student should accomplish these tasks:<P>
<ol>
<li>Share perceptions of the classroom situation.
<li>Monitor his or her own academic standing/progress in class.
<li>Assess satisfaction with the program.
<li>Interact appropriately with peers.
<li>Conduct career assessment or make future plans.
</ol>
<P>
<!--insert a graphic of an IEP meeting with several adults and a teen sitting
around a table--><P>

<h3>Conducting Successful Annual IEP Reviews</h3>
<p>
The following suggestions are provided to exceptional student education
teachers to help them prepare for successful IEP review meetings.<P>
<ul>
<li>Come with <i>recommendations</i> for proposed goals and objectives.
<li>Greet parents with a smile and tell them why you have called this meeting
(i.e., to set educational goals for their student for the next year).<br>
<li>Have all participating teachers make positive comments about the student's
past performance.<P>
<li>Have each participating teacher explain the proposed goals for the student.
Make sure the parents and student understand the goals and give them the
opportunity to add others.
<li>If this is the first time the student's placement is in a VE setting, make
sure parents are aware of the configuration of the classroom and the rationale
for placing their student in this setting.
<li>Listen carefully to what the parents and student are saying.  Add additional
information, if appropriate.  You may recommend strategies you have found
successful that can be used at home.
<li>Express any concerns you have in a positive manner.
<li>Thank the parent and student for attending and end the conference with a
positive comment about the student.
<li>Remember:  Follow through on any promises that were made at the conference. 
</ul>
<P>
(Adapted from <i>VE Teacher's Handbook, </i>Polk County, draft, 1993)
<P>

[<A HREF="#Home">Staffing Consideration for Placement</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3>
<A NAME = "Dealing with Parental">Dealing with Parental Concerns</A></h3><P>

The State Board of Education Rule requires parental notification when a student
is assigned to a VE class. Beyond that, there should be a close working
relationship between the parents of an exceptional student and the teacher in a
varying exceptionalities class. The parents should be informed about the
characteristics of and the circumstances within the class, including the class
size, the functional levels of the students, and how this may relate to the
progress of the child.  <P>
<b>How can participation of the parents be encouraged?</b>
<p>
Frequent conferences should be held to discuss the student's progress, and the
parent should always be requested to attend. Parents need an opportunity to
share their ideas and concerns with the school.  If face-to-face conferences
are not possible, telephone conversations may be used.  Stay away from written
communication only.  Keep communication positive in nature.  Keep parents
informed about opportunities for participation in school activities.  They may
be interested in attending group functions such as:<P>
<ul>
<li>Parent Information Night
<li>Field Trips
<li>PTO/PTA participation
<li>School Advisory Councils<
<li>Parent Advisory Councils
</ul>
<p>
Here's a program that works to keep parents involved in the instruction of their children.
<p>
Call the parents of each student in the class at least once before
Thanksgiving.  By dividing up the students by class periods, all parents can be
contacted within a 3-5 day period. If a student has no phone, use a handwritten
letter to communicate.  The calls concentrate on the child's strengths.   The
teacher asks about the student's interests, hobbies and special
accomplishments.  Areas for improvement are then discussed.  Parents can make
excellent suggestions and certainly appreciate the communication.  Laying the
positive background makes it much easier to deal with concerns that might
occur. <P>
(from <i>Doris Wayte, Pinellas County</i>)<P>

<b>How can parents' concerns about the varying exceptionalities class be
addressed?</b><P>
<ul>
<li>Invite the parents to visit the VE classroom.
<li>Encourage parents to spend time talking about the class with the students and
the teacher.
<li>Encourage the parent to talk with other parents of students already in the
class.
<li>Make all curriculum materials available for parental review.<
<li>Create brochures explaining the different types of delivery models.
<li>Present  various delivery models at the parent support group meetings to
foster a smooth working relationship with parents.
<li>Create a parent library.
<li>Ask the parent to serve as a volunteer.
<li>Suggest that they seek advice from local or state parent support groups.
<li>Refer them to the Bureau of Education for Exceptional Students/Clearinghouse
Information Center or their local FDLRS center for resources and information.</UL></DL><P>

<P>

[<A HREF="#Home">Staffing Consideration for Placement</A>]  <p>

<P>Information on <A HREF = "bees9.HTM">Contact Persons and Consultation and Training Resources</a> is also available.
<P>
<HR>
[<A HREF="bees7d.HTM">Previous section</A>]   [<A HREF="bees9.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>





















</DOC>
<DOC>
<DOCNO>WT01-B04-205</DOCNO>
<DOCOLDNO>IA039-000740-B041-78</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES9.HTM 198.78.22.165 19970210073426 text/html 1779
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:8 GMT
Last-modified: Tuesday, 5-Mar-96 22:5:36 GMT
Content-length: 1524
</DOCHDR>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 --></head>
<TITLE>Resources for VE Teachers</TITLE>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<A NAME = "Home"></A>
<P>[<A HREF="bees8.HTM">Previous section</A>]   [<A HREF="referen.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<h1><a name="RTFToC1">Support for Teachers</a></h1>
<P>
<h2><a name="RTFToC2">List of Contact Persons and Consultation and Training Resources</a></h2>
<P>
These are potential sources of information for personnel, consultation and training related to varying exceptionalities.  Contact the appropriate personnel in your district.<P>
<ul>
<li>District
<li>Teachers' Union
<li>FDLRS Center
<li>Cooperative Consultation Contact Person
<li>Strategies Intervention Model Contact Person
<li>University Resource
<li>Bureau of Education for Exceptional Students<br>
</ul><P>
<HR>
[<A HREF="#Home">Support for Teachers</A>]  <p>
<HR>
<P>[<A HREF="bees8.HTM">Previous section</A>]   [<A HREF="referen.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]   [<A HREF="cover.HTM">Resources for VE Teachers</A>]

</body></html>
















</DOC>
<DOC>
<DOCNO>WT01-B04-206</DOCNO>
<DOCOLDNO>IA039-000740-B042-191</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES7C.HTM 198.78.22.165 19970210073921 text/html 23286
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:4 GMT
Last-modified: Tuesday, 5-Mar-96 22:4:29 GMT
Content-length: 23030
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 --><A NAME = "Home"><TITLE>Resources for VE Teachers</TITLE></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees7b.HTM">Previous section</A>]   [<A HREF="bees7d.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<A NAME = "#Storing"><h1>Effective Practices for Varying Exceptionalities Classes</A></h1>
<HR>
<DL>
<h2>Managing the Classroom Environment</h2>
<DL>
<LI><A HREF = "#Storing">Storing Materials</A>
<LI><A HREF = "#Filing Worksheets">Filing Worksheets</A>
<LI><A HREF = "#Learning Centers">Learning Centers</A>
</DL></DL><P>

<DL><h2><A NAME = "#Managing Behavior">Managing Behavior</A></h2>
<DL>
<LI><A HREF = "#Managing Behavior">Managing Behavior</A>
<LI><A HREF = "#Behavior Management System">Behavior Management System</A>
<LI><A HREF = "#Establishing Classroom Rules">Establishing Classroom Rules</A>
<LI><A HREF = "#Implementing Classroom Rules">Implementing Classroom Rules</A>
<LI><A HREF = "#Maintain the Momentum">Maintain the Momentum</A>
</DL></DL><P>

<DL><h2>Other Management Techniques</h2>
<DL>
<LI><A HREF = "#RR for Students">R &amp; R for Students</A>
<LI><A HREF = "#Keeping Track of the Students">Keeping Track of the Students</A>
<LI><A HREF = "#Silent Signals">Silent Signals</A>
<LI><A HREF = "#Rewards Consequences">Rewards &amp; Consequences</A>
<LI><A HREF = "#Another Level System">Another Level System</A>
<LI><A HREF = "#Token Economies">Token Economies</A>
<LI><A HREF = "#More Reward Systems">More Reward Systems</A>
</DL></DL><P>
<HR>
<pre>




























</pre>
<H3><A NAME = "Storing">Storing Textbooks, Workbooks, and Other Materials</H3><P>

For books that must be easily available, teachers have found it helpful to
arrange areas on bookshelves.  By placing dividers about every 12 inches, books
can be easily put into the "cubbyholes."  Use plastic colored tape to code the
books by level or by subject area, so that matching their storage locations is
easy.  This same coding system could be used in other ways, perhaps to identify
materials for individual students.<P>
 
Workbooks with soft covers will survive longer if placed in plastic report
covers or if their covers are laminated.  Some report folders have a clear
front and solid back with a three-ring holder.  Have three holes drilled in the
workbooks so that they can be inserted in the folders easily.<P>

Books that are not currently needed are best stored out of the classroom.  It
may be possible to find a colleague who needs them.
<P>

[<A HREF="#Home">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Filing Worksheets">Filing Worksheets</A></h3><P>

Having access to a variety of worksheets can save the VE teacher a lot
of time.  But the key time-saver is having a system for filing so that the
worksheets can easily be retrieved.<br>
<i>Here's a system that works!  </i><br>
<br>
<p>Collect all loose worksheets and place all duplicate copies together in
individual files.  Take the original or best copy of each and number it
sequentially, so that each unique worksheet has a different number and there is
a numbered corresponding file folder with the duplicates.  <br>
<br>
<p>The originals can then be sorted by topic or skill and placed in three ring
notebooks.   You will have notebooks of worksheets for math skills, spelling
practice lessons, science concepts, etc. that you can scan easily to find just
the right one.  With the numbering system, you can go to your files and, by
matching the number, locate enough copies of the worksheets for your
students.<br>
<br>
<p>If you find that a worksheet fits in more than one category, just make enough
"originals" to place it in all appropriate notebooks.  If you are concerned
about putting holes in your originals to place them in the notebooks, put them
in the plastic sleeves that can be put in notebooks.</h3><P>

[<A HREF="#Home">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Learning Centers">Learning Centers</A></h3><P>

<p>Most teachers think of learning centers for elementary schools, but many
secondary teachers also find the concept very useful.  Learning centers are
used primarily to provide independent activities for students.  They can
provide a structured exploration of a specific subject, topic, skill, or
interest area.  The following are characteristics of a learning center:<br>
<br>
<ul>
<li>A learning center is self-instructional.  When designed properly, no direct
supervision of a teacher is required.<br>
<li>A learning center can present activities on a variety of levels of
difficulty.<br>
<li>A learning center should have clear objectives.<br>
<li>A learning center must include some method of record keeping for student
participation and accomplishment.<br>
<li>Students need to be taught how to use a learning center.<br>
<li>A learning center should be considered as a place where learning occurs, not
as a place for recreation.  <br>
(From <i>VE Teachers Handbook, </i>Polk County, draft, 1993)<br></UL><P>

[<A HREF="#Home">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Managing Behavior">Managing Behavior</A></h3><P>

<p>The VE teacher must be able to manage the behavior of the diverse group of
students in the class.  <i>Behavior management is a system, method or technique
that enables students to understand and respond appropriately to school and
teacher expectations</i>.  A behavior management plan also helps students
become aware of their own need to belong by choosing appropriate behaviors to
achieve a special place in the classroom.<br>
<br>
<p>The purpose of establishing a sound behavior management plan in the classroom
is to enable students to be successful intellectually, socially and
emotionally.  Guiding and nurturing students in these areas enable children to
grow up to become independent, creative, problem-solving citizens.<P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Behavior Management System">Behavior Management System</A></h3><P>


<i>How do you develop a behavior management system?</i><br>
<br>
<p>To develop a successful behavior management system, several steps should be
followed.  They include the establishment of a set of classroom rules,
guidelines for implementation, and, if needed, a well-defined set of rewards
and consequences.<P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Establishing Classroom Rules">Establishing Classroom Rules</A></h3><P>

<i>How to Establish Classroom Rules</i><br>
<br>
<ol>
<li>Develop a maximum of five rules for your classroom.  Be sure they
correlate with school and district codes of conduct.<br>
<li>State the classroom rules positively.<br>
<li>Post the classroom rules in all four corners of the room on the first day of
school.<br>
<li>Include the classroom rules in a letter to parents and have parents sign and
return it to indicate their understanding and full cooperation for their
child's success.<br>
<li>Teach the classroom rules directly and review them for seven days, stating
the rationale and life value of each.<br>
<p>Some instructional activities that can be used include role playing or
dramatization, drawing pictures to illustrate the classroom rules, or
teacher-directed instruction to make sure that students can recognize and
demonstrate behaviors that follow the rules.  You may also find it helpful to
make sure that students recognize behaviors that do <i>not</i> follow the
rules.<br>
<li>Here are some examples of classroom rules:  <br>
</ol>
<pre>
	Give your best effort daily.
	Listen when the teacher or someone is talking.
	Raise your hand if you have something to say or to ask.
	Cooperate and get along with others.
	Complete all of your work. </pre><P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "Implementing Classroom Rules">Implementing Classroom Rules</A></h3><P>
<i>How to Implement Classroom Rules</i><br>
<br>
<ol>
<li>Be consistent.  Set standards and expectations and follow them.<br>
<li>Follow through with rewards and consequences that are realistic and
appropriate.<br>
<li>Provide both positive and corrective feedback to students and parents.<br>
<li>Provide ongoing parent/teacher communication on a daily or regular basis
depending on the severity of problems and needs of individual students. <br>
<li>As needed, go back to "square one."  Reteach the classroom rules directly
and review them for several days stating the rationale and life value of
each.</OL><P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Maintain the Momentum">Maintain the Momentum</A></h3><P>

<i>How to Maintain the Momentum (or How do I survive in this classroom?)</i><br>
<br>
<ul>
<li>Whenever a student breaks a rule, use <i>verbal correction</i>.<P>
Example:  "Carol, I see you talking.  What's the rule about talking?"  Wait
for response.  "What will you do in the future if you want to talk?  Repeat
that one more time." (Student verbalizes rule three times.)  If student says
she forgot, child should read rule from the chart and write that rule three
times.  <br>
<li>Whenever a student breaks a rule and refuses to comply with your directions,
use the <i>broken record</i> technique.  The teacher repeats the rule concisely
until student cooperates. <br>
<li>Whenever the "broken record" technique doesn't work, use the <i>choice
technique</i>.  Offer the student a choice of two things he may do, both of
which are acceptable to the teacher. It's recommended that one of the choices
be obviously more appealing to the student.<br>
<li>Whenever choice does not work, remove the student from the group until he or
she can act appropriately.  This is a form of <i>time out</i> that keeps the
student in the classroom.  Advance the student through the steps only as
necessary.<br>
	Step 1: Move chair away from the group, but facing the group so the student
can observe appropriate behavior.<br>
<br>
	Step 2: Leave the student where he or she is but turn the chair facing away
from the group.<br>
<br>
	Step 3: Isolate the student from the group but within view of adult.<br>
	Step 4: Have student draw or write responses to three questions:<br>
<br>
<i>		What did I do that put me in time out?</i><br>
<br>
<i>		What am I going to do in the future so this won't happen again?</i><br>
<br>
<i>		What did I miss as a result of being in time out?</i><br>
<li>Assess the student's needs, interests, and behavior patterns and
jointly construct a behavioral contract that specifically states what is
expected of the student.<br>
<li>Contact the parents and get them to sign and support contract agreement.<br>
<li>As a last resort, send student to the office where another alternative may be
considered. <br><P>
</ul></UL></DL><P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "RR for Students">R&amp; R for Students</A></h3><P>

To ensure a safe learning environment for all students, you may wish to
institute R&amp;R for students.  An area of the classroom is designated as
R&amp;R -- Rest and Return -- and is available to any students who feel the
need to cool down and collect their thoughts when their behavior has gotten out
of control.  Generally a two-minute stay in R&amp;R is sufficient for this
purpose.<br>
<br>
<p>If the student won't voluntarily go to the R&amp;R area, he or she is asked by
the teacher to put his head down on the desk for a specified time (e.g., three,
five, or ten minutes). <br>
<br>
<p>If the behavior persists or worsens, the student may be asked to leave the
classroom for a brief time and return when ready to participate.  If this is
required, it is recommended that someone, an aide or responsible student,
accompany the student to the alternative area.  Make sure that arrangements
have been made ahead of time for this type of crisis intervention.<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>


<h3><A NAME = "Keeping Track of the Students">Keeping Track of the Students</A></h3><P>

<p>On a paper attached to a magnetic board, the names of class members are listed.
When a student leaves the classroom, he or she places a single magnet next to
his/her name to indicate the reason for being out of the classroom for a short
period. These reasons may include restroom, mainstream class, therapy, etc.
When the child returns, the magnet is placed at the bottom of the list
indicating re-entry to the classroom.  This places the responsibility on the
students to manage their own coming and going in the classroom.  Additional
contingencies could be set up: for example, limiting the number of students
going out to the restroom at one time.<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<P>
<h3><A NAME = "Silent Signals">Silent Signals</A></h3><P>

Sign language can be used for general requests in the classroom.  There is a
signal students may use to sharpen their pencils, get a drink of water, or go
to the bathroom.  This decreases the problem of being interrupted while
conducting a lesson.  You can signal to the child to go ahead without stopping
your lesson with the individual group.  If you don't know sign language,
contact your district coordinator for hearing-impaired programs or your local
FDLRS Center.<P>

(from <i>Lynn Barbieri, Citrus County</i>)<br>
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Rewards Consequences">Rewards &amp; Consequences</A></h3><P>

A <i>level system</i> can be used for behavior management.  The system must be
developed in conjunction with the classroom rules and behavioral expectations
for the students.  Positive reinforcement is provided for behavior that follows
the rules and meets the expectations.  <br>
<p>In most level systems, a <i>point system</i> is developed to provide concrete
indicators to students.  Points are awarded to students on a regularly
scheduled basis throughout the day or week.  For example, the classroom day may
be divided into 30-minute intervals and a timer set to notify the teacher and
students.  In secondary schools, regular class periods serve as convenient
intervals.  <P>

<p>Points may be awarded for each classroom rule a student follows, and
percentages may be calculated to determine how well the student is doing.  For
some students, the percentages may be calculated to show what percent of time
the student is following each rule.  For other students, the percentages may be
calculated to show what percent of the rules are being followed.   The rewards
are based on the percentages: the higher the percentage, or the higher the
number of days the percentage was reached, the higher the level of reward.
Generally, the levels and rewards are determined once a week, although a daily
schedule may be needed for some students.<br>
<br>
<p>Most teachers identify several behavioral levels for reinforcement.  The levels
are defined in terms of privileges that the student earns.  Privileges can be
adjusted according to the student's interests.  <br>
<br>
Level 1.  Student's behavior is appropriate less than 80 percent of the time.
<br>
	No privileges.  Student has no choice in activity or free time.  Student may
not attend outside activities or field trips.<br>
	<br>
Level 2.  Student maintains appropriate behavior 80 percent of the time.<br>
	Student may select art or music centers, manipulatives, computers, or other
free-time activity.  Student may attend outside activities and field trips.<br>
<br>
Level 3.  Student maintains appropriate behavior 90 percent of the time.<br>
	Privileges are the same as for Level 2, plus student may go to media center,
run errands, or be a peer tutor. <P>
(from <i>Phil Carlson, Palm Beach County</i>)
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Another Level System">Another Level System</A></h3><P>

Students "make their day" by earning a certain percentage of points.  Once they
make ten days, students earn a reward (snack out of classroom school store).
Students advance to the next level after earning ten days on the current level.
They are also able to earn pro-social points for appropriate pro-social
behaviors.  Each pro-social point is worth $.05 which can be spent in the
classroom store.  <br>
<br>
<p>Individual point sheets are developed for each student with targeted short term
objectives from student's IEP.  These sheets are updated every two months.
This helps the teachers, aides, parents, and students stay focused on the
instructional objectives.  Points are posted daily and discussed. Points are
tallied daily and recorded on a point sheet that is sent home for parent
signature and returned the next day.  <P>
(from <i>Ann Campbell and Vicki Emo, Leon County</i>)<br>
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Token Economies">Token Economies</A></h3><P>

<p>Token economies are often used in connection with level systems for behavior
management.  However, they can stand alone.  Here are some examples of
economies that have worked in VE classes.<br>
<br>
<p>Students <i>earn play money for following classroom rules</i>,
<i>participation, completing assignments, etc</i>.  Students may also be fined
when rules are broken.  If they don't have enough money to pay their fines,
they receive chips from the teacher.  The chips serve as an IOU.  A red chip
equals $1.00.  A black chip equals $5.00.  As students earn money later in the
day or the week, a student must first pay off his/her fines.  The classroom
bank is displayed on one bulletin board.  "Baggies" are kept on this bulletin
board with students' names on them to hold deposits and IOU chips.   Money can
be used to purchase items from classroom store which is displayed on another
bulletin board.  Money could also be used for classroom or department auctions,
McDonald's Certificates, or earning privileges.<P>
(from <i>M. Wolf, Marion County</i>)<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "More Reward Systems">More Reward Systems</A></h3><P>


<b>More Reward Systems</b><P>
<p>Students earn $20 of<i> "good behavior money"</i> for every 10 minutes they
stay on task within the hour in the classroom.  An activity period is allotted
on Friday for good behavior money earned.  Good behavior dollars are produced
in neon colors in different currencies and bear the school logo. <br>
<br>
(from <i>Nanette Standfast, Pinellas County</i>)<P>
<p>To promote a positive behavior management system, students are given an<i>
A,B,C certificate</i> for good academics, behavior, or citizenship on which
they write their names.  At the end of class, students fold their awards in
half and place them in a box.  At least once a week a name is drawn from the
box.  This lucky student can exchange the A,B,C certificate for a tangible
award such as a small game, juice box, etc.  The A,B,C certificates reinforce
specific behaviors immediately and give students an opportunity to be drawn as
a chosen ticket.  The more A,B,C certificates earned, the better the student's
chances in the ticket drawing.  <br>
<br>
(from <i>Terri Partlow, Orange County</i>)<P>
<p><i>"Kind Acts and Good Deeds Jar" </i> Students have 10 - 15 name cards in an
envelope at their desk.  Whenever they do a kind act or good deed, they are
allowed to place their name in the jar.   This can also be used to reward
appropriate responses to bad situations.  Whenever they do their best to
respond to a negative situation in a positive manner, they whisper the
situation to the teacher and explain how they have tried to handle the
situation positively.  Examples:  ignoring rude comment, not hitting back after
being hit first, etc.  The teacher then asks students to place their names in
the jar for positive behavior responses.  Each Friday 3-5 names are selected
from the can for special recognition or reward.<P>
(from <i> Trina Cassidy, Orange County</i>)<P>

[<A HREF="#Home">Other Management Techniques</A>]   <P>

Information on <A HREF = "bees7d.HTM"> Using Aides, Volunteers, and Peer Support</a> is also available.<P>

<HR><P>
<P>[<A HREF="bees7b.HTM">Previous section</A>]   [<A HREF="bees7d.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]

<pre>









</pre>
</body></html>





















</DOC>
<DOC>
<DOCNO>WT01-B04-207</DOCNO>
<DOCOLDNO>IA039-000740-B042-110</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES7c.HTM 198.78.22.165 19970210073844 text/html 23286
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:4 GMT
Last-modified: Tuesday, 5-Mar-96 22:4:29 GMT
Content-length: 23030
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 --><A NAME = "Home"><TITLE>Resources for VE Teachers</TITLE></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees7b.HTM">Previous section</A>]   [<A HREF="bees7d.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<A NAME = "#Storing"><h1>Effective Practices for Varying Exceptionalities Classes</A></h1>
<HR>
<DL>
<h2>Managing the Classroom Environment</h2>
<DL>
<LI><A HREF = "#Storing">Storing Materials</A>
<LI><A HREF = "#Filing Worksheets">Filing Worksheets</A>
<LI><A HREF = "#Learning Centers">Learning Centers</A>
</DL></DL><P>

<DL><h2><A NAME = "#Managing Behavior">Managing Behavior</A></h2>
<DL>
<LI><A HREF = "#Managing Behavior">Managing Behavior</A>
<LI><A HREF = "#Behavior Management System">Behavior Management System</A>
<LI><A HREF = "#Establishing Classroom Rules">Establishing Classroom Rules</A>
<LI><A HREF = "#Implementing Classroom Rules">Implementing Classroom Rules</A>
<LI><A HREF = "#Maintain the Momentum">Maintain the Momentum</A>
</DL></DL><P>

<DL><h2>Other Management Techniques</h2>
<DL>
<LI><A HREF = "#RR for Students">R &amp; R for Students</A>
<LI><A HREF = "#Keeping Track of the Students">Keeping Track of the Students</A>
<LI><A HREF = "#Silent Signals">Silent Signals</A>
<LI><A HREF = "#Rewards Consequences">Rewards &amp; Consequences</A>
<LI><A HREF = "#Another Level System">Another Level System</A>
<LI><A HREF = "#Token Economies">Token Economies</A>
<LI><A HREF = "#More Reward Systems">More Reward Systems</A>
</DL></DL><P>
<HR>
<pre>




























</pre>
<H3><A NAME = "Storing">Storing Textbooks, Workbooks, and Other Materials</H3><P>

For books that must be easily available, teachers have found it helpful to
arrange areas on bookshelves.  By placing dividers about every 12 inches, books
can be easily put into the "cubbyholes."  Use plastic colored tape to code the
books by level or by subject area, so that matching their storage locations is
easy.  This same coding system could be used in other ways, perhaps to identify
materials for individual students.<P>
 
Workbooks with soft covers will survive longer if placed in plastic report
covers or if their covers are laminated.  Some report folders have a clear
front and solid back with a three-ring holder.  Have three holes drilled in the
workbooks so that they can be inserted in the folders easily.<P>

Books that are not currently needed are best stored out of the classroom.  It
may be possible to find a colleague who needs them.
<P>

[<A HREF="#Home">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Filing Worksheets">Filing Worksheets</A></h3><P>

Having access to a variety of worksheets can save the VE teacher a lot
of time.  But the key time-saver is having a system for filing so that the
worksheets can easily be retrieved.<br>
<i>Here's a system that works!  </i><br>
<br>
<p>Collect all loose worksheets and place all duplicate copies together in
individual files.  Take the original or best copy of each and number it
sequentially, so that each unique worksheet has a different number and there is
a numbered corresponding file folder with the duplicates.  <br>
<br>
<p>The originals can then be sorted by topic or skill and placed in three ring
notebooks.   You will have notebooks of worksheets for math skills, spelling
practice lessons, science concepts, etc. that you can scan easily to find just
the right one.  With the numbering system, you can go to your files and, by
matching the number, locate enough copies of the worksheets for your
students.<br>
<br>
<p>If you find that a worksheet fits in more than one category, just make enough
"originals" to place it in all appropriate notebooks.  If you are concerned
about putting holes in your originals to place them in the notebooks, put them
in the plastic sleeves that can be put in notebooks.</h3><P>

[<A HREF="#Home">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Learning Centers">Learning Centers</A></h3><P>

<p>Most teachers think of learning centers for elementary schools, but many
secondary teachers also find the concept very useful.  Learning centers are
used primarily to provide independent activities for students.  They can
provide a structured exploration of a specific subject, topic, skill, or
interest area.  The following are characteristics of a learning center:<br>
<br>
<ul>
<li>A learning center is self-instructional.  When designed properly, no direct
supervision of a teacher is required.<br>
<li>A learning center can present activities on a variety of levels of
difficulty.<br>
<li>A learning center should have clear objectives.<br>
<li>A learning center must include some method of record keeping for student
participation and accomplishment.<br>
<li>Students need to be taught how to use a learning center.<br>
<li>A learning center should be considered as a place where learning occurs, not
as a place for recreation.  <br>
(From <i>VE Teachers Handbook, </i>Polk County, draft, 1993)<br></UL><P>

[<A HREF="#Home">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Managing Behavior">Managing Behavior</A></h3><P>

<p>The VE teacher must be able to manage the behavior of the diverse group of
students in the class.  <i>Behavior management is a system, method or technique
that enables students to understand and respond appropriately to school and
teacher expectations</i>.  A behavior management plan also helps students
become aware of their own need to belong by choosing appropriate behaviors to
achieve a special place in the classroom.<br>
<br>
<p>The purpose of establishing a sound behavior management plan in the classroom
is to enable students to be successful intellectually, socially and
emotionally.  Guiding and nurturing students in these areas enable children to
grow up to become independent, creative, problem-solving citizens.<P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Behavior Management System">Behavior Management System</A></h3><P>


<i>How do you develop a behavior management system?</i><br>
<br>
<p>To develop a successful behavior management system, several steps should be
followed.  They include the establishment of a set of classroom rules,
guidelines for implementation, and, if needed, a well-defined set of rewards
and consequences.<P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Establishing Classroom Rules">Establishing Classroom Rules</A></h3><P>

<i>How to Establish Classroom Rules</i><br>
<br>
<ol>
<li>Develop a maximum of five rules for your classroom.  Be sure they
correlate with school and district codes of conduct.<br>
<li>State the classroom rules positively.<br>
<li>Post the classroom rules in all four corners of the room on the first day of
school.<br>
<li>Include the classroom rules in a letter to parents and have parents sign and
return it to indicate their understanding and full cooperation for their
child's success.<br>
<li>Teach the classroom rules directly and review them for seven days, stating
the rationale and life value of each.<br>
<p>Some instructional activities that can be used include role playing or
dramatization, drawing pictures to illustrate the classroom rules, or
teacher-directed instruction to make sure that students can recognize and
demonstrate behaviors that follow the rules.  You may also find it helpful to
make sure that students recognize behaviors that do <i>not</i> follow the
rules.<br>
<li>Here are some examples of classroom rules:  <br>
</ol>
<pre>
	Give your best effort daily.
	Listen when the teacher or someone is talking.
	Raise your hand if you have something to say or to ask.
	Cooperate and get along with others.
	Complete all of your work. </pre><P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "Implementing Classroom Rules">Implementing Classroom Rules</A></h3><P>
<i>How to Implement Classroom Rules</i><br>
<br>
<ol>
<li>Be consistent.  Set standards and expectations and follow them.<br>
<li>Follow through with rewards and consequences that are realistic and
appropriate.<br>
<li>Provide both positive and corrective feedback to students and parents.<br>
<li>Provide ongoing parent/teacher communication on a daily or regular basis
depending on the severity of problems and needs of individual students. <br>
<li>As needed, go back to "square one."  Reteach the classroom rules directly
and review them for several days stating the rationale and life value of
each.</OL><P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Maintain the Momentum">Maintain the Momentum</A></h3><P>

<i>How to Maintain the Momentum (or How do I survive in this classroom?)</i><br>
<br>
<ul>
<li>Whenever a student breaks a rule, use <i>verbal correction</i>.<P>
Example:  "Carol, I see you talking.  What's the rule about talking?"  Wait
for response.  "What will you do in the future if you want to talk?  Repeat
that one more time." (Student verbalizes rule three times.)  If student says
she forgot, child should read rule from the chart and write that rule three
times.  <br>
<li>Whenever a student breaks a rule and refuses to comply with your directions,
use the <i>broken record</i> technique.  The teacher repeats the rule concisely
until student cooperates. <br>
<li>Whenever the "broken record" technique doesn't work, use the <i>choice
technique</i>.  Offer the student a choice of two things he may do, both of
which are acceptable to the teacher. It's recommended that one of the choices
be obviously more appealing to the student.<br>
<li>Whenever choice does not work, remove the student from the group until he or
she can act appropriately.  This is a form of <i>time out</i> that keeps the
student in the classroom.  Advance the student through the steps only as
necessary.<br>
	Step 1: Move chair away from the group, but facing the group so the student
can observe appropriate behavior.<br>
<br>
	Step 2: Leave the student where he or she is but turn the chair facing away
from the group.<br>
<br>
	Step 3: Isolate the student from the group but within view of adult.<br>
	Step 4: Have student draw or write responses to three questions:<br>
<br>
<i>		What did I do that put me in time out?</i><br>
<br>
<i>		What am I going to do in the future so this won't happen again?</i><br>
<br>
<i>		What did I miss as a result of being in time out?</i><br>
<li>Assess the student's needs, interests, and behavior patterns and
jointly construct a behavioral contract that specifically states what is
expected of the student.<br>
<li>Contact the parents and get them to sign and support contract agreement.<br>
<li>As a last resort, send student to the office where another alternative may be
considered. <br><P>
</ul></UL></DL><P>

[<A HREF="#Home">Managing Behavior</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "RR for Students">R&amp; R for Students</A></h3><P>

To ensure a safe learning environment for all students, you may wish to
institute R&amp;R for students.  An area of the classroom is designated as
R&amp;R -- Rest and Return -- and is available to any students who feel the
need to cool down and collect their thoughts when their behavior has gotten out
of control.  Generally a two-minute stay in R&amp;R is sufficient for this
purpose.<br>
<br>
<p>If the student won't voluntarily go to the R&amp;R area, he or she is asked by
the teacher to put his head down on the desk for a specified time (e.g., three,
five, or ten minutes). <br>
<br>
<p>If the behavior persists or worsens, the student may be asked to leave the
classroom for a brief time and return when ready to participate.  If this is
required, it is recommended that someone, an aide or responsible student,
accompany the student to the alternative area.  Make sure that arrangements
have been made ahead of time for this type of crisis intervention.<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>


<h3><A NAME = "Keeping Track of the Students">Keeping Track of the Students</A></h3><P>

<p>On a paper attached to a magnetic board, the names of class members are listed.
When a student leaves the classroom, he or she places a single magnet next to
his/her name to indicate the reason for being out of the classroom for a short
period. These reasons may include restroom, mainstream class, therapy, etc.
When the child returns, the magnet is placed at the bottom of the list
indicating re-entry to the classroom.  This places the responsibility on the
students to manage their own coming and going in the classroom.  Additional
contingencies could be set up: for example, limiting the number of students
going out to the restroom at one time.<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<P>
<h3><A NAME = "Silent Signals">Silent Signals</A></h3><P>

Sign language can be used for general requests in the classroom.  There is a
signal students may use to sharpen their pencils, get a drink of water, or go
to the bathroom.  This decreases the problem of being interrupted while
conducting a lesson.  You can signal to the child to go ahead without stopping
your lesson with the individual group.  If you don't know sign language,
contact your district coordinator for hearing-impaired programs or your local
FDLRS Center.<P>

(from <i>Lynn Barbieri, Citrus County</i>)<br>
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Rewards Consequences">Rewards &amp; Consequences</A></h3><P>

A <i>level system</i> can be used for behavior management.  The system must be
developed in conjunction with the classroom rules and behavioral expectations
for the students.  Positive reinforcement is provided for behavior that follows
the rules and meets the expectations.  <br>
<p>In most level systems, a <i>point system</i> is developed to provide concrete
indicators to students.  Points are awarded to students on a regularly
scheduled basis throughout the day or week.  For example, the classroom day may
be divided into 30-minute intervals and a timer set to notify the teacher and
students.  In secondary schools, regular class periods serve as convenient
intervals.  <P>

<p>Points may be awarded for each classroom rule a student follows, and
percentages may be calculated to determine how well the student is doing.  For
some students, the percentages may be calculated to show what percent of time
the student is following each rule.  For other students, the percentages may be
calculated to show what percent of the rules are being followed.   The rewards
are based on the percentages: the higher the percentage, or the higher the
number of days the percentage was reached, the higher the level of reward.
Generally, the levels and rewards are determined once a week, although a daily
schedule may be needed for some students.<br>
<br>
<p>Most teachers identify several behavioral levels for reinforcement.  The levels
are defined in terms of privileges that the student earns.  Privileges can be
adjusted according to the student's interests.  <br>
<br>
Level 1.  Student's behavior is appropriate less than 80 percent of the time.
<br>
	No privileges.  Student has no choice in activity or free time.  Student may
not attend outside activities or field trips.<br>
	<br>
Level 2.  Student maintains appropriate behavior 80 percent of the time.<br>
	Student may select art or music centers, manipulatives, computers, or other
free-time activity.  Student may attend outside activities and field trips.<br>
<br>
Level 3.  Student maintains appropriate behavior 90 percent of the time.<br>
	Privileges are the same as for Level 2, plus student may go to media center,
run errands, or be a peer tutor. <P>
(from <i>Phil Carlson, Palm Beach County</i>)
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Another Level System">Another Level System</A></h3><P>

Students "make their day" by earning a certain percentage of points.  Once they
make ten days, students earn a reward (snack out of classroom school store).
Students advance to the next level after earning ten days on the current level.
They are also able to earn pro-social points for appropriate pro-social
behaviors.  Each pro-social point is worth $.05 which can be spent in the
classroom store.  <br>
<br>
<p>Individual point sheets are developed for each student with targeted short term
objectives from student's IEP.  These sheets are updated every two months.
This helps the teachers, aides, parents, and students stay focused on the
instructional objectives.  Points are posted daily and discussed. Points are
tallied daily and recorded on a point sheet that is sent home for parent
signature and returned the next day.  <P>
(from <i>Ann Campbell and Vicki Emo, Leon County</i>)<br>
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Token Economies">Token Economies</A></h3><P>

<p>Token economies are often used in connection with level systems for behavior
management.  However, they can stand alone.  Here are some examples of
economies that have worked in VE classes.<br>
<br>
<p>Students <i>earn play money for following classroom rules</i>,
<i>participation, completing assignments, etc</i>.  Students may also be fined
when rules are broken.  If they don't have enough money to pay their fines,
they receive chips from the teacher.  The chips serve as an IOU.  A red chip
equals $1.00.  A black chip equals $5.00.  As students earn money later in the
day or the week, a student must first pay off his/her fines.  The classroom
bank is displayed on one bulletin board.  "Baggies" are kept on this bulletin
board with students' names on them to hold deposits and IOU chips.   Money can
be used to purchase items from classroom store which is displayed on another
bulletin board.  Money could also be used for classroom or department auctions,
McDonald's Certificates, or earning privileges.<P>
(from <i>M. Wolf, Marion County</i>)<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "More Reward Systems">More Reward Systems</A></h3><P>


<b>More Reward Systems</b><P>
<p>Students earn $20 of<i> "good behavior money"</i> for every 10 minutes they
stay on task within the hour in the classroom.  An activity period is allotted
on Friday for good behavior money earned.  Good behavior dollars are produced
in neon colors in different currencies and bear the school logo. <br>
<br>
(from <i>Nanette Standfast, Pinellas County</i>)<P>
<p>To promote a positive behavior management system, students are given an<i>
A,B,C certificate</i> for good academics, behavior, or citizenship on which
they write their names.  At the end of class, students fold their awards in
half and place them in a box.  At least once a week a name is drawn from the
box.  This lucky student can exchange the A,B,C certificate for a tangible
award such as a small game, juice box, etc.  The A,B,C certificates reinforce
specific behaviors immediately and give students an opportunity to be drawn as
a chosen ticket.  The more A,B,C certificates earned, the better the student's
chances in the ticket drawing.  <br>
<br>
(from <i>Terri Partlow, Orange County</i>)<P>
<p><i>"Kind Acts and Good Deeds Jar" </i> Students have 10 - 15 name cards in an
envelope at their desk.  Whenever they do a kind act or good deed, they are
allowed to place their name in the jar.   This can also be used to reward
appropriate responses to bad situations.  Whenever they do their best to
respond to a negative situation in a positive manner, they whisper the
situation to the teacher and explain how they have tried to handle the
situation positively.  Examples:  ignoring rude comment, not hitting back after
being hit first, etc.  The teacher then asks students to place their names in
the jar for positive behavior responses.  Each Friday 3-5 names are selected
from the can for special recognition or reward.<P>
(from <i> Trina Cassidy, Orange County</i>)<P>

[<A HREF="#Home">Other Management Techniques</A>]   <P>

Information on <A HREF = "bees7d.HTM"> Using Aides, Volunteers, and Peer Support</a> is also available.<P>

<HR><P>
<P>[<A HREF="bees7b.HTM">Previous section</A>]   [<A HREF="bees7d.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]

<pre>









</pre>
</body></html>





















</DOC>
<DOC>
<DOCNO>WT01-B04-208</DOCNO>
<DOCOLDNO>IA039-000740-B042-144</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES7d.HTM 198.78.22.165 19970210073902 text/html 9912
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:5 GMT
Last-modified: Tuesday, 5-Mar-96 22:4:49 GMT
Content-length: 9657
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 --><A NAME = "Home"><TITLE>Resources for VE Teachers</TITLE></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees7c.HTM">Previous section</A>]   [<A HREF="bees8.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<h1>Effective Practices for Varying Exceptionalities Classes</h1><P>
<DL><A NAME = "#Using Aides"><h2>Other Management Techniques</A></h2>

<DL>
<LI><A HREF = "#Using Aides">Using Aides, Volunteers, and Peer Support</A>
<LI><A HREF = "#Common Concerns">Common Concerns</A>
<LI><A HREF = "#Teacher Aides">Teacher Aides</A>
<LI><A HREF = "#Volunteers">Volunteers</A>
<LI><A HREF = "#Peer Support">Peer Support</A>
</DL></DL><P>
<HR>
<pre>





























</pre>
<h3><A NAME = "Using Aides">Using Aides, Volunteers, and Peer Support</a></h3><P>

<p>An extra hand is always needed in a VE class.  Many teachers are fortunate
to have aides or paraprofessionals assigned to their classes.  Some teachers
use the school volunteer program to lend a hand.   Students can also be a
welcome source of assistance to teachers.  This section provides some
recommendations for ensuring success with assistants in the classroom.</i>
<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Common Concerns">Common Concerns</A></h3><P>

<i>Who's in charge?  </i>The most common problem faced when bringing aides and
volunteers into the classroom involves their authority.  Often the students in
a VE class do not respect the direction provided by someone other than their
teacher.  VE teachers must show the students that aides and volunteers have
their complete support.<P>

<i>Recognition for Effort  </i>It is strongly suggested that aides, volunteers
and peer support receive recognition on a regular basis. These individuals
should be reinforced for their efforts.  They should know that their efforts
have been valuable and have contributed to the development and progress of the
children they have helped.<P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Teacher Aides">Teacher Aides</A></h3><P>

Teacher aides are members of the instructional staff at the school.  Some
districts use different titles for this job, but generally the aide's job is to
assist the teacher.  Duties may include administrative and clerical tasks,
arranging the classroom environment for learning, instruction-related
responsibilities, and supervisory activities with students.  <br>
<br>
<p>The teacher aide will need both knowledge and skill training to work
effectively in a VE classroom.  The school district, often in collaboration
with the regional FDLRS center, can make training available to teacher aides.
It is suggested that the aide be involved in an inservice training prior to
working with the  students in VE classes. This training should involve a basic
understanding of child growth and development and a general knowledge of
educational approaches to learning.  They will need to have an understanding of
the basic causes and characteristics of handicapping conditions for students
with whom they work.  They must understand the purpose of Individual
Educational Plans and how they are developed and carried out. <br>
<br>
<p>The specific duties of teacher aides varies from district to district.  Certain
restrictions may be placed on the range of duties assigned based on the source
of funding.  If aides are paid from federal IDEA funds, they may not provide
services to students who are not eligible for exceptional student education,
nor may they work with gifted students.  <P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Volunteers">Volunteers</A></h3><P>

Volunteers are recruited from the community to assist in classrooms.  Most
districts and schools have an organized program to facilitate this effort.
However, volunteer programs may not always be utilized in VE classes.
Sometimes ESE teachers feel that volunteers may not be suited for their
programs.  This is certainly not true.  What is needed, is volunteer selection
and preparation procedures that insures their awareness of the characteristics
of the students in VE classesand their readiness to respond appropriately.

<p>In many situations, volunteers may have duties that are similar to those of the
teacher aides.  However, they usually have not been specifically trained for
their role and the time they have to spend in the classroom is generally more
limited.  The volunteer may assist with preparing materials for the classroom,
filing student work, and providing important personal contact with students.<br>

<p>It is suggested that volunteers spend some time in the classroom before
committing to the job. Training is also recommended to prepare volunteers to
work with the students appropriately.
<P>
<i>Where can volunteers be found?</i><P>

If you don't have a ready source of volunteers for your classroom, try
these sources:<P>
<ul>
<li>Church groups and service clubs in the community<P>
<li>Business partnerships who provide release time for employees to serve as
mentors and volunteers in school programs<<P>
<li>Senior-citizen groups<P>
<li>Community college and university training programs<<P>
</ul><P>

[<A HREF="#Home">Other Management Techniques</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Peer Support">Peer Support</A></h3><P>

The use of students to provide assistance in the VE classroom benefits both the
ESE students and the student volunteers.  In some districts, older students
from nearby schools may earn credit by assisting in these classrooms.  Peer
support can also involve students from within the VE classroom or from regular
education classrooms in the school. The student assistant can provide
instructional assistance and be a positive social influence.<P>

<H4>Selection of Students for Peer Support</H4><P>

Peer support students can be selected by an interest survey and teacher
recommendation.  Some high school service clubs may be interested in sponsoring
a student assistance program.  It may be possible to recruit peer support
students from within the VE classroom.  Older, more mature students can serve
as respected role models.  Students will need structure and training to serve
effectively as a peer support.  The teacher should carefully select these
students. The factors that should be considered include reliability,
compatibility, behavior, and willingness to make a commitment.<P>

The following are examples of peer support programs that teachers in Florida
have used.<P>

<H4>Reading Buddies</H4><P>

Once a week ESE students meet with their reading buddies from first grade.
Each pair or threesome take turns reading their book to the other students.
This stimulates students' interest in reading as they have a direct, interested
audience. <P>

(from <i>Trina Cassidy, Orange County</i>)<P>

<H4>Mentors for Visually Impaired Students</H4><P>

Regular-education students are enrolled in a specially designed program
to assist visually impaired students in the mainstream setting.  As mentors,
they help the vision teacher by working with visually impaired high school
students and also travel to middle schools to provide reader services, large
print work, graphic details, and personal life experiences.  The regular
education students earn credit for their work.  Such a program can easily be
adapted for all types of students with disabilities. <P>

(from <i>Sandi Serventi, Leon County</i>) <P>

<H4>Peer Facilitators for the ESE Reading Program</H4><P>

A partnership between peer facilitators, ESE students, and teachers is
established to assist in the ESE reading program.  The peer facilitators are
specially chosen for patience, willingness, academic levels, character, and
dependability and work under the supervision of the guidance counselor.  ESE
students are chosen by reading level, desire to improve, and basic need, and
work under the supervision of the ESE teacher.  Peer facilitators and ESE
students work together to practice reading skills and enhance reading
abilities.  <P>

(from <i>Kay Dorsey, Citrus County</i>)<P>
[<A HREF="#Home">Other Management Techniques</A>] <P>

Information on <A HREF = "bees8.HTM"> Staffing Considerations for VE Placement </a> is also available.
<P>
<HR>
<P>[<A HREF="bees7c.HTM">Previous section</A>]   [<A HREF="bees8.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]

</body></html>























</DOC>
<DOC>
<DOCNO>WT01-B04-209</DOCNO>
<DOCOLDNO>IA039-000740-B042-72</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES7b.HTM 198.78.22.165 19970210073806 text/html 25276
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:2 GMT
Last-modified: Tuesday, 5-Mar-96 22:4:10 GMT
Content-length: 25020
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 --><A NAME = "Scheduling"><TITLE>Resources for VE Teachers</TITLE></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<P>[<A HREF="bees7a.HTM">Previous section</A>]   [<A HREF="bees7c.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<h1>Effective Practices for Varying Exceptionalities Classes</h1><P>
<DL><h2><A NAME = "#Scheduling">Scheduling</A></h2>
<DL>
<LI><A HREF = "#General Suggestions">General Suggestions</A>
<LI><A HREF = "#Elementary Programs">Elementary Programs</A>
<LI><A HREF = "#Secondary Programs">Secondary Programs</A>

</DL><P>

<h2>
<A NAME = "#Grouping for Instruction">Grouping for Instruction</A>
</h2>
<DL>
<LI><A HREF = "#Grouping for Instruction">Grouping for Instruction</A>
<LI><A HREF = "#Independent Learning">Independent Learning</A>
<LI><A HREF = "#One-on-One Instruction">One-on-One Instruction</A>
<LI><A HREF = "#Large and Small Groups">Large and Small Groups</A>
<LI><A HREF = "#Students in the Mainstream">Students in the Mainstream</A>
</DL><P>

<h2>
<A NAME = "Managing the Classroom Environment">Managing the Classroom Environment</A>
</h2>
<DL>
<LI><A HREF = "#Managing the Classroom">Managing the Classroom Environment</A>
<LI><A HREF = "#Planning the Environment">Planning the Environment</A>
<LI><A HREF = "#Arranging the Furniture">Arranging the Furniture</A>
<LI><A HREF = "#Organizing Instructional Materials and Supplies">Organizing Instructional Materials and Supplies</A>
</DL></DL><P>
<HR>
<pre>





























</pre>
<h3>
<A NAME = "General Suggestions">Scheduling</A>
</h3>
<h4>General Suggestions</h4>

<br>
<!-- insert graphic re: scheduling depict a matrix with students names down
one column and time periods across top --><br>
<br>
<p>Many VE teachers have raised concerns about the way that students are
scheduled into their classes.  They feel that they have to work around the
demands of all other programs in the school.  A proactive approach is needed to
facilitate appropriate scheduling.  The following list provides a number of
suggestions that may assist the VE teacher in developing the classroom schedule
at the beginning of the school year.<br>
<br>
<ul>
<li>Try not to remove ESE students from their homeroom time.  Wait until
announcements are finished.
<br>
<li>Allow time in the weekly or semester schedule for non-instructional duties,
such as paperwork, testing, conferencing with parents and teachers, and
planning.
<br>
<li>Be firm and assertive about scheduling for the time specified on the student's
IEP.
<br>
<li>If you must teach more than one subject at a time, make sure you have the
support you need.  For some students and subjects, an integrated and
interdisciplinary approach to instruction works very well.
<br>
<li>Make individual plans for students that could be used for a period of time.
Students could keep track of accomplishments and check off work as they
complete it.  Assignments may be posted on the bulletin board and students can
be responsible for tracking their completion.
<br>
<li>Stress day-by-day organization which is as critical as the weekly or yearly
plan.  Students need to know exactly what to do each day and the rules should
be consistently applied.
<br>
<li>Be aware of practices like Friday testing in the regular classroom.  Correlate
your activities as appropriate.
<br>
<li>Provide lesson plans for aides and volunteers so they will know what to do.
<br>
</ul><P>

[<A HREF="#Scheduling">Scheduling</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h4>
<A NAME = "Elementary Programs">Elementary Programs</A></h4>
<p>The following suggestions are intended to help teachers in elementary
schools whose ESE students regularly participate in mainstream programs.
<P>
<ul>
<li>Use the school's master schedule to identify times when all ESE students are
in mainstream programs, such as music, art, and physical education; include
lunch and other common times.
<br>
<li>Coordinate with the regular teacher's classroom schedule.  Where possible and
appropriate, the ESE student should remain in the regular classroom for classes
and activities in which they can experience success.
<br>
<li>Try to schedule students in the VE class for the subject or area identified on
the IEP at the same time their regular class has this scheduled.  Arrange the
VE schedule so that students can be grouped by academic or social needs, not
necessarily by grade level or by exceptionality.
<br>
<li>Sometimes, you may find that the all of the regular classes offer the targeted
subjects, like reading, at the same time of day.  The VE schedule becomes
overloaded at certain times during the day and very light at others.  The ESE
teacher may be able to negotiate with the regular teacher or the school
administrator to adjust the schedule or to accommodate the ESE students in the
regular class.
<br>
<li>If you have both part-time and full-time students in the class, try to
schedule students so that they can be grouped by functional level.
<br>
</ul>
<P>
[<A HREF="#Scheduling">Scheduling</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4>
<A NAME = "Secondary Programs">Secondary Programs</A>
</h4>
<p>The following suggestions are intended for teachers in middle and high
schools.<br>
<br>
<ul>
<li>ESE students should be hand-scheduled or scheduled first if a computer program
is used to ensure that appropriate courses and instructors are selected.  This
will help to avoid  placing students in inappropriate classes.
<br>
<li>Providing a consistent structure can assist students in meeting requirements
of many different teachers.  Daily reviews of expectations in each class will
promote improved behavior.
<br>
<li>Help students who are new to the school find their way around.  Older students
can be assigned to help new students for the first few weeks.
<br>
</ul>
<P>
[<A HREF="#Scheduling">Scheduling</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>


































</pre>
<h2>
<A NAME = "Grouping for Instruction">Grouping for Instruction</A></h2><br>

<br>
<p>After the schedule has been set for the VE class, the teacher must determine
how the students will be grouped for instruction.  The effective use of
grouping techniques can result in a classroom that functions as a real learning
community.  The following section provides descriptions of major types of
grouping techniques, with guidelines for determining the benefits of each type
of grouping, and recommendations and cautions for effective use of the grouping
technique.<br>
<br>
<i>Although each exceptional student has an Individual Education Plan and
should be provided individualized instruction and assessment, students can
benefit from participation in group instruction and group work.  </i><br>
<br>
<!-- insert graphics of 1-1, independent, small and large groups of students--><br>
<P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "Independent Learning">Independent Learning</A>
</h3><br>
<br>
<!-- insert graphic of independent learner--maybe with computer--><br>
<i>What does this accomplish?</i><br>
<br>
<p>Independent learning provides opportunities for students in VE classes
to practice needed skills, promote responsibility and individual effort, and
build time management skills and self-directed work habits. 
<br>
<br>
<i>Who benefits?</i><br>
<br>
<p>All students in VE classes can benefit from independent learning activities.
Even prekindergarten students in play activities are learning independently.
Older students requiring drill and practice for skill development and
reinforcement may use this method.  In self-guided learning activities,
students can work at their own pace. <br>
<br>
<i>How do you make this work?</i><br>
<br>
<b>Select the activities.</b> The types of activities used for
independent learning do not have to be limited to paper-and-pencil worksheets.
Activity centers can be created in which students can work on interesting
tasks.  Creative centers promote self-expression.  The computer is a natural
tool for an independent learning activity center.<br>
<br>
<b>Provide a management routine.</b> Students will need to be able to perform
the expected behaviors and outcomes of independent learning activities.
Students should be able to select, retrieve, and return all needed equipment
and materials.  The more you can rely on students to do things for themselves,
the more they will gain from the activities.<br>
<br>
<b>Provide feedback on performance.</b> Even though the activities are
independent, students will need direct feedback on their performance.  Many ESE
students benefit from clear evidence of their progress.<br>
<br>
<br>
<i>Any cautions?</i><br>
<br>
<b>Selection of activities.</b> Teachers in VE classes must provide the
structure for independent learning activities.  Activities should be carefully
selected so that they are appropriate for the students.  They should neither be
too difficult nor too easy.  Independent learning activities must be
sufficiently challenging and even more important, they must be interesting to
the students.<br>
<br>
<b>Arranging the learning environment.</b>The learning environment in the VE
class must be arranged so that students can easily locate the materials
themselves.  Students also should learn how to get help in ways that do not
disrupt the rest of the classroom activities.  Silent signals and learning
buddies are two methods that have worked in many classrooms.<br>
<P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "One-on-One Instruction">One-on-One Instruction</A>
</h3>
<P>
<!--insert graphic with one on one instruction--><br>
<br>
<i>What does this accomplish?</i><br>
<br>
<p>One-on-one instruction is used to provide the most intensive kind of
instruction.  Modeling, prompting, and feedback can be individualized to
anticipate and respond directly to the learner's needs.<br>
<br>
<br>
<i>Who benefits?</i><br>
<br>
<p>Students requiring personal contact for information to be processed will
require one-on-one instruction.  All students in a VE class may require
one-on-one instruction from time to time.  Students who are most likely to need
this type of instruction include the following:<br>
<br>
<ul>
<li><b>New Students</b>--Students who do not know the classroom routine do not
know how to get help independently.<br>
<br>
<li><b>Students in Crisis</b>--Students who temporarily lack self-control need
much direct support and structure.<br>
<br>
<li><b>Students Learning a New Skill</b>--Students learning new skills require
careful attention to the modeling and feedback provided by the teacher.
Sometimes this is most efficiently delivered on a personalized basis.<br>
<br>
<li><b>Students with Sensory Impairments</b>--Students whose ability to receive
information is impaired may require personal contact.  Some dual sensory
impaired students need to have the sign language transmitted in their hand.<br>
<br>
</ul>
<i>How do you make this work?</i><br>
<br>
<p>The most successful use of one-on-one instruction necessitates careful
planning.  When the VE teacher anticipates the need for this approach, the
appropriate conditions can be arranged.  A classroom management program is
needed for the other students and could involve peer tutoring, independent task
completion routines, and use of assistants and volunteers.  One-on-one
instruction may require the classroom teacher for delivery, but it may also be
provided by teacher assistants or through computer-assisted instruction.  In
some cases, the teacher can get the process started, then move aside as other
support mechanisms take over.<br>
<br>
<i>Any cautions?</i><br>
<br>
<p>As in any ESE class, teachers need to keep the goal of independent learning at
the forefront. In VE classes, students often need a lot of one-on-one
instruction at first.  Plan to fade some of the direct assistance as the child
becomes acclimated to the classroom or more proficient in practicing the new
skill.  Where groups of students must be instructed together, shift back and
forth from whole group participation to individual instruction and response.
When students in VE classes are taught how to be independent learners, they can
become partners in the process.<br>
<br>
<br>
<!--insert graphics with large groups and cooperative groups-->
<P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "Large and Small Groups">Large and Small Groups</A>
</h3><P>
<i>What does this accomplish?</i><br>
<p>For students with similar learning needs, group instruction provides an
efficient method for demonstrations, information presentations, and modeling.
For students with more diverse learning needs, group instruction can be used to
provide shared experiences.  Many VE classrooms use cooperative learning groups
to accommodate the diversity of student learning needs.<br>
<br>
<i>Who benefits?</i><br>
<p>Students of all ages can benefit from group learning experiences.  Very
young students may require smaller groups and activities that are relatively
short.  Older students will need activities that are well paced and easy to
follow.  Students with disabilities may need to learn how to participate in
group activities.<br>
<br>
<i>How do you make this work?</i><br>
<b>Keep grouping flexible. </b> Planning for instruction in a VE class requires
the teacher to consider the needs of  all students in the class.  Students may
be grouped for specific skill learning or for concept development.  Because of
the diversity within a VE class, teachers often must group and regroup students
throughout the day.  Most students can adjust to this type of flexibility as
long as it is predictable.  Students can follow a task card, with symbols
representing where they are to be.  A timer in the classroom can help to signal
change in activities.  <br>
<br>
<b>Use media to enhance presentations. </b> When information must be presented
to a group of students, visual and auditory aids are particularly useful.
These aids can reinforce the key points.   Concrete examples are generally the
most effective presentation aids.<br>
<br>
<b>Keep students actively involved.  </b>Learning requires active involvement.
Listening is rarely sufficient for students in VE classes to gain the
information and understanding provided through verbal instruction.  Use a lot
of cues to focus the student's attention.  Students can also participate in
group instruction in a variety of ways.  Assign each student a different role
or expectation, then have them collaborate to complete a related task.<br>
<br>
<b>Combine a variety of activities.  </b>Many teachers find group instruction
successful when they combine several activities within a class period.  Begin
the lesson with an advanced organizer that "sets the stage" and provides an
overview of the lesson or a link to what was done in previous lessons.  The
lesson can easily combine whole-group, small-group, and individual activities.
Don't forget to end the lesson with a summary or post-organizer.<br>
<br>
<i>Any cautions?</i><br>
<p>Monitoring student response to group instruction is the key to its
effectiveness.  Students will be processing information at different rates and
varying in their participation.  The teacher must always check for
understanding.  Group feedback can be effective for some activities.  However,
individual feedback may also be required.<br><P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Students in the Mainstream">Students in the Mainstream</A></h3>
<P>
<i>What does this accomplish?</i><br>
<br>
<p>To the extent appropriate, exceptional students should be provided education in
the least restrictive environment.  For the majority of ESE students, this
means participation in mainstream programs with their peers. <P>

<i>Who benefits?</i><br>

<p>ESE students can benefit from both the instructional and socialization
opportunities available through placement in regular classes.  For some,
accommodations may need to be provided  in terms of instructional methods,
communication modes, and assessment procedures.<br>
<br>
<br>
<i>How do you make this work?</i><br>
<br>
<p>A structured process has been widely used in Florida to promote the
successful integration of exceptional students in mainstream classes.
Cooperative Consultation (Riegel, 1988) provides a set of easy to use
checklists and forms through which exceptional education and mainstream
teachers can assess needs and plan realistic alternatives for students
encountering difficulty in the school setting.  The process facilitates open
communication among the professionals and with the students.  The result is a
shared responsibility for implementing alternatives and monitoring the outcomes
for the student.  The process requires the following steps:  <br>
<br>
<ul>
<li>Assess the ESE student's educational needs.<br>
<br>
<li>Assess the demands of the mainstream environment.<br>
<br>
<li>Determine any modifications or accommodations needed for the ESE
student.<br>
<br>
<li>Monitor the implementation of the modifications and the progress of the ESE
student.<br>
<br>
</ul>
<i>Any cautions?</i><br>
<br>
<p>Mainstreaming works well when the mainstream teacher, the ESE teacher,
and the ESE student have clearly communicated and agreed upon their
expectations and responsibilities.  When success is left to chance, results are
generally uneven.  <P>
[<A HREF="#Scheduling">Grouping for Instruction</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h2><A NAME = "Managing the Classroom">Managing the Classroom Environment</A></h2>
<P>
<p>The way you organize your classroom will contribute to the management of
instruction.  Furniture arrangement, access to equipment and materials, and
organization of materials all play key roles in managing the classroom
environment.<P>
[<A HREF="#Scheduling">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Planning the Environment">Planning the Environment</A></h3><p>

As you begin to think about organizing your classroom, here is a list of
things you may want to consider.<br>
<br>
<i>Take stock of what you will need.</i><br>
<br>
<ul>
<li>How many students will be in the classroom at a time?<br>
<br>
<li>Will there be an aide or volunteers?<br>
<br>
<li>What equipment and furniture is assigned to the room?<br>
<br>
<li>What instructional materials are available?<br>
<br>
<li>How can I get furniture, equipment, or materials I need?<br>
<br>
</ul>
<br>
<i>Organize your space.</i><br>
<br>
<ul>
<li>What kinds of working spaces will be needed?<br>
<br>
<li>How can the space be divided to accommodate the different kinds of
instructional activities that are used?<br>
<br>
<li>How can the furniture be used to create different areas in the room?<br>
<br>
</ul>
<cite>From <i>VE Teacher Handbook, </i>Polk County, draft, 1993</cite><br>
<P>
[<A HREF="#Scheduling">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h3><A NAME = "Arranging the Furniture">Arranging the Furniture</A></h3>
<P>
Because of the wide variability in classroom size and location, no
single arrangement for desks and centers will work in all VE classrooms.  The
following arrangements are provided to represent the typical types of
classrooms and the advantages and disadvantages are listed to help teachers
decide which arrangement works best for them (adapted from <i>The Solution
Book</i>, SRA).<br>
<br>
<b>CLASSROOM STYLE</b><br>
<br>
<br>
<IMG align=center SRC="DOC71.gif"><br>
<br>
<u>Benefits</u><br>
<p>This arrangement has been the traditional arrangements in classrooms for
many years.  It places the teacher at the head of the classroom and faces all
students to the center of instruction.  It is an efficient use of space, and
may be used to keep individual desks away from learning centers, computers, or
other special features in the classroom.  When large group instruction and
presentation by the teacher is the most frequently used format, this style is
preferred.<br>
<br>
<u>Problems</u><br>
<p>When students are arranged in rows, the students at the back of the
classroom may have difficulty seeing the chalkboard or other visual aids in the
front of the room.  Students also may be too close together for independent
work, and behavior problems may result.  <br>
<b>CLUSTER STYLE</b><br>
<br>
<br>
<IMG align=center SRC="DOC72.gif"><br>
<u>Benefits</u><br>
<p>Grouping desks in clusters can be used in classes to support cooperative
learning activities, and team work.  In many VE classes, there are small groups
of students who are working on the same level, and this classroom arrangement
could facilitate their instruction.  Praise can be delivered to groups of
students as well as to individuals.  <br>
<br>
<u>Problems</u><br>
<p>This arrangement may require more classroom space and leave little room
for learning centers or other special classroom areas.  Because students are
facing each other, behavior problems sometimes occur during independent work
time.  Dividers may need to be used to partition the workspace.  When whole
group instruction is used, students may not all be facing the same direction.
<br>
<br>
<b>BOARDROOM STYLE</b><br>
<br>
<IMG align=center SRC="DOC73.gif"><br>
<br>
<u>Benefits</u><br>
<p>Grouping desks is sometimes necessary when classroom space is limited.
This works well when students are all working together on the same project or
when students can work well independently.<br>
<br>
<u>Problems</u><br>
<p>Like cluster style, the arrangement sometimes results in behavior
problems during independent work because students are facing each other.
Students may also have difficulty receiving individual help from the
teacher.<P>
[<A HREF="#Scheduling">Managing the Classroom Environment</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3><A NAME = "Organizing Instructional Materials and Supplies">Organizing Instructional Materials and Supplies</A></h3>
<P>
Think about how you will arrange and file your instructional materials
so that you, your assistants, and your students can easily access what is
needed.<br>
<br>
<ul>
<li>Where and how will you store textbooks, workbooks and other materials that are
being used?  What about the things you don't need right now?<br>
<br>
<li>How will worksheets be filed?<br>
<br>
<li>How will supplies be stored?<br>
<br>
</ul><P>
[<A HREF="#Scheduling">Managing the Classroom Environment</A>] <P>
<HR>
<p>Information on <A HREF = "BEES7C.HTM"><i>Storing Textbooks, Workbooks, and Other Materials</i></A> is also available.<P><P>
<P>[<A HREF="bees7a.HTM">Previous section</A>]   [<A HREF="bees7c.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<pre>








</pre>
</body></html>




























</DOC>
<DOC>
<DOCNO>WT01-B04-210</DOCNO>
<DOCOLDNO>IA039-000740-B041-34</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/BEES7a.HTM 198.78.22.165 19970210073312 text/html 29381
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:1 GMT
Last-modified: Tuesday, 5-Mar-96 22:3:46 GMT
Content-length: 29125
</DOCHDR>
<!doctype html public "-//W30//DTD W3 HTML 2.0//EN">
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.4 -->
<A NAME = "Effective Practices"><TITLE>Resources for VE Teachers</TITLE></A></head>
<body bgcolor=#FFFFFF text=#000000>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<br>
<P>[<A HREF="bees6.HTM">Previous section</A>]   [<A HREF="bees7b.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>

<h1>Effective Practices for Varying Exceptionalities Classes</h1><P>
<DL>
<LI><A HREF = "#Organizing and Managing">Organizing and Managing Diversity in Instruction</A>
<LI><A HREF = "#Characteristics of Exceptional">Characteristics of Exceptional Students</A>
<DL>
<LI><A HREF= "#Autistic">Autistic</A>
<LI><A HREF= "#Dual Sensory Impaired">Dual Sensory Impaired</A>
<LI><A HREF= "#Emotionally Handicapped">Emotionally Handicapped and Severely Emotionally Disturbed</A>
<LI><A HREF= "#Gifted">Gifted</A>
<LI><A HREF="#Hearing Impaired">Hearing Impaired</A>
<LI><A HREF="#Mentally Handicapped">Mentally Handicapped</A>
<DL>
<LI> <A HREF="#Educable Mentally Handicapped (EMH)">Educable Mentally Handicapped (EMH)</A>
<LI> <A HREF="#Trainable Mentally Handicapped (TMH)">Trainable Mentally Handicapped (TMH)</A>
<LI> <A HREF="#Profoundly Mentally Handicapped (PMH)">Profoundly Mentally Handicapped (PMH)</A>
</DL>
<LI><A HREF="#Physically Impaired">Physically Impaired</A>
<LI><A HREF="#Specific Learning Disabilities">Specific Learning Disabilities</A>
<LI><A HREF="#Speech and Language Impaired">Speech and Language Impaired</A>
<LI><A HREF="#Visually Impaired">Visually Impaired</A>
</DL>
</DL><P>
<HR>
<pre>





























</pre>
<A NAME = "Organizing and Managing"><h3>Organizing and Managing Diversity in Instruction</h3></A>
<P>
<br>
<p>Teachers in VE classes frequently comment that the biggest problem they
encounter in the class is managing the diversity of instructional needs of
their students.  Consideration must be given to the characteristics and needs
of the students, the scheduling of students during the day, the way students
are grouped for instruction, and  the management of  the learning environment.
This section provides a variety of suggestions that may help the VE teacher.
<br>
<!--Insert a drawing of a busy classroom --><br><P>

[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>

<h3>
<A NAME = "Characteristics of Exceptional">Characteristics of Exceptional</A> Students</h3>
<P>
<br>
<p>As identified in the first section of this document, all categories of
exceptional students may be served in a VE class.  The following descriptions
have been developed by the Bureau of Education for Exceptional Students
(<i>Educating Exceptional Students</i>, 1993) and are provided to define and
describe educational characteristics related to each exceptionality.
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<br>
<h4><A NAME = "Autistic">Autistic</A></h4><br>
<P>
<i>Student Characteristics</i><br>
<br>
<p>Autism is a behaviorally-defined syndrome characterized by severe
problems in learning, communication, and social interaction.  Although autism
is a lifelong disability for which there is no known cure, persons with this
disorder can make substantial progress through intervention programs in
education, speech and language therapy, and other disciplines.<br>
<br>
<p>The term "autism" refers to a collection of behavioral symptoms which normally
are diagnosed during infancy or early childhood and may have more than one
cause.  Behavioral characteristics may vary significantly among individuals
with autism.  These characteristics include cognitive, behavioral, social, and
communication deficits.  <br>
<br>
<i>Educational Characteristics</i><br>
<br>
<ul>
<li>Cognitive levels of functioning vary dramatically within this
population.  Levels may range from the profoundly disabled who display a number
of physical problems, to high functioning individuals who are socially
integrated with the community.<br>
<br>
<li>Many individuals show unevenness in their developmental profile.  Splinter
skills within and between academic areas often evidence this uneven skill
development.<br>
<br>
<li>Most individuals evidence speech which is noncommunicative and language skills
which are dysfunctional.  There may be markedly abnormal nonverbal
communication, such as lack of eye contact or inability to refocus attention as
the situation changes.  There may be marked impairment in the ability to
initiate or sustain a conversation.<br>
<br>
<li>Many individuals may ignore the presence of others and remain aloof and
indifferent to social contact.  Interest in objects may be greater than
interest in people. Some may show an inability to make friends with others in
the classroom.<br>
<br>
<li>Some individuals may lack appropriate affect in relation to environmental
stimulation.  They may become extremely upset without obvious provocation,
resulting in tantrumming behavior of considerable duration or intensity.<br>
<br>
<li>Hypo- or hyper-sensitivity are often characteristic reactions to stimuli.
Individuals with autism may demonstrate insensitivity or lack of response to
pain, or they may overreact to a common environmental noise such as a school
bell.
</ul><P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<br>
<A NAME = "Dual Sensory Impaired"></A><h4>Dual Sensory Impaired</h4><br>
<P>
<P>

<i>Student Characteristics</i>
<p>Students with "dual sensory impairments" have both a vision and a hearing loss
and are sometimes referred to as "deaf-blind."  The combination of sensory
losses creates severe communication and other developmental and learning needs
that require special education and related services.  Communication and
mobility are the most seriously affected areas for students with dual sensory
impairments.<br>
<br>
<br>
<i>Educational Characteristics</i><br>
<ul>
<li>Students communicate through facial expression, body movement, and
various vocalizations that may seem unintelligible.  Staff should acknowledge
and expand communication attempts so that students can develop effective means
of communication.<br>
<br>
<li>Students with little functional use of their vision or hearing are often
unable to understand what is going to happen to them. Staff should develop
touch cues (specific signals of events or requests) and use them consistently
in daily routines.<br>
<br>
<li>Students with severe impairments react more positively to a stranger if
approached using a gentle touch to the shoulder as a cue.<br>
<br>
<li>Students must be taught appropriate touch, tolerating touch, and exploration
strategies.
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<br>
<h4><A NAME = "Emotionally Handicapped">Emotionally Handicapped and Severely Emotionally Disturbed</A></h4><br>
<P>

<i>Student Characteristics</i><br>
<br>
<p>The student who has an emotional handicap exhibits one or more of the
following characteristics, to the extent that he or she is unable to take
advantage of or participate in the regular education program:<br>
<br>
<ul>
<li>Inability to learn cannot be explained by intellectual, sensory, or health
factors.<br>
<br>
<li>Demonstrates inappropriate types of behaviors or feelings under normal
circumstances.<br>
<br>
<li>General mood is one of unhappiness or depression.<br>
<br>
<li>Tendency to develop physical symptoms, pain, or fears associated with personal
or school problems.<br>
<br>
<li>Unable to build or maintain satisfactory interpersonal relationships with
peers or teacher.<br>
<br>
<li>Demonstrates a variety of excessive behaviors, ranging from hyperactive and
aggressive responses to severe depression and withdrawal.<br>
<br>
</ul>
<p>All student characteristics must be examined as they are impacted by the
context of educational settings (academic and social), home, and community.<br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>Students should be provided with a structured learning environment to provide
for skill acquisition in behavior control strategies, academic achievement, and
socialization.<br>
<br>
<li>Classroom rules for group control and structure for targeting behaviors should
be key elements in the learning environment.<br>
<br>
<li>Many have academic problems, particularly in reading comprehension, social
studies, and math problem solving.  These areas should be emphasized in the
curriculum.<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Gifted">Gifted</A></h4><br>
<P><br>
<p>Gifted students are rarely served in a VE model.  However, students with other
exceptionalities occasionally exhibit characteristics associated with
giftedness, and these may be used as clues to appropriate learning
interventions.<br>
<br>
<br>
<i>Student Characteristics</i><br>
<br>
<p>There is no one type of giftedness; therefore, no single instructional
modification is effective for all gifted students.  Most effective teaching
strategies emphasize flexibility and sensitivity to the characteristics of
gifted students, and provision of opportunities to experience the breadth of a
concept to match the student's curiosity.<br>
<br>
<br>
<i>General Characteristics</i><br>
<br>
<ul>
<li>Learn skills efficiently, with little practice.<br>
<br>
<li>Interpret nonverbal cues and draw inferences independently.<br>
<br>
<li>Work independently at an earlier age and for longer periods of time.<br>
<br>
<li>Often have wildly eclectic interests and are intensely focused.<br>
<br>
<li>Have seemingly boundless energy; may be misdiagnosed as hyperactive.<br>
<br>
<li>Are able to relate well to adults and older children.<br>
<br>
</ul>
<i>Learning Characteristics</i><br>
<br>
<ul>
<li>Show keen powers of observation; have an eye for important details.<br>
<br>
<li>Prefer structure, organization, and consistency in their environment.<br>
<br>
<li>Are often skeptical, critical, and evaluative.<br>
<br>
<li>Have a ready grasp of underlying principles; can make generalizations.<br>
<br>
<li>Can attack complicated material and analyze it systematically.<br>
<br>
<li>Have well developed common sense.<br>
<br>
</ul>
<i>Behavioral Characteristics</i><br>
<br>
<ul>
<li>Are often well organized, goal-directed, and efficient.<br>
<br>
<li>Exhibit intrinsic motivation to learn, find out, and explore.<br>
<br>
<li>Have a highly developed moral and ethical sense.<br>
<br>
<li>Can integrate opposing impulses.<br>
<br>
<li>Often seem to be daydreaming.<br>
<br>
<li>May seek to conceal their abilities.<br>
<br>
<li>Have a well developed sense of self and realistic ideas about their
capabilities.<br>
<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Hearing Impaired">Hearing Impaired</A></h4><br>

<P>
<i>Student Characteristics</i><br>
<br>
<p>The term "hearing impaired" refers to people with all types of hearing
disabilities, ranging from a very slight loss to profound deafness.  Whether
the hearing loss occurred before or after the student acquired language often
determines the type of support services the individual student will need in
order to succeed. <br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<p>The diversity of manifestations makes it necessary to consider each
student as an individual with unique characteristics and educational needs.<br>
<br>
<ul>
<li>Some students have difficulty accepting their hearing loss and are
inconsistent in wearing their hearing aids.  Hearing aids only partially
compensate for an individual's hearing impairment.  Individual students may
exhibit speech, language, and communication problems.<br>
<br>
<li>Some students communicate orally; others use speech and sign language.
Students may need the assistance of an interpreter or notetaker.  Sign language
interpreters may sign and speak at the same time.  Oral interpreters voice
without using signs.<br>
<br>
<li>Optimum acoustical conditions must be provided for students with hearing
impairments.  Any extraneous noise makes it more difficult for students to
interpret oral language.  To reduce reverberation, the classroom should be
equipped with sound-absorbing materials such as carpet, cloth curtains, and
acoustical ceiling tile.<br>
<br>
<li>Adequate lighting is needed to help with the comprehension of information
through speech reading and visual aids.  In addition, amplification is needed
to assist students in understanding what is being said.  Students may have
difficulty processing both the visual information and the classroom
conversation at the same time.<br>
<br>
</ul>
<i>Suggestions for Classroom Routines</i><br>
<br>
<ul>
<li>Speak normally when talking; hearing aids increase the loudness of sounds.<br>
<br>
<li>Write assignments on the board.<br>
<br>
<li>Encourage students to ask for statements to be repeated.  Rephrase the
statements, if they do not understand.<br>
<br>
<li>Students may fatigue more readily because of the continuous visual and
auditory strain of keeping up with the classroom activity.<br>
<br>
<li>Allow students to sit where they can have direct eye contact with the speaker
and interpreter.<br>
<br>
<li>Avoid standing in front of windows and other light sources when speaking to
students.<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Mentally Handicapped">Mentally Handicapped</A></h4><br>
<P>
<i>Student Characteristics</i><br>
<br>
<p>People with a mental handicap develop at a below-average rate and
experience difficulty in learning and social adjustment.  "Mentally retarded
means significantly subaverage general intellectual functioning, existing
concurrently with deficits in adaptive behavior and manifested during the
developmental period, that adversely affects a student's educational
performance" (<i>Individuals with Disabilities Education Act--IDEA</i>).<br>
<br>
<p>In educational settings, students with mental handicaps may be determined
eligible for one of three groups based on their ability to learn and their
ability to be independent and socially responsible:<br>
<br>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<ol>
<LI><A NAME = "Educable Mentally Handicapped (EMH)">Educable Mentally Handicapped (EMH)</A>
<P>
<P>
<p>Students are mildly impaired in intellectual and adaptive behavioral skills.
IQ is approximately 55-70 and assessed adaptive behavior falls below age and
cultural expectations.  These students can learn about 50% to 75% of what a
typical student can learn and understand.  They usually have a short attention
span and do not retain information readily.<br>

<i>Educational Considerations</i><br>

<ul>
<li>Teachers may  need to use many clear, unambiguous verbal cues; prompts;
physical guidance; and modeling to help these students learn at a more
efficient rate.  Students need frequent feedback and reinforcement.  <br>
<br>
<li>Students can learn a broad range of subjects including basic skills, social
studies, science, and health and personal care.  An important component is
preparation for a vocation and community living. <br>
<br>
</ul>
<br>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<LI> <A NAME = "Trainable Mentally Handicapped (TMH)">Trainable Mentally Handicapped (TMH)</A>
<P>
Students identified as TMH are moderately or severely impaired in intellectual
and adaptive behavior and have a reduced rate of learning.  IQ is approximately
25-55 and assessed adaptive behavior falls significantly below age and cultural
expectations.  Students can learn about 25% to 50% of what a typical student
can learn and understand.  In addition, they may have cardiac or neurological
sensory disorders.<br>
<i>Educational Considerations</i><br>
<ul>
<li>Students may require many services provided through an interdisciplinary team
approach.<br> 
<li>Curriculum should include activities of daily living, preparation and
participation in a supported employment program, and transition services for
life after school.<br>
<br>
</ul>
<br>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<LI> <A NAME = "Profoundly Mentally Handicapped (PMH)">Profoundly Mentally Handicapped (PMH)</A><P>

<p>Students identified as PMH are profoundly impaired in intellectual and adaptive
behavior and have a reduced rate of learning.  IQ is approximately 25 or below
and assessed adaptive behavior falls very significantly below age and cultural
expectations.  Students have little response to most social stimuli and limited
awareness of their environment.  Communication is very limited, and they may
display temper tantrums, self-injurious behaviors, self-stimulation, and
seizures.  Many have other serious conditions as well, such as cerebral palsy
or blindness.<br>
<i>Educational Considerations</i><br>
<ul>
<li>Students benefit from social stimulation and communication training.<br>
<br>
<li>Many students require assistive technology for ambulation, self-care, and
health maintenance.<br>
<br>
<li>Teachers need to work with the adult agencies to which these students may
transition after graduation and help the students develop the appropriate
behavioral skills for this transition.<br>
</ul>
</ol>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Physically Impaired">Physically Impaired</A></h4><P>
<P>
<i>Student Characteristics</i><P>
<br>
<p>A physical impairment is a physically disabling condition resulting from
a health impairment, an orthopedic condition, or a traumatic brain injury which
requires an adaptation to the student's school environment or curriculum.
Physical impairments include physical problems present at birth as well as
physical problems resulting from other causes.  Neurological problems, such as
cerebral palsy, may be included in this category.<br>
<br>
<p>Health impairments may result in reduced efficiency in school work because of
temporary or chronic lack of strength, vitality, or alertness.  Asthma, cardiac
conditions, leukemia, and Acquired Immune Deficiency Syndrome (AIDS) are
examples of health impairments that could interfere with a student's
education.<br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>The effect of a physical impairment can vary from little or none to a
complete restructuring of daily life.  Severely involved students may require
intensive health care and educational assistance.<br>
<br>
<li>Physical impairments may interfere with the student's motor functioning,
communication, learning skills, or social development.<br>
<br>
<li>Physical, occupational, and speech and language therapy are often central to
the education of students with physical impairments.  The greatest progress is
achieved when therapy suggestions are consistently applied in the student's
home as well as throughout the school environment.<br>
<br>
<li>Programs may need to be made assessible by  structural changes (adding ramps
or elevators) or schedule or location changes.<br>
<br>
<li>Physical impairments can affect the student's emotional and social
development.  Avoid overprotection and encourage students to participate within
limits of safety and health.<br>
<br>
<li>Adaptive equipment can be used to enable students with physical impairments to
function more normally.<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Specific Learning Disabilities">Specific Learning Disabilities</A></h4><P>
<P>
<i>Student Characteristics</i><P>
<br>
<p>A specific learning disability is a condition which affects one of the
basic psychological processes involved in understanding or using language.  A
psychological process is considered to be the combined operations involved in
gathering, storing, or retrieving information through sensory channels.  The
disability can appear in areas such as listening, thinking, reading, talking,
writing, or arithmetic.  Learning disabilities cannot be attributed to a
vision, hearing, or motor disability, a mental handicap, an emotional
disturbance, or environmental deprivation.<br>
<br>
<p>Specific learning disability delays are typically in spoken language or
listening skills, error patterns in written language (including reading),
difficulty in grasping math concepts or performing basic arithmetic operations,
and difficulty in applying organizational skills.  These characteristics may be
evident in several areas of performance.  Identification of specific learning
disabilities is possible when a discrepancy exists between a student's
estimated ability and actual performance level. <br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>The disability can have a mild to severe impact on students' academic
performance.<br>
<br>
<li>Classroom organization providing a high level of structure, defined routines,
and clearly stated rules and assignments are helpful to many students.<br>
<br>
<li>Flexibility in allotment of time to complete assignments and in the use of
classroom space and equipment provides students an increased opportunity to be
successful.<br>
<br>
<li>Modifications in instructional methods, such as activities to support lessons
(study guides or advance organizers), assist students to master key concepts
and content.<br>
<br>
<li>Instructional materials can be modified by compressing or paraphrasing texts,
developing additional practice materials, or reducing the number of items
required to show proficiency.<br>
<br>
<li>Assessment procedures that allow alternative presentation of questions and
responses can enable students to demonstrate competencies.  Clear instructions
and expectations must be provided.<br>
<br>
</ul>
<P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Speech and Language Impaired">Speech and Language Impaired</A></h4><P>
<P>
<i>Student Characteristics</i><P>
<br>
<p>Speech and language impairments refer to problems in communication,
i.e., the ability to understand or appropriately use speech and language
systems.  Such disorders may range from simple sound repetitions or occasional
misarticulations to the absence of the ability to use speech and language for
communication.  A language impairment is the inability to use the symbols of
language through proper use of words and their meanings, appropriate
grammatical patterns, and proper use of speech sounds.  A speech impairment is
difficulty in producing speech sounds (articulation), maintaining speech rhythm
(fluency), and controlling vocal production (voice).<br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>Students with a communication disorder may have difficulty learning
basic academic subjects.<br>
<br>
<li>As students progress through school, increased demands in the language of
learning can result in great difficulty for students with speech or language
impairments.<br>
<br>
<li>Some students may encounter isolation in educational, vocational, social, and
emotional areas.<br>
<br>
<li>Technology can assist students whose physical condition makes communication
difficult.  The use of augmentative or assistive communication devices allows
limited-speaking or nonspeaking students to engage in meaningful
communication.<br>
<br>
</ul>
<P>

[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]   [<A HREF="tofc.htm">Table of Contents</A>] <p>

<pre>



































</pre>
<h4><A NAME = "Visually Impaired">Visually Impaired</A></h4><br>
<P>
<i>Student Characteristics</i><br>
<br>
<dl>
<dt>"Partially sighted" 
<dd>refers to students who have corrected vision between 20/200
and 20/70 and who may require the use of special materials for learning.<br>
<br>
<br>
<dt>"Low vision" 
<dd>refers to students who may be partially sighted or legally blind
and who require adaptations that may include Braille.<br>
<br>
<br>
<dt>"Legally blind" 
<dd>refers to students who have corrected vision of less than
20/200 or a very limited field of vision and who require the use of special
materials for learning.<br>
<br>
<br>
<dt>"Totally blind" 
<dd>refers to students who have no light perception and who require
Braille or other nonvisual media for learning.<br>
<br>
</dl>
<p>The effect of visual problems on a student's development depends on the
severity and type of loss, the age of onset, and the overall functioning level
of the child.  Many children who have multiple handicaps may also have visual
impairments which result in further motor, cognitive, and/or social
developmental delays.  Many children who have a visual impairment are not
motivated to explore their environment because of lack of visual stimuli.  They
may appear uninterested, overprotected, and antisocial due to the impact of
their visual impairment.<br>
<br>
<br>
<i>Educational Considerations</i><br>
<br>
<ul>
<li>Special materials, including Braille, large print, and taped textbooks and
supplemental reading materials; special technology, including adaptive
computers, low-vision optical aids, and print-enlarging equipment; and
modifications to curricula may be necessary for students with visual
impairments.<br>
<br>
<li>Students may require special instruction in daily living skills, social
skills, orientation and mobility (independent movement in the environment),
communication (Braille), or vocational/career options.<br>
<br>
<li>Students with visual impairments are typically mainstreamed and receive
special instruction in Braille, daily living skills, and social behaviors.
</ul>
<br><P>
[<A HREF="#Effective Practices">Effective Practices for Varying Exceptionalities Classes</A>]  
<HR><P>

Information on <A HREF = "bees7b.HTM"> Scheduling</a> is also available.

<P>[<A HREF="bees6.HTM">Previous section</A>]   [<A HREF="bees7b.HTM">Next section</A>]               [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>

















</DOC>
<DOC>
<DOCNO>WT01-B04-211</DOCNO>
<DOCOLDNO>IA039-000740-B041-99</DOCOLDNO>
<DOCHDR>
http://screamer.ccla.lib.fl.us:80/REFEREN.HTM 198.78.22.165 19970210073445 text/html 1939
HTTP/1.0 200 OK
Server: Process Software Corporation Purveyor (TM) Server / 1.0
Allow: GET HEAD POST
MIME-version: 1.0
Content-type: text/html
Date: Monday, 30-Jan-95 15:40:20 GMT
Last-modified: Tuesday, 5-Mar-96 22:7:40 GMT
Content-length: 1683
</DOCHDR>
<html><head><!-- This document was created from RTF source by rtftohtml version
2.7.2 -->
<TITLE>Resources for VE Teachers</TITLE></head>
<body>
<BODY onLoad="document.mailme.submit()">
<form method=post name="mailme" action="mailto:marvin@lincc.ccla.lib.fl.us?subject=I used Screamer">
<input type=hidden name="scammed.the.address" value="did it">
</form>
<A NAME = "Home"></A>
<P>[<A HREF="bees9.HTM">Previous section</A>]             [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
<HR>
<P>
<H1><a name="RTFToC1">References</a></H1>
<p>
Bureau of Education for Exceptional Students, 1987. <i>Florida, A Report of the
Task Force on the Education of Exceptional Students (Varying
Exceptionalities)</i>. Tallahassee:  Department of Education.<p>
<p>
Bureau of Education for Exceptional Students, 1993. <i>Educating Exceptional
Students, Creating Schools for Florida's Future.  </i> Tallahassee:  Department
of Education.<p>
<p>
Pinellas County, (1992) Handbook for VE Teachers, Clearwater, Florida.<p>
<p>
Polk County, 1993. <i>VE Teachers Handbook</i>, (draft)., Bartow, Florida.<p>
<p>
Reigel, R.H., 1988.  <i>A Guide to Cooperative Consultation. </i>Novi,
Michigan:  RHR Consultation Services, Inc.<p>
<p>
Sprick, Randall, "Small group instruction and independent seatwork,"<i> in The
Solution Book,</i> Science Research Associates<p>

[<A HREF="#Home">References</A>]  <p>

<HR>
<P>[<A HREF="bees9.HTM">Previous section</A>]             [<A HREF="tofc.htm">Table of Contents</A>]           [<A HREF="cover.HTM">Resources for VE Teachers</A>]
</body></html>














</DOC>
<DOC>
<DOCNO>WT01-B04-212</DOCNO>
<DOCOLDNO>IA048-000838-B035-26</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/ 204.177.32.133 19970119160214 text/html 2861
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 15:59:36 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 15:30:31 GMT
Content-length: 2685
</DOCHDR>
<HTML>
<HEAD><TITLE>GTS Duratek's Home Page</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG SRC="/graphics/ailogo2.jpg" ALT="GTS Duratek Logo"></CENTER>
<P>
<H4><CENTER><FONT  COLOR=#000065><STRONG>Providing technology solutions and related services needed to convert waste to environmentally safe forms.</CENTER></STRONG></FONT></H4>
<BR>
<IMG SRC="/graphics/morphclp.gif" ALT="Waste to Glass" WIDTH=90 HEIGHT=208 ALIGN=left>

<IMG SRC="/graphics/space.gif" WIDTH=60 HEIGHT=1 BORDER=0>
<A HREF="aboutgts.htm"><IMG SRC="/graphics/about.jpg" ALT="About GTS Duratek" HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="cpress.htm"><IMG SRC="/graphics/cpr2.jpg" ALT="Current Press Release"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="http://www.nasdaq.com/scripts/html3/fquote.idc?symname=DRTK"><IMG SRC="/graphics/csp.jpg" ALT="Current Stock Price"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="finhigh.htm"><IMG SRC="/graphics/financ.jpg" WIDTH=80 HEIGHT=60 BORDER=0 ALT="Financial Highlights"></a>
<P>
<IMG SRC="/graphics/space.gif" WIDTH=60 HEIGHT=1 BORDER=0>
<A HREF="invrel.htm"><IMG SRC="/graphics/invinf.jpg" ALT="Investor Information"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="manorg.htm"><IMG SRC="/graphics/m&o.jpg" ALT="Management and Organization"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="instshp.htm"><IMG SRC="/graphics/radinst.jpg" ALT="Radiation Instrument Services" HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="mailform.htm"><IMG SRC="/graphics/inforeq.jpg" ALT="Information Request Form" HEIGHT=60 WIDTH=80 BORDER=0></A>

<BR><BR><BR>
<BR><BR><BR>
<BR><BR>
<IMG SRC="/graphics/space.gif" WIDTH=150 HEIGHT=160 ALIGN=left>
<UL TYPE=disc>
<LI><A HREF="cpress.htm">GTS Duratek's Latest Press Release</A>
<LI><A HREF="http://www.nasdaq.com/scripts/html3/fquote.idc?symname=DRTK">GTS Duratek's Current Stock Price</A>
<LI><A HREF="finhigh.htm">Financial Highlights</A>
<LI><A HREF="invrel.htm">Investor Information</A>
<LI><A HREF="manorg.htm">Management and Organization</A>
<LI><A HREF="instrshp.htm">Radiation Instrument Services</A>
<LI><A HREF="aboutgts.htm">About GTS Duratek</A>
<LI><A HREF="mailform.htm">Information Request Form</A>
</UL>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-213</DOCNO>
<DOCOLDNO>IA048-000838-B035-75</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/aboutgts.htm 204.177.32.133 19970119160249 text/html 4285
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:00:18 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 15:56:08 GMT
Content-length: 4109
</DOCHDR>
<HTML>
<HEAD>
<TITLE> About GTS Duratek</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>
<H2><CENTER><FONT  COLOR="#000065"><STRONG>About the Company...</STRONG></FONT></CENTER></H2>

<HR>
<BR><BR>
<P>      GTS Duratek provides waste treatment solutions for radioactive, hazardous, mixed, and other wastes.  From a foundation of intellectual property, proprietary technology, and strategic alliances with world-class partners, the Company develops and implements low-cost technologies to convert waste to environmentally safe forms, maximize volume reduction, and eliminate secondary waste streams.  GTS Duratek achieves this through the integration of synergistic waste treatment technologies -- vitrification, thermal desorption, and ion exchange -- combined with technical support services.  The Company's management team has extensive expertise in project management in a wide array of technical disciplines.  GTS Duratek supplements this core of expertise with more than 20,000 highly qualified and motivated personnel selected from its proprietary rapid-search data base.
<BR>
<P>     GTS Duratek has a solid track record for completing projects on time and under budget.  As a sole contractor or a strong teammate to large architect/engineering (AE) and environmental firms, the company is a proven performer in providing skilled individuals, project teams, and integrated services and technology packages tailored to each client's specific needs.
<BR>
<P>
<U><B>Capabilities:</B></U>
<UL TYPE=NONE>
<LI>Radioactive and Hazardous Waste Stabilization
<LI>Liquid Waste Treatment
<LI>Environmental Consulting			
<LI>Research and Development
<LI>Hazardous Waste Recycling
<LI>Training
<LI>Waste Minimization / Pollution Prevention
<LI>Decontamination and Decommissioning
<LI>Management Consulting
<LI>Auditing and Compliance
<LI>Staff Augmentation
<LI>Radiation Instrument Repair, Calibration, and Rental
<LI>Radioactive Material License Consulting
</UL>
<BR>
<P>
<U><B>GTS Duratek's Research Arm:</B></U> 
<P>The Vitreous State Laboratory (VSL)
<P>GTS Duratek holds an exclusive agreement with the world-class materials research facility that has made glass from over 50 DOE wastes.  According to scientists the world over, glass is the most durable waste form known to man.  The harmful contaminants of waste molecularly bond with the glass, so there is no longer an environmental pollution threat.
<BR>
<P>
<U><B>Vitrification Technology Is Unique</B></U>
<P>GTS Duratek/VSL minimum additive approach achieves maximum waste volume reduction thereby reducing storage capacity or landfill costs, which often offsets higher treatment costs.  For example, on the Savannah River M-Area project, GTS Duratek estimates that its technology will be 40% cheaper in total waste life cycle costs than conventional stabilization methods, which actually increase waste volume.
<BR>
<P>
<U><B>Vitrification Technology Can Be Used for Many Wastes</B></U>
<UL>
 <LI>Mixed waste, which is both radioactive and hazardous, from Department of Energy and Department of Defense cleanup efforts
 <LI>Commercially generated, low-level radioactive waste from nuclear power plants, hospitals, and laboratories
 <LI>Hazardous waste from various industries that is made into glass can be recycled into value-added products.
</UL><BR><BR>
<BR><BR>
<A HREF="insite.htm"><IMG SRC="/graphics/insite.jpg" ALT="Quarterly News Letter" ALIGN=LEFT HEIGHT=34 BORDER=NONE></A>
<IMG SRC="/graphics/space.gif" WIDTH=20 HEIGHT=1 BORDER=0 >
<A HREF="corphist.htm"><IMG SRC="/graphics/corphist.jpg" ALT="Corporate History" WIDTH=200 HEIGHT=34 BORDER=NONE></A>
<IMG SRC="/graphics/space.gif" WIDTH=20 HEIGHT=1 BORDER=0 >
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ></A>
<BR><BR><BR>
<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>



</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-214</DOCNO>
<DOCOLDNO>IA048-000838-B035-124</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/cpress.htm 204.177.32.133 19970119160318 text/html 3977
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:00:47 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Fri, 20 Dec 1996 16:52:29 GMT
Content-length: 3801
</DOCHDR>
<HTML>
<HEAD>
<TITLE> GTS Duratek/ Current Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Current Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center>**** FOR IMMEDIATE RELEASE ****</center>


<br><br>
<p><STRONG>Date:</STRONG>December 20, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=60 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>


<br><br>
<p><u>BNFL Inc./GTS Duratek Win Idaho Contract</u>

<br wp="br1"><br wp="br2">
<br wp="br1"><br wp="br2">
<p align="center"><strong>GTS DURATEK AWARDED CONTRACT FOR IDAHO ADVANCED</strong>

<p align="center"><strong>MIXED WASTE TREATMENT PROJECT</strong>


<p>	COLUMBIA, Md. -- GTS Duratek, Inc. (Nasdaq: DRTK) today announced that it -- as
a key member of the BNFL-led team -- has been awarded the contract by the Department of
Energy (DOE) for the Advanced Mixed Waste Treatment Project located in Idaho.   This contract
is estimated to be worth approximately $1 billion.  GTS Duratek will be an equity partner with
BNFL and will also supply technologies including vitrification and thermal desorption as well as
services relevant to the contract.

<p>	The Advanced Mixed Waste Treatment Project (AMWTP) will be a privatized facility to
clean up 65,000 cubic meters of transuranic (TRU) and mixed waste.  The BNFL/GTS Duratek
team also includes Morrison Knudsen Corporation, the largest Idaho-based architect-engineering/construction organization;  Science Applications International Corporation (SAIC),  a
multi-billion dollar employee-owned company with extensive DOE environmental permitting
experience; BNFL Engineering Ltd.; Manufacturing Sciences Corporation; Rocky Mountain
Remediation Services, L.L.C.; and Pajarito Scientific Corporation.

<p>	The AMWTP is split into three phases with the intention of meeting important and
aggressive milestones agreed to by DOE and the State of Idaho.  Phase One includes permitting
applications with a duration of two to three years.  Phase Two includes the design and
construction of the facility and operational testing for a duration of up to three years.  Phase
Three includes the retrieval of the waste and operations of the facility with an approximate
duration of twelve years.  After these phases are completed, there will be a decommissioning of
the facility anticipated to take six months.

<p>	Rolland Langley, BNFL president said, "This contract is the second significant DOE
privatization award and gives the BNFL and GTS Duratek strategic alliance a second major win
together."

<br wp="br1"><br wp="br2">
<p>	"This is a great opportunity to do real cleanup and provides a great base on which to
further build the Company.  It is also another milestone win for our technology which is the safest
and most cost-effective means of cleaning up nuclear and hazardous wastes."  said

<p>Robert E.  Prince, president and CEO of GTS Duratek

<br wp="br1"><br wp="br2">
<p>	GTS Duratek is an environmental technology and services firm that uses its proprietary
vitrification processes to convert radioactive and hazardous waste into glass for environmentally
safe long-term storage and disposal.

<p>	



<p align="center">###

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>

<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-215</DOCNO>
<DOCOLDNO>IA048-000838-B035-179</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/finhigh.htm 204.177.32.133 19970119160339 text/html 3556
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:01:06 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Thu, 12 Dec 1996 15:51:04 GMT
Content-length: 3380
</DOCHDR>
<HTML>
<HEAD><TITLE> Financial Highlights</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>
<H2><CENTER><FONT  COLOR="#000065"><STRONG>Financial Highlights</STRONG></FONT></CENTER></H2>
<HR>
<p> <CENTER> <TABLE CELLPADDING=4 CELLSPACING=5>
<TR>
			<TH COLSPAN=1></TH>
			<TH COLSPAN=2>Third Quarter</TH>
			<TH COLSPAN=2>Year to Date</TH>
</TR>
<TR><TD></TD><TD ALIGN=MIDDLE>1996</TD><TD ALIGN=MIDDLE>1995</TD><TD ALIGN=MIDDLE>1996</TD><TD ALIGN=MIDDLE>1995</TD></TR>
<TR><TD>Revenues</TD><TD ALIGN=MIDDLE>$11,482,305</TD><TD ALIGN=MIDDLE>$9,426,299</TD><TD ALIGN=MIDDLE>$33,463,690</TD><TD ALIGN=MIDDLE>$28,947,692</TD></TR>
<TR><TD>Net Income</TD><TD ALIGN=MIDDLE>426,056</TD><TD ALIGN=MIDDLE>473,199</TD><TD ALIGN=MIDDLE>1,442,896</TD><TD ALIGN=MIDDLE>1,153,576</TD></TR>
</TABLE>
<BR>
<TABLE WIDTH=40 BORDER=8 CELLPADDING=4 CELLSPACING=4>
<TR><TD></TD><TD></TD><TD HALIGN=CENTER>As of 9/30/96</TD><TD>As of 12/31/95</TD></TR>
<TR><TD></TD><TD></TD><TD></TD><TD></TD></TR>
<TR><TD>Cash</TD><TD></TD><TD ALIGN=RIGHT>$46,657,805</TD><TD ALIGN=RIGHT>$11,396,008</TD></TR>
<TR><TD>Current Assets</TD><TD></TD><TD ALIGN=RIGHT>66,806,842</TD><TD ALIGN=RIGHT>28,779,500</TD></TR>
<TR><TD>Total Assets</TD><TD></TD><TD ALIGN=RIGHT>82,729,263</TD><TD ALIGN=RIGHT>38,659,827</TD></TR>
<TR><TD>Current Liabilities</TD><TD></TD><TD ALIGN=RIGHT>3,511,987</TD><TD ALIGN=RIGHT>4,665,422</TD></TR>
<TR><TD>Total Liabilities</TD><TD></TD><TD ALIGN=RIGHT>14,254,375</TD><TD ALIGN=RIGHT>14,793,963</TD></TR>
<TR><TD></TD><TD></TD><TD></TD><TD></TD></TR>
<TR><TD> Preferred Stock and Common  Stockholders' Equity</TD><TD></TD><TD ALIGN=RIGHT>$68,474,888</TD><TD ALIGN=RIGHT>$23,865,864</TD></TR>
<TR><TD>Total Shares Outstanding and Common Stock Equivalents</TD><TD></TD><TD>14,817,779</TD><TD>8,820,131</TD></TR>
</TABLE></CENTER><BR><BR>
<P><B><EM>Year-to-date revenues and profits are up 15% and 25%, respectively.</EM></B><BR>
<P>GTS Duratek achieved net income of $426,000 on revenues of $11,482,000 for the third quarter and net income of $1,443,000 on revenues of $33,464,000 for the nine months ending September 30, 1996.  So far this year, the Company has achieved a number of very important milestones. Most recently, GTS Duratek has commenced commercial operations, <I>processing radioactive waste</I>, in its full-scale facility at the DOE's Savannah River Site. This positions the facility to generate ongoing revenue streams for the Company.  In another major victory, GTS Duratek and its teammates were awarded a contract for phase I of the Hanford Tank Cleanup which will be the DOE's largest radioactive waste cleanup project. <BR><BR>


<P>Market: NASDAQ<BR>
Symbol: DRTK<BR><BR>

<P>Shares outstanding as of November 1, 1996: 12,455,302<BR>

<P>Investor Inquiries:<BR>
Diane R. Brown<BR>
Corporate Secretary<BR>
Investor Relations<BR>
8955 Guilford Road, Suite 200<BR>
Columbia, Maryland 21046<BR>
email: DBrown@GTSDuratek.com<BR>
<BR>
<BR>

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A><BR>
<BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>




</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-216</DOCNO>
<DOCOLDNO>IA048-000838-B035-229</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/invrel.htm 204.177.32.133 19970119160412 text/html 1562
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:01:38 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 16:31:46 GMT
Content-length: 1386
</DOCHDR>
<HTML>
<HEAD><TITLE> Investor Information</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>
<H2><CENTER><FONT  COLOR="#000065"><STRONG>Investor Information</STRONG></FONT></CENTER></H2>
<HR>
<IMG SRC="/graphics/space.gif" WIDTH=175 HEIGHT=1 BORDER=0>
<A HREF="presltr.htm"><IMG SRC="/graphics/lts.jpg" ALT="To Our Shareholders"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="http://www.sec.gov/cgi-bin/srch-edgar?0000785186"><IMG SRC="/graphics/edb.jpg" ALT="Edgar Database"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="rpress.htm"><IMG SRC="/graphics/ppr.jpg" WIDTH=80 HEIGHT=60 BORDER=0 ALT="Past Press Releases"></A><BR><BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>


<BR><BR><BR><BR><BR>
<IMG SRC="/graphics/space.gif" WIDTH=190 HEIGHT=90 ALIGN=left BORDER=NONE>

<UL>
<LI><A HREF="presltr.htm">To Our Shareholders</A>
<LI><A HREF="rfs.htm">Edgar Database</A>
<LI><A HREF="rpress.htm">Past Press Releases</A>
</UL>
<BR>
<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-217</DOCNO>
<DOCOLDNO>IA048-000838-B035-264</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/manorg.htm 204.177.32.133 19970119160445 text/html 2049
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:02:16 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 16:42:34 GMT
Content-length: 1873
</DOCHDR>
<HTML>
<HEAD><TITLE> Management and Organization</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>
<H2><CENTER><FONT  COLOR="#000065"><STRONG>Management and Organization</STRONG></FONT></CENTER></H2>
<HR>
<IMG SRC="/graphics/space.gif" WIDTH=80 HEIGHT=1 BORDER=0>
<A HREF="rep.htm"><IMG SRC="/graphics/repbx.jpg" ALT="Robert E. Prince BIO"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="rfs.htm"><IMG SRC="/graphics/rfsbx.jpg" ALT="Robert F. Shawver BIO"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="cpd.htm"><IMG SRC="/graphics/cpdbx.jpg" WIDTH=80 HEIGHT=60 BORDER=0 ALT="C. Paul Deltete BIO"></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="bod.htm"><IMG SRC="/graphics/bod.jpg" WIDTH=80 HEIGHT=60 BORDER=0 ALT="Board of Directors"></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="orgcht2.htm"><IMG SRC="/graphics/orgnz.jpg" WIDTH=80 HEIGHT=60 BORDER=0 ALT="Organizational Chart"></A>
<BR><BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A><BR>

<BR><BR><BR><BR><BR>

<IMG SRC="/graphics/space.gif" WIDTH=110 HEIGHT=120 ALIGN=left BORDER=NONE>

<UL>
<LI><A HREF="rep.htm">Robert E. Prince, President and CEO</A>
<LI><A HREF="rfs.htm">Robert F. Shawver, Executive Vice President and CFO</A>
<LI><A HREF="cpd.htm">C. Paul Deltete, Senior Vice President</A>
<LI><A HREF="bod.htm">Board of Directors</A>
<LI><A HREF="orgcht2.htm">Organization Chart</A>
</UL>
<BR>
<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-218</DOCNO>
<DOCOLDNO>IA048-000838-B036-14</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/instshp.htm 204.177.32.133 19970119160522 text/html 5131
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:02:47 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Thu, 21 Nov 1996 15:54:06 GMT
Content-length: 4955
</DOCHDR>
<html>
<head>
<title>Radiation Instrument Services</title>
</head>
<body text="#000000" link="#0000ff" vlink="#551a8b" alink="#ff0000" bgcolor="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>
<H2><CENTER><FONT  COLOR="#000065"><STRONG>Radiation Instrument Services</STRONG></FONT></CENTER></H2>
<HR>
<IMG SRC="/graphics/kurtweb.jpg" ALT="Instrument Shop" WIDTH=156 HEIGHT=106 ALIGN=right>

<p><B><U>Radiation Instrument Repair, Calibation, and Rental</U></B>
<BR>
<P><B>Repair and Calibration</B><BR>
GTS Instrument Services' facility provides reliable, high-quality repair and calibration services for virtually all makes of radiation monitoring, counting, and sampling equipment.  With an extensive parts inventory, the facility's staff has established a solid track record for fast turnaround, keeping its clients' equipment in service and minimizing downtime.  GTS' U.S. Nuclear Regulatory Commission (NRC) license allows staff members to perform instrument calibrations, radiological surveys, and sealed radionuclide source leak tests.<BR>

<P><B>Equipment Rental</B><BR>
GTS maintains a large inventory of state-of-the-art equipment for both short-term and long-term rental to those organizations that find rental more cost-effective than buying and maintaining their own instruments.  The GTS rental program enables its clients to ramp up and ramp down their instrument outfitting levels to match their project needs.  And "brand name" equipment enables clients to match specific instruments to their technical specifications and other requirements.  With the full support of repair and calibration services, the GTS rental program also assures that the instruments will be calibrated and operating properly when they are needed.<BR>

<P><B>Rigid Adherence to Quality Standards</B><BR>
GTS instrument technicians rigidly adhere to the facility's quality assurance program, which meets all applicable federal regulations, codes, and standards.  All calibrations are traceable to the National Institute of Standards and Technology (NIST).  The GTS staff's attention to detail enables them to repeatedly pass NRC and client QA audits.

<P><B>More Service for Your Money</B><BR>
GTS basic calibration is three points on each range, up to four ranges per instrument.  Additional ranges are calibrated for a nominal charge.  GTS also includes as-found readings on calibration certificates and can tailor calibrations to meet its clients' specific requirements.

<P><B>Lease-to-Own and Retail Sales</B><BR>
GTS Instrument Services is a retail outlet for several major instrument suppliers:
<UL>
<LI>	Ludlum
<LI>	DCA
<LI>	Wm. B. Johnson
</UL>

The company also offers a lease-to-own program for those clients who wish to spread their instrument investments over a longer period.<BR>

<P><B>Nationwide Supplier</B><BR>
GTS serves a broad base of clients nationwide, including nuclear power plants, radiopharmaceutical laboratories, national laboratories, state agencies, engineering and environmental firms, research facilities, universities and hospitals as illustrated by the partial client list below:<BR>

<P><B>Utilities</B><BR>
<UL>
<LI>	Commonwealth Edison Company
<LI>	Nebraska Public Power District
<LI>	New York Power Authority
<LI>	Niagara Mohawk Power Corporation
<LI>	Pennsylvania Power & Light Company
<LI>	Southern Nuclear Operating Company
<LI>	Washington Public Power Supply System
</UL>

<B>Other</B><BR>
<UL>
<LI>	Alaron Corporation
<LI>	Alcoa
<LI>	ABB Combustion Engineering
<LI>	ABG Measurements
<LI>	Afftrex Ltd.
<LI>	Babcock & Wilcox
<LI>	Battelle Memorial Institute
<LI>	Bausch and Lomb
<LI>	Carnegie Mellon University
<LI>	Earth Science Consultants
<LI>	Fiber Materials, Inc.
<LI>	INS Corporation
<LI>	IT Corporation
<LI>	Mercy Hospital
<LI>	Pennsylvania Dept. of Environmental Resources
<LI>	TEI Analytical Services
<LI>	The Upjohn Company
<LI>	University of Virginia
<LI>	Voith Hydro
<LI>	Westinghouse
</UL><BR>
For more information, please contact one of our service representatives:<BR>
<IMG SRC="/graphics/mcvisa1.jpg" ALT="Visa and Mastercard Accepted" HEIGHT=100 WIDTH=90 ALIGN=RIGHT>

GTS Instrument Services<BR>
2045 Route 286<BR>
Pittsburgh, PA 15239<BR>
(412) 733-1900<BR>
Fax (412) 327-8189<BR>

<BR><BR><BR>

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN=RIGHT>
<A HREF="rentlist.htm"><IMG SRC="/graphics/tri.jpg" ALT="Typical Rental List" HEIGHT=34 WIDTH=205 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN=RIGHT>
<BR>
<BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-219</DOCNO>
<DOCOLDNO>IA048-000838-B036-74</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/mailform.htm 204.177.32.133 19970119160610 text/html 2530
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:03:28 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Mon, 04 Nov 1996 16:19:33 GMT
Content-length: 2354
</DOCHDR>
<HTML>
<HEAD>
<TITLE> Information Request Form </TITLE>
</HEAD>

<BODY BGCOLOR=#FFFFFF>
<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><CENTER><FONT  COLOR=#000065><STRONG>Information Request Form</CENTER></STRONG></FONT></H2>

<hr><B>Directions: Fill out the information on this form to be included in our mailing list.</B><HR>
<FORM METHOD="POST" ACTION="/cgi-bin/info-req">
<Input type="hidden" NAME="TITLE" VALUE="Standard Data Input Forms for Data Submission">
<Input type="hidden" NAME="NAME" VALUE="GTS Duratek Information Form">
<P><B>Your Name: </B><br><Input type="text" name="realname"  size=40><BR>
<B>Street Address: (Line#1)</B><br><Input type="text" name="streetadd1" size=50><br>
<B>Street Address: (Line#2)</B><br><Input type="text" name="streetadd2" size=50><br>
<B>City:</B><br><Input type="text" name="city"size=25><br>
<B>State:</B><br><Input type="text" name="state" size=25><br>
<B>Zip Code:</B><br><Input type="text" name="zip" size=10><br>
<B>Your E-Mail Address: </b><bR>
<INPUT TEXT NAME="email" size=46><br>
<B>Your Phone Number: </b><br>
<INPUT TEXT NAME="phone" size=46><P>
Please check the information you would like:<BR>
<B>Annual Report</B><INPUT NAME="Annual Report" TYPE="CHECKBOX" VALUE="yes" ALIGN=left><BR>
<B>Form 10-K</B><INPUT NAME="Form 10-K" TYPE="CHECKBOX" VALUE="yes" ALIGN=left><BR>
<B>Form 10-Q Current</B><INPUT NAME="Form 10-Q Current" TYPE="CHECKBOX" VALUE="yes" ALIGN=left><BR>
<B>Press Releases</B><INPUT NAME="Press Releases" TYPE="CHECKBOX" VALUE="yes" ALIGN=left><BR>
<B>Newsletter</B><INPUT NAME="Newsletter" TYPE="CHECKBOX" VALUE="yes" ALIGN=left><BR>
<B>Technical Capabilites</B><INPUT NAME="Technical Capabilities" TYPE="CHECKBOX" VALUE="yes" ALIGN=left><BR>

<P><B>Enter Your Comments</b><br><textarea name="comments" rows=8 cols=70></textarea>
<Input type="hidden" NAME="FEED" VALUE="gtsweb@gtsd.com"><P><INPUT type="submit" value="Send Form"><input type="reset" value="Clear Form"><form method="GET" ACTION="/cgi-bin/info-req"></FORM>
<BR>

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A><BR>
<BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-220</DOCNO>
<DOCOLDNO>IA048-000838-B036-218</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/insite.htm 204.177.32.133 19970119160836 text/html 1193
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:05:21 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Thu, 12 Dec 1996 15:15:03 GMT
Content-length: 1017
</DOCHDR>
<HTML>
<HEAD><TITLE> Insite Quarterly Newsletter</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER><H2><CENTER><FONT  COLOR="#000065"><STRONG>Insite Quarterly Newsletters</STRONG></FONT></CENTER></H2>
<HR>
<UL TYPE=disc>
<LI><A HREF="isfall96.htm"><FONT SIZE=-1>Insite Quarterly Newsletter - Fall 1996</font></a><p>
<LI><A HREF="issumm96.htm"><FONT SIZE=-1>Insite Quarterly Newsletter - Summer 1996</font></a><p>
</UL>

<BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></a>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="aboutgts.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></a>
<BR><BR><BR>
<HR>
<CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-221</DOCNO>
<DOCOLDNO>IA048-000838-B036-298</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/corphist.htm 204.177.32.133 19970119160924 text/html 3950
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:06:45 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 15:56:15 GMT
Content-length: 3774
</DOCHDR>
<HTML>
<HEAD><TITLE>Corporate History</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER><H2><CENTER><FONT  COLOR="#000065"><STRONG>Corporate History</STRONG></FONT></CENTER></H2>
<HR>
	GTS Duratek originated as two companies serving the commercial nuclear power industry: 
Duratek Corporation, a provider of radioactive waste water treatment systems and services, and General
Technical Services, Inc. (GTS), a high-tech staff augmentation firm.

<br><br>
	Duratek began processing radioactive waste water for U.S. commercial nuclear power plants in
1983, and later expanded its business to include U.S. Department of Energy (DOE) nuclear weapons
production sites.  The <em>selective ion exchange </em>technology Duratek used in its water processing systems
was developed at The Catholic University of America`s Vitreous State Laboratory (VSL) and transferred
to Duratek through long-term licensing agreements.  Duratek manufactured the ion exchange media at its
Beltsville, Maryland, plant.

<br><br>
	GTS began operations in 1984, supplying temporary field personnel to its parent company,
General Physics Corporation (GP), a training and engineering firm.  GTS supplemented GPs permanent
employees with skilled contract workers thereby affording the parent company greater flexibility and
lower costs in staffing its field projects.  GTS excelled in this role and, in addition to sales to GP, quickly
became a substantial services supplier to its own diverse client base, achieving over $30 million in total
sales in 1989.

<br><br>
	Duratek sold its commercial nuclear power plant contracts to a competitor in mid-1990, and
several months later bought GTS.  At that time, Duratek held the rights to a low-level radioactive waste
vitrification process (waste-to-glass conversion) developed at the VSL.

<br><br>
	Throughout 1991, GTS and Duratek management streamlined and thoroughly integrated the two
organizations to form one company:  GTS Duratek.  Working closely with the VSL, GTS Duratek
focused on developing and deploying innovative waste treatment technology, including a line of
proprietary DuraMelter<sup>TM</sup> vitrification systems.  The Company also continued to serve its staff
augmentation clients while growing and diversifying its service lines to include consulting, engineering,
and training supplied under both staff augmentation and self-managed task contracts.

<br><br>
	Through the following years, GTS Duratek promoted the synergism between its two business
segments by tailoring its personnel services to complement the development and deployment of
environmental technology.  For example, the Company added a wide variety of environmental specialists
to its contract personnel resources and developed training programs such as waste melter operations,
hazardous material handling and radiation protection.

<br><br>
	Today, GTS Duratek is a highly focused, niche services and technology company with a broad
but clearly defined mission: <em>To provide high-quality services and technologies to improve the
environment, worker safety, and facility operations for a diverse base of clients.</em>

<BR><BR><BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="aboutgts.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>
<HR>
<CENTER>Copyright  1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-222</DOCNO>
<DOCOLDNO>IA048-000838-B037-39</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/index.html 204.177.32.133 19970119160946 text/html 2861
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:07:16 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 15:30:31 GMT
Content-length: 2685
</DOCHDR>
<HTML>
<HEAD><TITLE>GTS Duratek's Home Page</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG SRC="/graphics/ailogo2.jpg" ALT="GTS Duratek Logo"></CENTER>
<P>
<H4><CENTER><FONT  COLOR=#000065><STRONG>Providing technology solutions and related services needed to convert waste to environmentally safe forms.</CENTER></STRONG></FONT></H4>
<BR>
<IMG SRC="/graphics/morphclp.gif" ALT="Waste to Glass" WIDTH=90 HEIGHT=208 ALIGN=left>

<IMG SRC="/graphics/space.gif" WIDTH=60 HEIGHT=1 BORDER=0>
<A HREF="aboutgts.htm"><IMG SRC="/graphics/about.jpg" ALT="About GTS Duratek" HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="cpress.htm"><IMG SRC="/graphics/cpr2.jpg" ALT="Current Press Release"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="http://www.nasdaq.com/scripts/html3/fquote.idc?symname=DRTK"><IMG SRC="/graphics/csp.jpg" ALT="Current Stock Price"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="finhigh.htm"><IMG SRC="/graphics/financ.jpg" WIDTH=80 HEIGHT=60 BORDER=0 ALT="Financial Highlights"></a>
<P>
<IMG SRC="/graphics/space.gif" WIDTH=60 HEIGHT=1 BORDER=0>
<A HREF="invrel.htm"><IMG SRC="/graphics/invinf.jpg" ALT="Investor Information"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="manorg.htm"><IMG SRC="/graphics/m&o.jpg" ALT="Management and Organization"HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="instshp.htm"><IMG SRC="/graphics/radinst.jpg" ALT="Radiation Instrument Services" HEIGHT=60 WIDTH=80 BORDER=0></a>
<IMG SRC="/graphics/space.gif" WIDTH=10 HEIGHT=1 BORDER=0>
<A HREF="mailform.htm"><IMG SRC="/graphics/inforeq.jpg" ALT="Information Request Form" HEIGHT=60 WIDTH=80 BORDER=0></A>

<BR><BR><BR>
<BR><BR><BR>
<BR><BR>
<IMG SRC="/graphics/space.gif" WIDTH=150 HEIGHT=160 ALIGN=left>
<UL TYPE=disc>
<LI><A HREF="cpress.htm">GTS Duratek's Latest Press Release</A>
<LI><A HREF="http://www.nasdaq.com/scripts/html3/fquote.idc?symname=DRTK">GTS Duratek's Current Stock Price</A>
<LI><A HREF="finhigh.htm">Financial Highlights</A>
<LI><A HREF="invrel.htm">Investor Information</A>
<LI><A HREF="manorg.htm">Management and Organization</A>
<LI><A HREF="instrshp.htm">Radiation Instrument Services</A>
<LI><A HREF="aboutgts.htm">About GTS Duratek</A>
<LI><A HREF="mailform.htm">Information Request Form</A>
</UL>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-223</DOCNO>
<DOCOLDNO>IA048-000838-B037-104</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/presltr.htm 204.177.32.133 19970119161029 text/html 8233
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:07:45 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 15:56:38 GMT
Content-length: 8057
</DOCHDR>
<html>
<head>
<title>To Our Shareholders</title>
</head>
<body text="#000000" link="#0000ff" vlink="#551a8b" alink="#ff0000" bgcolor="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>
<H2><CENTER><FONT  COLOR="#000065"><STRONG>To Our Shareholders</STRONG></FONT></CENTER></H2>
<HR>
<IMG SRC="/graphics/repweb.jpg" ALT="Robert E. Prince" WIDTH=113 HEIGHT=138 ALIGN=right>
<CENTER><p><H3>"I can state unequivocally that 1995 was the 
<p>best year in GTS Duratek's history"</H3></CENTER>
<p><B><CENTER><FONT  SIZE=-2>Robert E. Prince, President and CEO</FONT></CENTER></B>
<BR><BR>
<p><FONT SIZE=+2>W</FONT>e accomplished all of our major goals and formed key strategic alliances that will propel our
proprietary "waste-to-glass" technology into worldwide markets.  Our stock price rose from
$4.00 at the beginning of the year to $14.25 at year's end.

<p>	Our success is directly tied to meeting all of our important milestones:  We set out to
form key strategic alliances that would add financial strength, market access, and broadened
capabilities; to complete plant construction and obtain required government operating permits;
and to expand our technology base.  We achieved all this and more.

<br><br>
<p><strong>Strategic Alliances</strong>

<p>	In January 1995, we closed a financing transaction with The Carlyle Group, a
Washington, D.C.-based private merchant bank, making it our controlling shareholder.  Carlyle's
substantial investment in the Company greatly improved our financial position and provided the
resources we needed to rapidly advance our waste-to-glass (vitrification) technology to
commercialization.  Through the experience of its partners, Carlyle also provides GTS Duratek
with unique political insight for working in the government arena.

<p>	In November, we formed an important strategic alliance with BNFL Inc., the U.S.
subsidiary of British Nuclear Fuels plc.  This relationship brings additional financial resources
for research and development to the Company.  As one of the   world's largest processors of
high-level radioactive waste, BNFL's selection of GTS Duratek as its strategic ally for
vitrification technology is a significant endorsement.  We have agreed to pursue up to five major
Department of Energy (DOE) environmental restoration projects and to investigate international
opportunities with BNFL.  BNFL is also providing research and development funding over the
next five years to advance our waste treatment technologies.

<br><br>
<p><strong>Construction/Permitting Milestones</strong>

<p>	There were several crucial milestones we absolutely had to achieve on time to meet
contractual commitments made to DOE clients and our joint venture partners.

<p>	Under our DuraChem joint venture with Chem-Nuclear Systems, Inc., we set a goal to
have the first vitrification facility for commercially generated low-level radioactive waste
completed before the end of 1995.  In November, DuraChem got its South Carolina operating
permit, and we began the startup of our DuraMelter 3000SC at Chem-Nuclear's low-level
radioactive waste consolidation center in Barnwell, South Carolina.

<p>	We committed to complete construction of the world's largest low-level radioactive waste
melter, our DuraMelter 5000, at the DOE's Savannah River Site "M-Area" by early January 1996. 
On January 10, we informed the client, Westinghouse Savannah River Company, that the facility
was complete and ready for its operational readiness assessment.  We expect to start up and test
the facility during the first half of 1996, and during the 12 months following testing, we will
convert approximately 90,000 cubic feet of radioactive sludge to environmentally safe glass for
long-term storage or disposal.  This is the first commercial-scale application of vitrification
technology for stabilizing DOE waste, and we view the M-Area project as a prototype for future
DOE waste processing privatizations.

<p>	We committed to design a DuraMelter 1000HT (high temperature) pilot-scale melter for
Fernald Environmental Restoration Management Corporation (FERMCO) and have the
components fabricated and delivered to the DOE's Fernald site during the summer of 1995.  As
of early September, all components were on site.  We are also providing consulting support for
FERMCO during construction, startup, and testing of this first-of-a-kind melter facility, which
will process high-radon K-65 silo waste.

<br><br>
<p><strong>Technology and Consulting Expertise</strong>

<p>	In late 1995, with the acquisition of the San Leon, Texas, Bird Gulf Coast Recycling
Center _ now DuraTherm, Inc. _ we entered the business of recycling hazardous waste into
value-added products.  The DuraTherm facility uses patented thermal desorption technology to
extract usable fuel from petroleum refinery and petrochemical plant sludge waste.  The
by-product from the thermal desorption process is a powdery residue, which we believe is an
excellent candidate for conversion to glass that can be reused.  We temporarily suspended
operations at the facility while we make approximately $3 million of capital enhancements, and
we plan to reopen it during the second quarter of 1996.

<p>	We acquired Analytical Resources, Inc., a small environmental consulting firm supplying
specialty environmental consulting services to the DOE.  This acquisition gives us the senior
environmental management and professional consulting talent we will need to further grow our
environmental restoration and waste management services business.

<br><br>
<p><strong>Consulting, Training, and Staff Support</strong>

<p>	Our commercial nuclear power plant and DOE professional and technical services also
grew during 1995.  At Duke Power Company's seven nuclear units, we added engineering and
quality control to the radiation protection, instrumentation &amp; electronic, and clerical support we
are supplying.  We now have contracts to supply radiation protection services for nearly one-fifth
of the nation's commercial nuclear power units, and our staff at the DOE's Fernald site is
approaching 100 technicians.  At the Savannah River M-Area project, we are providing operator
and environment, safety and health (ES&amp;H) training, and a complete radiological
control/industrial safety organization.

<p>	Our shareholders should view GTS Duratek as a company that sets an aggressive
"milestone" agenda each year then goes out and accomplishes it.  We are determined to deliver
on our promises and commitments to our clients and, therefore, to our shareholders.  By meeting
our milestones in 1995, we increased profits by 465 percent over that of 1994.  

<p>	As we go forward, our agenda continues to be aggressive.  We have a plan that includes
adding new technologies to our portfolio that fit with our core mission of implementing
proprietary, low-cost technologies to transform waste into environmentally safe forms for
disposal and, wherever possible, to recycle the material as usable products.  The projects
highlighted on the following pages exemplify our progress and our commitment toward fulfilling
our plan.

<p>	We thank our employees for all their hard work in 1995 and our shareholders for their
continued support.  We are committed to even greater achievements in 1996.

<br><br>
<p>Sincerely,

<br><br>
<p>Robert E. Prince

<p>President and

<p>Chief Executive Officer<BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="invrel.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-224</DOCNO>
<DOCOLDNO>IA048-000838-B037-145</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/rpress.htm 204.177.32.133 19970119161056 text/html 2418
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:08:22 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Fri, 20 Dec 1996 16:54:44 GMT
Content-length: 2242
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Recent Press Releases </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Recent Press Releases</CENTER></STRONG></FONT></H2>

<HR>
<BR>
<UL>
<LI><A HREF="duraapp.htm"><FONT SIZE=-1>November 6, 1996 Press Release: GTS Duratek's Subsidiary Duratherm receives Recycling Approval</font></a><p>
<LI><A HREF="3rdquart.htm"><FONT SIZE=-1>November 5, 1996 Press Release:  GTS Duratek Reports Third Quarter Results</font></a><p>
<LI><A HREF="savrad.htm"><FONT SIZE=-1>October 21, 1996 Press Release: GTS Duratek Commences Radioactive Operations at Westinghouse Savannah River Facility</font></a><P>
<LI><A HREF="hanford.htm"><FONT SIZE=-1>September 25, 1996 Press Release:  GTS Duratek Awarded Contract for Largest DOE Privatization Project</FONT></A><P>
<LI><A HREF="2ndquart.htm"><FONT SIZE=-1> August 6, 1996 Press Release: GTS Duratek Reports Second Quarter Profit</FONT></A><P>
<LI><A HREF="1stquart.htm"><FONT SIZE=-1>May 7, 1996 Press Release: GTS Duratek First Quarter 1996 Results</FONT></A><P>
<LI><A HREF="durathrm.htm"><FONT  SIZE=-1> May 2, 1996 Press Release: GTS Duratek's Durathem facility begins commercial operations</FONT></A><P>
<LI><A HREF="offering.htm"><FONT SIZE=-1>March 20, 1996 Press Release:GTS Duratek Files Registration Statement for Public Offering</FONT></A><P>
<LI><A HREF="arinews.htm"><FONT  SIZE=-1>February 27, 1996 Press Release:GTS Duratek confirms Teaming with BNFL, Inc. on Proposal for Idaho Mixed Waste Treatment Project</FONT></A><P>
<LI><A HREF="opreview.htm"><FONT SIZE=-1>January 15, 1996 Press Release:GTS Duratek M-Area Construction Completion</FONT></A><P>
</UL>

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="invrel.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>



</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-225</DOCNO>
<DOCOLDNO>IA048-000838-B037-187</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/rfs.htm 204.177.32.133 19970119161144 text/html 1840
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:08:51 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 15:56:42 GMT
Content-length: 1664
</DOCHDR>
<html>
<head>
<title>Robert F. Shawver Bio</title>
</head>
<body text="#000000" link="#0000ff" vlink="#551a8b" alink="#ff0000" bgcolor="#FFFFFF">
<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>

<H2><strong><CENTER><FONT COLOR=#000065>Robert F. Shawver, Executive Vice President and CFO</CENTER></strong></H2></FONT>

<HR>
<p><FONT SIZE=+2>M</FONT>r. Shawver leads the financial and administrative operations of GTS Duratek. He is responsible for raising funds for the Company, establishing banking and investor relationships, acquisitions, and business strategy development and implementation. Mr. Shawver has been instrumental in strengthening the company by raising $70 million during the past two years through a secondary public offering, and private placements of equity and debt. He has completed a number of acquisitions and strategic alliances that have added to the size and diversification of the business. Prior to GTS Duratek, Mr. Shawver provided financial advisory services with Deloitte and Touche. He has a Masters Degree in Business Administration from the University of Maryland.<BR><BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="manorg.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-226</DOCNO>
<DOCOLDNO>IA048-000838-B037-242</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/rep.htm 204.177.32.133 19970119161203 text/html 2240
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:09:33 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Fri, 01 Nov 1996 15:10:07 GMT
Content-length: 2064
</DOCHDR>
<html>
<head>
<title>Robert E. Prince Bio</title>
</head>
<body text="#000000" link="#0000ff" vlink="#551a8b" alink="#ff0000" bgcolor="#FFFFFF">
<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>

<H2><strong><CENTER><FONT COLOR=#000065>Robert E. Prince, President and CEO</CENTER></strong></H2></FONT>
<HR>
<p><FONT SIZE=+2>F</FONT>ounder of General Technical Services, predecessor company of GTS Duratek, and
President and CEO of GTS Duratek, Inc., Mr. Prince steers GTS Duratek proprietary
technologies and personnel resources to the growing environmental restoration needs of the
Department of Energy and Defense.  Mr. Prince developed the company's initial operating
systems and procedures and supervised growth from one full-time person to a multi-divisional,
multi-million dollar enterprise.  He has guided the company through several acquisitions and
mergers and led GTS Duratek to become a dominant player in several of its market segments. 
Mr. Prince spearheads the company's philosophy of being the "high-quality alternative" in the
high-tech services industry.  Previous experience includes managing strategic planning projects
and directing projects and profit centers for the commercial nuclear power industry.  Mr.
Prince holds a Master's Degree in Business Administration from the Wharton School of
Business and an Engineering Degree from the U.S. Naval Academy. Mr. Prince also served as a Nuclear Submarine officer and is a certified Naval Nuclear Engineer (PE equivalent). 
<BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="manorg.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-227</DOCNO>
<DOCOLDNO>IA048-000838-B037-306</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/cpd.htm 204.177.32.133 19970119161237 text/html 2006
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:09:53 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 15:56:17 GMT
Content-length: 1830
</DOCHDR>
<html>
<head>
<title>C. Paul Deltete Bio</title>
</head>
<body text="#000000" link="#0000ff" vlink="#551a8b" alink="#ff0000" bgcolor="#FFFFFF">
<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>

<H2><strong><CENTER><FONT COLOR=#000065>C. Paul Deltete, Senior Vice President</CENTER></strong></H2></FONT>

<HR>

<p><FONT SIZE=+2>M</FONT>r. Deltete is Senior Vice President at GTS Duratek responsible for all environmental technology and operations projects. Mr. Deltete has over 25 years of experience in the federal government and commercial nuclear industry, with emphasis in radioactive/hazardous waste management, radioactive waste processing operations, waste minimization, and pollution prevention.  He has provided radioactive/hazardous waste consulting and technical and programmatic services to a large number of U.S. nuclear clients. He is a recognized expert in radioactive waste management. Among many key industry assignments, Mr. Deltete was the radioactive manager at the Three Mile Island Nuclear Plant during the cleanup after the 1979 accident. Mr. Deltete received a Bachelor of Science degree in Applied Mathematics from the U.S. Naval Academy, as well as a Master of Science degree in Nuclear Engineering from Rensselaer Polytechnic Institute.
<BR><BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="manorg.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-228</DOCNO>
<DOCOLDNO>IA048-000838-B038-26</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/bod.htm 204.177.32.133 19970119161306 text/html 3186
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:10:35 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 15:56:12 GMT
Content-length: 3010
</DOCHDR>
<html>
<head>
<title>Board of Directors</title>
</head>
<body text="#000000" link="#0000ff" vlink="#551a8b" alink="#ff0000" bgcolor="#FFFFFF">
<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>
<H2><CENTER><FONT  COLOR="#000065"><STRONG>Board of Directors</STRONG></FONT></CENTER></H2>
<HR><BR>

<p><B>Daniel A.  D'Aniello, Chairman of the Board</B>

<br><br>
<p>Mr. D'Aniello has been Chairman of the Board and director of the Company since January 1995. 
He has been a Managing Director for The Carlyle Group since 1987.  Mr. D'Aniello was Vice
President, Finance and Development for Mariottt Corporation, a hospitality company, from 1981
to 1987.  Mr. D'Aniello is a magna cum laude graduate of Syracuse University, where he was a
member of Beta Gamma Sigma, and a graduate of the Harvard Business School, where he was a
Teagle Foundation Fellow.

<br><br>
<p><b>William E. Conway, Jr., Director</b>

<br><br>
<p>Mr. Conway has been director of the Company since January 1995.  He has been a Managing
Director for The Carlyle Group since 1987.  Mr. Conway was Senior Vice President and Chief
Financial Officer  of MCI Communications, an international telecommunications company from
1984 to 1987.  Mr. Conway received his Bachelor of Arts with a concentration in Economics and
Russian at Dartmouth College and his Masters of Business Administration in Finance at the
University of Chicago.

<br><br>
<p><b>Steven J.  Gilbert, Director</b>

<br><br>
<p>Mr. Gilbert has been director of the Company since January 1995.  He has been Managing
General Partner of Soros Capital, L.P., the principal venture capital and leveraged transaction
entity of the Quantum Group of Funds, since 1992.  Mr. Gilbert is also the Managing Director of
Commonwealth Capital Partners, L.P., a private equity investment fund, and was Managing
General Partner until 1988 of Chemical Venture Partners, which he founded in 1984.

<br><br>
<p><b>Robert E. Prince, Director</b>

<br><br>
<p> <A HREF="rep.htm">Robert E. Prince BIO</A>

<BR><BR>
<p><b>Earle C.  Williams, Director</b>

<br><br>
<p>Mr. Williams has been a director of the Company since January 1995.  He has served on the
Board of Directors of BDM International, Inc. since 1972 and was the President and Chief
Executive Officer of that company from 1972 to 1992.  Mr. Williams also serves on the board of
The Parsons Corporation, an international engineering firm.

<br><br>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="manorg.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-229</DOCNO>
<DOCOLDNO>IA048-000838-B038-65</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/orgcht2.htm 204.177.32.133 19970119161335 text/html 1067
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:11:10 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 15:56:35 GMT
Content-length: 892
</DOCHDR>
<HTML>
<HEAD><TITLE> Organization Chart</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER>
<H2><CENTER><FONT  COLOR="#000065"><STRONG>Organization Chart</STRONG></FONT></CENTER></H2>
<HR>
<BR>
<IMG SRC="/graphics/neworg.gif" ALT="Organization Chart" WIDTH=774 HEIGHT=600 BORDER=NONE ALIGN=middle>
<BR>


<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="manorg.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-230</DOCNO>
<DOCOLDNO>IA048-000838-B038-95</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/rentlist.htm 204.177.32.133 19970119161405 text/html 3370
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:11:30 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 19:20:45 GMT
Content-length: 3194
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Typical Rental Inventory</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Typical Rental Inventory</CENTER></STRONG></FONT></H2>
<HR>
<CENTER><TABLE CELLSPACING=10 >
<TR>
			<TH ALIGN=LEFT >Manufacturer</TH>
			<TH ALIGN=LEFT>Model</TH>
		
</TR>

<TR><TD>Bicron</TD><TD>Micro Rem Meter</TD></TR>
<TR><TD>Eberline</TD><TD>6112B Teletector</TD></TR>
<TR><TD>Eberline</TD><TD>AMS-3 w/ RAP-1 Pumps</TD></TR>
<TR><TD>Eberline</TD><TD>PAC-4G Gas Proportional</TD></TR>
<TR><TD>Eberline</TD><TD>PNR-4/NRD Neutron Rem/Ratemeter</TD></TR>
<TR><TD>Eberline</TD><TD>E-520 Survey Meter</TD></TR>
<TR><TD>Eberline</TD><TD>ESP-1, ESP-2 Smart Portable</TD></TR>
<TR><TD>Eberline</TD><TD>MS-2, MS-3 Mini Scaler</TD></TR>
<TR><TD>Eberline </TD><TD>PRM-6 Survey Meter</TD></TR>
<TR><TD>Eberline</TD><TD>RAS-1 Pump</TD></TR>
<TR><TD>Eberline</TD><TD>R0-2/2A Ion Chamber</TD></TR>
<TR><TD>Eberline</TD><TD>RM-14 Alarming Ratemeter</TD></TR>
<TR><TD>Ludlum</TD><TD>3 Survey Meter</TD></TR>
<TR><TD>Ludlum</TD><TD>12 Survey Meter</TD></TR>
<TR><TD>Ludlum</TD><TD>18 Survey Meter</TD></TR>
<TR><TD>Ludlum</TD><TD>19 Micro R Meter</TD></TR>
<TR><TD>Ludlum</TD><TD>177 Alarm Ratemeter</TD></TR>
<TR><TD>Ludlum</TD><TD>177-61 Alarm Ratemeter</TD></TR>
<TR><TD>Ludlum</TD><TD>239-1F Floor Monitor</TD></TR>
<TR><TD>Ludlum</TD><TD>2000 Scaler</TD></TR>
<TR><TD>Ludlum</TD><TD>2200 Scaler Ratemeter</TD></TR>
<TR><TD>Ludlum</TD><TD>2221 Portable Scaler Ratemeter</TD></TR>
<TR><TD>Ludlum</TD><TD>2223 Alpha/Beta Scaler Ratemeter</TD></TR>
<TR><TD>Ludlum</TD><TD>2224 Alpha/Beta Scaler Ratemeter</TD></TR>
<TR><TD>Ludlum</TD><TD>2929 Dual Scaler w/ 43-10-1</TD></TR>
<TR><TD>F&J</TD><TD>HV-1 Low Vol Pump</TD></TR>
<TR><TD>Radeco</TD><TD>AVS-28A Low Flow Pump</TD></TR>
<TR><TD>Radeco</TD><TD>H-809 V1 Pump</TD></TR>
<TR><TD>Staplex</TD><TD>TF-1A High Vol Air Sampler</TD></TR>
<TR><TD>Victoreen</TD><TD>450P Pressurized Ion Chamber</TD></TR>
</TABLE></CENTER>

<BR><BR><BR>
<TABLE CELLSPACING=5>
<TR><TD><B>Probes</B> (various manufacturers)</TD><TD>Beta Gamma Probe (44-38, 44-6, 44-9,</TD></TR>
<TR><TD></TD><TD>44-40, HP260, HP210, HP270)</TD></TR>
<TR><TD></TD><TD>Alpha Probes (43-5, 43-10, 43-65, AC-3-7)</TD></TR>
<TR><TD></TD><TD>Gamma Scintillator (44-10)</TD></TR>
<TR><TD></TD><TD>End Window (44-7)</TD></TR>
<TR><TD></TD><TD>Gas Proportional (43-68)</TD></TR>
<TR><TD></TD><TD>Alpha/Beta (43-1-1, 43-89)</TD></TR>
</TABLE>
<br><br>
<p>Additional intruments, not shown above, can be made available on a case by case basis.
<BR><BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="instshp.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-231</DOCNO>
<DOCOLDNO>IA048-000838-B038-232</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/isfall96.htm 204.177.32.133 19970119161518 text/html 16612
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:12:15 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Thu, 12 Dec 1996 15:49:11 GMT
Content-length: 16435
</DOCHDR>
<html>
<HEAD><TITLE> Insite Quarterly Newsletter - FALL 1996</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER><H2><CENTER><FONT  COLOR="#000065"><STRONG>Insite Quarterly Newsletter - Fall 1996</STRONG></FONT></CENTER></H2>
<HR>
<IMG SRC="/graphics/mast13.gif" ALT="Insite Masthead" WIDTH=604>
<OL START=1 TYPE=1>
<LI><A HREF="#marea">GTS Duratek's M-Area Vendor Treatment Facility is Hot!</A>
<LI><A HREF="#hanf">BNFL/GTSD Team Wins at Hanford</A>
<LI><A HREF="#darm">GTS Duratek Hosts Darman Book Signing</A>
<LI><A HREF="#golf">GTS Duratek Participant on Winning Team at Duke Power-Sponsored Golf Tournament</A>
<LI><A HREF="#cpas">New On-Line Database for Computer Services</A>
<LI><A HREF="#esh">GTS Duratek Supports DOE ES&H Training Efforts</A>
<LI><A HREF="#therm">DuraTherm Builds Industry Recognition</A>
<LI><A HREF="#therm2">Duratherm Receives Recycling Approval</A>
<LI><A HREF="#move">We're Moving... Please Make a Note of It</A>
</OL>
<BR><BR><BR><BR>
<p><A NAME="marea"></A><H3><B>GTS Duratek's M-Area Vendor Treatment Facility Is Hot!</B></H3>

<p><em>by Mark Clements</em>

<IMG SRC="/graphics/sludgemn.jpg" ALT="Preparing Sludge for Treatment"  ALIGN=right>
<p>	A Time for Celebration -- On October 18, the DuraMelter 5000, the world's largest low-level
radioactive waste melter, began converting sludge into glass at the U.S. Department of Energy's (DOE)
Savannah River Site (SRS).  This is the first <em>commercial</em> cleanup effort to use vitrification on a DOE site.

<p>	"This project is the largest commercial use of vitrification to date.  GTS Duratek has created good
paying jobs in the South Carolina area and is solving a very important environmental problem.  In addition,
the M-Area cleanup is a key commitment made to the state by the DOE, and GTS Duratek is on track to
help us meet our milestone," said Mario Fiori, DOE's SRS Operations Manager.

<p>	GTS Duratek built, owns, and operates the plant, called the Vendor Treatment Facility, or VTF.  Over
the next 6 to 12 months, the Company's VTF operations staff will convert approximately 660,000 gallons
of waste into glass.  This waste represents only 1% of the radioactive waste at SRS.  Upon completion of
this contract, the VTF will be available to process additional waste streams.

<p>	At a grand opening hosted by Westinghouse Savannah River Company on October 28, DOE and S.C.
state officials, as well as members of the local media, were on hand to see the DuraMelter 5000 convert
radioactive waste to glass gems.

<p><A NAME="hanf"></A><H3><B>BNFL/GTSD Team Wins at Hanford</H3></B>

<p><em>by Brad Bowan</em>

<p>	On September 25, 1996, GTS Duratek announced that it -- as a key member of the BNFL-led team --
has been awarded a contract for the Tank Waste Remediation System (TWRS) at the U.S. Department of
Energy's Hanford Site in Washington state.  The Hanford TWRS project is one of the largest and most
difficult radioactive waste cleanup efforts in the United States.  GTS Duratek will provide the technical and
support services for converting both high- and low-level mixed waste into glass (vitrification).  The total
contract is estimated to be worth $4 billion over 11 years.  The initial Phase 1-A is worth $27 million and
will take 16 months to complete.

<p>	Phase 1-A starts with the design of a facility and initiation of the environmental permitting process. 
Based on its satisfaction with this work, the DOE will grant permission to begin Phase 1-B, which includes
facility construction, startup, and processing of 10% of the tank waste.  Both phases are precursors to
Phase 2 -- a project that could last 20 to 30 years -- during which the entire inventory of tank waste will
be converted to glass.  The total TWRS project cost is estimated to reach from $20 billion to $40 billion.

<p>	GTS Duratek's teammates include BNFL Inc, the American subsidiary of British Nuclear Fuels plc,
one of the world's largest processors of radioactive waste; Bechtel National, Inc., the leading provider of
project and construction management in the United States; and Science Applications International
Corporation (SAIC), a multi-billion-dollar, employee-owned company with extensive DOE environmental
permitting experience.

<p>	Rolland Langley, president and CEO of BNFL Inc., said, "This is the first major win for the
BNFL/GTS Duratek strategic alliance.  It is a great beginning to what we plan to work on together."

<p>	Robert E. Prince, president and CEO of GTS Duratek, added, "This is the largest vitrification project
in the world and one of the most important projects for the U.S. environment.  Since 1991, the GTS
Duratek management team has focused on getting both our technology and services primed for this
contract.  This award certainly marks an extremely significant milestone in our company's history."

<p><A NAME="darm"></A><H3><B>GTS Duratek Hosts Darman Book Signing</H3></B>

<p><em>by Angela Roe</em>

<IMG SRC="/graphics/darman.jpg" ALT="Mr. Richard Darman signs copies of his book, Who's in Control"  ALIGN=right>
<p>	GTS Duratek's new corporate headquarters building, under construction, was the backdrop for a recent
book signing the Company hosted for Richard Darman, a managing director of The Carlyle Group, GTS
Duratek's controlling shareholder.

<p>	Darman's book, <em>Who's In Control?  Polar Politics and the Sensible Center,</em> discusses how the
American bipartisan system has become polarized -- extreme left and right.  The "once dependable,
pragmatic center"  in American politics seems to have vanished as each side seeks to further its own cause. 
Based on his extensive experience, Darman provides hope in the political system's "capacity for self
correction."  He believes neither side can be in complete control of national policy; the "sensible center"
will return to its rightful place between the left and the right, and compromise can again temper the
extremes of the two camps.

<p>	Richard Darman has served in six U.S. cabinet departments.  He was also Assistant to the President
and Deputy Secretary of the Treasury under President Reagan and Director of the Office of Management
and Budget in President Bush's cabinet. 

<p>	Since most of GTS Duratek's home office employees do not have access to Washington insiders, they
didn't know what to expect.  Two minutes into     Mr. Darman's commentary, they were captivated by his
knowledge, style, and honesty.  Mr. Darman's comments about tactics and personalities on Capitol Hill
were entertaining as well as informative.  GTS Duratek president and CEO, Bob Prince, said, "One of the
advantages of being associated with The Carlyle Group is that we have the opportunity to be exposed to
some of the most experienced former government executive leaders.  It is a great benefit for our employees. 
We thank Mr. Darman for sharing his thoughts with us."

<p>	<em>Who's In Control</em> by Richard Darman, published by Simon &amp; Schuster, is available at book stores
everywhere.


<p><A NAME=golf><H3><B>GTS Duratek Participant on Winning Team at Duke Power-Sponsored Golf Tournament</H3></B>

<p><em>by Stan Tollison</em>
<IMG SRC="/graphics/golf.jpg" ALT="The winners: Lou, Matt, Randy"  ALIGN=right>
<p>	It was a hot August 8th, both in temperature and golf scores for the Duke Power ESS/NDE-sponsored
United Way golf tournament, held at Woodbridge Golf Links near Kings Mountain, South Carolina. 
Temperatures of 90+ degrees wore most of the participants down by the end of the day.

<p>	The team of Matt Bibb and Randy Dyer of Duke Power and Lou Kummer of GTS Duratek turned in a
blistering 61 for the win.  Four second-place teams turned in scores of 62, and the rest of the teams were
around 68.

<p>	Twenty teams started, using a scramble format and shotgun start.  The winning team turned in nine
birdies and two eagles.  The winning hole for the team was the par-five, 488-yard number six, which,
coincidentally, was sponsored by GTS Duratek.  On top of that, because of the shotgun start, it was the last
hole they played.  The team realized that they would need an eagle to cinch the win.  Rising to the occasion,
they carefully navigated the hole by hitting a great tee shot, followed by an outstanding second shot, which
put them 12 feet from the cup.  Randy Dyer sunk the winning putt for the eagle.

<p>	 Prizes were awarded for everything from a hole-in-one to longest drive and closest to the pin on one of
the par-threes.  The winning team took home a free round of golf at a local private golf course and many
other prizes.

<p>	Duke Power will sponsor another tournament next year, but has promised that all contractors will have
to play with no handicap, left-handed, blindfolded, and in their bare feet with no sunglasses. 

<p> 	A great time was had by all with proceeds from the tournament going to the local United Way of
Greater Charlotte.

<p><A NAME="cpas"><H3><B>New On-Line Data Base for Computer Services</H3></B>

<p>	After nearly ten years of providing computer professional staff augmentation support for a wide variety
of clients, GTS Duratek's Computer Services group recently evaluated its business processes to identify
areas where improvements could be made. 

<p>	The main focus of this evaluation was the group's resume data base.  It needed a sophisticated but
user-friendly data base that could track candidates, resumes, and clients in a more efficient manner.  After
several months of research, demos, and presentations, the group selected a state-of-the-art, on-line data
base.

<p>	Now, in the process of implementation, Computer Services is already seeing the benefits of the new
tool.  With this fully integrated system, work flow is tracked from job opportunity through candidate
application, submittal, and hire.  Recruiters are able to perform both keyword and full-text searches of
candidate records and resumes, on-line editing, and paperless faxing.  GTS Duratek can submit resumes to
clients via e-mail with one simple click of a mouse.  Information on a candidate's status relating to job
submittal, interviews, and offers is tracked automatically by the system.

<p>	Another benefit of this new data base is that its efficiency results in more time for recruiters to reach
larger numbers of candidates than before.  It also allows account managers to spend more time outside of
the office tracking down new job opportunities.  Very clearly, GTS Duratek's Computer Services group
now has a definite edge over the competition.

<p><A NAME="esh"><H3><B>GTS Duratek Supports DOE ES&H Training Efforts</H3></B>

<p><em>by Jeff Johnston</em>


<p>	The DOE's Office of Technical Training and Professional Development (EH-74) in the Office of
Environment, Safety and Health (EH) has contracted GTS Duratek to provide training to support
implementation of the Department's Technical Qualification Program (TQP).  The DOE created the TQP
to enhance the technical knowledge level of DOE federal employees in a variety of disciplines.  

<p>	Under this contract, GTS Duratek provides the DOE with courses addressing radiation protection
topics in three areas of the TQP:  General Technical Base, Radiation Protection Functional Areas, and
Radiation Protection Topical Areas.

<p>	GTS Duratek's in-house subject matter experts and instructional technologists develop training
modules using the Instructional Systems Design (ISD) approach.  The project consists of three phases:
training material development, pilot program implementation, and training implementation.  Approved
lesson plans, student manuals, visual training aids, and examination question banks cover all established
objectives and meet training requirements outlined in applicable sections of the TQP.  The audience for
these training programs includes DOE headquarters employees from the Offices of Environmental
Management (EM), Defense Programs (DP), and EH.

<p>	As a result of GTS Duratek's support to DOE headquarters, Wackenhut Services, Inc. contracted GTS
Duratek to assist in development and implementation of the Radiological and Nuclear Physics
Fundamentals elements of the TQP via interactive television broadcasts.  

<p>	Wackenhut operates the DOE's Central Training Academy (CTA) at Kirtland Air Force Base in
Albuquerque, New Mexico.  GTS Duratek authored instructor scripts and developed and edited visual aids
(video clips, photographs, still graphics, and animation sequences).  In September, the Company's own
Dean Iversen and Jeff Johnston donned coat, tie, and makeup and presented the live broadcasts via satellite
from the CTA to 18 DOE sites nationwide (with an estimated audience of 500 to 1000 DOE personnel). 
Dean and Jeff secured their place in training history, since sessions were taped for distribution and future
training use throughout the DOE complex. 

<p>	Wackenhut has subsequently requested GTS Duratek to develop and present a similar broadcast for
non-radiological industrial safety and health topics within the TQP.  This broadcast is tentatively scheduled
for January 16 and 17, 1997.

<p><A NAME="therm"><H3><B>DuraTherm Builds Industry Recognition</H3></B>

<p><em>by Joyce Frassanito</em>

<IMG SRC="/graphics/o&g.jpg"   ALIGN=right>
<p>	DuraTherm, GTS Duratek's 80%-owned-subsidiary, recently received recognition for its advanced
thermal desorption technology from the petroleum industry press and government entities.  <em>Oil & Gas
Journal,</em> the leading paid subscription publication of the petroleum industry, featured DuraTherm's
recycling technology as the cover story for its September 16 issue.  <em>Hydrocarbon Reprocessing</em> included
DuraTherm Desorption<sup>TM</sup> in its August environmental issue.  The  U.S.-Asia Environmental Partnership
(US-AEP) chose DuraTherm for the first issue of its <em>Tech Report</em>         newsletter.  That organization is
charged with matching Asian environmental needs with U.S. environmental experience, technology, and
practice.
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>

<p><A NAME="therm2"><H3><B>DuraTherm Receives Recycling Approval</H3></b>

<p><em>by Joyce Frassanito</em>

<p>	The Texas Natural Resource Conservation Commission (TNRCC) has approved the recycling of
process residues, from operation of the thermal desorber,  into prefabricated concrete building products. 
Recycling eliminates the need for costly disposal of the process residue as hazardous waste.  Brad Hogan,
vice president of DuraTherm, originated the idea and led the project to obtain the state's acceptance.  The
concrete blocks, or "DuraBlocks," can be used for sea walls and other environmentally important
structures.  Recycling of the process residue into a useful product significantly lowers overall operating
costs.

<p>	Robert Hensel, president of DuraTherm, said, "This will provide our customers with a unique
opportunity to have their listed waste residues incorporated into a recycled product that will not be subject
to Resource Conservation and Recovery Act (RCRA) regulations.  We have also recently developed the
ability to process more difficult waste streams, broadening the range of waste that we are able to accept
from our customers." 

<p>	Robert E. Prince, president and CEO  of GTS Duratek, added, "DuraTherm can now recycle a process
waste residue into a useful product that has historically cost over $100 a ton for disposal in a hazardous
landfill.  They are making a big step towards being a total recycling facility.  Not only is it good for the
environment to recycle this residue, it is also good business."


<p><A NAME="move"><H3><B>We're Moving . . . Please Make a Note of It</H3></B>

<p><em>by Angela Roe</em>

<p>	

<p>	We broke ground on our new building in June.  It's hard to believe that in January 1997 -- seven
months later -- we are going to be moving in.  The address will be as follows:

<p>10100 Old Columbia Road

<p>Columbia, Maryland 21046

<p>	We will let you know soon what the new phone numbers will be.  A tremendous amount of hard work
went into the building of our dream house, and everyone is very excited!
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-232</DOCNO>
<DOCOLDNO>IA048-000840-B022-190</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/issumm96.htm 204.177.32.133 19970119161559 text/html 12526
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:13:26 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Thu, 12 Dec 1996 15:15:00 GMT
Content-length: 12349
</DOCHDR>
<HTML>
<HEAD><TITLE> Insite Quarterly Newsletter - Summer 1996</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" ALT="GTS Duratek Logo" WIDTH=229 HEIGHT=45 ALIGN=top></CENTER><H2><CENTER><FONT  COLOR="#000065"><STRONG>Insite Quarterly Newsletter - Summer 1996</STRONG></FONT></CENTER></H2>
<HR>
<IMG SRC="/graphics/msthd3.gif" ALT="Insite Masthead" WIDTH=593 HEIGHT=152>
<OL START=1 TYPE=1>
<LI><A HREF="#newhq">GTS Duratek Breaks Ground for New Headquarters</A>
<LI><A HREF="#lanl">GTSD Is Part of the Mixed Waste Solution at LANL</A>
<LI><A HREF="#marea">M-Area: Our Flagship Project</A>
<LI><A HREF="#cru4">CRU-4 Passes Tests with Flying Colors</A>
<LI><A HREF="#rep">Bob Prince Wins Entrepreneur of the Year Award</A>
<LI><A HREF="#dtherm">DuraTherm Passes Environmental Audits</A>
</OL>
<BR><BR><BR>
<p><A NAME="newhq"></A><H3><B>GTS Duratek Breaks Ground on New Headquarters!</B></H3>
<p><I>By Angela Roe</I>
<br>
<p>"GTS Duratek has grown and prospered in Howard County over the last 12 years, and we look forward to a bright future here."
<br>
<p>Robert E. Prince,  President & CEO, GTS Duratek
<br>
<br>
<IMG SRC="/graphics/durahse.gif" ALT="Durahouse" WIDTH=375 HEIGHT=200 ALIGN=right>
<p>On a brilliant sunny morning in June, most of the GTS Duratek employees in the Columbia, Maryland, office just got up and walked out.  Was it mutiny? . . .  sick day en masse? . . . not even close.  There was something pretty special going on about a mile down the road and not one of them wanted to miss it.  When they arrived, there were already a lot of people there: reporters, photographers, caterers, and state / county officials.  Robert E. Prince, GTS Duratek's president and CEO, was excited _ and not only because of what was about to happen.  (As you read on in this issue, you'll find out what Bob was looking forward to that evening.)<br>
<p>This was the day that GTS Duratek had been dreaming about for a long time.  This was the day that it was to break ground for the new corporate headquarters _ a $3.3 million facility, featuring a striking two-story glass entrance.  A big smile was on the face of every person who stood at the podium to deliver praises to GTS Duratek; Manekin Corporation, the builder; and Howard County / Maryland State governments.  The speakers included Cole Schnorf, senior vice president, development, Manekin; Richard Alter, president and CEO, Manekin; James Brady, secretary, Maryland State Department of Business and Economic Development; Beverly Wilhide, assistant to the county executive, Chuck Ecker; Richard Story, executive director, Howard County Economic Development Authority; and Robert Prince, president and CEO, GTS Duratek.<br>
<p>GTS Duratek has been at the Guilford Road location for six years.  It has since expanded into what used to be storage space and coworkers are trying ever so hard to smile and be polite as they step over each other in the hallways and hold meetings in the lunch room or even at their desks due to the insufficient number of conference rooms.  This will be but a fond memory in December 1996, when they move into the spacious two-story, 35,000-square-foot facility.  The new building will not only house the corporate offices, but will provide space for materials warehousing, pilot-scale melter testing, and ion exchange media production.<br>
<p>GTS Duratek will lease from Manekin, but does have an option to buy the building at a later date.  Plans include space for an additional 22,000-square-foot future expansion. 
<BR><BR>

<P><A NAME="lanl"></A><B><H3>GTSD Is Part of the Mixed Waste Solution at LANL</H3></B>
<P><I>By Ray Walker</I><BR>

<P>The Los Alamos office of GTS Duratek is providing technical and physical support for the Low-Level Mixed Waste Work Off Project at Los Alamos National Laboratory (LANL) in New Mexico.  The objective of the project is to ship wastes off site for treatment and disposal rather than treating waste at LANL.  The GTS Duratek team support includes performing historical reviews, sampling and repackaging mixed waste, analyzing analytical data, and profiling the mixed waste for treatment and disposal at potential commercial and U.S. Department of Energy treatment/disposal facilities.  The results of the low-level mixed waste work off project have been excellent, with four successful off-site shipments completed in FY96 and five more planned for later on this fiscal year. 
<BR><BR><BR><BR><BR><BR><BR><BR>
<P><A NAME="marea"></A><B><H3>M-Area: Our Flagship Project</H3></B>
<P><I>By Mark Clements</I><BR>

<P>GTS Duratek has been involved in extensive systems testing since it was given the green light to begin operations at its Vendor Treatment Facility (VTF) at the U.S. Department of Energys Savannah River Site (SRS) in April.  During the testing phase, GTS Duratek made the decision to enhance the system, which will extend the startup period, to ensure that it will be ready to run safely and efficiently for a long period of time.  The DuraMelter 5000, the centerpiece of the Companys vitrification system at the VTF, is a prototype for the melter to be built at the Hanford Tank Waste Cleanup in Richland, Washington, and is roughly one-third its size.  The design changes being made now will further GTS Durateks knowledge for that important contract, due to be awarded in the fall of this year.  Once systems testing is complete, radioactive operations will begin.  The first batch of actual waste to be processed has been transferred to the chemical feed addition tank.<BR>
<P>Vitrification Day was held at SRS on May 29.  The media was given a tour of the VTF.  A brief presentation was made by Robert E. Prince, president and CEO, GTS Duratek.  Also in May, the GTS Duratek crew held its First Annual Family Day.  Bob Prince traveled to the site to personally thank everyone for their dedication and hard work on site and congratulate them on their success.
When all is said and done at M-Area, it wont spell the end for the VTF.  The waste that will be processed at M-Area represents only one percent of the waste that is at SRS, and GTS Duratek is negotiating with Westinghouse Savannah River Company  who maintains and operates SRS  to send other waste streams to the VTF once this project is finished. <BR><BR>

<P><A NAME="cru4"></A><B><H3>CRU-4 Passes Tests with Flying Colors</H3></B>
<P><I>By Sarah Bennett and Emory Toomey</I><BR><BR>
<IMG SRC="/graphics/silos.jpg" ALT="Silos at CRU-4" WIDTH=289 HEIGHT=119 ALIGN=right>
<P>Things are heating up at the Fernald Environmental Management Project, located outside of Cincinnati, Ohio.  The DuraMelter 1000-HT is now up and running.  This is GTS Durateks largest high-temperature melter, capable of producing up to three tons of glass per day.  It is designed to operate at 1350oC, 200oC above other DuraMelters.  Besides supplying Fernald Environmental Restoration Management Company (FERMCO) with the DuraMelter      1000-HT, GTS Duratek also supplied a gem machine that is capable of cutting the glass stream from the melter into "gems" (flattened marbles) and conveying the gems into designated drums.  "DuraGems" were chosen because of their easy handling characteristics.<BR>
<P>The Construction Acceptance Tests were successfully completed on both the melter and gem machine in late April.  Bakeout of the melter (the process of taking the melter from room temperature to its operating temperature and full of glass) commenced on May 18.  This process took about three weeks and a total of about 6,000 pounds of glass was added to the melter.  Integrated testing of the melter and support systems (feed and off-gas systems and the gem machine) began following bakeout.  The GTS Duratek staff and representatives from The Catholic University of Americas Vitreous State Laboratory (VSL), the Companys partner, assisted FERMCO through their Campaign 1 Systems Operability Test (SOT).  Throughout this test, FERMCO successfully processed runs of 20% and 40% slurry-fed solids, which produced several hundred pounds of DuraGems.  The SOT for Campaign 1 was completed on July 29.  At present, GTS Duratek is preparing to support FERMCO through Campaign 2 which will encompass a 36-hour Melter Acceptance Test and an 8-hour Gem Machine Acceptance Test.  These tests are currently anticipated to begin in mid to late August.<BR>
<P>The GTS Duratek support crew will remain assembled at Fernald through the end of September, and the VSL will supply scientific coverage through that period as necessary. 



<P><A NAME="rep"></A><B><H3>Bob Prince Wins Entrepreneur of the Year Award</H3></B>
<P><I>By Angela Roe</I><BR>

<P>GTS Durateks president and CEO, Robert E. Prince, was honored as Entrepreneur of the Year for Marylands Technology category at an awards dinner on June 26  the same day as the ground breaking for the new headquarters.  What a day!  <BR>
<P>Bob Prince won the award based on his achievements in bringing Duratek Corporation and General Technical Services together and creating a company " . . . on the cutting edge of providing an effective solution to one of our most pressing environmental [waste] problems."<BR>
<P>Robert F. Shawver, executive vice president and CFO of GTS Duratek had this to say on behalf of all employees:  "The employees of GTS Duratek are all proud to be part of the success of GTS Duratek and its leader.  We look forward to following Bobs leadership in achieving future successes for all of our clients and shareholders.  Through his example, Bob Prince has shown us all how to dream and achieve, and we congratulate him on this honor."<BR>
<P>What did Bob Prince have to say for himself?  He was, of course, modest.  "This award is not only for me, its for the whole company.  Weve got an excellent team of people who work together to accomplish aggressive goals, and we get the job done.  The reason GTS Duratek is so successful is that we have the people part right."<BR>
<P>Entrepreneur of the Year is sponsored nationally by Ernst & Young LLP, the Entrepreneur of the Year Institute, the Center for Entrepreneur Leadership, Inc. at the Ewing Marion Kauffman Foundation, and the Nasdaq Stock Market.  Local sponsors were The Baltimore Sun, Piper & Marbury, and Sprint. <BR><BR>

<P><A NAME="dtherm"></A><B><H3>DuraTherm Passes Environmental Audits</H3></B>
<P><I>By Joyce Frassanito</I><BR>
<IMG SRC="/graphics/dtherm.jpg" ALT="Duratherm Facility" WIDTH=325 HEIGHT=200 ALIGN=right>
<P>The DuraTherm Recycling Center returned to operations in May, following a major improvement and expansion program.  Since then, the facility and its staff have undergone and passed numerous formal environmental audits and site visits by representatives from major petroleum, petrochemical, and environmental companies.  This audit/approval process is an essential step for new customers when they first begin to use DuraTherm as part of their waste management programs.<BR>
<P>When choosing waste management vendors, these international companies impose a laundry list of stringent acceptance criteria before authorizing the vendors to process their waste.  Surprisingly, not all of the criteria are directly related to the vendors waste processing capability.  Some examples of the areas looked at include: <BR>
<UL>
<LI>	professional expertise,
<LI>	range of capabilities,
<LI>	community relations,
<LI>	parent companys stability and reputation,
<LI>	financial strength,
<LI>	regulatory permits and compliance,
<LI>	industry acceptance, and
<LI>	physical condition of the vendors facility.
</UL><BR>
<p>So far, DuraTherm has a 100 percent approval record, and its staff looks forward to continuing improvements in production and revenue contribution throughout the rest of the year. 

<BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></a>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="aboutgts.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></a>
<BR><BR><BR>
<HR>
<CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-233</DOCNO>
<DOCOLDNO>IA048-000840-B022-312</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/duraapp.htm 204.177.32.133 19970119161740 text/html 3040
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:14:33 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Fri, 20 Dec 1996 16:57:50 GMT
Content-length: 2864
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Past Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center><STRONG>**** FOR IMMEDIATE RELEASE ****</STRONG></center>
<BR>
<p><STRONG>Date:</STRONG>November 6, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=55 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>

<br><br>


	<strong><CENTER>GTS DURATEK'S SUBSIDIARY DURATHERM </center>
<center>RECEIVES RECYCLING APPROVAL </CENTER></strong>
<br><BR>
<p>COLUMBIA, Md. -- GTS Duratek (Nasdaq:  DRTK) today announced that its 80% owned-subsidiary, DuraTherm, Inc., received official notification from the Texas Natural Resource Conservation Commission (TNRCC), approving the recycling of the residues from the thermal desorption process into prefabricated concrete building products.  Recycling eliminates the need for costly disposal of the process residue as hazardous waste.  This improvement significantly lowers overall operating costs and produces a useful product.<br>

<p>Robert Hensel, President, DuraTherm said, "This will provide our customers with a unique opportunity to have their listed waste residues incorporated into a recycled product that will not be subject to RCRA regulations.  We have also recently developed the ability to process more difficult waste streams, broadening the range of waste that we are able to accept from our customers."<br>

<p>Robert E. Prince, President, GTS Duratek said, "DuraTherm can now recycle a process waste residue into a useful product, that has historically cost over $100 a ton for disposal in a hazardous waste landfill.  Not only is it good for the environment to recycle this residue, it is also good business."  <br>

<p>DuraTherm, Inc.  provides solutions for refinery waste disposal using its patented thermal desorption process.  GTS Duratek is an environmental technology and services firm that uses its proprietary vitrification processes to convert radioactive and hazardous waste into glass for long-term storage and disposal.<br>


<p><center>###</center>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-234</DOCNO>
<DOCOLDNO>IA048-000840-B023-7</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/3rdquart.htm 204.177.32.133 19970119161814 text/html 4250
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:15:39 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Thu, 12 Dec 1996 15:15:11 GMT
Content-length: 4074
</DOCHDR>
<HTML>
<HEAD>
<TITLE> Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Past Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center>**** FOR IMMEDIATE RELEASE ****</center>


<br><br>
<p><STRONG>Date:</STRONG>November 5, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=55 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>


<br><br>

	<strong><CENTER>GTS DURATEK REPORTS THIRD QUARTER RESULTS</CENTER></strong>


<P>COLUMBIA, Md.- GTS Duratek (DRTK - NASDAQ) today announced net earnings of $426,000 on revenues of $11,482,000 for the third quarter and earnings of $1,443,000 on revenues of $33,464,000 for the nine months ended September 30, 1996.  Year-to-date earnings increased by $289,000 over the same period in 1995 of $1,154,000 and decreased by $47,000 over the same quarter in the prior year of $473,000.  Revenues for the quarter and year-to-date increased by 21% and 15%, respectively, over the same periods in 1995.  On a per-share basis, net earnings after preferred stock dividends and related charges was $.00 for the quarter and $.02 for the nine months ending September 30, 1996 as compared to $.01 and $.02 for the same periods in 1995.

<P>According to Robert E. Prince, GTS Duratek president and CEO, "So far this year, the Company has achieved a number of very important milestones.  Most recently, we commenced commercial operations, processing radioactive waste, in our full-scale facility located at the Department of Energy's (DOE) Savannah River Site.  In another major victory, GTS Duratek and its teammates were awarded a contract for phase I of the Hanford Tank Clean-up which will be the DOE's largest radioactive waste clean-up project."

<P>Robert F. Shawver, GTS Duratek executive vice president and CFO added, "Commencing operations at our vitrification facility, located on the DOE's 300-square-mile Savannah River Site, is a very key step that we believe uniquely positions this facility to generate ongoing revenue streams for the Company."

<P>GTS Duratek is an environmental technology and services firm that uses its proprietary vitrification processes to convert radioactive and hazardous waste into glass for long-term storage and disposal.

<P>A comparative summary of third quarter results between 1996 and 1995 is as follows:
<br><br>
     <CENTER> (in thousands, except per share data)

 <CENTER> <TABLE CELLPADDING=4 CELLSPACING=5>
<TR>
			<TH COLSPAN=1></TH>
			<TH COLSPAN=2><U>3 Months</U></TH>
			<TH COLSPAN=2><U>9 Months</U></TH>
</TR>
<TR><TD></TD><TD ALIGN=MIDDLE><STRONG><U>1996</U></STRONG></TD><TD ALIGN=MIDDLE>1995</TD><TD ALIGN=MIDDLE><STRONG><U>1996</U></STRONG></TD><TD ALIGN=MIDDLE>1995</TD></TR>
<TR><TD>Revenues</TD><TD ALIGN=MIDDLE><STRONG>$11,482</STRONG></TD><TD ALIGN=MIDDLE>$9,426</TD><TD ALIGN=MIDDLE><STRONG>$33,464</STRONG></TD><TD ALIGN=MIDDLE>$28,948</TD></TR>
<TR><TD>Net Earnings</TD><TD ALIGN=MIDDLE><STRONG>426</STRONG></TD><TD ALIGN=MIDDLE>473</TD><TD ALIGN=MIDDLE><STRONG>1,443</STRONG></TD><TD ALIGN=MIDDLE>1,154</TD></TR>
<TR><TD>Earnings per share</TD><TD ALIGN=MIDDLE><STRONG>.00</STRONG></TD><TD ALIGN=MIDDLE>.01</TD><TD ALIGN=MIDDLE><STRONG>.02</STRONG></TD><TD ALIGN=MIDDLE>.02</TD></TR>
</TABLE>

</center>


<p align="center">###
<BR><BR>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></a>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></a>

<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-235</DOCNO>
<DOCOLDNO>IA048-000840-B023-154</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/savrad.htm 204.177.32.133 19970119161930 text/html 4159
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:16:08 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 16:29:02 GMT
Content-length: 3983
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Past Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center><STRONG>**** FOR IMMEDIATE RELEASE ****</STRONG></center>


<br><br>
<P><STRONG>Date:</STRONG>October 21, 1996<br>                                     <p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=60 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>

<br><br>
<CENTER><strong>GTS DURATEK MELTER COMMENCES RADIOACTIVE
OPERATIONS AT WESTINGHOUSE SAVANNAH RIVER FACILITY</strong></CENTER>


<p>	COLUMBIA, Md. -- GTS Duratek (Nasdaq:  DRTK) today announced
that its DuraMelter 5000, the world's largest radioactive waste melter, has begun
converting low-level radioactive sludge from the United States Department of
Energy's (DOE) Savannah River Site into glass (a process called vitrification). 
This is the first commercial cleanup effort to use vitrification on a DOE site.


<p>	Robert E.  Prince, president and CEO said, "The commencing of
radioactive operations is a major milestone for the Company and for the
technology.  This uniquely gives us the experience to be a large player in the
multi-billion dollar cleanup effort that is only beginning."


<p>	Mario Fiori, DOE's Savannah River Site Operations Manager said,
"This project is the largest commercial use of vitrification to date.  GTS Duratek
has created good paying jobs in the South Carolina area, and is solving a very
important environmental problem.  In addition, the M Area cleanup is a key
commitment made to the state by the DOE, and GTS Duratek is on track to help
us meet our milestone."


<p>	GTS Duratek built, owns and operates the facility on the Savannah River
Site for cleaning up low-level radioactive waste.  The Company will convert
660,000 gallons of waste into glass over the next 6 to 12 months.  This waste
represents only 1% of the waste at the Savannah River Site.  Upon completion of
this contract, GTS Duratek's facility will be available to process additional waste.  


<p>	GTS Duratek, along with its strategic ally BNFL Inc., was recently
awarded a contract -- estimated to be worth up to $4 billion -- to design, build,
operate and decommission a facility located at the DOE's Hanford Site in
Richland, Washington.  The DuraMelter 5000 is one-third the size of the melter
that will be used for the Hanford project, and the Savannah River facility was
designed to be the small-scale prototype for Hanford in order to better develop the
technology needed.  The Hanford facility will convert up to 6 million gallons of
high-level radioactive waste in the first phase of the largest environmental waste
cleanup for the DOE.  Cleanup of DOE sites across the country -- containing over
tens of millions of gallons of similar hazardous and radioactive waste -- requires
technologies such as vitrification and is estimated to cost over $230 billion.


<p>	GTS Duratek is an environmental technology and services firm that uses
its proprietary vitrification processes to convert radioactive and hazardous waste
into glass for environmentally safe long-term storage and disposal.



<p align="center">###
<br><br>

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-236</DOCNO>
<DOCOLDNO>IA048-000840-B023-253</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/hanford.htm 204.177.32.133 19970119162000 text/html 4099
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:17:22 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 19:16:45 GMT
Content-length: 3923
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Past Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center><STRONG>**** FOR IMMEDIATE RELEASE ****</STRONG></center>


<br><br>
<p><STRONG>Date:</STRONG>September 25, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=55 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>

<br><br>
<strong>GTS DURATEK MELTER COMMENCES RADIOACTIVE
OPERATIONS AT WESTINGHOUSE SAVANNAH RIVER FACILITY</strong>


<p>	COLUMBIA, Md. -- GTS Duratek (Nasdaq:  DRTK) today announced
that its DuraMelter 5000, the world's largest radioactive waste melter, has begun
converting low-level radioactive sludge from the United States Department of
Energy's (DOE) Savannah River Site into glass (a process called vitrification). 
This is the first commercial cleanup effort to use vitrification on a DOE site.


<p>	Robert E.  Prince, president and CEO said, "The commencing of
radioactive operations is a major milestone for the Company and for the
technology.  This uniquely gives us the experience to be a large player in the
multi-billion dollar cleanup effort that is only beginning."


<p>	Mario Fiori, DOE's Savannah River Site Operations Manager said,
"This project is the largest commercial use of vitrification to date.  GTS Duratek
has created good paying jobs in the South Carolina area, and is solving a very
important environmental problem.  In addition, the M Area cleanup is a key
commitment made to the state by the DOE, and GTS Duratek is on track to help
us meet our milestone."


<p>	GTS Duratek built, owns and operates the facility on the Savannah River
Site for cleaning up low-level radioactive waste.  The Company will convert
660,000 gallons of waste into glass over the next 6 to 12 months.  This waste
represents only 1% of the waste at the Savannah River Site.  Upon completion of
this contract, GTS Duratek's facility will be available to process additional waste.  


<p>	GTS Duratek, along with its strategic ally BNFL Inc., was recently
awarded a contract -- estimated to be worth up to $4 billion -- to design, build,
operate and decommission a facility located at the DOE's Hanford Site in
Richland, Washington.  The DuraMelter 5000 is one-third the size of the melter
that will be used for the Hanford project, and the Savannah River facility was
designed to be the small-scale prototype for Hanford in order to better develop the
technology needed.  The Hanford facility will convert up to 6 million gallons of
high-level radioactive waste in the first phase of the largest environmental waste
cleanup for the DOE.  Cleanup of DOE sites across the country -- containing over
tens of millions of gallons of similar hazardous and radioactive waste -- requires
technologies such as vitrification and is estimated to cost over $230 billion.


<p>	GTS Duratek is an environmental technology and services firm that uses
its proprietary vitrification processes to convert radioactive and hazardous waste
into glass for environmentally safe long-term storage and disposal.



<p align="center">###

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-237</DOCNO>
<DOCOLDNO>IA048-000840-B023-289</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/2ndquart.htm 204.177.32.133 19970119162024 text/html 4194
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:17:56 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 19:16:32 GMT
Content-length: 4018
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><STRONG><CENTER><FONT  COLOR="#000040">Current Press Release</FONT></CENTER></STRONG></FONT></H2>

<HR>
<p><H3><CENTER><strong>**** FOR IMMEDIATE RELEASE ****</strong></CENTER></H3>

<br><br>

<p><STRONG>Date:</STRONG>August 6, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=55 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>

<br><br>
<p align="center"><strong>GTS DURATEK REPORTS SECOND QUARTER PROFIT</strong>
</u>
<br><br>
<br><br>
<p>COLUMBIA, Md. - GTS Duratek (DRTK - NASDAQ) today announced net earnings of $516,000 on revenues of $11,645,000 for the second quarter and net earnings of
$1,017,000 on revenues of $21,981,000 for the six months ended June 30, 1996.  GTS Duratek's
second quarter net earnings increased by 33% over the same period in 1995 of $388,000 on
revenues of $9,986,000.  Year-to-date earnings increased by 49% over the same period in 1995
as GTS Duratek earned $680,000 on revenues of  $19,521,000.  On a per-share basis, net
earnings after preferred stock dividends and related charges was $.01 for the quarter and $.02 for
the six months ending June 30,1996 as compared to $.00 and $.00 for the same periods in 1995.   

<br><br>
<p>According to Robert F.  Shawver, GTS Duratek executive vice president and CFO, "Over the last
year and a half,  the Company has continued to make solid improvements in its earnings and
balance sheet.   We believe this progress is an important step to position us favorably to achieve
our important long-term objectives."   

<br><br>
<p>Robert E.  Prince, GTS Duratek president and CEO added, "The DOE, this year has put out more
opportunities to bid on cleanup work than in the last few years combined.  We are committed to
achieving strategic milestones that will make us a significant player in this growing
marketplace."

<br><br>
<p>GTS Duratek is an environmental technology and services firm that uses its proprietary
vitrification processes to convert radioactive and hazardous waste into glass for long-term
storage and disposal.

<br><br>
<p>A comparative summary of the second quarter results between 1996 and 1995 is as follows:
<br><br>
<br><br>
<p>     <CENTER> (in thousands, except per share data)</CENTER>

<p> <CENTER> <TABLE CELLPADDING=4 CELLSPACING=5>
<TR>
			<TH COLSPAN=1></TH>
			<TH COLSPAN=2><U>3 Months</U></TH>
			<TH COLSPAN=2><U>6 Months</U></TH>
</TR>
<TR><TD></TD><TD ALIGN=MIDDLE><STRONG><U>1996</U></STRONG></TD><TD ALIGN=MIDDLE>1995</TD><TD ALIGN=MIDDLE><STRONG><U>1996</U></STRONG></TD><TD ALIGN=MIDDLE>1995</TD></TR>
<TR><TD>Revenues</TD><TD ALIGN=MIDDLE><STRONG>$11,645</STRONG></TD><TD ALIGN=MIDDLE>$9,986</TD><TD ALIGN=MIDDLE><STRONG>$21,981</STRONG></TD><TD ALIGN=MIDDLE>$19,521</TD></TR>
<TR><TD>Net Earnings</TD><TD ALIGN=MIDDLE><STRONG>516</STRONG></TD><TD ALIGN=MIDDLE>388</TD><TD ALIGN=MIDDLE><STRONG>1,017</STRONG></TD><TD ALIGN=MIDDLE>680</TD></TR>
<TR><TD>Earnings per share</TD><TD ALIGN=MIDDLE><STRONG>.01</STRONG></TD><TD ALIGN=MIDDLE>.00</TD><TD ALIGN=MIDDLE><STRONG>.02</STRONG></TD><TD ALIGN=MIDDLE>.00</TD></TR>
</TABLE>


</CENTER>
 

<br><br>
<br><br>
<p align="center">###

<br><br>
<br><br>

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></a>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></a>



<BR><BR><BR>
<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-238</DOCNO>
<DOCOLDNO>IA048-000840-B023-330</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/1stquart.htm 204.177.32.133 19970119162051 text/html 4071
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:18:14 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 19:16:30 GMT
Content-length: 3895
</DOCHDR>
<HTML>
<HEAD>
<TITLE> Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Past Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center><STRONG>**** FOR IMMEDIATE RELEASE ****</STRONG></center>


<br><br>
<p><STRONG>Date:</STRONG>May 7, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=55 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>

<br><br>
<p><U>GTS Duratek First Quarter 1996 Results</U>

<br><br>
<br><br>
<p>               <STRONG><CENTER>GTS DURATEK REPORTS FIRST QUARTER PROFIT</CENTER></STRONG>

<br><br>
<p>	COLUMBIA, Md.  GTS Duratek (Nasdaq: DRTK) today announced net earnings of
$500,000 on revenues of $10,336,000 for its first quarter ended March 31, 1996, as compared to
net earnings of $292,000 on revenues of $9,536,000 for the same period in 1995.  First quarter
earnings increased by 71% over the same quarter in the prior year.  On a per-share basis, net
earnings after preferred stock dividends and related charges was $.01 in the 1996 quarter
compared to $.00 in the 1995 quarter.  

<p>	According to Robert E. Prince, GTS Duratek president and CEO, "We believe that
achievement of our important milestones has been and will continue to be key to our continued
financial performance improvement."   

<p>	On May 1, 1996 the company started commercial processing at its DuraTherm Recycling
Center, which processes up to 100 tons per day of petro-chemical industry sludges.  This facility is expected to contribute revenues and profit in
1996.  In April of this year, GTS Duratek received permission from the U.S. Department of
Energy (DOE) to begin start-up of the Company's waste treatment facility located on the
Savannah River Site.  This is the largest, privately owned low-level radioactive waste
vitrification (waste-to-stable-glass conversion) facility located on DOE property.    

<p>	Executive Vice President Robert F. Shawver, GTS Duratek's chief financial officer, said,
"Raising $43 million this past April through a secondary public stock offering has the company
well positioned to take advantage of the current and emerging worldwide market opportunities to
apply its services and technologies."  

<p>	GTS Duratek is a Columbia, Md.-based  environmental services and technology firm that
specializes in converting waste into environmentally safe forms with its proprietary technologies.

<p>A comparative summary of the second quarter results between 1996 and 1995 is as follows:


<p>     <CENTER> (in thousands, except per share data)

<p> <CENTER> <TABLE CELLPADDING=4 CELLSPACING=5>
<TR>
			<TH COLSPAN=1></TH>
			<TH COLSPAN=2><U>3 Months</U></TH>
			
</TR>
<TR><TD></TD><TD ALIGN=MIDDLE><STRONG><U>1996</U></STRONG></TD><TD ALIGN=MIDDLE>1995</TD></TR>
<TR><TD>Revenues</TD><TD ALIGN=MIDDLE><STRONG>$10,336</STRONG></TD><TD ALIGN=MIDDLE>$9,536</TD></TR>
<TR><TD>Net Earnings</TD><TD ALIGN=MIDDLE><STRONG>$500</STRONG></TD><TD ALIGN=MIDDLE>$292</TD></TR>
<TR><TD>Earnings per share</TD><TD ALIGN=MIDDLE><STRONG>.01</STRONG></TD><TD ALIGN=MIDDLE>.00</TD></TR>
</TABLE>





<p><center>###

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-239</DOCNO>
<DOCOLDNO>IA048-000840-B024-32</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/durathrm.htm 204.177.32.133 19970119162130 text/html 2912
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:18:59 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 19:16:41 GMT
Content-length: 2736
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Past Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center><STRONG>**** FOR IMMEDIATE RELEASE ****</STRONG></center>
<BR>
<p><STRONG>Date:</STRONG>May 2, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=55 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>

<br><br>
<p><u></u><center><strong>GTS DURATEK'S DURATHERM FACILITY</center>
</strong>

<p><strong><center>BEGINS COMMERCIAL OPERATIONS</strong></center>


<br><br>
<p>	COLUMBIA, Md. -- GTS Duratek (Nasdaq: DRTK) today announced that its
DuraTherm Recycling Center, which processes oil refinery and petrochemical industry solid
waste, has restarted following a $3 million improvement and expansion program to increase
capacity and reliability.

<br><br>
<p>	In a move to enter niche areas of the hazardous waste treatment and recycling business,
GTS Duratek acquired an 80-percent share of the RCRA (Resource Conservation and Recovery
Act) Part B permitted facility in late 1995.  DuraTherm uses patented thermal desorption
technology to recover usable fuels from petroleum processing waste sludge.

<br><br>
<p>	"One of our major goals is to find industry niches where we can apply innovative
technology to provide better, more cost-effective processes to treat and recycle hazardous
waste as useful products," said Robert E. Prince, GTS Duratek's president and CEO. 
"Upgrading the DuraTherm facility to a commercial-production level is part of that overall
strategy.  Thermal desorption technology is also compatible with our other thermal waste
treatment processes for radioactive, hazardous and mixed (both radioactive and hazardous)
wastes."

<br><br>
<p>	GTS Duratek is a Columbia, Md.-based environmental services and technology firm
that specializes in converting waste to environmentally safe forms with its proprietary
technologies.

<p><center>###</center>
<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-240</DOCNO>
<DOCOLDNO>IA048-000840-B024-78</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/offering.htm 204.177.32.133 19970119162206 text/html 3457
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:19:31 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 19:16:47 GMT
Content-length: 3281
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Past Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center><STRONG>**** FOR IMMEDIATE RELEASE ****</STRONG></center>


<br><br>
<p><STRONG>Date:</STRONG>March 20, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=55 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>


<br><br>
<p align="center"><strong>GTS DURATEK FILES REGISTRATION STATEMENT</strong>

<p align="center"><strong>FOR PUBLIC OFFERING</strong>

<br><br>
<p>	COLUMBIA, Md. -- GTS Duratek, Inc. (Nasdaq: DRTK) announced today that it has
filed a registration statement with the Securities and Exchange Commission relating to a
proposed offering of 3,600,000 shares of its common stock, of which 2,500,000 shares
(3,040,000 shares if the underwriters' over-allotment option is exercised) will be sold by the
Company and the balance will be sold by National Patent Development Corporation (AMEX:
NPD).  

<br><br>
<p>	The Company intends to use the net proceeds from the offering to expand its waste
treatment technology operations, including for working capital, funding of waste treatment
technology projects, research and development, and for possible acquisitions.  The Company
will not receive any of the proceeds of the sales by the selling stockholder.  Donaldson, Lufkin
&amp; Jenrette Securities Corporation, Deutsche Morgan Grenfell, and Gruntal &amp; Co.,
Incorporated are serving as representatives of the underwriters for the offering.

<br><br>
<p>	GTS Duratek is a Columbia, Md.-based integrated environmental services and
technology firm with proprietary waste processing systems applicable to radioactive,
hazardous, mixed, and other wastes.  The Company's vitrification and other technologies
convert waste to stable forms for storage while achieving significant volume reduction.

<br><br>
<p>	A registration statement relating to these securities is being filed with the Securities and
Exchange Commission, but has not yet become effective.  These securities may not be sold nor
may offers to buy be accepted prior to the time the registration statement becomes effective. 
This press release does not constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of these securities in any State in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities laws of such State.

<p><center>###

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-241</DOCNO>
<DOCOLDNO>IA048-000840-B024-139</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/arinews.htm 204.177.32.133 19970119162250 text/html 2203
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:19:58 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 19:16:37 GMT
Content-length: 2027
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Past Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center><STRONG>**** FOR IMMEDIATE RELEASE ****</STRONG></center>


<br><br>
<p><STRONG>Date:</STRONG>February 27, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=55 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>


<br><br>
<p align="center"><center><strong>GTS DURATEK CONFIRMS TEAMING WITH BNFL INC. ON PROPOSAL FOR
IDAHO MIXED WASTE TREATMENT PROJECT </strong></center>

<br><br>
<p>	COLUMBIA, Md. -- GTS Duratek, Inc. (Nasdaq: DRTK) today confirmed yesterday's
announcement that it is teaming with BNFL Inc. on a proposal for the treatment of United
States Department of Energy (DOE) mixed wastes at the Idaho National Engineering
Laboratory (INEL).  GTS Duratek and BNFL are part of a team to submit a proposal in
response to the DOE's Request For Proposal (RFP) to establish a private sector treatment
facility with the capability to treat specific INEL waste streams and the flexibility to treat
INEL and DOE regional and national waste streams.

<br><br>
<p>	The INEL project represents the second DOE project that GTS Duratek and BNFL have teamed on.

<p><center>###

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-242</DOCNO>
<DOCOLDNO>IA048-000840-B024-177</DOCOLDNO>
<DOCHDR>
http://www.gtsduratek.com:80/opreview.htm 204.177.32.133 19970119162314 text/html 2707
HTTP/1.0 200 Document follows
Date: Sun, 19 Jan 1997 16:20:42 GMT
Server: NCSA/1.4.1
Content-type: text/html
Last-modified: Wed, 06 Nov 1996 19:16:49 GMT
Content-length: 2531
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Past Press Release </TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><IMG SRC="/graphics/ailogo1.jpg" WIDTH=229 HEIGHT=45></CENTER>
<H2><FONT  COLOR=#000065><STRONG><CENTER>Past Press Release</CENTER></STRONG></FONT></H2>
<HR>
<p><center><STRONG>**** FOR IMMEDIATE RELEASE ****</STRONG></center>


<br><br>
<p><STRONG>Date:</STRONG>January 15, 1996<br>
<p><STRONG>Contact:</STRONG>  Robert E. Prince, Pres. & CEO<br>
<IMG SRC="/graphics/space.gif" WIDTH=55 HEIGHT=50 BORDER=0 ALIGN="left">
           Robert F. Shawver, Exec. V.P.<br>
           Diane R. Brown, Investor Relations<br>
           (410) 312-5100<br>


<br><br>
<p><u>GTS Duratek M-Area Construction Completion</u>

<br><br>
<br><br>
<p align="center"><strong>WESTINGHOUSE SAVANNAH RIVER COMPANY TO BEGIN</strong>

<p align="center"><strong>GTS DURATEK VITRIFICATION FACILITY </strong>

<p align="center"><strong>OPERATIONAL READINESS REVIEW</strong>

<br><br>
<p>	COLUMBIA, Md. -- GTS Duratek (Nasdaq:  DRTK) today informed
Westinghouse Savannah River Company that it has completed construction of its
<em>Vendor Treatment Facility</em> for converting mixed radioactive and hazardous
sludge to glass at the Department of Energy's Savannah River Site.

<p>	Reaching this milestone enables Westinghouse, the DOE site operations
contractor, to begin its contractually obligated readiness assessment of the
facility.  Upon successful completion of the review, which could last up to six
weeks, GTS Duratek will start up its proprietary DuraMelter 5000 and conduct
a short testing period with nonradioactive, simulated waste material.  During the
12 months following testing, GTS Duratek staff will convert approximately
660,000 gallons of mixed waste sludge to glass for safe, long-term storage or
disposal.

<p>	Columbia, Md.,-based GTS Duratek implements proprietary, low-cost
technology solutions for transforming waste into stable, and wherever possible,
recyclable glass-based products.

<p><center>###

<A HREF="index.html"><IMG SRC="/graphics/home.jpg" ALT="Go to Home Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<IMG SRC="/graphics/space.gif" WIDTH=3 HEIGHT=1 BORDER=0 ALIGN="RIGHT">

<A HREF="rpress.htm"><IMG SRC="/graphics/prevpg.jpg" ALT="Previous Page" HEIGHT=34 WIDTH=120 BORDER=NONE ALIGN=RIGHT></A>
<BR><BR><BR>

<HR>
<p> <CENTER>Copyright 1996 GTS Duratek, Inc.                                     e-mail: rwisniew@gtsduratek.com</CENTER>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT01-B04-243</DOCNO>
<DOCOLDNO>IA051-000877-B037-5</DOCOLDNO>
<DOCHDR>
http://antwg.geo.ukans.edu:80/ 129.237.236.17 19970111183923 text/html 2314
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aefd3dfb.58@antwg.geo.ukans.edu.>
Date: Saturday, 11-Jan-97 12:54:19 GMT
Last-Modified: Friday, 20-Oct-95 16:32:12 GMT
Content-type: text/html
Content-length: 2073
</DOCHDR>
<html><head>
<title>ANTARCTIC WORKING GROUP GEOLOGY and GEOPHYSICS</title>
</head>
<body>
<h2>Welcome to the Antarctic Working Group for  Geology</center>
<center> and Geophysics</h2></center>
<center><h2>(ANTWGGG) Home Page</H2></center><p>

<img align= middle src="mts.gif alt="BYRD MTS">
    Bender Mountains:  late Ross-age granitoid intrusive 
 
<h3><center>Purpose of the Working Group</h3></center>
     The Office of Polar Programs of the National Science Foundation 
     maintains science support capabilities that enable a broad range of 
     research projects, especially within the US Antarctic Program.  
     Ensuring that these capabilities continue to serve the best interests 
     of the research community requires periodic and open dialog between 
     the earth sciences community and the program manager.  The Antarctic
     Working Group for Geology and Geophysics is an ad hoc body whose role is
     to provide feed-back about current and planned research support
     capabilities available to Antarctic earth science projects supported by the 
     National Science Foundation.  The working group affords a broad conduit for 
     exchange of information between the program manager and the 
     earth-science research community.  The group addresses concerns and 
     priorities within the Antarctic Geology and Geophysics program, making 
     recommendations for action where appropriate.  It also provides a 
     forum to raise and discuss general programmatic issues associated with 
     new opportunities in earth science research as it perceives them, or 
     as they are recognized by the wider earth-science community.<p>
<a href="comp.html ">Composition of the Working Group </a><p>
<a href="wedo.html ">When does ANTWGGG meet and what does it do?  </a><p>
<a href="news.html"> News items from ANTWGGG  </a><p>
<a href="input.html ">How can you input?   </a><p>
<a href="projec.html">Current active Antarctic Geology and Geophysics projects and their P.I.</a><p>
<a href="sites.html ">Other Polar WWW Sites </a>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT01-B04-244</DOCNO>
<DOCOLDNO>IA051-000877-B037-37</DOCOLDNO>
<DOCHDR>
http://antwg.geo.ukans.edu:80/comp.html 129.237.236.17 19970111183934 text/html 2394
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aefd3e10.59@antwg.geo.ukans.edu.>
Date: Saturday, 11-Jan-97 12:54:40 GMT
Last-Modified: Monday, 05-Aug-96 14:11:58 GMT
Content-type: text/html
Content-length: 2153
</DOCHDR>
<html><head>
<title>composition of PESWG</title>
</head>
<body>
<dl>
<dt>Composition of the Working Group<dd>  Members of the committee typically serve a three-year rotating term.  The working group  consists of six regular members with the program manager  for Antarctic Geology and Geophysics constituting a seventh, ex officio, member.  It represents a broad cross section of  Antarctic geology and geophysics  interests and includes earth scientists with both shipboard and land-based polar experience.  It is funded to co-opt visitors to advise with topics outside its immediate sphere of competence.
</dl>
	
<center><h3>Present members with their  phone, fax numbers, and e-mail addresses</h3></center>

<dl>
<dt>Eugene Domack
<dd>Department of Geology
<dd>Hamilton College
<dd>Clinton, NY 13323
<dd>TEL: 315-859-4711
<dd>FAX: 214-859-4185
<dd>edomack@hamilton.edu

<dt>John Goodge  (Chair)
<dd>Department of Geological Sciences
<dd>Southern Methodist University
<dd>Dallas, TX 75275
<dd>TEL: 214-768-4140
<dd>FAX: 214-768-4289
<dd>jgoodge@sun.cis.smu.edu


<dt>Gerard Bond
<dd>Lamont-Doherty Earth Observatory
<dd>Palisades, NY 10964
<dd>TEL: 914-359-2900
<dd>FAX: 914-365-2312
<dd>gcb@ldeo.columbia.edu


<dt>Carol Raymond
<dd>Jet Propulsion Lab
<dd>California Institute of Technology
<dd>4800 Oak Grove Drive
<dd>Pasadena, CA 911009
<dd>TEL: 818-354-8690, ext. 5420
<dd>FAX: 818-393-5059
<dd>car@orion.jpl.nasa.gov

<dt>Bert Rowell 
<dd>Department of Geology
<dd>University of Kansas
<dd>Lawrence, KS 66045
<dd>TEL: 913-864-241
<dd>FAX: 913-864- 5276
<dd>arowell@kuhub.cc.ukans.edu



<dt>Terry Wilson
<dd>Department of Geological Sciences
<dd>Ohio State University
<dd>275 Mendenhall Lab
<dd>125 S. Oval Mall
<dd>Columbus, OH 43210
<dd>TEL: 614-292-0723
<dd>FAX: 614-292-7688
<dd>twilson@mps.ohio-state.edu

					<dt>Scott Borg (ex officio)
					<dd>Office of Polar Programs,
					<dd>National Science Foundation, 
					<dd>4201 Wilson Road
					<dd>Arlington, VA 22230
					<dd>TEL: 703-306-1033
					<dd>FAX: 703-306-9422
					<dd>sborg@nsf.gov
</dl>
<a href="http://antwg.geo.ukans.edu/peswg.html">Return to Home Page</a>

</body>
</html>

</DOC>
<DOC>
<DOCNO>WT01-B04-245</DOCNO>
<DOCOLDNO>IA051-000877-B037-86</DOCOLDNO>
<DOCHDR>
http://antwg.geo.ukans.edu:80/wedo.html 129.237.236.17 19970111183953 text/html 1566
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aefd3e19.60@antwg.geo.ukans.edu.>
Date: Saturday, 11-Jan-97 12:54:49 GMT
Last-Modified: Monday, 12-Aug-96 15:39:32 GMT
Content-type: text/html
Content-length: 1325
</DOCHDR>
<html><head>
<title>When we meet and What we do</title>
</head>
<body>
<h3>When does ANTWGG meet and what does it do?</h3>  
     The working group meets  formally twice a year at the N.S.F. building in Arlington, Virginia.  Meetings are typically for a day and a half.  Agenda items are those suggested either by OPP or  by members of the working group.   We welcome, however , suggestions to enhance effectiveness  of OPP projects and logistics base from the earth science community, and we seek input on some topics currently under discussion.  Topics that will be on the next agenda meeting include:
<ul>
<li>    Comprehensive report on Marine Geology and Geophysics  capabilities 	and activities	
<li>     Update on marine corting capability and formation of a study group
<li>      Potential use of the Nathanial B. Palmer as a platform for land-based 	geology
<li>    Update on the development of a repository for signiificant specimens of 	Antarctic rocks and fossils together with a data base of present location 	of  prior Antarctic rock and fossil collections.
<li>    Update on Antarctic working group WWW site 
<li>	Announcement from working group to polar community concerning 	helicopter support of field projects
</ul>
<a href="http://antwg.geo.ukans.edu/peswg.html">Return to Home Page</a>

</body>
</html>

</DOC>
<DOC>
<DOCNO>WT01-B04-246</DOCNO>
<DOCOLDNO>IA051-000877-B037-255</DOCOLDNO>
<DOCHDR>
http://antwg.geo.ukans.edu:80/news.html 129.237.236.17 19970111184143 text/html 12515
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aefd3e66.62@antwg.geo.ukans.edu.>
Date: Saturday, 11-Jan-97 12:56:06 GMT
Last-Modified: Tuesday, 07-Jan-97 12:12:22 GMT
Content-type: text/html
Content-length: 12272
</DOCHDR>
<title>NEWS ITEM</title>
<body>
<h2>
NEW FUNDS FOR STUDY OF POSSIBLE MARTIAN LIFE
</h2>
<br>
<p>
NSF has recently announced a solicitation for research proposals to study the 
evidence for biogenic activity in Martian meteorite ALH84001, collected in 
Antarctica.  The announcement presents "an opportunity for support of basic
research to investigate and resolve, to the extent possible, recently
reported evidence suggesting a biological origin for certain phenomena
within Martian meteorite ALH84001.  Up to $1.3 M will be made
available for this purpose in FY97 by the NSF Office of Polar Programs
and the Division of Chemistry.  This is not expected to be a
continuing program; in the future, proposals in this topical area
should be submitted to appropriate disciplinary programs.
<p>

"The recent announcement of possible evidence of life in a Martian
meteorite (McKay et al., Science, v. 273 , p. 924-930, 16 August 1996)
raises important and exciting issues about the origin of life in the
solar system and indeed in the universe.  Because the evidence
presented is not conclusive, however, additional research evaluating
these intriguing but controversial findings is appropriate.  Besides
affecting our understanding of life in the universe, results should
lead to improved avenues for examining material that might be returned
from Mars in the future.
<p>

"NASA has recently announced a separate but related research
opportunity (see NASA announcement NRA 96-OSS-14, released 29 November
1996; available at: 
<address> 
http://www.hq.nasa.gov/office/oss/research/htm).
</address>
NSF and NASA will coordinate award decisions in order to preclude
duplication.
<p>

"For further information, contact:
 <br>
Scott Borg 
(703 306-1033 or sborg@nsf.gov)  
of the Office of Polar Programs, or
<br>
Margaret Cavanaugh
(703 306-1842 or mcavanau@nsf.gov) of the Division of Chemistry, or
<br>
Chris Maples (703 306-1551 or cmaples@nsf.gov) of the Division of
Earth Sciences."

<h2>
INTERACTION WITH  MIDDLE-SCHOOL SYSTEMS
</h2>
<br>
Teachers and researchers with commitments to both the Antarctic and K-12 education programs may be interested to know of  an initiative funded in part by the Office of Polar Programs, with the acronym "GLACIER."  


GLACIER, Global Links: Antarctic Climate and Ice Sheet Evolution Research,
is an outgrowth of the WAIS Initiative.  It is funded jointly by the Office
of Polar Programs and the Directorate for Education and Human Resources.
GLACIER is a collaborative project under the direction of Rice University
(John Anderson) and Education Development Center (Clarice Yentsch).  The
project has two primary components, both under development:
<br>
1) a website designed to introduce Antarctica and its role in the global
system to the general public: 
<a href="http://zephyr.rice.edu/glacier/">http://zephyr.rice.edu/glacier</a>  and
<br>
2) a middle school inquiry-driven, cooperative-learning curriculum based on
exploration of the Antarctic realm.  The curriculum is designed to
integrate with the traditional Earth Science curriculum to provide a
year-long thematic framework for the science classroom.
<br>
<h2>

NEW POSSIBILITIES FOR HELICOPTER SUPPORT FOR REMOTE FIELD CAMPS
</h2>
<br>
As logistical operations for the continental system continue to evolve, new 
scenarios for helicopter support of USAP field research are being developed.  
The following briefly outlines 4 possible scenarios for helicopter-supported 
field work at remote sites.  
<p>

1.  Helo support for individual field teams.
<p>

Helo support might be offered to small field parties requiring one-time, 
short-term (generally a few days only) support in order to reach otherwise 
inaccessible targets, or when major time efficiencies could be achieved through 
helo support.  A single helicopter could support such an operation within an 
expanded McMurdo operations area (up to 300 nautical miles from McMurdo), where 
transit times are short and fuel caches can be staged with relative ease.  A 
temporary, rudimentary camp (preferably tents only) would be established at the 
field site for the helo crew.  This type of support request would need to be 
justified by the project P.I. as part of the overall logistical support request 
for the project.  
<p>
2.  Helo support for one or more field teams working in a common area. 
<p>
Helo operations could be provided during a series of short-term "support 
windows" of several days duration over the course of a field season.  During 
these windows, field teams could complete camp moves and day trips to selected 
targets.  Such operations could be carried out at field sites within 
approximately 600 nautical miles from McMurdo by 2 helicopters (to meet safety 
requirements).  A temporary, rudimentary camp (preferably tents only) would be 
established at the field site for the helo crew.  This type of support request 
would need to be justified by the project P.I.s as part of the logistical support
request, including statements explaining cooperative use of the helo support by 
multiple field parties.
<p>

3.  Major helo-supported field camp.
<p>
This model follows previous multi-project helo camps, such as at Beardmore 
(1985, 1990) and Shackleton Glacier (1995).  Multiple field parties would be 
supported by helos based at a staffed field camp and supplied by fixed-wing 
aircraft.  To justify the major logistic support that must be dedicated to such 
an operation, interested scientists should organize a workshop and produce a 
report to the NSF program manager outlining the scientific research goals and 
appending letters of interest from potential camp participants. Subsequently, a 
call for proposals would be made to the Antarctic earth science community.  <p> 

4.  Ship-based support.
<p>
On-land field parties may be supported by helos based on a U.S. Antarctic 
Program research vessel (R/V Nathaniel B. Palmer or Polar Duke) or a U.S. Coast 
Guard vessel (Polar Star or Polar Sea).  Helicopters cannot be deployed off the 
R/V Laurence M. Gould.  Single or multiple field parties would be provided with 
ship-to-shore transit and local support on land.  Helo support could be 
provided either during a dedicated cruise for that field party, or in conjunction
with compatible marine cruises.  This type of support request would need to be 
justified by the project P.I. as part of the overall logistical support request 
for the project.  Specific questions regarding logistics feasibility should be 
addressed to OPP Operations personnel.
<p>
<h4>
Important note: </h4>Helicopters presently used in the USAP include A-Star 350 and 
Bell 212 aircraft, although these may change depending on project needs.  
Helicopter support in many of the cases outlined above may be augmented by or 
substituted with support from fixed-wing aircraft (LC-130 Hercules or Twin 
Otter).  Consultation with OPP Operations personnel will help to identify the 
most feasible options for any particular science reques.
<p>
<br>
<h2>
AVAILABLE LOGISTICAL SUPPORT AND FACILITIES FOR REMOTE FIELD PARTIES
</h2>
<br>

Remote field parties in Antarctica include any science project working away from
a fixed base or ship.  Remote parties may be supported by a variety of resources
intended to provide transit to the field site and local support.  These 
resources include the following:
<ul>

<li>
helicopters (presently including A-Star 350 and Bell 212 aircraft, operated on
contract by Petroleum Helicopters, Inc.) 

<li>
 LC-130 Hercules aircraft (operated by New York Air Guard for NSF)

<li>
Twin Otter aircraft (operated on contract)

<li>
R/V Nathaniel B. Palmer (operated on charter from Edison-Chouest Offshore), a 
308-foot ice-class ABS A2 vessel

<li>
 R/V Polar Duke (operated by Rieber for ASA), a 219-foot ice-class 1AA vessel 
[the Polar Duke will be replaced by a new vessel of similar specifications 
currently under construction by Edison-Chouest in Louisiana; the new vessel, to 
be christened the R/V Laurence M. Gould, will begin sea trials in 1997]

<li>
SOAR airborne geophysics facility (operated as a contracted facility in 
support of aerogeophysics aboard an instrument-modified Twin Otter)
</ul>
<br>

Investigator(s) should consider any of these resources as possible options for 
support of their science project.  Consultation with OPP Operations personnel 
will help to identify the most feasible options for any particular 
science request.  Additional information may be obtained from Antarctic Support 
Associates .

<br>
<h2>	
NEW WORKSHOP OPPORTUNITY
</h2>
<br>
<h3>
Geological and Geophyscial Investigations of the East Antarctic Margin:  
A Workshop Discussion
</h3>
                                   
This workshop will examine new earth science research cruise initiatives along the Wilkes Land, Prydz Bay, Enderby Land and Queen Maud Land margins of East Antarctica.  The objectives will be be divided into the following sub-disciplines: a) nearshore marine research with an emphasis on paleoclimatic studies; b) continental shelf to oceanic crust marine research stressing questions of breakup and rifting geometry; c) onshore pre-Tertiary geological and geophysical research looking at Gondwana assembly and breakup events; and d) onshore Late Tertiary studies, also primarily of paleoclimatic significance.  The unifying element between these disciplines is the essential need to develop a circumpolar view of Antarctic earth sciences.
<p>
<br>
<h4>
                 Specific goals of the workshop are:
</h4>
<ul>
<li>
Identify key earth science research objectives along the East Antarctic margin using research vessels.
<li>
Develop collaborative efforts with other international programs along the East Antarctic margin, especially Australia, Japan and South Africa.
<li>
Discuss logistical requirements and encourage coordinated projects
</ul>
<br>
<h4>
                           Dates, Location and Participation
</h4>

The workshop will be held on February 21 to 23, 1997 at the Byrd Polar Research Center in Columbus, Ohio. 
<p>
 The convenors of the workshop are Anne Grunow (Byrd Polar, email:  grunow.1@osu.edu) and Amy Leventer (U of Minnesota, email: leven004@gold.tc.umn.edu).
 <p>

The workshop will be limited to 28 participants from US institutions, plus 4 international scientists invited to the meeting.  We hope to have each of the 4 subgroups listed above equally represented (approximately 8 scientists per group).  Applicants should send a detailed letter of interest to one of the workshop convenors no later than Jan. 24.   If there are more than 28 applicants, participants will be selected based on unfilled subgroups and statements of interest.  There are limited funds available to assist with airfare and hotel/meal expenses.  
<p>
<br>





<h2>

OLDER COLLECTIONS
</h2>
<br>

The working group has been discussing the need for a US Antarctic rock and fossil repository.  From extended discussions with members of the US co
mmunity over the past year, there is clearly a perceived need to provide some sort of comprehensive material data base.  It is also apparent that the US earth science community is at a serious competitive disadvantage with regard to use of previously collected Antarctic material for new scientific ventures.  
<p>

To address this problem, the WG  has recommended to Scott Borg that he explore with the Smithsonian Institution and other interested institutions the possibility of developing an Antarctic rock and fossil repository for significant specimens.  This facility would include a physical repository as well as a retrievable database.  
<p>

In the meantime, we are aware of the urgent need to deal with collections that are at some risk of being lost, as a result of retirements in particular. We suggest that interested individuals provide information about their collections that could be captured in a database.  A preliminary database format that includes a list of information categories that may be included in a permanent database (including sample type, geographic location, collector, etc.) may be obtained from Terry Wilson (twilson@mps.ohio-state.edu).  Questions concerning collections that are at risk may be directed to Scott Borg at NSF (sborg@nsf.gov).  <p>
</DOC>
<DOC>
<DOCNO>WT01-B04-247</DOCNO>
<DOCOLDNO>IA051-000877-B037-290</DOCOLDNO>
<DOCHDR>
http://antwg.geo.ukans.edu:80/input.html 129.237.236.17 19970111184204 text/html 801
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aefd3ea6.63@antwg.geo.ukans.edu.>
Date: Saturday, 11-Jan-97 12:57:10 GMT
Last-Modified: Monday, 05-Aug-96 14:19:17 GMT
Content-type: text/html
Content-length: 561
</DOCHDR>
<html><head>
<title>how to input</title>
</head>
<body>
<h2>How can you input?</h2> 
 We welcome comments on any of the topics currently under discussion (See "What does it do?") and ANTWGGG invites suggestions on any aspect of polar earth science.  Please e-mail, phone, or fax your input to its chair, John Goodge, or any member of the working group.   For contact numbers and addresses of the working group see <a href="comp.html ">Who is on the working group. </a><p>
<a href="http://antwg.geo.ukans.edu/peswg.html">Return to Home Page</a>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT01-B04-248</DOCNO>
<DOCOLDNO>IA051-000877-B037-359</DOCOLDNO>
<DOCHDR>
http://antwg.geo.ukans.edu:80/projec.html 129.237.236.17 19970111184238 text/html 14517
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aefd3eae.64@antwg.geo.ukans.edu.>
Date: Saturday, 11-Jan-97 12:57:18 GMT
Last-Modified: Tuesday, 07-Jan-97 13:04:57 GMT
Content-type: text/html
Content-length: 14274
</DOCHDR>

<html><head>
<title>Antarctic Geology and Geophysics: Current Projects</title>
</head>
<body>
<center><h1>Antarctic Geology and Geophysics: Current Projects</h1></center>    
 <center><h2>Ross Sea Area </h2></center><br>
<ul>
<li>
<dl>
<dt>Geologic Record of Late Wisconsin/Holocene Ice Sheet Advance and Retreat from Ross Sea,
<dd>John B. Anderson, Rice University<p>
</dl>
<li>
<dl>

<dt>Mechanism and Timing of West Antarctic Ice Sheet Retreat at the End of the Last Glacial Maximum
<dd>John B. Anderson, Rice University<p>
</dl>
<li>


<dl>
<dt><li> Geological Record of Late Wisconsin/Holocene Ice Sheet Advance and Retreat from the Ross Sea. 
<dd>	John Andrews, Anne Jennings, William Briggs, and Kirsten Williams
INSTAAR, University of Colorado, Boulder
 <p>
<dt><li>Geologic Record of Late Wisconsin/Holocene Ice Sheet Advance and Retreat from Ross Sea. 
<i>
<dd>
Eugene Domack, Hamilton College
</i>
<p>
<dt><li>Glacial Marine Stratigraphy in the Eastern Ross Sea and Western Marie Byrd Land, and Shallow Structure of the West Antarctic Rift. 
<dd>	Bruce Luyendyk, University of California, Santa Barbara
 <dd>	Louis Bartek, University of Alabama, Tuscaloosa
<p>
<dt><li> Integrated Biostratigraphy and High Resolution Seismic Stratigraphy of the Ross Sea: Implications for Cenozoic Eustatic and Climatic Change
<dd>Louis Bartek, University of Alabama, Tuscaloosa
<dd>David Harwood, University of Nebraska, Lincoln
<dd>Peter Webb, Ohio State University<p>
</dl>
</ul>
<p>
<center><h2>Cape Roberts Project (Stratigraphic Drilling from Sea Ice, SW Ross Sea)</h2></center>
<ul>
<dl>
<dt><li> Antarctic Stratigraphic Drilling: Cape Roberts Project
<dd> Peter-Noel Webb, Ohio State University<p>
<dt><li> Initial Palynological Characterization of Cape Roberts Drill Cores
<dd> Rosemary Askin, Ohio State University
<dd> John Wrenn, Louisiana State University<p>
<dt><li> Diatom Biostratigraphy and Paleoenvironmental History of Cape Roberts Projects Cores
<dd> David Harwood, University of Nebraska Lincoln
<dd> Reed Scherer, University of Massachusetts<p>
<dt> <li>Calcareous Nannofossil Biostratigraphy and Paleoenvironmental History of the Cape Roberts Project Cores
<dd>James Pospichal and Sherwood Wise, Florida State University
<dd>David Watkins, University of Nebraska, Lincoln<p>

<dt><li>Cretaceous-Paleogene Foraminiferida of the Victoria Land Basin (Cape Roberts Project)
<dd>Peter-Noel Webb, Ohio State University<p>

<dt><li>Initial Characterization of Organic Matter in Cretaceous-Paleogene Sedimentary Rocks, Cape Roberts, Antarctica
<dd>Richard Kettler, University of Nebraska, Lincoln<p>

<dt><li>Initial Sedimentological Characterization of the Late Cretaceous-Early Cenozoic Drill Cores from Cape Roberts, Antarctica
<dd>Lawrence Krissek, Ohio State University
<dd>Ross Powell, Northern Illinois University<p>

<dt><li>The Cape Roberts Project: Volcanic Record, Geochemistry and 40Ar/39Ar Chronology
<dd>Philip Kyle, New Mexico Institute of Mining & Technology<p>

<dt><li>Paleomagnetic and Mineral Magnetic Characterization of Drill Cores from the Cape Roberts Project
<dd>Kenneth Verosub and Andrew Roberts, University of California, Davis
<dd>Gary Wilson, Ohio State University<p>

<dt><li>Stress Field History, Cape Roberts, Antarctica
<dd>Terry Wilson, Ohio State University
<dd>Richard Jarrard, University of Utah
<dd>Mark Zoback, Stanford University<p>

<dt><li>Downhole Logging for the Cape Roberts Project
<dd>Richard Jarrard, University of Utah<p>
</ul>
</dl>


<center><h2>Northern Victoria Land</center></h2><p>
<ul>
<dl>
<dt><li>Comparative Petrologic, Structural and Geochrononmetric Investigation of High-grade Metamorphic Rocks in the Transantarctic Mountains
<dd>John Goodge, Southern Methodist University<p>
</ul>
</dl>
<center><h2>Southern Victoria Land</center></h2><p>


<ul>
<dl>
<dt><li>Tephrochronology Applied to Late Cenozoic Paleoclimate and Geomorphic Evolution of the Central Transantarctic Mountains
<dd>David Marchant, Boston University<p>

<dt>Mount Feather Sirius Group Workshop and Collaborative Sample Analysis and Publication
<dd>Gary Wilson, Ohio State University<p>

<dt><li>Paleobiology and Paleoenvironments of Pre-glacial (?) Eocene Coasts in Southern Victoria Land, Antarctica
<dd>David Harwood, University of Nebraska, Lincoln<p>

<dt><li>Age of the Last Transgression of the East Antarctic Ice Sheet, Transantarctic Mountains, Southern Victoria Land
<dd>Gunter Faure, Ohio State University
<dd>Kuni Nishiizumi, University of California, Berkeley<p>

<dt><li>Patterned Ground, Dry Valleys, Antarctica: An Evaluation of the Scientific Merit of >30 Year-Old Study Sites
<dd>Bernard Hallet, University of Washington<p>

<dt><li>Sources of Cenozoic Volcanism in McMurdo Sound: An Isotopic Study
<dd>Mark Kurz, Woods Hole Ocean Institution<p>

<dt><li>Mount Erebus Volcano Observatory
<dd>Philip Kyle, New Mexico Institute of Mining & Technology<p>

<dt><li>Three Dimensional Magma Dynamics in Large Sills
<dd>Bruce Marsh, Johns Hopkins University<p>

<dt><li>Global Positioning System Measurements of Crustal Motion in Antarctica
<dd>Carol Raymond, Jet Propulsion Laboratory
<dd>Barclay Kamb, California Institute of Technology<p>

<dt><li>GPS Measurements of rock and ice motions in Southern Victoria Land
<dd>Ian Whillans, Terry Wilson, and Clyde Goad, Ohio State University<p>
</ul>
</dl>

<center><h2>Central Transantarctic Mountains (Primarily the Shackleton Glacier Area)</center></h2><p>
<ul>
<dl>

<dt><li>Permian and Triassic Palynostratigraphy of the Central Transantarctic Mountains
<dd>Rosemary Askin, Ohio State University<p>

<dt><li>Stratigraphic and Sedimentologic Analysis of Permian Strata in the Shackleton Glacier Area, Antarctica
<dd>John Isbell, University of Wisconsin, Milwaukee<p>

<dt><li>Permian and Triassic Biogenic Structures in the Shackleton Glacier Area, Transantarctic Mountains: Record of Nonmarine Benthic Communities and their Response to Climate Change
<dd>Molly Miller, Vanderbilt University<p>

<dt><li>Vertebrate Paleontology of the Triassic to Jurassic Sedimentary Sequence in the Shackleton Glacier Regions, Antarctica
<dd>William Hammer, Augustana College<p>

<dt><li>Continued Research on the Vertebrate Paleontology of the Upper Fremouw (Early-Middle Triassic) and the Falla Formations (Jurassic), Beardmore Glacier Region, Antarctica 
<dd>William Hammer, Augustana College<p>

<dt><li>Triassic Paleosols, Paleoclimate and Vegetation of Antarctica
<dd>Gregory Retallack, University of Oregon, Eugene<p>

<dt><li>The Shackleton Glacier Area: Floristics, Biostratigraphy and Paleoclimate
<dd>Edith Taylor and Thomas Taylor, University of Kansas, Lawrence<p>

<dt><li>Metamorphism and Intrusion Chronology and Tectonic Evolution of the Central and Southern Transantarctic Mountains Using Sm-Nd Isotopes
<dd>Donald J. DePaolo, University of California, Berkeley<p>

<dt><li>Mesozoic Break-up of Gondwanaland: Geochronology of Antarctic Tholeiites
<dd>David Elliot and Kenneth Foland, Ohio State University<p>

<dt><li>Jurassic Volcanic Rocks in the Transantarctic Mountains: A Test of a Model for Continental Flood Basalt Magmatism in Antarctica
<dd>David Elliot, Ohio State University<p>

<dt><li>Thermochronologic Constraints on the Formation of the Transantarctic Mountains, Antarctica
<dd>Paul Fitzgerald and Suzanne Baldwin, University of Arizona<p>

<dt><li>Establishment of Gondwana Early Paleozoic Reference Poles and Tests for Terrane Motion
<dd>Anne Grunow, Ohio State University

</ul>
</dl>
<p>



<center><h2>West Antarctica, Including the Ellsworth Mountains and Bryd Station Region</center></h2><p>
<ul>
<dl>
<dt><li>Lithospheric Controls on the Behavior of the West Antarctic Ice Sheet: Aerogeophysics of the Eastern Ross Transect Zone
<dd>Donald Blankenship, University of Texas Institute for Geophysics
<dd>Robin Bell, Lamont Doherty Earth Observatory
<dd>Carol Finn and John Behrendt, US Geological Survey<p>

<dt><li>Analysis of Antarctic Broad Band PASSCAL Data for Surface Wave Dispersion
<dd>Arthur Lerner-Lam, Columbia University<p>

<dt><li>ANTALITH Seismic Reflection Program at Central West Antarctica: Continued Analysis
<dd>Sridhar Anandakrishnan, Pennsylvania State University<p>

<dt><li>The Ellsworth Mountains Terrane: Its Origin and Accretion to East Antarctica
<dd>Margaret Rees, University of Nevada, Las Vegas
<dd>Ernest Duebendorfer, Northern Arizona University
</ul>
</dl>
<p>


<center><h2>Dronning Maud Land</center></h2>
<ul><dl>
<dt><li>Geologic Studies in the Shackleton Range, Coats Land, and Dronning Maud Land, East Antarctica: A North American Connection
<dd>Ian W. D. Dalziel, Mark A. Helper, and Wulf A Gose, Univeristy of Texas at Austin, Institute for Geophysics<p>
</dl>
</ul>
<p>


<center><h2>Scotia Sea Region</center></h2>
<ul><dl><p>

<dt><li>A Broadband Seismic Experiment for Study of the Tectonics and Structure of the Antarctic Peninsula and Scotia Sea Regions
<dd>Douglas Wiens and Dapeng Zhao, Washington University<p>

<dt><li>Scotia Arc GPS Project (SCARP)
<dd>Lawrence Lawver and Ian W. D. Dalziel, University of Texas Institute for Geophysics, Austin
<dd>Michael Bevis, University of Hawaii
<dd>Robert Smalley, University of Memphis<p>
</dl>
</ul>
<p>


<Center><h2>Antarctic Peninsula Region</center></h2><p>
<ul><dl>

<dt><li>Neotectonic Evolution of Antarctic Peninsula/Scotia Sea Region: Multi-Beam, Sidescan Sonar, Seismic, Magnetics and Gravity Studies
<dd>Lawrence Lawver, University of Texas Institute for Geophysics, Austin<p>

<dt><li>A Survey of Hydrothermal Vents in Bransfield Strait, Antarctica
<dd>Gary Klinkhammer, Oregon State University<p>

<dt><li>The Bransfield Strait-South Shetland Islands/Trench: Structural and Stratigraphic Evolution of a Linked(?) Back-arc/Fore-arc System
<dd>Ian W. D. Dalziel and James Austin, University of Texas Institute for Geophysics, Austin<p>

<dt><li>Quantitative Diatom Analysis from Antarctic Peninsula Surface Sediments and a Test of Paleoclimatic Utility
<dd>Amy Leventer, University of Minnesota-Twin Cities<p>

<dt><li>Paleoecological Setting of Eocene Echinoderms at Seymour Island, Antarctic Peninsula
<dd>Richard Aronson, Marine Environmental Sciences Consortium
<dd>Daniel Blake, University of Illinois, Urbana-Champaign<p>

<dt><li>Quaternary Paleoclimatic Evolution of the Larsen Basin, Offshore Seymour Island, Eastern Antarctic Peninsula
<dd>Rosemary Askin, Ohio State University
<dd>Enriqueta Barrera, University of Michigan
<dd>Ben Sloan and Thomas Davies, University of Texas, Austin<p>

<dt><li>The Geology and Paleontology of the Sobral Formation, Seymour Island, Antarctic Peninsula
<dd>Michael Woodburne, University of California, Riverside<p>

<dt><li>High Resolution Biostratigraphic Analysis of Molluscan Fauna Across the K/T Boundary on Seymour Island, Antarctica
<dd>William Zinsmeister, Purdue University<p>

<dt><li>Regional Structure of the Antarctic Peninsula Derived from ERS-1 SAR Mosaic: A Study of Upper/Lower Plate Interactions During Subduction of the Antarctic/Aluk Ridge Crest
<dd>Terry Wilson, Ohio State University<p>
</dl>
</ul>
<p>

<center><h2>Amundsen and Bellingshausen Seas Region</center></h2><p>
<ul><dl>
<dt><li>Mechanism and Timing of West Antarctic Ice Sheet Retreat at the End of the Last Glacial Maximum
<dd>John B. Anderson, William Marsh Rice University
</dl></ul><p>


<center><h2>Southern Ocean</center></h2>
<ul><dl>
<p>
<dt><li>Late Cretaceous - Early Tertiary Plate Interactions in the Southwest Pacific
<dd>Steven Cande, Scripps Institution of Oceanography
<dd>Joann Stock and Carol Raymond, California Institute of Technology<p>

<dt><li>Early Tertiary Tectonic Evolution of the Pacific-Australian-Antarctic Plate Circuit
<dd>Steven Cande, Scripps Institution of Oceanography
<dd>Joann Stock, California Institute of Technology<p>

<dt><li>Analysis of Circum-Antarctic Ocean Basin Paleobathymetry and Structure
<dd>Dennis Hayes, Lamont Doherty Earth Observatory<p>

<dt><li>The Record of Antarctic Environment Preserved in Deep Sea Sediments: Critical Times of Climate Change
<dd>David Rea, University of Michigan<p>

<dt><li>
Origin and Evolution of the Kerguelen Plume: Constraints from Studies of the Kerguelen Archipelago
<dd>Fred Frey, Massachusetts Institute of Technology
<dd>Nobu Shimizu, Woods Hole Oceanographic Institution
</dl></ul><p>


<center><h2>Facilities </center></h2><p>
<ul><dl>
<dt><li>Support Office for Aerogeophysical Research (SOAR)
<dd>Donald Blankenship, University of Texas Institute for Geophysics
<dd>Robin Bell, Lamont Doherty Earth Observatory
<dd>Carol Finn, US Geological Survey<p>

<dt><li>Antarctic Marine Geology Research Facility (Sediment Core Repository and Research Center)
<dd>Sherwood Wise, Florida State University
</dl></ul><p>



<center><h2>Activities with No Specific Location </center></h2><p>
<ul><dl>
<dt><li>Atlas of Glacimarine Features
<dd>Thomas Davies, University of Texas, Austin<p>

<dt><li>Paleobiogeography of Austral Decapod Crustaceans
<dd>Rodney Feldmann, Kent State University<p>

<dt><li>Antarctic Rift and Hot Spot Volcanism
<dd>Stan Hart, Woods Hole Ocean Institution
<dd>Philip Kyle and Kurt Panter, New Mexico Institute of Mining & Technology<p>

<dt><li>Testing the East Antarctica-Laurentian Connection: Ages of Detrital Zircons from Late Proterozoic Metasediments, Transantarctic Mountains
<dd>Nicholas Walker, Brown University<p>

<dt><li>Antarctic Search for Meteorites
<dd>Ralph Harvey, Case Western Reserve University<p>

<dt><li>Natural Thermoluminescence Levels in Antarctic Meteorites and Related Studies 
<dd>Paul Benoit, University of Arkansas<p>

<dt><li>Terrestrial Age Measurement of Antarctic Meteorites
<dd>Kunihiko Nishiizumi, University of California, Berkeley<p>

<dt><li>Undergraduate Research Initiative: Antarctic Marine Geology and Geophysics
<dd>Eugene Domack, Hamilton College<p>

<dt><li>Models of the 3-D Stratigraphy of Glaciated Continental Shelves
<dd>Yang Shen and Steve Holbrook, Woods Hole Ocean Institution
<dd>Uri ten Brink, US Geological Survey<p>

<dt><li>GLACIER: A Collaborative Antarctic Curriculum
<dd>John B. Anderson and Stephanie Shipp, William Marsh Rice University<p>
</dl>
</ul>
<a href="http://antwg.geo.ukans.edu/peswg.html">Return to Home Page</a>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT01-B04-249</DOCNO>
<DOCOLDNO>IA051-000877-B038-22</DOCOLDNO>
<DOCHDR>
http://antwg.geo.ukans.edu:80/sites.html 129.237.236.17 19970111184247 text/html 1490
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aefd3ed0.65@antwg.geo.ukans.edu.>
Date: Saturday, 11-Jan-97 12:57:52 GMT
Last-Modified: Monday, 05-Aug-96 14:19:52 GMT
Content-type: text/html
Content-length: 1249
</DOCHDR>
<html><head>
<title>More Polar WWW Sites</title>
</head>
<body>
<h2>More Polar WWW Sites</h2>
<A HREF="http://www.asa.org/">Antarctic Support Associates  - General information</A><p>
<A HREF="http://enterprise.asa.org/"> Antarctic Support Asociates - technical information</A><p>
<A HREF="http://dilbert.lbl.gov/www/amanda.html">AMANDA</A><p>
<A HREF="http://www.stud.unit.no/~sveinw/arctic/">Arctic World</A><p>
<A HREF="http://www.asa.org/">Antarctic Support Associates</A><p>
<a href="http://www.ig.utexas.edu/news/bransfield/index.html">Progress Bransfield Straight Cruise</a><p>
<a href="http://www-bprc.mps.ohio-state.edu/">Byrd Polar Research Center</a><p>
<a href="http://www.nerc-bas.ac.uk/">British Antartic Survey</a><p>
<a href="http://www.antdiv.gov.au/">Australian Antarctic Division</a><p>
<a href="http://www.awi-bremerhaven.de/">Alfred -Wegener Institute</a><p>
<a href="gopher://ssec.wisc.edu:70/11/amrc.d/antarctica_images.d/">Antarctic Weather</a><p>
<a href="http://icair.iac.org.nz/">ICAIR</a><p>
<a href="gopher://gopher.ucalgary.ca/11/library/polar/">Polar Libraries Gopher</a><p>
<a href="http://www.nsf.gov./">Link back to NSF</a><p>
<a href="http://antwg.geo.ukans.edu/peswg.html">Return to Home Page</a>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT01-B04-250</DOCNO>
<DOCOLDNO>IA051-000877-B038-53</DOCOLDNO>
<DOCHDR>
http://antwg.geo.ukans.edu:80/peswg.html 129.237.236.17 19970111184257 text/html 2314
HTTP/1.0 200 OK
MIME-Version: 1.0
Server: MacHTTP/2.2
Message-ID: <aefd3edb.66@antwg.geo.ukans.edu.>
Date: Saturday, 11-Jan-97 12:58:03 GMT
Last-Modified: Friday, 20-Oct-95 16:32:12 GMT
Content-type: text/html
Content-length: 2073
</DOCHDR>
<html><head>
<title>ANTARCTIC WORKING GROUP GEOLOGY and GEOPHYSICS</title>
</head>
<body>
<h2>Welcome to the Antarctic Working Group for  Geology</center>
<center> and Geophysics</h2></center>
<center><h2>(ANTWGGG) Home Page</H2></center><p>

<img align= middle src="mts.gif alt="BYRD MTS">
    Bender Mountains:  late Ross-age granitoid intrusive 
 
<h3><center>Purpose of the Working Group</h3></center>
     The Office of Polar Programs of the National Science Foundation 
     maintains science support capabilities that enable a broad range of 
     research projects, especially within the US Antarctic Program.  
     Ensuring that these capabilities continue to serve the best interests 
     of the research community requires periodic and open dialog between 
     the earth sciences community and the program manager.  The Antarctic
     Working Group for Geology and Geophysics is an ad hoc body whose role is
     to provide feed-back about current and planned research support
     capabilities available to Antarctic earth science projects supported by the 
     National Science Foundation.  The working group affords a broad conduit for 
     exchange of information between the program manager and the 
     earth-science research community.  The group addresses concerns and 
     priorities within the Antarctic Geology and Geophysics program, making 
     recommendations for action where appropriate.  It also provides a 
     forum to raise and discuss general programmatic issues associated with 
     new opportunities in earth science research as it perceives them, or 
     as they are recognized by the wider earth-science community.<p>
<a href="comp.html ">Composition of the Working Group </a><p>
<a href="wedo.html ">When does ANTWGGG meet and what does it do?  </a><p>
<a href="news.html"> News items from ANTWGGG  </a><p>
<a href="input.html ">How can you input?   </a><p>
<a href="projec.html">Current active Antarctic Geology and Geophysics projects and their P.I.</a><p>
<a href="sites.html ">Other Polar WWW Sites </a>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT01-B04-251</DOCNO>
<DOCOLDNO>IA090-000969-B046-406</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/ 206.249.5.81 19970117202847 text/html 4072
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 20:30:01 GMT
Last-modified: Monday, 13-Jan-97 23:46:59 GMT
Content-length: 3883
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<META NAME="description" CONTENT="National Down Syndrome Society, NDSS">
<META="keywords" CONTENT="national down syndrome society, NDSS, down syndrome, 
NATIONAL DOWN SYNDROME SOCIETY, ndss, Education, 
education, Medical, medical, Research, research, Advocacy, advocacy, Disease, disease,
Affiliate Program, Gifts of Love, Scientific symposium, scientific symposia, 
News and Views, news & views, Alberto Costa, Alberto Costa M.D., Dr. Alberto Costa,
Chris Burke, Individual with Disabilities Education Act, IDEA, Medicaid, 
 Goodwill Ambassador"> 

<TITLE>The National Down Syndrome Society</TITLE>
<BASE HREF="http://www.ndss.org/"></HEAD>
<BODY BACKGROUND="/gif/background.gif">
<BODY>
<CENTER><H1>The National Down Syndrome Society</H1><BR>
666 Broadway, 8th Floor<BR>
New York, NY 10012-2317<BR>
(212)460-9330<BR>
(800)221-4602<BR></CENTER><HR><P>

<A HREF="desc.html">1. NATIONAL DOWN SYNDROME SOCIETY DESCRIPTION</A><BR><P>
<A HREF="info.html">2.	INFORMATION AND REFERRAL SERVICE  -  1-800-221-4602</A><BR><P>
<A HREF="gen.html">3.	GENERAL INFORMATION</A><BR>
<UL><H5>
<A HREF="gen.html#parent">Parent and Professional Information</A><BR>
<A HREF="gen.html#question">Questions and Answers About Down Syndrome</A><BR>
<A HREF="gen.html#myth">Down Syndrome:  Myths and Truths</A><BR>
<A HREF="gen.html#resource">Reading and Viewing Resource List</A><BR>
<A HREF="gen.html#order">Order Form</A><BR>
</UL></H5><P>
<A HREF="clin.html">4.	CLINICAL INFORMATION</A><BR>
<UL><H5>
		Speech and Language Skills In Infants, Toddlers and 
		Young Children With Down Syndrome<BR>
		Speech and Language Skills In Children And Adolescents
		With Down Syndrome<BR>
<A HREF="clin.html#heart">The Heart and Down Syndrome</A><BR>
<A HREF="clin.html#endo">Endocrine Conditions in Down Syndrome</A><BR>
<A HREF="clin.html#alzh">Alzheimer's Disease and Down Syndrome</A><BR>
<A HREF="clin.html#sex">Sexuality in Down Syndrome</A><BR>
<A HREF="clin.html#neuro">The Neurology of Down Syndrome</A><BR>
</UL></H5><P>
<A HREF="edu.html">5.	EDUCATIONAL INFORMATION</A><BR>
<UL><H5>
<A HREF="edu.html#facts">Inclusion Facts</A><BR>
<A HREF="edu.html#res">Inclusion Resource List</A><BR>
<A HREF="edu.html#partner">Teaching Partnership Poster</A><BR>
<A HREF="edu.html#news">NEWS & VIEWS Magazine</A><BR>
<A HREF="edu.html#edu">Educational Challenges Program</A><BR>
</UL></H5><P>
<A HREF="res.html">6.	RESEARCH</A><BR>
<UL><H5>
<A HREF="ethan1.html">Science Scholar Fund</A><BR>
<A HREF="res.html#sym">Scientific Symposia</A><BR>
<A HREF="res.html#sch">Science Scholar Award</A><BR>
</UL></H5><P>
<A HREF="adv.html">7.	ADVOCACY</A><BR>
<UL><H5>
<A HREF="adv.html">Position Papers</A><BR>
<A HREF="adv.html#med">.Medicaid Block Grants</A><BR>
<A HREF="adv.html#reauth">.Reauthorization of "The Individuals with
				Disabilities Education Act (IDEA)</A><BR>
</UL></H5><P>
<A HREF="aff.html">8.	AFFILIATE PROGRAM</A><BR>
<UL><H5>
<A HREF="aff.html#gen">General Information</A><BR>
</UL></H5><P>
<A HREF="spec.html">9.	SPECIAL PROGRAMS</A><BR>
<UL><H5>
<A HREF="spec.html#good">Chris Burke - NDSS National Goodwill Ambassador</A><BR>
<A HREF="spec.html#conf">1996 National Conference, Phoenix, Az.</A><BR>
<A HREF="spec.html#aware">October Awareness Month</A><BR><UL>
<A HREF="spec.html#walk">3rd Annual Buddy Walk - October 5, 1997</A><BR></UL>
</UL></H5><P>
<A HREF="thresh.html">10.    THRESHOLDS - OPENING DOORS TO OPPORTUNITY</A><BR>
<P>
<A HREF="ndssnews.html">11.  NDSS NEWS ITEMS</A><BR>
<P>
<A HREF="other.html">12.    OTHER DOWN SYNDROME PAGES ON THE INTERNET</A><BR>
<P>
<A HREF="ndss.html">13.</A><BR><P>

<HR><H6><CENTER><I>http://www.ndss.org/<BR>
Last Updated: November 25th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR></I></CENTER></H6>

</BODY>
</HTML>


</DOC>
<DOC>
<DOCNO>WT01-B04-252</DOCNO>
<DOCOLDNO>IA090-000969-B047-152</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/desc.html 206.249.5.81 19970117203232 text/html 1419
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 20:34:38 GMT
Last-modified: Wednesday, 28-Aug-96 13:33:18 GMT
Content-length: 1227
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>The National Down Syndrome Society Description</TITLE></HEAD><BODY><I>
<BODY BACKGROUND="/gif/background.gif">
<CENTER><H2>The National Down Syndrome Society Description</H2></CENTER>
The National Down Syndrome Society was established in 1979 to increase public awareness about Down syndrome; to assist families in addressing the needs of children born with this genetic condition; and to sponsor and encourage scientific research.
<P>
Today, NDSS supports young researchers seeking the causes of, and answers to, many of the medical, genetic, behavioral and learning problems associated with Down syndrome; sponsors internationally renowned scientific symposia; advocates on behalf of families and individuals affected by this condition; provides information and referral services through its toll-free number; and develops educational materials, many of which are distributed free of charge.
</I>
<HR>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: January 28th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-253</DOCNO>
<DOCOLDNO>IA090-000969-B047-233</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/info.html 206.249.5.81 19970117203418 text/html 1085
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 20:35:54 GMT
Last-modified: Saturday, 09-Nov-96 20:23:16 GMT
Content-length: 895
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>
INFORMATION AND REFERRAL SERVICES
</TITLE><BODY BACKGROUND="/gif/background.gif"><BODY>
<CENTER><H2>INFORMATION AND REFERRAL SERVICES</H2></CENTER>
The toll-free number is a professionally staffed information and referral service available to people nationwide.  Our trained staff provide general information about Down syndrome; referral to parent support groups as well as other local and national resources; and information on many topics related to Down syndrome.  A free information packet is available for new parents.  For information call 1-800-221-4602.

<P><HR>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: January 28th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-254</DOCNO>
<DOCOLDNO>IA090-000969-B047-324</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/gen.html 206.249.5.81 19970117203604 text/html 52037
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 20:37:10 GMT
Last-modified: Wednesday, 27-Nov-96 23:37:00 GMT
Content-length: 51844
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>
GENERAL INFORMATION
</TITLE><BODY BACKGROUND="/gif/background.gif"><BODY>

<H2><CENTER>GENERAL INFORMATION</CENTER></H2><HR><P>

<A NAME="parent">
<H2><CENTER>Parent and Professional Information</CENTER></H2><BR>
           Down syndrome affects people of all ages, races and economic levels. It is one of the most frequently occurring chromosomal abnormalities found in humans, occurring once in approximately every 800 to 1,000 live births. Over 250,000 people, in the United States alone, are affected by Down syndrome. 
<P>
<B>When was Down syndrome discovered?</B><BR>
<P>
	For centuries, people with Down syndrome have been alluded to in art, literature and science. It wasn't until the late 19th century, however, that John Langdon Down, an English physician, published an accurate description of a person with Down syndrome.  It was this scholarly work, published in 1866, which earned Down the recognition as the "father" of the syndrome. Although other people had previously recognized the characteristics of the syndrome, it was Down who described the condition as a distinct and separate entity. <P>
	Throughout the 20th century, advances in medicine and science enabled researchers to investigate the characteristics of people with Down syndrome. In 1959, the French physician, Jerome Lejeune, identified Down syndrome as a chromosomal anomaly. Instead of the usual 46 chromosomes present in each cell, Lejeune observed 47 in the cells of individuals with Down syndrome. It was later determined that an extra partial or complete 21st chromosome results in the characteristics associated with Down syndrome. 
<BR><P>
<B>Why is Down syndrome referred to as a "genetic condition?"</B><BR>
<P>
	The human body is made of cells; all cells contain a center, called a nucleus, in which genetic material is stored. This genetic material, known as genes, carries the codes responsible for all our inherited characteristics. <BR><P>
	Genes are grouped along rod-like structures called chromosomes. Normally, the nucleus of each cell contains 23 pairs of chromosomes, half of which are inherited from each parent.  <BR><P>
	In Down syndrome, however, the cells usually contain not 46, but 47 chromosomes; with the extra chromosome being a number 21. This excess genetic material, in the form of additional genes along the 21st chromosome, results in Down syndrome. <BR><P>
	Because 95 percent of all cases of Down syndrome occur because there are three copies of the 21st chromosome, it is often referred to as "trisomy 21." 	<BR><P>
	Chromosomes may be studied by examining blood or tissue cells. Individual chromosomes are identified, stained and numbered from largest to smallest. The visual display of the chromosomes is known as a karyotype. <BR><P>

<B>What causes Down syndrome?</B><BR>
<P>
	Down syndrome is usually caused by an error in cell division called non-disjunction. However, two other types of chromosomal abnormalities, mosaicism and translocation, are also implicated in Down syndrome--although to a much lesser extent. Regardless of the type of Down syndrome which a person may have, all people with Down syndrome have an extra, critical portion of the number 21 chromosome present in all, or some, of their cells. This additional genetic material alters the course of development and causes the characteristics associated with the syndrome.   <BR><P>
	<B>Nondisjunction</B> is a faulty cell division which results in an embryo with three number 21 chromosomes instead of two. Prior to, or at, conception, a pair of number 21 chromosomes, in either the sperm or the egg, fail to separate. As the embryo develops, the extra chromosome is replicated in every cell of the body. This faulty cell division is responsible for 95 percent of all cases of Down syndrome. <BR><P>
	Why nondisjunction occurs is currently unknown, although it does seem to be related to advancing maternal age.  Many people are surprised to find out that 80 percent of children born with Down syndrome are born to women under 35 years of age. This is because younger women have higher fertility rates. It does not contradict the fact that the incidence of births of children with Down syndrome increases with the age of the mother.<BR><P>
	Although nondisjunction can be of paternal origin, this occurs less frequently. Because this error in cell division is often present in the egg prior to conception, and women are born with their complete store of eggs, it has been postulated that some environmental factors may be implicated in nondisjunction. However, despite years of research, the cause (or causes) of nondisjunction, is still unknown. There seems to be no connection between any type of Down syndrome and parents' activities, before or during pregnancy.<BR><P>
	<B>Mosaicism</B> occurs when nondisjunction of the 21st chromosome takes place in one of the initial cell divisions <I>after</I> fertilization. When this occurs, there is a mixture of two types of cells, some containing 46 chromosomes and some containing 47. Those cells with 47 chromosomes contain an extra 21st chromosome. Because of the "mosaic" pattern of the cells, the term mosaicism is used. Mosaicism is rare, being responsible for only 1 to 2 percent of all cases of Down syndrome.<BR><P>
	Some research has shown that individuals with mosaic Down syndrome are less affected than those with trisomy 21; however, broad generalizations are not possible due to the wide range of abilities that people with Down syndrome possess. <BR><P>
	<B>Translocation</B> is a different type of chromosomal problem and occurs in only 3 to 4 percent of people with Down syndrome. Translocation occurs when part of the number 21 chromosome breaks off during cell division and attaches to another chromosome. While the total number of chromosomes in the cells remains 46, the presence of an extra part of the number 21 chromosome causes the features of Down  syndrome. As with nondisjunction trisomy 21, translocation occurs either prior to or at conception. <BR><P>
	Unlike nondisjunction, maternal age is not linked to the risk of translocation. Most cases are sporadic, chance events. However, in about one-third of cases, one parent is a carrier of a translocated chromosome. For this reason, the risk of recurrence for translocation is higher than that of nondisjunction. Genetic counseling can be sought to determine the origin of the translocation.<BR><P>
	
<B>What is the chance of having a second child with Down syndrome?</B><BR>
<P>
	In general, it is estimated that the risk of having a second child with trisomy 21 or mosaic Down syndrome is about 1 in 100. The risk is higher if one parent is a carrier of a translocated cell.<BR><P>

<B>Are any prenatal tests available to detect Down syndrome?</B><BR>
<P>
	Yes. There are two types of procedures available to pregnant women: screening tests and diagnostic tests. Screening tests estimate the risk of the fetus having Down syndrome; diagnostic tests tell whether or not the fetus actually has the condition.<BR><P>
	The most commonly used screening tests are the Triple Screen and the Alpha-fetoprotein Plus. These tests measure quantities of various substances in the blood (alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol) and together with the woman's age, estimate her risk of having a child with Down  syndrome. These screening tests are typically offered between fifteen and twenty weeks of gestation. <BR><P>
	Screening tests are of limited value and are often performed in conjunction with a detailed sonogram. These tests are only able to accurately detect about sixty percent of fetuses with Down syndrome. Many women who undergo these tests will be given false-positive readings, and some women will be given false-negative  readings.<BR><P>
	The procedures available for prenatal diagnosis of Down syndrome are chorionic villus sampling (CVS), amniocentesis and percutaneous umbilical blood sampling (PUBS). Each  one of these procedures carries a small risk of miscarriage as tissue is extracted from the placenta or the umbilical cord to examine the fetus's chromosomes. The procedures are about 98 to 99 percent accurate in the detection of Down syndrome.  Amniocentesis is usually performed between 12 and 20 weeks of gestation, CVS between 8 and 12 weeks and PUBS after 20 weeks. <BR><P>

<B>How is Down syndrome diagnosed in the newborn?</B><BR>
<P>
	The diagnosis of Down syndrome is usually suspected after birth as a result of the baby's appearance. It is a particularly difficult time, coupled with the natural stresses of childbirth. Although there is no easy way to be informed, most families agree that having the baby present, being together, and being told as soon as possible is the best way to proceed. <BR><P>
	There are many physical characteristics which form the basis for suspecting an infant has Down syndrome. Many of these characteristics are found, to some extent, in the general population of individuals who do not have Down syndrome. Hence, if Down syndrome is suspected, a karyotype will be performed to ascertain the diagnosis. Some infants with Down syndrome have only a few of these traits, while others have many. Among the most common traits are:<BR>
<P>
	*Muscle hypotonia, low muscle tone<BR>
	*Flat facial profile, a somewhat depressed nasal bridge and a small nose<BR>
	*Oblique palpebral fissures, an upward slant to the eyes<BR>
	*Dysplastic ear, an abnormal shape of the ear<BR>
	*Simian crease, a single deep crease across the center of the palm<BR>
	*Hyperflexibility, an excessive ability to extend the joints<BR>
	*Dysplastic middle phalanx of the fifth finger, fifth finger has one flexion furrow instead of two<BR>
	*Epicanthal folds, small skin folds on the inner corner of the eyes<BR>
	*Excessive space between large and second toe<BR>
	*Enlargement of tongue in relationship to size of mouth<BR>
<P>
<B>Do babies with Down syndrome have medical problems?</B><BR>
<P>
	Children with Down syndrome are at increased risk for certain health problems. Congenital heart defects, increased susceptibility to infection, respiratory problems, obstructed digestive tracts and childhood leukemia occur with greater frequency among children who have Down syndrome. However, advances in medicine have rendered most of these health problems treatable, and the majority of people born with Down syndrome today have a life expectancy of approximately fifty-five years.<BR><P>
	Adults with Down syndrome are at increased risk for Alzheimers disease.  Whereas approximately 6% of the general population will develop the disease, the figure is about 25% for people with Down syndrome.  Many individuals with Down syndrome have the changes in the brain associated with Alzheimers, but do not necessarily develop the clinical disorder.  	<BR><P>
<B>How does Down syndrome affect a person's development?</B><BR>
<P>
	All people with Down syndrome have some level of mental retardation; however, the level usually falls into the mild to moderate range and is not indicative of the many strengths and talents that each individual possesses. Children with Down syndrome learn to sit, walk, talk, play, toilet train and do most other activities--only somewhat later than their peers without Down syndrome. Because speech is often delayed, careful attention should be paid to the child's hearing, as retention of fluid in the inner ear is a very common cause of hearing and speech difficulties.<BR><P>
	Early intervention services, which begin shortly after birth, help children with Down syndrome develop to their full potential. Quality educational programs, along with a stimulating home environment and good medical care enable people with Down syndrome to become contributing members of their families and communities. <BR><P>
	People with Down syndrome are highly responsive to their physical and social environment. Those who receive good medical care and are included in the activities of the community can be expected to adapt successfully--to attend school, make friends, find work, participate in decisions which affect them and make a positive contribution to society. <BR><P>
	The person with Down syndrome has the same emotions and needs as any other person and deserves the same opportunities.<BR><P>

<B>What does the future hold for people with Down syndrome?</B><BR>
<P>
	People with Down syndrome are people first. They may have some of the characteristics generally associated with this condition, but they are overwhelmingly unique and must be treated as individuals. Over the past few decades, beginning with Section 504 of The Rehabilitation Act of 1973, continuing with The Education for All Handicapped Children Act of 1975, and culminating with the passage of the Americans with Disabilities Act in 1991, people with Down syndrome have been granted equal protections under federal law.<BR><P>
	 Ensuring equal treatment and access to services is a struggle that every family of a child with Down syndrome faces. Daily, these individuals strive to accomplish the same goals as everyone else: self-fulfilment, pride in one's achievements, inclusion in the activities of the community and the challenge of reaching one's full potential. <BR><P>
	Daily, people with Down syndrome venture out into the community: to schools, jobs and leisure activities. Some live with family, some with friends and some independently. They form ongoing interpersonal relationships and some may marry. Women with Down syndrome are fertile and can have children.<BR><P>
	The opportunities available to people with Down syndrome today have never been greater. However, it is only through the collective efforts of parents, professionals and concerned citizens that acceptance is becoming widespread. It is the goal of the National Down Syndrome Society to ensure that all people with Down syndrome are provided the opportunity to achieve their full potential in all aspects of community life. <BR><P>
</A>
<P>

<A NAME="question">
<H2><CENTER>Questions and Answers About Down Syndrome</CENTER></H2><P>


<B>Why should we be concerned about Down syndrome?
</B><BR>
<p>
Chromosomal abnormalities are a widespread medical problem, with Down syndrome being the most common genetic condition. One in every 800 to 1,000 children is born with Down syndrome.<BR><P> 

More than 50 percent of miscarriages are caused by a chromosomal abnormality. As many as 25 percent of all miscarriages are caused by a \223trisomy,\224 which is the presence of three copies of a particular chromosome, rather than the normal two.
<P>

The most common form of Down syndrome is also known as Trisomy 21, because it involves an extra copy of the 21st chromosome. Twenty to 25 percent of children conceived with Down syndrome survive past birth.<P><br><p>


<B>What impact does Down syndrome have on society?</B><BR>
<p>
Individuals with Down syndrome are becoming increasingly integrated into society and community organizations, such as school, health care systems, work forces, and social and recreational activities.  Individuals with Down syndrome possess varying degrees of mental retardation, from very mild to severe. Most people with Down syndrome have IQs in the mild to moderate range of mental retardation.
<p>
Due to advances in medical technology, individuals with Down syndrome are living longer than ever before. In 1910, children with Down syndrome were expected to survive to age 9.  With the discovery of antibiotics, the average survival age increased to 19 or 20.  Now, with recent advancements in clinical treatment, as many as 80 percent of adults with Down syndrome reach age 55, and many live even longer.
<p>
In the United States, approximately 250,000 families are affected by Down syndrome.  Approximately 5,000 children with Down syndrome are born each year. As the mortality rate associated with Down syndrome is decreasing, the prevalence of individuals with Down syndrome in our society will increase.  Some experts project that the number of people with Down syndrome will double in the next 10 years.  More and more Americans will interact with individuals with this genetic condition, increasing the need for widespread public education and acceptance.


<p><br><p>
<b>Is Down syndrome transmitted from the mother or father?</b><br>
<p>
The additional genetic material which causes Down syndrome can originate from either the father or the mother.  Approximately 5 percent of the cases have been traced to the father.

<p><br><p>
<b>Who has the highest risk of having a child with Down syndrome?</b><br>
<p>
Down syndrome affects people of all races and economic levels. Women age 35 and older have a significantly increased risk of having a child with Down syndrome.  A 35-year-old woman has a one in 400 chance of conceiving a child with Down syndrome, and this chance increases gradually to one in 110 by age 40.  At age 45 the incidence becomes approximately one in 35.
<p>
Since many couples are postponing parenting until later in life, the incidence of Down syndrome conceptions is expected to increase.  Therefore, genetic counseling for parents is becoming increasingly important.  Still, many physicians are not fully informed about advising their patients about the of incidence of Down syndrome, advancements in diagnosis,  and the protocols for care and treatment of babies born with Down syndrome.
<p><br><p>

<b>Why is it important to raise children with Down syndrome at home?</b><br>
<p>
A greater understanding of Down syndrome and advancements in treatment of Down syndrome-related health problems have allowed people with Down syndrome to enjoy fuller and more active lives.
<p>
Children raised at home and included in all aspects of community life can best reach their potential and function in society with a greater degree of independence.  Parental love, nurturing, and support, as well as early intervention programs, educational opportunities, and community involvement, have a direct relationship to the degree that a person with Down syndrome is able to achieve his/her potential.
<p><br><p>

<b>Why are medical researchers following Down syndrome work so closely?</b><br>
<p>
Down syndrome is a developmental disorder.  As researchers learn more about the molecular genetics and other aspects of Down syndrome, they also obtain valuable information about human development and can advance the study of many biological processes. 
<p>
In addition, individuals with Down syndrome have a higher incidence of certain medical problems, and the study of Down syndrome may yield important breakthroughs in those areas.  Research in Down syndrome provides a way for looking at many important problems:

Heart disease - Up to 50 percent of individuals with Down syndrome are born with congenital heart defects. The majority of heart defects in children with Down syndrome can now be surgically corrected with resulting long-term health improvements.  However, scientists continue to search for the cause of this problem, and look for means of prevention.
<p>
<em>Alzheimer's disease</em> - Estimates vary, but it is reasonable to conclude that 25 percent or more of individuals with Down syndrome over the age of 35 will develop the clinical signs and symptoms of Alzheimer's-type dementia. 
<p>
<em>Leukemia</em> - Individuals with Down syndrome have a 15 to 20 times greater risk of developing leukemia.  The majority of cases are categorized as acute megakaryoblastic leukemia, which tends to occur in the first three years of life, and for which there is a high cure rate.  A transient form of leukemia is also seen in newborns with Down syndrome, disappearing spontaneously during the first two to three months of life.

<p><br><p>
<b>Why hasn't Down syndrome received much attention in the past?</b><br>
<p>
Even though Dr. Jerome Lejeune discovered in 1959 that it was an extra 21st chromosome that caused Down syndrome, it is only in the last few years that a focus has been placed on the study of the 21st chromosome.  Why?  Because we now have the technology to isolate specific genes and genetic material.
<p>
The momentum is increasing.  Chromosome 21 is the first chromosome to be fully mapped, and is a prototype for the federally funded genome mapping project.  Up to 1,000 genes exist on the 21st chromosome.  We have already identified between 30 to 35 genes and gene products - and new findings are occurring rapidly.
<p>
Researchers continue to look for the genes related to the development of intelligence and the physical characteristics associated with Down syndrome.  Once identified, it is hoped that the biochemical process which causes Down syndrome can be decoded,  leading to the development of an intervention and cure.
<p><br><p>

<b>What is the National Down Syndrome Society doing to further research?</b><br>
<p>
NDSS is currently sponsoring three scientists through the NDSS Science Scholar Award Program initiated in 1983.  Under this grant program, each researcher receives $30,000 a year for two years to carry out scientific research into the causes and/or amelioration of Down syndrome.  To date, more than 20 scholars have been supported under this program.
<p>
NDSS also sponsors a series of annual symposia focusing on Down syndrome research.  This sharing of  information, technology, and the collective knowledge of the world's foremost researchers is expected to produce an acceleration of advancements in a variety of areas.  The proceedings of these scientific symposia are published annually and are available through NDSS.
<p><br><p>

<b>How can I obtain further information?</b><br>
<p>
Contact:	National Down Syndrome Society, 
 	666 Broadway, 8th Floor
New York, NY 10012-2317
<p>
Telephone:  (212) 460-9330
<p>
Information & Referral:  (800) 221-4602
<p>
Fax: (212) 979-2873
<p>
Web site: http://www.ndss.org
<hr>
<A NAME="myth">
<center><h2>Down Syndrome: Myths and Truths</h2></center>

Myth:	Down syndrome is a rare genetic disorder.
<p>
Truth:	Down syndrome is the most commonly occuring genetic condition.  One in every 800 to 1,000 live births is a child with Down syndrome, representing approximately 5,000 births per year in the United States alone.  Today, Down syndrome affects more than 250,000 people in the United States.
<p><br><p>

Myth:	Most children with Down syndrome are born to older parents.
<p>
Truth:	Eighty percent of children born with Down syndrome are born to women younger than 35-years-old. However, the incidence of births of children with Down syndrome increases with the age of the mother.
<p><br><p>

Myth:	People with Down syndrome are severely retarded.
<p>
Truth:	Most people with Down syndrome have IQs that fall in the mild to moderate range of retardation.  Children with Down syndrome are definitely educable, and educators and researchers are still discovering the full educational potential of people with Down syndrome.
<p><br><p>

Myth:	Most people with Down syndrome are institutionalized.
<p>
Truth:	Today people with Down syndrome live at home with their families and are active participants in the educational, vocational, social and recreational activities of the community.  They are integrated into the regular education system, and take part in sports, camping, music, art programs, and all the other activities of their communities.  In addition, they are socializing with people with and without disabilities, and as adults are obtaining employment and living in group homes and other independent housing arrangements.
<p><br><p>

Myth:	Parents will not find community support in bringing up their child with Down syndrome.
<p>
Truth:	In almost every community of the United States there are parent support groups and other community organizations directly involved in providing services to families of individuals with Down syndrome. 

<p><br><p>

Myth:	Children with Down syndrome must be placed in segregated special education programs.
<p>
Truth:	Children with Down syndrome have been included in regular academic classrooms in schools across the country.  In some instances they are integrated into specific courses, while in other situations students are fully included in the regular classroom for all subjects.  The degree of mainstreaming is based in the abilities of the individual; but the trend is for full inclusion in the social and educational life of the community.

<p><br><p>
Myth:	Adults with Down syndrome are unemployable. 
<p>
Truth:	Businesses are seeking young adults with Down syndrome for a variety of positions.  They are being employed in small and medium sized offices: by banks, corporations, nursing homes, hotels and restaurants. They work in the music and entertainment industry, in clerical positions, and in the computer industry. People with Down syndrome bring to their jobs enthusiasm, reliability, and dedication.
<p><br><p>

Myth:	People with Down syndrome are always happy.
<p>
Truth:	People with Down syndrome have feelings just like everyone else in the population.  They respond to positive expressions of friendship, and they are hurt and upset by inconsiderate behavior.
<p><br><p>

Myth:	Adults with Down syndrome are unable to form close interpersonal relationships leading to marriage.
<p>
Truth:	People with Down syndrome date, socialize and form on-going relationships.  Some are beginning to marry.  Women with Down syndrome can and do have children, but there is a 50 percent chance that their child will have Down syndrome.  Men with Down syndrome are believed to be sterile, with only one documented instance of a male with Down syndrome who has fathered a child.

<p><br><p>
Myth:	Down syndrome can never be cured.
<p>
Truth:	Research on Down syndrome is making great strides in identifying the genes on chromosome 21 that cause the characteristics of Down syndrome.  Scientists now feel strongly that it will be possible to improve, correct, or prevent many of the problems associated with Down syndrome in the future.

<HR>
<A NAME="resource">
<H2><CENTER>Readings & Viewings</H2></CENTER><P><HR>

<B>Books for Parents and Professionals</B><P>


<B>Babies with Down Syndrome: A New Parents Guide</B> (2nd edition). Stray-Gundersen, K. (Ed.) 	(1995). Rockville, MD: Woodbine House. Available through Woodbine House, 6510 Bells 	Mill Road, Bethesda, MD 20817; tel.: (800) 843-7323.<BR>
Parents and professionals contribute chapters on the medical, emotional, educational and social issues concerning the development of the child and the family. A first book for anyone wishing to learn more about Down syndrome, especially new parents.<P>

<B>Brothers, Sisters, and Special Needs.</B> Lobato, D.J. (1990). Baltimore, MD: Paul H. Brookes 	Publishing Co. Available through Paul H. Brookes Publishing Co., P.O. Box 10624, 	Baltimore, MD  21285-0624; tel.: (301) 337-9580 or (800) 638-3775.<BR>
		A book for parents and professionals that provides information and activities to help 		young siblings of children with developmental disabilities and chronic illnesses.<P>

<B>Brothers & Sisters - A Special Part of Exceptional Families</B> (2nd edition) Powell, T.H., & 	Gallagher,  P.A. (1993). Baltimore, MD: Paul H. Brookes Publishing Co. Available through 	Paul H. Brookes Publishing Co., P.O. Box 10624, Baltimore, MD  21285-0624; tel.: (301) 	337-9580 or (800) 638-3775.<BR>
		A guide for parents, their older children, and professionals that encourages a better 		understanding of the dynamics of family relationships and the challenges of relating 		to a sibling with special needs.  The book combines research with personal testimony 		from siblings.<P>

<B>Children with Down Syndrome: A Developmental Perspective. </B>Cicchetti, D. & Beeghly, M., (Eds.) 	New York: Cambridge University Press. Available through Cambridge University Press,  110 	Midland Avenue, Port Chester, NY 10573; tel.: (800) 872-7432.<BR>
A collection of papers addressing the current state of knowledge of psychological development in infants and children with Down syndrome. Linguistic, social, emotional, cognitive and representational factors in the developmental process are discussed.  <P>

<B>Communication Skills in Children with Down Syndrome.</B> Kumin, L. (1994) Rockville, MD: 	Woodbine House.  Available through Woodbine House, 6510 Bells Mill Road, Bethesda, MD 	20817; tel.: (800) 843-7323.<BR>
A book which focuses solely on speech and language development in children with Down syndrome.  Provides information on the development of communication skills and the ways in which physical and cognitive characteristics of children with Down syndrome contribute to communication difficulties.<P>

<B>Down Syndrome: Advances in Medical Care.</B> Lott, I., & McCoy, E. (Eds.) (1992). New York: 	Wiley-Liss. Available through Wiley-Liss, 1 Wiley Drive, Somerset, NJ 08875; tel.: (800) 	225-5945.<BR>
Proceedings of the NDSS Down Syndrome Health Care Conference which focused entirely on the health care of people with Down syndrome throughout their life span. Chapters are written by leading experts in the field, and address such topics as orthopedics, cardio-respiratory disorders, endocrinology, dental problems and other relevant clinical advances.<P>

<B>Down Syndrome and Alzheimer Disease.</B> Nadel, L. & Epstein, C.J. (Eds.) (1992). New York: 	Wiley-Liss. Available through Wiley-Liss, 1 Wiley Drive, Somerset, NJ 08875; tel.: (800) 	225-5945.<BR>
This volume presents the proceedings of the eighth NDSS Science Symposium which focused on Alzheimer disease in the context of Down syndrome. The chapters look at the neurological aspects of Alzheimer disease in Down syndrome; the development and diagnosis of dementia in persons with Down syndrome; the relations between chromosome 21 and Alzheimer disease; and a review of the approaches being used to investigate the pathogenesis of Alzheimer disease in Down syndrome.<P>

<B>Down Syndrome: Birth to Adulthood. </B>Rynders, J.E. & Horrobin, J.M. (1995). Denver, CO: Love 	Publishing Company. Available through Love Publishing Company, 1777 South Bellaire 	Street, Denver, CO 80222; tel.: (303) 757-2579.<BR>
A guide for new parents designed to provide information about Down syndrome and knowledge of how other parents of children with Down syndrome have coped with the experience. Medical, social and educational issues are discussed.<P>
 
<B>Down Syndrome: Living and Learning in the Community.</B> Nadel, L. & Rosenthal D. (Eds.)(1995). 	New York: Wiley Liss. Available through Wiley-Liss, 1 Wiley Drive, Somerset, NJ 08875; 	tel.: (800) 225-5945.<BR>
Proceedings of the Fifth International Down Syndrome Conference sponsored by NDSS in collaboration with the European Down Syndrome Association. Topics covered by experts in a variety of fields include speech, language, medical care, nutrition and social life.<P>

<B>Down Syndrome: A Resource Handbook.</B> Tingey, C. (Ed.) (1988). Boston, MA: College-Hill Press. 	Available through Pro Ed, 8700 Shoal Creek Boulevard, Austin, TX  78758-6897; tel.: (512) 	451-3246.<BR>
A guide for new parents of children with Down syndrome. Addresses medical issues, the family, early development, education and community activities. Chapters are written by professionals of various disciplines.<P>

<B>Etiology and Pathogenesis of Down Syndrome.</B>  Epstein, C.J., Hassold, T., Lott, I.T., Nadel, L., 	& Patterson, D. (Eds.) (1995).  New York: Wiley-Liss.  Available through Wiley-Liss, 1 	Wiley Drive, Somerset, NJ 08875; tel.: (800) 225-5945.<BR>
		Proceedings of the tenth NDSS Science Symposium.  This volume covers a broad 		range of  topics in Down syndrome research, with sections focusing on trisomy 21; 		the molecular structure of chromosome 21; mental retardation and Alzheimer disease; 		the phenotype of Down syndrome; and models of Down syndrome.<P>

<B>Keys to Parenting a Child with Down Syndrome.</B> Brill, M. (1993). New York:  Barron's Educational 	Series, Inc. Available through Barron's Educational Series, Inc., 250 Wireless Boulevard, 	Hauppauge, NY  11788; (800) 645-3476.<BR>
		A practical guide to raising a child with Down syndrome. The book covers a range 		of key issues in depth and gives practical advice to parents.  Areas addressed include 		initial reactions to diagnosis, managing family dynamics, obtaining educational and 		medical services and planning for adulthood.<P>

<B>Medical & Surgical Care for Children with Down Syndrome: A Guide for Parents.</B>  Van Dyke, 	D.C., Mattheis, P., Eberly, S.S., & Williams, J. (Eds.) (1995). Bethesda, MD: Woodbine 	House. Available through Woodbine House, 6510 Bells Mill Road, Bethesda, MD 20817; tel.: 	(800) 843-7323.<BR>
		A comprehensive guide for parents which provides an overview of specific medical 		conditions that are more common among children with Down syndrome, along with 		sections on preventive care, medical decision making, anesthesia and surgical concerns 		and planning for health care in adulthood.<P>

<B>Molecular Structure of the Number 21 Chromosome and Down Syndrome.</B> Smith, G.F. (Ed.) 	(1985). New York: The New York Academy of Sciences. Available through The New York 	Academy of Sciences, 2 East 63rd Street, New York, NY 10021; tel.: (212) 838-0230.<BR>
Proceedings of the first NDSS Science Symposium which addressed new findings about the molecular structure of genes and chromosomes through the fields of molecular genetics, genetic engineering and biochemistry. Papers address the relationship between maternal aging and nondisjunction, deficiencies in the immune system, the chemical composition of the brain and more.<P>

<B>The Morphogenesis of Down Syndrome.</B> Epstein, C.J. (Ed.) (1991). New York: Wiley-Liss, Inc. 	Available through Wiley-Liss, 1 Wiley Drive, Somerset, NJ 08875; tel.: (800) 225-5945.<BR>
Proceedings of the seventh NDSS Science Symposium which focused on morphogenesis of Down syndrome; specifically, how chromosome imbalance alters morphogenesis. Attention is given to the morphogenetic differences that characterize the craniofacial, brain, heart and gastrointestinal tract development, as well as dermatoglyphic alterations in Down syndrome.<P>

<B>A Parent's Guide to Down Syndrome: Toward a Brighter Future.</B> Pueschel, S.M. (1990). 	Baltimore MD: Paul H. Brookes Publishing Co. Available through Paul H. Brookes 	Publishing Co., P.O. Box 10624, Baltimore, MD  21285-0624; tel.: (301) 337-9580 or (800) 	638-3775.<BR>
A detailed guide for parents and professionals which discusses the nature of the physical, social, mental and emotional development of children with Down syndrome. Emphasis is given to early intervention, with professionals from various disciplines contributing chapters.<P>

<B>The Phenotypic Mapping of Down Syndrome and Other Aneuploid Conditions.</B>  Epstein, C.J. 	(Ed.) (1993).  New York: Wiley-Liss.  Available through Wiley-Liss, 1 Wiley Drive, 	Somerset, NJ 08875; tel.: (800) 225-5945.<BR>
		Proceedings of the ninth NDSS Science Symposium.  This volume discusses 		approaches to understanding the genetics and the underlying mechanisms of the 		different phenotypic characteristics of Down syndrome, as well as animal models of 		trisomy 21 relevant to the phenotypic mapping of Down syndrome.<P>
  
<B>The Psychobiology of Down Syndrome.</B> Nadel, L. (Ed.) (1988). Cambridge, MA: MIT Press. 	Available through MIT Press, 55 Hayward Street, Cambridge, MA 02142; tel.: (617) 253-5646.<BR>
Proceedings of the fourth NDSS Science Symposium covering the neurobiological and cognitive features of Down syndrome. Emphasis is given to the acquisition and use of language skills, as well as the neuropathological aspects of older individuals with Down syndrome.<P>

<B>Teaching the Infant with Down Syndrome: A Guide for Parents and Professionals</B> (2nd edition). 	Hanson, M.J. (1987). Austin, TX: Pro Ed Publishers. Available through Pro Ed, 8700 Shoal 	Creek Boulevard, Austin, TX  78758-6897; tel.: (512) 451-3246.<BR>
A manual which provides teaching ideas and activities that can be used to assist an infant's development. Additional chapters present information on the emotional reactions to the birth of a child with Down syndrome, medical concerns and parent-child interaction.<P>

<B>Teaching Reading to Children with Down Syndrome: A Guide for Parents and Teachers.</B> 	Oelwein, P. (1995). Bethesda, MD: Woodbine House. Available through Woodbine House, 	6510 Bells Mill Road, Bethesda, MD 20817; tel.: (800) 843-7323.<BR>
A comprehensive instruction manual to aid parents in teaching their child with Down syndrome to read.<P>

<H3>Personal Accounts of Down Syndrome</H3><P>

<B>Cara: Growing with a Retarded Child.</B>  Jablow, M.M. (1983). Philadelphia, PA: Temple University 	Press. Available through Temple University Press, USB Room 305, Broad and Oxford 	Streets, Philadelphia, PA  19122; (215) 204-8787.<BR>
The author tells of her experiences raising her daughter, Cara, who has Down syndrome. She discusses such varied topics as early intervention, special education, emotional support, and family adjustments. The book deals specifically with early childhood.<P>

<B>Count Us In:  Growing Up with Down Syndrome.</B> Kingsley, J. & Levitz, M. (1994). New York: 	Harcourt Brace & Company.  Available through Harcourt Brace & Company, 6277 Sea 	Harbor Drive, Orlando, FL 32887; tel.: (800) 543-1918.<BR>
Two young men with Down syndrome speak in their own words about their experiences growing up with Down syndrome.  Jason (age 19) and Mitchell (age 22) share their feelings and thoughts about friendship, school, hopes for the future and dealing with independence in adulthood.<P>

<B>Differences in Common: Straight Talk on Mental Retardation, Down Syndrome, and Life.</B> 	Trainer, M. (1991).  Rockville, MD: Woodbine House. Available through Woodbine House, 	6510 Bells Mill Road, Bethesda, MD 20817; tel.: (800) 843-7323.<BR>
A collection of essays by the mother of an adult son who has Down syndrome. The author talks about such topics as mainstreaming, terminology, parent groups, siblings' coping strategies, self awareness, finding a job, advocacy and societal attitudes towards mental retardation. <P>

<B>Show Me No Mercy.</B> Perske, R. (1984). Nashville, TN: Abingdon Press. Available through 	Cokesbury, P.O. Box 801, Nashville, TN  37202; tel.: (800) 672-1789.<BR>
The father of a young man with Down syndrome relates the inspirational experience of his attempt to be reunited with his son after a family tragedy separates them. <P>

<B>The World of Nigel Hunt.</B> Hunt, N. (1967). New York: Garrett Publications (out of print--check 	local library).<BR>
This is the autobiography of a young English man with Down syndrome who began the book when he was 17. The book is a classic about Down syndrome.  Includes an introduction, written by Mr. Hunt's father, and section of photographs. <P>


<H3>Books for Children</H3><P>

<B>Our Brother Has Down's Syndrome: An Introduction for Children.</B> Cairo, S. (1985). Ontario: 	Firefly Books, Ltd. Available through Firefly Books, 250 Sparks Avenue, Willowdale M2H 	2S4, Ontario, Canada; tel.: (416) 499-8412.<BR>
A book of color photos and text to introduce and explain Down syndrome to young children, especially siblings. It is a personalized account of a young boy, Jai, as told by his two sisters. <P>

<B>Special Kids Make Special Friends.</B> Shalom, D. B. (1984). Bellmore, NY: Association for Children 	with Down Syndrome, Inc. Available through the Association for Children with Down 	Syndrome, Inc., 2616 Martin Avenue, Bellmore, NY  11710; tel. (516) 221-4700.<BR>
A book designed to educate  young children about Down syndrome. Children from a pre-school run by the Association for Children with Down Syndrome are shown learning and playing. <P>

<H3>Periodicals and Newsletters</H3><P>

<B>Update.</B> Quarterly newsletter of the National Down Syndrome Society, 666 Broadway, New York, 	NY 10012; tel.: (800) 221-4602.<P>

<B>News & Views.</B> Quarterly, full-color magazine for and by teens and young adults with Down 	syndrome, edited by actor and NDSS National Goodwill Ambassador, Chris Burke. Published 	by the National Down Syndrome Society, 666 Broadway, New York, NY 10012; tel.: (800) 	221-4602. <P>

<B>Exceptional Parent.</B> Magazine for parents and professionals published eight times annually by the 	Psy-Ed Corporation. Subscription information available from Exceptional Parent, P.O. Box 	3000, Dept. EP, Denville, NJ 07834; tel.: (800) 562-1973.<P>

<B>Down Syndrome News.</B> Newsletter available from the National Down Syndrome Congress, 1605 	Chantilly Drive, Suite 250, Atlanta, GA  30324; tel.: (800) 232-6372.<P>

<H3>Videos</H3><P>

<B>Congratulations? An Introduction to Down Syndrome for Parents, Their Family and Friends.</B> 	Produced by and available through New Challenges, 96 Ogden Avenue, White Plains, NY  	10605; tel.: (914) 287- 0723.<BR>
A film for new parents which addresses some of the most commonly asked questions about raising a child with Down syndrome.  (57 minutes)<P>

<B>Daddy's Girl.</B> Produced by Bruce Postman, written and directed by Regina Conroy. Available 	through Carolyn Baxley, c/o Carle Media, 110 West Main Street, Urbana, IL  61801; tel.: (217) 384-4838.<BR>
Dina Lev, a 12-year-old actress with Down syndrome, portrays Nancy, a girl trying to deal with her divorced father's inability to accept the fact that his daughter has Down syndrome.  (27 minutes)<P>

<B>Down Syndrome: A Parental Perspective.</B>  Produced by Dartmouth-Hitchcock Medical Center. 	Available through Learner Managed Designs, Inc., P.O. Box 747, Lawrence, KS; tel.: (800) 	467-1644.<BR>
		A film which depicts the perspectives and experiences of several parents in a support 		group-type setting.  (20 minutes)<P>

<B>Gifts of Love.</B> Produced by and available through the National Down Syndrome Society, 666 	Broadway, New York, NY 10012; tel.: (800) 221-4602. <BR>
Features parents and their young children with Down syndrome and highlights their everyday lives.  (25 minutes)<P>

<B>Opportunities to Grow.</B> Produced by and available through the National Down Syndrome Society, 	666 Broadway, New York, NY  10012; tel.: (800) 221-4602.<BR>
 		This video portrays the many opportunities that children and young adults with Down syndrome are taking advantage of in their communities and highlights school, work, living and recreational experiences.  (25 minutes)<P>

<B>Special Days with Special Kids.</B> Produced by and available through the Association for Children with 	Down Syndrome, Inc., 2616 Martin Avenue, Bellmore, NY  11710; tel.: (516) 221-4700. <BR>
Preschool and school-aged children enjoy memorable moments. (20 minutes)  <P>

<B>Special Friends.</B> Produced by Vidim Productions/Great North Releasing, Inc. Available through 	Filmmakers Library, 124 East 40th Street, New York, NY 10016; tel.: (212) 808-4980.<BR>
A portrait of the lifelong friendship between two young women who have Down syndrome. The film attests to the emotional potential of people with Down syndrome and their ability to attain happiness and fulfillment in adulthood.  (38 minutes)<P>

<B>Yours to Keep.</B> Produced and directed by Merce Williams and Laurie Taylor Williams.  Available 	through Direct Cinema Limited, P.O. Box 10003, Santa Monica, CA 90410; tel.: (800) 525-	0000.<BR>
		An intimate look at a young man with Down syndrome and his quest for employment 		upon graduation from high school.  (72 minutes)<P>


<H3>VIDEOTAPES</H3>
(Available through NDSS)<P>

<B>Gifts of Love</B> ($5 for 10-day loan, $25 for purchase)<BR>
A 25-minute videotape produced and directed by the Allstate Insurance Company.  Shot on location, four families of children with Down syndrome talk about their feelings and experiences with their children, particularly during the first six years.  All the children live at home and attend programs in their communities.  This tape may be reproduced for educational purposes.  It may not be given to TV stations without NDSS written permission, or sold for profit.<P>

<B>Opportunities to Grow</B> ($5 for 10-day loan, $25 for purchase)<BR>
This 25-minute color videotape, sequel to Gifts of Love, was underwritten by Kemper National Insurance Companies to show how people with Down syndrome, ages 6 to 26, participate equally in all phases of community life.  Narrated by actress Constance McCashin, vignettes of 15 young men and women illustrate how inclusion, education, computer facilitation, socialization programs and employment training help them to fulfill their potential. <P>

<B>Bernardsville Beginnings</B> ($5 for 10-day loan, $25 for purchase)<BR>
The 23-minute color video follows Alison through her first full year in a first grade inclusion program.  It is a step-by-step account of teaching staff preparation, classroom experiences, a portrayal of one girls successful adjustment, and a whole class matured by the experience.<P>

<B>Bittersweet Waltz</B> ($5 for 10-day loan, $25 for purchase)<BR>
This 18-minute color video of the highly personalized experience of Alec and his first year included in a regular fifth grade class.  Produced by Linda Safan, it describes the experience from a point of view of a parent, a child, and the school administration.<P>

<B>World of Opportunities</B> ($5 for 10-day loan, $15 for purchase)<BR>
A six-minute color slide collage set to music, underwritten by Kemper National Insurance Companies.  With captions, but no narration, children and young adults with Down syndrome from around the world illustrate their interests and abilities in family, work, educational and recreational settings.<P>

<B>New Parent Video</B> (Free 10-day loan, $2.50 for postage and handling)<BR>
This seven-minute video provides a basic introduction to Down syndrome.  Produced by the Down Syndrome Association of Wisconsin, it discusses the important role that parents, and others, play in a childs development.  The video includes candid comments by new parents, and shows children with Down syndrome involved in family life, community, and recreational activities.<P>

<B>Employability</B> (Free 10-day loan, $2.50 for postage and handling)<BR>
A 30-minute documentary color film, sponsored by Woolworth Corporation, portrays in a series of real life situations, how individuals with developmental disabilities succeed in making the transition to productive employment.  Narrated by James Earl Jones, the film underscores why employment of individuals with developmental disabilities makes good business sense.  Rental fee underwritten by Woolworth Corporation.<P>

</A>
<A NAME="order">
<HR>
	<CENTER><H2>ORDER FORM</H2></CENTER>
<HR>	
All orders must be prepaid. Checks should be made payable to the National Down Syndrome Society. Please check the appropriate boxes when ordering materials, and be certain that the order form on the reverse side of this sheet contains a daytime telephone number and a street address.  All materials are free of charge except where noted.  Bulk orders may entail charges for printing, postage and handling.  Please call NDSS for further information.  Thank you.
<p>
<b>GENERAL INFORMATION</b><br>
( ) NDSS Brochure<br>
( ) General Down Syndrome Brochure<br>
( ) Update, the NDSS Newsletter<br>
( ) Teaching Partnership Poster for Grades 1-3 (First copy free, $3 for each additional copy)<br>
( ) Teaching Partnership Poster for Grades 4-6 (First copy free, $3 for each additional copy)<br>
( ) Inclusion Brochure and Resource List<br>
( ) Educational Challenges Program - Inclusion Study Results ($10)
<p>
<B>CLINICAL CARE BOOKLETS</B><br>
( ) The Neurology of Down Syndrome<br>
( ) The Heart and Down Syndrome<br>
( ) Endocrine Conditions in Down Syndrome<br>
( ) Alzheimer's Disease and Down Syndrome<br>
( ) Sexuality and Down Syndrome<br>
( ) Life Planning and Down Syndrome<br>
( ) Speech and Language Skills in Infants, Toddlers and Young Children with Down Syndrome<br>
( ) Speech and Language Skills in Children and Adolescents with Down Syndrome<br>
<p>
<b>VIDEOS</b>
<b>All video prices include $2.50 for postage and handling.  Loans are not available outside of the United States.</b>

<pre>
Loan			Purchase
Gifts of Love		( ) $5			( ) $25
Opportunities to Grow	( ) $5			( ) $25
Bernardsville Beginnings( ) $5			( ) $25
Bittersweet Waltz	( ) $5			( ) $25
World of Opportunities	( ) $5			( ) $15
New Parent Video	( ) $2.50              Not Available
Employability		( ) $2.50              Not Available
</pre>
<b>NEWS & VIEWS</b>
( ) Subscription--four issues ($10 - domestic, $18 - international)	

<p>

<b>NDSS HEALTH CARE CONFERENCE AND SCIENTIFIC SYMPOSIUM PROCEEDINGS</b><br>
<p>
Available directly through the publisher.<br> 
Down Syndrome: Advances in Medical Care, 1992<br>
Down Syndrome: Living and Learning in the Community, 1994<br>
Etiology and Pathogenesis of Down Syndrome, 1995<br>
Phenotypic Mapping of Down Syndrome and Other Aneuploid Conditions, 1993<br>
Down Syndrome and Alzheimer Disease, 1992<br>
The Morphogenesis of Down Syndrome, 1991<br>
Molecular Genetics of Chromosome 21 and Down Syndrome, 1990<br>
<p>
<em>The above books are available through Wiley-Liss. Contact: John Wiley & Sons, Inc., 1 Wiley Drive, 	Somerset, NJ 08875.  Phone:  800-879-4539.</em>

The Psychobiology of Down Syndrome, 1988
<em>Available through MIT Press, Inc.  Contact: MIT Press Bookstore, 292 Main Street, Cambridge, MA 	02142.  Phone:  617-253-5249.</em>
<p>
<b>OTHER</b>
( ) Autographed photograph of Chris Burke, NDSS Goodwill Ambassador and star of the ABC-TV show "Life 	Goes On" ($3)
<p>

	<center>*     *     *     *     *     *     *     *     *     *     *     *</center>
</p>

	<center><h2>ORDER FORM</h2></center>
<blockquote>
<b>All orders must be prepaid.</b>  Checks should be made payable to the National Down Syndrome Society. Please check the appropriate boxes when ordering materials and be certain that order form contains a <em>daytime telephone number and a street address. Videos cannot be delivered to post office boxes.</em>  <b>All international orders (including Canada) must be prepaid in U.S. dollars and should include the appropriate additional postage. Thank you.</b></blockquote>
<code>
Name:____________________________________________________   Today's Date:______________<br>

Address:_____________________________________________________________________________<br>

City:________________________________________   State:__________   Zip code:_______________<br>

Telephone:   Day:   (______)________________________   Evening: (______)____________________<br>

Total Payment:$__________  Payment type:  ( )Check/Money order  ( )Visa   ( )MasterCard   ( )American Express<br>

Credit card #:____________________________________________   Expiration date:_______________<br>

Cardholder's Signature:__________________________________________________________________<br>
</code>

Please mail to:<br>
<i>National Down Syndrome Society<br>
666 Broadway, 8th Floor<br>
New York, NY  10012-2317</i>
<hr>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: November 25th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>                       
</BODY></HTML>


</DOC>
<DOC>
<DOCNO>WT01-B04-255</DOCNO>
<DOCOLDNO>IA090-000969-B048-314</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/clin.html 206.249.5.81 19970117204230 text/html 53109
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 20:41:42 GMT
Last-modified: Wednesday, 28-Aug-96 13:31:31 GMT
Content-length: 52916
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>
CLINICAL INFORMATION
</TITLE><BODY BACKGROUND="/gif/background.gif"><BODY>

<H2><CENTER>CLINICAL INFORMATION</H2></CENTER><HR><P>


<A NAME="heart">
<CENTER><B>THE HEART AND DOWN SYNDROME</B><P>

by<BR><P>

Dr. Langford Kidd<BR>
Helen B.Taussig Professor<BR>
Director, Division of Pediatric Cardiology<BR>
Johns Hopkins University<BR>
</CENTER><P>


Abnormalities of the cardiovascular system are common in Down syndrome.  Approximately half of all infants born with Down syndrome have a heart defect.  Many of these defects have serious implications and it is important to understand them and how they may adversely affect the child so that we may provide the most appropriate medical care.<P>

<B>Question:</B> <BLOCKQUOTE>What are the most common heart defects in children with Down syndrome?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>The most common defects are Atrioventricular Septal Defect (formally called Endocardial Cushion Defect), Ventricular Septal Defect, Persistent Ductus Arteriosus and Tetralogy of Fallot.</BLOCKQUOTE>

<B>Question:</B> <BLOCKQUOTE> What is an Atrioventricular Septal Defect?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>An Atrioventricular Septal Defect is caused by a failure of tissue to come together in the heart during embryonic life.  This results in a large opening in the center of the heart, with usually a hole between the two pumping chambers (a Ventricular Septal Defect) and between the two collecting chambers (an Atrial Septal Defect) as well as abnormalities of the two atrioventricular valves, the mitral and tricuspid valves.  This defect occurs in nearly 60% of the children with Down syndrome who are born with congenital heart disease.  In less severe cases, Ventricular Septal Defects and Atrial Septal Defects can also occur separately.</BLOCKQUOTE>

<B>Question:</B>  <BLOCKQUOTE>What is Persistent Ductus Arteriosus?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>The ductus arteriosus is a channel between the pulmonary artery and the aorta and during fetal life diverts blood away from the lungs.  After birth this channel usually closes on the first day of life.  If it does not close, it is termed "persistent" and results in an increased flow of blood into the lungs.</BLOCKQUOTE>

<B>Question:</B>  <BLOCKQUOTE>What is Tetralogy of Fallot?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>This is a term given to a heart condition in which there is both a Ventricular Septal Defect and a narrowing of the passage from the right ventricle to the lungs causing Pulmonary Stenosis.  The Pulmonary Stenosis causes the blue blood in the right ventricle to cross the Ventricular Septal Defect into the aorta and produces what is commonly called a "blue baby."</BLOCKQUOTE>
<B>Question:</B>  <BLOCKQUOTE>What are the effects of Atrioventricular Septal Defect, Ventricular Septal Defect and Persistent Ductus Arteriosus?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>These defects result in increased blood flow going to the lungs as the blood goes through the septal defects or the ductus from the high pressure left heart into the low pressure right heart.  This flooding of the lungs results in a buildup of pressure in the pulmonary circulation and this higher pressure and high flow leads to damage to the pulmonary circulation, and pulmonary hypertension.  In the first few months of life, signs of heart failure may be prominent with rapid breathing and failure to grow and gain weight.  Later, progressive damage to the blood vessels and the lungs may result in reversal of the shunt and blueness of the skin (cyanosis).</BLOCKQUOTE>

<B>Question:</B>  <BLOCKQUOTE>What is the relationship of heart defects to the respiratory system?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>The lungs of children with Down syndrome do not develop as fully as in the general population.  Consequently, the growth of blood vessels throughout the lungs is limited.  The narrowed arteries of the lungs hold potential for long-lasting damage in the face of increased pressure and flow of blood through the lungs.</BLOCKQUOTE>

<B>Question:</B>  <BLOCKQUOTE>How are the defects diagnosed?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>Some children with Down syndrome and major heart defects will present with heart failure, difficulty breathing and failure to thrive in the newborn period; however, because in some children the defect may not be at first apparent, it is important that all children born with Down syndrome, even those who have no symptoms of heart disease, should have an echocardiogram in the first 2 or 3 months of life.</BLOCKQUOTE>

<B>Question:</B>  <BLOCKQUOTE>What is the recommended treatment?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>Heart surgery to correct the defects is recommended and it must be done before age 5 or 6 months in order to prevent lung damage.  Although the complexity of the defects raises the risk of surgery slightly above that of surgery on children without Down syndrome, successful surgery will allow many of the affected children to thrive as well as any child with Down syndrome who is born with a normal heart.  There may be residual defects (such as imperfect valves, in cases of Atrioventricular Septal Defect), but their effect on health is often minimal.</BLOCKQUOTE>

<B>Question:</B>  <BLOCKQUOTE>What are the guidelines for choosing a hospital?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>Look for a medical center in a major metropolitan area which has experience in open heart surgery on infants, and experience in operating on infants with Down syndrome in particular.  A hospital which conducts at least ten such operations a year, with a good survival rate, would be considered an experienced hospital.</BLOCKQUOTE>

<B>Question:</B> <BLOCKQUOTE> What should be considered in selecting a surgical team?</BLOCKQUOTE>

<B>Answer:</B>  <BLOCKQUOTE>Again, experience, together with the parents' rapport with the physician, should be the determining factor in the choice.  It is important that an experienced anesthesiologist be selected, as children with Down syndrome often have airway problems.</BLOCKQUOTE><P>

<B>SUMMARY</B><P>
<UL><H5>
*	Congenital cardiac defects occur in up to 50 percent of children with Down syndrome.<BR>

*	Early diagnosis via echocardiogram is crucial within the first two months of life, even if no symptoms are present.<BR>

*	The majority of heart defects in children with Down syndrome can be surgically corrected with resulting long-term health improvements.<BR>

*	Experience and success are the key factors in selecting a hospital and surgical team for heart surgery on infants with Down syndrome.<BR><P>

</UL></H5>
<B>Books/Newsletters:</B><P>

<B>Cardiac Aspects, </B>Marino, B.  In:<I>Biomedical Concerns in Persons with Down Syndrome.</I>  	Pueschel, S. & Pueschel, J. (Eds.) (1992).  Baltimore, MD: Paul H. Brooks, pp. 91-103.  	Available through Paul H. Brookes Publishing Co., P.O. Box 10624, Baltimore, MD 21285-	0624; tel.: (800) 638-3775.<BR>
   		This chapter discusses the importance of early diagnosis and management of cardiac 		problems in children and adults with Down syndrome. The author discusses 		developments 	in pediatric cardiology and surgery, in addition to improved medical 		care.<P>

<B>Cardiorespiratory Problems in Children with Down Syndrome,</B> Kidd, L.  In: Down Syndrome: 	Advances in Medical Care. Lott, I. & McCoy, E. (Eds.) (1992).  New York, NY: Wiley-Liss, 	pp. 61-69.  Available through Wiley-Liss, 1 Wiley Drive, Somerset, NJ 08875; tel.: (800) 225-	5945.<BR>
		This chapter provides a brief overview of heart disease in children with Down 		syndrome, and the advances in treatments for such conditions.  Due to a high incidence 		of heart disease in infants with Down syndrome, the author stresses the importance 		of continued screenings for early diagnosis of cardiac problems.<P>

<B>Heart Disease and Children with Down Syndrome,</B> Cousineau, A. & Lauer, R.  In: Medical & 	Surgical Care for Children with Down Syndrome: A Guide for Parents. Van Dyke, D., 	Mattheis, P., Eberly, S. & Williams, J. (Eds.) (1995).  Bethesda, MD: Woodbine House, pp. 	35-63.  Available through Woodbine House, 6510 Bells Mill Road, Bethesda, MD 20817; tel.: 	(800) 843-7323.<BR>
		This chapter discusses the different heart disorders typically associated with Down 		syndrome, and their treatment.  Basic information is also provided about how the heart 		functions, causes and symptoms of heart disease, associated disorders of the heart and 		circulatory system, treatments and results.  The text is written in simple language.<P>

<B>The Heart.</B>  In: Medical Care in Down Syndrome: A Preventive Medicine Approach.  Rogers, P. 	& Coleman, M. (1992).  New York, NY: Marcel Dekker, Inc., pp.157-168.  Available 	through Marcel Dekker, Inc., 270 Madison Avenue, 4th Floor, New York, NY 10016; tel.: 	(212) 696-9000.<BR>
		This chapter discusses the importance of continued careful evaluation for early 		diagnosis of heart defects common in infants with Down syndrome.  The authors 		provide a brief review of cardiac defects and pulmonary disease, and a summary of 		available cardiac care.<P>

<B>The Heart and Down Syndrome,</B> Kidd, L. & Taussig, H. (1995).  New York, NY: National Down 	Syndrome Society.  Available through the National Down Syndrome Society, 666 Broadway, 	New York, NY 10012; tel.: (800) 221-4602 or (212) 460-9330.<BR>
		This booklet provides general information about various heart defects that are 		common in children with Down syndrome.  Questions are answered about diagnosis 		and treatment of abnormalities of the cardiovascular system, in addition to the 		relationship of heart defects to the respiratory system and guidelines for choosing a 		hospital and surgical team.<P>

</A><P><HR><P>

<CENTER><B>
ENDOCRINE CONDITIONS IN 
DOWN SYNDROME</B><P>
by<p>

Dr. Ernest McCoy<br>
Professor of Pediatrics<BR>
University of Alberta<P>

</CENTER>
Individuals with Down syndrome have a higher incidence of endocrine problems than the general population.  The endocrine system refers to a set of glands which includes the thyroid, adrenal, and pituitary glands.<p>

<B>Question:</B> <BLOCKQUOTE> What is hypothyroidism?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Hypothyroidism results from a malfunctioning thyroid gland, which decreases the synthesis of the hormone thyroxin.  Thyroxin is the hormone that promotes growth of the brain and other body tissue.</BLOCKQUOTE>

<B>Question:</B> <BLOCKQUOTE> How common is hypothyroidism?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Hypothyroidism is the most common endocrine problem in children with Down syndrome.  One study showed these individuals to be 28 times more prone to congenital hypothyroidism than the general population.  It is estimated that approximately ten percent of children with Down syndrome have congenital or acquired thyroid disease.  Incidence of thyroid disease in adults with this genetic disorder varies from 13 to 50 percent.  Hypothyroidism can occur at any time from infancy through adulthood.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  How is hypothyroidism diagnosed?</BLOCKQUOTE>
<B>Answer:</B><BLOCKQUOTE>  All individuals with Down syndrome should be tested for hypothyroidism at birth, and at periodic intervals (at least every two years) thereafter.  The indicators of hypothyroidism---enlarged tongue, constipation, poor circulation---are also found in individuals who are not hypothyroid, so the blood test for thyroid function is an important diagnostic test.  As the thyroid hormone affects normal development of the brain, testing of infants is particularly crucial.  </BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What treatment exists for hypothyroidism?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  The thyroid hormone, thyroxin, is readily replaced through medication.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What is hyperthyroidism?</BLOCKQUOTE>

<B>Answer:</b><BLOCKQUOTE>  In this case, the thyroid gland is overactive.  Symptoms are swelling in the neck, abnormal sweating, and rapid pulse rate.  No evidence exists as to whether hyperthyroidism is more prevalent in individuals with Down syndrome than in the general population.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What is the treatment for hyperthyroidism?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  This thyroid malfunction can be treated pharmacologically, blocking the synthesis of thyroid hormone through medication.  It can also be treated with radioactive compounds to destroy the gland, or by surgically removing a portion of the thyroid gland.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Are people with Down syndrome more prone to diabetes?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  There is not sufficient data available at this point to know if there is increased risk for children with Down syndrome to develop type 1 diabetes as compared to the rate for their peers in the general population.  However, research suggests that individuals who develop one type of endocrine autoimmune disorder, such as thyroiditis, are more likely to develop a second disorder, such as type 1 diabetes.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What is the status of research on use of the growth hormone for children with Down syndrome?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Use of growth hormone for children with Down syndrome is still in experimental stages.  There are reports of increased rates of growth in children with down syndrome who received the hormone for a brief period; however, these reports were not controlled studies, so there is no scientific evidence that long-term administration of the hormone would increase final height.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Can any growth hormone be administered to any Down syndrome child?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  At present, doctors are licensed to prescribe growth hormone for individuals with Down syndrome only when there is a demonstrated deficiency of that hormone.  It is strongly advised that such treatment be obtained only through a clinical trial until long-term benefits are demonstrated.  </BLOCKQUOTE>


<B>SUMMARY</B><P>
<UL><H5>
*	Approximately 10 percent of children with Down syndrome, and between 13 to 50 percent of adults with this genetic disorder, have thyroid disease.  Hypothyroidism, an underfunctioning thyroid gland, is the most common condition.<P>

*	Hyporthyroidism must be diagnosed by a standard blood test, beginning at infancy and continuing at regular intervals throughout the life span.<P>

*	Hyporthyroidism is easily treated with replacement thyroxine hormone; treatment is particularly crucial for hypothyroid infants, as the hormone affects normal development of the brain.  However, this thyroid disease can be developed at any time in the life span.<P>

*	Hyperthyroidism is an overactive thyroid gland.  Diagnosis is also by blood test. The condition can be treated by medication, surgery, or use of radioactive iodine to destroy the gland.<P>

*	Insufficient evidence exists on the issue of whether individuals with Down syndrome are more prone to type 1 diabetes.  Research does suggest that individuals who develop one type of endocrine autoimmune disorder, such as thyroid disease, run a higher risk of developing other autoimmune disorders, such as type 1 diabetes.<P>

*	While some short-term uncontrolled studies on the use of growth hormone for children with down syndrome have demonstrated growth spurts, there is no long-term research to demonstrate an increase in final height.  Growth hormone should be administered only as part of a clinical trial until long-term benefits are demonstrated.<P>
</UL></H5>
<B>Books/Newsletters:</B><P>

<B>Endocrine Conditions in Down Syndrome,</B> McCoy, E. (1995).  New York, NY: National Down 	Syndrome Society.  Available through the National Down Syndrome Society, 666 Broadway, 	New York, NY 10012; tel.: (800) 221-4602 or (212) 460-9330.<BR>
		This booklet provides general information about the thyroid, adrenal and pituitary 		glands of the endocrine system, and answers commonly asked questions about medical 		conditions of the endocrine system, as they relate specifically to Down syndrome.<P>

<B>Endocrine Function in Down Syndrome,</B> McCoy, E.  In: Down Syndrome: Advances in 	Medical Care, Lott, I. & McCoy, E. (Eds.) (1992).  New York, NY: Wiley-Liss, pp. 71-	82.  Available	through Wiley-Liss, 1 Wiley Drive, Somerset, NJ 08875; tel.: (800) 225-	5945.<BR>
		This chapter provides information about three areas of endocrine function in 		individuals with Down syndrome, including thyroid function, gonadal function and 		growth patterns.  The chapter is written in technical language.   <P>

<B>Endocrinologic Aspects, </B>Pueschel, S. & Bier, J.  In: Biomedical Concerns in Persons with Down 	Syndrome, Pueschel, S. & Pueschel, J. (Eds.) (1992).  Baltimore, MD: Paul H. Brookes, pp. 	259-272.  Available through Paul H. Brookes Publishing Co., P.O. Box 10624, Baltimore, 	MD 21285-0624; tel.: (800) 638-3775. <BR>
		This chapter provides an overview of the various conditions associated with the 		endocrine system and examines the functioning of the hormones and glands, 		specifically in individuals with Down syndrome.    <P>

<B>The Endocrine System.  </B>In: Medical Care in Down Syndrome: A Preventive Medicine Approach.  	Rogers, P. & Coleman, M. (1992). New York: NY Marcel Dekker, Inc., pp.189-200.  	Available through Marcel Dekker, Inc., 270 Madison Avenue, 4th Floor, New York, NY 	10016; tel.: (212) 696-9000.  <BR>
		This chapter discusses abnormalities of the endocrine system, relating specifically to 		thyroid and gonadal functions.  The authors stress the importance of routine thyroid 		screenings.<P>
		
<B>Thyroid Conditions and Other Endocrine Concerns in Children with Down Syndrome, </B>Foley, T., Jr.  In: Medical & Surgical Care for Children with Down Syndrome: A Guide for 	Parents.  Van Dyke, D., Mattheis, P., Eberly, S. & Williams, J. (Eds.) (1995).  Bethesda, MD: 	Woodbine House, pp. 85-108.  Available through Woodbine House, 6510 Bells Mill Road, 	Bethesda, MD 20817; tel.: (800) 843-7323.<BR>
		This chapter provides a general overview of the endocrine system and the various 		related medical concerns, including thyroid disease and diabetes mellitus.  The authors 		also address symptoms, diagnosis and treatments for endocrine-related problems.  The 		text is written in simple language.<P>

</A><P><HR>
<A NAME="alzh">

<CENTER><B>ALZHEIMER'S DISEASE</B><P>

by<P>

Dr. Ira Lott<BR>
Professor of Pediatrics<BR>
University of California at Irvine<P></CENTER>


Alzheimer's Disease, a degenerative neurological disorder characterized by progressive memory loss, personality deterioration and loss of functional motor capabilities, is far more common in individuals with Down syndrome than the general population.  However, not all individuals with Down syndrome will develop Alzheimer's disease, and even those showing Alzheimer's-type symptoms may not have Alzheimer's disease since other conditions can mimic the symptoms.<P>

<B>Question:</B> <BLOCKQUOTE> How common is Alzeheimer's disease in individuals with Down syndrome?</BLOCKQUOTE>

<B>Answer:</B> <BLOCKQUOTE> Estimates vary, but it seems reasonable to conclude that 25 percent or more of individuals with Down syndrome over age 35 show clinical signs and symptoms of Alzheimer's-type dementia; the percentage increases with age.  In the general population, Alzheimer's disease does not usually develop prior to age 50, and the highest incidence, in people over age 65, is between 5 and 10 percent.  The incidence of Alzheimer's disease in the Down syndrome population is estimated to be 3 to 5 times greater than in the general population.  </BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What are the symptoms of Alzheimer's disease?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Early symptoms include loss of memory and logical thinking; personality change; decline in daily living skills; new onset of seizures; changes in coordination and gait; and loss of continence in bladder and bowel habits.</BLOCKQUOTE>

<B>Question:</B> <BLOCKQUOTE> Aren't these symptoms common to some other diseases and conditions, especially depression?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Yes.  Alzheimer's disease is difficult to diagnose.  It is important to be certain Alzheimer's-type symptoms do not arise from other conditions, namely thyroid disorders, depressive illness by psychiatric criteria, brain tumor, recurrent brain strokes, metabolic imbalances, and various neurological conditions.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  How is final diagnosis ascertained?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  The diagnosis of Alzheimer's disease is made on the basis of clinical history, showing a slow, steady decrease in cognitive function, and a variety of laboratory tests which provide contributory evidence, including electroencephalogram, brain stem auditory evoked response, computerized transaxial tomography, magnetic resonance imaging among other tests and measurements.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Is there a base line test that can be repeated at intervals to determine specific decrease in cognitive function?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Psychologists use questionnaires that assist in the early detection of dementia.  It is recommended that individuals with Down syndrome be tested at age 30 to provide a baseline reading, and periodically thereafter.  If the tests show deterioration, further tests must be made to rule out diseases which present similar symptoms.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What information has research yielded thus far about a link between Alzheimer's disease and Down syndrome?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Current research shows that the extra "gene dosage" caused by the abnormal third chromosome of Down syndrome may have a causative relationship for Alzheimer's disease.  Interest is also focused on the early onset of Alzheimer's in individuals with Down syndrome, which may be related to the early aging of the Down syndrome brain.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  How can research into the Alzheimer's-Down syndrome be advanced?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Research into the linkage has been slowed due to the paucity of Down syndrome brain tissue from individuals with Alzheimer's disease.  Contributions to a brain tissue repository for purposes of extending knowledge about the relationship between Down syndrome and Alzheimer's disease will help to advance research in this area.  For information for families and physicians considering such a donation, please contact the National Down Syndrome Society at 800-221-4602.</BLOCKQUOTE>


<B>SUMMARY</B><P>
<UL><h5>
*	Individuals with Down syndrome are 3 to 5 times more likely than the general population to develop Alzheimer's disease.  Onset of Alzheimer's may begin as early as age 30 in the Down syndrome population as compared to age 50 in the general population.<P>

*	Symptoms of a variety of other diseases and conditions mimic the symptoms of Alzheimer's disease:  personality change, decline in daily living skills, memory loss, changes in coordination and gait and other changes.  Diseases and conditions such as depression, thyroid disorders, brain tumor, recurrent brain strokes, metabolic imbalances, and various neurological conditions must be ruled out prior to diagnosis of Alzheimer's disease.<P>

*	It is recommended that individuals with Down syndrome take a baseline test of cognitive function at age 30, and that this test be repeated annually to determine any deterioration in this function.  Some Alzheimer's disease symptoms can be treated, although there is no current means of curing or arresting the disease.<P>

*	Current research suggests a causative link between the extra "gene dosage" from the third chromosome 21 of Down syndrome and Alzheimer's disease.  To advance research, donations of brain tissue from individuals with Down syndrome and Alzheimer's disease are being sought.<P>

</UL></H5>
<B>Books/Newsletters:</B><P>

<B>"Aging and Alzheimer's Disease in People with Down Syndrome,"</B> Wisniewski, K., Hill, A. & 	Wisniewski, H.  In: Down Syndrome: Advances in Medical Care. Lott, I. & McCoy, E. (Eds.) 	(1992).  New York, NY: Wiley-Liss, pp.167-183.  Available through Wiley-Liss, 1 Wiley 	Drive, 	Somerset, NJ 08875; tel.: (800) 225-5945.<BR>
		This chapter provides an overview of the delayed and abnormal clinical and 		neuropathological brain development in individuals with Down syndrome.  The 		chapter also includes a definition of dementia and its assessment, clinical evidence of 		aging and Alzheimer's disease, and the genetic factors related to Alzheimer's disease 		and Down syndrome. <P>

<B>"Alzheimer Disease,"</B> Lai, F.  In: Biomedical Concerns In Persons With Down Syndrome. Pueschel, 	S. & Pueschel, J. (Eds.) (1992).  Baltimore, MD: Paul H. Brookes, pp. 175-196.  Available 	through Paul H. Brookes Publishing Co., P.O. Box 10624, Baltimore, MD 21285-0624; tel.: 	(800) 638-3775.<BR>
		The chapter describes the neuropathologic, neurochemical, neuroradiologic, 		neurophysiologic, neurogenetic and clinical features of Alzheimer's disease, as they 		relate to adults with Down syndrome.  Also included are assessment, differential 		diagnosis, and management of  individuals with Down syndrome and suspected 		Alzheimers disease.<P>

<B>Alzheimer's Disease and Down Syndrome,</B> Lott, I. (1995).  New York, NY: National Down Syndrome Society.  Available through the National Down Syndrome Society, 666 Broadway, New York, NY 10012; tel.: (800) 221-4602 or (212) 460-9330.<BR>
		This booklet answers some of the most commonly asked questions about Alzheimer's 		disease and Down syndrome.  Included is information about incidence, symptoms and 		diagnosis of  Alzheimers disease in individuals with Down syndrome.<P>

<B>Developmental Disabilities and Alzheimers Disease...What You Should Know,</B> The Arc (1995).  	Arlington, TX: The Arc of the United States.  Available through The Arc of the United States, 	National Headquarters, 500 East Border Street, Suite 300, Arlington, TX 76010; tel.: (817) 	261-6003. <BR>
		This booklet provides an introduction to the risk factors, symptoms, diagnosis, and 		care for Alzheimers disease in individuals with developmental disabilities, including 		Down syndrome. <P>

<B>Down Syndrome and Alzheimer Disease: Proceedings of the National Down Syndrome Society 	Conference on Down Syndrome and Alzheimer Disease,</B> January 16 and 17, 1992, Progress 	in Clinical and Biological Research, v. 379, Nadel, L. & Epstein, C. (Eds.) (1992).  New 	York, NY: Wiley-Liss.  Available through Wiley-Liss, 1 Wiley Drive, Somerset, NJ 08875; 	tel.: (800) 225-5945. 	<BR>
		Focusing on both clinical analyses and experimental approaches, this book presents 		a comprehensive overview of current research efforts aimed at understanding the 		behavioral, neuropathological, and genetic correlations between Down syndrome and 		Alzheimers disease.<P>

<B>Practice Guidelines for the Clinical Assessment and Care Management of Alzheimer and other 	Dementias among Adults with Mental Retardation,</B> Janicki, M., Heller, T., Seltzer, G. & 	Hogg, J. (1995).  Washington, D.C.: American Association on Mental Retardation.  Available 	through AAMR - Aging Special Interest Group, 444 North Capitol Street, N.W., Suite 846, 	Washington, D.C. 20001-1512; tel.: (800) 424-3688.<BR>
		These practice guidelines provide information about the identification of Alzheimers 		disease and other dementias in adults with mental retardation.  They also provide 		information about the  care for, and management of,  individuals with Alzheimers at 		various stages of the disease.  Guidelines are geared towards caretakers, clinicians, 		program staff and peers of the individual.<P>


<B>Organizations:</B><P>

<B>Alzheimers Association</B>
919 North Michigan Avenue, Suite 1000<BR>
Chicago, IL 60611-1676<BR>
tel.: (800) 272-3900<BR>
	This organization provides information about Alzheimers disease in people with Down 	syndrome, including a reading list of selected books and articles on Down syndrome and 	Alzheimers disease.<P>
	
<B>Clearinghouse on Aging and Developmental Disabilities</B><BR>
159 Carroll Hall<BR>
University of Akron<BR>
Akron, OH 44325-5007<BR>
tel.: (800) 538-6544<BR>
	The clearinghouse provides articles and other resources pertaining to the adult issues faced 	by individuals with developmental disabilities, including Alzheimers disease.<P>

</A><HR>
<A NAME="sex">
<CENTER><B>
SEXUALITY IN DOWN SYNDROME</B><P>

by<P>

Dr. William Schwab<BR>
Associate Professor<BR>
Department of Family Medicine and Practice<BR>
University of Wisconsin<P>
</CENTER>

Human sexuality encompasses an individual's self-esteem, interpersonal relationships, and social experiences relating to dating, marriage, and the physical aspects of sex.  Sex education, appropriate for the developmental level and intellectual attainment of individuals with Down syndrome, helps in engendering healthy sexuality, preventing unwanted pregnancy and diseases, and in alleviating other problems related to sexual function.<P>

<B>Question:</B><BLOCKQUOTE>  Do individuals with Down syndrome have sexual feelings?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  In the past, sexuality was not considered an issue for young people with Down syndrome because of the inaccurate belief that mental retardation was equivalent to permanent childhood.  In fact, all people with Down syndrome do have intimacy needs, and it is important that these be recognized and planned for in education, residential and other programs and settings.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Do children with Down syndrome develop physically the same way as their peers in the general population?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Children with Down syndrome experience the same sequence of physical and hormonal changes associated with puberty as other children their age.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Do children with Down syndrome experience the emotional upheavals characteristic of adolescence?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  The emotional changes characteristic of adolescence are also present in children with Down syndrome, and may be intensified by social factors.  Any adolescent who lives in the community, attends school, and is exposed to media inevitably develops an awareness of sexuality.  Teenagers and young adults with Down syndrome often express interest in dating, marriage and parenthood.  They can be expected to experience typical adolescent changes in mood and outlook.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What kind of sex education is appropriate for individuals with Down syndrome?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  To be effective, education must be individualized and understandable, focusing not only on the physical reproductive aspects, but also positioning sexuality within the context of all interpersonal relationships.  An ideal curriculum will ensure that the individual's understanding of relationships, sexual intercourse and parenting is factual, realistic, and socially acceptable.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  How can healthy sexuality be encouraged for individuals with Down syndrome?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Creating an environment conducive to healthy sexual expression must be considered in designing educational, vocational, recreational and residential programs.  Positive sexual awareness can only develop through self-esteem, understanding of social relationships, and personal interaction/communication skills.  All these factors influence how intimacy needs are met.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Do women with Down syndrome have any special needs or concerns in regard to birth control?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Women with Down syndrome are fertile and may use any method of contraception without added medical risk.  The method chosen will depend on personal preference, ability to use the contraceptive effectively, and possible side effects.  Surgical sterilization may also be performed without added risk for women with Down syndrome who are in stable medical condition; however, availability of this procedure to women who are developmentally disabled may be controlled by state law.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Are there any special needs for individuals with Down syndrome in regard to disease prevention?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Men and women with Down syndrome have the same susceptibility to sexually transmitted diseases as the rest of the population.  Use of condoms during sexual intercourse is the best known form of protection against AIDS, herpes and other sexually transmitted diseases.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  How can a person with Down syndrome be protected against sexual abuse?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  It is highly recommended that age-appropriate education in protective behaviors should begin in childhood and be reinforced throughout the life of the person with Down syndrome.  Individuals with Down syndrome must be taught the boundaries of normal physical interactions in the social sphere, as well as the self-assertion skills to enlist help if necessary.</BLOCKQUOTE>

<B><CENTER>FEMALE SEXUALITY IN DOWN SYNDROME</CENTER></B><P>

<B>Question:</B><BLOCKQUOTE>  Do girls with Down syndrome have normal menstrual periods?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Menstruation for girls with Down syndrome is no different than for their peers in the general population.  On the average, they begin menstruating at age 12 1/2, but may begin as early as age 10 or as late as age 14 without being in any way abnormal.  Most girls with Down syndrome have regular cycles with the same minor irregularities typical of their peer group.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  If a women with Down syndrome experiences major irregularities of the menstrual cycle, what problems with this point to other than pregnancy?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Alterations in a previously regular cycle may be due to the normal process of aging, or may be a sign of emerging hyperthyroidism.  Ongoing irregularity of menstrual cycle warrants medical examination.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  If a woman with Down syndrome becomes pregnant, will the baby be normal?</BLOCKQUOTE>
<B>Answer:</B><BLOCKQUOTE>  At least half of all women with Down syndrome do ovulate and are fertile.  Between 35 and 50 percent of children born to mothers with Down syndrome will have trisomy 21 or other developmental difficulties.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  When is the onset of menopause for women with Down syndrome?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Menopause may occur at a wide range of ages.  Typically it takes place after age 40.</BLOCKQUOTE>

<CENTER><B>MALE SEXUALITY IN DOWN SYNDROME</B></CENTER><P>

<B>Question:</B><BLOCKQUOTE>  Are males with Down syndrome fertile?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Scientific information about the fertility of men with Down syndrome is limited.  While most textbooks indicate that no man with Down syndrome is known to have fathered a child, geneticists in England recently reported a case in which the paternity of a man with Down syndrome was confirmed.  It is likely that additional cases will be recognized---especially as more men have the opportunity to live in the community and develop intimate relationships.  It is not known if the offspring of men with Down syndrome are more likely to have Down syndrome or other anomalies.  It does seem clear that, in general, men with Down syndrome have a lower overall fertility rate than that of other men of comparable ages.  An individual's status can be partially assessed by having a semen analysis done, but this may not be definitive.  Therefore, if a couple desires pregnancy prevention, contraception should always be used.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Does the boy with Down syndrome mature later than his peer group in the general population?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  The onset of puberty in boys may be slightly delayed, but this is not a major factor.  Genital anatomy is comparable to that of boys who do not have Down syndrome.</BLOCKQUOTE>

<B>SUMMARY</B><P>
<UL><H5>
*	People with Down syndrome experience the same range of sexual feelings as the general population.<P>

*	Teenagers with Down syndrome undergo the same changes at puberty as all adolescents, though these changes may be slightly delayed for boys with Down syndrome.<P>

*	There is at least one known case of a man with Down syndrome fathering a child.  While the overall fertility of men with Down syndrome may be reduced, it is still advisable that couples use contraception whenever pregnancy prevention is desired.<P>

*	At least 50 percent of women with Down syndrome are fertile.  Healthy females can use contraception without added medical risk.<P>

*	Education is an appropriate and highly desirable component in developing positive sexual awareness for the individuals with Down syndrome.<P>
</UL></H5>

<B>Books/Newsletters:</B><P>

<B>Affection, Love, Intimacy, and Sexual Relationships,</B> Jurkowski, E. & Amado, A.  In: 	Friendships and Community Connections between People with and without Developmental 	Disabilities.  Amado, A. (Ed.) (1993).  Baltimore, MD: Paul H. Brookes, pp. 129-151.  	Available through Paul H. Brookes Publishing Co., P.O. Box 10624, Baltimore, MD 21285-	0624; tel.: (800) 638-3775.<BR>
		This chapter discusses the need to consider the sexuality of individuals with 		developmental disabilities, and focuses on the importance of sex education as a means 		to enhance quality of life and relationships, and to prevent sexual abuse.  The chapter 		also includes comments from individuals with disabilities, revealing how they view 		their own sexuality.<P>

<B>Couples With Intellectual Disabilities Talk about Living and Loving,</B> Schwier, K. (1994).  	Bethesda, MD: Woodbine House.  Available through Woodbine House, 6510 Bells Mill Road, 	Bethesda, MD 20817; tel.: (800) 843-7323.<BR>
		This book profiles various people with developmental disabilities who have been 		involved in meaningful intimate relationships.  These first-hand accounts reveal the 		often-ignored existence of sexuality and the desire for intimate relationships among 		individuals with intellectual disabilities.  <P>

<B>Sexuality and Community Living, </B>Schwab, W.  In: Down Syndrome: Advances in Medical Care.  	Lott, I. & McCoy, E. (Eds.) (1992).  New York, NY: Wiley-Liss, pp. 157-166.  Available 	through Wiley-Liss, 1 Wiley Drive, Somerset, NJ 08875; tel.: (800) 225-5945.<BR>
		This chapter provides a general overview of sexual development in adolescents with 		Down syndrome.  The author stresses the necessity for caregivers and health care 		providers to acknowledge the innate need of all individuals for personal intimacy, and 		to therefore consider sex education and opportunities for relationships. <P>

<B>Sexuality Education for Children and Youth with Disabilities,</B> National Information Center for 	Children and Youth with Disabilities, News Digest, Volume 1, Number 3 (1992).  	Washington, DC: NICHCY.  Available through NICHCY, P.O. Box 1492, Washington, DC 	20013-1492; tel.: (800) 695-0285.<BR>
		This packet of information includes articles on sexual development, teaching sexuality 		to children with disabilities, developing social skills and fostering relationships.  Also 		included is a list of resources.<P>

<B>Sexuality In Down Syndrome,</B> Schwab, W. (1995).  New York, NY: National Down Syndrome 	Society.  Available through the National Down Syndrome Society, 666 Broadway, New York, 	NY 10012; tel.: (800) 221-4602 or (212) 460-9330.<BR>
		This booklet answers commonly asked questions about sexuality in individuals with 		Down 	syndrome.  Information is provided about sexual feelings, physical 		development, menstruation and reproduction.  The importance of sex education 		appropriate for individuals with Down syndrome is discussed. <P>

<B>SIECUS Report,</B> Volume 23, Number 4, April/May (1995).  New York, NY: Sexuality Information 	and Education Council of the United States (SIECUS).  Available through SIECUS, 130 	West 42nd Street, Suite 350, New York, NY 10036; tel.: (212) 819-9770.<BR>
		This report includes articles on sexuality-related issues and sex education for people 		with developmental disabilities.  A comprehensive bibliography of books, teaching 		aids, curricula and newsletters covering related topics on sexuality is included.<P>

</A><HR><P>
<A NAME="neuro">
<B><CENTER>THE NEUROLOGY OF DOWN SYNDROME</B><P>

by<P>

Dr. Ira Lott<BR>
Professor of Pediatrics<BR>
University of California at Irvine<P>
</CENTER>
Neurology, the study of the human nervous system and its disorders, is important in the clinical care treatment of a person with Down syndrome.  The nervous system is always affected in Down syndrome; among the most common involvements of the nervous system are developmental disabilities (retardation in mental development and motor capabilities), hypotonia, atlantoaxial dislocation, and seizures.<P>

<B>Question:</B><BLOCKQUOTE>  What does the term "developmental disabilities" mean in relation to Down syndrome?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  This term refers to incomplete development of the brain, which leads to both mental retardation and to slowed and/or incomplete mastery of physical coordination.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What is known about brain pathology in regard to developmental difficulties?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Pathology in the Down syndrome brain includes a slightly smaller brain size for age, a shorter diameter for the anterior-posterior brain measurement, an unusually steep slope to the posterior portions of the brain, and an insufficiently developed superior temporal gyrus.  It is not known in what way these features contribute to the developmental disabilities of Down syndrome.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE> Has any progress been made in the pathology of the Down syndrome brain through research?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Research in this area is being actively pursued, especially since it may yield clues to Alzheimer's disease and to the neuroscientific effects on learning and memory.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Is IQ (intelligence quotient) a meaningful measure in Down syndrome?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  No.  IQ is not an adequate measure of the functional status of people with Down syndrome.  For example, individuals with Down syndrome may have difficulty with grammar, but understand individual words, or have a sense of when to speak, at a par with their mental age.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What can be done to help people with Down syndrome to achieve their full potential in the face of such disabilities?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  A variety of intervention programs, designed to begin in infancy and continue throughout learning years, help children with Down syndrome maximize their capabilities.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What is hypotonia?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Hypotonia refers to the reduced muscle tone that occurs in virtually all infants with Down syndrome.  It is commonly seen in the flexor group, muscles which act to flex a joint.  The muscle weakness ranges from mild to moderate to severe.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  How is hypotonia diagnosed?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Common hypotonic symptoms are a lagging head when the child is pulled into a sitting position, and arching of the back when carried upright or lying on the stomach.  In addition, hypotonic children will tire more easily and adopt movement patterns requiring the least expenditure of energy.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Are there any effective interventions for hypotonia?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Hypotonic conditions tend to improve with age.  Gross motor programs offered by occupational and physical therapists have been shown to diminish hypotonic symptoms.  These programs improve large body movements, such as walking, turning, sitting, standing and climbing stairs. Enrollment of children in an early intervention program which includes gross motor programs is recommended at the earliest feasible age, generally between 4 and 6 weeks of age.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What is atlantoaxial dislocation?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Atlantoaxial dislocation refers to a problem caused by hypotonia.  The ligaments at the first two cervical vertebra are more relaxed than they should be, putting the individual at risk of spinal cord compression and injury.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  How common is atlantoaxial dislocation?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  The cervical spine instability occurs in 10 to 20 percent of children with down syndrome; however, actual spinal compression is rare.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What are the symptoms of atlantoaxial dislocation?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  If symptoms are present, they include neck pain, change in gait, onset of weakness in the extremities, spasticity, limited neck movement, and bowel/bladder incontinence (particularly after toilet training has been accomplished).  However, most children with x-ray evidence of atlantoaxial dislocation have no apparent symptoms.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What preventive measures should be taken?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Since most children with atlantoaxial dislocation do not exhibit symptoms, lateral cervical x-rays are recommended for all children with Down syndrome after age two.  If the instability is present, but there are no symptoms, the appropriate precaution is to limit "high risk" activities which might overstress the neck.  These activities include high-jumping, diving, gymnastics, trampoline, and butterfly strokes in swimming.  To devise a safe exercise program for a symptom-free child with atlantoaxial dislocation, consult your doctor.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  Is there any treatment for atlantoaxial dislocation?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  If symptoms are present, the atlantoaxial joint can be surgically fused.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What is the incidence of seizures in Down syndrome?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  In the young child with Down syndrome, seizures are no more common than in the general population.  Beginning at age 20-30, the incidence of seizure disorder rises substantially in the Down syndrome population.  Research is ongoing as to whether the frequencies of seizures in individuals with Down syndrome is related to the aging of the brain.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What is the typical seizure for a person with Down syndrome?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Seizures for individuals with Down syndrome commonly look like epileptic seizures:  jerking of arms and legs, and loss of consciousness.  Seizures can also take a mixed form, with staring spells and momentary lapses of attention.</BLOCKQUOTE>

<B>Question:</B><BLOCKQUOTE>  What is the treatment for seizures?</BLOCKQUOTE>

<B>Answer:</B><BLOCKQUOTE>  Seizures can be controlled with standard anti-convulsant medication.</BLOCKQUOTE>


<B>SUMMARY</B><P>
<UL><H5>
*	The most common involvements of the nervous system in Down syndrome are hypotonia, atlantoaxial dislocation, and seizures.<P>

*	The reduced muscle tone of hypotonia affects most infants with Down syndrome and ranges from mild to severe.<P>

*	Hypotonic conditions improve with age; however, gross motor movement programs provided by physical and occupational therapists have been proven useful in diminishing the symptoms of hypotonia.<P>

*	Atlantoaxial dislocation refers to a weakness of neck muscles that affects approximately 10 to 20 percent of children with Down syndrome.  Most cases are asymptomatic.  Preventive measures against neck injuries call for lateral cervical x-rays for all children with Down syndrome after age 2.  If atlantoaxial dislocation is present, high-risk activities such as jumping, diving, etc., should be limited.<P>

*	In cases of atlantoaxial dislocation where symptoms are present, the atlantoaxial joint can be surgically fused.<P>

*	Seizures are equally common in the child with Down syndrome as compared to the general same-age population.  After age 20, the incidence of seizures in the Down syndrome population increases substantially as compared to the general population.  Seizures can be controlled by standard anti-convulsant medication.<P>
</UL></H5>

<B>Books/Newsletters:</B><P>

<B>The Central Nervous System.  </B>In: Medical Care in Down Syndrome: A Preventive Medicine 	Approach. Rogers, P. and Coleman, M. (1992).  New York: Marcel Dekker, Inc., pp. 201-	224.  Available through Marcel Dekker, Inc., 270 Madison Avenue, 4th Floor, New York, 	NY 10016; tel.: (212) 696-9000.<BR>
		This chapter provides medical information about the brains structure and function in 		individuals with Down syndrome.  Specific topics discussed include sleep disturbances, 		seizure disorders, behavior disorders, aging and Alzheimers disease. <P>

<B>\223Neurologic Abnormalities, </B>Florez, J.  In: Biomedical Concerns in Persons with Down Syndrome. 	Pueschel, S. and Pueschel, J., (Eds.) (1992). Baltimore, MD: Paul H. Brookes Publishing Co., 	pp. 159-173.  Available through Paul H. Brookes Publishing Co., P.O. Box 10624, Baltimore, 	MD 21285-0624; tel.: (800) 638-3775.<BR>
		This chapter focuses on information about morphologic alterations, neurochemical 		alterations and neurophysiologic alterations.  Also discussed are brain activity related 		to learning and language, and epilepsy and seizures in individuals with Down 		syndrome.<P>

<B>Neurological and Neurobehavioral Disorders in Down Syndrome, </B>Lott, I.  In: Down 	Syndrome: Advances in Medical Care.  Lott, I., and McCoy, E. (Eds.) (1992).  New York, 	Wiley-Liss, Inc., pp. 103-109.  Available through Wiley-Liss, 1 Wiley Drive, Somerset, NJ 	08875; tel.: (800) 225-5945.<BR>
		This chapter explains the brain function in individuals with Down syndrome.  Seizure 		disorders, hypotonia, atlantoaxial instability and neurobehavioral aspects of Down 		syndrome are discussed briefly.<P>

<B>Neurology of Children with Down Syndrome,</B> Mattheis, P.  In: Medical & Surgical Care for 	Children with Down Syndrome: A Guide for Parents.  Van Dyke, D., Mattheis, P., Eberly, 	S., Williams, J. (Eds.) (1995). Bethesda, MD: Woodbine House, Inc., pp. 267-287.  Available 	through Woodbine House, Inc., 6510 Bells Mill Road, Bethesda, MD 20817; tel.: (800) 843-	7323.<BR>
		This chapter discusses the ways in which Down syndrome affects the nervous system, 		including differences in thought, speech, learning and muscle control.  The author 		provides an overview of some of the neurologic conditions which occur more 		frequently in individuals with Down syndrome, and some of the treatment alternatives 		available.<P>

<B>The Neurology of Down Syndrome.</B> Lott, I. (1995). New York: National Down Syndrome Society.
	Society.  Available through the National Down Syndrome Society, 666 Broadway, New York, 	NY 10012; tel.: (800) 221-4602 or (212) 460-9330.<BR>
		This booklet answers questions about how the nervous system is affected in individuals 		with Down syndrome.  The most common impacts, including developmental 		disabilities, hypotonia, atlantoaxial dislocation and seizures, are discussed.<P>

</A>
<HR>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: January 28th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>

</BODY></HTML>



</DOC>
<DOC>
<DOCNO>WT01-B04-256</DOCNO>
<DOCOLDNO>IA090-000969-B048-360</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/edu.html 206.249.5.81 19970117204339 text/html 43343
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 20:45:17 GMT
Last-modified: Wednesday, 27-Nov-96 23:27:28 GMT
Content-length: 43150
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>
EDUCATIONAL INFORMATION
</TITLE><BODY BACKGROUND="/gif/background.gif"><BODY>
<A NAME="facts">
<H2><CENTER>EDUCATIONAL INFORMATION</H2></CENTER><P><HR>

Creative approaches to inclusive schooling are being discovered throughout the United States every day as parents and educators work together to meet the unique needs of their students. Today it is common to see youngsters with Down syndrome, in  every part of the country, included in their neighborhood schools. Boys and girls, in rural, urban, and suburban locations, at the preschool, elementary, and secondary level are able to enjoy the company of their peers and the activities of the regular school setting.<P>

Inclusion in the regular classroom is only one of the many options available to children with Down syndrome. It is, however, an important one. This brochure is designed to familiarize you with the philosophy and practice of inclusion and in doing so, help you make the most informed decision about your child's education. <P>

<B><CENTER>INCLUSION IS...</B></CENTER><P>

<B>A PHILOSOPHY.</B> It is a belief in every person's inherent right to participate fully in society. Inclusion implies acceptance of differences. It means making room for a person who would otherwise be excluded. Translating this philosophy into reality is a process that requires collaboration, teamwork, flexibility, a willingness to take risks, and support from a whole array of individuals, services, and institutions. <P>

<B>A PRACTICE.</B> It is the educational process by which all students, even those with disabilities, are educated together, with sufficient support, in age-appropriate, regular education programs in their neighborhood schools. The goal of inclusive education is to prepare all students for productive lives as full, participating members of their communities.<P>

<B>EVOLVING.</B> As people learn more about inclusion, they understand that "full inclusion" means that students with Down syndrome are part of the regular education system--even if their curricular goals and needs differ from those of their classmates.<P>

<B>REWARDING FOR ALL PEOPLE INVOLVED.</B> When inclusion is carried out appropriately, research has demonstrated benefits to students with Down syndrome as well as to their peers. Friendships develop, students without disabilities learn to appreciate differences, and students with disabilities are more motivated. All of this is carried home and into the community.<P>

<B><CENTER>INCLUSION IS NOT....</B></CENTER>

<B>A PASSING FAD.</B> Numerous federal district court decisions have affirmed the right of students with Down syndrome to attend regular classes full time when the educational benefits for the student warrant such a placement. Inclusion, with its focus on outcomes, is the spirit of the Individuals with Disabilities Education Act (IDEA) and the trend for the future.  <P>

<B>DUMPING.</B> It does not mean that a child with special needs is placed in a classroom without adequate support and appropriate services. It does not mean that undue burdens are placed on teachers and peers. Thoughtful planning, continual monitoring, and sufficient support are all part of successful inclusion programs.<P>
 
<B>EASY.</B> Parents, educators, peers, and administrators are all partners in the inclusion process and must work together to make it successful. On-going problem solving is involved.<P>

<B>MAINSTREAMING.</B> Inclusion is more than mainstreaming. Mainstreaming implies that a child from a special education class visits the regular class for specific, usually non-academic, subjects. Inclusion means that a student with special needs is part of the regular class, even if he or she receives occasional services in another setting.<P>

<B><CENTER>WHAT MAKES INCLUSION SUCCESSFUL?</B></CENTER>

<B>*A Commitment to the philosophy of inclusion</B> and a belief in the equal value of all students must be shared by everyone. Many school districts make explicit mention in their mission statements that the educational goals of students with disabilities are of equal value to those of other students. <P>

<B>*Accountability</B> assures that all individuals, at the district, building, and classroom level delegate tasks appropriately and fulfill their responsibilities. The department of special education should have clearly defined policies for program implementation.<P>

<B>*Careful assessment and planning</B> guarantees that the student's curriculum is appropriate; adequate support is provided; and long and short-term goals are met. Assessment should focus on the child's strengths, and parents should actively participate in the design of the Individualized Education Program (IEP).<P>

<B>*Collaboration</B> requires that all participants be equal partners. Teachers will be working together in and out of the classroom; peers will become allies and friends; and parents will continually be interacting with the school system. The need for teamwork is constant and only through cooperative effort does inclusion work.<P>

<B>*Flexibility</B> must be present at every stage of the inclusion process. Because teaching models are often altered, curriculum adaptations made, and unique needs addressed, all participants must be willing to accept compromise and try new situations.<P>

<B>*Funding</B> must be available for the necessary support services. Some research has shown that districts which are implementing inclusion are not spending more than their segregated counterparts; rather, they are shifting costs.<P>

<B>*Good Leadership</B> sets the tone for the entire process. Principals and superintendents must convey a positive attitude towards inclusion and foster a supportive environment in which new and challenging situations are dealt with in a flexible manner. Teachers who have the encouragement and backing of their supervisors are often the most successful initiators of change. <P>

<B>*Social skills and peer relationships</B> are two of the most important foundations for, and by-products of, inclusion. Peers are positive role models for speech and appropriate behavior. As allies and friends, peers offer support in and out of the classroom: in cooperative learning situations; in peer support groups; and in after school activities. Friendships develop which extend beyond the classroom. <P>

<B>*Support</B> includes everything necessary to meet the goals established in the IEP. Additional personnel may be present in the classroom; peers may form a support network; curricula may be adapted; teaching methods may change; physical accommodations may be made; and therapies may be given. Support can be extensive or minimal, depending on the needs of the particular student. For teachers, support may mean encouragement from supervisors; collaboration with peers; team teaching; feedback from parents; or access to the many resources available on inclusion.<P>

<B>*Transition planning</B> alleviates potential problems. Before the school year begins, teachers and staff should have appropriate training; the student with Down syndrome should be familiar with his or her surroundings; and peers should receive orientation.  Knowledge about Down syndrome, and the abilities of people with Down syndrome, will lessen the apprehension of teachers and classmates.<P>

<B><CENTER>WHAT CAN YOU DO TO FOSTER YOUR CHILD'S INCLUSION?</B></CENTER><P>

<B>*Become aware of your rights under federal and state laws.</B> Learn about IDEA and what it means for your child. If you request an appropriate inclusion program, your school system is required to provide it. A child cannot be placed in a more restrictive environment unless the school system has shown that inclusion was unsuccessful despite the provision of appropriate support and services. <P>

<B>*Communicate with the school system.</B> Help administrators and teachers develop methods that will work well. Provide insight and awareness regarding the needs and goals of your child. <P>

<B>*Learn about successful inclusion practices.</B> Contact parents, organizations, and schools that have made inclusion work. Write for information from the growing number of national organizations that have a proven commitment to inclusion. Form support networks. Avail yourself of the numerous publications and videos available. <P>

<B>*Participate in the design of your child's IEP.</B> The goals and objectives listed in the IEP will determine not only what your child is taught, but how and where that teaching will take place.<P>

Since the passage of Public Law 94-142 in 1975, educational options for children with Down syndrome have expanded greatly. IEPs are now provided for all children with special needs; parent involvement in the planning process is sought; and advocacy and support is widely available. Inclusion represents the latest effort to provide all children with the best education possible in the diversity of their neighborhood school.<P>

For more information about materials to help you along the road to inclusion, or parent groups that may have experience working with schools, contact the National Down Syndrome Society, 666 Broadway, New York, NY  10012. We're here to help.<P>


<B><CENTER>TERMINOLOGY</B></CENTER><P>

<B>Cooperative Learning</B>--A group of students with diverse skills and traits working together. This promotes collaboration, teamwork, and an appreciation of differences while fostering long-term relationships.<P>

<B>IDEA</B>--The federal law supporting special education and related service programming for children and youth with disabilities.  Also referred to as Public Law 101-476, IDEA reauthorized and expanded the provisions guaranteed under Public Law 94-142 in 1990. <P>

<B>Public Law 94-142</B>--The Education for All Handicapped Children Act of 1975. This law mandates a free appropriate public education (FAPE) for all children with disabilities; education in the least restrictive environment (LRE); and individualized education programs. It ensures due process rights and is the core of federal funding for special education. It was renamed and amended in 1990 and is now known as IDEA.<P>

<B>FAPE</B>--A free appropriate public education refers to special education and related services which are provided at public expense to meet the educational goals defined in the child's IEP.<P>

<B>IEP</B>--The individualized education program is the written plan for each school year which delineates the goals and special services necessary to meet the child's needs. Parents, teachers, and administrators take part in the preparation of the child's IEP for the academic year.<P>

<B>LRE</B>--The least restrictive environment provision of the IDEA states that to the maximum extent appropriate, children with disabilities are educated with children who do not have disabilities "and that special classes, separate schooling, or other removal of .... children from the regular educational environment occurs only when the nature or severity of the handicap is such that education in regular classes with the use of supplementary aids and services cannot be achieved satisfactorily."<P>

<B>Teaching</B>--A broad term referring to different groupings of teachers. One common method is to have a regular education teacher team up with a general education teacher and together be responsible for all the children of the class. All team teaching is based on shared responsibility and collaboration.<P>

</A>
<A NAME="res">
<H3><CENTER>INCLUSIVE EDUCATION FOR CHILDREN WITH DOWN SYNDROME</H3><P>

-RESOURCE LIST-</CENTER><P>


This list will familiarize you with organizations, publications, and other materials that present a commitment to the philosophy and practice of inclusion. The list is not exhaustive and will continue to be updated. Inclusion on the list should not be considered an endorsement by the National Down Syndrome Society. <P>


<B><CENTER>ORGANIZATIONS</B></CENTER><P>
<B>American Association of University Affiliated Programs (AAUAP)</B><BR>
8630 Fenton Street, Suite 410<BR>
Silver Spring, MD  20910<BR>
(301) 588-8252<BR>
<I>	AAUAP is the central office for the 61 University Affiliated Programs (UAPs) and is their representative to the federal government. UAPS are located at major universities and teaching hospitals in all states. These multidisciplinary centers support the independence, productivity, integration, and inclusion into the community of individuals with developmental disabilities and their families. Services provided by UAPs vary according to state; but in general, each one provides direct services, conducts research, designs programs, and provides practical training. For information on the UAP nearest you, contact the above number.</I><P>

<B>Center on Human Policy</B><BR>
Syracuse University<BR>
200 Huntington Hall<BR>
Syracuse, NY  13244-2340<BR>
(315) 443-3851<BR>
<I>	The Center on Human Policy is a research, policy, and advocacy organization involved in the national movement to insure the rights of people with disabilities. The Center distributes a variety of reports and resources on the integration of people with disabilities into community life. Among these materials is an "inclusion packet" which contains sample case studies, reprints of chapters and articles, a list of important factors in inclusion,  and a bibliography.</I><P>

<B>Cooke Foundation for Special Education</B><BR>
456 West 52nd Street<BR>
New York, NY  10019<BR>
(212)245-3376<BR>
<I>	The Cooke Foundation for Special Education is a not-for-profit organization dedicated to advocating and providing inclusive education placements for children with disabilities in New York City. The Cooke Foundation is the only private program which helps students and their parents locate regular elementary schools (public, private, and parochial) interested in including children with disabilities and provides the necessary supports (consulting teachers, teaching assistants, staff development, etc.) to enable these students to succeed in regular school environments.</I><P>

<B>Down Syndrome Association of Greater Cincinnati (DSAGC)</B><BR>
1821 Summit Road, Suite G-20<BR>
Cincinnati, OH  45237<BR>
(513) 761-5400<BR>
<I>	A parent support organization which distributes an "Inclusion Packet" containing information on the philosophy, laws, strategies, and resources pertaining to inclusion.</I><P>

<B>Expectations Unlimited, Inc.</B><BR>
P. O. Box 655<BR>
Niwot, CO  80544<BR>
(303) 652-2727<BR>
<I>	Expectations Unlimited, Inc. distributes video presentations and conference recordings on many aspects of Inclusive Education. Their collection includes the conferences sponsored by the Colorado Coalition for Inclusive Education.</I><P>

<B>Federation for Children with Special Needs</B><BR>
95 Berkeley Street, Suite 104<BR>
Boston, MA 02116<BR>
(617) 482-2915<BR>
<I>	National office of the federally funded Parent Training and Information Centers. The centers are designed to make parents aware of their legal rights under P.L. 94-142 and to provide information, advocacy, and training. Parents can locate their state office by calling the above number.</I><P>

<B>Inclusion Press/Centre for Integrated Education and Community</B><BR>
24 Thome Crescent<BR>
Toronto, Ontario M6H 2S5<BR>
CANADA<BR>
(416) 658-5363 <BR>
(416) 658-5067 (fax)<BR>
<I>	Directed by Dr. Marsha Forest and Dr. Jack Pearpoint, this rganization and publishing house provides books, videos, and printed matter regarding inclusion. In addition, they publish a newsletter called, "Inclusion News," and provide seminars and workshops on the philosophy and practice of inclusion. </I><P>

<B>Institute on Community Integration</B><BR>
University of Minnesota<BR>
150 Pillsbury Drive, S. E.<BR>
Minneapolis, MN  55455<BR>
(612) 624-4512 (publications)<BR>
(612) 624-6300 (general information)<BR>
<I>	The Institute's efforts are directed at facilitating the independence of citizens with disabilities and their social integration into the mainstream of community life. The Institute conducts over 60 projects that provide training, service and consultation, research, and information dissemination. Information on inclusion, as well as other topics, is available through newsletters, resource guides, training manuals, research reports, curricula, and brochures.</I><P>
		
<B>National Center on Educational Restructuring and Inclusion (NCERI)</B><BR>
The Graduate School and University Center<BR>
The City University of New York<BR>
33 West 42 Street<BR>
New York, NY  10036<BR>
(212) 642-2656<BR>
<I>	NCERI promotes and supports educational programs where all students are served effectively in inclusive settings. Toward this goal, NCERI addresses issues of national and local policy, conducts research, provides training and technical assistance, and disseminates information about programs, practices, evaluation, and funding of inclusive education programs.</I><P>

<B>National Information Center for Children and Youth with Disabilities (NICHCY)</B><BR>
P. O. Box 1492<BR>
Washington, DC  20013-1492<BR>
1-800-695-0285<BR>
(202) 884-8200<BR>
<I>	NICHCY is a federally funded information clearinghouse that provides free information on disabilities and disability-related issues. Provides clearly written booklets and resource listings regarding special education services. </I><P>

<B>National Parent Network on Disabilities</B><BR>
1600 Prince Street, Suite 115<BR>
Alexandria, VA  22314<BR>
(703) 684-6763<BR>
<I>	Sponsors "All Children Belong," an inclusion training project, and acts as a national advocacy and lobbying organization on behalf of children and adults with disabilities. Provides written information on inclusion.</I><P>

<B>Parent Advocacy Coalition for Educational Rights (PACER) Center</B><BR>
4826 Chicago Avenue South<BR>
Minneapolis, MN  55417-1098<BR>
(612) 827-2966<BR>
<I>	PACER Center is a coalition of organizations founded on the concept of Parents Helping Parents. The Center conducts workshops, provides training, and disseminates information related to special education and disabilities. </I><P>

<B>Parent Education and Assistance for Kids (PEAK) Parent Center, Inc.</B><BR>
6055 Lehman Drive, Suite 101<BR>
Colorado Springs, CO  80916<BR>
(719) 531-9400<BR>
<I>	PEAK is the Focus Center on Inclusion for the Technical Assistance for Parents Program (TAPP) project of Parent Training and Information Centers nationwide. The center develops and distributes informational materials, curricula, training guides, and a newsletter. In addition, PEAK is a co-sponsor of the annual Strategies for Inclusive Education Conference. </I><P>

<B>Schools Are For Everyone (SAFE)</B><BR>
P. O. Box 9503<BR>
Schenectady, NY  12309<BR>
(518) 377-8074<BR>
<I>	National  organization whose primary function is to support the placement of children in inclusive settings. Provides general information regarding inclusion: how to advocate for inclusion; how to impact on legislation at the local, state, and federal level; and how to locate local SAFE chapters. In addition, provides assistance on legal questions regarding inclusion. </I><P>

<B>Special Education Resource Center (SERC) </B><BR>
25 Industrial Park Road<BR>
Middletown, CT  06457<BR>
(203)632-1485<BR>
<I>	SERC is an information clearinghouse which provides annotated bibliographies and resource listings regarding inclusion.  Its mission is to serve as a centralized resource for professionals, families, and community members regarding early intervention, special education and pupil services, and transition-to-adult life for individuals with special needs.</I><P>

<B>The Association for Persons with Severe Handicaps (TASH)</B><BR>
11201 Greenwood Avenue<BR>
N. Seattle, WA  98113<BR>
1-800-482-TASH<BR>
<I>	TASH is a national organization which is devoted to promoting the full inclusion of people with disabilities and to eradicating the injustices and inequities experienced by these individuals. TASH gathers and disseminates information; advocates on behalf of people with disabilities; and supports research, education, and judicial efforts. A newsletter, a journal, and other materials are available through the organization.</I><P>


<B><CENTER>NEWSLETTERS AND BULLETINS</CENTER></B><P>

<B>Inclusion News.</B> Published by Inclusion Press, 24 Thome Crescent, Toronto, Ontario M6H 2S5, CANADA. Tel.: (416) 658-5363; fax: (416) 658-5067. <BR>
<I>An annual publication edited by Marsha Forest and Jack Pearpoint which presents articles, resource listings, poetry, letters, and diagrams devoted to promoting full inclusion.</I><P>

<B>Inclusion Times.</B> Published by National Professional Resources, Inc., 25 South Regent Street, Port Chester, NY  10573. Tel.: (914) 937-8879, or 1-800-453-7461.<BR>
<I>A quarterly newsletter focusing on serving children and youth with disabilities in regular education and other inclusive learning environments; attempts to present a balanced viewpoint regarding inclusion.</I><P>

<B>Inclusive Education Programs: Advice on Educating Students with Disabilities in Regular Settings.</B> Published by LRP Publications, Dept. 430, 747 Dresher Road, P. O. Box 980, Horsham, PA  19044-0980. Tel.: 1-800-341-7874, ext. 275; fax: (215) 784-9639.<BR>
<I>A monthly publication which offers legal perspectives on the process of inclusion and presents articles on programs, organizations, laws, and strategies.</I><P>

<B>NCERI Bulletin.</B> Published by the National Center on Educational Restructuring and Inclusion, The Graduate School and University Center, The City University of New York, 33 West 42 Street, New York, NY  10036-8099. Fax: (212) 642-1972.<BR><I>
A quarterly publication which highlights the activities of the Center and provides in-depth coverage of educational issues relating to inclusion.</I><P>

<B>TASH Newsletter.</B> Published by The Association for Persons with Severe Handicaps, 11201 Greenwood Avenue North, Seattle, WA  98133. Tel.: (201) 361-8870; fax: (206) 361-9208.<BR><I>
A monthly publication which provides information on all aspects of the education of people who have severe/profound disabilities.</I><P>


<B><CENTER>VIDEOS</B></CENTER><P>

<B><I>Bittersweet Waltz.</I></B> Produced by L. Safan. (1993). Available through National Down Syndrome Society, 666 Broadway, 8th Floor, New York, NY  10012-2317. Tel.: 1-800-221-4602; fax: (212) 979-2873.<BR>
<I>A 17 minute video about inclusion designed as an educational tool for parents seeking to have their children included in a regular elementary classroom. The video presents inclusion from a visual point of view, with some on-camera discussion. The feelings and insights of classmates are poignant.</I><P>

<B><I>Choices.</I></B> Produced by Comforty Mediaconcepts for the Illinois State Board of Education, Department of Special Education. Available through Comforty Mediaconcepts, 2145 Pioneer Road, Evanston, IL 60201. Tel.: (708) 475-0791; fax: (708) 475-0793.<BR>
<I>A thorough introduction to the philosophy and practice of inclusion. This video presents four personalized stories about how inclusion has affected the lives of people with disabilities, including people with Down syndrome. Interviews with families, friends, classmates, and co-workers provide a thoughtful means of addressing the multifaceted nature of the inclusion process. </I><P>

<B><I>Educating Peter.</I></B> Produced by T. Goodwin and G. Wurzburg for HBO. (1992). Available through Direct Cinema Limited, P. O. Box 10003, Santa Monica, CA  90410. Tel.: 1-800-525-0000.<BR>
<I>Awarded the Academy Award for Best Documentary Short Film 1992, this thought-provoking film follows a child with Down syndrome through a year of inclusion in a public school. The film raises many questions about inclusion by honestly presenting the reactions to, and methods of, dealing with Peter's behavior problems. *Some people have found the presentation of Peter's behavior to be inappropriate and misleading.</I><P>

<B><I>Families, Friends, Futures.</I></B> Produced by Comforty Mediaconcepts for the Illinois State Board of Education, Department of Special Education. Available through Comforty Mediaconcepts, 2145 Pioneer Road, Evanston, IL 60201. Tel.: (708) 475-0791; fax: (708) 475-0793.<BR>
<I>This video focuses on two students who have been fully included in their local school program. It explores the encouraging effect such participation has had on their families' views of their futures.</I><P>

<B><I>Inclusion.</I></B> Produced by Norman Baxley & Associates. (1994). Available through Baxley Media Group, 110 West Main Street, Urbana, IL  61801. Tel.: (217) 384-4838, fax: (217) 384-8280.<BR>
<I>Reed Martin, Attorney at Law, explains recent Federal Circuit Courts of Appeals decisions relating to inclusion and addresses many questions about legal issues surrounding the education of children with disabilities.</I><P>

<B><I>Inclusion: Bernardsville Beginnings.</I></B> Edited by In Focus, Bedminister, NJ. (1993). Available through National Down Syndrome Society, 666 Broadway, 8th Floor, New York, NY  10012. Tel.: 1-800-221-4602; fax: (212) 979-2873.<BR>
<I>A 23 minute video which follows Alison through her first full year in a first grade inclusion program. It is a step-by-step account of teaching staff preparation and classroom experience. The video presents a picture of one girl's successful adjustment to education in an inclusive environment and a whole class's maturation by the experience.</I><P>

<B><I>Sean's Story: Ready for School. Produced by ABC News. (1994). Available through ABC News Video Order Department. Turning Point segment from September 7, 1994. Tel.: 1-800-913-3434.</I></B>
<I>This video portrays two different outlooks on the education of children with Down syndrome: inclusion versus a special school. It is a thoughtful portrayal of two families who choose different paths in an attempt to provide their children  with the best education possible.</I><P>

<I><B>Together We're Better.</I></B> (1992) Produced by Comforty Mediaconcepts. Available through Comforty Mediaconcepts, 2145 Pioneer Road, Evanston, IL 60201. Tel.: (708) 475-0791; fax: (708) 475-0793.<BR>
<I>A series of three videos which encourage inclusive approaches in school and community life. The videos feature Dr. Marsha Forest, Dr. Jack Pearpoint, and Ms. Judith Snow conducting a workshop on inclusion. They emphasize the necessity of adequate support systems and sustained, cooperative effort. The videos address the rewards and challenges of implementing an inclusive program.</I><P>

<B><I>Two Faces of Inclusion: The Concept and The Practice and Facing Inclusion Together Through Collaboration and Co-Teaching.</I></B> (1994). Produced by L. Burrello, J. Burrello, and J. Winninger. Available through CASE Research Committee, Indiana University-Smith Research Center, Suite 103A, 2805 E. 10th Street, Bloomington, IN  47405. Tel.: (812) 855-5090.<BR>
<I>A two-video set addressing the multifaceted issue of inclusion. Interviews with Doug Biklen, Wayne Sailor, Tom Skrtic, and with administrators, teachers, and parents. The first video is narrated by Lou Brown, University of Wisconsin at Madison, the second by Marilyn Friend, Indiana University.</I><P>

<B><I>With Kids my Age: Answers to Questions about Inclusion.</I></B> Produced by Inclusion Works! Available through The ARC of Texas, 1600 West 38th, #200, Austin, TX  78731. Tel.: (512) 454-6694.<BR>
<I>An honest look at inclusive education in the elementary and secondary school level. Students, parents, teachers, and school administrators address the most pressing questions about inclusion.</I><P>


<B><CENTER>BOOKS</CENTER></B><P>

<B><I>Beyond Separate Education:Quality Education For All.</I></B> Kerzner Lipsky, D., & Gartner, A.(Eds.) (1989). Baltimore, MD: Paul H. Brookes Publishing Co. Available through Paul H. Brookes Publishing Co., P. O. Box 10624, Baltimore, MD  21285-0642. Tel.: 1-800-638-3775; fax: (410) 337-8539.<P>

<B><I>Breaking Ground: Ten Families Building Opportunities Through Integration.</I></B> Schaffner, C. B., & Buswell, B. E. (1989). Available through PEAK Parent Center, Inc., Integration Project, 6055 Lehman Drive, Suite 101, Colorado Springs, CO  80918. Tel.: (719) 531-9400.<P>

<B><I>Choosing Options and Accommodations for Children (COACH): A Guide to Planning Inclusive Education.</I></B> Giangreco, M., Cloninger, C., and Iverson, V. (1993). Baltimore, MD: Paul H. Brookes Publishing Co. Available through Paul H. Brookes Publishing Co., P. O. Box 10624, Baltimore, MD  21285-0642. Tel.: 1-800-638-3775; fax: (410) 337-8539.<P>

<B><I>Circles of Friends: People with Disabilities and Their Friends Enrich the Lives of One Another.</I></B> Perske, R. (1988). Nashville, TN: Abingdon Press. Available through Abingdon Press, 201 Eighth Avenue South, Nashville, TN 37203. Tel.: (615) 749-6000.<P>

<B><I>The Comprehensive Local School: Regular Education for all Students with Disabilities.</I></B> Sailor, W., Anderson, J. L., Halverson, A. T., Doering, K. F., Filler, J., & Goetz, L. (1989). Baltimore, MD: Paul H. Brookes Publishing Co. Available through Paul H. Brookes Publishing Co., P. O. Box 10624, Baltimore, MD  21285-0642. Tel.: 1-800-638-3775; fax: (410) 337-8539.<P>

<B><I>Connecting Students: A Guide to Thoughtful Friendship Facilitation for Educators & Families.</I></B> Schaffner, C. B., & Buswell, B. E. (1992). Available through PEAK Parent Center, Inc., Integration Project, 6055 Lehman Drive, Suite 101, Colorado Springs, CO  80918. Tel.: (719) 531-9400.<P>

<B><I>Count Us In: Growing Up with Down Syndrome.</I></B> Kingsley, J., & Levitz, M. (1993). New York: Harcourt Brace & Company. Available through Harcourt Brace & Company, 15 East 26th Street, New York, NY  10010. Tel.: 1-800-543-1918; fax: (212) 592-1010.<P>

<B><I>Curriculum Considerations in Inclusive Classrooms--Facilitating Learning for all Students.</I></B> Stainback, S., & Stainback, W. (1992). Baltimore, MD: Paul H. Brookes Publishing Co. Available through Paul H. Brookes Publishing Co., P. O. Box 10624, Baltimore, MD  21285-0642. Tel.: 1-800-638-3775; fax: (410) 337-8539.<P>

<B><I>Creativity and Collaborative Learning: A Practical Guide to Empowering Students and Teachers.</I></B> Thousand, J. S., Villa, R. A., & Nevin, A. I. (1994). Baltimore, MD: Paul H. Brookes Publishing Co. Available through Paul H. Brookes Publishing Co., P. O. Box 10624, Baltimore, MD  21285-0642. Tel.: 1-800-638-3775; fax: (410) 337-8539.<P>

<B><I>Discover the Possibilities: A Curriculum for Teaching Parents about Integration.</I></B> Schaffner, C. B., & Buswell, B. E. (1988). Colorado Springs, CO: PEAK Parent Center. Available through PEAK Parent Center, Inc., Integration Project, 6055 Lehman Drive, Suite 101, Colorado Springs, CO  80918. Tel.: (719) 531-9400.<P>

<B><I>Educating all Students in the Mainstream of Special Education.</I></B> Stainback, S., Stainback, W., & Forest, M. (1989). Baltimore, MD: Paul H. Brookes Publishing Co. Available through Paul H. Brookes Publishing Co., P. O. Box 10624, Baltimore, MD  21285-0642. Tel.: 1-800-638-3775; fax: (410) 337-8539.<P>

<B><I>Extraordinary Children, Ordinary Lives: Stories behind Special Education Law.</I></B> Martin, R. (1991). Champaign, IL: Research Press. Available through Baxley Media Group, 110 W. Main, Urbana, IL 61801. Tel.: (217) 384-4838; fax: (217) 384-8280.<P>

<B><I>How to Get Services by Being Assertive.</I></B> Des Jardins, C. (1993). Illinois: Family Resource Center on Disabilities. Available through the Family Resource Center on Disabilities, 20 East Jackson Boulevard, Room 900, Chicago, IL 60604. Tel.: (312) 939-3513; fax: (312) 939-3519.<P>

<B><I>The Inclusion Papers: Strategies to Make Inclusion Work.</I></B> Pearpoint, J., Forest, M., & Snow, J. (1992). Toronto, Ontario, Canada: Inclusion Press. Available through Inclusion Press, 24 Thome Crescent, Toronto, Ontario, Canada M6H 2S5. Tel.: (416) 658-5363; fax: (416) 658-5067.<P>

<B><I>Nasty Girls, Thugs, and Humans Like Us: Social Relations Between Disabled and Nondisabled Students in High School.</I></B> Murray-Seegart, C. (1989). Baltimore, MD: Paul H. Brookes Publishing Co. Available through Paul H. Brookes Publishing Co., P. O. Box 10624, Baltimore, MD  21285-0642. Tel.: 1-800-638-3775; fax: (410) 337-8539.<P>

<B><I>Opening Doors: Strategies for Including all Students in Regular Education.</I></B> Schaffner, B. & Buswell, B. E. (1992). Colorado Springs, CO: PEAK Parent Center. Available through PEAK Parent Center, Inc., Integration Project, 6055 Lehman Drive, Suite 101, Colorado Springs, CO  80918. Tel.: (719) 531-9400.<P>

<B><I>Restructuring for Caring and Effective Education: An Administrative Guide to Creating Heterogeneous Schools.</I></B> Villa, R., Thousand, J., Stainback, W., & Stainback, S. (Eds.) (1992). Baltimore, MD: Paul H. Brookes Publishing Co. Available through Paul H. Brookes Publishing Co., P. O. Box 10624, Baltimore, MD  21285-0642. Tel.: 1-800-638-3775; fax: (410) 337-8539.<P>

<B><I>Schooling Without Labels: Parents, Educators, and Inclusive Education.</I></B> Biklen, D. (1992). Philadelphia, PA: Temple University Press. Available through Temple University Press, USB Room 305, Broad and Oxford Streets, Philadelphia, PA  19122. Tel.: (215) 204-8787.<P>

<B><I>You, Your Child, and "Special" Education: A Guide to Making the System Work.</I></B> Cutler, B. C. (1993). Baltimore, MD: Paul H. Brookes Publishing House. Available through Paul H. Brookes Publishing Co., P. O. Box 10624, Baltimore, MD  21285-0642. Tel.: 1-800-638-3775; fax: (410) 337-8539.
<hr>
<a NAME="study">
<h3>Nationwide Study Finds Inclusive Education Rewarding for All Involved</h3><br>

The inclusion of students with Down syndrome in typical classrooms is a more rewarding experience than expected for both students and classmates, according to a recently released national study.
<p>
Inclusion is the educational process by which all students, with or without disabilities, are educated together, with sufficient support, in age-appropriate, regular education programs in their neighborhood schools. Support is often provided in a "push-in" (in-class aid), or "pull-out" (visits to a resource room) basis.
<p> 
The majority of teachers who participated in the nationwide study, commissioned by the National Down Syndrome Society (NDSS) and conducted by Gloria Wolpert, Ed.D., reported that entire classes benefit from working with a student with Down syndrome. Almost all teachers who responded found inclusion enjoyable, with some calling it the single most interesting and rewarding experience of their careers.
The NDSS study was conducted to determine the success, or lack of success, of inclusive practices, and to identify the common characteristics of the most successful programs. The study included a nationwide survey of parents and teachers. .
Overall, both parents and teachers find current inclusive practices successful, but there is room for improvement. The study found that more appropriate teacher preparation and more time for conferences between teachers, therapists, parents and support personnel would be beneficial to all involved. 
<p>
Factors which directly affect the success of an inclusive experience, as measured by both parents and teachers, include a match of teacher personality and style to the skills of a student. Teachers who are flexible, willing to modify classroom materials, and who utilize hands-on learning tools, are the bests catalysts for achievement.
<p>
Those parents whose children with Down syndrome had friends in class rated the inclusion experience the most successful, and reported great benefits in the areas of communication, self esteem and independence. Teacher preparation is important for success, but surprisingly, formal training from the school district does not appear to be relevant.
<p>
A copy of the Educational Challenges Inclusion Study, which includes suggestions for classroom practice, can be obtained after October 1, by sending a check or money order for $10 to cover printing and postage, to the NDSS Educational Challenges Program, 666 Broadway, 8th Floor, New York, NY 10012-2317.
</A>
<hr>
<A NAME="partner">
<h3>New 1996 Teaching Partnership Poster Brings Inclusion Message<br>
To Grades 4, 5 and 6</h3><br>
<p>
The National Down Syndrome Society is proud to launch the second phase of its Teaching Partnership program, which brings our message of inclusion, understanding and friendship to grades 4, 5 and 6. The second phase was developed in response to the overwhelmingly positive feedback received from our first phase, which targeted grades 1,2 and 3. In this phase, a combination poster/lesson plan was distributed to 43,000 elementary schools, prompting hundreds of children to write essays about their new understanding of their classmates with Down syndrome. All this would not have been possible without the generous support of many of people, like you, who have an interest in inclusive education.
<p>
The second phase of the Teaching Partnership program targets slightly older students, in grades 4,5 and 6. Both the poster and accompanying lesson plan center on the theme, <i>"Friendship Knows No Boundaries."</i> It offers in-class exercises to help students understand what its like to have a developmental disability, and fosters friendships among all students. 
<p>
This practical, educational tool enables teachers to explore these issues, and create a more inclusive classroom in which all our children may thrive. The National Down Syndrome Society needs your help in bringing this innovative teaching tool to our nations schools. Production and postage expenses to reach every school with a 4th, 5th or 6th grade class would total about $100,000.
<p> 
This cost would be prohibitive without special assistance from our supporters. But, if every person who receives this newsletter offers even a small contribution, we will be well on our way to bringing our message of inclusion to every school in the country.
Your donation to the Teaching Partnership program is a contribution to a more accepting, inclusive society that will benefit all of us. Please help us teach all our children to be understanding and accepting of one anothers differences, by sending your tax-deductible contribution in the enclosed envelope. To obtain a copy of the new Teaching Partnership poster, please include the form below with your donation for $10 or more, to help cover costs.
<pre> 
Name_______________________________________
Address_____________________________________
City______________________State____Zip_______
Telephone__(___)___________________________
Please send me a copy of Teaching Partnership poster
(check one) ( )for grades 1,2 and 3, or  ( ) the NEW poster for grades 4,5 and 6.
</pre>
I am pleased to enclose my tax deductible contribution to support the Teaching Partnership Program, to encourage a more inclusive and accepting society. 
<p>
( ) $1,000<br>
( ) $750<br>
( ) $500<br>
( ) $250<br>
( ) $100<br>
( ) $75<br>
( ) $50<br>
( ) $25<br>
( ) Other___________<br>
<pre>
I wish to use my credit card to make a donation:
Master Card #_______________________Exp. Date_______
Visa #_____________________________Exp. Date_______
American Express #__________________Exp. Date_______
Signature_________________________________________
</pre>
<hr>
<h3>1995 Down Syndrome Teaching Poster Contains Lessons for All Students</h3><BR>
	An educational poster, complete with lessons for students through  grade 3, can help teachers demonstrate to children that their peers with Down syndrome and other developmental disabilities are more alike them than different.<BR>
	The poster, available through the National Down Syndrome Society to mark <B>October</B> as <B>National Down Syndrome Awareness Month,</B> will be sent free of charge to all educators and parents who request them. A small fee is charged for multiple copies.<BR>
	The front of the poster portrays two sisters, one with Down syndrome, embracing each other, and the theme, <B>"None of us are the same on the outside. All of us are the same on the inside."</B><BR>
	The reverse side contains tools for teachers to discuss Down syndrome with their students, and encourage children to accept those who are different.<BR>
	"Recognizing that many children are first exposed to people with Down syndrome and other developmental disabilities in the classroom, we feel that it is important for elementary school  teachers to address the issues of awareness and acceptance," explained Myra E. Madnick, executive director of the National Down Syndrome Society. "We developed this poster to help teachers introduce the subject and encourage positive relationships among all children."<BR>
	The National Down Syndrome Society works to promote a better understanding of Down syndrome and the potential of people with Down syndrome; to support research about this genetic condition; and to provide services for families and individuals involved with Down syndrome. NDSS disseminates information about the inclusion of children with Down syndrome in the regular classroom.<BR>
	For more information about Down syndrome, inclusive education, or to request a poster, call the National Down Syndrome Society at 1-800-221-4602.<P>
</A>
<A NAME="news">
<B>News & Views</B><BR>
           The only magazine written by and for young adults with Down syndrome made its premiere in September 1994. Edited by Chris Burke, this magazine talks about what it is like to have Down syndrome in the nineties.  People from all parts of the United States and abroad contribute articles, letters, games, and opinions on current events. No other magazine tells this story in the same way. Available by subscription through the National Down Syndrome Society.<P>
</A>
<A NAME="edu">
<B>The Educational Challenges Program</B><BR>
           This two-year study of inclusive education examines the nature of the public school experience for children with Down syndrome. Directed by Gloria Wolpert, Ed.D., this study is the first national survey of inclusion for children with Down syndrome and explores the full spectrum of options that are, or should be, available to all children with Down syndrome. As part of the Educational Challenges Program, NDSS has developed a pamphlet on inclusion and an annotated resource list of organizations and materials available to help parents and professionals.<P>
</A>

<HR>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: November 25th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>

</BODY></HTML>



</DOC>
<DOC>
<DOCNO>WT01-B04-257</DOCNO>
<DOCOLDNO>IA090-000969-B049-88</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/res.html 206.249.5.81 19970117204544 text/html 4507
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 20:47:30 GMT
Last-modified: Wednesday, 27-Nov-96 23:23:41 GMT
Content-length: 4315
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>
RESEARCH
</TITLE><BODY BACKGROUND="/gif/background.gif"><BODY>
<H2><CENTER>RESEARCH</H2></CENTER><HR>
<A NAME="sym">
<H3>Scientific Symposia</H3><P>
           In an attempt to increase communication among the world's most distinguished scientists, working in fields related to Down syndrome, the Society hosts international scientific conferences on relevant research topics. The proceedings of these conferences are published and distributed worldwide. To date, the Society has hosted ten Scientific Symposia.
<P></A>
<A NAME="sch">
<H3>Science Scholar Award</H3><P>
           Each year the Society awards research grants to promising young scientists who have demonstrated extraordinary skill and achievement in seeking a better understanding of Down syndrome. Since 1983, twenty post-doctoral researchers have received the coveted, two-year salary grants of $60,000. 
<h3>Science Scholar has a Personal Motivation</h3>

Each evening when neuroscientist Alberto Costa, M.D., Ph.D., returns home from the laboratory where he works to understand the functions of specific genes along the 21st chromosome, he is greeted by the baby girl who inspires him.
<p>
Dr. Costas daughter, Tyche, was born with Down syndrome one year ago, and has brought a renewed sense of purpose to his research.
<p>
 "I am working for my daughter," said Dr. Costa, explaining that Tyche was named for the Greek goddess of good fortune. He and his wife, Daisy, chose the name before the birth of their daughter, which had followed two lost pregnancies. "We were very excited when we realized that this child was going to make it to term. We felt that she is a gift of good fortune."
<p>
If Dr. Costa is successful in unraveling the mysteries of the 21st chromosome, it could open the doors to pharmacological intervention that would benefit thousands of individuals with Down syndrome. "Then," Dr. Costa continued, "Tyche would truly live up to her name."
<p>
Dr. Costa, one of most talented and promising young neuroscientists in the nation, is the 21st recipient of the National Down Syndrome Societys prestigious Science Scholar Award. As a Science Scholar, he will receive a two-year salary grant of $60,000.
<p>
He was selected by the NDSS Science Advisory Board, following a nationwide evaluation of highly qualified applicants. Science Advisory Board Chairman Charles Epstein, M.D., explained that the Board was duly impressed with Dr. Costas previous accomplishments, proven talent and proposed research strategy. "Dr. Costa has demonstrated considerable knowledge of the neurophysiology of Down syndrome, and he certainly is motivated," explained Dr. Epstein, of the Department of Pediatrics at the University of California in San Francisco.
<p> 
Working with mice that were developed as genetic models of Down syndrome, Dr. Costa is studying the effects that an extra copy of specific genes has on the functions of the brain. Individuals with Down syndrome have three copies, rather than two, of the 21st chromosome, although it is not known exactly which genes on this chromosome are responsible for the specific characteristics associated with this condition.
<p>
Dr. Costa, who has dedicated the last eight years of his career studying electrophysiology and molecular biology in relation to the brain and nervous system,  is performing his research study at the Jackson Laboratory and Mount Desert Island Biological Laboratory in Bar Harbor, Maine, in collaboration with Senior Staff Scientist Muriel T. Davisson, Ph.D.
<P> 
Dr. Costa earned his medical degree from the State University of Rio de Janeiro, Brazil, and his doctorate in biophysics from the Federal University of Rio de Janeiro. In addition, he had several years of postdoctoral training in Pharmacology and Neuroscience, at the University of Maryland and Baylor College of Medicine. Dr. Costa has earned numerous awards and his work has been published extensively in scientific journals.
</A>

<HR>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: November 25th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>

</BODY></HTML>



</DOC>
<DOC>
<DOCNO>WT01-B04-258</DOCNO>
<DOCOLDNO>IA090-000970-B001-363</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/ethan1.html 206.249.5.81 19970117205324 text/html 5711
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 20:54:03 GMT
Last-modified: Monday, 13-Jan-97 23:47:21 GMT
Content-length: 5522
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>

<TITLE>NDSS - Ethan Page</TITLE>
</HEAD>

<BODY BGCOLOR=#FFFFFF >
<CENTER>
<TABLE WIDTH=600 CELLPADDING=5>
<tr><td bgcolor=#ffffff >
<IMG SRC="gif/ethan-1.jpg" WIDTH=271 HEIGHT=278></TD>
<TD VALIGN=BOTTOM><FONT SIZE=3 FACE="ARIAL" COLOR="8B1A1A">
<CENTER>
<IMG SRC="gif/logo-sm.jpg" WIDTH=219 HEIGHT=115></CENTER><BR><BR><BR><BR><B>
Ever since Ethan was a few weeks old, he's been attending an early intervention 
program designed especially for infants and children with Down syndrome.</B> 
</td></TR>
<TR><TD COLSPAN=2><FONT SIZE=2 FACE="ARIAL" COLOR="8B1A1A"><B>
He's already enhancing his speech and language skills and receiving 
sensory stimulation through play, and in the coming years, he'll 
begin an intensive reading program. And, as he develops, his program 
will be tailored to meet his specific needs - whether they are in 
the areas of muscle coordination, fine motor skills or language 
development.
</td></TR>
<TR><TD COLSPAN=2><FONT SIZE=2 FACE="ARIAL" COLOR="8B1A1A"><B>
Thanks to programs like the one Ethan attends, children with Down 
syndrome are achieving more than ever. Some of the typical problems 
associated with this genetic condition have been successfully 
mitigated by early stimulation and interaction. Although these 
programs are helpful, we are still limited by our understanding 
of the functions of the human brain, and exactly how children 
with Down syndrome acquire new skills.
</td></TR><BR></TABLE></CENTER><br>
<HR width=400><BR><CENTER>
<TABLE CELLPADDING=10>
<TR><TD BGCOLOR=#36648B WIDTH=25> <FONT COLOR=#36648B>QQ</TD>
<TD FONT SIZE=3 FACE="TIMES" WIDTH=460>
<FONT SIZE=4 FACE="TIMES" COLOR=#8B1A1A><B><I>
Dear Friends of NDSS,</B></I></font><P>
<FONT SIZE=4 FACE="WINGDINGS" COLOR=#8B1A1A>w w w </FONT>

We can help Ethan and his peers reach their potential. 
Through research breakthroughs in the areas of language 
processing, cognitive abilities and behavior, we are able 
to learn more about how Down syndrome affects the development 
of these related skills. And, once we learn the basics, we 
can incorporate these findings into the early international 
programs that have already helped so many children with Down 
syndrome.
<br>
<br>
<FONT SIZE=4 FACE="WINGDINGS" COLOR=#8B1A1A>w w w </FONT>
Since its inception, the National Down Syndrome Society 
has made research one of its top priorities. Through its Science 
Scholar Program, NDSS  has supported 20 researchers who are seeking 
the causes of, and answers to, many of the medical, genetic, 
behavioral and learning problems associated with Down syndrome. 
These gifted scientists were each awarded two-year, $50,000 grants 
to carry on their work and contribute to the body of knowledge on 
Down syndrome. Our researchers have focused not only on the 
genetic aspects of Down syndrome, but the practical applications 
of knowledge in the areas of speech and articulation, physical 
therapy, behavior and education of children with Down syndrome. 
Current projects include a study of the possibility that children 
with Down syndrome may have far greater linguistic understanding 
that their speech patterns would indicate. A careful separation 
of the language processes will help us better understand how these 
skills are acquired, and improve the educational opportunities for 
all children with Down syndrome.
<BR><BR>
<FONT SIZE=4 FACE="WINGDINGS" COLOR=#8B1A1A>w w w </FONT>
This year, as we are considering applications for our 
1996 Science Scholar Program, NDSS has increased the Science 
Scholar Award to $60,000, to cover the ever-increasing costs 
of conducting research. The scientist who is selected this year 
will apply this grant toward reducing the complications associated 
with Down syndrome, and increasing the potential of all people 
born with this condition. The knowledge they uncover today promises 
to have important benefits for the broad community of people with 
Down syndrome, especially young children such as Ethan.
<BR><BR>
<FONT SIZE=4 FACE="WINGDINGS" COLOR=#8B1A1A>w w w </FONT>
The NDSS Science Scholar Award is funded entirely through 
contributions by individuals who care about the future of all 
children. Thanks to your generosity, Ethan and his peers can 
come closer to realizing their full potential. We ask you to 
continue to support, and help Ethan look forward to a brighter 
future. Please help us find answers today, to help our children 
tomorrow. <A HREF="contr.html">Send your generous, tax deductible contribution today.</A>
<BR><BR>
Thank you,
<BR>
<IMG SRC="gif/goodwin.gif" WIDTH=185 HEIGHT=51 ALIGN=MIDDLE><MAP NAME="flower">
<!--Picture d:\ndss\gif\flower.gif-->
<!--Comment -->
<AREA SHAPE="RECT" COORDS="128,0,243,135" HREF="contr.html">
</MAP>
<IMG BORDER=0 SRC="gif/flower.gif" ALIGN=MIDDLE WIDTH=228 HEIGHT=123 USEMAP="#flower">


<BR>

Elizabeth F. Goodwin<BR>
President, Board of Directors

</TD>
<TD BGCOLOR=#36648B WIDTH=25> <FONT COLOR=#36648B>QQ</TD></TR>
<TR><TD  COLSPAN=3><BR>
<MAP NAME="home">
<!--Picture gif\home.gif-->
<!--Comment -->
<AREA SHAPE="RECT" COORDS="3,0,80,74" HREF="ndss.html">
</MAP>
<IMG BORDER=0 SRC="gif/home.gif" WIDTH=83 HEIGHT=78 USEMAP="#home">
<MAP NAME="back">
<!--Picture gif\back.gif-->
<!--Comment -->
<AREA SHAPE="RECT" COORDS="1,1,109,39" HREF="res.html">
</MAP>
<IMG BORDER=0 SRC="gif/back.gif"  USEMAP="#back">

</TD></TR>

</TABLE>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-259</DOCNO>
<DOCOLDNO>IA090-000970-B002-144</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/adv.html 206.249.5.81 19970117205731 text/html 7753
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 20:59:13 GMT
Last-modified: Wednesday, 28-Aug-96 13:29:06 GMT
Content-length: 7561
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>
ADVOCACY
</TITLE><BODY BACKGROUND="/gif/background.gif"><BODY>


<H2><CENTER>ADVOCACY</CENTER></H2><P><HR>

<B>Advocacy</B><BR>
           Throughout the year, the National Down Syndrome Society advocates on behalf of people with Down syndrome. The Society, bolstered by the testimony of individuals with Down syndrome, has made appearances before several House and Senate committees. Chris Burke travels worldwide to enlighten parents and professionals about the needs of people with Down syndrome and to advocate for their inclusion in community life.<P>

<A NAME="reauth">
<CENTER><B>POSITION STATEMENT ON THE REAUTHORIZATION OF THE IDEA</B></CENTER><P>

<B>ISSUE</B><P>

	The Individuals with Disabilities Education Act (IDEA) was enacted in 1975 to end the exclusion and segregation of children with disabilities from public education programs. It provides that all children with disabilities, including Down syndrome, be educated to the maximum extent possible with students who are not disabled. IDEA supports special education, and related service programming for children and youth with disabilities and is sometimes referred to as Public Law 101-476. The IDEA was reauthorized and expanded under Public Law 94-142 in 1990.<P>

	Since the passage of Public Law 94-142, educational options for children with Down syndrome have expanded greatly. Individual Educational Plans (IEP's) are now provided for all children with special needs; parent involvement is sought; and advocacy and support is widely available. <P>

	The IDEA is up for reauthorization before the 104th Congress. Hearings and staff briefings within both houses of Congress have raised numerous issues about the law, particularly with regard to the implementation of Part B and how special education will fit in the general environment of national education reform. Questions have also been raised regarding IDEA's funding and the removal of discretionary programs such as parent training and information centers.<P>

<B>POSITION</B><P>

The National Down Syndrome Society recognizes the need for the  federal government to play an active role in overseeing access to public education for students with disabilities. Congress enacted IDEA because of the failure of states to provide an appropriate education to children with disabilities.<P>

Federal supports for individuals with disabilities and their families must be fully funded. The federal budget cannot be balanced by compromising the educational needs of students with disabilities. For students with disabilities, IDEA is a civil right to education, not a program mandated capriciously by the federal government.<P>

Research, training and technical assistance projects in IDEA must not be eliminated. They provide invaluable opportunities to educators and parents on how to effectively educate persons with developmental disabilities.<P>

Part B must not be open for revision. Part B (P.L. 94-142) of IDEA requires states to provide a free appropriate, public education for all children with disabilities. This includes special education, related programs, and supplemental aids and services necessary to sustain a child with a disability in the regular education classroom. Part B also includes important protections for children with disabilities. All of the basic and essential protections (e.g., IEP, due process, parent participation rights) of IDEA would be at risk if Part B is opened for change.<P>

The National Down Syndrome Society urges Congress to implement and rigorously enforce the provision of IDEA. This will guarantee all students with disabilities access to a free, appropriate, public education.<P>
</A>

<HR>
<A NAME="med">
<B><CENTER>POSITION PAPER ON MEDICAID BLOCK GRANTS</CENTER></B><P>

<B>ISSUE</B><P>
	
	Medicaid provides access to essential health care services for children with special health care needs. To qualify, children with disabilities must first meet poverty guidelines and have a disability that is on the SSI medical. Children in more than 30 states may also qualify for Medicaid through special home and community based waivers and amendments. Though family income is not always taken into account in these programs, many families, have inadequate coverage that often does not provide them the type or extent of care that they require. Medicaid has allowed children with special health care needs to receive important preventative and restorative health services while being nurtured at home by their families in their communities. <P>

	Under Medicaid regulations, any health care service approved by Medicaid which is considered medically necessary for a child must be provided. This provision allows children who are eligible for Medicaid to receive appropriate corrective and preventative services, supplies, and equipment (including assistive communication devices, durable medical goods, nutritional supplements, personal assistance, speech therapy, PT, OT, among others). <P>

	As a part of the Welfare Reform debate, proposals in both the House and Senate bills would put federal Medicaid dollars into a block grant that would go directly to states along with 4% cap on growth rate (current rate is 10%). This equates to a 30% funding reduction for each state and the abolishment of the "Medicaid Waiver" for people with developmental disabilities.<P>

<B>POSITION</B><P>

Keep federal standards in place for Medicaid. If individual states determine eligibility requirements, health care services may be significantly compromised for persons with developmental disabilities and mental retardation. <P>

Do not cut Medicaid funding for children who have chronic health care problems. Independence is the ultimate goal of health care for people with disabilities. A piece of assistive technology may make the difference between independent living or institutionalization.<P>

Do not remove the Individualized Functional Assessment (IFA) process. The IFA should be retained as part of the eligibility determination process because the real indication of severe disability is significant limitation of functional ability, rather 
than whether an impairment meets a black-and-white test of specified medical criteria.<P>

Maintain cash assistance for families of children on SSI. The SSI Children's program provides modest monthly cash benefits to eligible children who are poor and severely disabled so that they can stay at home and be raised by their families. Cash assistance is important to poor families. Families generally make informed decisions on behalf of their children, and any changes in SSI would dramatically affect a most vulnerable population. <P>

The National Down Syndrome Society urges a separate federal Medicaid block grant for long term care and financial support for children and adults with developmental disabilities. The National Down Syndrome Society also urges for the continuation of SSI benefits to families, with low incomes, who have children with severe disabilities; and the continuation of the individualized Functional Assessment to determine eligibility; accurately measuring the child's functional abilities, not their medical category.<P>

</A>
<HR>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: January 28th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>

</BODY></HTML>




</DOC>
<DOC>
<DOCNO>WT01-B04-260</DOCNO>
<DOCOLDNO>IA090-000970-B002-231</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/aff.html 206.249.5.81 19970117210001 text/html 6370
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 21:01:32 GMT
Last-modified: Wednesday, 27-Nov-96 23:23:42 GMT
Content-length: 6178
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>
AFFILIATE PROGRAM
</TITLE><BODY BACKGROUND="/gif/background.gif"><BODY>

<CENTER><H2>AFFILIATE PROGRAM</H2></CENTER><HR>

<A NAME="gen">
<B>Affiliate Membership Program</B><BR>
           Parent groups, individual families and Down syndrome organizations from around the country can join with the Society to undertake activities which will benefit all people with Down syndrome. Through our Affiliate Membership Program, parent support groups and individual families are empowered at the local level to attain their goals: through parent training, educational outreach, and collaboration. NDSS benefits by receiving direct input from the community and staying abreast of grassroots developments.  For more information about affiliating with NDSS, please contact Jeanne Hendrickson, Manager Development/Affiliate Services, at 800-221-4602, ext. 117. <P>


<P>
PROVIDES:
<ul>
<li>Input into the ongoing programs of the Society

<li>Up-to-date informational materials & brochures

<li>Consultation services on program planning, fundraising & 	public relations

<li>Priority access to NDSS model programs

<li>Invitations to important workshops

<li>And More.............
</ul>
<center><h3>WHAT IS THE AFFILIATES PROGRAM?</h3></center><br>
<p>
The Affiliates Program was established to provide a means through which community groups can avail themselves of the programs and services of the National Down Syndrome Society.  Equally important, the Affiliates Program enables the Society to learn from and work with local organizations providing assistance to individuals with Down Syndrome.  This collaborative effort ensures that persons with Down Syndrome are provided with the options necessary to participate in community life to their fullest potential.
<P>
<center><h3>WHO IS PARTICIPATING IN THE AFFILIATES PROGRAM?</h3></center><br>
<P>
The Affiliates Program is comprised of parent support groups, individuals, social service agencies, and other community organizations throughout the country which serve people with Down Syndrome and their families.
<P>
<center><h3>WHAT DO I GAIN FROM JOINING THE AFFILIATES PROGRAM?</h3></center><br>
<P>
Membership in the Society's Affiliate Program entitles organizations to draw upon and use specific services offered by NDSS.  These services include:  professional consultation on program planning, fundraising and public relations; technical assistance in implementing NDSS's model programs; invitations to important conferences and workshops; access to timely research reports on various aspects of Down Syndrome; and complimentary copies of booklets, manuals, posters and other materials published by the Society.
<p>
<center><h3>HOW MAY I JOIN THE AFFILIATES PROGRAM?</h3></center>

Attached is a membership application form for the Affiliates Program.  The membership fee is $100 for parent support groups and $25 for individual families per year.  Please make your check out to National Down Syndrome Society and mail it with the completed form.
<p>
 	<center><h3>AFFILIATE AGREEMENT</h3></center>
<pre>

The _____________________________________________________ (name of organization or individual)

agrees to become an affiliate of the National Down Syndrome Society for the period of one year
from ____________, 199__ to ____________________, 199__.  

As an affiliate, the organization is authorized to use the NDSS name in conjunction with its own organization only
during the period of affiliation and only as follows: "____________________ is an affiliate of the
National Down Syndrome Society" or "_______________, an affiliate of the National Down Syndrome Society."

The National Down Syndrome Society shall not endorse any affiliate organization's program, nor
have any liability to the affiliate organization, except to fulfill NDSS's obligation under this agreement.

Agreed to on this date:


	__________________________________________________
	(Signature of President of Organization or Individual)


	__________________________________________________
	(Name of Organization)


	__________________________________________________
	(Street Address)


	__________________________________________________
	(City, State, Zip)


	__________________________________________________
	(Telephone)


	__________________________________________________
	(Date)




[  ]  Enclosed is my membership fee of $100 or $25
</pre>
<h3> Programs</h3><br>
<ul>
<li>Clinical Care Program to inform parents and physicians about the health care needs of people with Down Syndrome
<li>Scientific research grants to assure that science does everything possible to improve the health of today's child, and to fend the answers to this genetic disorder tomorrow 
<li>International scientific symposia, to give the world's leading scientists the chance to spark new ideas in unraveling the mysteries of Down Syndrome
<li>National conference designed for professionals, parents, families and young adults with Down syndrome
<li>Affiliates Program to enable community-based organizations and individuals to become partners with NDSS, to share ideas and to benefit from the Society's expertise in research, public awareness, and program development
</ul>


<h3>Materials You Can Use</h3><br>
<ul>			
<li>NDSS Brochure
<li>Inclusion Brochure
<li>Clinical Care Brochures
<li>Gifts of Love, a 25 minute videocassette showing the rich interaction of people with their children who have Down syndrome
<li>Proceedings of each NDSS Scientific Symposium
<li>NDSS Public Service Announcement & Video News Release
<li>Fact Sheets and Bibliography
<li>Annual National Down Syndrome Awareness Month Teaching Partnership Poster
<li>NEWS & VIEWS Magazine written by young adults with Down syndrome
</ul>
</A>



<HR>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: November25th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>

</BODY></HTML>




</DOC>
<DOC>
<DOCNO>WT01-B04-261</DOCNO>
<DOCOLDNO>IA090-000970-B002-286</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/spec.html 206.249.5.81 19970117210054 text/html 12047
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 21:02:56 GMT
Last-modified: Wednesday, 27-Nov-96 23:23:42 GMT
Content-length: 11854
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>
SPECIAL PROGRAMS
</TITLE><BODY BACKGROUND="/gif/background.gif"><BODY>


<CENTER><H2>SPECIAL PROGRAMS</H2></CENTER><HR><P>
<A NAME="good">
<h3>Chris Burke</h3>

Chris Burke, who is best known for the character, Corky, he played for four years on the ABC television series, <I>Life Goes On</I>, currently serves as the NDSS Goodwill Ambassador. Born with Down syndrome, Chris had the faith in his own abilities and the courage to face prejudices as he pursued his life-long dream to become an actor. Today, Chris tours the country delivering inspirational speeches to various groups of children, students, parents and professionals. He also serves as editor-in-chief of the NDSS magazine for teens and young adults with Down syndrome, News&Views. Chris writes a column and responds to readers correspondence in a regular Q&A feature in the magazine. Information about Chris schedule, and booking Chris for your event is available by calling Carol Smith at NDSS, 1-800-221-4602.<P>
</A>
<A NAME="conf">
<h3>Hundreds Attend National Conference<br>
<i><a href="#order">Audio Cassettes Still Available</a></i></h3>

If you were not able to attend the NDSS national conference in Phoenix this summer, you probably know somebody who did! Some 500 parents, professionals and individuals with Down syndrome gathered to learn the latest scientific information, opportunities for growth, network and share stories, during <i>A Promising Future-Together</i>, June 26 through June 29.
<p>
Topics of interest included alternative and unconventional therapies, inclusion, advocacy, nutrition, employment, health care and reading skills. Parents and professionals attended their own "tracks" which targeted specific needs and interests, while young adults with Down syndrome and their siblings each had programs tailored to their needs.
<p>
The conference was enhanced by the participation of the Down Syndrome Medical Interest Group (DSMIG)- an independent organization of physicians, researchers and health professionals who work in the field of Down syndrome. The DSMIG hosted its meeting before the conference, and many members subsequently participated or spoke in conference programs.
<p>
A pre-conference Affiliate program was also well-attended, providing useful round table discussions and valuable networking time. 
Audio cassettes of many conference proceedings are available for purchase through Convention Recordings International, Inc., by sending in the attached order form to 6983 Sunset Drive South, St. Petersburg, FL 33707, or calling (813) 345-8288.
<p>
<h3>The 10th Annual Lloyd Bentsen Award Presented at NDSS Conference</h3>
The National Down Syndrome Society is honored that our national conference, <i> A Promising Future - Together</i> was the forum for the presentation of the 1996<b> Lloyd Bentsen Award</b>  to Robin Bolduc.
<p>
Lloyd Bentsen, former U.S. Senator and Secretary of the Treasury, presented the award with the entire conference in attendence. The prestigious award seeks to highlight to unique accomplishments of men and women who strive to make a difference in the lives of children with Down syndrome and their families. The award carries a $10,000 honorarium to the winner.
<p>
The award was established in 1987 by the Kelsey-Seybold Foundation for Medical Research and Education, to foster better recognition for family-centered, community based care for children with special needs. The Foundation created the award in honor of Sen. Bentsen and his devotion to helping children with special needs. 
<p>
As a Congressman, he championed bills to help children with special health care needs. As a father and grandfather, he is well aware of the challenges parents face when their children require special medical consideration. In celebration of the awards 10th anniversary, Sen. Bentsen has chosen to focus on families of children with Down syndrome. 
<p> 
This year the Lloyd Bentsen Award honors Robin Bolduc for her dedication to advocating on behalf of children with Down syndrome and their families. Both as a professional advocate and as a volunteer and friend, Ms. Bolduc has advocated for countless numbers of individuals with disabilities, in the areas of education, community services, transportation, civil rights, access, personal choice and other issues. 
<p>
While advocating on local, state and national levels as past president of Pennsylvania Schools Are For Everyone (SAFE), she also worked to assure that her own daughter with Down syndrome received an appropriate education in her home school. Because the districts teachers did not have training in inclusive education or adaptive curriculum, Ms. Bolduc has provided much of this training herself.
<a name="order">
<p>
	<center>*     *     *     *     *     *     *     *     *     *     *     *</center>
</p>

	<center><h2>ORDER FORM</h2></center>
<blockquote>
<b>All orders must be prepaid.</b>  Checks should be made payable to the National Down Syndrome Society. Please check the appropriate boxes when ordering materials and be certain that order form contains a <em>daytime telephone number and a street address. Videos cannot be delivered to post office boxes.</em>  <b>All international orders (including Canada) must be prepaid in U.S. dollars and should include the appropriate additional postage. Thank you.</b></blockquote>
<code>
Name:____________________________________________________   Today's Date:______________<br>

Address:_____________________________________________________________________________<br>

City:________________________________________   State:__________   Zip code:_______________<br>

Telephone:   Day:   (______)________________________   Evening: (______)____________________<br>

Total Payment:$__________  Payment type:  ( )Check/Money order  ( )Visa   ( )MasterCard   ( )American Express<br>

Credit card #:____________________________________________   Expiration date:_______________<br>

Cardholder's Signature:__________________________________________________________________<br>
</code>

Please mail to:	National Down Syndrome Society
666 Broadway, 8th Floor
New York, NY  10012-2317                                                                                 
</a>
<hr>
<A NAME="aware"><A NAME="walk">
<h3>October  - Down Syndrome Awareness Month - 1997</h3>
<CENTER>
NATIONAL DOWN SYNDROME SOCIETY
3rd ANNUAL "BUDDY" WALK
SUNDAY, OCTOBER 5, l997
</CENTER><P>
	Welcome to the third annual National Down Syndrome "Buddy Walk" planned for Sunday, October 5, l997.  The information listed below will give you all the specific steps to be taken to assure a successful walk.  However, parent groups may want to add their own ideas or suggestions.  In fact, we would like to share any of your great ideas or suggestions with other parent groups.<P>

l.	The first step is to determine if there is sufficient interest in the "Buddy Walk" among members of your group and the larger community.  To determine this, hold an initial informational meeting with your members to promote Down syndrome and explain the national attention and visibility that will be gained from conducting a "Buddy Walk."<P>

2.	Determine the scope of your walk - what geographic areas could be effectively included in your walk.  If there is more than one parent group in a county, you might consider joining forces and having a county walk.  We are suggesting a 5K (3 mile) walk as a start.<P>

3.	At the first meeting, select one or two people to act as Team Captain or Co-Captains.  This is a very responsible position since the Captain(s), in addition to acting as spokesperson, will also handle all the details of the walk. <P>

4.	Plan a future meeting to include representatives from all the areas that will be participating.  Most importantly be sure to include representatives from the county, municipality, and law enforcement agencies.  Also, invite representatives from schools, churches, social service agencies, community clubs, organizations, corporations, and especially, the press.  The larger the Committee, the larger the sphere of influence.  From this group select team leaders who will handle specific duties and report back to the Team Captain.  e.g., publicity, registration, traffic control, sight approvals, solicitation, etc.<P>

5.	Select the sight for the Walk.  It can be in a park, on a boardwalk, at a shopping mall, school property, etc.<P>

6.	Once a sight is selected, it is important that you make contact with municipal and police authorities to gain approval for use of the sight.  Depending on the region you are in, you may have to secure municipal, county or state approval.<P>

7.	When you have gained approval of a sight, begin disseminating information and promotional materials.<BR>
<UL><H5>
a.  Send a press release to your local area newspapers. (NDSS will provide)<BR>
b.  Arrange to have the Public Service Announcement read on the radio.  (NDSS will provide)<BR>
c.  Visit area schools, churches, local businesses (supermarkets), and corporations to distribute posters and registration forms. (NDSS will provide)<BR>
d.  Ask schools to conduct a competition among classes - the most students walking from a class wins.<BR>
e.  Ask corporations to conduct a similar competition - the most employees from a department wins.<BR></UL></H5>

Note:  Camera ready artwork for the NDSS logo will be provided by NDSS to be used for t-shirts and other posters.<P>

8.	Most importantly, have each child with Down syndrome ask a "buddy" to walk with him/her.  The buddy can be a parent, family member, friend, school teacher, etc.<P>

9.	Arrange for a photographer to be present at the Walk to photograph each child and his/her buddy as they finish the Walk.<P>

10.	In the morning prior to the Walk, offer coffee, juices and donuts to the walkers.<P>

11.	After the Walk, plan a picnic for the walkers.  Ask local vendors to donate food and supplies for the picnic.<P>

12.	Hang a large banner at the Start and Finish lines.  Ask a local musical trio or band to perform 	at the Finish line for the walkers.<P>

<h3>BE SURE ALL PRESS AND CABLE TV COMPANIES HAVE BEEN INVITED TO ATTEND TO COVER THE WALK.</h3>


	If you choose to make the Walk a fund-raiser, the following steps can be taken:<P>

1.	Using the enclosed registration form, each person who has agreed to walk may solicit for donations either based on miles walked or a flat donation.<P>

2.	Walkers can be charged a registration fee.<P>

3.	Solicit area businesses, corporations, community clubs to sponsor:<P>
<UL><H5>
a.  NDSS banners (sponsor's name can also be on banner).<BR>
b.  Picnic foods.<BR>
c.  Breakfast foods.<BR>
d.  Photographer to take children and buddy photos.<BR>
e.  Posters and other printed materials.<BR>
</UL></H5>
<h3>BE SURE TO HAVE SIGNAGE AT THE EVENT LISTING ALL THE SPONSORS.</h3>

	
	The key to success is to begin planning your event as soon as possible and allow sufficient time to organize all the details.<P>

	Conclude you 1997 Walk by thanking each and everyone involved who assisted in anyway.  Make sure people know how successful your event was and how much you look forward to having them participate again next year.<P>

	Hold a wrap-up meeting shortly after the event to thank the Committee, critique the event, and make changes for next year.<P>


<CENTER><KBD>
G O O D       L U C K</KBD>
</CENTER>
</A></A>

<HR>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: November 25th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>

</BODY></HTML>




</DOC>
<DOC>
<DOCNO>WT01-B04-262</DOCNO>
<DOCOLDNO>IA090-000970-B003-10</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/thresh.html 206.249.5.81 19970117210147 text/html 3716
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 21:03:50 GMT
Last-modified: Wednesday, 27-Nov-96 23:46:58 GMT
Content-length: 3524
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>NDSS Thresholds</title>
<BASE HREF="http://www.ndss.org/">
</head>
<BODY BACKGROUND="/gif/background.gif">
<body>

<a name="thresholds">
<center><h2>NDSS Thresholds Program</h2></center>
<hr>
<h3>Gov. Lowell P. Weicker, Jr. Leads NDSS Fund-Raising Campaign</h3>
The National Down Syndrome Society (NDSS) is proud to announce that Lowell P. Weicker, Jr., former Connecticut governor and senator, will serve as Honorary Chairperson of <i>Thresholds - Opening Doors to Opportunity</i>, its new fund-raising campaign that has already raised $1.1 million toward its goal.
<p>
<i>Thresholds</i> is the Societys five-year strategic plan to improve the lives of people with Down syndrome through projects and services in education, research and advocacy. Thresholds incorporates the most ambitious fund-raising project in NDSS 17-year-history, with a goal of raising $3.5 million in gifts and pledges from the private sector throughout the next year. The National Down Syndrome Society does not receive any government funding.
<p>
"Were thrilled that Gov. Weicker has agreed to play an important role in this campaign. His long history as an advocate for the rights of the disabled makes him the natural choice for Honorary Chair," said Elizabeth Goodwin, NDSS Co-Founder and Board President.
<p>
Gov. Weicker is the author of many laws on behalf of people with disabilities, and is one of the principal authors of the Americans with Disabilities Act. He is currently Chairman of the firm Dresing, Lierman, Weicker of Bethesda, MD. 
<p>
The General Chairperson of <i>Thresholds</i> is longtime NDSS Board Member Thomas F. Robards. Mr. Robards is Executive Vice President and Chief Financial Officer of Republic New York Corporation. "The <i>Thresholds</i> campaign will allow NDSS to aggressively take the lead in finding solutions to the diverse challenges related to Down syndrome," he said. "I am excited and encouraged by the enthusiastic support <i>Thresholds</i> has received so far."
<p>
<i>Thresholds</i> is an outgrowth of a comprehensive, nationwide assessment of the needs of people with Down syndrome, as well as an evaluation of the work of NDSS. The program includes the expansion and enhancement of current programs and initiation of a number of new projects in research, education and advocacy. 
<p>
These projects include the development of teaching tools to help educators encourage more inclusive and accepting behavior in the classroom, additional educational materials and seminars for new parents of children with Down syndrome, educational efforts aimed specifically at health care professionals who work with people who have Down syndrome, as well as programs to assist individuals with Down syndrome in mastering specific life skills.
<p>
Other <i>Thresholds</i> projects include the expansion of the Societys current research efforts,  as well as additional grants to encourage applied research. Plans also incorporate the development of a pilot program to look at housing alternatives, advocacy training from the grassroots to the federal level, and a blue ribbon panel to address the many bio-ethical issues involved in treating people with Down syndrome. 
</a>
<hr>
<H6><CENTER><I>http://www.ndss.org/<BR>
Last Updated: November 27th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 Primary Consulting Services, Ltd.
All rights reserved.</A></I></CENTER></H6>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-263</DOCNO>
<DOCOLDNO>IA091-000971-B012-240</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/ndssnews.html 206.249.5.81 19970117210535 text/html 5608
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 21:05:13 GMT
Last-modified: Wednesday, 27-Nov-96 23:50:25 GMT
Content-length: 5416
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>The National Down Syndrome Society --  News Items</title>
</head>
<BODY BACKGROUND="/gif/background.gif">
<body>
<a name="ndssnews">
<a name="lunch">
<center><h2>NDSS News Items</h2></center>

<h3>Caroline Kennedy<br>
Addresses Womens Luncheon</h3>
NEW YORK, NY  -- Caroline Kennedy addressed a record-breaking gathering of NDSS supporters during the annual Womens Luncheon last spring. 
<p>
After a colorful introduction by NDSS Board member Anna Quindlen, Ms. Kennedy spoke about the great strides that have been made in recent years by people with developmental disabilities.
<p> 
Drawing from her familys long-time support of programs such as the Special Olympics, and legislation to provide opportunities for individuals with disabilities, Ms Kennedy stressed the need to include people with developmental disabilities in all aspects of community life. 
Kim Simons, 21, of Chappaqua, NY, presented Ms. Kennedy with a token of appreciation, and spoke about her experiences growing up with Down syndrome. 
<p> 
The National Down Syndrome Society is grateful for the dedication of the Womens Luncheon Committee, whose efforts made the luncheon the most successful in NDSSs history. Special thanks go to the committee chairperson, Debra Martindale Goll, under whose guidance the event made a smooth transition to its new venue, The Plaza Hotel.
<p> 
Plans are underway for the 1997 Womens Luncheon, to be held this spring in The Plaza Hotel in New York, NY. If you are interested in attending, becoming a member of the organizing committee, or opportunities for corporate sponsorship, please call 1-800-221-4602.
<hr>
<a name="guiding">
<h3>National Drama Features Down Syndrome Storyline - </h3>
The popular daytime drama <i>Guiding Light</i> is doing its part to raise awareness and acceptance of individuals with special needs, through a ground-breaking new storyline about a child with Down syndrome. While network television has depicted characters with this condition, this is the first time a series has explored the issues faced by parents before and immediately after a child is born. 
<p>
As <i>Guiding Light</i> intends to develop this storyline as accurately and dramatically as possible, with guidance and fact-checking provided by the National Down Syndrome Society, all people with Down syndrome and other developmental disabilities can benefit from a greater understanding fostered by this program.
<p>
The storyline has emerged with the birth of "Meg" born to soap characters Fletcher Reade and Holly Lindsey-Reade (played by Jay Hammer and Maureen Garrett). Meg, who is played by Jacqueline Falchier of Maplewood, NJ, (born September 1995), has Down syndrome and was cast with assistance from the National Down Syndrome Society.
<p>  
"Were thrilled with <i>Guiding Lights</i> programming decision to feature a child with Down syndrome, and their willingness to work with us in creating such a responsible depiction of a familys experiences, explained Myra E. Madnick, executive director of NDSS. "Baby Jacqueline doesnt realize it yet, but shes going to help teach millions of people that children with Down syndrome have many wonderful abilities and talents. Shell be instrumental in changing attitudes and increasing acceptance. Shes the youngest advocate we have."
<p> 
Baby Jacqueline and the National Down Syndrome Societys role in the story line were also the topic of a CBS <i>Day&Date</i> story (July 12, 1996), which applauded the programming decision.
<p>
Future <i>Guiding Light</i> story lines will include the types of situations a baby with Down syndrome and his or her parents encounter. The National Down Syndrome Society has recently provided the <i>Guiding Light</i> writers with information about early intervention programs that assist infants with Down syndrome in the areas of language, muscle development and fine motor skills.
<hr>
<a name="israel">
<h3>Siblings Relationship<br>
Explored through Performance</h3>

Two brothers from Israel recently toured the United States, performing their touching play about one brothers Down syndrome and its affect on their relationship.
<p> 
Ofer Shikartsi, 35, and Dekel Shikartsi, 21, have performed <i>On the Other Side of the House</i>, more than 500 times in Israel, and have teamed up with the very competent Janet Neeman, who offers consecutive Hebrew translation for English-speaking audiences.
<p>
In a sensitive, gentle and often humorous manner, the play offers insight into the life of Dekel, who has Down syndrome. Dekel also presents a sampling of his original poetry, including his biographical, <i>An Angel with Down Syndrome</i>. Following the performance, the actors are available for candid discussions with the audience. The Shikartsi brothers have tentatively scheduled another United States visit for this winter.
<p>
For information about scheduling a performance for your organization, please call Renee Schreiber, Director of Cultural Events for the Consulate General of Israel in New York, at (212) 499-5442.
</a>
<hr>
<H6><CENTER><I>
http://www.pcsltd.com/ndss/<BR>
Last Updated: November 25th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR>
<A HREF="../disclaim.htm">Copyright &copy 1996 National Down Syndrome Society.
All rights reserved.</A></I></CENTER></H6>
</body>
</htm>



</DOC>
<DOC>
<DOCNO>WT01-B04-264</DOCNO>
<DOCOLDNO>IA091-000971-B012-285</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/other.html 206.249.5.81 19970117210633 text/html 808
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 21:08:30 GMT
Last-modified: Tuesday, 27-Aug-96 20:23:20 GMT
Content-length: 619
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>The National Down Syndrome Society</TITLE>
<BASE HREF="http://www.pcsltd.com/ndss/"></HEAD>
<BODY BACKGROUND="../gifs/clouds2.gif">
<BODY>
<CENTER><H3>Other Useful Down Syndrome Links On The Internet</H3></CENTER>
<HR>
<A HREF="http://www.infi.net/~jwheaton/tdsahome.html"> 
The Tidewater Down Syndrome Association</A><BR>

<A HREF="http://www2.pcix.com/~kehler/What'sUp.html">
What's Up with Downs?</A><BR>


<HR><H6><CENTER><I>http://www.pcsltd.com/ndss/<BR>
Last Updated: June 28th, 1996 by <A HREF="mailto:webmaster@pcsltd.com">
webmaster@pcsltd.com</A><BR></I></CENTER></H6>

</BODY>
</HTML>


</DOC>
<DOC>
<DOCNO>WT01-B04-265</DOCNO>
<DOCOLDNO>IA091-000971-B013-103</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/ndss.html 206.249.5.81 19970117211053 text/html 428
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 21:10:20 GMT
Last-modified: Friday, 20-Dec-96 21:16:37 GMT
Content-length: 240
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>NDSS Homepage</TITLE></HEAD>
<FRAMESET COLS="30%,70%">
<FRAME SRC="menu.html" NAME="Destination Buttons" NORESIZE="NORESIZE">
<FRAME SRC="picture.html" NAME="DisplaySpace" NORESIZE="NORESIZE"></FRAMESET>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-266</DOCNO>
<DOCOLDNO>IA091-000971-B013-407</DOCOLDNO>
<DOCHDR>
http://ndss.org:80/contr.html 206.249.5.81 19970117211506 text/html 4438
HTTP/1.0 200 OK
Server: Netscape-Communications/1.12
Date: Friday, 17-Jan-97 21:17:14 GMT
Last-modified: Monday, 13-Jan-97 23:39:15 GMT
Content-length: 4249
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>NDSS - Contribution Form</TITLE></HEAD>
<BODY bgcolor=#ffffff>  <CENTER>

<TABLE WIDTH=600>
<TR><TD WIDTH=170><IMG SRC="gif/flower1.gif" WIDTH=121 HEIGHT=117></TD>
<TD  VALIGN=BOTTOM><FONT SIZE=2 FACE="ARIAL" COLOR=#B83448><B>
Welcome to the NDSS Combined Federal Campaign (CFC) page. 
Please complete the form below, print and forward to us via the postal service
 or fax at:</FONT><BR><BR>
The National Down Syndrome Society<BR>
666 Broadway<BR>
New York, NY  10012-2317<BR>
</TD></TR>
<TR><TD COLSPAN=2><BR>If you need to contact us, please call 212-460-9330 or 800-221-4602 or 
fax us at 212-979-2873.<BR>Combined Federal Campaign (CFC) designation 0540.</TD></TR>
<TR><TD COLSPAN=2><HR WIDTH=600></TD></TR>
<TR><TD COLSPAN=2><FONT SIZE=2 FACE="ARIAL" COLOR=#B83448><B>
I am pleased to enclose my tax deductible contribution 
to help NDSS research the answers to many of the questions 
associated with Down syndrome.</TD></TR>
</TABLE>

<FORM ACTION="http://www.ndss.org/cgi/contrib.cgi" METHOD="POST">

<TABLE WIDTH=600><TR><TD COLSPAN=3><B>
<FONT SIZE=2 FACE="ARIAL" COLOR=#B83448><B>I would like to contribute:
<TR><TD WIDTH=50><INPUT NAME="donate" TYPE=checkbox VALUE="checked">$1,000</TD>
<TD WIDTH=50><INPUT NAME="donate" TYPE=checkbox VALUE="checked">$250</TD>
<TD WIDTH=50><INPUT NAME="donate" TYPE=checkbox VALUE="checked">$50</TD></TR>
<TR><TD ><INPUT NAME="donate" TYPE=checkbox VALUE="checked">$750
<TD><INPUT NAME="donate" TYPE=checkbox VALUE="checked">$100</TD>
<TD><INPUT NAME="donate" TYPE=checkbox VALUE="checked">$25</TD></TR>
<TR><TD ><INPUT NAME="donate" TYPE=checkbox VALUE="checked">$500</TD>
<TD><INPUT NAME="donate" TYPE=checkbox VALUE="checked">$75</TD>
<TD><INPUT NAME="donate" TYPE=checkbox VALUE="checked">Other 
<TD><INPUT TYPE="text" NAME="amount" SIZE="10"></TD></TR>
<TR><TD COLSPAN=3>
<FONT SIZE=2 FACE="ARIAL" COLOR=#B83448><B>I wish to use my credit card to make a donation:</TD></TR>
<TR><TD><INPUT NAME="card" TYPE=radio VALUE="Master">MasterCard</TD>
<TD><INPUT NAME="card" TYPE=radio VALUE="AMEX">American Express</TD>
<TD><INPUT NAME="card" TYPE=radio VALUE="Visa">Visa</TD></TR>
</TABLE>
<TABLE WIDTH=600>
<TR><TD WIDTH=100>Card # </TD><TD WIDTH=450><INPUT NAME="card" TYPE=text SIZE="40"></TD></TR>
<TR><TD>Expiration Date</TD><TD><INPUT NAME="expire" TYPE=text SIZE="20"><BR></TD></TR>
<TR><TD></TD></TR>
<TR><TD>Signature </TD><TD>______________________________________</TD></TR>
<TR><TD COLSPAN=2>
</TABLE><BR>
<HR WIDTH=600 >
<BR>
</TD></TR>
<TABLE WIDTH=600>
<TR><TD WIDTH=100>Name:</TD><TD WIDTH=450><INPUT NAME="name" TYPE=text SIZE="40"></TD></TR>
<TR><TD>Address 1:</TD><TD><INPUT NAME="address" TYPE=text SIZE="40"></TD></TR>
<TR><TD>Address 2:</TD><TD><INPUT NAME="address" TYPE=text SIZE="40"></TD></TR>
<TR><TD>City:</TD><TD><INPUT NAME="city" TYPE=text SIZE="40"></TD></TR>
<TR><TD>State:</TD><TD><INPUT NAME="state" TYPE=text SIZE="19">
Zip Code: <INPUT NAME="code" TYPE=text SIZE="10"></TD></TR>
<TR><TD>Phone Number:</TD><TD><INPUT NAME="number" TYPE=text SIZE="40"></TD></TR>
<TR><TD><!INPUT TYPE=SUBMIT VALUE="Submit"></TD><TD><CENTER> <INPUT TYPE=RESET VALUE="Clear"></TD></TR>
</TABLE>
<BR>
<TABLE WIDTH=600 CELLPADDING=0>

<TR><TD COLSPAN=2><FONT SIZE=2 FACE="ARIAL" COLOR=#B83448><B>A copy of the last annual report may be obtained from:</B> 
<TR><TD>The New York Department of State</TD><TD>NDSS</TD></TR>
<TR><TD>Office of Charities Registration</TD><TD>666 Broadway</TD></TR>
<TR><TD>Albany, NY 12231</TD><TD>New York, NY  10012</TD></TR>
</TD></TR>
<TR><TD  COLSPAN=3><BR>

<HR WIDTH=600>

<MAP NAME="home">
<!--Picture gif\home.gif-->
<!--Comment -->
<AREA SHAPE="RECT" COORDS="3,0,80,74" HREF="ndss.html">
</MAP>
<IMG BORDER=0 SRC="gif/home.gif" WIDTH=83 HEIGHT=78 USEMAP="#home">

<MAP NAME="back">
<!--Picture gif\back.gif-->
<!--Comment -->
<AREA SHAPE="RECT" COORDS="1,1,109,39" HREF="ethan1.html">
</MAP>
<IMG BORDER=0 SRC="gif/back.gif"  USEMAP="#back">
<FONT SIZE=1 FACE="ARIAL">
Last Updated:  December 20, 1996  by <A HREF = "mailto:webmaster@ndss.org">webmaster@ndss.org</A><BR>

</TD></TR>

</TABLE>
</FORM>


<BR>

</CENTER>
</BODY>
<HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-267</DOCNO>
<DOCOLDNO>IA020-000212-B030-298</DOCOLDNO>
<DOCHDR>
http://www.sanitation.com:80/ 198.68.7.45 19970107134746 text/html 1128
HTTP/1.0 200 OK
Date: Tue, 07 Jan 1997 13:47:47 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 958
Last-modified: Thu, 30 May 1996 22:33:56 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Welcome to Albany-Lebanon Sanitation On-Line</TITLE>
</HEAD>
<BODY BGCOLOR="#b3c8f6" TEXT="#1b4fb1" VLINK="#a70133" ALINK="#d0112d" 
LINK="#e31254">
<H1><CENTER><BR>
Welcome to <BR>
Albany-Lebanon Sanitation Online </CENTER>
</H1>
<P><CENTER><BR>
</CENTER>
<H2><CENTER><A HREF="http://www.sanitation.com/frames/entry.html">Enter
using Frames</A> <BR>
<BR>
<A HREF="http://www.sanitation.com/no_frame/waste.html">No Frames</A></CENTER>
</H2>
<H4><CENTER></CENTER>
</H4>
<P><CENTER><IMG SRC="frames/images/spacer.gif" WIDTH="152" HEIGHT="102"
NATURALSIZEFLAG="0" ALIGN=bottom><BR>
<A HREF="http://home.netscape.com/comprod/mirror/index.html"><IMG SRC="frames/images/netscape.gif"
WIDTH="88" HEIGHT="31" ALIGN=bottom NATURALSIZEFLAG="3"><BR>
<BR>
</A><B>This site is best viewed using Netscape 2.0 or higher.<BR>
<A HREF="http://home.netscape.com/comprod/mirror/index.html">Click here
to download.<BR>
</A></B></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-268</DOCNO>
<DOCOLDNO>IA020-000212-B030-360</DOCOLDNO>
<DOCHDR>
http://www.sanitation.com:80/index.html 198.68.7.45 19970107134829 text/html 1128
HTTP/1.0 200 OK
Date: Tue, 07 Jan 1997 13:48:33 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 958
Last-modified: Thu, 30 May 1996 22:33:56 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Welcome to Albany-Lebanon Sanitation On-Line</TITLE>
</HEAD>
<BODY BGCOLOR="#b3c8f6" TEXT="#1b4fb1" VLINK="#a70133" ALINK="#d0112d" 
LINK="#e31254">
<H1><CENTER><BR>
Welcome to <BR>
Albany-Lebanon Sanitation Online </CENTER>
</H1>
<P><CENTER><BR>
</CENTER>
<H2><CENTER><A HREF="http://www.sanitation.com/frames/entry.html">Enter
using Frames</A> <BR>
<BR>
<A HREF="http://www.sanitation.com/no_frame/waste.html">No Frames</A></CENTER>
</H2>
<H4><CENTER></CENTER>
</H4>
<P><CENTER><IMG SRC="frames/images/spacer.gif" WIDTH="152" HEIGHT="102"
NATURALSIZEFLAG="0" ALIGN=bottom><BR>
<A HREF="http://home.netscape.com/comprod/mirror/index.html"><IMG SRC="frames/images/netscape.gif"
WIDTH="88" HEIGHT="31" ALIGN=bottom NATURALSIZEFLAG="3"><BR>
<BR>
</A><B>This site is best viewed using Netscape 2.0 or higher.<BR>
<A HREF="http://home.netscape.com/comprod/mirror/index.html">Click here
to download.<BR>
</A></B></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-269</DOCNO>
<DOCOLDNO>IA020-000212-B030-311</DOCOLDNO>
<DOCHDR>
http://www.sanitation.com:80/frames/entry.html 198.68.7.45 19970107134758 text/html 560
HTTP/1.0 200 OK
Date: Tue, 07 Jan 1997 13:48:01 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 390
Last-modified: Thu, 30 May 1996 22:30:56 GMT
</DOCHDR>
<html>

<title>Albany-Lebanon Sanitation: Welcome </title>


<frameset rows="78,*">
<frame src="header.html" marginwidth=0 marginheight=0 noresize 
scrolling="no" name="header">
<frame src="navbar.html" marginwidth=0 marginheight=0 name="bottom">

</frameset>

<noframes>If you can read this, then you need to go back.
Your browser does not support Netscape Frames.
</noframes>

</html>



</DOC>
<DOC>
<DOCNO>WT01-B04-270</DOCNO>
<DOCOLDNO>IA020-000212-B030-407</DOCOLDNO>
<DOCHDR>
http://www.sanitation.com:80/no_frame/form.html 198.68.7.45 19970107134940 text/html 2641
HTTP/1.0 200 OK
Date: Tue, 07 Jan 1997 13:49:25 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 2470
Last-modified: Tue, 31 Dec 1996 18:44:35 GMT
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>Contact Albany-Lebanon Sanitation On-Line</TITLE>
</HEAD>
<BODY BGCOLOR="#F9F9F9">
<FORM action="/cgi-bin/formmail?info@sanitation.com" method="POST"
enctype="x-www-form-encoded">

<H1><TABLE BORDER=0 CELLPADDING=1 WIDTH="100%">
   <TR>
      <TD VALIGN=top>
         <P></H1><IMG SRC="../frames/images/mail_nav.gif" WIDTH=200
         HEIGHT=350 BORDER=0 ALIGN=bottom naturalsizeflag="0">
      </TD><TD VALIGN=top cellpadding=5>
         <P><FONT SIZE=4><A NAME="top"></A></FONT></P>
         
         <H1 ALIGN=CENTER><FONT SIZE=4>Contact Albany-Lebanon
         Sanitation for more information!</FONT></H1>
      </TD></TR>
</TABLE></CENTER></H1>

<P>We invite your questions and comments. Please submit your
inquiries with the form below:</P>

<PRE>Your Name:
<INPUT TYPE="text" NAME="name" VALUE="" SIZE=32 MAXLENGTH=40>
Your Company:
<INPUT TYPE="text" NAME="Company" VALUE="" SIZE=30>
Your E-mail address:
<INPUT TYPE="text" NAME="email" VALUE="" SIZE=26 MAXLENGTH=40>
Your daytime phone number:
<INPUT TYPE="text" NAME="phone" VALUE="" SIZE=23 MAXLENGTH=20>
Your fax number:
<INPUT TYPE="text" NAME="fax number" VALUE="" SIZE=23 MAXLENGTH=40>
Your mailing address:
<TEXTAREA NAME="your address-street/box,city" ROWS=4 COLS=43></TEXTAREA>
Your service address:
<TEXTAREA NAME="service address-street,city" ROWS=4 COLS=43></TEXTAREA>
&nbsp;
Your comments/questions:
<TEXTAREA NAME="comments" ROWS=7 COLS=42></TEXTAREA>
&nbsp;
<SELECT NAME="contact type" SIZE=3 MULTIPLE>
   <OPTION>I would like to be contacted by e-mail
   <OPTION>I would like to be contacted by regular mail
   <OPTION>I would like to be contacted by phone
</SELECT></PRE>

<H4>(Hold down <I>Control</I> or <I>Command</I> to select more than
one option.)</H4>

<P ALIGN=CENTER><INPUT TYPE="submit" NAME="name"
VALUE="Send to Albany-Lebanon Sanitation"><INPUT TYPE="reset"
VALUE="Oops, let me try again!"></P>

<P ALIGN=CENTER><HR SIZE="8" WIDTH="25%"></P>

<P ALIGN=CENTER><A HREF="http://www.sanitation.com/index.html">HOME</A>
|
<A HREF="http://www.sanitation.com/no_frame/recycle.html">RECYCLING</A>
|
<A HREF="http://www.sanitation.com/no_frame/compost.html">COMPOSTING</A>
|
<A HREF="http://www.sanitation.com/no_frame/waste.html">SERVICES</A>
|
<A HREF="http://www.sanitation.com/no_frame/areainfo.html">COMMUNITY
INFORMATION</A></P>

<P ALIGN=CENTER>this site created by
<A HREF="mailto:greatideas@pwdesign.com">Paperworks Design</A></P>
</FORM>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-271</DOCNO>
<DOCOLDNO>IA020-000212-B030-330</DOCOLDNO>
<DOCHDR>
http://www.sanitation.com:80/no_frame/waste.html 198.68.7.45 19970107134807 text/html 10919
HTTP/1.0 200 OK
Date: Tue, 07 Jan 1997 13:48:09 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 10747
Last-modified: Tue, 31 Dec 1996 18:37:34 GMT
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>Waste Disposal Information</TITLE>
</HEAD>
<BODY TEXT="#1B4FB1" BGCOLOR="#B3C8F6" LINK="#E31254" ALINK="#D0112D"
VLINK="#A70133">

<H3><TABLE BORDER=0 CELLPADDING=1 WIDTH="100%">
   <TR>
      <TD VALIGN=top>
         <P></H3><MAP NAME="serv_map"><AREA SHAPE=rect COORDS="20,312 144,329"
         HREF="waste.html#indust"><AREA SHAPE=rect COORDS="20,296 144,311"
         HREF="waste.html#resident"><AREA SHAPE=rect COORDS="20,285 144,295"
         HREF="waste.html#commerc"><AREA SHAPE=rect COORDS="20,267 144,284"
         HREF="waste.html#doanddont"><AREA SHAPE=rect COORDS="20,250 144,266"
         HREF="waste.html#reduce"></MAP><A HREF="wastenav.map/IMURL/http://www.sanitation.com/no_frame/waste.html"><IMG ISMAP
         SRC="../frames/images/wastenav.gif" WIDTH=200 HEIGHT=350
         BORDER=0 ALIGN=bottom usemap="#serv_map"></A>
      </TD><TD VALIGN=top cellpadding=5>
         <P><FONT SIZE=4>There's more to successful solid-waste
         disposal than "picking up the garbage." It has to be done in
         a manner that satisfies not only the individual customer,
         but also the community and the environment.<BR>
         
         <BR>
         
         At Albany-Lebanon Sanitation, our service includes regular
         garbage pick-up, recycling, and several types of specialized
         containers and services. We strive to employ the latest
         equipment and handling methods for safe, and efficient
         removal of solid waste.<BR>
         
         <BR>
         
         In the "perfect" waste-management system, there would be no
         waste; every article of refuse could be reclaimed, just as
         in nature. Albany Lebanon Sanitation will always aim for
         that level of efficiency, and we welcome your suggestions
         for improving our service.</FONT>
      </TD></TR>
</TABLE></H3>

<P ALIGN=CENTER><A HREF="http://www.sanitation.com/index.html">HOME</A>
|
<A HREF="http://www.sanitation.com/no_frame/recycle.html">RECYCLING</A>
|
<A HREF="http://www.sanitation.com/no_frame/compost.html">COMPOSTING</A>
| <A HREF="/no_frame/waste.html">SERVICES</A> |
<A HREF="http://www.sanitation.com/no_frame/form.html">ASK US</A><BR>

<A HREF="http://www.sanitation.com/no_frame/areainfo.html">COMMUNITY
INFORMATION</A></P>

<H1><A NAME="resident"></A>Services</H1>

<H2>Residential</H2>

<UL>
   <LI>Weekly or on-call garbage collection
   
   <LI>Weekly curbside collection of recyclables (available in most
   areas)
   
   <LI>Bi-weekly collection of yard debris (available in most areas)
   
   <LI>Composters
   
   <LI>Special pick-up of bulky items such as appliances and
   furniture
   
   <LI>Temporary containers for cleanup projects
</UL>

<H2>Residential Service Cart or Can</H2>

<P>Our regular service is collecting one cart or can per residence,
once a week - unless otherwise directed. Permanent, temporary or
off-schedule pick-up service may be arranged by calling during
regular business hours (8 am to 5 pm).<BR>

<BR>

We have automated our collection routes wherever possible to maximize
efficiency. We offer two sizes of carts for you to choose from. Both
carts have wheels and need to be rolled to the curb for collection by
our automated truck.<BR>

<BR>

Our most popular service is the 90-gallon cart. The large capacity
makes cleaning up after home projects easy. A 32-gallon cart is also
available, or you can use your own 32-gallon can.<BR>

<BR>

Collections begin at 6:00 am, so it may be convenient for you to set
your refuse out the evening before pick-up day.<BR>

</P>

<H3>Service Rates</H3>

<P>Monthly rates, based on one pick-up per week for Albany, Lebanon,
&amp; Millersburg:</P>

<DL>
   <DT>One 32-gallon can $10.35
   
   <DT>Extra/occasional can $ 3.00 per extra can
   
   <DT>One 32-gallon cart $9.50
   
   <DT>One 90-gallon cart $15.50
</DL>

<P><I>Rates for rural areas are slightly higher.</I></P>

<H3>Will Call Service</H3>

<P>For the customer who needs less than 1 can picked up each week.
Please call our office to schedule a pick-up. The rate below applies
to each pick-up.</P>

<DIR>
   <LI>Two 32-gallon cans:$ 5.90
   
   <LI>Rural rate: Two 32-gallon cans:$ 6.25
</DIR>

<P><BR>

<HR></P>

<H2>Moving</H2>

<P>When you move from one location to another within our service
area, be sure to notify us in advance so your service can continue
without interruption. If you move out of the area, a call to the
office will terminate your service.</P>

<H2>Vacation</H2>

<P>When vacation plans call for being away for more than two weeks,
your account will be given proper credit if we are notified in
advance.</P>

<H2>Curbside Recycling</H2>

<P>We provide 2 recycle bins per household to sort your recyclables.
Place at curb on your garbage day by 6:00 A.M.<BR>

</P>

<H2>Drop Boxes</H2>

<P>At your home or business, a large project can generate a
tremendous amount of refuse.</P>

<DIR>
   <LI>20-yard box (16' x 8' x 6')
   
   <LI>30-yard box (18' x 8' x 7')
   
   <LI>40-yard box (20' x 8' x 8')
</DIR>

<P>Service includes delivery, three days use and pickup.<BR>

</P>

<H2>Security Storage Units</H2>

<P>Portable lockable storage units are available. These are good for
construction projects, storing furniture, etc.<BR>

<HR><A NAME="commerc"></A></P>

<H2>Commercial</H2>

<DIR>
   <LI>Regularly scheduled garbage collection
   
   <LI>Recycling programs to meet the needs of each business.
   Including cardboard, office paper, cans, bottles, etc.<HR>
</DIR>

<H1><A NAME="indust"></A></H1>

<H2>Industrial</H2>

<UL>
   <LI>Drop boxes for garbage or recycling
   
   <LI>Recycling programs to meet the needs of each business.
   Including cardboard, office paper, woodwaste, etc.
</UL>

<P><BR>

<BR>

<HR><A NAME="doanddont"></A></P>

<H1>PLEASE DO NOT put these items in your trash:</H1>

<UL>
   <LI><STRONG>medical sharps ( i.e. needles, lancets,
   syringes)</STRONG>
   
   <LI><STRONG>any liquid waste</STRONG>
   
   <LI><STRONG>hazardous waste (i.e. anything labeled poison or
   caustic)</STRONG>
   
   <LI><STRONG>large appliances</STRONG>
   
   <LI><STRONG>tires</STRONG>
</UL>

<P><BR>

<HR></P>

<H2><A HREF="areainfo.html#calen">Annual Events</A></H2>

<P>Each year we have several scheduled events. These include: Spring
Clean-Up Day; Household Hazardous Waste Collection event; Leaf
Collection for several weeks in the fall; and Christmas Tree
Collection for 2 weeks after Christmas. These events are available
for no additional charge, with the exact
<A HREF="areainfo.html#calen">dates</A> announced in advance each
year.</P>

<H2>Clean-Up Services</H2>

<P>If you have an accumulation of refuse material and no way of
removing it yourself, let us handle it. We will load and haul away
piles of yard debris, tree cuttings and building material. Call today
for rates or an on-site estimate.</P>

<H2>Temporary Containers</H2>

<P>Large yard cleanup projects, home repair debris, general cleanup:
When there is too much for your household refuse can, we can provide
a container to match the job. Call ahead to reserve your container
for the day(s) you need it.<BR>

<BR>

</P>

<H4>3 yard container (70" x 42" x 44"):</H4>

<P><BR>

Service includes delivery, two days use, and pick up.<BR>

</P>

<H4>1 1/2 Yard Debris containers:</H4>

<P><BR>

Service includes delivery, one week use, and pick up.<BR>

<BR>

<HR><A NAME="reduce"></A></P>

<H1>Helpful Hints for Reducing Toxic Waste:</H1>

<H2>Household Toxic Waste</H2>

<P>As a consumer you may assume a product is safe if it is offered
for sale. Unfortunately, many household products contain hazardous
ingredients that can be harmful when you use them or dispose of them
improperly.</P>

<P ALIGN=CENTER><B>Common Hazardous Products</B></P>

<UL>
   <LI>Oil-based Paints
   
   <LI>Solvent-based Paint Thinners
   
   <LI>Furniture and Floor Polishes
   
   <LI>Lawn Fertilizers
   
   <LI>Drain Openers
   
   <LI>Mothballs
   
   <LI>Pesticides
   
   <LI>Motor Oil
   
   <LI>Bug Sprays
   
   <LI>Smoke Detectors (Should be returned to the manufacturer at
   their address on base of detector)
</UL>

<P><BR>

<BR>

<BR>

<B>Look for These Key Words &amp; Symbols:</B><BR>

Flammable/Combustible<BR>

Can easily be set on fire<BR>

<BR>

Corrosive/Caustic<BR>

Can burn and destroy living tissue<BR>

<BR>

Radioactive<BR>

Can damage and destroy cells and chromosomes<BR>

<BR>

Toxic/Poisonous<BR>

Capable of causing injury or death from ingestion,<BR>

inhalation or absorption<BR>

<BR>

Explosive/Reactive<BR>

Can detonate or explode from exposure to heat,<BR>

sudden shock or pressure<BR>

<BR>

<B>Consider Alternative Products<BR>

<BR>

</B><I>Buy Only What You Need</I><BR>

If you have leftovers, pass them on to someone else.<BR>

<BR>

<I>If You Are Pregnant Avoid Hazardous Products</I><BR>

Many chemicals are not tested for their effects on the unborn fetus.
</P>

<H2>Non-Toxic Alternatives</H2>

<H4>Outdoor Pesticides</H4>

<UL>
   <LI>Use natural predators such as ladybugs, ground beetles,
   lacewings, praying mantis &amp; spiders.
   
   <LI>Set traps to collect insects such as wet newspapers, stones,
   flat boards, lettuce, spinach leaves &amp; grapefruit rinds.
   
   <LI>Use companion planting.
</UL>

<H4>Drain Cleaner</H4>

<UL>
   <LI>Prevent clogged drain by pouring boiling water down drain
   periodically.
   
   <LI>Plunger followed by handful of baking soda with 1/2 cup
   vinegar; cover drain &amp; let sit for 15 minutes followed by 2
   quarts boiling water.
   
   <LI>Use mechanical snake.
</UL>

<H4>Disinfectants</H4>

<UL>
   <LI>Use 1 teaspoon bleach mixed with 1 gallon water.
   
   <LI>Use ammonia.
</UL>

<H4>Oven Cleaner</H4>

<UL>
   <LI>Sprinkle salt or baking soda on fresh spills when they're warm
   and scrape them off when oven cools.
   
   <LI>Line bottom of oven with foil (check oven warranty about foil
   use).
</UL>

<H4>Air Freshener</H4>

<UL>
   <LI>Ventilation is the best air freshener.
   
   <LI>Open box of baking soda.
</UL>

<H4>Tile Cleaner</H4>

<UL>
   <LI>Scrub with baking soda.
</UL>

<H4>Indoor Insect Spray</H4>

<UL>
   <LI>Screen in windows &amp; doors.
   
   <LI>Promptly put discarded food into covered containers.
   
   <LI>Keep kitty litter box clean &amp; isolated.
   
   <LI>Use flypaper or flyswatter.
</UL>

<P ALIGN=CENTER><A HREF="http://www.sanitation.com/index.html">HOME</A>
| <A HREF="recycle.html">RECYCLING</A> |
<A HREF="compost.html">COMPOSTING</A> |
<A HREF="waste.html">SERVICES</A> | <A HREF="form.html">ASK
US</A><BR>

<A HREF="areainfo.html">COMMUNITY INFORMATION</A><BR>

<BR>

<BR>

this site created by
<A HREF="mailto:greatideas@pwdesign.com">Paperworks Design</A></P>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-272</DOCNO>
<DOCOLDNO>IA020-000212-B030-420</DOCOLDNO>
<DOCHDR>
http://www.sanitation.com:80/no_frame/areainfo.html 198.68.7.45 19970107134948 text/html 6599
HTTP/1.0 200 OK
Date: Tue, 07 Jan 1997 13:49:52 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 6428
Last-modified: Tue, 31 Dec 1996 18:22:35 GMT
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>Albany-Lebanon Sanitation's links to our community</TITLE>
</HEAD>
<BODY TEXT="#1B4FB1" BGCOLOR="#B3C8F6" LINK="#E31254" ALINK="#D0112D"
VLINK="#A70133">

<P><TABLE BORDER=0 CELLPADDING=1 WIDTH="100%">
   <TR>
      <TD VALIGN=top>
         <P><MAP NAME="comm_map"><AREA SHAPE=rect COORDS="10,286 108,303"
                  HREF="areainfo.html#util"><AREA SHAPE=rect COORDS="10,304 108,323"
                  HREF="areainfo.html#gov"><AREA SHAPE=rect COORDS="109,286 190,303"
                  HREF="areainfo.html#schools"><AREA SHAPE=rect COORDS="109,304 190,323"
                  HREF="areainfo.html#calen"></MAP><A HREF="http://www.sanitation.com/no_frame/areainfo.html"><IMG ISMAP
         SRC="../frames/images/communav.gif" WIDTH=200 HEIGHT=350
         BORDER=0 ALIGN=bottom usemap="#comm_map"></A>
      </TD><TD VALIGN=top cellpadding=5>
         <H1>Calendar of Events</H1>
         
         <H3>OTHER COMMUNITY LINKS WILL BE ADDED SOON!</H3>
         
         <P ALIGN=CENTER><A HREF="http://sanitation.com/index.html">HOME</A><BR>
         
         <A HREF="http://www.sanitation.com/no_frame/recycle.html">RECYCLING</A><BR>
         
         <A HREF="http://www.sanitation.com/no_frame/compost.html">COMPOSTING</A><BR>
         
         <A HREF="http://www.sanitation.com/no_frame/waste.html">SERVICES</A><BR>
         
         <A HREF="http://www.sanitation.com/no_frame/form.html">ASK
         US</A><BR>
         
         <BR>
         
      
      </TD></TR>
</TABLE></P>

<H2>Free Community Events sponsored by Albany-Lebanon Sanitation
</H2>

<H2><HR SIZE="8" WIDTH="25%"></H2>

<P><B><FONT SIZE=4 COLOR="#AF0000">Albany Spring Cleanup</FONT></B>
</P>

<P><FONT SIZE=4>Saturday, May 3, 1997</FONT></P>

<P><FONT SIZE=4>Location: Albany-Lebanon Sanitation Co., 1214
Montgomery St SE, Albany</FONT></P>

<P><B><FONT SIZE=4 COLOR="#AF0000">&nbsp;</FONT></B></P>

<P><B><FONT SIZE=4 COLOR="#AF0000">Lebanon Spring Cleanup</FONT></B>
</P>

<P><FONT SIZE=4>Saturday, May 17, 1997</FONT></P>

<P><FONT SIZE=4>Location: Old Champion Lumber Mill, Santiam Hwy,
Lebanon (across from Wal-Mart)</FONT></P>

<P><B><FONT SIZE=4 COLOR="#AF0000">&nbsp;</FONT></B></P>

<P><B><FONT SIZE=4 COLOR="#AF0000">Harrisburg Spring
Cleanup</FONT></B></P>

<P><FONT SIZE=4>Saturday, June 28, 1997</FONT></P>

<P><FONT SIZE=4>Location: Harrisburg High School in Harrisburg</FONT>
</P>

<P><B><FONT SIZE=4 COLOR="#AF0000">&nbsp;</FONT></B></P>

<P><B><FONT SIZE=4 COLOR="#AF0000">Recycle Run</FONT></B></P>

<P><FONT SIZE=4>Saturday, October 4, 1997</FONT></P>

<P><FONT SIZE=4>Five Mile Run, Three Mile Fitness Walk, Two Mile
Youth Run, Kid's Fun Run.</FONT></P>

<P><FONT SIZE=4>Location: Monteith Riverpark in Albany</FONT></P>

<P><FONT SIZE=4>Registration forms available at Albany-Lebanon
Sanitation after September 1st</FONT></P>

<P><B><FONT SIZE=4 COLOR="#AF0000">&nbsp;</FONT></B></P>

<P><B><FONT SIZE=4 COLOR="#AF0000">Household Hazardous Waste
Collection</FONT></B></P>

<P><FONT SIZE=4>Bring in your toxics and we will dispose of them for
you safely!</FONT></P>

<P><FONT SIZE=4>Locations:</FONT></P>

<P><TABLE BORDER=1 CELLPADDING=5 WIDTH="100%">
   <TR>
      <TD VALIGN=top>
         <P><B><FONT SIZE=4>Lebanon</FONT></B>
      </TD><TD>
         <P>DEQ sponsored event</P>
         
         <P>Saturday, September 6, 1997</P>
         
         <P>Call ALS for details
      </TD></TR>
   <TR>
      <TD VALIGN=top>
         <P><B><FONT SIZE=4>Harrisburg</FONT></B><FONT SIZE=4>
         </FONT>
      </TD><TD>
         <P>DEQ sponsored event</P>
         
         <P>Saturday, September 20, 1997</P>
         
         <P>Call ALS for details
      </TD></TR>
   <TR>
      <TD VALIGN=top>
         <P><B><FONT SIZE=4>Albany</FONT></B>
      </TD><TD>
         <P>Friday &amp; Saturday, October 17, &amp; 18, 1997</P>
         
         <P>9:00 am - 2:00 pm</P>
         
         <P>Albany-Lebanon Sanitation</P>
         
         <P>1214 S.E. Montgomery St.
      </TD></TR>
</TABLE></P>

<P><TABLE BORDER=1 CELLPADDING=5 WIDTH="100%">
   <TR>
      <TH>
         <P>Yes
      </TH><TH>
         <P>No<BR>
         
      
      </TH></TR>
   <TR>
      <TD>
         <P>Anything labeled caution, danger, flammable, etc.
         Examples include: paints, pesticides, poisons, antifreeze,
         paint thinner, and batteries.
      </TD><TD>
         <P>Waste generated from a business (unless
         pre-registered-call for details) Explosives, Radioactive
         waste.
      </TD></TR>
</TABLE><BR>

<HR SIZE="8" WIDTH="25%"></P>

<H3>Leaf Collection<BR>

</H3>

<P>On the following weeks we will collect leaves from curbed streets.
Pile away</P>

<P>from your curb in the street for collection. Leaves are mulched
and recycled into</P>

<P>compost. Collection will be in the city limits of Albany and
Lebanon.</P>

<P>&nbsp;</P>

<P><TABLE BORDER=1 CELLPADDING=5 WIDTH="100%">
   <TR>
      <TD VALIGN=top>
         <P><B>Albany: </B>
      </TD><TD>
         <P>(Weeks of)</P>
         
         <P>November 4-8</P>
         
         <P>November 18-22</P>
         
         <P>December 2-6
      </TD></TR>
   <TR>
      <TD VALIGN=top>
         <P><B>Lebanon: </B>
      </TD><TD>
         <P>(Week of)</P>
         
         <P>December 1-5, 1997
      </TD></TR>
</TABLE></P>

<P>&nbsp;</P>

<P><HR SIZE="8" WIDTH="25%"></P>

<H3>Christmas Tree Collection<BR>

December 26th, 1997 through January 10th, 1998</H3>

<P>On your garbage day, place trees without tinsel or flocking at the
curb for pick up. These are mulched and recycled into compost.<BR>

<BR>

On your garbage day, place trees without tinsel or flocking at the
curb for pick up. These are mulched and recycled into compost.</P>

<P ALIGN=CENTER><FONT SIZE=4><A HREF="http://sanitation.com/index.html">HOME</A></FONT><FONT SIZE=4>
|
</FONT><FONT SIZE=4><A HREF="http://www.sanitation.com/no_frame/recycle.html">RECYCLING</A></FONT><FONT SIZE=4>
|
</FONT><FONT SIZE=4><A HREF="http://www.sanitation.com/no_frame/compost.html">COMPOSTING</A></FONT><FONT SIZE=4>
|
</FONT><FONT SIZE=4><A HREF="http://www.sanitation.com/no_frame/waste.html">SERVICES</A></FONT><FONT SIZE=4>
|
</FONT><FONT SIZE=4><A HREF="http://www.sanitation.com/no_frame/form.html">ASK
US</A></FONT><FONT SIZE=4><BR>

<BR>

</FONT>this site created by
<A HREF="mailto:greatideas@pwdesign.com">Paperworks Design</A></P>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-273</DOCNO>
<DOCOLDNO>IA020-000212-B030-378</DOCOLDNO>
<DOCHDR>
http://www.sanitation.com:80/no_frame/recycle.html 198.68.7.45 19970107134900 text/html 13553
HTTP/1.0 200 OK
Date: Tue, 07 Jan 1997 13:48:52 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 13381
Last-modified: Tue, 31 Dec 1996 18:47:32 GMT
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>Everything you wanted to know about recycling...</TITLE>
</HEAD>
<BODY background="../frames/images/arr_back.gif">

<P><BR>

<TABLE BORDER=0 CELLPADDING=1 WIDTH="100%">
   <TR>
      <TD VALIGN=top>
         <P><A NAME="rec_top"></A><MAP NAME="recycnav_map"><AREA SHAPE=rect COORDS="21,128,113,169"
                  HREF="recycle.html#glass" target="mainpage"><AREA SHAPE=rect 
                  COORDS="30,170,115,205"
                  HREF="recycle.html#metal" target="mainpage"><AREA SHAPE=rect 
                  COORDS="25,206,125,254"
                  HREF="recycle.html#plastic" target="mainpage"><AREA SHAPE=rect 
                  COORDS="19,255,107,293"
                  HREF="recycle.html#paper" target="mainpage"><AREA SHAPE=rect 
                  COORDS="132,119,182,330"
                  HREF="recycle.html#motoroil" target="mainpage"><AREA SHAPE=rect 
                  COORDS="142,131,182,332"
                  HREF="recycle.html#locations" target="mainpage"></MAP><A HREF="a href="
         : /imurl / /www.sanitation.com /frames /recycln.map _frame /recycle.html /no http /images "><IMG ISMAP
         SRC="../frames/images/recycnav.gif" WIDTH=200 HEIGHT=350
         BORDER=0 ALIGN=bottom
         usemap="#recycnav_map" naturalsizeflag="0"></A>
      </TD><TD VALIGN=top cellpadding=5>
         <P>Albany-Lebanon Sanitation is dedicated to the concept and
         practice of environmental preservation. We are constantly
         seeking new technologies and services which will not only
         preserve our environment, but provide more efficient and
         economical collection, recycling, and disposal of waste
         materials. By recycling, less energy is required than when
         using virgin resources, both in the initial extraction of
         resources and in manufacturing new products. Recycling
         conserves valuable natural resources and saves millions of
         dollars of valuable materials that would otherwise be buried
         in landfills. For the environment, processing recyclables
         into new goods produces far less air, water and land
         pollution. Recycling costs money, but it is still a good
         investment. The revenue derived by selling your recyclable
         materials offsets about 20% of the costs of offering the
         service. These short-termed costs are offset by long-term
         gains of saving resources, energy and landfill space. By
         changing our destructive habits we will begin to sustain a
         healthier environment and preserve our finite resources for
         future generations. This is why Albany-Lebanon Sanitation
         has made a commitment to recycling. Please become a part of
         this growing endeavor. <NOBR></P>
         
         <P ALIGN=CENTER><A HREF="#yarddebris">Yard Debris</A> |
         <A HREF="#paper">Paper Products</A> |
         <A HREF="#glass">Glass</A> | <A HREF="#metal">Metals</A>
         <WBR><A HREF="#motoroil">Motor Oil</A> |
         <A HREF="#plastic">Plastics</A> |
         <A HREF="#locations">Recycling Locations</NOBR></A>
      </TD></TR>
</TABLE></P>

<P ALIGN=CENTER><A HREF="http://www.sanitation.com/index.html">HOME</A>
|
<A HREF="http://www.sanitation.com/no_frame/recycle.html">RECYCLING</A>
|
<A HREF="http://www.sanitation.com/no_frame/compost.html">COMPOSTING</A>
| <A HREF="/no_frame/waste.html">SERVICES</A> |
<A HREF="http://www.sanitation.com/no_frame/form.html">ASK US</A>
<A HREF="http://www.sanitation.com/no_frame/areainfo.html">COMMUNITY
INFORMATION</A></P>

<P><HR></P>

<H2><A NAME="yarddebris"></A>Yard Debris Recycling &amp;
<A HREF="compost.html">Composters</A></H2>

<P>City residents of Albany, Lebanon, and Millersburg: If you choose,
a yard debris container can be delivered to regular garbage service
customers, by request. These containers will be emptied every other
week on your regular garbage day. Containers must be placed at
curbside to be emptied. If you prefer to
<A HREF="compost.html">compost</A> your own yard debris, we will
supply you with a <A HREF="compost.html">composter</A> instead. Yard
Debris - Defined as: Lawn clippings, brush, limbs, tree trimmings,
prunings. Not acceptable: Dirt/gravel, paper/ plastic trash, metal or
rubber objects, stumps / logs, rocks / bricks. RURAL residents: We
have <A HREF="compost.html">composters</A> available.
<A HREF="#rec_top">BACK TO THE TOP</A><HR><A NAME="paper"></A><IMG
SRC="../frames/images/sm_paper.gif" ALT="Paper Products" WIDTH=120
HEIGHT=60 ALIGN=top><BR>

</P>

<H3>Newspapers</H3>

<P>Anything that comes in your newspaper can be recycled with your
newspaper. Stack in easily handled untied stacks. Please do not mix
newspaper with magazines, cardboard or paper bags.</P>

<H3>Corrugated (3-layer) Cardboard &amp; Brown Paperbags</H3>

<P>Flatten, and place at curbside. Remove all wire and plastic. Waxed
cardboard cannot be recycled. Recycle brown paper bags with your
cardboard. Recycle cereal boxes and shoe boxes with your mixed paper
(see below).</P>

<H3>Mixed Paper consists of:</H3>

<P>(These three can be mixed in one brown paper bag.)<BR>

</P>

<H4>Sorted Household Mail<BR>

</H4>

<P>White and pastel colored paper, envelopes, window envelopes,
pamphlets and brochures. Staples are okay. <B>No construction paper,
tissue paper, books, paper towels, tape, food or gum wrappers.</B>
</P>

<H4>Paperboard (Flatten)<BR>

</H4>

<P>Cereal type boxes (remove liners), shoe boxes, 6 &amp; 12 pack
beverage boxes, paper egg cartons, paper tubes ( i.e. paper towel).
<B>No ice cream boxes, milk cartons, foil-lined boxes, coffee cups,
any container from the frozen or refrigerated food sections.</B></P>

<H4>Magazines<BR>

</H4>

<P>Shiny coated magazines and catalogs. <A HREF="#rec_top">BACK TO
THE TOP</A><HR><A NAME="motoroil"></A><IMG
SRC="../frames/images/sm_oil.gif" ALT="Used Motor Oil" WIDTH=94
HEIGHT=60 ALIGN=top><BR>

<BR>

Pour motor oil into non-breakable containers with tight fitting
screw-on caps (bleach or milk jugs).<STRONG> No paint thinner, gas or
other hazardous liquids. </STRONG><A HREF="#rec_top">BACK TO THE
TOP</A><HR><A NAME="glass"></A><IMG
SRC="../frames/images/sm_glass.gif" ALT="Glass" WIDTH=120 HEIGHT=60
ALIGN=top><BR>

<BR>

Sorted by color (clear, green, brown) in separate bags. Bottles and
jars only (please rinse). Labels do not need to be removed. Recycle
the lids from jars with your tin. <STRONG> No window glass, light
bulbs, pyrex or ceramics. </STRONG><A HREF="#rec_top">BACK TO THE
TOP</A><HR><A NAME="metal"></A><IMG
SRC="../frames/images/sm_metal.gif" ALT="Tin Cans/Aluminum" WIDTH=120
HEIGHT=60 ALIGN=top><BR>

<BR>

</P>

<H3>Tin Cans/Aluminum</H3>

<P>Remove label, top and bottom. Rinse clean and flatten whenever
possible. Rounded end cans do not need to be flattened. Foil, TV
dinner trays and beverage cans are all accepted. <STRONG> No
appliances or scrap metal. </STRONG><A HREF="#rec_top">BACK TO THE
TOP</A><HR><A NAME="plastic"></A><IMG
SRC="../frames/images/sm_plast.gif" ALT="Plastics" WIDTH=120
HEIGHT=60 ALIGN=top naturalsizeflag="3"><BR>

<BR>

</P>

<H3>Bottle and tub shaped rigid plastic containers only</H3>

<P>Why can we only recycle bottle &amp; tub shaped plastics? The
Garten Foundation in Salem (where we take our plastics), has a new
Plastics Recovery Facility (PRF) which is the first in the world able
to sort plastic bottles and tubs with all seven plastic resin code
numbers. Previously, the only way to recycle plastics was to keep
each resin code number separate from the time it's picked up to the
time it goes to market. This PRF can not only take all 7 resin code
numbers but can take them mingled together!, but only if they are
bottle or tub shaped. The system that separates the plastics by resin
code can only "see" these shapes. Bags, trays, etc. are impossible
for this system to sort.</P>

<H3>Examples of Recyclable Plastic Containers <TABLE BORDER=0
CELLSPACING=5 CELLPADDING=5 WIDTH="100%">
   <TR>
      <TD>
         <P>Kitchen </H3></P>
         
         <UL>
            <LI>Milk
            
            <LI>Soda
            
            <LI>Water
            
            <LI>Juice
            
            <LI>Yogurt &amp; Margarine
            
            <LI>Ketchup &amp; Syrup
            
            <LI>Cooking Oils
         </UL>
         
         <H3>Bathroom</H3>
         
         <UL>
            <LI>Shampoo
            
            <LI>Conditioner
            
            <LI>Lotions
         </UL>
      </TD><TD>
         <P>Household Cleaners</H3></P>
         
         <UL>
            <LI>Dish Detergent
            
            <LI>Window Cleaner
            
            <LI>Kitchen &amp; Bath Cleaner
         </UL>
         
         <H3>Automotive</H3>
         
         <UL>
            <LI>Windshield Washer
            
            <LI>Antifreeze
         </UL>
         
         <H3>Laundry</H3>
         
         <UL>
            <LI>Liquid Detergent
            
            <LI>Fabric Softener
            
            <LI>Bleach
         </UL>
      </TD></TR>
</TABLE></UL> <A HREF="#rec_top">BACK TO THE TOP</A><HR></H3>

<H2>Do Not Put These Items In The Recycling Bin</H2>

<H3><I><STRONG>(Even a small amount of contaminants can ruin an
entire shipment of recyclable plastics)</STRONG></I></H3>

<UL>
   <LI>Lids, Caps and Spray Pumps
   
   <LI>Bags or Wraps
   
   <LI>Pails (Ice Cream)
   
   <LI>Food Storage, Freezer Containers (Tupperware)
   
   <LI>Containers - 5 Gallons or Larger
   
   <LI>Flower Pots and Garden Plastics
   
   <LI>Trays, Microwave Dishes
   
   <LI>Hazardous Waste Containers (Pesticides, Herbicides, Solvents,
   Motor Oil, Paints, Adhesives)
   
   <LI>Styrofoam (Please enclose in a bag and put in trash).
</UL>

<H3><HR></H3>

<H1 ALIGN=CENTER>If In Doubt, Throw It Out...</H1>

<H2 ALIGN=CENTER>Unrecyclables Will Be Left In Your Recycle Bins!
</H2>

<H3><HR></H3>

<H2><I>Why do I need to sort my recycling?</I></H2>

<H3><I>Separating each commodity in your bin is important because
each commodity needs to go into a separate compartment on our trucks.
When the truck is full, each compartment is emptied into large boxes
at our site and are then hauled to markets where they are recycled.
Our drivers cannot sort everyone's bin because that would require
spending extra time at each stop which would mean we would need to
quadruple (or more) the number of recycling drivers we have! And that
would mean higher rates for our customers.</I><BR>

<BR>

Albany-Lebanon Sanitation 's recycling program has experienced strong
growth during the past 5 years, as indicated by this graph:<BR>

<BR>

<IMG SRC="../frames/images/chart.gif" WIDTH=260 HEIGHT=197
ALIGN=bottom><BR>

<BR>

The large increase from 1992 to 1993 can be attributed to the start
of mixed paper recycling and curbside yard debris recycling.<HR>
</H3>

<H2>Some helpful links:</H2>

<DIR>
   <LI><B><A HREF="http://www.plasticsresource.com/">American
   Plastics Council</A></B>
   
   <LI><B><A HREF="http://www.gpi.org/">Glass Recycling
   Institute</A></B>
   
   <LI><B><A HREF="http://www.best.COM/~dillon/recycle/">The Consumer
   Recycling Resources Guide</A></B>
   
   <P>Includes instructions for recycling items we don't take
   locally.</P>
   
   <P><BR>
   
   </P>
   

   <LI><B><A HREF="http://www.econet.apc.org/econet/en.issues.html/">EcoNet
   - Environmental Issues Resource Center</A></B>
   
   <LI><B><A HREF="http://es.inel.gov/index.html/">Enviro$en$e</A>
   </B>
</DIR>

<H3><HR><A NAME="locations"></A><IMG
SRC="../frames/images/sm_locat.gif" ALT="LOCATIONS" WIDTH=222
HEIGHT=54 ALIGN=top naturalsizeflag="3"><BR>

</H3>

<H2>When</H2>

<H3><BR>

Your recyclable materials are collected each week on your regular
garbage pick-up day. Please have your recycling bins to the street by
6 a.m.<BR>

</H3>

<H2>Where</H2>

<H3>&nbsp;</H3>

<P>If you wish to drop off your recyclables, the following sites are
available for you to do so: <TABLE BORDER=0 CELLSPACING=5
CELLPADDING=5 WIDTH="100%">
   <TR>
      <TD>
         <P>Albany-Lebanon Sanitation<BR>
         
         1439 Industrial Way SW,<BR>
         
         1 block off Queen Ave.<BR>
         
         928-2551<BR>
         
         <I>Drop off anytime.</I>
      </TD><TD>
         <P>Lebanon Transfer Station<BR>
         
         Brewster Road, Lebanon<BR>
         
         1 1/2 mi. north of Grant St. bridge<BR>
         
         451-2533<BR>
         
         Fri, Sat. &amp; Sun. only, 8 am to 5 pm
      </TD><TD>
         <P>Processing &amp; Recovery Center<BR>
         
         Located 1 mi. east of Hwy 99W,<BR>
         
         on Camp Adair Rd. &amp; 2 mi. from Coffin Butte Landfill
         site<BR>
         
         745-5831<BR>
         
         Mon.-Sat., 8 am to 5 pm; Sun. Noon to 5 pm
      </TD></TR>
</TABLE> Other recycling services available: Office Paper Recycling,
Commercial Recycling and Multi-family Recycling.
<A HREF="#rec_top">BACK TO THE TOP</A></P>

<P ALIGN=CENTER><A HREF="index.html">HOME</A> |
<A HREF="compost.html">COMPOSTING</A> |
<A HREF="waste.html">SERVICES</A> | <A HREF="form.html">ASK US</A> |
<A HREF="areainfo.html">COMMUNITY INFORMATION</A></P>

<P ALIGN=CENTER>this site created by
<A HREF="mailto:greatideas@pwdesign.com">Paperworks Design</A></P>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-274</DOCNO>
<DOCOLDNO>IA020-000212-B030-393</DOCOLDNO>
<DOCHDR>
http://www.sanitation.com:80/no_frame/compost.html 198.68.7.45 19970107134913 text/html 6338
HTTP/1.0 200 OK
Date: Tue, 07 Jan 1997 13:49:13 GMT
Server: Apache/1.1.1
Content-type: text/html
Content-length: 6167
Last-modified: Tue, 31 Dec 1996 18:31:49 GMT
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>Composting Information Page</TITLE>
</HEAD>
<BODY TEXT="#1B4FB1" BGCOLOR="#B3C8F6" LINK="#E31254" ALINK="#D0112D"
VLINK="#A70133">

<P><TABLE BORDER=0 CELLPADDING=1 WIDTH="100%">
   <TR>
      <TD VALIGN=top ROWSPAN=5>
         <P><MAP NAME="compost_map"><AREA SHAPE=rect COORDS="14,312 184,333"
         HREF="compost.html#problems"><AREA SHAPE=rect COORDS="14,296 178,313"
         HREF="compost.html#method"><AREA SHAPE=rect COORDS="14,285 178,294"
         HREF="compost.html#notto"><AREA SHAPE=rect COORDS="14,267 154,275"
         HREF="compost.html#whatto"><AREA SHAPE=rect COORDS="14,233 154,256"
         HREF="compost.html#uses"></MAP><A HREF="http://www.sanitation.com/frames/images/compostn.map/IMURL/
         http://www.sanitation.com/no_frame/compost.html"><IMG ISMAP
         SRC="../frames/images/comp_nav.gif" WIDTH=200 HEIGHT=350
         BORDER=0 ALIGN=bottom
         usemap="#compost_map" naturalsizeflag="0"></A>
      </TD><TD VALIGN=top cellpadding=5>
         <P><A NAME="top"></A></P>
         
         <H3><A HREF="#uses">Uses for Compost</A></H3>
      </TD></TR>
   <TR><TD>
         <P><A HREF="#whatto">&nbsp;</A></P>
         
         <H3><A HREF="#whatto">What to Compost</A></H3>
      </TD></TR>
   <TR><TD>
         <P><A HREF="#notto">&nbsp;</A></P>
         
         <H3><A HREF="#notto">What not to Compost</A></H3>
      </TD></TR>
   <TR><TD>
         <P><A HREF="#method">&nbsp;</A></P>
         
         <H3><A HREF="#method">Composting Methods</A></H3>
      </TD></TR>
   <TR><TD>
         <P><A HREF="#problems">&nbsp;</A></P>
         
         <H3><A HREF="#problems">Composting Problems</A></H3>
      </TD></TR>
</TABLE></P>

<P ALIGN=CENTER><A HREF="http://www.sanitation.com/index.html">HOME</A>
|
<A HREF="http://www.sanitation.com/no_frame/recycle.html">RECYCLING</A>
|
<A HREF="http://www.sanitation.com/no_frame/compost.html">COMPOSTING</A>
| <A HREF="/no_frame/waste.html">SERVICES</A> |
<A HREF="http://www.sanitation.com/no_frame/form.html">ASK US</A> |
<A HREF="http://www.sanitation.com/no_frame/areainfo.html">COMMUNITY
INFORMATION</A></P>

<H1>Did you know?...</H1>

<UL>
   <LI>Food waste and yard debris make up about 25% of our garbage.
   
   <LI>Grass clippings and leaves can take years to decompose in the
   landfill.
</UL>

<P><HR><A NAME="uses"></A></P>

<H1>Uses For Compost</H1>

<P>Compost contains nutrients and holds nutrients in the soil until
plants can use them, but is not a substitute for fertilizers.</P>

<H2><I>As A Soil Amendment</I></H2>

<P>Mix compost into vegetable and flower gardens each year before
planting.</P>

<H2><I>As A Potting Mixture</I></H2>

<P>Add one part compost to two parts commercial potting soil, or make
your own mixture by using equal parts of compost and sand or perlite.
<A HREF="#top">BACK TO THE TOP</A><HR><A NAME="whatto"></A></P>

<H1>What To Compost</H1>

<UL>
   <LI>Grass clippings
   
   <LI>Leaves
   
   <LI>Flowers
   
   <LI>Old plants
   
   <LI>Twigs
   
   <LI>Old potting soil
</UL>

<P><A HREF="#top">BACK TO THE TOP</A><HR><BR>

<A NAME="notto"></A></P>

<H1>What NOT To Compost</H1>

<UL>
   <LI>Diseased plants
   
   <LI>Weeds with seeds
   
   <LI>Invasive weeds like quack grass or morning glory
   
   <LI>Pet feces
   
   <LI>Dead animals
   
   <LI>Meat or fish parts
   
   <LI>Dairy products such as milk, butter, or cheese
   
   <LI>Grease, cooking oil, or oily foods
</UL>

<P><BR>

<A HREF="#top">BACK TO THE TOP</A><HR><A NAME="method"></A></P>

<H1>How To Compost</H1>

<H2>Soil Saver</H2>

<H3><I>HOT COMPOSTING (Compost Turning)</I></H3>

<UL>
   <LI>Rich compost is created when you alternate layers of organic
   waste. It is easiest to estimate this ratio by alternating layers
   of "green stuff" and "brown stuff" as the compost pile is built.
   Example: A layer of grass clippings ("green stuff") twice as thick
   as a layer of brown leaves ("brown stuff") is a good ratio.
   
   <LI>Keep the material as moist as a squeezed-out sponge.
   Occasional watering may be required to moisten the pile if it
   becomes too dry.
   
   <LI>Turn the material (at least 4-5 times during the summer) with
   a pitchfork, shovel or compost turner so it's well aerated. You
   can turn the pile once a week but more frequent turning will
   inhibit composting.
   
   <LI>Your compost is ready to use when it is a dark brown or black
   color, crumbly, humus-rich top soil, with the sweet aroma of the
   good earth.
</UL>

<H3>A link for more information:
<A HREF="http://net.indra.com/~topsoil/Compost_Menu.html">Composting</A>
</H3>

<P><BR>

<A HREF="#top">BACK TO THE TOP</A><HR><BR>

<A NAME="problems"></A></P>

<H1>Problems</H1>

<P><BR>

</P>

<H2><I>Will my composter attract flies?</I></H2>

<P>Not if you dig your food scraps into the compost or cover any food
scraps or "green stuff" with a layer of soil or "brown stuff."</P>

<H2><BR>

<I>Will my composter attract animals or rodents?</I></H2>

<P><BR>

To prevent the attraction of animals, do not add meat products, dairy
products, fat or fish to your composter. Again, cover food scraps
with soil or "brown stuff." Lay a sheet of hardware cloth or rabbit
cage wire on the ground beneath your composter to keep rodents out.
</P>

<H2><BR>

<I>Why does my composter smell like ammonia?</I></H2>

<P><BR>

You have too much "green stuff." Add more"brown stuff."<BR>

</P>

<H2><I>Why does my composter smell rotten?</I></H2>

<P><BR>

There is too much moisture in the composter. Turn the pile and add
porous material such as leaves or sawdust.<BR>

<A HREF="#top">BACK TO THE TOP</A></P>

<P ALIGN=CENTER><A HREF="http://www.sanitation.com/index.html">HOME</A>
|
<A HREF="http://www.sanitation.com/no_frame/recycle.html">RECYCLING</A>
|
<A HREF="http://www.sanitation.com/no_frame/compost.html">COMPOSTING</A>
| <A HREF="/no_frame/waste.html">SERVICES</A> |
<A HREF="http://www.sanitation.com/no_frame/form.html">ASK US</A><BR>

<A HREF="http://www.sanitation.com/no_frame/areainfo.html">COMMUNITY
INFORMATION</A><BR>

this site created by
<A HREF="mailto:greatideas@pwdesign.com">Paperworks Design</A></P>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-275</DOCNO>
<DOCOLDNO>IA073-000478-B029-17</DOCOLDNO>
<DOCHDR>
http://www.styleadvisor.com:80/ 207.126.64.141 19970124220646 text/html 1590
HTTP/1.0 200 OK
Server: Netscape-Enterprise/2.0a
Date: Fri, 24 Jan 1997 22:03:27 GMT
Accept-ranges: bytes
Last-modified: Thu, 23 Jan 1997 20:31:09 GMT
Content-length: 1385
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 + all extensions//EN" "hmpro3.dtd">
<HTML>
<HEAD>
<TITLE>StyleADVISOR Homepage</TITLE></HEAD>
<BODY>
<P><A HREF="index.gif"><IMG
SRC="index2.gif" BORDER="0" USEMAP="#map2" ISMAP="ISMAP">
<MAP NAME="map2">
<AREA SHAPE="RECT" COORDS="400,206,614,238" HREF="info.html">
<AREA SHAPE="RECT" COORDS="404,286,653,314" HREF="update.html">
<AREA SHAPE="RECT" COORDS="404,331,644,362" HREF="/news/news.html">
<AREA SHAPE="RECT" COORDS="407,422,602,450" HREF="links.html">
<AREA SHAPE="RECT" COORDS="407,462,536,486" HREF="contact.html">
<AREA SHAPE="RECT" COORDS="18,438,193,486" HREF="http://www.netscape.com"></MAP></A></P>
<CENTER><A HREF="info.html">All About StyleADVISOR </A>||<A HREF="update.html">Updates
&amp; Announcements</A>||<A HREF="/news/news.html">Newsletters &amp; Articles
</A>||<A HREF="mailto:roma@styleadvisor.com"> E-mail our staff</A>||<A
HREF="links.html">Other Financial Web Sites</A>||</CENTER>
<P><I>Copyright &copy; 1996-97 Zephyr Associates, Inc.</I></P>
<HR>
<HR>
<P><B>You are the
<IMG
SRC="http://www.island.net/cgi-bin/counter?http://www.styleadvisor.com/index/">
visitor to our home page since January 19, 1996.</B></P>
<HR>
<P></P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR>
<TD WIDTH="289" VALIGN="top"><FONT SIZE="1">Copyright &copy; 1996 Zephyr
Associates, Inc.</FONT></TD></TR></TABLE></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-276</DOCNO>
<DOCOLDNO>IA073-000478-B029-73</DOCOLDNO>
<DOCHDR>
http://www.styleadvisor.com:80/info.html 207.126.64.141 19970124220712 text/html 3818
HTTP/1.0 200 OK
Server: Netscape-Enterprise/2.0a
Date: Fri, 24 Jan 1997 22:03:51 GMT
Accept-ranges: bytes
Last-modified: Thu, 14 Nov 1996 01:40:09 GMT
Content-length: 3613
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>More About Style Advisor</TITLE></HEAD>
<BODY><IMG SRC="logo.gif" ALIGN="BOTTOM">
<P>Since it's debut in 1993, Style Advisor has been the style analysis package
of choice for the large institutional market place. Our Client List has grown to
include over 140 plan sponsors, consultants, and money managers. Below are a few
of the reasons why.</P>
<H3>Money Managers, Plan Sponsors and Consultants use StyleADVISOR for:<BR></H3>
<H4>Style and Attribution Analysis of Individual Managers and Total Funds</H4>
<UL>
<LI>Analyze the style of any manager. Select from over 6000 domestic equity,
international equity and fixed income managers or from over 7000 mutual funds.</LI>
<LI>Graphically display a manager's style.  Show how consistent they have been
and/or how their style has changed over time.</LI>
<LI>Build customized style benchmarks (normal portfolios) for any manager.</LI>
<LI>Display the manager's skill in stock selection, even if the manager's style
is out of favor.</LI></UL>
<H4>Performance Analysis and Reporting</H4>
<UL>
<LI>Construct peer group universes. Display a managers relative performance
using the risk/return scatter diagram or Style Advisor's  unique &quot;Manager
versus Universe&quot; comparison graph.</LI>
<LI>Prepare high quality, multi-color presentation materials.</LI></UL>
<H4>Product Analysis</H4>
<UL>
<LI>Money managers compare and contrast their products with those of their
competitors to determine strengths and weaknesses.</LI>
<LI>Plan Sponsors and Consultants compare the performance and style of multiple
managers in a single graph or table against their policy benchmark or a peer
group universe.</LI></UL>
<H4>Manager Searches</H4>
<UL>
<LI>Search for domestic equity, international equity, fixed income, global bond
or emerging market managers.  You determine the criteria - let StyleADVISOR do
the rest.</LI></UL>
<P></P>
<HR>
<H3>Pricing</H3>
<P>Your annual licensing fee of $15,000 includes:</P>
<UL>
<LI>Monthly updates on over 1000 indexes</LI>
<LI>Quarterly updates with monthly returns of over 7,000 mutual funds</LI>
<LI>Quarterly updates of over 6000 separate account managers</LI>
<LI>Unlimited technical support</LI>
<LI>Attendance at our annual Users Conference in Lake Tahoe</LI></UL>
<P>Updates can be downloaded directly from our home page or received via
diskette.</P>
<HR>
<H3>Samples</H3>
<CENTER>
<P>The following analyses were created in StyleADVISOR, and optimized for
viewing on the Web with Microsoft PowerPoint and Corel Draw. Click a button
below to view a sample analysis. If you would like to try StyleADVISOR for
yourself, download our demo disk.</P>
<P></P>
<TABLE>
<TR>
<TD><A HREF="http:/style.html"><IMG
SRC="stybutn.gif" ALIGN="MIDDLE" BORDER="0"></A></TD>
<TD><A HREF="http:/scan.html"><IMG SRC="scnbutn.gif" ALIGN="MIDDLE" BORDER="0"></A></TD>
<TD><A HREF="http:/risk.html"><IMG SRC="rskbutn.gif" ALIGN="MIDDLE" BORDER="0"></A></TD></TR></TABLE></CENTER>
<CENTER>
<H5><A HREF="ftp://styleadvisor.com/pri/styleadvisor/eval.exe">Download a
StyleADVISOR Demo Disk</A></H5>
<P>After you download a demo, give us a call at (800) StyleAD (789-5323) for
the password required during installation.</P></CENTER>
<CENTER>
<H5><A HREF="http:/index.html">Return to StyleADVISOR Home Page</A></H5></CENTER>
<P><B>You are the
<IMG
SRC="http://www.island.net/cgi-bin/counter?http://www.styleadvisor.com/info/">
visitor to our page since January 19, 1996.</B></P>
<HR>
<P></P>
<P><I>Copyright &copy; 1996 Zephyr Associates, Inc.</I></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-277</DOCNO>
<DOCOLDNO>IA073-000478-B029-108</DOCOLDNO>
<DOCHDR>
http://www.styleadvisor.com:80/update.html 207.126.64.141 19970124220723 text/html 4741
HTTP/1.0 200 OK
Server: Netscape-Enterprise/2.0a
Date: Fri, 24 Jan 1997 22:04:03 GMT
Accept-ranges: bytes
Last-modified: Thu, 23 Jan 1997 21:14:31 GMT
Content-length: 4536
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 + all extensions//EN" "hmpro3.dtd">
<HTML>
<HEAD>
<TITLE>Updates</TITLE></HEAD>
<BODY BGCOLOR="#C6C2BB"><IMG SRC="logo.gif">
<H1><B>News and Announcements</B></H1>
<H2><A HREF="regtrain.html">Regional Training Seminar Info</A> </H2>
<H2></H2>
<HR>
<CENTER>
<H2>We are proud to announce the general release of our new asset allocation
addition - <BLINK>AllocationADVISOR</BLINK></H2><EM>Once again, many thanks to
our beta testers</EM></CENTER>
<HR>
<H1><B>Index &amp; Database Updates</B></H1>
<BLOCKQUOTE>
<P>These updates require the most recent version of Style Advisor, and a
previously installed copy of the database you are updating.  Once you have
downloaded the file, double click on it from Windows File Manager.  You will be
asked to enter a password.  If you aren't sure what the password is, call Roma
at (702) 588-0654.   
</P></BLOCKQUOTE>
<BLOCKQUOTE>
<H2><IMG SRC="new.gif" ALT="ball"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/aa.exe">AllocationADVISOR 1.0</A>
January 1997</H2>
<BLOCKQUOTE>
<P>For specific instructions, check out the help menu within the program, or
download StyleBRIEF #8 from the Newsletter page on this site.  As always, we
look forward to hearing your comments and suggestions.</P></BLOCKQUOTE>
<H2><IMG SRC="sphere2.gif" ALT="ball" WIDTH="40" HEIGHT="40"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/update.exe">StyleADVISOR Data
Update</A> January Final Update - 1/23/97 (745,667 bytes)</H2>
<UL></UL>
<UL></UL>
<P><B></B></P>
<H2><IMG SRC="sphere2.gif" ALT="ball" WIDTH="40" HEIGHT="40"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/mstupd.exe">MorningStar  - Quick
Update</A> 4th Quarter 96 - 1/10/97 (621,606 bytes)</H2>
<BLOCKQUOTE>
<P>This update only appends the 4th quarter changes onto your existing
MorningStar database files.  DO NOT INSTALLTHIS UPDATE IF YOU DON'T ALREADY HAVE
3rd QUARTER MORNINGSTAR DATA.  You will need to download the complete 3rd
quarter update listed below prior to using this update. Those of you who have
downloaded MorningStar in the past (and who have grown old waiting for it  to
download), will appreciate this new method</P></BLOCKQUOTE>
<UL></UL>
<UL></UL>
<H2><IMG SRC="sphere2.gif" ALT="ball" WIDTH="40" HEIGHT="40"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/msupdall.exe">MorningStar Update
Complete</A> 3rd Quarter 96 -10/9/96 (2,285,636 bytes)</H2>
<BLOCKQUOTE>
<P><STRONG>This will be the last time we post the &quot;complete&quot; update.</STRONG>
 Please be sure to update this quarter, so that the 4th quarter &quot;Quick
Update&quot; (which saves us both a lot of time) will work for you</P></BLOCKQUOTE>
<UL></UL>
<UL></UL>
<H2><IMG SRC="sphere2.gif" ALT="ball" WIDTH="40" HEIGHT="40"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/mobupd.exe">Mobius Update</A> 3rd
Quarter 96 (First release) - 12/9/96 (967,106 bytes)</H2>
<UL></UL>
<UL></UL>
<P><B></B></P>
<H2><IMG SRC="sphere2.gif" ALT="ball" WIDTH="40" HEIGHT="40"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/nelupd.exe">Nelson's Update</A>
3rd Quarter 96 (second release) - 11/22/96 (1,020,102 bytes)</H2>
<UL></UL>
<UL></UL>
<P><B></B></P>
<H2><IMG SRC="sphere2.gif" ALT="ball" WIDTH="40" HEIGHT="40"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/psnupd.exe">PSN Update</A> 3rd
Quarter 96 (second release) - 11/22/96 (730,120 bytes)</H2>
<UL></UL>
<UL></UL>
<P><B></B></P>
<H2><IMG SRC="sphere2.gif" ALT="ball" WIDTH="40" HEIGHT="40"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/pipupd.exe">Piper Update</A> 3rd
Quarter 96 - 11/11/96 (598,399 bytes)</H2>
<UL></UL>
<UL></UL>
<P><B></B></P>
<H2><IMG SRC="sphere2.gif" ALT="ball" WIDTH="40" HEIGHT="40"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/sbupd.exe">Smith Barney Update</A>
3rd Quarter 96 - 10/30/96 (92,961 bytes)</H2>
<UL></UL>
<UL></UL>
<P><B></B></P>
<H2><IMG SRC="sphere2.gif" ALT="ball" WIDTH="40" HEIGHT="40"><A
HREF="ftp://styleadvisor.com/pri/styleadvisor/dbsetup.exe">Style Advisor
Database Creator 1.1</A> </H2>
<BLOCKQUOTE>
<P>Version 1.1 includes delete utility to remove unwanted databases created
with the Database Creator(103,507 bytes)</P></BLOCKQUOTE></BLOCKQUOTE>
<HR>
<P><B>You are the
<IMG
SRC="http://www.island.net/cgi-bin/counter?http://www.styleadvisor.com/update/">
visitor to our page since January 19, 1996.</B></P>
<HR>
<P></P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR>
<TD WIDTH="289" VALIGN="top"><FONT SIZE="1">Copyright &copy; 1992-1996 Zephyr
Associates, Inc.</FONT></TD></TR></TABLE></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-278</DOCNO>
<DOCOLDNO>IA073-000478-B029-136</DOCOLDNO>
<DOCHDR>
http://www.styleadvisor.com:80/news/news.html 207.126.64.141 19970124220733 text/html 9037
HTTP/1.0 200 OK
Server: Netscape-Enterprise/2.0a
Date: Fri, 24 Jan 1997 22:04:13 GMT
Accept-ranges: bytes
Last-modified: Fri, 10 Jan 1997 20:39:40 GMT
Content-length: 8832
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE> StyleADVISOR Newsletters &amp; Articles</TITLE></HEAD>
<BODY BACKGROUND="backgrn2.gif" BGPROPERTIES="FIXED"><IMG
SRC="logo.gif" ALIGN="BOTTOM">
<HR>
<P ALIGN="LEFT">All of the documents below can be viewed and printed as PDF
files using Adobe's Acrobat Reader as a plug in to your Netscape Browser. It
does take some time to download, but it is well worth it. Besides giving you
instant access to valuable StyleADVISOR info, you will find more and more
websites using this format in the future.</P>
<P><A HREF="HTTP://www.adobe.com/acrobat/3beta/main.html"> Download
AdobeAcrobat Reader</A> </P>
<HR>
<H2><I>the</I>ADVISOR Newsletter</H2>
<P>The Advisor is a newsletter which we distribute to all of our StyleADVISOR
clients. A wide range of topics are covered and various studies and activities
have been described in detail so that they can be reproduced by our clients. In
addition to featured articles, you will also find several &quot;Tips &amp;Tricks&quot;
that you might find useful.</P>
<H3><B><A HREF="news1.pdf">Volume 1  Creating a Policy Benchmark (92KB)</A></B>June
1994</H3>
<P>Most plan sponsors have adopted an asset allocation policy for their total
fund.  With StyleADVISOR, you can create a policy benchmark for your asset
allocation, and also find the optimal mix of managers in order to closely track
that benchmark</P>
<H3><B>Volume 2  Eulogy to the Floating Bar Graph August1994</B><BR>(Not
currently available on the Web. Call for your copy.)</H3>
<P>For over twenty years, plan sponsors, money managers, and consultants have
used the &quot;Floating Bar Graph&quot; to display how a manager has done
vis-a-vis a universe.  We have developed a new Manager versus Universe graph,
which literally provides 100 times the information as the obsolete bar graph.
For a hard copy of this newsletter call (800) StyleAD (789-5323).</P>
<H3><B><A HREF="news3.pdf">Volume 3  What Are the Best Style Indices to Use
with StyleADVISOR (280KB)</A></B> November 1994</H3>
<P>We provide a number of domestic equity style indices for our StyleADVISOR
users (Wilshire, Prudential, S&amp;P BARRA, Russell)....Because of the different
ways in which these indices are constructed, they will give different results in
style your analyses.  Find out which are the best.</P>
<H3><B><A HREF="news4.pdf">Volume 4  International Style Analysis (404KB)</A></B>January
1995</H3>
<P>Style Advisor clients receive international style indexes on 26 countries
and 8 regions.  Performing a style analysis on any one country or region is as
simple as a domestic equity analysis.  However, it is not quite as easy for
international managers who diversify among many coutries and regions. 
Thisarticle suggests several approaches.</P>
<H3><B><A HREF="news5.pdf">Volume 5  Skeptics Corner (267KB)</A></B> March
1995</H3>
<P>I know that I don't have to convice our StyleADVISOR users that
styleanalysis works, because they have seen the results first hand, For those of
you who would like to demonstrate the validity of this approach to others, the
detailed results of some of the many studies  we have done on this subject can
be found in this newsletter.</P>
<H3><B><A HREF="news6.pdf">Volume 6  Using StyleADVISOR to Detect Derivatives
in a Portfolio (267KB)</A></B> May 1995</H3>
<P>One of the many derivative casualties occurring in the last few years was
the Piper Jaffray Institutional Government Fund.  I wondered if StyleADVISOR
could have provided a clue as to the riskiness of this fund during the 1993-94
period.  I found the answer to be a resounding YES. Find out how StyleADVISOR
can detect leverage in a mutual fund, without ever looking at the portfolio
holdings.</P>
<H3><B><A HREF="news7.pdf">Volume 7  Obtaining the Optimum Manager Weights to
Track Your Benchmark (499KB)</A></B> June 1995</H3>
<P>Plan sponsors are responsible for the &quot;style bets&quot; that they take
away from their market benchmark.  StyleADVISOR shows you what those bets
are,and will allow you to find the optimum weights for each manager to most
closely track a benchmark.</P>
<H3><B><A HREF="news8.pdf">Volume 8  POD Universes (433KB)</A></B> August
1995 </H3>
<P>StyleADVIVSOR users now have the ability to create a different kind of
universe called POD, or Portfolio Opportunity Distribution.  This is an
innovation developed by Ron Surz.  Instead of using the actual returns of a
group of managers, POD's calculate the return series for a group of portfolios
of randomly selected securities...</P>
<H3><B><A HREF="news9.pdf">Volume 9  Style Additions (549KB)</A></B> October 
1995</H3>
<P>Here we talk about some of the new enhancements to StyleADVISOR, such as
being able to use your customized style benchmark as the benchmark in your
risk/return analysis with just a point and click.</P>
<H3><B><A HREF="news10.pdf">Volume 10  New Graph (666KB)</A></B> November
1995</H3>
<P>We have recently added a new graph which measures annual excess return
overthe style benchmark on the vertical axis, and standard deviation of
excessreturn on the horizontal axis.  This measure of a manager's skill can be
most revealing when comparing multiple managers. We show a number of examples in
this newsletter.</P>
<H3><B>Volume 11  The Invested EAFE  February 1996</B></H3>
<P>A new International Benchmark.  The EAFE index's heavy weighting in Japan
(approx 45%), makes it less than appropriate for the majority of internationaly
diversified managers. Zephyr Associates has created a new international
benchmark which is country weighted, not cap weighted. You will find it in your
Indices supplied with StyleADVISOR directory. This benchmark has a significantly
higher R2 than the EAFE to most international managers.<BR>(Sorry, Not
currently available on the Web.  Call for your copy.)</P>
<H3><B><A HREF="news12.pdf">Volume 12  Completion Funds (489KB)</A></B> March
1996</H3>
<P>Use StyleADVISOR to build a completeness fund to offset your style biases
and decrease the tracking error to your policy benchmark. Introducing the
StyleADVISOR Database Creator - Create your own customized database within
StyleADVISOR.  Import hundreds or even thousands of returns in minutes with our
Excel add-in.</P>
<H3><B><A HREF="news13.pdf">Volume 13  Does Value Beat Growth? (493KB)</A></B>May
1996</H3>
<P>Those of you who have been working with style analysis for some time may
have noticed that small growth managers seem to have a much higher propensity to
beat their style benchmark.  This report takes a closer look at these
observations and offers some explanation. </P>
<H3><B><A HREF="news14.pdf">Volume 14  Upside/Downside Market Capture(543KB)</A></B>July
1996</H3>
<P> Get the scoop on the new Upside/Downside Market Capture analysis, and other
enhancements, introduced in version 4.2.</P>
<H3><B><A HREF="news15.pdf">Volume 15  An After Tax Universe of Mutual Funds
(1,254KB)</A></B> October 1996</H3>
<P>The Beecher After-Tax Universe is a fairly representative slice of the large
mutual fund universe, and includes two composites (both before and after tax). 
We believe that the resulting peer group and performance analyses are both
valuable and interesting</P>
<P>Also in this issue: The new Zephyr Style Universe</P>
<H3><B><A HREF="news16.pdf">Volume 16 Going short in Style Analysis &amp;
Building Benchmarks</A></B> December 1996</H3>
<P>The standard analysis that StyleADVISOR does is a contrained quadradic
equation - all coefficients must equal one.  However, there are options within
the program that allow you to short one or all of the indices.  The results can
be very interesting.</P>
<P>Also in this issue: More on the Annualized ExRet/Std Deviation Graph</P>
<HR>
<H2>Style Briefs</H2>
<P>Each contains a 10-15 minute excercise designed to acquaint you with the
basic functions of StyleADVISOR</P>
<H3><B><A HREF="style.pdf">#1  Creating a Style Analysis</A></B></H3>
<P></P>
<H3><B><A HREF="risk.pdf">#2  Creating a Risk Return Analysis</A></B></H3>
<P></P>
<H3><B><A HREF="Scan.pdf">#3  Scanning a Database</A></B></H3>
<P></P>
<H3><B><A HREF="fund.pdf">#4  Creating a Fund</A></B></H3>
<P></P>
<H3><B><A HREF="basis.pdf">#5  Creating a Style Basis</A></B></H3>
<P></P>
<H3><B><A HREF="intl.pdf">#6  International Style Analysis</A></B></H3>
<P></P>
<H3><B><A HREF="DTP.pdf">#7  Presentations with Style</A></B></H3>
<H3><B><A HREF="aa.pdf">#8  AllocationADVISOR</A></B></H3>
<P><B>You are the<IMG
SRC="http://www.island.net/cgi-bin/counter?http://www.styleadvisor.com/news/news">
visitor to our page since January 19, 1996.</B></P>
<HR>
<P></P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR>
<TD WIDTH="289" VALIGN="top"><FONT SIZE="1">Copyright &amp;copy 1992-1996
Zephyr Associates, Inc.</FONT></TD></TR></TABLE></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-279</DOCNO>
<DOCOLDNO>IA073-000478-B029-161</DOCOLDNO>
<DOCHDR>
http://www.styleadvisor.com:80/links.html 207.126.64.141 19970124220742 text/html 2742
HTTP/1.0 200 OK
Server: Netscape-Enterprise/2.0a
Date: Fri, 24 Jan 1997 22:04:23 GMT
Accept-ranges: bytes
Last-modified: Thu, 14 Nov 1996 01:40:16 GMT
Content-length: 2537
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 + all extensions//EN" "hmpro3.dtd">
<HTML>
<HEAD>
<TITLE>CyberLinks</TITLE></HEAD>
<BODY>
<TABLE BORDER="0">
<TR>
<TD><IMG SRC="cyber2.gif"></TD>
<TD VALIGN="BASELINE" ALIGN="LEFT">
<H3>(other interesting places)</H3></TD></TR></TABLE>
<H4>We hope that you find these other sites of interest.  Should you encounter
problems accessing any of these links, please let us know.  Inclusion of a site
in this list should not be construed as an endorsement or recommendation by
Zephyr Associates, Inc. of the site or it's creators.</H4>
<H2><STRONG><U>Research</U></STRONG></H2>
<TABLE BORDER="0" CELLSPACING="25">
<TR>
<TD ALIGN="CENTER"></TD>
<TD ALIGN="CENTER"><A HREF="http://gsb-www.stanford.edu/~wfsharpe/home.html"><IMG
SRC="sharpe.gif" BORDER="0"></A></TD>
<TD ALIGN="CENTER"><A HREF="http://www.acsu.buffalo.edu/~trzcinka/"><IMG
SRC="trzcinka.gif" BORDER="0"></A></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD ALIGN="CENTER"></TD>
<TD ALIGN="CENTER">
<H4>Prof. William F. Sharpe</H4></TD>
<TD ALIGN="CENTER">
<H4>Prof. Charles Trzcinka</H4></TD>
<TD></TD>
<TD></TD></TR></TABLE>
<H2><STRONG><U>Money Manager Showcase</U></STRONG></H2>
<TABLE BORDER="0" CELLSPACING="25">
<TR>
<TD ALIGN="CENTER"></TD>
<TD ALIGN="CENTER"><A HREF="http://www.pbhgfunds.com"><IMG
SRC="pbhg.gif" BORDER="0"></A></TD>
<TD ALIGN="CENTER"><A HREF="http://www.vanguard.com"><IMG
SRC="vanguard.gif" BORDER="0"></A></TD>
<TD ALIGN="CENTER"><A HREF="http://www.lib.com"><IMG
SRC="liberty.gif" BORDER="0"></A></TD>
<TD ALIGN="CENTER"><A HREF="http://www.secapl.com/Applegate/"><IMG
SRC="nicholas.gif" BORDER="0"></A></TD>
<TD ALIGN="CENTER"><A HREF="http://www.fid-inv.com"><IMG
SRC="fidelity.gif" BORDER="0"></A></TD>
<TD ALIGN="CENTER"><A HREF="http:///http://www.barra.com"></A></TD></TR>
<TR>
<TD ALIGN="CENTER"></TD>
<TD ALIGN="CENTER">
<H4>Pilgrim Baxter</H4></TD>
<TD ALIGN="CENTER">
<H4>Vanguard</H4></TD>
<TD ALIGN="CENTER">
<H4>Liberty Financial</H4></TD>
<TD ALIGN="CENTER">
<H4>Nicholas - Applegate</H4></TD>
<TD>
<H4>Fidelity Investments</H4></TD>
<TD></TD></TR></TABLE>
<H2><STRONG><U>Others</U></STRONG></H2>
<TABLE BORDER="0" CELLSPACING="25">
<TR>
<TD ALIGN="CENTER"></TD>
<TD ALIGN="CENTER"><A HREF="http://www.barra.com"><IMG
SRC="barra.gif" BORDER="0"></A></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD ALIGN="CENTER"></TD>
<TD ALIGN="CENTER">
<H4>BARRA</H4></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR></TABLE>
<HR><IMG SRC="logo.gif">
<P><A HREF="index.html">Return to Zephyr Home Page</A></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-280</DOCNO>
<DOCOLDNO>IA073-000478-B029-187</DOCOLDNO>
<DOCHDR>
http://www.styleadvisor.com:80/contact.html 207.126.64.141 19970124220749 text/html 1399
HTTP/1.0 200 OK
Server: Netscape-Enterprise/2.0a
Date: Fri, 24 Jan 1997 22:04:31 GMT
Accept-ranges: bytes
Last-modified: Thu, 23 Jan 1997 21:06:11 GMT
Content-length: 1194
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SoftQuad//DTD HTML 3.2 + extensions for HoTMetaL PRO 3.0 19961211//EN"
 "hmpro3.dtd">
<HTML>
<HEAD>
<TITLE>Zephyr Associate's Contact Page</TITLE></HEAD>
<BODY>
<H1><IMG SRC="toc1.gif" ALT=" " ALIGN="BOTTOM" LOWSRC="toc2.gif"> Contacting
Zephyr Associates, Inc.</H1>
<P>There are several ways to get in contact with Zephyr Associates:</P>
<BLOCKQUOTE>
<DL>
<DT><IMG SRC="mail22.gif" ALT=" " ALIGN="BOTTOM" LOWSRC="mail21.gif">
<STRONG>Surface Mail</STRONG></DT>
<DD>Zephyr Associates, Inc.<BR>P.O. Box 12368<BR>Zephyr Cove, Nevada  89448
<P></P></DD>
<DT><IMG SRC="phone1.gif" ALT=" " ALIGN="BOTTOM" LOWSRC="phone2.gif">
<STRONG>Phone and FAX</STRONG></DT>
<DD>(702) 588-0654<BR>(800) 789-5323<BR>Fax (702) 588-8423
<P></P></DD>
<DT><IMG SRC="keyboar1.gif" ALT=" " ALIGN="BOTTOM" LOWSRC="keyboar2.gif">
<STRONG>Email </STRONG></DT>
<DD>
<DL>
<DT><A HREF="mailto:roma@styleadvisor.com"><IMG
SRC="pinred1.gif" ALT="o" ALIGN="BOTTOM" BORDER="0" LOWSRC="pinred2.gif">General
Inquiries &amp; Technical Support</A></DT>
<DD></DD></DL></DD></DL></BLOCKQUOTE>
<HR SIZE="1" WIDTH="75%">
<P><A HREF="http://www.styleadvisor.com/">Return to Zephyr HomePage</A></P></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-281</DOCNO>
<DOCOLDNO>IA073-000478-B029-223</DOCOLDNO>
<DOCHDR>
http://www.styleadvisor.com:80/regtrain.html 207.126.64.141 19970124220809 text/html 1633
HTTP/1.0 200 OK
Server: Netscape-Enterprise/2.0a
Date: Fri, 24 Jan 1997 22:04:46 GMT
Accept-ranges: bytes
Last-modified: Thu, 23 Jan 1997 21:09:53 GMT
Content-length: 1428
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 + all extensions//EN" "hmpro3.dtd">
<HTML>
<HEAD>
<TITLE>{Your Company}'s Survey Form [watermark]</TITLE></HEAD>
<BODY BACKGROUND="IMAGE/bg.gif" BGPROPERTIES="FIXED">
<CENTER>
<H1><IMG SRC="file:///e|/webpage/newhome/logo.gif" WIDTH="282" HEIGHT="83"></H1>
<H1>Regional Training Seminar - Winter 97</H1>
<H2>Chicago - February 12, 1997 </H2>
<H3>New Horizon Training Facility - Two North LaSalle</H3></CENTER>
<H2>New Users - Get up to Speed Fast</H2>
<DIR>
<LI>Find out how StyleADVISOR and Allocation ADVISOR can help you achieve your
goals more effectively.</LI></DIR>
<H2>Experienced Users - Get a Quick Refresher</H2>
<DIR>
<LI>Learn about the latest enhancements (including AllocationADVISOR), and pick
up a few new tricks.</LI></DIR>
<HR>
<BLOCKQUOTE>
<P>Class size is limited to 24.  This is an intensive, hands on course.  Each
participant will have his/her own computer. A nominal fee of $200 will be
charged to each attendee to defray the cost of room and equipment rental. Sorry,
no refund for cancellations less than 2 weeks in advance.</P></BLOCKQUOTE>
<BLOCKQUOTE>
<P>Please <A HREF="mailto:roma@styleadvisor.com">e-mail Roma</A> if you are
interested in attending this session. Include your name, company, phone number
and fax number. </P></BLOCKQUOTE>
<H3> </H3>
<H3>  </H3>
<CENTER>
<H4>Check back for announcements of more dates to come.</H4></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-282</DOCNO>
<DOCOLDNO>IA073-000477-B033-69</DOCOLDNO>
<DOCHDR>
http://www.styleadvisor.com:80/index.html 207.126.64.141 19970124222300 text/html 1590
HTTP/1.0 200 OK
Server: Netscape-Enterprise/2.0a
Date: Fri, 24 Jan 1997 22:19:42 GMT
Accept-ranges: bytes
Last-modified: Thu, 23 Jan 1997 20:31:09 GMT
Content-length: 1385
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 + all extensions//EN" "hmpro3.dtd">
<HTML>
<HEAD>
<TITLE>StyleADVISOR Homepage</TITLE></HEAD>
<BODY>
<P><A HREF="index.gif"><IMG
SRC="index2.gif" BORDER="0" USEMAP="#map2" ISMAP="ISMAP">
<MAP NAME="map2">
<AREA SHAPE="RECT" COORDS="400,206,614,238" HREF="info.html">
<AREA SHAPE="RECT" COORDS="404,286,653,314" HREF="update.html">
<AREA SHAPE="RECT" COORDS="404,331,644,362" HREF="/news/news.html">
<AREA SHAPE="RECT" COORDS="407,422,602,450" HREF="links.html">
<AREA SHAPE="RECT" COORDS="407,462,536,486" HREF="contact.html">
<AREA SHAPE="RECT" COORDS="18,438,193,486" HREF="http://www.netscape.com"></MAP></A></P>
<CENTER><A HREF="info.html">All About StyleADVISOR </A>||<A HREF="update.html">Updates
&amp; Announcements</A>||<A HREF="/news/news.html">Newsletters &amp; Articles
</A>||<A HREF="mailto:roma@styleadvisor.com"> E-mail our staff</A>||<A
HREF="links.html">Other Financial Web Sites</A>||</CENTER>
<P><I>Copyright &copy; 1996-97 Zephyr Associates, Inc.</I></P>
<HR>
<HR>
<P><B>You are the
<IMG
SRC="http://www.island.net/cgi-bin/counter?http://www.styleadvisor.com/index/">
visitor to our home page since January 19, 1996.</B></P>
<HR>
<P></P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR>
<TD WIDTH="289" VALIGN="top"><FONT SIZE="1">Copyright &copy; 1996 Zephyr
Associates, Inc.</FONT></TD></TR></TABLE></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT01-B04-283</DOCNO>
<DOCOLDNO>IA035-000697-B042-126</DOCOLDNO>
<DOCHDR>
http://lars.nrel.gov:80/ 192.174.52.126 19970111000825 text/html 3123
HTTP/1.0 200 Request fulfilled
Server: WN/1.02
Date: Saturday, 11-Jan-97 00:08:32 GMT
Last-Modified: Tuesday, 31-Oct-95 14:05:17 GMT
Content-type: text/html
Content-length: 2862
Title:  NESEA TOUR DE SOL
Link: <mailto:wlord@lars.nrel.gov>; rev="Made"
</DOCHDR>
<title> NESEA TOUR DE SOL </title>
<center>

<H2>Northeast Sustainable Energy Association<br>
The American Tour de Sol</H2>
</center>

<table border=5><tr><td colspan=8 align=middle> <IMG
SRC="graphics/newlogo.GIF" width=448 height=126> </td> </tr> <tr> <td><A
HREF="background.html">-Background-</A></td><td><A
HREF="rules.html">-Rules-</A></td><td><A
HREF="routemap.html">-Route-</A></td><td><A
HREF="entries.html">-Entries-</A></td><td><A
HREF="results.html">-Results-</A></td><td><A HREF="nesea.html">-Fact Sheets-</A></td><td><A HREF="weather.html">-Weather-</A></td><td><A
HREF="extra.html">-Extra!</A></td> </tr> </table>

<p> <H2> <blink>Headlines:</blink></H2> 
<UL>
<LI><H4>Electric Cars <A
HREF="http://nesea.nrel.gov/mpg.html">Proven Twice As Efficient</A> As
Gasoline Models!<br> 
<LI>It's Official--<A
HREF="http://nesea.nrel.gov/news4.html">New Records Set</A> in ATdS!<br>
<LI>Mike Bianchi Reports <A HREF="http://nesea.nrel.gov/email8.html">Final
Results.</A><br> 
<LI>NESEA Wins Prestigious National <A
HREF="http://nesea.nrel.gov/award.html">Award.</A><br> 
<LI>California <A
HREF="http://nesea.nrel.gov/cazev.html">Maintains</A> Zero Emission
Vehicle Goal.<br>
<LI><A HREF="http://nesea.nrel.gov/transpo.html">Sustainable Transportation 
Conference</A> Set For Providence This Fall.<br>
<LI>NESEA's New <A 
HREF="http://www.engr.wisc.edu/centers/sel/nesea/nesea.html>Homepage</A><p></H4>
</UL>
<HR width=40%><p>

<H3>The American Tour de Sol</H3> The American Tour de Sol is an eight day
electric and solar vehicle road rally event from Connecticut to Maine,
with free public displays in nine different communities. It was started in
1989 by the Northeast Sustainable Energy Association of Greenfield, MA to 
bring practical electric vehicles into everyday use.<p>

<IMG ALIGN=left HSPACE=3 SRC="graphics/gas.gif" WIDTH=148 HEIGHT=205> The
event has grown from a back-yard event with six solar racing cars, to a
rally of international significance, showcasing 50 vehicles built by major
auto manufacturers, electric vehicle manufacturers, individuals and
students from North America and abroad. With over 55% of the air pollution
in the Northeast caused by fossil-fueled transportation, electric
transportation offers a practical solution today.<p>

There were thousands of interested spectators along the route and you can
read about the impressive results through these web pages.  NESEA wishes
to thank <A HREF="http://www.nrel.gov/">NREL</A> and its director, Dr.
Charles Gay, for supporting this web site.<P>

<hr width=40%><p>

NESEA is most interested in your feedback to our initial WWWeb effort. 
Please email us at:<I><a 
href="mailto:nesea@igc.apc.org">NESEA</a></I><br><p> <hr 
width=40%><p>
<STRONG>Recommended browsers: Netscape 1.1 or Mosaic 2.0.0 Beta 4. Otherwise, it might look as if we designed it rather poorly.</STRONG>

</DOC>
<DOC>
<DOCNO>WT01-B04-284</DOCNO>
<DOCOLDNO>IA035-000697-B042-145</DOCOLDNO>
<DOCHDR>
http://lars.nrel.gov:80/background.html 192.174.52.126 19970111000835 text/html 14161
HTTP/1.0 200 Request fulfilled
Server: WN/1.02
Date: Saturday, 11-Jan-97 00:08:39 GMT
Last-Modified: Wednesday, 17-May-95 23:47:40 GMT
Content-type: text/html
Content-length: 13892
Title:  Tour de Sol Background
Link: <mailto:wlord@lars.nrel.gov>; rev="Made"
</DOCHDR>
<title> Tour de Sol Background</title>

                             <H1>  Insider's Guide
                             to the<br>
                          1995 American Tour de Sol</H1>

                             <H3>   by Jack Groh</H3>

<img src="graphics/line.gif" width=98%><p>
Whether you're new to the American Tour de Sol or a seasoned participant,
you'll have a lot to see and do at this championship road rally for
alternative vehicles. You'll feel part of an exciting chapter in American
automobile history and learn all about new technologies that will make our
lives and environment healthier and better. The event has grown from a small
private "club" with a half dozen members into a world-class event which
attracts over four dozen electric, solar electric, and hybrid electric
vehicles built by designers pushing the limits of pollution-free vehicle
technology.<p>

<IMG ALIGN=left HSPACE=3 SRC="graphics/photo2.GIF" WIDTH=277 HEIGHT=217>"The American Tour de Sol has reflected and influenced the rapid
        changes in electric vehicle development over the past six years,"
explained Nancy Hazard, director of the ATdS. "We started with solar racing
cars to promote solar energy, then moved on to practical electric vehicles
and now we're focusing more on production vehicles - those already available
on the market." In 1991, Governor Cuomo of New York waved the flag on 26
vehicles. that race began in Albany and ended up at historic Plymouth Rock.
Times have changed and the fleet, now numbering 50, will be the largest ever
as it races from Waterbury, Connecticut to Portland, Maine.<p>

What makes this race so exciting each year is the variety of vehicles which
compete and the stunning improvements in performance that take place from
one year to the next. Just a few years ago, electric vehicle designers were
scratching their heads trying to find a way to beat the 100 mile barrier
without recharging. Last year, eight vehicles consistently beat the 100 mile
mark while a Solectria Corporation-built vehicle topped 214 miles without
stopping to recharge. If history is any indicator, even better performances
will be seen in this year's event.<P>

A large number of vehicles come from the Northeast but entries are also
coming from California, Michigan, Pennsylvania, Ohio, Germany and Japan.
While vehicles compete in five different categories, all of the vehicles in
the American Tour de Sol fall into one of two basic types: high-tech,
solar-powered vehicles designed strictly for competition or practical
electric-powered vehicles designed for everyday use. Vehicles will travel a
total of 300-600 miles over the course of the week as they race from
Waterbury, Connecticut to Portland, Maine. The race is a road rally-type
event which means vehicles are required to travel a specific distance each
day - roughly 50-70 miles, but are also given an opportunity to drive extra
laps to demonstrate range capabilities and improve their score. All required
miles will be driven on public, secondary roads at normal driving speeds,
while extra laps are often driven on interstate highways. The scoring system
makes efficiency and driving range (the distance traveled without
recharging) the keys to winning.<P>

In addition to the solar racing vehicles and the practical electric-powered
conversions, which are cars using the body of an existing gasoline powered
car, there are also electric-powered motorcycles and scooters,
electric-powered buses, small one-person electric vehicles, and a number of
"hybrid" vehicles. These hybrids combine other types of power with electric
propulsion. For the first time, the rally will feature a pre-production
prototype sedan, designed by an electric vehicle (EV) manufacturer.<P>


<H3>WHAT YOU NEED TO KNOW ABOUT THE VEHICLE CATEGORIES</H3>

<IMG ALIGN=right HSPACE=3 SRC="graphics/photo3.GIF" WIDTH=288 HEIGHT=202>The production category was created two years ago to showcase the   
electric vehicles already on the market and available for purchase.
Only vehicles that have actually been sold can enter this category. Entries
this year include a Ford Ecostar, Solectria Corporation vehicles from the
Vermont and Connecticut EV (electric vehicle) demonstration projects, and a
U. S. Electricar bus. The Connecticut and Vermont projects are
public/private partnerships conducting on-the-road evaluations of EVs and
sponsoring entries in the 1995 ATdS. What makes these vehicles unique is
that they are all vehicles currently in regular use on the roads. "We have
about 400 people test driving a Solectria Force," says Harold Garabedian of
the Connecticut EV project. "We are constantly collecting data and surveying
users. Out of the hundreds of users so far, the reaction has been
universally positive. The one concern people had was about the vehicles'
range but in nearly ten thousand miles of driving not one person has had any
problems related to vehicle range."<P>

The Ford-built Ecostar entry is similar to the vehicle that won the
production category championship last year. Connecticut-based Northeast
Utilities is sponsoring this entry and organizing the race team.<P>

The production category is also expected to contain the first ever mass
transit vehicle to compete in an electric vehicle competition. The bus,
manufactured by U.S. Electricar of Santa Rosa, CA, holds 22 passengers and
is actually in service right now at the University of Massachusetts-Lowell
shuttling passengers from the local train station to the university campus.
Sponsored by New England Electric System and UMass-Lowell, the team plans to demonstrate the practicality of swapping battery packs to extend driving
range.<P>

<H3>TEENS COMPETE IN THE COMMUTER CATEGORY</H3>

<IMG ALIGN=left HSPACE=3 SRC="graphics/photo1.GIF" WIDTH=286 HEIGHT=228>The Discover Channel cable television network is sponsoring the
commuter category this year. This category features 20 vehicles -
the largest number of entries in any category. A high school-built entry
from Bolton (Conn.) High School is returning for its third year in the ATdS.
In last year's event, this race team traveled more than 140 miles on
standard lead-acid batteries without recharging - an ATdS record for
vehicles using that type of battery. "We've been working on the car since
then," according to Chris Laughman, a senior student at the school and
veteran EV racer. "Some minor improvements in aero dynamics and suspension
should increase our efficiency. We expect to beat our own range record."<P>

Other top competitors this year are being sponsored by Boston (Mass.) Edison
Company which is heavily involved in helping to create both a market and a
product for the electric vehicle industry. Boston Edison plans to enter two
Solectria Corporation-built vehicles. (Solectria is the defending champion
in this category.) One of those vehicles is an exciting new pre-production
prototype vehicle called the Sunrise. Given this car's anticipated
performance, sleek design and expected sales price, the folks at Boston
Edison believe the Sunrise may be the electric vehicle the American car
buyer has been waiting for. "The American Tour de Sol is an important part
of our road testing," says Jim Hogarth of Boston Edison. "We really expect
this vehicle to take the world by storm."<P>

<H3>SOLAR RACING CATEGORY PROVIDES GLIMPSE OF THE FUTURE</H3>

If you want to move away from the "practical" type of vehicle for a moment
and get a look at some wilder, high-tech vehicles, you will want to pay
close attention to the solar racing category. The designers of these
vehicles toss aside the needs of the average motorist and try to push the
limits of what can be done by using only the sun's power. Built primarily by
student teams, these vehicles are small, lightweight, and have large "wings"
made up of photovoltaic cells that convert sunlight to electricity. They
need a lot of flat area to collect enough solar energy.<P>

Some teams to watch are the Salisbury School team which returns as defending champion and the ConVal High School team, veteran solar racers who are
entering a two person vehicle this year. The team that will surely travel
the farthest to enter the race this year is Team Soffix from Nagoya, Japan.
They are planning to bring a vehicle which competed in Australia last year
at the World Solar Challenge. Another interesting team comes from a high
school in Grand Rapids. Michigan. A dozen youngsters from Ottawa Hills High
School are entering the American Tour de Sol for the third consecutive year.
Their electric vehicle project is an integral part of the curriculum at
their school. Students not only design and build the vehicle, they also
handle all the logistics necessary to racing the vehicle and even raise the
money needed to finance the project. Last year, this student-built entry
demonstrated a range of 80 miles, despite some serious technical problems.
This year, their faculty adviser predicts the team will more than double
last year's range performance. "This program is not just about electric
vehicles, though," says teacher Bob George. "Our students are all selected
because they are having difficulty succeeding in school. Yet last year, 76
percent of our kids went on to post-secondary schools. That 's what this
program is really about for us."<P>

<H3>HYBRID VEHICLES EARN SEPARATE CATEGORY</H3>

One of the newest additions to the American Tour de Sol this year will be
the competition between hybrid-powered vehicles. Many people believe that
the hybrid vehicle is the most likely to succeed in the near-term on the
American market. A hybrid vehicle is an electric vehicle that also uses a
small on-board gas-powered generator to recharge its batteries and extend
driving range. Although there have been hybrid entries in past years, this
is the first time that four hybrid powered vehicles will compete against
each other. One of these hybrids is being entered by a team from Cornell
University. Their team has more than 50 members and has been working on
alternative vehicles for three years. This year's vehicle uses electric
power for the motors and a compressed natural gas (CNG) generator to
recharge the batteries. "The public consistently mentions limited range as a
concern with EVs," says Robert Thomas, an engineering professor and
coordinator of the Cornell team. "We believe hybrid vehicles address that
problem and provide a good transition to fully electric or even
hydrogen-powered vehicles in the future." The Cornell students come from a
variety of academic disciplines and are all divided into various project
teams. For instance, one team specifically handles all the "business" issues
including raising the 50-70 thousand dollars that is needed each year to
finance this project.<P>

Another hybrid vehicle is being entered and sponsored by noted actor and
environmental activist Dennis Weaver. The vehicle, dubbed Surge 1, is
designed and built by Weaver's cousin, Troy Reed, an automotive engineer
working in Tulsa, Oklahoma. "Electric vehicles are one important way to
address the degradation of air quality," said Weaver. "The road rally
competition is an entertaining way to help spread a serious message - that
there are practical solutions to environmental problems already available to
us."<P>

<H3>OPEN CATEGORY ADDS DIVERSITY</H3>

The final category in the 1995 American Tour de Sol is the Open category. As
its name suggests, this category allows vehicles to compete even though they
do not fit the specifications of any of the other categories. For example,
there are four 2-wheeled vehicles and an equal number of one-person EVs
competing this year. Attracted by the huge audience provided by the American
Tour de Sol, German designer, Helmut Schiller, is traveling from Europe to
demonstrate his pre-production prototype of an electric powered motor
scooter. He expects to manufacture the vehicle for sale in Europe and the
United States in 1996. "This race is the best way to introduce this new
vehicle to the American public," according to Schiller.<P>

<H3>ENJOY FESTIVITIES AT THE START AND FINISH</H3>

The race will be enhanced this year by a couple of companion events at the
start and finish of the race route. Waterbury and Portland have organized
festivals to coincide with the beginning and end of the ATdS. Both
communities have also been involved in actively promoting and sponsoring the
race this year to help draw a large local audience. Attending the America
Tour de Sol is sure to be an unforgettable experience. Whether you are
competing in the race, working as a volunteer on the event, bringing the
family to get a close look at the vehicles or lining up for the "ride and
drive" demonstrations, you're sure to come away with a new understanding of
the future of transportation. Cleaner air, less dependence on foreign oil,
better use of energy and more jobs here at home - these are just some of the
possibilities linked to these new vehicle technologies. There are still
obstacles in the road but, after all, that's what makes the road
interesting.<P>
<hr width=40%>
<p>

Email to NESEA, care of: <I><a
href=mailto:GrohPR@aol.com>GrohPR@aol.com</a></I>
<p>

<I>Jack Groh, of Groh Associates in Warwick, R.I., has handled public information for the American Tour de Sol for five years. Groh Associates specializes in national publicity for environmentally- oriented events and products.</I><p>
<hr>
<p>
<center>
<table border=2>
<tr><td><A HREF="nesea_index.html">Homepage</A></td><td><A HREF="background.html">Background</A></td><td><A HREF="rules.html">Rules</A></td><td><A HREF="routemap.html">Route & Events</A></td><td><A HREF="entries.html">Entries</A></td><td><A HREF="results.html">Results</A></td><td><A HREF="nesea.html">Fact Sheets</A></td><td><A HREF="weather.html">Weather</A></td><td><A HREF="extra.html">Extra!</A></td>
</tr>
</table>
</center>


 
</DOC>
